%PDF-1.6 % 151 0 obj <> endobj 179 0 obj <>/Filter/FlateDecode/ID[<9D214E4BFEECAE46902997841A5DDEB1>]/Index[151 39]/Info 150 0 R/Length 116/Prev 889745/Root 152 0 R/Size 190/Type/XRef/W[1 2 1]>>stream hbbd``b` @ H0z X D| Y6-D e "$DtȀ @n6DԀ V5jX b1pa`bdP?Sa endstream endobj startxref 0 %%EOF 189 0 obj <>stream hb```c````e`! ĀB L@Q00(;S3LV~l׾. g Xd?c o)Jq^` @!1~a-?eLX@g 2޻pW2@DE|Š ݍ- endstream endobj 152 0 obj <> endobj 153 0 obj <>/ProcSet[/PDF/Text/ImageB/ImageC]/XObject<>>>/Rotate 0/Type/Page>> endobj 154 0 obj <>stream hެQj0 Cq( %+;8W ݑt[ҳFA(9dQˊ(VK Zžd\z-Fn# `0Xګ4dbSbG*bWhqAߔH ᵮգ1H<[K7}h9aio̸֞hI:- W9~WsbU{NٗZȶR endstream endobj 155 0 obj <>stream HWn7}Wc 4N ѴQZ&V`kIN oK$6 M̙/3΄k ?7ι'޼f;̤c qBX ւL*Ld3@eҢs @Ap18d/pL*\zh/𙐹 )j`, U̓N$j|Vz@ Dh19ƁdmbqoOm Q^|<̒3B&W-H^O WĘmTc(,KJ,x ԃ4eB_pXBEϠO dRIh._tUBоKLGPHUx=GӆOҀ jqfloj3LCB)iݻm iFWDM۬^:J<6r߼zuuӭ?ׯ4$@4O3ȵ ֝cX1rYWzEt~ (uTi6-2Ez@H.-l˝$0iqžݥ]' *&.:I=3%6}ޱO^Af$uU5ؤ5 9/<W\wCw)bg3Y1mrLĂ>r<`n8(;mv\pnh7ê&  ػ܄ yv߶tp3>mcXJqqw]{{x 7A#_({҄ \ 4a tN2B]oG_rrEkPӭ(Q3/BkDRѱA)U@ omaAn{{T%W44^O9Jy ř&2xt,ZuRy[u&1Xh'#%<:b/8wy ZЌ؃ gQ=p6Rz<е QhW7z#٥>vd%s$T +f=N3`!څvtq &\+_,!S)O0M|PQA2hi("Wr endstream endobj 156 0 obj <>stream HWn6+)o`t]zPl KNSe1AG jK@@Ϙi_djԴٜZC5/:U֡7UIe\uX?洮3X%+0;}0L\%ѿC/H -#άӦB3DK~rK_5j/ x-_sطmnY=L)]Ȅ} e" Fv"ٗK{N]pTY'eSWjs{,wy`mqF"-wˆ=K))S-&vuj̉2gLK0Eb=4uwMQcvy$2?:2s n<舚}=6պwmWOӉB%l]{i+q`<D‰P:hQ u\`$YToӀ/G_u^s]6b"%lHGv&4a{Đ@ qFa4_![Jʐ`;͜ g[zC7W4-U>ǕSbĴBIYz}9Asu}uCnӏ{߾}G̵{ZPի# YQ Trej 8(?ܙD+gWt%mmjU.q QQh$.χ.4cV/祵;50M1X5$%qSs^B*n~ߜDq"665 dZ22謩pIYvdZR'PN@٠ qF 󹑺%IY.!irzn53ƅieLQOi@.M CrQw !DGO$ BL_29V3=1q-*6o#ԋ_f253OUI6Fո-\:IHYD 5^:LE%eMKoQST-ZXAz ;bKc+EG.) D%$24 &GP ZOrq]P 50D!i Dl Ht$$\)41$LL?>LwuhmS'c:xqtk묒yb3jϗZ]JgiP^'+!-@ѡ {ږp$' *HH^FPV endstream endobj 157 0 obj <>stream HWKoFWR;ECR#('#]DA}g\Q$=Dy|7Q }[06X .VeWܬ0"^ ;p0{",L?T]5J)G⊅#ula`^ b.tߞu FF5!1Һz>v9K!Ʉڮ*\$ )tGٔ?szCŇ?#o+7)HztA6vF#n +2Fѝj[}zw5]Up$kIıT\TSJ GDFn_MCJHM?$\OoRNq`r6/ec wTOeV晦 >(bLjȵ]U6f!7y٤=21̗ |r׋7 ˜ 섆!* mϕ. %Zh6qyiAq+|~ ]84OzKKo:浓dG~n!B`#u5%j:zCZ\QQ9p=r⯈c 1'.*Owꐺaʹ<<\+ϻxRUN~/LnmJD9͋ l0vRa*`ԑ#fwt%Vs2JRz(8.೚" [0SI62~Vp(AlKVhYq:T;C׋`vLE]/zX4Ҋa .ߞ8;qp0eDA@cWtA@BfW*w{jv#52 Ir߆MJxE<% gL6h0^{2~v_eF1|f'tѧ aTyaCݦ?ϴ`+`'d:Amf]]n8n`fZ+@%0p=0'`a"]ٲF|hO$ /Ǵo"h"%QM15c TTB\Qoa8i,rZ7e&aC!eqkq=J7~/C{.vc"+%Lyl5gSPr/⍸Qnڷa#y%%i-q믺\f8##`/)@_q endstream endobj 158 0 obj <>stream HWێD}߯c2_ DBBd!ӛ5ڃeznxErFK:ui~WOmWQ-I#DuT /FbF"N*I1ҦzHp´sfh~U昃z 9 x^`P{*D)gC"Roz=MI1VT40ջ# YmEjCVLJ~؎q8bȏ$NcXpc&xdzP,`۱W@ JL9iD&aDL%$ r_h,Ďy(fcs`ÑLJn @_%LǨC&;i#4o;H1SK$J?4L~dיLaTCkn8.EO O& (A*RO.9O:YI~nI,falUVUj ɒۡ۶%R{8ch*Z-\ Ky0O;jMH~[vVQE7ťaꍡM 97b<7&-B@Xk[G3cA8y~HOj}C5arfFBstީ(H-N:c<[6 q@N%[CpTBð2\ ,X).pcv^Y5@V⼛MۜbÀQۭexI?4- N㜥E~W7e&KcNmvBR<=pD'E $} \~S)q7GzV=9]oMng:q 7GfP nIƔ/i*QN-\E`?=pr[\TΈ 6)WQ?B!2 1Y+f}ybЀ4i 53/5ɹPYyzti]'?g@ endstream endobj 159 0 obj <>stream HWYoF~ϯK6{F"AhEASkD $]ʌaff[T+1 16榽<|Efo`D)Sg;Y-2`g{sc=׭ JX F(NFNQI+GDe[yw]! ,a:kt0Na %^Ci->O̴S Zq5 +Eo sKJ]AmewuhFed>ag3޶N ̑ c, Q~IǻTͩdUBM|Ȧ3rLɈȈX+p. *w1FuDX/0)`DbljbBVW[T襻 &.ScUf?; c?c =O|D)dtxIE`_d ^gBѨTY5oIh϶('l}KqJwSӅw,W]PG7tۘalDUA"Phz qֈQp+3%eDIo\x(Q~eT.7H=moqja o2j - b h1D*54kղD>X>stream HWnH+xt`s%f$ f7ER'0 VWu-^ ]9b2 ?7hqj2}U~l(*9.XS0l>p.2iϬoY&Jc*n6AZGf1Jb2ALY*]ɕWsAR1 h1^2=s( Uw9#;>rP}5W#R5"4"Uye$:]y/h0?67W#+m$q_w_cEDOܚ|( {їns=E{w?eʗ7Q[|V˷+snEp!3 0#}F;LJ>;ߒ8a*6բ}yU?CM89Yī"y 5$؄J(5|>A{}f q{ˋTA*";; iMjh:tS^4f_SA/"Vĉx}iFdB[>5X ],PX n$UR=/ =MLX]<0>mYm*LpW0W[J*WO9¥ ׼ (KJ$ۧ^M##p9)cC2ʺ骺\t*]*!sXNM<c:a1-iY]yfIȅHU0ľz JWVw~|eFNMi~ju?Qdʆ8WuP()8pmP%h!h'/0.eڎP3lzwc] *0 PM)]pWR[EiP.nLncWT,V00.a\XM{Wu3Ju)= NP&Ɔ}ke9e%EZL{*Ǧ=Ŋ(%8yOjwNU…x{JiQggBh@hCٽVx r`aꂁem=YGtW\h'픢/Kot2tVL]x,v5Wnźr8ƼWh(b|Q >w6̴R:g+BSxYPe.A!(ۿUY_P piDh<4:i=2N`wԀe{%׮+/;n؂3#[O'E-j誛:&lUFX)eD%_t9G6j"@,Gx6m, Ҙ0Ԏtnq]>v/อKUDӅHxX?2(oyYb@F!aǀӧŜ+OI!#($o=,K hވ`x8 endstream endobj 161 0 obj <>stream HWKoFWz !i^znNP4e1Hb/RgfgY0VFOuFXO)m(|ς.C9}tG &֔)kM`"vfxfTьcT u0;վl8#e~iѿ8O<2fbp&i!_2tdytR0g~6t.30UDrlUI=4.KdfY4>s $9W8Xn_˦]X>D ̳<;ǩuOL2aQvZ0)Sjå0MHNv32~irf0]qxzniKx &'K=|eNvyxXnϖ86g/s姂qֻ #XFѸ&6]G:дiuIҳj,erf=9An鄳i̬:yי8% vw(r}BpDD0ʿm>olt>}bV[')P&l!a%$ٿ0eܹ@p,%%LlӖWO0oiUpS|ʋOOK#%n I  yφ$&[F@nN}yHC2%\Z3XWvq]% 5 K{Z<.y{-q1nw 3 YnuPT:2"tjkΞ&!9oӪz^n( ,0}]z״$Ay~=JbbkZ۷MrFxH 7i>stream HWn8 +].,\G}'?ڛʲeN —C<$R$,1Ԕp-q钿^?Q9 ߤxrP+~WdvpgbX,M^Ŕ BL0as!_n0%*Q")w^:@G81b2Ϫ]8R;)$%`i_Y`14?)Qk\%UD.Bn.ڗqXєDXlꫨ#Pc-EEvQ.&'XTZYAnRJ .6^7^NY^vUa[y]ueջFjHF""ϕ`8\ݸR6YW7G^gP3lzt 5 w,qAVq| (ʮ1<zqe]姫\ۮ@ t0@B Vu ϓ&O`T@Ksx)-ZNj]yŕ!`fhg&A?NeÈ4_\xI`8xʔ@)M tPdu~ͪssvGNo8rB 8J}MFn ^WH}T."8{vGb(2Sv#=fg0׼5! evSjzگH(!R }'xb)}5чȐ}LFj(bE)&tD,|Y{{c#-Gsʚ!8f7NCT5 n=?!o !3jl=g 2fʮox6(P GH_FnA2[w98&:0W*Lp@Lqˆ!T6{y:#N;>4<Say_WY:fx[GV!Vt>;`[ 42TL9 ~ M y GOrX72h }lkY=[4:mqmQzZBhq\ĦM0)/j̋?/EȁSO|]1"lFQ9>[ C9<dSvrnVgEuKSlkzѡcpazJt`%%अEK,M KXbvg^ qtmޔoHb l8b|Hd>Մf| nQ캢>wqJX[!0GEiG7qa ,PPLǃ;j‚Evgۦ*ߜf4ۙsr R,Lƛ}&%b˱3B$ΰP|qAa_ $1IY$~tT_)ljq* t3go`>2 Kq0+\O߯O e^ endstream endobj 163 0 obj <>/Filter/JBIG2Decode/Height 1752/ImageMask true/Length 23125/Name/X/Subtype/Image/Type/XObject/Width 1240>>stream 4 + +=D;Pʅ}lzOw@-n~![i+wIA@-Tjk)Eh=f-'Y}0'#]Lд'":4Lp[$ěs,BzGNHn)M /4q0Z>Q&!^#3oNOWj5$ZUofQ(P(3- 9ord cORk2P@ ߣLغɔrWq4ݨs I]6 ]̓J: ?T\{:!]u"}Y?д~~w$T?+me D,;¾ztmG !WBУX@=nAl) Yh ,&9IS,H@V< 6|v6F+1dJcѨ64JS%Hu5!?9~Ẅ wŪ&R78ir{>NreݏM>u_BW\mn=oa%=Ts&`"һs[*s7{lE^vjٌ?_#G*3F̶]5RâR` bft):K`hք˲EO0>8ʡNQ"FuwX*St,c*B [+%卆u!;vpEmdкS<+AWkf8CԠJ=r,LO`1YrZɕz\+2۔-+>WMK/j0<#{=5PiއxJj6\;s61+;D-w%հiE;R>_2hsL4kS=JG1M3xT~C,e+9q{$bnm$EϲX;Cftc"j^¶㚔*P|h-&b?.rioGaN n_A~N1x7iN }4Δ$cr~aCT\t tf%gn itif1`wXˠWi s:ei =VROp:؞g;\:Rع ?hz&ە0@-%jE>x|߭K9K؈/+AW9:Յ"0m A1 +e!of6ѿ۽5CI8S̴"F9N3F卺't՗ޭ]9.ҿ29/#m0ƃ5}Clz@'tHl(o: 5(,j1 iIR-36 )\BT[~9Xb4eXduPw,p~WH 7^!g"N[]@YECPQDOk}j2ẅJRTC ^@d_mVv2\R6ð`VJ>K-e5Æ;VPMa+\s]àD¦ Vl =ȝӪټY(#abuLc7nAM8},LH. C$9t=ˈID,KcKhGn[Ą` =qWw\ @#}"Z>U6jGK: 1sv}Fh$OvCIABEiF12D-`*C?96 h+ j 'ٻi>A~ !< +]4Bߙ.Qz ~gv"VQ"II/5=sxE3_:t<{gF oEh,\ٓ&J o+)h&g*T&KEŏu J$Ы h T 171z%sh:3 _y 3'*H<*@ uyeqeݎ7 1]hLb5ŗ(g\1b8$n%(Z7qmAuD 4ؙǚJOe:r;mvx[Y}XkBE d`ߥtSV{@Dli D56A:,3'V/{3$Ur@V ˋ=Ix$7<dž3 ,SWnOɯO!;]F׽W)ߧͅVyAF? *PQYZ x;2-Fβ6X(hƴrZt䖲ߠnŜII55m]9wnNK0M1 BaeD:[krT`괖H>Z?Guۥ hX_L5a:EJƁq ]볾WGjFkS]|֡5N; t,$/_p.pOo,FȱgMj!UEU_ڛ^6%OYnOެ]ō KGvh@zqǭS ,!l̤7@a' ;% 0mocUk< QZb ك0O$c4H4yKƆtfS+P+_S GFx98cP/@C;! Slm{fRal V^E $ Y3e/آv{0fȰDy\ *}}]Uz C[)n[-L9ʏuRＤyD!,[IIo4J.($]2#b;הI<4|{ˆ`O_dș9k͕n=y7-{ LƵAL8'\iIb+#En~8Yle4dD%O˓>|eeGx"aѱK "ny_/lT 030a)h!J@Я!E{I!c$ (˂9ǝ~SM@ I٨~B9(1Xeы9@)`ȢG@RPEG-~&d"kZXFd~̕C-->R 08wDvm3 E *Ysfk?'5e40^|%&>(nY("㼿>} .C-y)'yimw)2 0(*y!  R(1V%:0F7{roXڍ8@-#&:w9EgX֛[S> 愎%NmIʩiHed(Ok{^f;9nO]=ЊN}XAfƜFOIR+ CVZ1SdҧeOR (~YK/(9*-bgQܲ | )]Q&3Tˠ#v bhr*!.5Nd )Vl'9$P5V&ܽ3MZỶ~-_{D*4Y*iG*6OWH`s\%t1Oa(~{SkOycXMYM ujV7G5p~V:ֆ8;A0dǍ3=PIz .#wG{e@Wd+@8QqC."W}98?>"u}+-5yadrgyoY# qt[@^ڢ{v:5Mv>ӋJBߏ|LĈ5"v "YMC-6|C֣Qҵ|Ku\5 s` gIW&i:/⭟s'{dn*7@4 Lcf;&"\q҉riDB;S H1VͬL9ѡj=AC{cxʚDߡcainKnԚ*}ٴYl :'LHEz$=|u-,̖G_Ci|RT5bX綼>pvG0,KDrHCz/B >0{-:,.KM (TNPhL#j^J)2I2H1 nž6EMg@h"jTt%^ }Lu,u'Mt7 C"b|& ȔTwld' Z,YxmBa+p{0bq*ҌQz.ݎ?6OFHoc鴷BԸ9|%)`wqε + aJ]eӫ1"Aȟ=l:w0ŘX2)ʩ Lɡ]< Q >Rxa~UM2_P\ _6ǔj9z{\Y3!ldpXD~ #3ޓx 2 > zsfm8Fך YN@>wR&4L×>{t^֛ܠ3{VK-N([24cxy;fO#ҴNw^D$ZyCz74zvץ̅jA  $<m R#ʕp/7k(Ƚ]!XD[?fҁ{zg=$݌onX[91I}@?''z, /n[:5'FrbY 6ğ=jѩ)`K1k,%C&L(!bwUp7i"];z@ ]qzz+n ;@{Z$AL6\!>tf5 nO9tG͍=t~1 co{)uZ(Xו!b,,v}V"=wsi+fLIuEL)M`)V@I1-t8LF9к/[| N? cT g0C뙯C{>=e$NՅ`H&PJuW=a{; %:b̪Eh+äjhu.c-S<~5~wDu]k)KŃ{q:Byb;؎rM_1QŸ 3SE{s.d/,J/p:F)3MڲT6$Uf_٘TpP bQ# ԇhK2_/k Mؐ-s,Yc[o23Q!6YfНC7(n,$HFM<v[LٲUI5,GΜnd]ĝb<7E2[ /B~)2]]$qV}ST"A/n[Vñoڇ %Don'uעCpƄ^g!kwCNdD bظ kϨ |L۽箤"+ m1L:F|[*#A3GՈ??d&-Dk#uQ['/4t]qSCBeCk w^$1M֤AEȒZbs1LKcLMjk#O~%eT!ciF9X]OD6ш$zk}~B7֋^5}VSnf/ 2]l1zhW(Rɴ0jy{?A'MܘjixYO1|\u)DA [s U==\RzM*.Gz<Rʗ<"ʛ\Da"gh4k7}H.Ko_b KSMu _7FP]mOU~l0EUi];У$$!X$je,aEyZm#>}Gskv,%Eafd~1"5D3k&DBv _#xHk7|ZNEo%wG1c:bHރQ46wмj@myqռGUS {jTF05{sdUs2pL[Gq`luQ i\2ŀ|@_G̽#;DrY\%z-ÿý<擀b]fr&!4soJ =90D$V?A&uvvxh5)vħMϐ pWY@|p{_of]- hh@V2Rf '{ׅ%ܚ: ?wmPhV|_in[3]@k93˼}&CJHd\ q9ċg ˝)'#^ L*=£9ǰXK<Rl׊KCE0v.7aڐ/q*\ 3s/DI,Oc2eRk#o| w$ȵ*ykNl=V6pKʼnɶvywܛ9* JG?5Ml>bӰr=$Jjޮpd}י|节JkԼXV*0ȥspk,$p[Kho B%9CĊ4(LC:_qS&FW 9;~"n]֣ H<8Z1NI  MC`PT%w/ŞsoH8*N1Z#~3[otcHSGisaDyz}t16rL]5:܋u" ̇į)]VtSFe*9Õ8z_9 n[]f]AːZ)%!k>+ɠΙ|Uq8,YOosZK\Z\MOVsx[D޼F\i_ ?O0}1tA/?y\hiu'D 8tXH yT|N!yPek3{˼W:P(*hSưEBM yYb",MlkչIW\ g.e.B` |EJ]pS ISj3+ӓg7rIA"9.WҦ0` E/Lbr}VbQQx c,Lڔ\dVr[ Hb*i-Y]ohRT܁GpϨ`p~zwAlr"x(+N{hAQЮ."&=dCbq; :2.ZWo '5@ Nc_6=.:ArSw>h$6kcqG:MOа]I&ncϧgT˹sF\>\?|Y4 +5 S]uﻼ(3n 'jD*?t2*Wn -6:-(>A)^?&=*IlzB1 V8  qb TrIu[M 7 [Vn𳲀 dml n}'ĢJ ECfVN&޿Ef+.<2kVRA WĻ@ !$I'7s 2^e?"]fr7]F3H0 pkPD+=8M$~ 9kDP)oC#htou h51imX`g4CѠj8g+vPx&DO~qiN5S7wӱlhTp9uh|m}S^/eYW+{jx0%Dǫ2oQAItXcOdh<5cMfzF_ ʓʸh;\=ª U^"e3_IT:雂.DEK3rpaj6mf/]E?.iv\uhGhtOC$@].UG&)Zȶi:~#{d1hҾc|$]:+Niwj5rRTFӻ|ˇ5UY$7hÜH{& j|: OS%גH:}oZ=n5xx@Gjs{ѷwhvs&S}!I4!cFI"h^-ܼC rbšکUtMߥ+S$yԯj2X_3HƜ-&EI Z Lߚ/wJN$ah.4b9]*$ رSZTX,x }LCB1y,IUֱ%\tD~h߇m\sY.m#k.XT;ICկe@_UnJ1-ٗ(L |8j% 唅s>8kf wn4T-8 D54xppLPEwX[0V@C6Mh0{y\֎"rQ#D1CszNj;'hkޢQ/oq*J ^7ߤ4Mr)񻱳+yo;Ʀ~79wa/YlyF4 u,٤R$ꖴ4 /9H-+zAyln1s/0j@AXmpI:UshE_kO|`:Ja06w~+gi[p(սLEvoF( N3MTQn'lޅ|(JJfo|LD0A\1J0*w=u I%aLOG녨'[#!sFGHp/6 lף s uc-ek\B uDRhEwpSkq)|0ݑ'qn5zt8B%aṪx+?X=Oӫ&fD!&|48v_xpLvr PBLlO#w2Pz5{L֦!Di4i~C @\2$ӻ;T=W-1#Jkc\Q3;JQZLB|=J>' vsJ4pEX5RBV+N~kn+@cE$1/$SE]eiT(lEO[F [Mz|0w('$䢳 +ޘ*MW5"_X6'`\/LťgCrvf7MC[v$p0sN;`eO?]*ɟ5vi4@Е1F!nY\Z?'`݈s#\`z3)V]h[Eu_2M`Z?-A9bYσ,IYh %v1fTKG!.jp*fn[ą2qeVghӂsX30@ %,αN>q +eZBE] 7xTqn9o:vLxٛ[fjaV\eZWt;H+y/3K_]C,o<Йjt .) y 5d /ޚ(5KgFi{]xTuM%}OXVR(e}ءf,ɕ5 a`L}Ҡ}^;E'^ґ>Z<+ؗ ,AM4Qk+L쌘SofQԄ3bՂܙI(o*_hʌ(? , ϯ;`L!RpRҽQD|h'W.AqMT"-k)_Z[=S`zR@_.ŰxWN&N>p0Z"_ū&ziW/!rWIn(1PÎ È%e/ O4 -si;ޖ%3 y9<qI׍}4ovN)d휊FBZ.* fx5Fٛ.Sc f͌cW`W|~vK\g}-ɫlG@E+u죦8l^cMޜس|S/_nYAM] EpԠOμO 駒[N) ]p~R_L38`$ CڰTQWر]o^-MVKD)}ô<ԝ| QAJ7Lf%7v=?Ю6b@{oJ~k%@LzbGKidbMޞITYD1Ix)+B;E IǧTY Ye{t}SB;}Ɯ-x(NBϘջ*Hpqpt-  Ǥͅ\XPnl.{jkYFJD́939mCӑnϲeUhrZT{݈ܨdpQ_;Mq9b2]¯[y&6̞)B$մLXߦ 2ErS1ڏw5JɈ /;7Q|0 łlu ]ȸ.\0׽)W=b-ߤSwC׭$hߨZ8J7J)ȳHOvȯ൨?t^/<ͣϐØ0]1 B`/|.3sB`(&񧹛47uLTT+"i?BF2\f|} SCVTͿmmQ +J&#}/‚zV(sEŘVZ!28ze`>oٍ_&z\ڢ.o(H%w;P9%_Sٌy=+piiNUk0F8;o?}Ė76(,PG_d8d\;0\ o4++#ptʮḆ[.< w|pv:SvŪ;iL-'LRH| JdnTI=O&Oc]EWV@ _26\Uy*1Ԛ2Юb\DWFwSv1@_H`q/ .kDr]}9stˮ!U*b7Ek`nW'^ĝ _l-'12Tpc"A*9CTUb]!9Ix zVXo_T/5#:" c{QbMݸ7 f<.K<fIʪȍ*ٰoߗێcW)Ռ] eY XHW)J:,U=0N}\^s+q#Xx|e=q&\~yy@ٖj̮Qtӌ''#% { Hr4+ӞhɛԨcvvΖJb-wS1XhTk̦ⱽWObߐWG0MG9"1#?jVb"1Q͋n (T\y>՘΀g؞^n@2-F+^Cw\qLH[PgB%{oTTվX}Gk gXߥl^IWDx4d-VrLzCI}YKf ʇo^k<9O;Gw(Q z~LyD-_DEA]y< ܦd\_@Z@ch ͭ)udw}Exˆs~L`󯓍U@vS$TN[P\8oh'727J8*FxKK}vC4A-EՠHS0 ԰T*ZZE~`D,Fktm^zk)eGrg1Iґf CϾg'WPǓm?pO3Po?YFKLIPu/&Tu׾dr|ɡcѥW3'-0ROא(xpov~on“f^Qguc|RtnIV>3ɅCxT*gkk* ؔLԑt%W!g7jxaq^Txx˧nzol)%jܤ;lV>w=ApT*x^;cuf)'=ίcǼ(Y?m?3)'45b&syuQбA]M@US^vP)Tn"sj|dǖl|C(EFksyGTOdJ{w5. ;9oWm/fHL;FGܢPL57cxˬW] "V Q}5Mq;Jz\îȨ{]խu7na{tjhgسg8|w~e⹫γ@!SE&V~&~֒}{Y~aFBJ+ͩo&EÕj -<<|ܿDA8 3+Gʥ%]Z{vZ~Vt~\бI$VvJg<&F"x~!`wE6{1D-z'<i͗ Y mIWXw%b#{ygz2{\'ߋ,5Im>j1_]|gg-8~<?͝@Dz-5~&$\um4#ch# q6_%! ԡj1K/J(eBtLq@II5^ryt(Bq g?/PUUBhG [l<)d[݄TO:W{ϋ|rs;œ;;RM'f>_Ƣ@-AHLgX@ m˟u /T*FቍIَjxQ>}9?*X F(=* D—Gڦ&Bf9\S d W~&dʎYhv$rO7Ż4$*'VifG<, 3@=y j%ż[XeLFQv[b> ˏPݬdcG};.dj|Ff[~&R_Z3 [ [Q |n|1ژpX?w<\zD*v^il~cj.ns^3AI .iUo{rZ46Hە_U8Hb'FiFO@ ! ."RGȚ.q,h: uW_<^Oͼ͢k9$q3FfEMRm zjx *NO\oިamf'0H6ln'Y]Sx-rc9ZᏘ.$Ѕ~r݂i{< 'lu{yn}"BiPx2veM.fXJl; 61m0c¤BmȮ{KC#?PKъ )=FⰷБ_&eMhyE~A:'ӫPx$ve@PGIu:S,zוq!IM\c\kcS28"%8=[bJOa_zQ? eH﷔dLO&J&3UeHcxͰ|tP>h I-.ث*3kDw72B^ku5zfL[X:0oEl 3(5"S[B˒|v NءuQ#$Is[Ǻ '̅*Չ<|iNx_bܜO[d"Hz r2? }nUhecT!~Vs_UCՍO"ałVc'TɑޖImZtwNj^M50 *4./QJ7<̡ t)E䄗OdxsZ]}3"QuD9Yj3}bч#b}I:-p"y48߿g_T̰ ?L{7-} ߜZ+EQ.7M/䬟 ڛi;.{xNhmzIl0 %tɃ+S|)3٫@ Ie 8Ge*YΊ{l$nJYb"@)2߾W(pEh&K1z8b_p϶i}y h+9ȾU LXjdϤ$mG9J{'DD;VŒ;1F{̑;X?Wy(mbÂ{[N&0V~V @٬)u'*q<4}祩HFa" vYd ]%#&y1=˹-Y0h}㪏 1igI(ـn%U.cIV:P2 FEKdOUa%(HuZbĮ5Ns -\XyJ=nw\LlP(1[*i;ioWD'`p'k"L+M ! z}9@>f2^m-%9j1IoP=]"bnO `@}%ܫpTfיqm>C&JRh: @>ϿHɤwd蚂;Iin!2{L^.ja׈#&o[%1]:u_{׶U|:!3Ϥv /{s񻛕ޥo멊V_ #Q4?ReJgk='_jbH *{QP 1ܜT1tZ;޼m,L$'7w}E!~7&¢ Rzq5cw7-}$hJKx O uWPCPղ !UႢF؄n= W[B>Fqַ0N~֣< 4'}Ơ?f!*t7:2ΟYk~b6gT51J8L. 2޴i"1fNŀKM7&埽h2pS;>3S(,!;1+ Uӂ_sCx]1lX܋Z8IRWhkBVAO(AAñc'&"b(ViHWy!2z!_:EP ٓX> KL GAVnKyѠEwֻY%H99w[^N`#(B*`F9 Wߢ8: gB7ۇ²joCZ*eF=LƌZs32 #TX-Gׁٵ_h VbaYm#usSI971@ אpA4d"f`y=5.N,١:>P_sK׌/˵է++(ijK6(vPRaG~v0 dJEndKg,̙3m9%pUB7@%Agq; F'}E"w%DsHOfZ1GPь˂1ŁtXsRsRYi)~-K֬U u| V],!%®Fհj=" }ú7cq+b99)t`ͬjh^M VL "$턏ozq5n{ rJdmiQ‰L=1١5n%ګ^\N6IIJuh~{ + `+?xǢxie.ऀxv5m0cs?SkJx} T"5Ν}St!Te!?˦p]ʙfS"P'k癦枖_%|mn~k)( %6mTƕ|}C $ %kݿ%!uݥ-L)Тk0~^˙enj6I9Z$I7¦ c2O),B6}[@+W@6}r㘨>z{&S H|7ҧO=09:hIA[)hpoW$;%hy6 E-+Hg@ړP'K.,R&ӶUҚfvC潕٬Bvk؊#5]5.u,9YBHc6 z=2.cxk8>[h6MQ&w/og;]Xͅ!4z)5ᖹ~(дy-jƜ~\]54́]!.*`2}}YT=:ZPða C7a\IJlZ_աK"0ӿ3+jj&|B)[RVfp=x&ˆ`$1V;ZT@o4SAw,o j=AgA&om \s16=%>26#MwIhlgiLc,^ %9ʱ<4m6S=Y5h2.v|XG>=t_.7RU[@YdE׍%_!f;e8 endstream endobj 164 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr,;colrjp2cOQ/;,;,R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴFC "  .@: :Ѐ 4 @ 1:$ ;\ |#@: {s$X: |    endstream endobj 165 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrcolr}jp2cOQ/R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴt @ -@ : @qy0  +}   endstream endobj 166 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr colrvjp2cOQ/  R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴt :  .: Ѐr|!|!@>/d݀    endstream endobj 167 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr*colrjp2cOQ/**R \#B@HHPHHPHHPHHP880 ϴ 最  ǀ +~xPwu]_f?a 9ϔt|%RVj6!*ADY {Ѷю fυ",@&,ldq6qю툐WSNgݼv=8k(*vW( δ1^2RoAh';G-8`Fb]̕Ŧ0l]( UoGN+hƶÅ[CEݭ MMg0x?Is1!ubJːs-vS瀀 endstream endobj 168 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrcolrjp2cOQ/R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHP]$B@HHPHHPHHPHHP880 CwȀ ' ?ht@ < LAq .L|A(GH$vlZDC>D <P(\#?ݼ3#֯jtz B5`Qef endstream endobj 169 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr6colrgjp2cOQ/66R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ t   h@ |"^u t`p8   endstream endobj 170 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr|Jcolrjp2cOQ/J|J|R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ$8ֱ4EGv#\ 2@S:$(X2gSvl F@$t`%%q$8$C:\P E i3^ۑd~ q`8;搉4NPpi UfÜ?@_ g%M endstream endobj 171 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr$fcolrjp2cOQ/f$f$R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴڞ2E&"u 1@: :Ѐ̲   0Q$tP,' v,uF :P-   endstream endobj 172 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr$&colrijp2cOQ/&$&$R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHP]$B@HHPHHPHHPHHPHHPϴGC $"  $:       endstream endobj 173 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr$Ncolrjp2cOQ/N$N$R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴM`DL"[ +@: :Ѐ V  %:%p$uzt~    endstream endobj 174 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr$6colrnjp2cOQ/6$6$R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ[}C $! *@: r     endstream endobj 175 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr$`colrjp2cOQ/`$`$R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴMm`D[أ"[ (:Ѐ _ t #:+xp+w_g҂A    endstream endobj 176 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr&colrjjp2cOQ/&&R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ t  : ڠ@  >{K    endstream endobj 177 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrFcolrjp2cOQ/FFR \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ #t  +:@@   )_|" Klaz $PA1ȋŀ   endstream endobj 178 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrcolr}jp2cOQ/R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴt @ +r: x] :#\M   endstream endobj 1 0 obj <>/ProcSet[/PDF/Text/ImageC]/XObject<>>>/Rotate 0/Type/Page>> endobj 2 0 obj <>stream q 595.1999969 0 0 840.9600067 0 0 cm /Im0 Do Q q 595.1999969 0 0 840.9600067 0 0 cm /Im1 Do Q BT 0.302 0.302 0.298 rg /T1_0 1 Tf -0.0205 Tc 3 Tr 10 0 0 10 60.9 778.8 Tm (274 )Tj ET BT /Suspect <>BDC /T1_1 1 Tf 0.05 Tc 8.3683 0 0 7.5001 258.12 778.8 Tm (C.E. )Tj EMC /Suspect <>BDC 8.5014 0 0 7.5001 280.62 778.8 Tm (MAPP )Tj EMC ET BT /T1_1 1 Tf 8.2109 0 0 7.5001 309.89 778.8 Tm (ET )Tj 8.6723 0 0 7.5001 324.97 778.8 Tm (AL)Tj 0.416 0.42 0.412 rg 0 Tc 7.5001 0 0 7.5001 337.72 778.8 Tm (. )Tj 0.302 0.302 0.298 rg /T1_0 1 Tf 0.0303 Tc 10 0 0 10 60.5 754.8 Tm (period, )Tj 0.05 Tc 10.0163 0 0 10 96.86 754.8 Tm (or )Tj 0.0071 Tc 10 0 0 10 111.76 754.8 Tm (in )Tj 0.0152 Tc 1.446 0 Td (the )Tj 0.0121 Tc 1.815 0 Td (evening )Tj 0.05 Tc 10.5727 0 0 10 182.78 754.8 Tm (or )Tj 0.0103 Tc 10 0 0 10 198.23 754.8 Tm (night, )Tj -0.0055 Tc 3.024 0 Td (were )Tj 0.0192 Tc 2.531 0 Td (studied)Tj 0.416 0.42 0.412 rg 0 Tc 3.113 0 Td (. )Tj 0.302 0.302 0.298 rg 0.0318 Tc -22.461 -1.056 Td (Symptoms )Tj 0.0046 Tc 5.098 0 Td (included )Tj 0.0242 Tc 4.074 0 Td (shortness )Tj 0.05 Tc 11.1292 0 0 10 196.21 744.24 Tm (of )Tj 0.0319 Tc 10 0 0 10 210.73 744.24 Tm (breath, )Tj 0.0008 Tc 3.502 0 Td (wheezing, )Tj 0.034 Tc -18.536 -1.103 Td (dry )Tj 0.0303 Tc 1.631 0 Td (cough )Tj 0.05 Tc 10.5727 0 0 10 105.5 733.21 Tm (or )Tj 0.02 Tc 10 0 0 10 116.54 733.21 Tm (chest )Tj 0.0098 Tc 2.456 0 Td (tightness. )Tj 0.05 Tc 10.1596 0 0 10 182.93 733.21 Tm (None )Tj 11.1292 0 0 10 208.69 733.21 Tm (of )Tj 0.0152 Tc 10 0 0 10 220.3 733.21 Tm (the )Tj 0.017 Tc 1.476 0 Td (subjects )Tj 0.0245 Tc 3.661 0 Td (had )Tj 0.0337 Tc -21.133 -1.104 Td (symptomatic )Tj 0.0412 Tc 5.764 0 Td (asthma )Tj 0.0099 Tc (before )Tj 0.0267 Tc 6.24 0 Td (occupational )Tj 0.0223 Tc 5.711 0 Td (exposure )Tj 0.0413 Tc 4.089 0 Td (to )Tj 0.227 0.227 0.223 rg 0.026 Tc -21.846 -1.056 Td (isocyanates)Tj 0.416 0.42 0.412 rg 0 Tc 4.931 0 Td (. )Tj ET BT /Suspect <>BDC 0.302 0.302 0.298 rg /T1_0 1 Tf -0.035 Tc 8.8941 0 0 10 115.66 711.61 Tm (AU )Tj EMC ET BT /T1_0 1 Tf 0.0102 Tc 10 0 0 10 132.82 711.61 Tm (subjects )Tj 0.0248 Tc 3.758 0 Td (underwent )Tj 0.0161 Tc 4.887 0 Td (detailed )Tj 0.0084 Tc 3.743 0 Td (clinical )Tj 0.028 Tc -19.632 -1.105 Td (and )Tj 0.031 Tc 1.872 0 Td (occupational )Tj 0.018 Tc 5.817 0 Td (history)Tj 0.416 0.42 0.412 rg 0 Tc 2.961 0 Td (, )Tj 0.302 0.302 0.298 rg 0.0037 Tc 0.534 0 Td (allergy )Tj -0.0029 Tc 3.116 0 Td (skin )Tj 0.0128 Tc 2.028 0 Td [(tests )-45(\(using )]TJ 0.0152 Tc 5.04 0 Td (the )Tj 0.0309 Tc -21.366 -1.103 Td (intradermal )Tj 0.0351 Tc 5.382 0 Td (method )Tj 0.0015 Tc 3.697 0 Td (with )Tj -0.035 Tc 9.7271 0 0 10 173.66 689.53 Tm (ex)Tj 0.416 0.42 0.412 rg 0 Tc 10 0 0 10 183.34 689.53 Tm (t)Tj 0.302 0.302 0.298 rg 0.0208 Tc 0.289 0 Td (racts )Tj 0.05 Tc 10.5727 0 0 10 210.62 689.53 Tm (of )Tj 0.0342 Tc 10 0 0 10 223.58 689.53 Tm (common )Tj 0.013 Tc 4.128 0 Td (aller\255)Tj 0.0024 Tc -20.494 -1.056 Td (gens\) )Tj 0.05 Tc 10.0265 0 0 10 85.34 678.97 Tm (and )Tj 0.0419 Tc 10 0 0 10 104.66 678.97 Tm (pulmonary )Tj 0.0221 Tc 4.979 0 Td (function )Tj -0.0013 Tc 3.897 0 Td (tests. )Tj -0.0111 Tc 2.448 0 Td (All )Tj 0.017 Tc 1.62 0 Td (subjects )Tj 0.0245 Tc 3.709 0 Td (had )Tj -0.0015 Tc -21.07 -1.105 Td (been )Tj -0.0117 Tc 2.34 0 Td (free )Tj 0.0179 Tc 1.968 0 Td (from )Tj 0.028 Tc 2.458 0 Td (respiratory )Tj 0.0121 Tc 5.033 0 Td (infections )Tj 0.05 Tc 10.5727 0 0 10 223.1 667.92 Tm (or )Tj 0.0223 Tc 10 0 0 10 236.05 667.92 Tm (exposure )Tj 0.0413 Tc 4.185 0 Td (to )Tj 0.227 0.227 0.223 rg 0.0164 Tc -21.75 -1.103 Td (isocyanates )Tj 0.302 0.302 0.298 rg 0.0314 Tc 5.181 0 Td (for )Tj 0.05 Tc 10.1194 0 0 10 129.02 656.89 Tm (at )Tj 0.227 0.227 0.223 rg 0.0146 Tc 10 0 0 10 141.52 656.89 Tm (least )Tj 0.302 0.302 0.298 rg -0.0043 Tc 2.31 0 Td (two )Tj -0.0205 Tc 1.969 0 Td (weeks. )Tj 0.05 Tc 10.5656 0 0 10 215.57 656.89 Tm (No )Tj 0.0207 Tc 10 0 0 10 233.14 656.89 Tm (subject )Tj 0.0324 Tc 3.42 0 Td (took )Tj 0.0265 Tc -20.744 -1.056 Td (cromolyn, )Tj 0.0152 Tc 4.856 0 Td (theophylline, )Tj 0.0234 Tc 5.988 0 Td (sympathomimetics )Tj 0.05 Tc 10.5727 0 0 10 252.38 646.33 Tm (or )Tj 0.0253 Tc 10 0 0 10 266.78 646.33 Tm (anti\255)Tj 0.0218 Tc -20.679 -1.104 Td (histamines )Tj 0.0183 Tc 4.896 0 Td (within )Tj -0.0247 Tc 3.069 0 Td (48 )Tj 0 Tc 1.443 0 Td (h )Tj 0.05 Tc 11.1292 0 0 10 163.09 635.29 Tm (of )Tj 0.028 Tc 10 0 0 10 176.06 635.29 Tm (any )Tj 0.0115 Tc 1.964 0 Td (study. )Tj 0 Tc 2.988 0 Td (A )Tj 0.0207 Tc 1.14 0 Td (subject )Tj -0.0068 Tc 3.373 0 Td (was )Tj 0.0227 Tc -21.129 -1.105 Td (considered )Tj -0.0067 Tc 5.192 0 Td (to )Tj 0.0266 Tc 1.395 0 Td (be )Tj 0.0326 Tc 1.525 0 Td (atopic )Tj 0.0301 Tc 3.218 0 Td (if )Tj 0.0176 Tc 1.158 0 Td (there )Tj -0.0068 Tc 2.641 0 Td (was )Tj 0 Tc 2.103 0 Td (a )Tj 0.018 Tc 1.113 0 Td (history )Tj 0.05 Tc 11.1292 0 0 10 277.33 624.24 Tm (of )Tj 0.006 Tc 10 0 0 10 59.9 613.68 Tm (allergic )Tj 0.005 Tc 3.513 0 Td (rhinitis, )Tj 0.015 Tc 3.542 0 Td (eczema, )Tj 0.05 Tc 10.5727 0 0 10 167.9 613.68 Tm (or )Tj 0.0089 Tc 10 0 0 10 181.46 613.68 Tm (positive )Tj 0.0131 Tc 3.632 0 Td (skin )Tj 0.227 0.227 0.223 rg 0.0275 Tc 2.173 0 Td (reaction )Tj 0.302 0.302 0.298 rg 0.0413 Tc 3.839 0 Td (to )Tj 0.0197 Tc -21.792 -1.103 Td (two )Tj 0.05 Tc 11.1292 0 0 10 82.45 602.65 Tm (or )Tj 0.0371 Tc 10 0 0 10 98.86 602.65 Tm (more )Tj 0.0438 Tc 2.824 0 Td (common )Tj 0.0084 Tc 4.464 0 Td (allergen )Tj 0.0211 Tc 3.983 0 Td (extracts. )Tj 0 Tc 4.281 0 Td (A )Tj 0.0291 Tc 1.428 0 Td (skin )Tj 0.227 0.227 0.223 rg 0.0206 Tc -20.867 -1.104 Td (reaction )Tj 0.302 0.302 0.298 rg -0.0068 Tc 3.84 0 Td (was )Tj 0.0227 Tc 1.959 0 Td (considered )Tj 0.0413 Tc 5 0 Td (to )Tj 0.05 Tc 10.2502 0 0 10 180.97 591.61 Tm (be )Tj 0.0089 Tc 10 0 0 10 194.9 591.61 Tm (positive )Tj 0.227 0.227 0.223 rg 0.0094 Tc 3.645 0 Td (when, )Tj 0.302 0.302 0.298 rg 0.05 Tc 10.7518 0 0 10 260.53 591.61 Tm (at )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0152 Tc 10 0 0 10 273.58 591.61 Tm (the )Tj EMC ET BT /T1_0 1 Tf 0.0104 Tc 10 0 0 10 59.38 580.56 Tm (site )Tj 0.05 Tc 11.1292 0 0 10 81.49 580.56 Tm (of )Tj 0.0152 Tc 10 0 0 10 98.38 580.56 Tm (the )Tj 0.0153 Tc 2.01 0 Td (injection )Tj 0.05 Tc 10.5727 0 0 10 162.62 580.56 Tm (of )Tj 0.028 Tc 10 0 0 10 178.94 580.56 Tm (any )Tj 0.0068 Tc 2.304 0 Td (allergens)Tj 0.416 0.42 0.412 rg 0 Tc 3.69 0 Td (, )Tj 0.302 0.302 0.298 rg 1.014 0 Td (a )Tj 0.0049 Tc 1.257 0 Td (wheal )Tj 0.0159 Tc -20.216 -1.056 Td (developed )Tj 0.0458 Tc 4.759 0 Td (that )Tj -0.0068 Tc 2.113 0 Td (was )Tj 0.0365 Tc 1.961 0 Td (greater )Tj 0.05 Tc 10.0233 0 0 10 181.9 570 Tm (than )Tj 0.0458 Tc 10 0 0 10 205.42 570 Tm (that )Tj 0.05 Tc 10.5727 0 0 10 226.46 570 Tm (of )Tj 0.0392 Tc 10 0 0 10 239.5 570 Tm (the )Tj 0.0272 Tc 1.721 0 Td (diluent )Tj 0.0325 Tc -19.729 -1.103 Td (con)Tj 0.416 0.42 0.412 rg 0 Tc 1.592 0 Td (t)Tj 0.302 0.302 0.298 rg -0.0268 Tc 0.337 0 Td (rol )Tj 0.05 Tc 10.0265 0 0 10 95.9 558.97 Tm (and )Tj 0.0282 Tc 10 0 0 10 117.01 558.97 Tm (equal )Tj -0.0067 Tc 2.985 0 Td (to )Tj 0.05 Tc 10.5727 0 0 10 160.7 558.97 Tm (or )Tj 0.0285 Tc 10 0 0 10 175.6 558.97 Tm (greater )Tj 0.0354 Tc 3.558 0 Td (than )Tj 0.0458 Tc 2.496 0 Td (that )Tj 0.05 Tc 11.1292 0 0 10 258.61 558.97 Tm (of )Tj 0.0392 Tc 10 0 0 10 273.1 558.97 Tm (the )Tj 0.0251 Tc -21.359 -1.105 Td (histamine )Tj 0.0277 Tc 4.407 0 Td (control )Tj 0.0254 Tc 3.404 0 Td (solution. )Tj 0.034 Tc -6.806 -1.103 Td (Forced )Tj 0.0019 Tc 3.314 0 Td (vital )Tj 0.0214 Tc 2.152 0 Td (capacity )Tj 0.0242 Tc 3.838 0 Td (\(FVC\) )Tj 0.05 Tc 10.0265 0 0 10 193.34 536.89 Tm (and )Tj 0.0042 Tc 10 0 0 10 212.53 536.89 Tm (forced )Tj 0.0313 Tc 2.928 0 Td (expiratory )Tj 0.0161 Tc -18.231 -1.104 Td (volume )Tj -0.035 Tc 9.9195 0 0 10 94 525.85 Tm (in )Tj 0.0327 Tc 10 0 0 10 104.54 525.85 Tm (one )Tj 0.0069 Tc 1.868 0 Td (second )Tj 0.05 Tc 3.17 0 Td (\(FEV )Tj /T1_1 1 Tf 0 Tc 6.2 0 0 6.2 179.32 523.44 Tm (1)Tj 0.556 0.389 Td (\) )Tj /T1_0 1 Tf -0.0055 Tc 10 0 0 10 189.59 525.85 Tm (were )Tj 0.0298 Tc 2.207 0 Td (measured )Tj 0.227 0.227 0.223 rg 0.0226 Tc 4.37 0 Td (using )Tj 0.302 0.302 0.298 rg 0 Tc 2.582 0 Td (a )Tj 0.034 Tc -22.223 -1.056 Td (dry )Tj -0.0044 Tc 2.122 0 Td (bellows )Tj 0.0295 Tc 3.681 0 Td (spirometer )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0217 Tc 10 0 0 10 168.36 515.29 Tm (\(Ohio )Tj EMC /Suspect <>BDC 0.0193 Tc 3.128 0 Td (Mod.840)Tj 0.416 0.42 0.412 rg 0 Tc 3.78 0 Td (, )Tj EMC ET BT 0.227 0.227 0.223 rg /T1_0 1 Tf 0.05 Tc 10.0521 0 0 10 246.19 515.29 Tm (Houston)Tj 0.416 0.42 0.412 rg 0 Tc 10 0 0 10 283.52 515.29 Tm (, )Tj 0.302 0.302 0.298 rg 0.0232 Tc -22.457 -1.104 Td (TX\). )Tj 0.0297 Tc 2.693 0 Td (Methacholine )Tj 0.0273 Tc 6.428 0 Td (inhalation )Tj 0.0188 Tc 4.902 0 Td (test )Tj 0.028 Tc 2.056 0 Td (and )Tj 0.0188 Tc 2.21 0 Td (isocyanate )Tj 0.0327 Tc -18.288 -1.104 Td (inhalation )Tj 0.0128 Tc 4.662 0 Td (tests )Tj 0.0105 Tc 2.161 0 Td (were )Tj 0.0213 Tc 2.295 0 Td (carried )Tj 0.05 Tc 10.261 0 0 10 182.78 493.21 Tm (out )Tj 0.0071 Tc 10 0 0 10 200.56 493.21 Tm (in )Tj -0.013 Tc 1.102 0 Td (all )Tj 0.0152 Tc 1.352 0 Td (the )Tj 0.017 Tc 1.572 0 Td (subjects )Tj 0.05 Tc 10.1194 0 0 10 277.82 493.21 Tm (at )Tj 0.0152 Tc 10 0 0 10 59.5 482.16 Tm (the )Tj 0.0014 Tc 1.584 0 Td (time )Tj 0.05 Tc 10.5727 0 0 10 95.9 482.16 Tm (of )Tj 0.0392 Tc 10 0 0 10 107.5 482.16 Tm (the )Tj 0.0152 Tc 1.529 0 Td (diagnosis )Tj 0.05 Tc 11.1292 0 0 10 164.53 482.16 Tm (of )Tj 0.031 Tc 10 0 0 10 176.06 482.16 Tm (occupational )Tj 0.0327 Tc 5.712 0 Td (asthma. )Tj 0.0477 Tc 3.601 0 Td (The )Tj 0.0351 Tc -21.017 -1.055 Td (method )Tj 0.05 Tc 11.1292 0 0 10 97.33 471.61 Tm (of )Tj 0.227 0.227 0.223 rg 0.0262 Tc 10 0 0 10 112.3 471.61 Tm (methacholine )Tj 0.302 0.302 0.298 rg 0.0327 Tc 6.282 0 Td (inhalation )Tj 0.0028 Tc 4.998 0 Td (test )Tj 0.227 0.227 0.223 rg 0.032 Tc 2.065 0 Td (has )Tj 0.302 0.302 0.298 rg 0.0145 Tc 2.066 0 Td (been )Tj 0.0146 Tc -20.746 -1.105 Td (described )Tj 0.0122 Tc 4.811 0 Td (previously )Tj -0.035 Tc 9.9277 0 0 10 158.64 460.56 Tm ([22]. )Tj -0.0039 Tc 10 0 0 10 184.76 460.56 Tm (Briefly)Tj 0.416 0.42 0.412 rg 0 Tc 2.82 0 Td (, )Tj 0.302 0.302 0.298 rg 0.0207 Tc 1.062 0 Td (aerosols )Tj 0.0105 Tc 4.233 0 Td (were )Tj 0.0266 Tc -20.743 -1.103 Td (generated )Tj -0.0304 Tc 4.713 0 Td (by )Tj 0 Tc 1.525 0 Td (a )Tj 0.227 0.227 0.223 rg 0.0066 Tc 1.061 0 Td (DeVilbiss )Tj -0.0177 Tc 4.601 0 Td (646 )Tj 0.302 0.302 0.298 rg 0.0159 Tc 2.027 0 Td (nebulizer )Tj 0.0097 Tc 4.357 0 Td (\(DeVilbi)Tj 0.416 0.42 0.412 rg 0 Tc 3.646 0 Td (s)Tj 0.302 0.302 0.298 rg 0.432 0 Td (s )Tj 0.0228 Tc -22.316 -1.104 Td (Co.)Tj 0.416 0.42 0.412 rg 0 Tc 1.53 0 Td (, )Tj 0.302 0.302 0.298 rg 0.0183 Tc 0.526 0 Td (Somerset, )Tj ET BT /Suspect <>BDC 0.227 0.227 0.223 rg /T1_0 1 Tf -0.0058 Tc 10 0 0 10 124.76 438.49 Tm (PA\) )Tj EMC ET BT 0.302 0.302 0.298 rg /T1_0 1 Tf 0.0304 Tc 10 0 0 10 143.42 438.49 Tm (connected )Tj -0.0067 Tc 4.664 0 Td (to )Tj 0 Tc 1.096 0 Td (a )Tj 0.227 0.227 0.223 rg 0.0229 Tc 0.869 0 Td (Rosenthal)Tj 0.416 0.42 0.412 rg 0 Tc 4.265 0 Td (-)Tj 0.227 0.227 0.223 rg 0.034 Tc 0.344 0 Td (French )Tj 0.302 0.302 0.298 rg 0.0307 Tc -19.733 -1.056 Td (dosimeter )Tj 0.0395 Tc 4.557 0 Td (\(R\) )Tj 0.0372 Tc 1.776 0 Td [(\(John )-144(Hopkins )]TJ 0.0145 Tc 6.875 0 Td (University, )Tj 0.227 0.227 0.223 rg 0.0256 Tc 5.037 0 Td (Baltimore)Tj 0.416 0.42 0.412 rg 0 Tc 4.212 0 Td (, )Tj 0.227 0.227 0.223 rg 0.0413 Tc -22.404 -1.104 Td (MA\))Tj 0.416 0.42 0.412 rg 0 Tc 2.1 0 Td (, )Tj 0.302 0.302 0.298 rg 0.0288 Tc 0.439 0 Td (driven )Tj 0.0176 Tc 2.986 0 Td (by )Tj 0.0168 Tc 1.237 0 Td (compressed )Tj 0.0174 Tc 5.184 0 Td (air. )Tj 0.0057 Tc 1.734 0 Td (Five )Tj 0.0289 Tc 2.06 0 Td (inhalations )Tj -0.0055 Tc 4.951 0 Td (were )Tj 0.0358 Tc -20.737 -1.105 Td (taken )Tj 0.0074 Tc 3.015 0 Td (for )Tj 0.227 0.227 0.223 rg 0.0235 Tc 1.885 0 Td (phosphate-buffered )Tj 0.302 0.302 0.298 rg 0.0193 Tc 8.768 0 Td (saline )Tj 0.05 Tc 10.0265 0 0 10 225.5 405.84 Tm (and )Tj 0.0314 Tc 10 0 0 10 247.57 405.84 Tm (for )Tj 0.0209 Tc 1.872 0 Td (each )Tj 0.227 0.227 0.223 rg 0.0125 Tc -20.781 -1.103 Td (increasing, )Tj 0.302 0.302 0.298 rg 0.0284 Tc 4.895 0 Td (doubling )Tj 0.0163 Tc 4.128 0 Td (dose )Tj 0.05 Tc 11.1292 0 0 10 171.25 394.81 Tm (of )Tj 0.0262 Tc 10 0 0 10 183.34 394.81 Tm (methacholine )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0094 Tc 10 0 0 10 243.72 394.81 Tm (\(0.5 )Tj EMC ET BT /T1_0 1 Tf 0.0413 Tc 10 0 0 10 263.5 394.81 Tm (to )Tj -0.0154 Tc 1.19 0 Td (64 )Tj 0.0271 Tc -21.734 -1.056 Td (mgjml\) )Tj 0.0251 Tc 3.448 0 Td (administered )Tj 0.05 Tc 10.7518 0 0 10 151.09 384.25 Tm (at )Tj 0 Tc 10 0 0 10 163.06 384.25 Tm (5 )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0412 Tc 10 0 0 10 171.34 384.25 Tm (min )Tj EMC ET BT /T1_0 1 Tf 0.0161 Tc 10 0 0 10 191.44 384.25 Tm (intervals)Tj 0.416 0.42 0.412 rg 0 Tc 3.64 0 Td (, )Tj 0.227 0.227 0.223 rg 0.0224 Tc 0.592 0 Td (until )Tj 0.302 0.302 0.298 rg 0 Tc 2.342 0 Td (a )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.05 Tc 10.0309 0 0 10 265.38 384.25 Tm (20% )Tj EMC ET BT /T1_0 1 Tf -0.0337 Tc 10 0 0 10 58.45 373.21 Tm (fall )Tj 0.0071 Tc 1.587 0 Td (in )Tj 0.0486 Tc 1.06 0 Td (FEV )Tj 0 Tc 6.2 0 0 6.2 106.35 370.81 Tm (1 )Tj -0.0068 Tc 10 0 0 10 112.31 373.21 Tm (was )Tj 0.0183 Tc 1.815 0 Td (observed. )Tj 0.0486 Tc 4.326 0 Td (FEY )Tj 0 Tc 6.2 0 0 6.2 194.67 370.81 Tm (1 )Tj -0.0068 Tc 10 0 0 10 200.63 373.21 Tm (was )Tj 0.0229 Tc 1.823 0 Td (measured )Tj 0 Tc 4.31 0 Td (3 )Tj 0.0172 Tc 0.73 0 Td (min )Tj 0.0375 Tc -21.128 -1.105 Td (after )Tj 0.0152 Tc 2.648 0 Td (the )Tj 0.0176 Tc 1.923 0 Td (beginning )Tj 0.05 Tc 11.1292 0 0 10 151.09 362.16 Tm (of )Tj 0.0209 Tc 10 0 0 10 165.49 362.16 Tm (each )Tj 0.0341 Tc 2.541 0 Td (set )Tj 0.05 Tc 11.1292 0 0 10 208.69 362.16 Tm (of )Tj 0.227 0.227 0.223 rg 0.0289 Tc 10 0 0 10 223.6 362.16 Tm (inhalations )Tj 0.302 0.302 0.298 rg 0.05 Tc 11.1292 0 0 10 276.37 362.16 Tm (of )Tj 0.0167 Tc 10 0 0 10 57.98 351.12 Tm (aerosolized )Tj 0.0192 Tc 5.24 0 Td (methacholine. )Tj 0.0162 Tc 6.432 0 Td (Airway )Tj 0.227 0.227 0.223 rg 0.0115 Tc 3.553 0 Td (responsiveness )Tj 0.302 0.302 0.298 rg 0.0413 Tc 6.671 0 Td (to )Tj 0.0262 Tc -21.888 -1.103 Td (methacholine )Tj -0.0068 Tc 6.481 0 Td (was )Tj 0.0229 Tc 2.351 0 Td (measured )Tj 0.0392 Tc 4.8 0 Td (the )Tj 0.227 0.227 0.223 rg 0.027 Tc 2.057 0 Td (day )Tj 0.0195 Tc 2.314 0 Td (before )Tj 0.302 0.302 0.298 rg 0.0392 Tc 3.405 0 Td (the )Tj 0.038 Tc -21.462 -1.056 Td (inhalation )Tj 0.0163 Tc 5.422 0 Td (challenge )Tj 0.0015 Tc 5.001 0 Td (with )Tj 0.0224 Tc 2.927 0 Td (toluene )Tj 0.027 Tc 4.121 0 Td (diisocyanate )Tj -0.0233 Tc -17.427 -1.104 Td (\(TDT\))Tj 0.416 0.42 0.412 rg 0 Tc 2.583 0 Td (. )Tj 0.302 0.302 0.298 rg 0.0225 Tc 0.833 0 Td (Most )Tj 0.0331 Tc 2.778 0 Td (asthmatic )Tj 0.0239 Tc 4.716 0 Td (patients )Tj -0.035 Tc 9.9195 0 0 10 205.84 318.49 Tm (in )Tj 0.05 Tc 10.194 0 0 10 219.74 318.49 Tm (our )Tj 0.0415 Tc 10 0 0 10 239.92 318.49 Tm (laboratory )Tj 0.227 0.227 0.223 rg 0.0246 Tc -18.185 -1.105 Td (respond )Tj 0.302 0.302 0.298 rg -0.0067 Tc 3.791 0 Td (to )Tj -0.0143 Tc 1.146 0 Td (less )Tj 0.05 Tc 10.0233 0 0 10 125.74 307.44 Tm (than )Tj 0 Tc 10 0 0 10 149.41 307.44 Tm (1 )Tj 0.0234 Tc 0.753 0 Td (mg )Tj 0.05 Tc 11.1292 0 0 10 173.17 307.44 Tm (of )Tj 0.0262 Tc 10 0 0 10 185.74 307.44 Tm (methacholine )Tj 0.0106 Tc 6.05 0 Td (using )Tj 0.0152 Tc 2.59 0 Td (the )Tj 0.0292 Tc -21.462 -1.103 Td (generation )Tj 0.0069 Tc 4.842 0 Td (system )Tj 0.0146 Tc 3.221 0 Td (described )Tj 0.0222 Tc 4.319 0 Td (above. )Tj 0.05 Tc 10.2656 0 0 10 67.11 285.84 Tm (The )Tj 0.0284 Tc 10 0 0 10 91.18 285.84 Tm (methods )Tj 0.05 Tc 11.1292 0 0 10 133.81 285.84 Tm (of )Tj 0.0224 Tc 10 0 0 10 149.74 285.84 Tm (toluene )Tj 0.0226 Tc 3.785 0 Td (diisocyanate )Tj 0.05 Tc 10.0265 0 0 10 246.62 285.84 Tm (and )Tj 0.227 0.227 0.223 rg 0.0404 Tc 10 0 0 10 269.24 285.84 Tm (4,4' )Tj 0.302 0.302 0.298 rg 0.016 Tc -21.173 -1.103 Td (diphenyl )Tj 0.0369 Tc 4.039 0 Td (methane )Tj 0.0226 Tc 4.025 0 Td (diisocyanate )Tj 0.227 0.227 0.223 rg 0.0327 Tc 5.665 0 Td (inhalation )Tj 0.302 0.302 0.298 rg 0.0126 Tc 4.711 0 Td (have )Tj -0.0015 Tc 2.354 0 Td (been )Tj 0.0146 Tc -20.794 -1.105 Td (described )Tj -0.035 Tc 9.9195 0 0 10 106 263.76 Tm (in )Tj 0.0192 Tc 10 0 0 10 122.31 263.76 Tm (detail )Tj 0.0176 Tc 3.227 0 Td (previously )Tj -0.035 Tc 9.982 0 0 10 206.64 263.76 Tm ([21, )Tj 9.8692 0 0 10 230.34 263.76 Tm (29]. )Tj 0.227 0.227 0.223 rg -0.0119 Tc 10 0 0 10 254.36 263.76 Tm (Briefly)Tj 0.416 0.42 0.412 rg 0 Tc 2.82 0 Td (, )Tj 0.302 0.302 0.298 rg 0.017 Tc -22.51 -1.103 Td (subjects )Tj -0.0215 Tc 3.757 0 Td (were )Tj 0.0095 Tc 2.294 0 Td (exposed )Tj 0.0413 Tc 3.801 0 Td (to )Tj 0.0304 Tc 1.248 0 Td (toluene )Tj 0.027 Tc 3.449 0 Td (diisocyanate )Tj 0.046 Tc 5.661 0 Td (\(TDI\) )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0094 Tc 10 0 0 10 57.48 241.69 Tm (\(0.0 )Tj EMC ET BT 0.227 0.227 0.223 rg /T1_0 1 Tf -0.035 Tc 9.1317 0 0 10 74.56 241.69 Tm (18 )Tj 0.416 0.42 0.412 rg 0 Tc 10 0 0 10 84.95 241.69 Tm (\261 )Tj ET BT /Suspect <>BDC 0.302 0.302 0.298 rg /T1_0 1 Tf 0.0069 Tc 10 0 0 10 93.02 241.69 Tm (0.005 )Tj EMC ET BT /T1_0 1 Tf 0.0357 Tc 10 0 0 10 118.58 241.69 Tm (ppm\) )Tj 0.05 Tc 10.5727 0 0 10 143.9 241.69 Tm (or )Tj 0.0306 Tc 10 0 0 10 155.48 241.69 Tm (4,4)Tj 0.416 0.42 0.412 rg 0 Tc 1.289 0 Td (' )Tj 0.302 0.302 0.298 rg 0.0229 Tc 0.53 0 Td (diphenyl )Tj 0.0369 Tc 3.943 0 Td (methane )Tj 0.227 0.227 0.223 rg 0.0009 Tc 3.881 0 Td (diisocy\255)Tj 0.302 0.302 0.298 rg 0.0403 Tc -19.441 -1.104 Td (anate )Tj 0.05 Tc 10.1466 0 0 10 86.28 230.65 Tm (\(MDI\) )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.004 Tc 10 0 0 10 120.84 230.65 Tm (\(0.016)Tj 0.416 0.42 0.412 rg 0 Tc 2.747 0 Td (\261)Tj 0.302 0.302 0.298 rg -0.0291 Tc 0.807 0 Td (0.001 )Tj EMC ET BT 0.227 0.227 0.223 rg /T1_0 1 Tf 0.0357 Tc 10 0 0 10 185.3 230.65 Tm (ppm\) )Tj -0.035 Tc 9.9195 0 0 10 214 230.65 Tm (in )Tj 0.302 0.302 0.298 rg 0 Tc 10 0 0 10 227.42 230.65 Tm (a )Tj 0.0198 Tc 1.113 0 Td (nine )Tj 0.0283 Tc 2.343 0 Td (cubic )Tj 0.0209 Tc -20.44 -1.056 Td (metre )Tj 0.0291 Tc 3.015 0 Td (exposure )Tj 0.0313 Tc 4.465 0 Td (chamber. )Tj 0 Tc 4.664 0 Td (A )Tj -0.0236 Tc 1.431 0 Td (fan )Tj 0.227 0.227 0.223 rg -0.035 Tc 9.9195 0 0 10 213.52 220.09 Tm (in )Tj 0.302 0.302 0.298 rg 0.0152 Tc 10 0 0 10 228.46 220.09 Tm (the )Tj 0.0462 Tc 1.912 0 Td (chamber )Tj 0.0293 Tc -19.057 -1.104 Td (ensured )Tj 0.0432 Tc 3.745 0 Td (adequate )Tj 0.0203 Tc 4.328 0 Td (mixing )Tj 0.05 Tc 10.3398 0 0 10 171.25 209.05 Tm (and )Tj 0.0186 Tc 10 0 0 10 191.9 209.05 Tm (circulation. )Tj 0.0477 Tc 5.233 0 Td (The )Tj 0.0148 Tc 2.119 0 Td (tem\255)Tj 0.0344 Tc -20.78 -1.104 Td (perature )Tj -0.035 Tc 9.9195 0 0 10 98.32 198.01 Tm (in )Tj 0.0152 Tc 10 0 0 10 111.82 198.01 Tm (the )Tj 0.0462 Tc 1.768 0 Td (chamber )Tj -0.0068 Tc 4.281 0 Td (was )Tj 0.0302 Tc 2.111 0 Td (maintained )Tj 0.05 Tc 10.1194 0 0 10 246.14 198.01 Tm (at )Tj 10.1622 0 0 10 259.58 198.01 Tm (about )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0211 Tc 10 0 0 10 57.06 186.97 Tm (24)Tj 0.416 0.42 0.412 rg 0 Tc 1 0 Td (\260)Tj 0.302 0.302 0.298 rg 0.0176 Tc 0.388 0 Td (C. )Tj EMC ET BT /T1_0 1 Tf 0.0477 Tc 10 0 0 10 83.91 186.97 Tm (The )Tj 0.0467 Tc 1.968 0 Td (duration )Tj 0.05 Tc 11.1292 0 0 10 143.89 186.97 Tm (of )Tj 0.0291 Tc 10 0 0 10 155.89 186.97 Tm (exposure )Tj -0.0068 Tc 4.186 0 Td (was )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0031 Tc 10 0 0 10 216.84 186.97 Tm (30 )Tj EMC ET BT /T1_0 1 Tf 0.0081 Tc 10 0 0 10 229.9 186.97 Tm (min, )Tj 0.05 Tc 11.1292 0 0 10 251.89 186.97 Tm (or )Tj -0.0016 Tc 10 0 0 10 265.44 186.97 Tm (until )Tj 0.0392 Tc -20.834 -1.056 Td (the )Tj 0.0356 Tc 1.528 0 Td (appearance )Tj 0.05 Tc 11.1292 0 0 10 123.25 176.41 Tm (of )Tj 0.0406 Tc 10 0 0 10 134.26 176.41 Tm (symptoms )Tj 0.05 Tc 10.5727 0 0 10 180.86 176.41 Tm (of )Tj 0.0316 Tc 10 0 0 10 191.9 176.41 Tm (asthma )Tj 0.227 0.227 0.223 rg 0.0071 Tc 3.314 0 Td (in )Tj 0.302 0.302 0.298 rg 0.0152 Tc 1.11 0 Td (the )Tj 0.017 Tc 1.476 0 Td (subjects )Tj 0.0052 Tc -19.379 -1.104 Td (who )Tj 0.0219 Tc 2.44 0 Td (developed )Tj 0.0281 Tc 4.991 0 Td (an )Tj 0.0219 Tc 1.679 0 Td (early )Tj 0.0391 Tc 2.785 0 Td (asthmatic )Tj 0.0206 Tc 4.857 0 Td (reaction)Tj 0.416 0.42 0.412 rg 0 Tc 3.436 0 Td (. )Tj 0.227 0.227 0.223 rg 0.0477 Tc 0.876 0 Td (The )Tj 0.302 0.302 0.298 rg 0.0367 Tc -21.121 -1.104 Td (concentration )Tj 0.05 Tc 11.1292 0 0 10 118.45 154.33 Tm (of )Tj 0.0212 Tc 10 0 0 10 130 154.33 Tm (isocyanates )Tj 0.0266 Tc 5.136 0 Td (generated )Tj -0.0068 Tc 4.375 0 Td (was )Tj 0.0298 Tc 1.871 0 Td (measured )Tj 0.227 0.227 0.223 rg 0.0015 Tc -18.671 -1.104 Td (with )Tj 0.302 0.302 0.298 rg 0 Tc 2.631 0 Td (a )Tj 0.227 0.227 0.223 rg 0.05 Tc 10.1055 0 0 10 96.91 143.29 Tm (MDA )Tj 0.302 0.302 0.298 rg 0.0129 Tc 10 0 0 10 130.54 143.29 Tm (model )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0185 Tc 10 0 0 10 165.01 143.29 Tm (7005 )Tj EMC ET BT /T1_0 1 Tf 0.0241 Tc 10 0 0 10 192.88 143.29 Tm (isocyanate )Tj 0.227 0.227 0.223 rg 0.0236 Tc 5.231 0 Td (detection )Tj 0.302 0.302 0.298 rg 0.0333 Tc -18.866 -1.056 Td (equipment )Tj 0.05 Tc 10.2964 0 0 10 105 132.73 Tm (\(MDA )Tj 0.0001 Tc 10 0 0 10 137.58 132.73 Tm (Scientific )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0157 Tc 10 0 0 10 179.93 132.73 Tm (Inc., )Tj EMC ET BT /T1_0 1 Tf 0.0071 Tc 10 0 0 10 201.98 132.73 Tm (Glenview, )Tj 0.227 0.227 0.223 rg 0.0242 Tc 4.563 0 Td (IL\). )Tj 0.302 0.302 0.298 rg 0.05 Tc 10.2656 0 0 10 267.27 132.73 Tm (The )Tj 0.0207 Tc 10 0 0 10 56.5 121.68 Tm (subject )Tj 0.0172 Tc 3.565 0 Td (was )Tj 0.0245 Tc 2.147 0 Td (seated )Tj 0.008 Tc 3.22 0 Td (close )Tj 0.0413 Tc 2.696 0 Td (to )Tj 0.0152 Tc 1.488 0 Td (the )Tj 0.0414 Tc 1.872 0 Td (monitor )Tj 0.05 Tc 10.3398 0 0 10 246.13 121.68 Tm (and )Tj -0.0068 Tc 10 0 0 10 268.79 121.68 Tm (was )Tj 0.0223 Tc -21.225 -1.104 Td (observed )Tj 0.0421 Tc 4.088 0 Td (through )Tj 0.0152 Tc 3.696 0 Td (the )Tj 0.0151 Tc 1.537 0 Td (windows )Tj 0.05 Tc 11.1292 0 0 10 189.97 110.64 Tm (of )Tj 0.0152 Tc 10 0 0 10 202.06 110.64 Tm (the )Tj 0.0462 Tc 1.48 0 Td (chamber)Tj 0.416 0.42 0.412 rg 0 Tc 3.733 0 Td (. )Tj 0.302 0.302 0.298 rg 0.0486 Tc 0.545 0 Td (FEY )Tj 0.227 0.227 0.223 rg 0 Tc 6.5001 0 0 6.5001 280.58 108.25 Tm (1 )Tj -0.0068 Tc 10 0 0 10 56.63 99.6 Tm (was )Tj 0.302 0.302 0.298 rg 0.0161 Tc 1.919 0 Td [(measured )-135(immediately )]TJ 0.227 0.227 0.223 rg 0.0195 Tc 9.891 0 Td (before )Tj 0.302 0.302 0.298 rg 0.05 Tc 10.0265 0 0 10 204.38 99.6 Tm (and )Tj 0.0375 Tc 10 0 0 10 223.58 99.6 Tm (after )Tj 0.0291 Tc 2.255 0 Td (exposure )Tj 0.0413 Tc 6.489 65.52 Td (to )Tj 0.014 Tc 1.626 0 Td (isocyanates, )Tj 0.0354 Tc 5.766 0 Td (then )Tj 0.026 Tc 2.593 0 Td (hourly )Tj 0.0314 Tc 3.494 0 Td (for )Tj 0 Tc 1.961 0 Td (8 )Tj 0.0219 Tc 1.265 0 Td (h. )Tj 0.227 0.227 0.223 rg 0.0423 Tc 1.53 0 Td (Inhalation )Tj 0.302 0.302 0.298 rg 0.0163 Tc -18.291 -1.056 Td (challenge )Tj 0.0175 Tc 4.377 0 Td (with )Tj -0.0182 Tc 2.253 0 Td (MD1 )Tj -0.0068 Tc 2.595 0 Td (was )Tj 0.0293 Tc 1.959 0 Td (carried )Tj 0.05 Tc 10.6148 0 0 10 455.9 744.24 Tm (out )Tj 10.6555 0 0 10 474.63 744.24 Tm (in )Tj 0.0217 Tc 10 0 0 10 487.09 744.24 Tm (eight )Tj 0.05 Tc 11.1292 0 0 10 512.05 744.24 Tm (of )Tj 0.0152 Tc 10 0 0 10 525.58 744.24 Tm (the )Tj 0.227 0.227 0.223 rg -0.035 Tc 9.5393 0 0 10 312.15 733.21 Tm (162 )Tj 0.302 0.302 0.298 rg 0.0077 Tc 10 0 0 10 329.14 733.21 Tm (subjects. )Tj -0.0099 Tc -0.82 -1.104 Td (Specific )Tj 0.227 0.227 0.223 rg 0.0299 Tc 3.995 0 Td (IgE )Tj 0.302 0.302 0.298 rg 0.025 Tc 2.301 0 Td (antibodies )Tj 0.0413 Tc 5.192 0 Td (to )Tj 0.227 0.227 0.223 rg 0.05 Tc 10.0676 0 0 10 452.07 722.17 Tm (TDI-human )Tj 0.302 0.302 0.298 rg 0.0318 Tc 10 0 0 10 512.02 722.17 Tm (serum )Tj 0.0242 Tc -20.108 -1.056 Td (albumin )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0374 Tc 10 0 0 10 350.76 711.61 Tm (\(TDI-HSA\) )Tj EMC ET BT /T1_0 1 Tf 0.05 Tc 10.0265 0 0 10 405.5 711.61 Tm (and )Tj 0.227 0.227 0.223 rg 0.0413 Tc 10 0 0 10 427.18 711.61 Tm (to )Tj ET BT /Suspect <>BDC 0.302 0.302 0.298 rg /T1_0 1 Tf 0.05 Tc 10.3227 0 0 10 441.07 711.61 Tm (MDl-HSA )Tj EMC ET BT /T1_0 1 Tf 0.0289 Tc 10 0 0 10 492.38 711.61 Tm (conjugates )Tj -0.0055 Tc -18.135 -1.105 Td (were )Tj 0.0161 Tc 2.495 0 Td (measured )Tj 0.0071 Tc 4.506 0 Td (in )Tj 0.0236 Tc 1.343 0 Td (duplicate )Tj -0.0304 Tc 4.426 0 Td (by )Tj 0.0325 Tc 1.534 0 Td (radioallergosorbent )Tj 0.0188 Tc -14.305 -1.103 Td (test )Tj 0.0087 Tc 2.553 0 Td ({RAST, )Tj 0.033 Tc 4.549 0 Td (Pharmacia )Tj 0.227 0.227 0.223 rg 0.0335 Tc 5.615 0 Td (Diagnostic, )Tj 0.0459 Tc 6.1 0 Td (Uppsala, )Tj 0.302 0.302 0.298 rg 0.0149 Tc -18.881 -1.105 Td (Sweden\) )Tj -0.035 Tc 9.9195 0 0 10 353.2 678.48 Tm (in )Tj 8.6772 0 0 10 368.05 678.48 Tm (61 )Tj 0.0077 Tc 10 0 0 10 384.34 678.48 Tm (subjects. )Tj 0.227 0.227 0.223 rg 0.0174 Tc 4.284 0 Td (Allergo-Discs )Tj 0.302 0.302 0.298 rg 0.0284 Tc 6.523 0 Td (Isocyanate )Tj 0.0016 Tc -18.147 -1.056 Td (allergen )Tj 0.0319 Tc 3.66 0 Td (preparations )Tj -0.0002 Tc 5.661 0 Td (when )Tj -0.0025 Tc 2.545 0 Td (used )Tj 0.0071 Tc 2.248 0 Td (in )Tj 0.227 0.227 0.223 rg 0.0459 Tc 1.108 0 Td (Phadebas )Tj 0.302 0.302 0.298 rg 0.0316 Tc 4.463 0 Td (RAST, )Tj 0.0413 Tc -19.677 -1.103 Td (to )Tj 0.0221 Tc 1.392 0 Td (measure )Tj 0.0392 Tc 4.032 0 Td (the )Tj 0.227 0.227 0.223 rg -0.0252 Tc 1.866 0 Td (level )Tj 0.302 0.302 0.298 rg 0.05 Tc 11.1292 0 0 10 407.89 656.89 Tm (of )Tj 0.0214 Tc 10 0 0 10 422.3 656.89 Tm (circulating )Tj 0.227 0.227 0.223 rg 0.05 Tc 10.4366 0 0 10 472.71 656.89 Tm (lgE )Tj 0.302 0.302 0.298 rg 0.0303 Tc 10 0 0 10 493.82 656.89 Tm (antibodies )Tj -0.008 Tc -18.34 -1.056 Td (specific )Tj 0.0413 Tc 3.324 0 Td (to )Tj 0.0085 Tc 1.1 0 Td (2,4 )Tj 0.028 Tc 1.532 0 Td (and )Tj -0.0155 Tc 1.828 0 Td (2,6 )Tj 0.0224 Tc 1.54 0 Td (toluene )Tj 0.0314 Tc 3.305 0 Td (diisocyanate )Tj 0.05 Tc 10.0265 0 0 10 492.38 646.33 Tm (and )Tj 0.0413 Tc 10 0 0 10 511.18 646.33 Tm (to )Tj 0.227 0.227 0.223 rg 0 Tc 1.102 0 Td (4)Tj 0.416 0.42 0.412 rg 0.516 0 Td (,)Tj 0.227 0.227 0.223 rg 0.05 Tc 10.0742 0 0 10 529.88 646.33 Tm (4' )Tj 0.302 0.302 0.298 rg 0.0269 Tc 10 0 0 10 310.47 635.29 Tm (diphenylmethane )Tj 0.0199 Tc 8.16 0 Td (diisocyanate. )Tj 0.227 0.227 0.223 rg 0.0251 Tc 6.436 0 Td (Discs )Tj 0.302 0.302 0.298 rg 0.0175 Tc 3.22 0 Td (with )Tj 0.227 0.227 0.223 rg 0.0376 Tc 2.78 0 Td (HSA )Tj 0.302 0.302 0.298 rg 0.0115 Tc -20.601 -1.105 Td (served )Tj 0.0431 Tc 3.268 0 Td (as )Tj 0.0357 Tc 1.488 0 Td (control)Tj 0.416 0.42 0.412 rg 0 Tc 3.114 0 Td (, )Tj 0.302 0.302 0.298 rg 0.027 Tc 0.822 0 Td (correcting )Tj 0.0314 Tc 4.895 0 Td (for )Tj 0.028 Tc 1.921 0 Td (any )Tj 0.0052 Tc 2.217 0 Td (non-specific )Tj 0.0206 Tc -17.662 -1.056 Td (binding )Tj 0.05 Tc 11.1292 0 0 10 347.41 613.68 Tm (of )Tj 10.0505 0 0 10 360.89 613.68 Tm (IgE )Tj 0.0413 Tc 10 0 0 10 381.1 613.68 Tm (to )Tj 0.227 0.227 0.223 rg 0.0136 Tc 1.389 0 Td (HSA )Tj 0.302 0.302 0.298 rg 0.05 Tc 10.2564 0 0 10 420.38 613.68 Tm (on )Tj 0.0152 Tc 10 0 0 10 436.78 613.68 Tm (the )Tj 0.0265 Tc 1.722 0 Td (isocyanate-albumin )Tj -0.0158 Tc -14.353 -1.103 Td (discs. )Tj 0.227 0.227 0.223 rg 0.0477 Tc 2.736 0 Td (The )Tj 0.302 0.302 0.298 rg 0.0075 Tc 2.168 0 Td (result )Tj 0.0172 Tc 2.784 0 Td (was )Tj 0.008 Tc 2.054 0 Td (expressed )Tj 0.0431 Tc 4.513 0 Td (as )Tj 0 Tc 1.392 0 Td (a )Tj 0.0346 Tc 1.017 0 Td (ratio )Tj 0.05 Tc 10.5727 0 0 10 501.98 602.65 Tm (of )Tj 10.1335 0 0 10 515.43 602.65 Tm (TDI\255)Tj 10.0003 0 0 10 309.98 591.61 Tm (count )Tj 0.0454 Tc 10 0 0 10 337.91 591.61 Tm (rate )Tj 0.05 Tc 10.0163 0 0 10 357.98 591.61 Tm (or )Tj 0.227 0.227 0.223 rg 10.0196 0 0 10 370.52 591.61 Tm (MDI-count )Tj 0.0454 Tc 10 0 0 10 423.35 591.61 Tm (rate )Tj 0.302 0.302 0.298 rg 0.0413 Tc 2.015 0 Td (to )Tj 0.05 Tc 10.215 0 0 10 455.98 591.61 Tm (that )Tj 11.1292 0 0 10 476.05 591.61 Tm (of )Tj 0.227 0.227 0.223 rg 0.0383 Tc 10 0 0 10 488.59 591.61 Tm (HSA-count )Tj 0.302 0.302 0.298 rg 0.0294 Tc -17.804 -1.105 Td (rate )Tj 0.0074 Tc 2.15 0 Td (for )Tj 0.0209 Tc 1.728 0 Td (each )Tj 0.011 Tc 2.397 0 Td (sample. )Tj 0.227 0.227 0.223 rg 0 Tc 3.756 0 Td (A )Tj 0.302 0.302 0.298 rg 0.0466 Tc 1.201 0 Td (ratio )Tj 0.05 Tc 10.5727 0 0 10 448.7 580.56 Tm (of )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0085 Tc 10 0 0 10 462.66 580.56 Tm (2.0 )Tj EMC ET BT /T1_0 1 Tf 0.05 Tc 10.5727 0 0 10 480.38 580.56 Tm (or )Tj 0.0371 Tc 10 0 0 10 494.38 580.56 Tm (more )Tj -0.0068 Tc 2.737 0 Td (was )Tj 0.0227 Tc -21.177 -1.056 Td (considered )Tj 0 Tc 4.896 0 Td (a )Tj 0.0157 Tc 0.828 0 Td (positive )Tj -0.0004 Tc 3.644 0 Td (test. )Tj 0.227 0.227 0.223 rg 0.0323 Tc -1.984 -2.735 Td (Statistical )Tj 0.0082 Tc 4.616 0 Td (analysis )Tj 0.05 Tc 10.2355 0 0 10 320.14 526.33 Tm (An )Tj 0.302 0.302 0.298 rg 0.0213 Tc 10 0 0 10 341.2 526.33 Tm (immediate )Tj 0.05 Tc 10.5727 0 0 10 393.02 526.33 Tm (or )Tj 10.0592 0 0 10 409.82 526.33 Tm (dual )Tj 0.0391 Tc 10 0 0 10 436.7 526.33 Tm (asthmatic )Tj 0.227 0.227 0.223 rg 0.0275 Tc 4.953 0 Td (reaction )Tj 0.302 0.302 0.298 rg -0.0067 Tc 4.271 0 Td (to )Tj 0.0212 Tc -21.894 -1.104 Td (isocyanates )Tj -0.0068 Tc 5.479 0 Td (was )Tj 0.0227 Tc 2.151 0 Td (considered )Tj 0.05 Tc 10.4772 0 0 10 438.21 515.29 Tm (to )Tj 0.0383 Tc 10 0 0 10 453.5 515.29 Tm (occur )Tj -0.0002 Tc 3.033 0 Td (when )Tj 0.227 0.227 0.223 rg 0.0486 Tc 2.925 0 Td (FEY )Tj 0.302 0.302 0.298 rg 0 Tc 6.2 0 0 6.2 534.03 512.89 Tm (1 )Tj 0.013 Tc 10 0 0 10 309.99 504.25 Tm (decreased )Tj 0.0176 Tc 4.33 0 Td (by )Tj 0.227 0.227 0.223 rg 0.05 Tc 10.1194 0 0 10 366.14 504.25 Tm (at )Tj 0.302 0.302 0.298 rg 0.0266 Tc 10 0 0 10 376.24 504.25 Tm (least )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.029 Tc 10 0 0 10 397.86 504.25 Tm (20% )Tj EMC ET BT /T1_0 1 Tf 0.0179 Tc 10 0 0 10 419.89 504.25 Tm (from )Tj 0.0139 Tc 2.364 0 Td (baseline )Tj 0.0183 Tc 3.598 0 Td (within )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0031 Tc 10 0 0 10 508.68 504.25 Tm (30 )Tj EMC /Suspect <>BDC 0.0172 Tc 1.21 0 Td (min )Tj EMC ET BT /T1_0 1 Tf 0.018 Tc 10 0 0 10 309.96 493.69 Tm (\(early )Tj 0.0415 Tc 2.69 0 Td (component )Tj 0.05 Tc 11.1292 0 0 10 387.25 493.69 Tm (of )Tj 0 Tc 10 0 0 10 399.26 493.69 Tm (a )Tj 0.0377 Tc 0.769 0 Td (dual )Tj 0.0343 Tc 2.168 0 Td (reaction )Tj 0.05 Tc 10.5727 0 0 10 466.46 493.69 Tm (or )Tj 0.0219 Tc 10 0 0 10 478.45 493.69 Tm (early )Tj 0.0206 Tc 2.458 0 Td (reaction )Tj 0.0214 Tc -19.305 -1.104 Td (alone\) )Tj 0.05 Tc 10.0265 0 0 10 339.74 482.65 Tm (and )Tj 10.088 0 0 10 359.42 482.65 Tm (one )Tj 10.5727 0 0 10 378.62 482.65 Tm (or )Tj 0.0211 Tc 10 0 0 10 392.14 482.65 Tm (more )Tj 0.0455 Tc 2.545 0 Td (hours )Tj 0.0295 Tc 2.773 0 Td (\(late )Tj 0.0475 Tc 2.258 0 Td (component )Tj 0.05 Tc 11.1292 0 0 10 519.73 482.65 Tm (of )Tj 0 Tc 10 0 0 10 532.22 482.65 Tm (a )Tj 0.0217 Tc -22.223 -1.104 Td (dual )Tj 0.0206 Tc 2.168 0 Td (reaction )Tj 0.05 Tc 10.5727 0 0 10 368.54 471.61 Tm (or )Tj 0.227 0.227 0.223 rg 0.0211 Tc 10 0 0 10 380.56 471.61 Tm (late )Tj 0.302 0.302 0.298 rg 0.0206 Tc 1.831 0 Td (reaction )Tj 0.227 0.227 0.223 rg 0.0214 Tc 3.687 0 Td (alone\) )Tj 0.302 0.302 0.298 rg 0.0375 Tc 2.928 0 Td (after )Tj 0.0291 Tc 2.255 0 Td (exposure )Tj 0.0413 Tc 4.089 0 Td (to )Tj 0.0184 Tc -21.894 -1.105 Td (isocyanates. )Tj 0.05 Tc 10.074 0 0 10 319.59 450 Tm (To )Tj 0.0034 Tc 10 0 0 10 338.78 450 Tm (assess )Tj 0.0154 Tc 3.168 0 Td (airway )Tj 0.0134 Tc 3.561 0 Td (responsiveness, )Tj 0.0209 Tc 7.144 0 Td (dose-response )Tj 0.02 Tc -16.801 -1.103 Td (curves )Tj 0.0413 Tc 3.08 0 Td (to )Tj 0.0219 Tc 1.248 0 Td (methacholine )Tj -0.0055 Tc 6.049 0 Td (were )Tj 0.0359 Tc 2.247 0 Td (constructed )Tj 0.227 0.227 0.223 rg 0.0176 Tc 5.387 0 Td (by )Tj 0.0304 Tc 1.393 0 Td (plotting )Tj 0.302 0.302 0.298 rg 0.0152 Tc -19.348 -1.104 Td (the )Tj 0.0071 Tc 1.635 0 Td (baseline )Tj 0.0126 Tc 3.693 0 Td (value )Tj 0.0314 Tc 2.535 0 Td (for )Tj 0.0486 Tc 1.591 0 Td (FEY )Tj 0 Tc 6.2 0 0 6.2 425.55 426 Tm (1 )Tj 0.05 Tc 10.3398 0 0 10 431.89 427.93 Tm (and )Tj 0.0392 Tc 10 0 0 10 451.66 427.93 Tm (the )Tj 0.0303 Tc 1.636 0 Td (peak )Tj 0.0126 Tc 2.348 0 Td (value )Tj 0.0255 Tc 2.584 0 Td (after )Tj 0.0209 Tc -20.785 -1.104 Td (each )Tj 0.0262 Tc 2.313 0 Td (methacholine )Tj 0.0323 Tc 6.041 0 Td (dose )Tj 0.0343 Tc 2.303 0 Td (against )Tj 0.227 0.227 0.223 rg 0.0392 Tc 3.416 0 Td (the )Tj 0.302 0.302 0.298 rg 0.0266 Tc 1.672 0 Td (cumulative )Tj 0.227 0.227 0.223 rg 0.0323 Tc 5.041 0 Td (dose )Tj 0.302 0.302 0.298 rg 0.0162 Tc -20.787 -1.105 Td (\(nebulizer )Tj 0.227 0.227 0.223 rg 0.05 Tc 10.1739 0 0 10 354.62 405.84 Tm (output )Tj 0.302 0.302 0.298 rg 0 Tc 10 0 0 10 385.41 405.84 Tm (x )Tj 0.0305 Tc 0.757 0 Td (solution )Tj 0.0378 Tc 3.7 0 Td (concentration\) )Tj 0.05 Tc 11.1292 0 0 10 495.25 405.84 Tm (of )Tj 0.0415 Tc 10 0 0 10 506.86 405.84 Tm (metha\255)Tj 0.0173 Tc -19.736 -1.056 Td (choline )Tj 0.0137 Tc 3.313 0 Td (delivered, )Tj 0.05 Tc 10.2564 0 0 10 386.3 395.28 Tm (on )Tj 0 Tc 10 0 0 10 400.22 395.28 Tm (a )Tj 0.227 0.227 0.223 rg -0.0069 Tc 0.77 0 Td (log )Tj 0.302 0.302 0.298 rg -0.0023 Tc 1.53 0 Td (scale. )Tj 0.227 0.227 0.223 rg 0.05 Tc 10.2656 0 0 10 448.71 395.28 Tm (The )Tj 0.302 0.302 0.298 rg 0.0266 Tc 10 0 0 10 468.38 395.28 Tm (cumulative )Tj 0.227 0.227 0.223 rg 0.0323 Tc 4.897 0 Td (dose )Tj 0.302 0.302 0.298 rg 0.05 Tc 11.1292 0 0 10 309.49 384.25 Tm (of )Tj 0.0262 Tc 10 0 0 10 324.94 384.25 Tm (methacholine )Tj 0.0345 Tc 6.34 0 Td (producing )Tj 0 Tc 4.98 0 Td (a )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.05 Tc 10.0309 0 0 10 450.18 384.25 Tm (20% )Tj EMC ET BT 0.227 0.227 0.223 rg /T1_0 1 Tf -0.0177 Tc 10 0 0 10 477.01 384.25 Tm (fall )Tj 0.302 0.302 0.298 rg -0.035 Tc 9.9195 0 0 10 497.2 384.25 Tm (in )Tj 0.227 0.227 0.223 rg 0.0486 Tc 10 0 0 10 512.6 384.25 Tm (FEY )Tj ET BT /Suspect <>BDC 0.302 0.302 0.298 rg /T1_0 1 Tf 0 Tc 6.2 0 0 6.2 533.07 381.84 Tm (1 )Tj EMC /Suspect <>BDC 0.05 Tc 10.2122 0 0 10 309.48 373.21 Tm (\(PD)Tj 7.9139 0 0 6.9001 327.31 370.81 Tm (20)Tj 0.0246 Tc 10 0 0 10 336.44 373.21 Tm (FEY )Tj EMC ET BT /T1_0 1 Tf 0 Tc 6.9001 0 0 6.9001 356.88 371.28 Tm (1)Tj 0.516 0.28 Td (\) )Tj 0.0172 Tc 10 0 0 10 369.11 373.21 Tm (was )Tj 0.022 Tc 2.103 0 Td (calculated )Tj 0.0176 Tc 4.907 0 Td (by )Tj 0.227 0.227 0.223 rg 0.036 Tc 1.575 0 Td (interpolation )Tj 0.302 0.302 0.298 rg 0.0019 Tc 6.141 0 Td (from )Tj 0.227 0.227 0.223 rg 0.0249 Tc -20.734 -1.105 Td (dose-response )Tj 0.302 0.302 0.298 rg 0.02 Tc 6.335 0 Td (curves )Tj 0.05 Tc 10.0265 0 0 10 403.58 362.16 Tm (and )Tj 0.227 0.227 0.223 rg 0.0172 Tc 10 0 0 10 423.35 362.16 Tm (was )Tj 0.302 0.302 0.298 rg 0.0135 Tc 2.017 0 Td (used )Tj 0.0431 Tc 2.342 0 Td (as )Tj 0 Tc 1.296 0 Td (a )Tj 0.0221 Tc 0.92 0 Td (measure )Tj 0.05 Tc 11.1292 0 0 10 527.89 362.16 Tm (of )Tj 0.025 Tc 10 0 0 10 309.5 351.61 Tm (airway )Tj 0.227 0.227 0.223 rg 0.0065 Tc 3.225 0 Td (responsiveness. )Tj 0.0457 Tc 6.81 0 Td (In )Tj 0.302 0.302 0.298 rg 0.05 Tc 10.194 0 0 10 422.3 351.61 Tm (our )Tj 0.227 0.227 0.223 rg 0.0411 Tc 10 0 0 10 440.56 351.61 Tm (laboratory, )Tj 0.302 0.302 0.298 rg 0.0392 Tc 5.19 0 Td (the )Tj 0.227 0.227 0.223 rg 0.05 Tc 10.0131 0 0 10 508.71 351.61 Tm (day )Tj 0.302 0.302 0.298 rg 0.0413 Tc 10 0 0 10 527.98 351.61 Tm (to )Tj 0.05 Tc 10.0131 0 0 10 309.03 340.56 Tm (day )Tj 0.0174 Tc 10 0 0 10 327.34 340.56 Tm (variability )Tj 0.05 Tc 10.5727 0 0 10 372.86 340.56 Tm (of )Tj ET BT /Suspect <>BDC 0.227 0.227 0.223 rg /T1_0 1 Tf 0.0333 Tc 10 0 0 10 384.44 340.56 Tm (PD)Tj 0.05 Tc 7.9139 0 0 6.5001 398.35 338.16 Tm (20)Tj 10.2291 0 0 10 407 340.56 Tm (FEY )Tj EMC ET BT 0.302 0.302 0.298 rg /T1_0 1 Tf 0 Tc 6.5001 0 0 6.5001 427.94 338.16 Tm (1 )Tj 0.0172 Tc 10 0 0 10 433.91 340.56 Tm (was )Tj 0.0221 Tc 1.872 0 Td (never )Tj 0.0365 Tc 2.537 0 Td (greater )Tj 0.05 Tc 10.0233 0 0 10 510.22 340.56 Tm (than )Tj 0 Tc 10 0 0 10 531.74 340.56 Tm (a )Tj 0.0353 Tc -22.271 -1.103 Td (doubling )Tj 0.0273 Tc 4.225 0 Td (inhalation )Tj 0.0323 Tc 4.655 0 Td (dose )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.035 Tc 9.6519 0 0 10 420.73 329.53 Tm ([30]. )Tj EMC ET BT 0.227 0.227 0.223 rg /T1_0 1 Tf 0.0307 Tc 10 0 0 10 442.98 329.53 Tm (Logarithmic )Tj 0.302 0.302 0.298 rg 0.0262 Tc 5.668 0 Td (transfor\255)Tj 0.0317 Tc -19.008 -1.104 Td (mation )Tj 0.05 Tc 11.1292 0 0 10 345.49 318.49 Tm (of )Tj ET BT /Suspect <>BDC 0.227 0.227 0.223 rg /T1_0 1 Tf 10.6045 0 0 10 359.95 318.49 Tm (PD)Tj 7.4484 0 0 6.9001 374.84 316.09 Tm (20 )Tj EMC ET BT 0.302 0.302 0.298 rg /T1_0 1 Tf 0.0172 Tc 10 0 0 10 388.79 318.49 Tm (was )Tj 0.227 0.227 0.223 rg 0.0135 Tc 2.209 0 Td (used )Tj 0.302 0.302 0.298 rg 0.0314 Tc 2.485 0 Td (for )Tj 0.0308 Tc 1.821 0 Td (statistica)Tj 0.082 0.082 0.071 rg 0 Tc 3.798 0 Td (l )Tj 0.302 0.302 0.298 rg 0.0059 Tc 0.862 0 Td (analysis. )Tj 0.227 0.227 0.223 rg 0.0227 Tc -19.16 -1.105 Td (Statistical )Tj 0.0082 Tc 4.664 0 Td (analysis )Tj 0.302 0.302 0.298 rg 0.0172 Tc 3.753 0 Td (was )Tj 0.0293 Tc 2.007 0 Td (carried )Tj 0.05 Tc 10.6148 0 0 10 447.74 307.44 Tm (out )Tj 0.0175 Tc 10 0 0 10 466.55 307.44 Tm (with )Tj 0.015 Tc 2.343 0 Td (analysis )Tj 0.05 Tc 11.1292 0 0 10 527.41 307.44 Tm (of )Tj 0.0147 Tc 10 0 0 10 309.58 296.89 Tm (variance, )Tj 0.0252 Tc 4.216 0 Td (chi-square )Tj 0.0188 Tc 4.856 0 Td (test )Tj 0.05 Tc 10.0265 0 0 10 419.42 296.89 Tm (and )Tj 0.0219 Tc 10 0 0 10 439.58 296.89 Tm (analysis )Tj 0.227 0.227 0.223 rg 0.05 Tc 11.6856 0 0 10 477.49 296.89 Tm (of )Tj 0.302 0.302 0.298 rg 0.0283 Tc 10 0 0 10 490.46 296.89 Tm (covariance )Tj 0.0149 Tc -18.135 -1.105 Td (where )Tj 0.227 0.227 0.223 rg 0.05 Tc 10.615 0 0 10 337.83 285.84 Tm (it )Tj -0.0068 Tc 10 0 0 10 347.03 285.84 Tm (was )Tj 0.0454 Tc 1.911 0 Td (appropriate )Tj 0.302 0.302 0.298 rg -0.035 Tc 9.3842 0 0 10 419.29 285.84 Tm ([31 )Tj 0.227 0.227 0.223 rg 9.3641 0 0 10 431.9 285.84 Tm (]. )Tj 0.0142 Tc 10 0 0 10 407.47 258.49 Tm (Results )Tj 0.302 0.302 0.298 rg 0.0477 Tc -8.884 -1.633 Td (The )Tj 0.0016 Tc 1.871 0 Td (clinical )Tj 0.012 Tc 3.167 0 Td (features )Tj 0.05 Tc 11.1292 0 0 10 404.05 242.16 Tm (of )Tj 0.0152 Tc 10 0 0 10 415.66 242.16 Tm (the )Tj 0.0102 Tc 1.476 0 Td (subjects )Tj 0.05 Tc 10.7518 0 0 10 465.49 242.16 Tm (at )Tj 0.0152 Tc 10 0 0 10 476.62 242.16 Tm (the )Tj 0.0014 Tc 1.536 0 Td (time )Tj 0.05 Tc 11.1292 0 0 10 512.05 242.16 Tm (of )Tj 0.0152 Tc 10 0 0 10 523.66 242.16 Tm (the )Tj 0.0092 Tc -21.463 -1.103 Td (diagnosis )Tj 0.05 Tc 11.1292 0 0 10 349.81 231.13 Tm (of )Tj 0.0179 Tc 10 0 0 10 361.34 231.13 Tm (occupational )Tj 0.0316 Tc 5.616 0 Td (asthma )Tj 0.044 Tc 3.264 0 Td (are )Tj 0.0256 Tc 1.532 0 Td (shown )Tj 0.0071 Tc 2.982 0 Td (in )Tj 0.0196 Tc 1.062 0 Td (table )Tj 0.227 0.227 0.223 rg -0.035 Tc 8.9497 0 0 10.5 529.61 231.13 Tm (1. )Tj 0.0339 Tc 10 0 0 10 308.55 220.09 Tm (There )Tj 0.302 0.302 0.298 rg -0.0215 Tc 2.984 0 Td (were )Tj 0.227 0.227 0.223 rg 0.05 Tc 10.0889 0 0 10 362.39 220.09 Tm (no )Tj 0.302 0.302 0.298 rg -0.006 Tc 10 0 0 10 378.15 220.09 Tm (differences )Tj 0.227 0.227 0.223 rg -0.035 Tc 9.9195 0 0 10 427.12 220.09 Tm (in )Tj 0.302 0.302 0.298 rg 0.0152 Tc 10 0 0 10 440.62 220.09 Tm (the )Tj 0.227 0.227 0.223 rg 0.0111 Tc 1.732 0 Td (prevalence )Tj 0.302 0.302 0.298 rg 0.05 Tc 10.5727 0 0 10 507.26 220.09 Tm (of )Tj -0.0229 Tc 10 0 0 10 520.66 220.09 Tm (sex, )Tj 0.0224 Tc -21.216 -1.104 Td (smoking )Tj 0.0132 Tc 3.853 0 Td (habits )Tj 0.028 Tc 2.727 0 Td (and )Tj 0.0358 Tc 1.824 0 Td (atopy )Tj -0.035 Tc 9.9195 0 0 10 418.96 209.05 Tm (in )Tj 0.0152 Tc 10 0 0 10 429.58 209.05 Tm (the )Tj 0.0324 Tc 1.482 0 Td (group )Tj 0.05 Tc 11.1292 0 0 10 471.73 209.05 Tm (of )Tj 0.0033 Tc 10 0 0 10 482.74 209.05 Tm (subjects )Tj 0.0015 Tc 3.517 0 Td (with )Tj 0 Tc -20.937 -1.056 Td (a )Tj 0.0089 Tc 0.972 0 Td (positive )Tj 0.0135 Tc 3.638 0 Td (isocyanate )Tj 0.0167 Tc 4.8 0 Td (inhalation )Tj 0.008 Tc 4.606 0 Td (challenge, )Tj 0.0299 Tc 4.56 0 Td (compared )Tj -0.0067 Tc -18.52 -1.105 Td (to )Tj 0.0392 Tc 1.056 0 Td (the )Tj 0.0324 Tc 1.53 0 Td (group )Tj 0.0175 Tc 2.695 0 Td (with )Tj 0 Tc 2.103 0 Td (a )Tj 0.004 Tc 0.729 0 Td (negative )Tj -0.0004 Tc 3.647 0 Td (test. )Tj 0.227 0.227 0.223 rg 0.0477 Tc 1.913 0 Td (The )Tj 0.302 0.302 0.298 rg 0.0444 Tc 1.873 0 Td (group )Tj 0.05 Tc 11.1292 0 0 10 491.89 187.44 Tm (of )Tj 0.0216 Tc 10 0 0 10 502.55 187.44 Tm (reactors )Tj 0.0245 Tc -19.344 -1.103 Td (had )Tj 0 Tc 2.247 0 Td (a )Tj -0.002 Tc 1.196 0 Td (significantly )Tj 0.0204 Tc 5.718 0 Td (longer )Tj 0.0467 Tc 3.311 0 Td (duration )Tj 0.05 Tc 10.5727 0 0 10 477.98 176.41 Tm (of )Tj 0.02 Tc 10 0 0 10 493.3 176.41 Tm (symptoms )Tj 0.0367 Tc -18.524 -1.104 Td (compared )Tj 0.0413 Tc 4.472 0 Td (to )Tj 0.0152 Tc 1.104 0 Td (the )Tj 0.0444 Tc 1.434 0 Td (group )Tj 0.05 Tc 11.1292 0 0 10 405.49 165.37 Tm (of )Tj 0.227 0.227 0.223 rg 0.0219 Tc 10 0 0 10 416.63 165.37 Tm (non-reactors )Tj 0.0499 Tc 5.509 0 Td (\(p )Tj 0.302 0.302 0.298 rg 0 Tc 10.5 0 0 10.5 482.35 165.37 Tm (< )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0321 Tc 10 0 0 10 489.98 165.37 Tm (0.01 )Tj EMC ET BT /T1_0 1 Tf -0.035 Tc 9.9793 0 0 10 507.3 165.37 Tm (\). )Tj 0.0105 Tc 10 0 0 10 515.96 165.37 Tm (Fifty )Tj -0.0104 Tc -20.746 -1.057 Td (seven )Tj 0.0157 Tc 2.608 0 Td (percent )Tj 0.05 Tc 11.1292 0 0 10 368.05 154.8 Tm (of )Tj 0.0392 Tc 10 0 0 10 380.14 154.8 Tm (the )Tj 0.0102 Tc 1.572 0 Td (subjects )Tj 0.0175 Tc 3.613 0 Td (with )Tj 0 Tc 2.151 0 Td (a )Tj 0.227 0.227 0.223 rg 0.01 Tc 0.873 0 Td (history )Tj 0.302 0.302 0.298 rg -0.0019 Tc 3.155 0 Td (suggestive )Tj 0.05 Tc 11.1292 0 0 10 308.53 143.76 Tm (of )Tj 0.0199 Tc 10 0 0 10 319.6 143.76 Tm (isocyanate-asthma )Tj 0.227 0.227 0.223 rg 0.0245 Tc 8.023 0 Td (had )Tj 0.302 0.302 0.298 rg 0 Tc 1.815 0 Td (a )Tj 0.002 Tc 0.828 0 Td (positive )Tj 0.0135 Tc 3.446 0 Td (isocyanate )Tj 0.0205 Tc 4.608 0 Td (inhala\255)Tj 0.0108 Tc -19.818 -1.103 Td (tion )Tj -0.0124 Tc 2.256 0 Td (test. )Tj 0 Tc 2.256 0 Td (A )Tj 0.0056 Tc 1.284 0 Td (small )Tj 0.0388 Tc 2.752 0 Td (proportion )Tj 0.05 Tc 11.1292 0 0 10 445.33 132.73 Tm (of )Tj 0.0152 Tc 10 0 0 10 460.3 132.73 Tm (the )Tj 0.0033 Tc 1.812 0 Td (subjects )Tj -0.0055 Tc 3.805 0 Td (were )Tj 0.025 Tc -20.845 -1.105 Td (smokers )Tj 0.0204 Tc 4.13 0 Td (\(7.5%\) )Tj 0.028 Tc 3.506 0 Td (and )Tj 0.0326 Tc 2.208 0 Td (atopic )Tj 0.0103 Tc 3.214 0 Td (\(21.5%\). )Tj 0.227 0.227 0.223 rg 0.0477 Tc 4.275 0 Td (The )Tj 0.0123 Tc 2.255 0 Td (average )Tj 0.0399 Tc -19.583 -1.104 Td (duration )Tj 0.302 0.302 0.298 rg 0.05 Tc 11.1292 0 0 10 348.85 110.64 Tm (of )Tj 0.0223 Tc 10 0 0 10 361.81 110.64 Tm (exposure )Tj 0.0413 Tc 4.233 0 Td (to )Tj 0.0116 Tc 1.29 0 Td (isocyanates )Tj 0.0131 Tc 5.191 0 Td (ranged )Tj 0.227 0.227 0.223 rg -0.0011 Tc 3.314 0 Td (between )Tj 0.0038 Tc -19.346 -1.056 Td (nine )Tj 0.302 0.302 0.298 rg 0.05 Tc 10.0265 0 0 10 330.14 100.08 Tm (and )Tj 0.227 0.227 0.223 rg 0.0154 Tc 10 0 0 10 349.81 100.08 Tm (fourteen )Tj 0.302 0.302 0.298 rg 0.0018 Tc 3.898 0 Td (years )Tj 0.028 Tc 2.583 0 Td (and )Tj 0.0152 Tc 1.976 0 Td (the )Tj 0.0123 Tc 1.672 0 Td (average )Tj 0.227 0.227 0.223 rg 0.033 Tc 3.601 0 Td (duration )Tj 0.302 0.302 0.298 rg 0.05 Tc 11.1292 0 0 10 526.93 100.08 Tm (of )Tj ET endstream endobj 3 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrcolrjp2cOQ/R \#B@HHPHHPHHPHHP((( ߇N@^7ؐZ/ڦͳ}G,Tm0BB_7B^{ܼYøΏ|-" =zҨU#V, ğH =C&vBĀ/[zamڸcDYa:/0Lj4B)%|vω_R&RCA¶>i!㳉wZRoE|fϡ$ك9U8Ri*O%`Cp[bOX5g]̔C ^91.ƊBqD ӽ&naM4CQ$(dEWs҅Rx4;4 ɜT@^&t ']$B@HHPHHPHHPHHP(((]$B@HHPHHPHHPHHPHHP]$B@HHPHHPHHPHHPHHP߅"Lj[5,Z=:d]N&^Ne6|;hp~ׄl.LE9$vyٵ<ީ7Ϟft5m7W c2MPkU{.jŔoZZU7$IuÑ uH_?uB^K9.]|(u 9߆΀> k@G2a޷(Sz(O,k|.8`KK͖ QT>@x0} *İ%fh,\0Ҕ!Y^<;f,;]t.LHTv3dP-B41E܁.Z Jˡ2TOPDkk/IΦDZy{H1!Q'/t->x*oVͤՅ˩D_%qg ⣥&k`eQWTYE7kYS䣲 %aigoSI:3E42>,s ϟd1C:ɪN>-slf~"Yt/'9m; ]$B@HHPHHPHHPHHP(((]$B@HHPHHPHHPHHP(((]$B@HHPHHPHHPHHPHHPϵH\jݩSlyFk&$v9.Wh[mů߆ sK/ց%jk?kagnEANyIu>&stG&j4 t|(RqFrbLF%B0~a^/]`^xnQ(U*F34]dOʼg+˲.-(UrbAvfH*N"m]U& rK$[9^Ul^}n۔f(L*e)GFxuit`Q$PakY*)4'հg8[1t/g.[m(r=2{.0%v?xDpTYFG4- Y 0b$~1҇C>Ak|H2$ N/"F2!lrOaYiffK Yd{#9kd ]Dg x{^ }v絛f vRufˀI5s.)c/jVSw}T--kjθ80XM N9v돋mm/vPhCpz{IڡrޯST$g%  |h 2<~ 0Ol|մ$JD-ӛX|JxKσ΃#21%lV uZvZVjg(X\'bR[ŧs.t"M|?d6hq6n[G)Ƹ%'e6Mv`3倀 (>=Ph͙镩AW/ٵ ~;6c*PB wœrY^[92."a;etMkr ~ߘmia'`dE6泰9MPiۡcCG6ѹ Xa^U ZR̐mI3Z/6t У?QOuq' ZJvSEdYħT;$D*[0f u31؅**ӽgK70OhT2;!SO}vRIc.wzliCX+iWIŕ ^ybKCEoGhD}XrZȺJ5 )i] qqH®ˎGhG۞ 7PF&i\HXEfD{, [PI/- `$ػtɐ $Y +Xgi>h.?\_DwC8&VRy`-E5ڬxXR|VOrl(^pc+F5bňjڀ;)8`[ w$CdzH0ÕCH%ϼwW6QkޑӲ6Xz/)-$vrvԞVZW:kN۫BXoJe3}.9iפ9 =q;};/ԟ z"P=ط&,{Rr7 r;{ZN,[E b#wO^|2ׄ]4PǪ^3l2)| }e";9yC 6:q!46}KZYiN(v_o(4Qؓ]g&uqڍ!m9خa4Nlnu#Kfs8M-؉)MHhbf41o aMb"iޟ6Ѝhbjm沲> A/1IVg d0p(wkS* d`PUdi,ċӕJZ)@B _{zNP-P6D\ՔGA3泖RѴFrEMgdKX@.g$HW)PbI\<6ujr߈@#%|QoS[q3Y~P?C"v|Yzyѐj(y. n.y}Vإin`AKï*'ؿs=,_5wyKy^LSʤ*;q.Rg$ʕv9>3e52P du.f h_VJ2l&0 #|e111M0tVL=r T/~ӄQŇ4qSpw o$ɱZwVG}B(?Hf$+xjY#h#jA iS$| 2"45(ueE-txyhFΨ 1ܺt:xI_]iW›eL==N9(Jɔ6zOvnvCvWJčv?8,P&Y}=ygy~fWUm?urR+nh7>t2pvʞk4Ô0ͰeGL?o.i9Cv]RˬJ,xIj /Dj"VGjDFо.?oA_:8ri52.wzx͌\BZ(AFG!搀!@i`OJ\t%jk33pta<.ȫܱxePC{WA T:e!,o(68F[gGD؇q'GJUMI KFP"2NJ{CWihh2q/0tP"H iAvԳjKNB-L gF&*/WLUoǝMQQDFJ39 }A($;t~R=gkdD{ i56&{#nz#a-W* tFQp?hkpslV5Ej[e'n\omVd4p3Xv+;jS'ܢOi 0u^Ŏ)D@Uvr$~42):5*aF\z?҅Q@r/OOH$Ί3+[rjF+F%^rhiǂEt!D)5BG>t7 JSl6?%/U5R3+_S5K0 `$NjeQ|u3a˓w+lGX3D8GlffjFk Չpۼ ^){.&ӡXyg] /(:Dv0F/@QK)']px_7yW$m%Ai6iA4pn柼̞8DQ"ќ&/|mҡ;Z=lC s'iskб&B}4cS"Ι-`M) :A6WU?@eoF\w)d>.R LMQ3ͬ 6 Yh-8c~KAI{3qs[ʍKN-V҄tV8."8dKq&t^ZXZ?*߮֜O4γ ߈>#BHM۪ؔ؉:Kr q8_/vU}({6W\t3r+ｷY7Us~'T Qe$Tq09fH,]2u u+`OWC 7ʊfޜ K/iOƚ(_/8JhٖT\\9w5;nפ%Wɷ/% >WL$*`cy5VcܳՌ(!"%({@I+KpI]|՜XVb2DvNjLr 7FOె/Mt8F:M瑱ʶq,v_QvQr*"=nY"ڏ1Qswljͦ.iZݠMװPe=y.Z^b( l>p^8_^BuؓO{}e76Dvy鋝Qoߏw%OPy8+0JY ѴK q 'XI B]4>%S߃%PF|%0/DUw#lذ*A6R_!;ys}+QxIo[MNOaê2 HWLn4QͳWR)|3^iAFЎ$'k=4fYr\,ؿ$U"i:˯ɗ{92N%!' D|,`|P"£uzĤ2${{6GHVUfњEf])>(K΋QlDTFB>])Vmj-r]|dgp15 /esk N+rUGqUB y:Ϝ2t?w\s^X"iǛj=d䰇٪f>$==j ֱ:]^vhW G8ͤD1zQKu:!)ͼ%&[Vj~`A ^1z}-QN`F-h_0[@gLm S@"EPXJ]Zl<t9o5&fgi+~Ƭ y̆|Aa|\:[/s28YeۿՎBH[gGrygɑ9.GA("1"NAf9"X@֣cv?ٳ`u>Aw~.b8jZs^`|GVA~6NQzbHWʨ84Aθ髒Yy9V5<&vig"xZTX'v48Klg3wWOi5^}tް8 )-{< 8[9T1z!8IODgFV: ~Sx^S+":_ҹ x;ӫ;w-;螅Щd.$Kl{Hgb|4VJ_G͡VA6]c}\95Z俊T[ThuOݑBw RU@7!Ʃ"V6lNQοTh {+GI7XOg{Ҍ0踸,$} DZf˖AWMyUN<?̈2H}?`_ŽSN"?ǺX{-F 9@X%M*XAgH!2i&wںAROP۾$O雨_5VX[ޢ/ПYM ,'> Q8v"LP0#ӓ֪Q ЀC;OZlCJ;&S =Uif2DKqԵ|^ ojr7|j\?B9 !r I_.;4G[ؼ  ?% GouӅ {4u@ 2's(H-OIK^\h:); 9:R"ML=pLf{g({x7~T5wVʸ`g™/CBG})|BG!%u!诡Z-JmwJg  :._0bM[V-3CS7Q5Dݤ~exyl.b'Q` KY+}5C\I:+j-_]P>Qas~9xZ*~ xǶZGVBSavk ht͌;$I (X$oWm,x7m<%W  0vk#ۀ Fw sN(V!Գ6y%~ FdS^xb^(4T;"or}Cr'IQ8J!Փ.n3#5Ö69 6΁%@Ѣ7E'/ϗ`7{T*Twuǝj1-s@b8Ro_ 6C7N>0 +) CCט#i/(B RKk.{:PxG#뀀 u/â~?g?`={ ۋ'w]:_{Cwpz<7.]?z?~wú]Kz @8 Fs{ Ȋu)YpCA@6y3aN@˯ԅ|Ho@F֭&IVBq_ŽB]LV10eCAz/X 6 E*w=pk=,`O)3cń۽{:K34 PzB-pXBaND~CW5 23W*=]}d ?<_9ч}($Bu.-9'h9\]e$> ĂM5|ǪZ6D[F 24"[4m{. !T'+1vzGݫU5̃ 6^EPt>&%xټ#f|)r9 ϲ7x nRw ҤHvYpjh%=U)kF[Nh(gIXTO}`= 'KB'䟟t?WݬҺ4!Mj4OMM֕l~rq74&WJ(tv3ߕh'YPNRnTiY +9ݪC)MƹzL"o]nJSz~'Ip|_*:߷\DAT8D ԟg7dmB'n*.[VMQWibM$]GsV5p(I R@†k]ΙMMdy klT)71#d/c+R:mFIVf-Rijقˉ 9{3a{I 3&X왬#W } koVYfh6œ_rz;#'ľo7)6_加mVѝh`kpN2C8ް#y4ɐ$SQݮwd*!xU\!rDFvdvs/Z^0w޾N hYq#}^qlf(>-4~g&!L2Z/M@&q`Ck2/XwZHIX%X1ԫORhvu6io!?욏vxr਄~0Z-n`'.c(?q+eOlZwLWk%nSR"ncE%Tnx, : y6+^`M:u:.snCNz(L `yj"a3PÅ@t,ݨ:ͻæK01%mRGlgJėkץ?yG[}|eAe |6S)`)>1DqtP*fR(so x:}'S yt%w-߭oH}(:Q쿺 (ˆF֖-˧a;AXhŦ:!F2gXD4٦;AT=b B8*2S<%%I.څTu+w ))Qi Fz3BK@>Oc ^bV~_!Ș oz⮿2\3.e]R~&q̚isV`QjҌtY5RuE FWi]XʈR_*Cp!-u_3{fAV] Lv6GAFgҠ^Ifhg>2 lm476e49 y8 68xZ]ߔ;{,3EƈSB=uI`Ԯ0& w_Qt<܏Eu#Gs}2oX1 lB)qRqY KF0Wqwm;X\˜? iw޴mɜkt7)<ښk\[xU"{-Åu) !gRo%= zH᷍nW!ȇ<˦J&|1F\p6Uo $@)397&`yi>NL{`O]F|$B-s1o,t 0Sf^eti=z"'5N-`Ngm] ghvPTaDlrJJay$r!X"P3O~0þ~ΟˤL}7-VL, 8n&c/;;d>6,]jo,VKض#pSA3sj5#5ڵUD%+)Hպ>mNV@)#("|Yz V*W7JeG67gm/ށ}p9Qz24nKct`~dƈK[jb{-cYȦcz$-sӛ \ͯmjONzofG}'P{:Bkr_Sb ͥ^>ԃTZjPEP:vAdzK+4+3Zf 7ݱ%Lvf]hFsj;)c㺍RqjMNxY?PTp_eTؚƚ0o@年dw?Qqih&WOu`Yϯ +&#ݷb45GzZ򷵕t!*seo_ywczˇZaCP#|_4i.I|T M6u,-tZM0hכ&!>[ 8SX$˩q"Nz$ʶ{6ϛQ/Gz#PPH 2xꡥX4 Ln)<SGd\,Qw1z{$s%^ݰ7ufb!4Bmv)<!%G &Z3vu8d io)σ+}xA pUdSW/Qiv9hv"bvRb! sRD6TE=2C7.fVMloi~323ԅ[;UB|$qGmqDwkBFqvKHōgiPֿ©逧SĈޓTw/'z0pzhD% I/ޜ`?U=ɷp>;dsҥ)#dYߖ)v1[-pwOF^SS_O7G| n#UC#GQUn.GI z~:u! C帵&0̍Tr{3)DqqN`6m^ԝ$İ4\P:D@m/ Z%sB[a2;RˮNMf7FU Q׻xB^!LIAo \ō%҂IyX ~| )i=3+]?9ޯ? RP\T#R4ϖ$Z IMҎP9 48΁i#@̒;vƬ?%yœLe.BnѴ+Ryr7>|!"6,9>k$D7p3#`|nvBѤ@h+$TW v<Ƽ٬_Vܝ&(- MF[0Rl%ѐ'YMځݨ`RS1S@thϵڽ ܞ˽=vaxw4vPyhtUףa=%>p!RQb^%|tu2')59Ds&xseiQ\Bo9.N1m`- AFyٺ)M maoS;63tqr|HqճKL8>O-wd;+Se PQ/Jڧ;Ckl8ĭ+6L`0D /5nzemۀ\%aVeiW*.7찭$dyld?lKa b0Pޣ>|]EܯW NMEepȴ?YDwI:J>4o8oj.̇]DK/ܵQHtp? $}8ㅳf4utp@茙/hwcn.rZḰyIh~b9VsؒMoWb@e)5 ZN `]XB4 mo\= M+"RAw)p6&19&0@}W\i6^tBDa`V4:(ԝἡ:I">ַ"]KTTу-m45oULSmf[v ݄O70Y^9"͵` K?Hf8dDsL]"Y|O>팚i_cz o0x+5N,pBK}193i}P7ᤅPĢGhe00e& mhx+foK#;!r71faL yðCâd0LM!Uv) yjTwJPC$1ٞ}БL Pk2\%WY~iXcHa}0=Q~hӑa}\6&G3E8ޯ$+yMD=!|C:F!/Jx1WQ-gSF)%jA_B zEQw5dEj%yÕ'F$?Knk0+31&`bvD0G?ߗG[ݨ24RqNΙZ|qHE-Y&8'xՄ]5^w[h%٧[/s2E(V*3DcZe=C*ieHT?qDjiח@+#.Z3րcʷǁy8NU np&62K;FnϪ2"=.a[.iJf46hl9Zse[nȺMDI:H0˧xV%逝~P.Gð}|L¨nQdz*+fTΩc1☓9ujap%Hh5< 4==z/u_|,^пC~=}ޣսkzg;ށ:/߇6onѺTb;E_ :/яwl];#&Xm@aԕh5.#S\O?RJ̍8tPTa0VPA3s͎[PU՗M޾:ehnt$kб½ ,7**G|f$DS;kMI_Tجyl7!Tgy]e7%vKxʧwisC䐈}ޕM- tĸ-,ߐ8Dԁė>Q9tPKNs',h9KϕWB: 9 gePj5Ofx5sboXjF-w3STL/kxf tȽ\ZZtӓm`e2(2vֽ&MJ\1Q/ wb=Bϭ~H/c-O76GvBP[~[TU?UyKT`rsi]esyV>O 5,WlV@aɥ : wp!o9!B={I&뼁x]|'*jGͳP^GAg v:34(BTSDڋny. Az}k~<8 VZ!TU2 7^epZ)eΓ=='%[H R"(7C]K>"<~_tG1 vݡ$emG_CV O6OP)y<7N ;WD"VZ"#ܕ ?|O'&a\_y$&.#4\wgwbmt+ 0R4>?P D'1?HI-9!&bzDF?WCqz_aS+NX$v8B7n_O{-&F42_r 9J6+id(׀l@Фg#0N -͂N;>y+B!R8$8RrO8Fmn&\նxNmH AJLeu; k|VjCل$0yJ횮+k5/S<"Y .lՏ6՞]$h"9[o#YUu`dxēgN׻ؔ`@#S.}FU9t)%oh(I& SmivJg'Fb]E ZՇEWѾWH k1m V,\u3`KJ]LHŠ'e,${jA7tϦ1#+˅&$U>dvB23"I+HSZq4ˏsHY#2nJ[.,Q.cE_ӱR}ar,#Zd dI`tUBg9@[<3j2 Khjx>%I!ZTDI Rz-Ա0gWo*.:Btq L #HKe{Pb\?8\Pt^OIUeBM >6V:SLg}V%s_. yz<QFr"N&-Dd8@هl޿W¢O]K--v㗡u߉ڞ--X XowI2t=(4] sV2ޘueȘlgڻ}0Lmbvndw9+_Q*ͅ\P2`H(9:[E@*y©K$dLS~zRC^Cfn$TqjƑq%7PgŗgmLg RŽ6$.)zRw/+snNn~V}֎0#ߛKӧq|Ţ矎 \I>eNpx>SI l='$_g>yyp虹Vu:k0;\jtwzDJP/WoLφrbW@^:hdYn9n1:'e SlԽ__r po8Jdw-CLieL(Q: v oe 8IbO6K@l2_Ujc5 lTă-"P|W^_0=$vm qM:t:wk (Th䒺D`q`.0zofBUcEfYiZEi c:,ZÍ5S{Qr{D2\FӫUex N4uc~@R귌G1SY]su&Mu Kͮ=T dUB$3r(!܇:b'b'[Wjy)fZRn"귑^|a KP]00Хk\&DyP@^uOuI5)D-ũ'6Lx%^=/O!,mA`xiũ`F3-r"1d0P5@඀ CK˥X$D:+| FrK(56ZLXl=Kd|$`x{kj dM>y_qp@cUqd9w\W>׊Ɉ{&"$* >nc,#R%C ;e/F]H1Qe\x~oY6-qOͻ2ă;lxHPm\bkrUG7e9-ʪ嚬ذ0ǯAxp2gUU3ȰJ^!&qBpt{ $M^ ܄Z Nt_N==˪tuDҠC", W|4OE~Kq mS/+2q x欯~rIF$Eui׶\"|kT: iBcOMT>7`A0U w+90u[69n>BJ) ͊%K"/:Ir<[<ĦN&%Tie h0''*{1'0N7"e/sQs ޵lZa@ EYsu/ûoN7L*煰*۹ q1-erIdmkV46Phh꼶JÆcMӴn4Lk+#rck;> $Fړr /9+Km>Q9/ɗ w%婻~[X􏝚Zcb{n Qs9v-zz8Itۘ]4Z m+kEBpwDw],}JPɳl'züy)*&7[-YrXm[>9*9R*}' 闙"U*Fn).\[REF(c":fN{֏#.u%eOOmj2o-t^sA蕍L jFoSmijaj:?agkqVs}SlS}+u-]s#;waDRyVr]EtS61n4}ݮGr [J ]vdP<A=BDFVSkq0NۧRHڍod6 :w=G׿t_пn?z3Wwk;?mwvmݫވoއw?]`nf|=w;wz+;wnwtR7u_Cԟ2#{uu?nýwvýuVgr]ۿwc:ݻݏowxwï}KC]{]kUo_ùþwѝݳ=ݮMzzW7N&EۋKpwJWY[{c݉嫷7uuuMf9wf:~v]{OR;W(~weG_G𠓞 zHA\l'XbL^s(kaڋ3 Y8qM}\ ]D_lHsp)HniqL8fdL־Gy@ϴc]\tf8@%H6O$Y(MXߘ-̨.y_K,x4wB k"|=+䣷DEps[>ҿ bpJWĐ 6/hTJg`RFwQ$`ak{(gLYw[gqWYEFp-j|3Qm,GZ6, ]2aYZ3Lwu'P[H8^ň wNEOł'ˋG":%Ң*k3S$?F_SVD7m}#t{)LWA6Qo9[_pޏ[}򶴰pC;Y[quqU{"@? 2wsu QP8J5 2(o 㐜+`W@&M*Yd͡W/V 8VHXB.ZP4 hOaYt]HҊy8ɣBw=2z "8LCwm=]|.ĵj2ƨɋr)A!캭Q_r)mW6 x UӪ`΂L;ט{?gzƒWqA+1򦗐Hhpw{Q*E߂|XP9ey#.])]8ڟ[]Đz~lϏ If@TTBxE= i _*:!PgMǩ&>Q]B-Fb\|6lVUMzUL'1{Mv l.@HK"OmH>_w{A#猨81V]'@*k +'LO64Df?˅a@:lU'{P)|u(#wT̵6U|hqcx6YD }O74$^ P7شd$/qvPg=ܺXӑC$_>ǰ%eq<~:834e-jqCD#xOϗC҂ G-7CSsT&?'%p#굖T4^ v2ee"+mC{K|9g"~ Ϛ6O49 cM*ʧ.ic=N&{&}Hh4G5.l?]@hhr9x )Nmˣeu+ %u1mY=Edl+cjH48ͨ%g{;XoMh5Md.g@%ft@!HײY+Wm{'j~CwhBSCCv;oܭ)XLb{hs9xlUEj ̍-ridPsv|+ ,pSȑ cQ{Uc7Wvq=8Nں?A֒w2 =՗/%h}}񻦕פ{h-G.PY $(2J^yJS$gk X3 $+x,,9ܕhoߡ!yvNdŒd}g^Ἥ6*njG{ O0s 9Ӆ( U ׳sIHT<0v$CAG)2"ȲAϩގ|W~{ŭW[U @G.qf #ex"q^ d552roώG{gtݞX<>^ק}8sP-F:'v͸šns`AuW,ː]Q oʸdtb8μ" uΩǶj)=sx!IMC\R[^+?G`OGa4 _^ &ˑh-uocO9SUX_ml{ +'uWJWJz"ً͐^Iӳ'-+5 9p@M8:@dcߏKWnIbu$Q4M\ʸ0ol,Krp;Ep&5e65)|A_R iA);Ѓ8)T^"+z#fKued`J 񾄂B)œ&$H8C[?u/vxǡ`Q]\3RO%ۧ߁q97~G1/dJtd c13-j]p< W#˜ =8kN@4Z 2ek" acL% O:SPu2^jSC҆<.UB0+s9< <?o@.|eIab9Ru Tr|ʯ-ʅv WCSH Sg9?ۥ)ф^);|WBBBa\>viB R6PhAޒ',߮2@]2Zu0#]rP|suH7cS/pEg/<ϏHtȩ"FX(㎍2!un㥂JZ(eb5pS\/?Kv jF|ԅ9N墉B;YV2_⃹czh&';(7L^FanL繁wO0i r&016Qà>L޴&vvR5|`GaT4;*j6Br*+vq3VF(KՆ[uȝjazDHpi :{C;Srk1olya^ Tji jg;̦.;JW=k|bߣ#]"r#_lgpy|;@% VJ"h]@;3B e4@V>}GJ;|37V:B0[)h @>d,@{Ѐ/<\ d2< F/q@y \E@J HC' I} ͗זվ!gcݩ Ɏ 9q@ϩ5|(zQv)6RN~n* mb7D^"|_9eP$j4-O&C Tz7U<q}-_*8~[iwHge?n}56xvR){柂pJ>B ήQ,_6`K7vH*wBÕ-!!ur>LhfVŽK.[kFݠeA #ӏQ>EhN=!?D "&C (SIR;IlAUsboY+Q Ȯn:NiQ},F g`@Sۂ'-&R| e7M3U:2~Y+eZLFnyqא[]m?"ǎ RN: Oz>c;ZM\{22tst pm=O̸ZRj!vxn-EB`ډhp$x>VowXYYĿ阈بe1Jç`sRR.n1ShVmu71DIЩ Ҹ S,@@vPᨉ.6,}p |S3>TH5( ~{x5*. f-cAag((`Bԓ WqZ#nJqÁT&xkZ2 6FZ( ;IzເIvU-ߦ{^oCsA!VIjHaJH,rÕ:^֙wzpAMCOvnd$a Z *D| 2޾bkf+ˠt뫮à#8// JiO9cաOp tbF:MZU @E@%{me|gKz'WA-NVQ۰r9f" 9ù2hۅNcnjBVW<\O՟\XnQ&[z Prq(=AvHCWqy<(Nt; d Fn"/# Kd|B'|/odא{at}OaH1eM=%#)%6>A h'dv0NS,["πxx9I/c2m^O4yfg+I7s|`¶ >egD=\%anhZ훉F$ D\k7! ;!r'pg5O4on;*R!CGRoHq!@(41xdOT3 @ IjsfJǘҠǞ qkq`ۉ>(Q9=Qwgl <:IM\SjR6뒓]Տi9AP0~ø̀óv-u ?zÓ&&{=/P0`WCV[?Oخ١r"kD tϩb Zr4!(?=𘁍n`[i)eIܷ!e$Gjw_9aWBC>Hz jbR_E\Jm164No/n m~GpYv?I!6?4~ |EHXL'I_ G,Ί>6 킵o !fܠhϴT22^<帶Kuh0_ꟓh[bn07[Ap,ul3WD49Ś/TZS2(ݜ$w=p2\yhu#$Ԓ(BBiiry2N63:B1MXhh00iGBe7%(R 8LQ&$f% [tn4*gVM?J%!-\z-%OFM2i3SQCxL|:!+}BO=dc6$5Pv7,'w EaaxQS6IS0ٴPrWe;Z|EdBZ0g>Ejظ7FKʸ@1~~K Lv'k[n JFo圐=D h1L]ФǮ]GLTc." c'&wd /$ߦS͉hBBo3\3JVZHs%Of;}18?كz4K9rnRnS׉47=uw_}⢯ѭ?(Y|Ҿ M0㬪A;\X[-+C~-:ц=@nty N /&! :_,a3J*&7ʝώ|YG ֧Ryǂ7%xs1  "p$A1e B3|{Γ?CsФ,qyr5J E^O#dnx /EHB>ܙ(p oNWeXޚůCU~`P Xm7$Wav!)Y^=0aWqX8'_tx}1Ոsv["U "VX`1r|]LNqV]`F 2y0|؈(щYoF#w?H*^x)Y.W=|LYD` I6- ֕?PGtb jy*:u1z#^"4\*S9cˋA߾,},Vu@C4ˁ. ]AkGlH)p N~iĺېЌՅx-UZQh \o$ӫ u#^AF?_1CRqԔk%SCal=,K1 {#ODන(kGֿ7}LtpQ)MP&Sj H節6Fr~˫[8Ş ~>4Om>-oC*;;v@wxɡ U\rL[>X'lyH7Nx\7e򪂨]@]1h8 quǕcAF%i ۀTQ'D]`d7X㯽3Zyf9OB1Oa6L}AAGf,.̗hmZ 7i*,o_$\~qrg R7ҥ9J6QVYяjGr_3Чu!{G|_x|eb8Id]nQuF<[RYaZ{MR6ćaut20p%lF0ch}@R6Wc?J>Nag^!7?E#ns'daXTFȋFU43Iگ-sqkPl!{О̳0:y!(&yP11ҬeN)4ᓳ.@L i w֚c7JPzI̫do/0|ס't^ G!38w A!v zBu^E^{?2-kSꤲnHQLO}`k83doLMg7Z1<#^Wt&8p۪#^1VBtdj7L$ -?t>cӟ`'e;x0r$HguN Ӱd, IoVc < dYS g18Jg4ZlNP]$T@Dθ9C_l+LGGeXȂZ&" h[[q&;ʈBBVom ܤ> O{ͫ_P6EEn,N Ҕs0{L ¡yGyӨkϲN#2^h0SgCwTYY1k8ִr'C\<%mQ%,,1ԭ:P՞֧\ &W,k%Y0>fN^"-~Sl+&y`ٷ_3jt}d`LVt)UaK^*;Ze寳ֶ<43D@~UrO+wa*oﻎ\QGwf%^W:lMdbl9ćL]2RF4j*'"Kds<\Ysu߳z~L<@-wiG<~u5_nC MQ3q*D'"6Xp]:bl\t--&4.?[=ex|grM#]?L>pat3}D:9kI:Wr#_R辫 O}qkeh{>K鷌(%~Ѥ.hfOL?=VniטO/w߄ڢqg y@x90cr`v KX+zJ c%SJ7|K33hP`,l"Gxp=N +1ԺU/@@&=*SJGoc%0xK$IGgP/O%.V)ULrhrNϺTp+7VmŠtա1;z'\ĊsLatR [pfH*[4ڳhWc%7v^bL`K}b{b7ho/!~s#ovI-쨭LfP8e i2x4f`Rv_YRTA,ӽ}ɫfgu]M7D#O&NzJAٱzWE%_BdІAK:2ޛ}\-cSgQov`3"''<:&V4m?5,3f=NTvX5:tԁG3ç{XHN#~zؿmc¾;N7k j|K=6MItDڦĈ8tg\qܪ3mDO,.oRIks'>&ѱP!xB@٩d|#O*LˮNi~$?V4С9JuR (GVqj v\,?ӇL(k:!7%R4iW 訔ոsTٲ-`}Y<U#|6Ŭ FOIbJ/!˃aMc {HH5 Q$f${KN<z'q' -?GFr7g|Pgdda/+e"!  SDeE3Ԁ֖{?~p)2${;tp9\v\Yn]~<0a@⻴ BV ؟\M NE$ N3JGY!V[ 75X'">lh;jt;]d#j.5=rAs,4%PEL"O. x6Z{)(fb0(m֑Qr5+d'WX,t8c" 1AH߳{:"Ot1)Q]oK >5nvmhh.e"Y@w֚B_vZ$ %C=>-0@V-$C."_./z"N"'P1訃 Т¼ ~=uS^$)#:R@k5^u eإ64HJ!}\X%8ylO/~q/n'qwj_4Ŋ" o=l!.U8xc2Bj㊞Izٔ [QT9Qk.f>i+O "Ylce -%[[YXWF$ely2k_&ֶE6^ Dg X M<=%Go]328RUʃtR+UZ\v;(jd̎f5x.ċ' {h]~+W/=ϞxfY]ݘ$dBbq_'J6w~@²UGxNaƱH}j@GW-1AQfYuljmp ͔#B­mN=h(+XNKGnɓ܌LH} ƺNLrDR+D)wC n2JAi~э:zRfЕ]?R:UuIk)vM+Q~ǡ7Da2a>{>tvyVc*pq"˦dv>tojl?&X6ܛ=1'̖!ӭ ŷ~'"+{~6kw.[}NB'w"/EtR X7w/#@quRX .N@ x=&=+'V\vD #'132fM}ٗZ@׫.DB(݋깕f:xj|W/c2WrCk"AZ$L~K=&' 80Eܗ̢@kmF8,a*KrsD)}U=N3dAz0q=,'OuwXwK] vQ[Vn}m Shhe[|޸dR,'^dڿ1.^{intE8),_=*[(ypn<(֖b:MB qZIxTDSyN"v|}Q~C*wJ[qTD~ct9Ye0ȠH{+ ѐRA"vsʹQ~ GgԬ i;h(|z)= :1@j- xUr+D /dKnz9# F-U+y0xׄ='c=^`9\ JJLwg1K+kEBLlus1 Ҹ\&q,[G_iJ1UE0OcH.QH,"cpa} AdAKEJ|Q?(d,GLd ZlG'[@ j8 X7|M |'w7 ؟4}ja4UGvvNlJhm_+DzP5ԵJF@p4\3R]P+݃/Fkfz8}.t[\)D7R y N,v{Bͽcr;rt=E*grM|^.w:4spgP1beω@WjFVȁA4T;&׮-hOѧi[ NmNnVBk_s>Lܷ%P^5+'D-97<0%0:6`ㅺ܇O dW&%QP"Q 4("sˢ`-1lD?:i3[~4` ]" D_l'PtAGD2ӛUkz?%7Fa뾼?7^#65rnT+z/%@)L_K~yW&V_&xBa0AK? X%(+{FAQɞj}0?v*xV~q#CjfO@pU7 Vֻl#!H[Br bP ht+9JtRA`9@7[~N^^i1OiOτp 1ǟp0Jkda/zMvQ-L/goH.W6Gݤa蓤oP~ eltLr^`GeބO܇j+xvB!~,ä2JVTcJRЭYC chgh$H19Qb|ۇoi(]\p޻%<5~+\ey"ي/q֣%p(mRzY p%|W;TVG 2vbk6벰)`ᠻꔚ59WWaXyj*TPp~چIR+cdEh?]RLLē49hc29кMZͺM K%G<8ih|%'Pԃ@nsrށdt]D6!eGtjR:P?_]pUcSXk5i1_1,Xc@ $?;IO+Q6YIn aŲPqyڅP%>%2qȂgR- ~)ܒ+'TQMះMED}S ߬H=@vわ*/ՒB&=;LX99aհڟ9 0ƻwY$3" //R:GQ pK.ͫkQ^C#@BJ\( l$no}ez!kP(5v@`V0StbKaW.?V8?Y'.z2"0)hT+.[]W{NڲF2#ֶop%;"w=YG{tMfk\e#Ec+ЂYԓ6hkgcAͲޡ %a}hW-qt!+D);;ۂU_RDض B)ZHi |jC ᥜO=NTc-Yk:g<7L%:QC' 5`?5 M'-GfU)b~5{Γ,mN]dRi01d7S^%Ƽ̳R `?^Y:0sߐpL*exGLJXT+%z\%ByMBubaV){QW,}@:ʗl!0X&u4LkE<9V3_sTWD<Q԰zu;v+7?"aDpK"'h{HYp_a4AJNEOMb/-.* [;[ 7왥Ji \6`'#4U)* `xx84 u%m0pQa^A0|h&^?ޱ~(ST߰հ pyʓ^ oo4ۛ6pFSw#_xԟƍFʓkwB\A@&Hf*EDHäeh&Ehx%LJ׵8[ňW|Y.XaJG: ^iS/ 6* ,JD'Uu2#cJKb#޶Fȉ1},>uUpUp*mK -ܵ k>{.^DU/RQˢ/zyٟ2)ZS&u#'u^`<] -̨ku@+)ppBQ3D/rStɖI+;[Mh/0Vt]6B`X`WSȟv{!܇ bmIlHr$8&I#A`uq+ hu@ˆ9MC.úyukN_Yؼ3Z| N[ ]&\{K݃r]$!&cN"Ό&*6ChQzMV4\xD3\\/0;e]d.0"[yϖMz+J'?Ηٰ##ӯqP ,W[mp>LZ/&8؅ ( PPQg7 PZ҆}.}r>p *3jKCJ0Y:% O3VΝ}rX%Ryv }^iՒbfQ'^:6s]y)JɂS4bR"ͱ3#D:d.W|a].d^l3hFM.\G*;`Aw'7mfQ-0٩ PɱJ[gJ'C%#0Ypunچ] EЫ̚{41/.a EdL9QUH$lC `*q/nE9RfP@O4aRc%I"|rHsY _` U߀[ y4ٳ M$ZLXl(=Y=iV*_ř 'ā/g^38sS~+]0[@㬈JZ~e{4&cڧ% y_ZVR55W63r|ա:0ə>xV H4߁4EO3m.om=,·X\]yN0>b "Z0" NJ3{c {n' ae"Dfindq\EsL0BVġ#M,FNH ROsS>VKW ,Jtg*dQ ~=F9lGPW3B+t~aI"#d#rꛖhRi.y?+MZw"=Jja ،ߛ$%f4-[I|' ֧,?kkJ~"̎Fw͌=~)m$x~FEi,2J𢩕!̬TH.-ЊgQN ,AazB+Pڝo: FkM2ngn:A*\DM:޺DN Ms>wOvDA>wpOR7l;꫰M4[C}*^c`FPu2.0D 3cou;'ɫIqt|`|!֡)!ث I86HO7u#.K.K{J49r ?`T+!S%7 Y+4M* 7SEU0²g: P8yh$ù/4'#SDe®e\fZlj{Ȱ@Wj\V{[,RfWp՗ ""ݤ29d6 UsV~@+F/X'-j+LMgئ04֬yeJXU.qѨ~ : ]Bg.*@/f(:40Xr" oGs}`"v[f)HdG |4V&6f9Cyn fQ iAi|"ްָqiWPR_iJѰZ“h{KLC==Q G) rd߬C~w6)] V*>(}֏H(@WJ*?,Xi`,YV5S:]ޝZDgRvZ8YޡĽůی̋ߠe7H5>42!+hcy߭]HH%EM2J юzDW%ۆH`;ZBlێՆn QnD%s8 ;Y4S[c } r"@Ƽ,Ⱦ|2p)T>gcTQZi(hZI4&l2sVw/0 Zj®TckWkv$@@La؀%I`B46 "vZKR30o}~ȹQ{輵Elhg<2صyi9v dykd2v)X %bX@vdUS@Z7Cu(͓P|N1<܅$ũUﵾkvޏ5rw0^UR$egiRP `_%Hܶ9p4`F6|*+ͺ?PѼ>t"iم zR۰i>3SJ/Gd_IH ʒLNq@ *-bC9Sx%\L s5OFEۓkSWh_no[1hS?njf\8Qc fWbS2ruπ'q- O'@ẅ́Uqם /9Ex 4t/_ܱ ܮD튻Ìj#䬑pbllKX9Q IH,C@@ 5tDsyZO"o]W۳D G ip#^ex-ymX̬4 B #`[Kj'Ҵ~H$\@vho ʴd#Ȅ5VADv t&| aP1vJQ_aߞz^{pbJy%[wu!tS^%Z m"s7,FYܘ%.q}M/5" ĹDOO'fq՞ffQBx? iFyÛlH(r.Ұƚ'Ά;JW|mhTo"xS2/s4 e gqܿ8 MJ O 9!( 1SBb~S'F,b"o:%$Ǖ~Qwێ|D"Mp.uM9gYoY&B:vkJ=,4V$8$ZwF/>$ziOkҼŲnY;%̨|ۯ3̈ΤvIsou%(Qfj^Vo# $[}-P럭$`gYS঎w*`r,{b(x\ZfS7XC`c;7{Ʃ5/}5"Iv#L <_jtx,u| >bf^0]@/;x,̗ۇqj^H1]vYh}#PKЀծLdo5e 8j&fVvu6(B 2QOuf^<~]xt C#%qNF8%Ik6h%o$8#Ҿ]QԽnL[!.x8V4kR3&-}zD+8F OTIV%1"wf$,uGCCHtp9e@8K/e^왜zTy>gzP clMg,{Rd-[e9~oSi FIJP1VKYUVs&-!7<=\Mžw>iN~5)2m F[9VC{5K#;K?dpa9ԛ 9z/eb94iĉnRgynhɹ>0p-s{e츾y hV=|oԁrmeixT bXŭƨ~+ hunFU`e|%pDcӣt5LN5վ؂vly*C~L!9{CK+`^RXfg%bbqhЭ %X p$gBi'BO<5q7l6[CT,?heݵʑ5߆5p0lKuE |ѧ2c |ƣPb1-rҟ7JӏƯ&;m4%csVY EwNuGjL|d8e^"V8ycj8Oق#uOU Z[FCc|$Иuz%mf5S YI=S, 8߁&>KmMtY޷|=ij2!qEG H\v{o {mf\ iکoY`.o`Xmq=1*ni# r9])d: u?U)FH!Y ycsaMp0;>V#8PxbI)E[Lo;B7q{r]wn\v[_S,Y  Q#lex;^2m5fͧ{S|'1@myw oI~Q7=c?*﷛+{CޅwXv͗uM.?w{;۱~vmzvjQX۟z͏uwyvm>Z&l'v{nWg+wn{_M=woݟ}/ퟻ_{ퟻ'v.;U\ng}=}*槵]'hAhmGۮVzݡӶM>Ev^[E/6^k6V_]펧S+}}5*u7p{k5ѝ۟(:=޿.k^buv=O/O7m Z~f{~Ik/otrͧj{yOw>ni?[Ai۵iށ=[ux뻅ބK.l6ycGIďzWgNz׵O[yJC݃~}[k<<߻;݋usV{}Yk]hk;KnvK靠Nk~h^XX:ߖ}LW}GڝgufhGnB^ll3[Oz5{o4kGQ}g݇˓헚ݷh}_JWﶾk/T{;Oݓ}kˀScչIuLӯ 4M()i11 noG֖2=Qs)rS#Y.st{P©>2D.̕'a7{Hؗ<-zMqZAlA7hM8#Lg] ?n& zaӿXD%xc֩("+jj^h,0WI%(nFMK"*DIF('8ԥ f} s]Vg 0A Qe[l,!޸)חqmR}FѬl5D!M6}C$ ].BS_yPt5'Ùü[R&VDi k#Oi !c)џ-k|v91hcF;8T]˛A <]4\).Cܢ=56%m)R9\D0VD0Il xmٳ M2a QՎp:*o2OlsW!>?nBb ~n:~!owa^0fV-Qxauӥeů,&#, {Ay҄J2zЪAD|ĸHN%Cdbx7WY/n5HgH~ߠ>4&+X!]}(*aS!hDچ|C- U~\Lf_4~q1-{-J#)wt]W4o,ǀL,_1~w(2P0\Rv Cpc@:8M1ggƻoh%vsZJ%HW]݄p?TM$̇z1o]ZIܛ$ST[Lq7vQ35.Nds n P ý:nZPr|<}X# wvB1K2 ()pć^w:-JdbUzt@/2>:+c|޽4 e RH—R?ZW1廁j`EOC0v9;i),A:fDMEFSuсx֔8˟Ԫo%&"42v 1f#λyȵ]; K+KWK!Amm+UuDŽGvw.ɳ|Oe<;C@"(ty.^-7@T"7o7^Ybk*FpUH[l_@= E ZmVIL+.^]jx].:O _HFdf f,JvriT3J86|Jbml'(H߾eyE}7)Qᚗ5?/ߥ[(  B LS$FeQw-1LO3 iZߞaNr* BَNj-֧>珈⮘כ(;5tD: m93>͑$|QPw8NڜF8 yRΨ4S F%JbifZ(Lib3=-6P[8́J#"P.x[Gv\݊"i.*n@vÏu'&Pv6XbI[]8j@ܢ]q@GC depbY7S䉘uZ/n7Un.62r`JnV߮HD/gלg穃8t&~EӜRgS~R64@* fIj`@z=$]I#f=u3" t5BEv+Sä9q0hȜ}^|b,M>nw`R}[磘t z K<{x!g b#OꏹKÚ?.[#n((H y=fr\Uh%쪯h\Cl{cPIDs(w-Y5@' zi&.͆sgsstVT1 IMPDzFi[Jcr"UJl;C>cߗ0튘 SsжA+uPS᧜G%lrP 4Ɣ"X'[U -Q4\k"__8hP+x5\" {gcckѾ4)s}{p~DǬZ. /9aCZ/ 4M+ްX+"؄FZ ]SwY+3vw8 L4oq]xmXh7q?큪Ls0ZsUWhT[ [gZaɴ5EJGكH+k^+R&rx6Z;N{iNr J:S`ȏmڶ8^L^nj'U/&^VӯRןC$ݛŰӈYbV?5 ><2<y%F s.ED7n~u1nRzm Iׯ[l4[\>[Ku]<5TuF:Xx2pU6-]Z(ҙwp8H  FrDv" !U Oi4mȁ`\(w++/R;dV h2ϢEyn5й!eH:xJ?.&Cf κPmJHd;7!>Q.N38?hliܫHut{-P{eZGP$*rp!ZE4 ê/L\'XZp?(_#h50 u1$Vq-Lb=0 /?2UWRڴ[7?+4Ap>OpY#pnGT :Ok(.+KƗPa,!DNv7C ܠ &||U*Y,_ |T%7Y$4/1:R,77E /0#XnV36%E.=G,;nAD sІbbZm20 kCP*#9_z6Ќڗ d vCAC1hĢo P>] ;.!tȐŐ,ͪ/#jV1!, Eb9Nĩdj> ɂOJ9_%Tϯ{*mC0n)}e vU??q26$$|a Fj 5n<9BDv;8.kbC(vs*F.y[Uq1|hhGjfpfZ&? F XI!Z#XmVx5>Ʃ݃rUךn:P,tΩw'(ϰ)Rt{^{cS4!ţ`Ua!}2,cs5ȝ)&%>>b| C7mVC)L5bh  lK(vB`O,  е#m۱6q1Hߦ" @REDu CYُVdwI]P,-R,~7ڻlMeG'<qMMV?qx 8 ^c:tGCjbS(DsN+KCVN80)t"ީ}éq UGoinnO,GQg?IDN;(DTH^zL?kqKH]\&ӕLΏ&TثEaB]r D2M9xpd>ieOG&8CT ic3˴y6iu+ˇcl{(.Z h~YZ,R[_Q͠v nU-wk;ԓ+2s[--YA`z ^TY,M}6lt'0t}wNd>k=5 ]u#郅J2׷-9m6ؑڮ6Ѣ(pr]wx-_¢K,:`.O^HJ郞ϥ]`w;" Ol=OwH: z{ 82ZKlgnc#u6Ӱw>9rYReMɸ %H冐2^c" wdZ\~x.e;@utT uŒdB:V78WΦk?A:9>m &EΣ]vTe _AFj1-ON̳Y X?QF̯~]l=opH(TBbCFRb"!HCBc;FK/C]˂y&;U-ݱϧ=$;|SG,-M]ܪ%EjeW'k*a0yͳO&uW %UƀH敮4-yFK'hO]͜D@inW{1x:5ʄ6 *j}y3˙2埸1x7{|"#ߧ$mk{'Y*a@wveb&i5QW8sRo3qlVI+Q@qFQcW(WN'/W2!KZ(ZAwG'D$o51<0&гxK.c//Aych^ێl$T0[b|t΢&yZ־p7Az}EZEBmI[T[ U4zS[ݯf>X:L\ Yu]'z$+&'Mz]Q9ŵJ 5SiX`! m!oP딨2@ƑݓϩP¦V$  jG>/wq\؛@ YB&Tєybo,뮈eHeyc64Ʒͯgξ"L=V9ӒΩ7"IN\jN 9Ǚ~$ bi6.Pe؜YWޛREy1#"D'lDjPgOrrZueJ.7Ob wV >hUTuێ5&XqPWW>ES?!$N 6丗~sBCAL_"sۡ }tzpp,5)d 7@KyN5(z^g(`$uWUQǠ4),zhJdYh2無>͉ix8GD5k-nh<%!, ]Ϊ!M#[|'^Ö(h'ĪsA^E{5c Kŵ"<=?"j7YV_<iiT)n;zM+xuv 31YFFR*x^#H}62wni +yL#MHo6Kkæ1077E.d[>Ѽzjlh}b`NjED*Oߗf评"bTr*4^/OwJZf>S!)25OI*b]Fl~' IKRzh9d|K!JR<bidʸլϹNRZJ|;H 5eiLT%Myi^-1i+sOoY9S (b]X Iv9SֳGqM0 Րɜi.( '8>C,U!w 9 ̾&\[|F8*3!5Jߦ(++T@v4@rnfRPc\ {׊}xd?04bIR:I͞] z;*Ǒ*`$ڡ a nC :3}gPsN1CtnS3 mhcʹ&Κ?G#jz,Oz{_u_n2 +|,iPVArbrbýl}gQқيx%؛q^./jٯ^!5w]f=Y'lBwvՊ>!cPGX|fl}cB' N1,dO?rG:%\ n:@!Ij.3** &-$x|*y.Ik=%$'N̖ɅH`!r u~za ߹!Gq.>c &L]\OWc?\nh9N>ON֘$RWϚc)"8:ivc cU7M2ZUoЄ<~ 46zF,.*."4vm%.9X::/ioƒv7\'i]me$ׯAQ̝9\}R "MBn! 7Tؤ ؒ z_[j8}-<{y=ɟV?:Kwڰ$.$\b;ԇ[`)#t2;wA50AUo,@ЅɪEۢ "e؊JHaL̇f2rf7(2j]9 x\_%NcRKUYF::^$"&9'2w8oЏP/2^,8qcS۩lgr sA@D ԜkD3crHFF8Q`oȀyޯB8`0 +X̕HvbH&?a/Rt{_Q'90 / ˍ|b ETp%C{IT9 !sJ|3ωcq tRZF0qIIaڴ 9!ɀy!ݮbF  ;Nz i'wZLh5l)AF=qTd\[ ҧq\%-n uA*M+iI a_s@$|n$Yo5P <F Yx$:? g Et9}7*t PLxBeP$\li>WM)x,--U^,X~+H0B*ߛ^7>9]3 {+it"^j 7ɖR[f+kT8c1K*=h1y&eB"Xjju@"4*R'aL"D&o#A)ex|4>:qu g-w+v6 en7g~H Y7d%!B`$@.@?:!:_ uqRyM\t){l%lQ&zp C-d+ ARQ6𮥥o0ODq$ rNh=t=[;!%lpJwmh]%!'Ԕt0) D~7e B xYRd+b @,l;*)?lV ɐ:֠۸W3CYf^,MON{smǠ\Vs`2H6)BZAԤ_O㣦@d|-P'4ӕ2"54Nu9/(t|g uJ %;3Fɐ;I5tU5a[~SVjVj ?+g{LkeVxIH}D8/%yWitE[z?&I U 7D#b)`6b V6#gj(ю c38qŐ?,_Z.Ӗ1ws\栕[nǞˍ~{_!b.2aZZnhT `w@=$ 8(z.]kջ'̌:B—UsEs#"H&80/OBv 9LٯhX>4ggΚ!~#lهXI4~G;ElpB2D?|#>sr}N({+SK*A }ƭ>7"3C:pE ',hskiꥹ;7CI3l1C i9e3䍁w gG(.C%U0"tVMzLSN݂_l-Wˀ /oo/")u X +_8х-b wC{G"~ 3:n9 yYY[^G?7>P ]R-$Mz('"EǀC8/pJerk oByZ1@,81U@U^L0~?@("[|F[e؃Ֆii1Ukk$9ڀ[- iKوUjK?du",$GZ2YVyϖ5Viszxe|B@p2#T 3o3 L$r:3 B';Zx[A.bC^{۬F"Ȭ6cV/Q"rRG/4K 5D6MԊ(wd+ɂq/L"To7ea ldĤ Qقg"l~TM CjeG[jA43&# @lO?䚺=Et-7[;0 qt5oJjZ2\0Sz<,[b/Ȟ:jٔ,h<+mN<8P"*^ZvkÿHUEʐli-C- L-ڒN5!H*pUXWX F[NdsgzOfēL)}-Qg9s M`@s.6ϔ(=~9^ICJ2W΋) dp'ʹh"nVT5eCI@pj6?9BxG3\unp9}c(t>zK\ -$b"U5^whFcO9AUA Έ)}+u>vOr +eW![;~́^r5!dc[|{aafpBBQVM# 3!MB /aK)łkt)a-q=8Dln\TsB SPGg}^1;s8| 즏m{쬄bm шIg5pխ;`SǞSЦuw{gFoo4رK=aueE~/?l XMD28sfIc gXߕΨF&4j̨#%ࡲ:@"Wut 837U+́8֧%bKް8-5V\[L (TjެrPk# Wihy& zn}r [_x%:d> ه}%vy֒=Gάx\&:35@*"6rW%%2YXWD5O;o8 /n hTz43Sk*_^G?~`|vτ%כMngϿB9L4 D%&iYv\ËnJd\_؈sQn),*cQΰ,fTX2?Xa9w 3ߒ@ D76 _Nq>53pTɟyJd'dXiTC'KIx# խiMlSxi[p.َk*U?a*q% @qYC%(tbFR ݡfk0N+ܹsRBŪ)Vg [7s܍t+/!Ec"d4!LVf)$D@`o{S%H)\GsL">#}\Hz֥=Z dW@g;ކ(d[跽8aeZH$F^/q՛C,st12͎3wܔwJ% `۰V0,THN?ulUlMֈx籬Y~870͛6(E2WmoZyծJhVZ ,蜪D:<0|Yx@7G}ŬwH-bII+f ּSԸ‡.+V ?Q \aA6 c ۩wo S3rzT eaU|FpR=mt'? ِSt~%a K"XuT:1>I~lmܴ22T뫷BɻOwy_XJβby𯚈D&7,|xut ߮%ie{Vrˆ.UfC$VKi2}/gb1M̒o`\S.Qd vD܋WkoAÑ5rr!#8i4hݺN' hDhR7[87"S(/! PNhkeA;Tz(hLj7p{:8{rHAjF]ׇ0R2s;ssN>;KҘ >}t@b!8 upO|\ph_hwp{w3Ǻ0]CzZ] #X0,a. %uvI|pĤ)HqU TlZl4ƻ{1}KX{+5Opx݈L礵X;w1ҥc^Q;QhoM.)-Rtr*MyȰ53I]Bo(]d?< Shn;++Ҡ|6jP%6e0&rQ%(%rcxVK)௥ `{ 6S뒒zdl{BbeIA ݭ!z9%8cjz=Rm߀do048x'5Ἲtkm,xj^LHǣ7yۣ "[gc,e?""gҙeӫSiIf jvonYM蹛p2r^[+TbFU bY;]G2JёwJG](\94:4xC17Dԗp;F=ު :;ս@%uf"IwkwT[򎩡tm \ܴC }|g$:ંYg іJLz6" W")j:\洫xລ^C[4h6ضpzsJR!ԦCHEd贂ߺZx5QC7bGX? \}D< BuWRg R)*x @S9SpCYڜz=Ci msQzE3:ԘF'75ѓOaD|IT1Q~$ڮ0ŷJI_:c~3Ys<x0reqEjE{Hz.}$0(ɚN弔b1D5.݈75"'v<е}:]1e=;'_/XUI鬨gC*A9 c`N %f~u.GegQ0?NO'L+%wK'UL",?&sjῬ#idadf7@uWu"8#{jѿomDoopDÙ,h:L"xP`OZ|аQgU1ҵN8, *=l@9YN3Mxg+Fזdn칊C 9+ γ$M$2b>]ۄ Nidb7&lO`y0Kz()$Ri^x%gs7s}22ҨR}@.ּ`Q`qQv-Utj}S}3S)vWl_t:pe:CHd7bc!E`ً )sL8x' þ%)4)ĽVD19 LMXJ3 eu5 *ptk~Σ2)@Gޘd;NGudLQ.~;0;8ai| 7m]lCQg+aѨ D*Z_(h8Ce:gyvpnꉴuĘXqk˭X[%L~eS[}@OcEkLk&'[?!5ǧ-XeIt)!q3 *+ơ Qܞ#&#wg%+j\*!>(oOT.ccmgCp / ΂x ZZaPhGk{  |Z Ua[ Xyiˠ!ZNU8W9Si<6Gx_j {쁂Vb%m[EK%bcgceG^uƆN(nĩ]֓Oߊ:,\U9!jPŷހLRj￯#58& ȯJҫ tBu[&>C] MG$\l°YW2[Kv3rB@s4OШ!}CG< B!<ۍ~<~\!pJ]^ %I&*{.[cWڼmԾ&_sA51'N|?VdLP|-A+Z@YX=%H!;,WA"M:o\A8j\ #R۴fG`Cխ4])C6<2[}yd@$n^OhuZW҂-WĘ'x}rx2|Բ\GaQ5)YS$4 Ǖ}ߦY./itm5.ɜ8xlp+$؆_doL2d iR{HV{dǜj!+}3|ĈRog9|e bhGU]kĪ$ګ 1A$ej7$f~r{ 7m,t7-?!4l*uHqܠDCu/o-̓- tjZ&' { ͥ*s8+8ZVr):- p+]IҞ`zy]ƷT\5d5*.?v s=p\́ܩp6;L^ﲓrZ1e d^K& ӾK4o3T^޻ߛՀa.T o?Ț GF{/E#wvFdG@a۩7O'>aGm>+ Dtl@ yJ0Ў/TQҙH#rɅ~A[P:r{k8R E+$QECth8z$dF[,n$tTeDߺnv ŵքD,Eb xLC` ng 馵I}c 0~0?HJc}F$b8a5r'Ljn|Z3N ^˵3ͭR/?ꎉ\`ECB)`;%r녖W]9K H$=0ԮXI4왈A=ߙӠ ǫծ]"~iZOMM&v{ĮgL ISؑS$FI ̜uA;)nB6zm׏Xs|}o$\SjL0tbspFɠҝxf `Brk.0<^P@mB5CܱG=Co''P,Ny[Zb #H@UM}j VcWu kgsEacFP9߯0*9|t#q򢣭C1SRːǑ57€=05K I(0p ƪLH!h8$3ZCIze³ڧFމV? dsgO|m"Coԡ`s]A0ؼCe.-I'JXcPBA AL:Hɯw&W"8Q0Lb:isZG>t8aNUcof⅟^x^sz'ȷ7BXf|_&lr,| TAބɮ|?ʷ#ufz=Dyv{pC,ec%iFݝ$fWr!|Z6]J`cAQ+wLJ^7rú!ҠŚ>>Nrhg5 4+$ԸЮXΔS/ 1#/OO:/u@ z\_*W49D:4H0{ H3G8k;S~ed`jSKcu2S/ۉ͖G7cs<@cs2:ꨦ~S쨛$[n F[P;_U9wk2Qkol hV@ٷq=fGاEFS"u鞎09KQ,F!AY k@\MȈ腨ԛ_+[sɢ-V.R1K2RTN%&;1?6w.cXKkD7,Ucn|~b_ESuNz;e*.R->xjfOgg^$i$!@uШF̻%O9_vGhVQ6g/m-E`yy0D4D@|kVNn + Ν2^e9# Y:b~F*r-=alKtg܎:5a4q_5N$d3'ZpUkguJ<"g%O 30̵o=VQr"0Tי"2[KقfkɐNJR. 6/YOE㘜M42ny߆=q{|>9 MK' J.[ݒqi!gt RxP#e-SF'ԞM %=>_*׃0/Ojo sDAb= n}5#;K!Hj~V/'refFØ1z-bSs/cn]Mº6;#iW=hfe_CQ7 itܨ̤g0-,4bs齁*7n8bzQÎS_A=o/eG l9s;*d:wB -GbF77y#,k4B0ŗQxz'\<Ը87k_UťxQn;v `K<~LJRT0A+\+Wb٫SSky)|wv[* oyd+S!"}N8Cggp*F6KaK-81# yhYD&<}= &@~cMV>te8WћӕȧKC i͂hdY`L1 HZEsEy$AIyuu|zh)/zWi`+Vۯm`X!N;Il֥IyXk`R Cm~%[-GqrX$? rRA^'QT)"HaТY^VЁ@ D@Im3B~Y\x[HįpJqb50ۦh[\*&+-I -41"/IWP9ĆQCQf -%A' bS'ǧIN ߍ֯^/ݢzm#!Bx',p[o-׭(\!o6EJ.o u~rti4G-#03$8$o{X;訆 ;#YW93S)P2.#U۲P{ֳ[_{Y#EOVHAvsƒfe(rV8^\S\(8V3(+EbVμXs+P! A^(de-~#D9%&ix&zDbǯV>GK)F%yR[q| r׵}ahc$ÑW2/H(L9lU:%k2 E&͝Gqjot-MN$ 5㘅\OT8;.s$ EU8wr*T.Z:M[wHwyz-le @Wr&C&2~vڦK5˭8+ 1A.jL\kB0w1*lrV>1dJᜒOԅ|2f,"LAżiOX9C=7%$hm6#Kˠt@m=lqߠaYn\WY0RL6@ QSu u|þfv$!^;sl93. 2Wl <ũ %1ղʂ_2>3n/a<6E Ime|Ax]Ƹt;2ӄZU+Βm{Qǩ`n775We[CVX=.a;U}+όµh 2J`8@, ś/nڙ*6y##`bdTnYQ׷PN<ص_Ƀ?uq/%̃ X3ܕګhNTJ%M)LRGآXv(R{h(&ӃuIm@oXpǏ_t/' ~)%C<ϓ[=A~$Vjג4,VznysIFM. psP4/@>;W.W)Rd i1"A+x%;QЍ(m2T ESՓ:xbJF!\pXF;8 O)6PA=Z%||B%$H F "y]d n:d  q=woiݽlzӶ^\w@_l>~msۃ+ߴ{Dz_-w^_czi[SY>'ꝧua\Wv}m<@G#P #%4%:vp(s+W A4u9t+&mcCFm|ڱ=F)f G Ly3-OAerW ]>O(dBF#FXEC mSb"bBPs/8%mmʦ1l`ۏ ף)wGKؐg.c3keh!2 [mHՊ@>S3jzhIG &rZC 6:!1Bl-x-0P,qq [x!N:}3%@D>p'$aӳG6aEL2c><*(&1*׶JLMݲQt1WN*R6=V8-i n+ĉa2"J'wB<-4tF+\$i$GQR_l":;%Wk>e Ve%Mqs\$#'#-ed 4TF- j] %`S&wfh 紤k#6=^u&t8&$LeUU:Y4c \! .tXv >vltsRV۔;I(sP JO4\e3;2gl!_B _]|}d:s0+S@KG8FJTNlg.4'ȁT}5 6Ў!l#xy#l0nJVO9w{2D=J\xJ(rbSh?!jΩaL|͉^c<V1>yȖH)u]e3̫}gpF$gh 9$`/ 3Mߢœ+ΐ3(<njzg +ɷ'ݎg`D&}˜h.o@x.?,1L/ '+ݟpڛ|1! ٠$Ark{_K7ղ)N,j`o) 3rn!Z u=lVC9}sh]^\"k8$D1w(|TBm~IJ6*4E#D_+6#F⽰"sncWP}UBǍ˖#5(w]ʓ~`jQԎYڀz0T3vLɑO+WTߴGF071Iw`F!6ە@ƯF VC1o\ĸR _lFRzwgg< $m(8̓ .6?XTސ!%| 2K]{VFxgiMiN;thևN mAd;U=58`` >ZHwa5tklVGzA׷~MFqlAqАD.؛ e.'#n{Xv$I%97z5Io!5 TE<9؋^ )yx|f7k E5Ie:$oM? Q gBE+r@rݛV姲ns&)&U/[ |ӥn~+&>+;АԅSq1?iƘ΄XBT˒)jQ*{iύy5t}80` cOT-Vn.HP='FKz];;19]=/'ՇjwPzE y7ƅp!Ȫ ;F:+ i.bj%oueFFJ&d]y6֎g>=QqKb޴fW_YO@ b CLu\],T)%L Ը/|iA}de-%3sDD2a H$M*<_('w*PvYy̆(Eb"j"NP="uD9L@[ I[Y  +4RmԕQnh5=xW38`;bMˆ2o4E*.a!z_][\ Fx66n7x >uǓ[pp L\gO]d,mJ@t0lʊ<1>܄> 6{/j[a".P og^k W^&ET<fO֖-h8}j=Пj)K[rRTȠ1Zy=׿N4%ZDN&axOBÐ7p4壏ϝnpZK-"yڤigvvT ^DѢ6^n]5 QYw^lA{}]4;Wvy-v|jmajmGw*pVҾԷ?wjگgjnozޒ Bm]wF}ޞ=ޏ?[[{ncns^ctOi{S{~tens.wns{dw|߮?~Y~Z/l.=~moW~ .Hv͇|<ՖJ+ھh?÷zzmzT]W֥:5=ݫ]\~ Y~ۿÿ{==请Cwzh]WghW5n˚;~n?ü[[߭ݳ[[%kKhvQmhow?v.oVݣnU~Q7uS׿wݻ^|b]Skl^ǛN+뽧ɺ׿)o{c{vyX&};Sw~;经wwu[U[Cϻ_v=e꿖6Mt?u5uvu^z<ר%<-M? v;ۋ&+IϺ\ =~WÏ(vULAѻh(N CnM3[mhۯLvѸaS 3^uASz1ge\vXmH%5tA+x]"$$jjZ37W9-UV0I%XF@A ` @ df66wph~j-O t<#r']]t31HMZjm,C!˜0g٬} <4@yN$s#'1wfdhMB<;HMo,O!-[{(Hw7^amN7;Zk4a)\[egblo 7xڇjYA;.{TT~s‹N8s w*@fiJ`@$r--`J <^~7+شRP^TK<+x~@\K5j/,L[H=QHGM->dnFdd ^`wV4WyY mFwa+NPr4o9? Q %]9KG/#0QBj)"V7j7sv#>!!6]h$[P+_Ol)rL+R? rxBhVh~C98j4vyJxO ; C0='37Hr{B]y.߼R7R-勚ѫDG%yI;$yYKD#IF`4ޚiG@l̕gyi]-6#Ȩa2 7egAN:IE͐G ̿0oX#Ӕ7ds'.>:?`]!S@9xtq( P~T{P?Hx7୲,F m;|\:jrS:҉Υ6bES__Mdу &׊`={xv}y\l߰ə;{ADJ@G!.M-eIC>V) ͢Zq 3nJSg:=%;ςl~Hb~m!9 ީR:zF%Ϥ+ së+IUm(lθOFM.m/җ/o[A@oRhI<}'Xᗥ1[!&n`H;B]s 7}ѓ(yl~$GOoȽ*吣PfR ِ0/ŵjpl"E0_!kӊ ;bK:#.au5tf!+[<FR=RKT.a7Z"rh&LJuJ ) K|}jK,1oqI,J˱7˨Vpvo?4tDFWj),-,N*i|V|R>ģu W/*;W?~6s9 Q*қ [dEB(#Al)QUq bet+KBnn$pY}\ n6!p@꩑,N=ב@d|-h}w{ wO30f͉F!D{j.'$qAh|F/'~[(&|jZsoIkT#iF< jqrQCN}؟O0EL? FI{g 3-PОwP@fz2F VǓ53E32j>|j}Q; oH2K zb=)D 6ݹʘm`~tm?qBucLdɔap= CI =[uxz]`HzKg :wdV+'ijyȳ9(jv0Qq*)'m!5b=}2Tuݑv@.?,^u,X .)s2̝^ 鐎IzRO\bG-˵] 3+b w= O7MbFJ0FX|]=_aAIc8_/Z]kr>0u]Q4o+mh_5:r%*.m-+`@f;*:䴫|钃)d}˓?VxP1\lfQ1X>,[mv*1o*>ZpVF b*K}K{BBLQ{Ju5lVK(OQjjIs=/8JOA9DD1I}AI% L\V|\#x1'E$#iTY|E荥1ޚBQӪw9+PJS Ɂ=eȫ݉t U>껝03]RR!/)U0X$GgQ(e:LdK]7I @N")[tW*Q6Q-#&}I!(Mܜ{wX#"tVmY:IP.#,%~ta Nժb7LZQxSφxc2 puGBrg7%Kӱ<_C] P/Ô$b#㶂9mNCxHn18vr+dvmW^A7G *"8w`u0%= x:tl}x$FTO5aW슂{@?kV~FX*1P  ßuΞx̰00#P) ;?<2/wL+~Pw8pwBj8{$Yy+BpBg޸g)c1D{ʃa86Z ڃCe0fRpݞ#Ujшa:/AWe裧3%џ,)Ex1Enq꣊s&Y gO"ˋN&(ϤjT dF^ϝz誨tm}c#@]?Io]#} "dŐZަ=fkwmā@6+,h ^3K+8* 4%pr R׀:j8Ӽ>q;/|;5w+RWeX˥m#yFx4֨~cNt45+K}]%ߩJv#ƴToLrc<*OEN~#`:K`&X='+z' bW&!a*n=-jWnp Ğ(PFZT$Wx-[fSSӑxXC详qfsl>益W Jv=I<hqڤ rp(fw5MU/]0{?`! QEڐ Ie6y,w Ч#),1\^0Du{Q m .τ:d#ё`JՕ -4~e+'c_(9 @vQ -{#i O0q|gIU)rYm@BuK9BA[V}IQa*k_f$ PIdh3#.$?@R-m4-兩ZǢGqjbwn2b,.W tE {aIi4q< }fi#]G:k:jj1$Y:D [8KCw\$= /{*3u1fQ4=`,Sl,7Qr.P4jQGHuZDrb !z)mpoFdPiܖ.>~詆r\xC|ތxM]i^YUdZ{re\GZWM݊LR|/)EM&%*QuH97'9A.;*XCw0!w* :d`Ϧ>]*Nl02Q0g -rӞsoxwܛCEFSa" ~ZS ^};3̢lIxmDWn}[Z?CĨA{uloL_bF(<$L`ɒdTg&*tHB9ƶ[qWDmeƑUZFիWJ 3ak/?QRXs._60=҅{ Ad:IF ˃,(<"^{vcG"4a7o$%4!b-}?L 3Q_A4ǩ'ai0Kٰ8BL:=#7I:+gc ^Q#>N"6Ui$"%jHͨ(vAr4N]|(@NS;ixߢgåOK'<ؕ=7n?,D9, HaL/ڕjMeBz['Fk8z{ ڡ>#]{ȀhjdNK3jcZ>Y% ̥Q*|_ETGPgj= #}?Ո,e2@?(=|F-8i| Qp1[*@(#.Kaak*av;k<*wHS:./l#'{r-_tT7FE4Q #|!@ޟ|AF\2XLDh"-T/@Sdh1W+2yA=Ԇn_AD)ad8ԈMKăH)e0lE<̆1hkyӘSuՕsã^GumCy+ƶ?OKrYa0h[$0JD-qd-QWƭX] NmpSG pY1M+f4"K+c aO#[DaMX(fsjxu{ll)2@fdSV ZZ&z:,PJo4 hv֚y..bߨ؁#Hȝ?{L%op:-9:&OCؘm=9a7Y ͕1>u|csYbcK܉eE?|KR|X!b.h jRCn-)lSm݀߁j`<%R%M}쐮τH)mƖnb.,Q`JĵhXCόy3 H Fm w!,-6U_H}~00%KR<"%b2xe8׼$}օ ?QKYǺjr3'j^@V?fAתp Bֈ=qK+Ee5Mxf"TEq;%T) oLõ֘<>!%Uo` &j¸ ].J!.gO Ⲩ! -G0阵.-WߢnoLq} }Q#lḔ&z5?$K}akdtbϳ EM29<֛epEEOx(^w/yQRБ-.JP5X« J洙trGvbïaa5''J}ܑEKG4gkD\\iNd Hs< E\~'<(udbWn]{D'g}dWᬕb$m ߾n|Ԛf TY8 bnD(a*74c@h>+h oHl4Ke/\Fz}/ TȰD b1ICZ*į]S-Xs-zh3pV)b1mَGۘ7sΈIm] @CG#vFz ٲhILJ BDsn1%_5RzJGo%s jܔHZoza3}"I47mRSjFUUR["۷2ov ڛ/nӍSTY?眻3[-00XNlD"C=Q;13@8=|x[- FV.,` BvfH VigO&-Jܝ,a8Sb*Ue߉ܪdɓ8IL@1Q" tԶ<5]%tjP ȳ T>Avc (P.zK5Aiܬ q%Fq!0j]wn65e(7Kt'+%"p%vt4T ({̕P0(4NQj85&,:(+o6G7c%rgfvOzyϓC!iAsqq: Ӄ$kJl?3,`Of R _aF75a[sg12ah"6"yr$:1&OA)Gz޽XْGvlRN:RG{u ? +*f2oԡ.&GZEt"n4\,hL^v.N2Q;ޙ[QS:o6* a79`RKQ<D it[/kǖˇ"h؁ꉪGp*(8wdKM3.!H'&!Dҝ/1N37pǹoSEB"/SGkTΰ6e HB.>iKc:"1O$ =9Y)[y~U7 z-~h\2 3t ߍ;{/p^XZ]"KΣJ'VXw?euh% i^; <"ԳOlq7s09G=Yj@SYqj>6ړE_e9e  <Ȼgmk;V\qYL>&&)^ߌBtk ZA31|&U#G >a cjn=H1} —b5V )n()9\V9P4l˽=. /OA>O]EOu̾mB(8 .GimjIC`Yۄ|8I޵lx蜁P(TNӒN4CnbgE~1ٺ[0bsl/m%vT&BT`~N}pq.pn&7AC\굨_ miInN0tgzˑ&*WMD3IbHRT@h~~~b*C!217".詸ݐK1H 3iħ#r#}(!0ZѨݵ4Z=wjlM = 2Of?cʴ5GQݭhKhrR$_& NΡqڤxda5ƕ54րvWU4(,}T6W4ʰNG@,),iw}csՖe>8 ܅歂j >]rM6FoA)ES6+@Cj?{z9P_``2GS7rvfKGP;=&Vˆp>?\mmLy~`Q>iAaĄ?uoYdd?ݰeGp˺;3'?:EMd˸O0標QKlyl'l?NJ6%! P8a$n#N~ x1e[)J|r4V uPڀ荪UXFUB3o .^N]mkmDcMi[HZ!_x6KN L+4CTN/Rn%PȢ[  [ou[I2'Z.FpLCDnV4nnI^k܉g]RY~uϿkx“30i",Fy7 L yh+i( "-evAԲ?De47>6%\[ϡp!z P(h/$tŕݓRr4o$G-6(M@L]ץ]ȌGr\]h?ToUk8R>>C]SpIR(-Vx\ۄc1[.jΛ)81˔A,xI}sq}6= 9|~M3&n5ĹUVq5=1i#K 6I:ТƈUOPOݍ bjֻX!`Cav5=arl,ԶX+t!C% IBٝߒL>uc[ /dy ~f}r7M|rd,!.%_ ^r>f'1ep(t@17cJqb>sd0'WS6|̟m+QN`ySȿ{ceʌm rhW>"q[&JNkBڽU;#AylWf*j?V8*}6ޗ6[@,^hT-i"B3:`˺1 )B`UĊI9TA=?y;Vﭮ!ujL)8M'aMSBz4dU ٝ[C hBMJDўgtdGwS> `Iv6 hM-mJv+7XS겅K n݅)zlC[7>*AXnKVBmR$ uw}ySúNT:1)O1_LnBaB;Z{6#.= RBab#[N)$w ^b!>ӈNlE8 iGY"< {8J )j'mt[4HZh9;Rb2vkOif*ڦrS=`*?   4 3o$l3$*m%;-<_w?jmllFH)&@z{W-zF00#̈́ƣ2U/DbVvD!P8}OaMcHU"h6^gΐi P@en4BpW[Уfpjb8銼當x~8-B[מNȘ>>u$ͿH5)°(sx2F0l(RD+Y)>3u:VW\.Z#R.F1quͭW(ѻHx#<2ojU R-21ǪztQ+.F t`|Ϩ201A,-[RHjavy,42Z(:)<lq-9Y[-dK*|Xcn+ {w°_{a{Oi66OR5'wza>0Hd-z$ѝm˭%(xQ*#[~Ou!R@^R#xdm4M #&εaZymn_]$)(cե6$|st uyebXA_ gCN""8s3s8Tw0;+MF o,ٵm5*˼Rpqp!P^ÏF9m GҦ`V]/=. юoH1Ց5ukD2zIZ5nSɅ]H$T&zX\\ݭ>2ib1wg|a]N!jWFjP=*->Liv[ rm5ーcdҟuԻl%?s~eNy]`.x҆l i@&y&:3/HKn0+ig܀6kzc ZkUb I:%9}#@0ǵ~j{ +չAM`G@b7 o)0iq~ 8*Ao!vT]q*Jma $l2y' NFjA=B:exR &:`{s^4Cc)GdXj=\#eKeꛫ^3?-a`:h~sjM Y\ ^O \Yv !8M]+@70#ߢ=Q]#RYQr@JF&Nye Zxf n&,=F/wx}cgxRᄎꎫ_ƺYD$+r)HHËY_6`S(nY*a)e-`!S#J?r`uGޛ%lcyPwY4)h0sÕb. ?p߶k;QYS7#]g/ssF௶*LmgMϹ ف$@֍e_rs"3~-: YR(l|Al(=>3}(KGmaa!fc1lw>,;ID^SｲX;1LIc\z09>),j0b:a=vrUy%ZԞN|K/]~ V,Y66, 3 EyS+q~*ݵ@OS.l5:<II ڧ^7[GRyQ 8ز˕poBq#A<<{@1&]0 X0[y^f tdǓ`sgD{)۰{-u=2(ԡghzeWIpJuȘLKcn-C A YkkxgLe|fI*?șt/V`T| fgݍٳغA Dh'_zll{r 4;]@UrSR1-ʕE9{[]EG&-N?蝵6`KvD_ nue`ʽ1l'EU,S Soa:/9X˹4p qa0}U&X1ViBNm(RB\+5semKwNT rJ*ZA@e1,Zfr;|1r;,`v$p Dd 1Lj]p'^{u<>N6zmhbA.#N^c?`M= Xv9hoȓuAlbDȹ?;Cwl ^n'4\Q"R;%,UΦMYJ}kQeHIQ!i~KT3?2~XܹPR[s8Z}Cq1A7' YR@D2d#XNkSi,T"6CQ q0Ң$7G PƆAE߽HaF<*d1# .Jy=.q_s05/2s{ќXdNp[< \zPZ" [VqAF-&'rz\Md*7i4ԧcYHRqFuN'Pe 5q& 㕵QUӇklĝCef@K-+'{v>]1C HRzoè{TRbdCL:GdS$jq5PH(/Y@w2yy#> l =rp  x;QCrAy!ieq|-ARUI 6yP8t,䜹E'a^Y&@A'uc ݜWڳ7脂ȀV㬓=Xت-i&H76*DtךWgҬh+,bfț5FTcTHQGބ~wB j]Hgcꮈ[޿mH [C3VvDQ6gp<6foժŏ܊db& [ja!rGuo)2H\a^g#GjuPIJcƚ7E{C׃p\}h=djQ%p@dX';Pz՘ ;^D|,3A3v je?–*5MrM=Kj3nts|F~^`e-֏3gaXR٤k0_ZwΔq[2EU}JYmzeR$c4@*8.DX/G?YIH_Uf^õ]uioKgHīO=>ccݮԤ\`#JR4#2'R/PGUO_ݿ\7_..%LsZ^xiYb#RHzq+WCje㋢V꺤OA3 v~JDQ`*1 6xRfQV0pW@0x,mDMG;+J₮{ lV$ǠzJO%$ȰK!矖d|= KuF퉭(ב T(=ZfVrugҠjWضo}-֝ Ӟo?y]TK3yȫj9{F+T ZP؅mudtޚp%E%ctDK_%Jq}olMjf=Ӽ%zuC^}<_k>NB>q)OPN|.?R6ncsyxdALz&@tB;cC\L@hb( '+ҭ^Y +RY]}4@ӓ+NQ;,lT,Wf慉5M'8FJMfz+B@d(~(}&U _NC1^0Lʿd܍Ru}ȿ_2?mׅ!r뷬 &+.mȽl{$(h.d5as0jQ9gYıkJ]؅SQ&Nd!$"5laz-#@@${oڴDoپA_YcoVKtR'K؁m&]ofیQQQdR+*p :'6T*׺2lEb ]kP1Jq*7:߅:/hkjP!-D|v?oGdf_ _y w:fM隬!o(oyj Y`1@V꠭Dͳu4CxFgl6(BvltpMw!jM#߃^C옞"ΝqdiRb"b`_D:/(zZqŨ^ ${G.:~Ҧ畋3?$E6xt/"0fAh7^XU(OEx77 e waA( WQNh4wUV,8#51'ҢTF03(ګ3-_qV[K\P^!]U?=K!.FTʞ/a6&TAΥgOmܩjr$b@Q&:b}1)qrf ZhU L-+ofaޢ,W4:=ɁWbm\X!G}L EWԷ& AA7R~.od@U.^: qPGfT֢yC6^19>Yk6&f⍷3DɴXAKɮ@BՂI~jU>+%oac]15[L )I E.Xyj>ѓ2_ O9w2WuF: 4I ꣑8L4[<gU,l /=.@٣7:LMX3/<:,%wؒ9J¾f[դDyR!C! (H.y宕΃<+rRc@4XhOb8E!#٠f>s70$5Wj6+=Z .F8‰_] #] !! ]3F$ۣ[}.3p3 }E*.EdB_zn9i1k|جtQ/(43xUKB. Sbhmky$vѷ "^<:Q&ƞ Im& K\P&6`ya+(~oF)~~SďBm?A% um/t5FaN|;0\ m[ˡ:h/ t@5~7B^D^68ß6oQAN9R5v\apxߎb'er{$_9\V)FF&.7.\N7U6  r- T^Ǧ[ASd*V<1 .acP jY3 P㛉C@MQ H!@Lf'<"/Q/D"G8Уrow弒Bzr$F`3%v8SSW$}BC\6@ z65#-ZQ_ A:iwuZC#CݿEhB&Eh$K( a56 'nLn1v_}wGu31'd45I9WbuC ޵pAr4xp1[3`B^^d0S>l"S:Ě_ Z-X{pd%6"%`(7A|=gh3@nt({. x۔C㥱PD3\.U%Tײ3edqrS So$`$5 hgA#UXGJ[/-Ar@._Tyz.i=/6&#h/sN^;^~W<')uWe1 D5޸`i)[k7.#;iI0I٭˧{(64.`v'ns~vKLz'MFk#⠅#0+ H~J6L fzX >1{O/2BY״YŕHpmmj=KKl:9 ZJn !PFxܳas[̨vi}3~i@n :oL!cʍdK%z0cʖxl#r\" F< 3~S9\V9s4r;AGq潮&KO .d":m0?>_ǎyRp&d7ʑ!D;KZ:q2nj{-slPġܝGוќ|C\ zm(zjwZu\@2hcԓac/MmK[8UFI&G۝_ @@v78A;&jk\VƗO/A,?S&oFP1%; rk?'6MJ!2\30BJFw_m% IRHڣo[śNZ?~fݜp6gh@rKݞw}h6Wτ)KDC 8pBdR~$El<( ɩh%Cj'»'-$Ƽcf _h2IOA~w:lgSc}X> "޵ަ`%(}K2F5Op䐛2-g g4%\bO WKAHk'L$\!2nZDd,d*̀W6GL oKdԈރ(۹72qx,}I,w>Jm(4_#Ap ɎI'" `r +8(g_Vs6pG4N͉AiAf>/+`b%A\ftQ#-amX1ջ6wK4jz]El^ϸ/RHިY"{hhM#ljju{ O˖z?yʫfU 9xP5BFN:tyk؆q CYCӸ3GSO{SwQM\@W/=NALVe<&D 37<ŇNe0\h_XZxrqX/c~$2=+r9 ~Kdփ$Ų{jq% h`x.mk|=liszqi*/2Þl%Em#) fv5(b.ۚ} , ȇhE7pߑ-nϐM Ħ17 *365J݁{ Poی} d`?3&NO)=xł:)q}@c̳\>t`F [#21](^HLg^;Rj;1GH QCwuLbs-j9Y}F{/CIH?-UG Z,'!uRf+2!y)P !#C_W--Ry[%o^8*A/HYݘGVf./$hiwɓU8Qf606ZJ7PE7$$J>@n)֩hfћLoaIND!I1cmATADZa89^5yXpjRvS;92WWR#8"W@Ց"v,\ QrEk=Ωɮ>M!'4OA\$cyoT0 H ޭ g j>"ZtbD׸<;U="A4%-oMRzşmc9扣A/n}R+MpVemqyOİClOhHzSxu0(^WY szYʿ'~H]+>/Filter/JBIG2Decode/Height 1752/ImageMask true/Length 26809/Name/X/Subtype/Image/Type/XObject/Width 1240>>stream 3, a cX%fpyK\YCvH+ DHųq?ֳH*eKI24'P4_Zͣ\"3G5ۣ!bp;ߣV$fžUgV~@H#MW; ):z~\7;3=>ޣ/a?"6ʊecH?oЛ?sPLt}ˆEi@Adgp>7Ђ4[1J=`I3sr x/(2Yot˽&`UC"k3jrJ$@v")s8f8K @m9ۜ3:鴟n;/sϤT}v>[`wć!8~U 16|Y (W$p#č^m@BQe,_ Il٩UщE>Qtcn9cd "|&nćkHQY\k鯳bN!S$qμ<9li!C:YtUyGJフ ?ly6yq5oəe*/|F00m}XnyMݩ.!7 +v;o+?万Tg-84O?Yv`Lf]y[ͺP5pQ[=Fs?* }}1St]L:琫SEh,79rhr_wθȋXТYJ*iGc6놈FO/ܡX&Mh2 :._Lघl%1\TqB{8(uęƚS}3}: !yYC9M#햭.C:̠r_(cG@#cwSC;6 zܢ]GO#Ts ^au૒`^T y$2`)p8񔑄+DL&IȚ{¸GlKH:f~p;!$kք0,c%١`]gt7f\lFeX3D4N^/|W-)1UȬUch\$ !6.5QʲhD$U_,WǑFOw]®X{EGd SwY$M&aUSlh}>Y7ILRb`5 S[olZ:BӏtpXPLWT+8<<;!9ym9_G$nJF2pAwک?ﻇ W۟b 0nkC T{Y+ J8@`*eJdJj.44rOCBġ>7~p]tsvώgb5.&!0;~,. FH_dzI nṡ.VG$T42*J_=^ ô46äx`vKe% >X\ȅUJCֲk^iTγ\b-v*5~Ző9!sS% 9ە;GE4HY.Ȟ /8pN*Jd-[]x8)6ޣ cu,Q56o%`Nj$G#r7axNz"Hbk񽉓h= QENyw\^h?r \7ϋjQoS]{A@c7sR 'Y0?e*[:*chڌ?Rcڕ8|o5/"Qg,%s)8xڨz h#( jb+~+$F%Z4pF$pze?4vq {BN@nل9& 2_d :`TJayDif uYdФ=yn?vC*LF[u*0,cd9 ܖtp>~# ^#{|-$0Nq@LY@yz?Q,x5oB C++[7}$ȸ1ecGQtŅo7N (EjMd1*Hskh~Hny5P F<e,Wzn.-DzgL8MjƠ* 0:U !gsM! ާ97ʍ:N1jD/bPK%[K^:[▸%+?Yv" '.A%o\H(N@!C7xa mnJH%|yX#cڈldw IX3Gl-QΑuonkBRG;M|rIDAaet9"%9#MwK\ y*^C x,gSzK`%6Ιa_ h>KpzX<ݲU])-NҠ#yJ#y^ >ڿƒk::ΐ!ACoLe %-tF$ϭ"-C7,!/PG"=%kUPqVޕV,6!g*ɸX/$ ‹C6݌6luP <XfّK*'O)BV5zخ;S#,d;wݩ$w>O8Bz"ND6BYd(U@Ѿ-U]36-?{!Sz¤F93oUMg@S̼ 7$'2bMըm2rx`#YFnPC!1zQpB"{Bx|byJzpKԳ}8I7(F"A-cໟoxy ߔ x-ccTxH!6W.??X{@y|"7{SSz`-'t LĊPg"w=;g&<-Jx?&Fwr9^/}e 8 QPE[{$Iwj&̰1v)T D熞:e7I2]֟TmQP'JOĄ[ jkA Ȣ5L M) L]w r 7>x[_]șŏק`q(c% Y2?2`}.rHc suZf9V)w"HctOjd{N5W{/rᎥuNl'(}~" XX&Z+Qf `~q12d ٫kȴq^Qy@NvK{l;GRyL 6YM;H^B`|2o4?cHF=$TrWh՝EB*G_W:a  MVҀ,Ÿu R J~ Ng x|ܷeueҪhޭٯ ` (X tbl0(A5*0l/N7ךKDd zQ֨&@x` Zyo^6{bL1ΠZ$7 9WG[@g;]zZmĕȃޢVbE9 m88Yei$/gwF9@\N>MJo~Ee2iG:dA݂$AQ V6j$ow۰G1 (YKZ-4vɜB<'g/0}l #ZZ4#`<TS@1 fStwϒU=X_jHrdd'w# Y c~!HkH~+y<=#Ď90Ky T(W8M$AIlP\\J&9R>T: Z&&XDLwvRL5*6i{iI'kU⛳<_Mjy^ hb/Q_-H c^da4"tE U8z+@|-M:.e'P/%7i\Tc5y5baS?u1gJ42ɻSY/?eXHY; 1|Ld@`XDmFr" |!6E;'+7}>cH[@T,&DkvuD(uv!}nop<V ov]BűXUCn}Y e#g)՟9z\mg.H>yAIے֏ +_S+MqDTWwvUܥ3/ǡr#ܪMsQgb$5k$!9*UOX^a$P^!}P`%̺),33 6-ipv=͏ bVUQW '3rֵ܆7.Sw>͛CrSUH j,K$WN+9 {gFz L7X61}S|v@^m&Vh{zޏ<wS8ʿ`1saPhRu7ʻGTЏLK ܹ\f֔"?Lq5i{A{O@pa/]x,G'HFtV_b䯯K$WL/EN徽%&Ma/" [lJ4/Nm%n?SD}}Vat9U{ݎ ΥCl%{qs[:eϪR2Bn)KWOZR`ǺNҿpU\Iق6;Hà?ᔉdu6A{{J=&4 VxЀxvZ) 15vv;ل5*!^04 86 <:UT'òY*HV ÐmFK3måF4<$=v=R y ]nCP4 Hlz&ZgĩɤX\ҩ{'GY{[ oDٴۼUz/0`φ7,R}߀+ȿNBag0W5۫;n.HuN6Pֈx+x3mnH$*ᕸDv& $ lkA pfiG0f5h}ى6z b;`S/2@ F.~67YHv$[f u !u!jAZ ʓ+ގ&' !BrX]'Rq`hm&R|]C> ʨnԈV(Htc`=`~i2]6m83oXzCA-q8f[|U_'C;;QiMݱJjVk4h +,ޚ>dظړH $NR7Tѽh-5xsؐ.0X=4 'PsMt[eu^@>:0ҵ^&#q("U<Y!&7"3ָ|8'۔iMxXGԝNŽb^5jy.uiPo5Gt,ڋCӋu묗 ֔p3 i*YyTX%;AK׊~ڡzRBG'<Uqr kdx7ˆBgVW?FC_CP|t5 %v$QDQĹ ?Yf~3G'Ps\$2sb 4UTEr;V2V;nn r)3"<?݀ks5O)fبosIn{rr"EgxspSJ$vWB7$+OhYIt:-$?9itg%WQy^DQƲ3Kܣ.c1 Ytr4)-׵ 8d΅2 X.i;h EKó6Y2,Hzg&g0PKi:>zϑXL(W _8yu $eR7AJJP0h0FX-{X6~3==.4e;AQ1}v^M33Z'3хVm~Tl6dGAEneM#|7 `m>\0[>2mgfП~O>j( k!&+4qf _)Y0 !2Mu>!3~Ɣ2q/Tި[Ɓ] tQʀOGJvXJs.iLj(9(IǗ|a,w' :h ?TRgq[LMjUFs EYQ1aJIdros"lWH<|3< :_;`wIx5c{'4"MɊza0oe.}f#mwq?H췦jMqQ{sxZ4`]P:[kPS%*vYr4εu3f4wA1d>3>($ &殈*\!y09tq[gOv4E.Ou }$Y1F3yD Q}=dOZ8,CrW[=7 ɮnPl5nì}}LlKp3BږGxS˳9ܡpzKW>G*L/Q"P{튝=aڀ;<rz-¨wcA>CW՛L_/0ߑow a$$oCSi+2xA< um (+3DeH:dzL}(G&sgc` 1PBtՖ>e7Ő- A=ʱiV˗a7OBA3ƴA]";4kffSCr~j~l{zM 2 N[Qؿ)gpV!j‡#V ;ի;_ͭNEn6иlTB_chm3>gU23%p\ d!Y[0~ݍ(J_: i]Xڈ%ʤF(Z(]8}_Ӓ3|8d6WW%(7gbbG36+y'hyH[,52NMkڃh%0YK 8E?%fbBFC^uӨJ [X },ӿJ=z!>ܶMuYL)ٽKT'ioM"jRGtdAb&3н6bC!Dk#:0SC})X6D|cK 6KJ _*5Vzh(T!ۋ:#6KCó=1X[l]狶4i))g.H$|`|=VP钜)WWt L+!*Kl3}ntEpg^Ș>}*e/ƷPch?gB2 e+ $ x6X@mDWɃ4VNh_ !4 uj#_V"Z2,VGt:@}oU8md`n"޺P>-n;*Ϧ&9JTx_l4o"u HY݇Ԛ,U/2=2^W/P6zUQѡ%ƂG}u5?bxD7)i-pg}MnPq ~tF^I\A'"3?Yvكԋ`C>PC Wicuu9Ѩ%@N<|-13]p5ySl^བྷ9%N~߾;?<[֩9U8>pnL=iIx=Լ+^oJ&ODɬ?vw+ 8)$j(G`C)a\)vFμ'wYO&4\ϝ)I+~K_Ev<$bf?{Dl}͖5yd/`_ Eԟv]d*GY` b:z4S:r$ҕjw5-HSQ'|֬MsP_<{Åe1Z 4-f'S0 1̀/\fGH2r,;dND$0Un騊pB3Ƽ0@ 5X&Դ5)pynx ª&k>-ɖ ftTSI!yoHsldzAg- c=TP&Ba^)n%q#[5,rFyA02ϦdMk8 ]&z}sFZF1`Ͱc@^mLބjeqXBYXSp! G"KPDv1]eR8'B1]-EGZ-k@bMܲROD|z(Շ(pymBb3jX(10ђS )y%g:ދ6u؍Q"? YMBz- ^UN Em dлks }C±'"&ˁf ¯Ffl/3<'$:O`2$sšAH[SCY~bRTb89&Ds[jld+/<)F+Kx3^_դ>@بӛc>Wxڸ0ۤQ<70Lq lUiJX$- ^kc6=|^h>H*EF`/qo OՈXÄ>@ÍPC 1T='l`kg /"nc]KsL"pKJ4Ru)90;&RfJqy &*9(K[Q~EC٧gËFᐄ +xª7~yϟtGx.x 1@ݙ&78!r~A%/񸣑 QlQU5;}R&IVdf m(K;jWConbG j&,{E`E?!ָJ2-뀞C8e֪+<*<]ptBLDALf(wZ;Yp|o/ ^BOC -Jz# Ǭ}|\hE֖P&vgm~xGg_$ޥjrj .q+m]LQڿҾڥ s#p[RQҞfJubUװ\78e<= I H3l-`!kT:?wY\ʅrp|u8K[9CvE}.XB_\X:ZaEVSRˬUfUڙpoa NJ~V &r?̎U9 ^v^ VaƜ1!+ -,= o]ִFP[DgW[.<"*Yr}fo>2hCP&VvIUG'fmѢ]H`FXNJ 9 !>K:Ȳ^Es+LyXֱeɭ g|@a_aZ9DM  R,ٮ [թL;qn;J3RP c@p)Tc'67:SlZ6٢6G8tq[+\2?z>C|9I|rutϓ@/@ջw!q֘s{clZ?Z{ԞI5 o wK :p<*-y^Fא(}sb <ςsS_ IyQdʚwr+mXF|қS )}WCα[Is\vT(u#Cec?_p'jl#Dr;6O.2 Vu8RTX.Wcٝ 6:T` N̼ plwAs@/وTQi:WjW6djVCWj\~$o".3xL~N J)fP-_uNv_3^ Rr$f |_ag4@>q 2/NXeOpl83v҇Ϸabm`%vSra ~}~$͂sO,ȣlIʰCGʷ;ӳgmHz0g|M4C_N֝H;:-Vy[a4mJh̘cr{_[}0_5sf%'Ar,oyv Μڙ2CYMt̆q>Mf! SzOUY$G'n­vϜM/)@~ U eB[Fx98L_F7L Z_6/5z:\`H H2zw'ж yxK:@X*,{`䷦bc!NטFdiK80IffrR TA^ʻ)XhY'aJ6pG}P]M S5J#LH6 nb_/0`iM7bK. MaZ;[dv{Yfh:D y_q1 ȲA0(%s6 u`rLJlchX߿=]]5>gJPЭ+}Y,>&vW1z{@j豒#5zasB2t0<@K}utB,%rd/'noÆaw#A -h-ȩ?- _I>J+ܤhh*x79` 1r}%6glF—~n[9YQfwN!e%N>CӃ(Qs[y;ӗXk'([Z# ݡR"ؔ~۷z$s2_2V@DҺSW/P))P@J(wHLZǯA,*S^pW`MzࢄvNoyG\G.mF'x=<&`&~4k[^7*-NI$ʾe=;#UP!s. wfd8ֈJol ^w{[vY\6ZI A/˴M -{A=c)PTᬄqkgzEQs+(1Rt x+YsiEi)l)x(ȃv28xuAnb'/" ΢%%P3(@y%!X6$m|[e;IN&_\ ? 0wm2k🦔qnN2[LLgܖ Aκ }gD9/yC݊v:Uuznm:);̘}!4ۏu>C-iW~pMFd) ,0ax 0gB虁7+(`)ei:@O Kv)8zH/Nϔf*O )nGp~1A(-=>pG`ZnE\*ó`@xXZcuƓOxphiBg-x2{Z,mV!%Я}jS㻅QJ)3jy_Ajx2wW s:&O2N=E *憎2;W<$wYЫTy$R5=Q]qooWWAp'Nx@:Og1h5 #GU5v_NJC^+Bp&UjVL$ }).m "v ?v g]@?Yx$l=$EƄHC(.)vQbƂ8dYUf HH_v^wyX8{t-'>q Tnv9K4de `=-*Jpq{ IЫ,M5j)x]PkE/b`j:2QUwײ 3,\0Y@}qEai$leIߧdK.$4CĦb`*Q:+*Ru &Bܡ ,J6—Q՛DxrO6=j鞑-:Xve"WjQRuWrׇXVƌ*o= ènIZЕ|%ID]b}$}vFp4P [irXHrh!T=JYz6`iԪE3jvx,-Pb$mY}yV&a`Vń;M 7 !\+yY54BFB2ZH><Չ%f>KN"X89GMM53 mX RF$ǵB$0b *TC"e~Q;wO&ny({60ֈG]WMvF:} OzkǾwqLAH:ۍwXw-0kgI|'4uhMoڬ |<$lnۖc;|h@V-s޽UvyЋ B᫪iAmq(=[*U]C%5np0A R,E8vvrȆֲ`újSK A8Jבk/:VU(x;#fERܳ nnP9 u]m6B'o[ (T WGr V2=3fyՉ+jψw{6Ц2ڱK`7܇iq󊻳HY&4>ƘI:m&W]A2{F]`O> D|SYDQ-]-:ۧFC;8ly1ɄS' 21IEq4 lalt{#b@Jd2O8 c v|~*Q# V5`)a;TQ[v ASٙ R3ֽ*阖hT-9ʓ"ƍg XyC9 b_ra`|-[} 2 [VT5ϺN:ݒ=t#hXwfSţOע!YZ߆ U+N%.4$˹g֥6:8tχ-kM޺{QJ1=o=bۊJY? mLDd0 W#p2m%Ɖ)~} }yV<ʌNڪ' 0ޓ$鲝" .t׵kǒڠcc* ( g}s_ a 7y0M@ |>ҴQ^ k@^L"XeK|¤߃dH;(T ҕ-KhC]枋`%ȒMe4jx*O5DNؑ7נxrL0ݦ eq[I2[Fz !n>Q[p2Z1N|\7ǜpqFEnppk~ҞӀjQ;{1O->Y$mttH_4W12Pz#ُ3>VW/M4aM-mPxàS8ZPg@UU3fG٣ebT$)+sNбOz!ߘh~ hq=0SUqE.'Z 8o3b95?1uM)9 7_#N];A |ح]|RӧaS{Q *ZRVl^DZ٪P1SP #l@sAsRF,&tb_VbVN5H`y @ ЦWMڲ#z0-4QW}tոiiaP$!Q[fPɎlvܱ+2G'&);b|1SGZu]Ͼ:υ8NvWytb(4#=?&5{z. -d:] pd7"dvL˧qkfԽ[ !׹'i!yZ兆+*ۭ7F9p6؞W 3fWI& Y:L$űNIV<Lu(c6b3Dj_+hz+xa"Lud=^*ޅ_dv7%S$,Dl7$wpIJ)EV^3DоNrNW\F{ʺ(9Uz*VݢQQD4 $Sxt#aOoL;YX1"OՔ6^dYJHmRs@TA}iPu) kgF] #3rx4:l0qk=OCLҙ%^40a- 'pi5:9ge]P բXtYxBl)䕡FdE^Q.<?T^Te%Z`Tl 09lXf6!jjYyx[}| wWZ[xyNcF(v Χxc h6*{#O5#(24 (W2^Op7ffIʼnݠ;ɨ^{9rY${<BنXN zˍvo3Yz5-l E(e5z.p~,,Xpl$AZ/L=~ߨFjA/:0G-Q-aR%qV_356o۰3;77M8pu#ճ,4!P)™y~`"TJ/ X.3$M}ZZ@bA9cU ָHD7W)ZxZX?m1S(_>ʒ>|6x[{#J |#HM&nlG R?mQ]],"w Ao\Q(+e|PCÅ*VU%C/َDuZlv/Qd5B%m+ohv <%ߺ7] aXǏFآП?ijE/pd)nxTw 03>7*OoW 5rc9=٨้ cWny12eOTm&StM#I,>1߸G H=\1sˠ<=bnOM")k7{s^GʖkGpLOTO",nXYbкZ 1=@4FXtp'.z"S=9$Wh )ۅ V.I=oKv?M@}0ϫa9"褫ԟ}8Lk9ϏMj4G/C}Cc\UpH&Ecc vQe;޴\ӯꮋѧ|*}U˧援rN}\.Pxv6m+LԿIaˁB‹]mŢ5n{"W<}go6D[ pI{SN!}۔%ԎU}kVO~>lr߄$q_~,%#ȱ Qos Ei4b _ 2*FCe78P8]*aQ$Ze+.up/H?s/HOEVԱ"6oF&/gpQj:H"> sz8JVrD*9Bplc7 kBHxgf,ʹu/8_|잡k՛԰)YCwݼv%ompp8I:@mD5қ's B}a{(^ u Ëc$"ϴpo;Y/9z'$5RduΒ^,6C+j\>hոw@ B &)%>AT9d%LPU U1ܐ-hr]ZiԂqލ|7q:wmՙּ2^Cg9W2`-uH[.tJmׅgxn4 YH!r$;/6p()[i&\w1@%kiw8~òd{a>) Pw h@+tkMޟ1 t}y6w4MJaM|O+s)v=sU" 5U[2H**ua¯'8t++G hgg"j$]E8FƁg6e8Y;ї));+ݶ|*^s]#ǧt q9,lqc)2^ʼ;.QJQ#ǙtVb'E>Nq~h@*}r|aA :1t"Y#PmEyOX.7G3Ηadڐ"=`)+@VQn 'w7C3 Uʄm Ge>s&Fu`hy`@MOhMY85:ԲT_WE);>`+K'E+Oq "OADץ= TbJAqp )ða88zxEz(^~y) %D HnyW,yGW=#J:ikџ!lpl,릀h7ͬ3hNWfv,K!BCȾ;^to9,c΍Gw`a*!߷fpZxঽpÓزE##MDԎ:LTldzc kf덿*o0<4GF<"O&/Yl[+q!b)L)d;{l>2|T:1WC2N܊BB#|t4U>:Hܦ p|ޝbb1 Q-5Z. 5D,yLb 88I^@`/uwGLc1b}d%E=h[~DISHcV=!C7ޭ+.\9ZA8VvqfS998@ p df}sެ:[X 7,j3]"Q QY Kg:ųTڱ%F i6$G\ݰJ>~16*8vtpPjSMF}[ِLsS-\cd&AH2Hv?x_(׌#Ap'/v& ^m=M?jc~4B)wvхi39>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrllcolr6 jp2cOQ/llllR \#B@HHPHHPHHPHHP((( ]$B@HHPHHPHHPHHP(((]$B@HHPHHPHHPHHP(((]$B@HHPHHPHHPHHPHHPϷT@/ '>-bd \oRSV-&sGPD|rJIo6l"xC&(HKz)/nF'}>ER; QhCCFPp%RA:n ֡=G@N{"!(qicHC1l!%Uj8uoH&Qb›"۵r7O$qI5r<+ׇZX8~ZyS[@ fMݕHT9i3H9ʎ](|hk?OLIkgTMcs6STJDS4~JB>AIgMW^RLINnQ ou~IlKiFnkY*}0egνq0RB7̛VxϤSYr(%ُs˜=9jvŽ>j+4+Z^2qTIۼP] hi@29 >eCTnNq DoQ\W16Cb1]U"\xunEXG K{>?lWV_g@wK"ͲvDRʣ;PxFngحj9_nˊ۹8h kaKB>Kn4A#)"vIA)"q_>TKl!shU"<3\XLeOxrB㊎mMOTc(64o,%M(XB}* }YFK4S\۵̮ ;r~]MZ28c*:G/ !S;ǖ-W/>S\g(W\ZѴqkxDXz_HPkYqg:@)9w{\ po/Gc F[mۙ1h!ң?+U3$/39"%-zo8*K F ͯNBn&Kڗh;+}}' g Nth||.r^P:S['[o_BhC0А xX)Vh}֯Zmev>i.sHC9Ba_MWYg.U%:&U.i?eC;457ŴS10Ml M$'ٷ!V1QZ_R\C* B7WLM3@x.': ' 4@.Jz7"2 tGĎWmȳo8_Ij7Cp>$g6Fpā=;4bDKʀEfL% :bwWbN+:)g o @JT=|dCΰ𖇾2Pfqi?gm #f T/&qjqTaqhz*ɩlo3z;ymrI |˘BG$`9 "　 }=4>^֗z{Gww{ލw^NU׽thpV5}Eq ',=y s(La溺S;F/&dn1kհs5P=:JC+k3l\|y~@8bd`.yq `*eldQ 0dAR7ĺ9Yb VSPG tqI2U lva ۇcLFGma-c>~otO'e%).VUFb~F^5Ttt, a9pűƳǪ"!\c9$ރ!'2Wdcc 6FnmC ۂ&bǣ#)g;` a2,B%ž}Yh+SpG4" ǘ+566pxMr'J%J`NLCS@#!8DwLtG:Q+vM: 6)i7h4|iǯDtvy49ʺ~,UFf6&uqLLβ*+BF30z"IgGbkJ TWsIZ8Y0* T/jMHl:8wkGpxD\N{~(]!+sk4D_^nrp\pjO uRa`7jP{n=CǡNH5=xrt Xvq~B *fMFnנ;7흿Ogyw|6fSl*Sגe&̘Qdg4íƨ͢Ap#E^mRav[~/6=/d9.6r 3r=Wd-JB- \"QNtv,Q)MUC,u8 hnx@TCX`D J@jFg ̓'v0o[ZL<,R3ubSu>ǸT]nol9|wc1'NQ]$P'L64@%H0F24^f ' #M7 C:+WXw+nKRCm0%(g%|i%B kvî3=q\u ѳ r7Q<={6Etj5(γ-0+dwz7R5zOcP)8@:`X_?ڠ>iI)katEl <+h`xCY6ZD23]0? GW0^ ǀ u&ЗhӫFQi[D-ߪ|n6saip+-Gts{kXh9Mq(1AE 0;&ÍI] rf=R*DdÁ%͙-q4- |uһT2ȐgJ˷+2[lʗTڥ}u(|TO]5 *(@Ț9 l8Cn&[¸Mmۙ>9?b{C9V,^&# CFzJ3I>F=Z0jMISR ,Q X",'GއVǝuI >~koG_Ws}}t^V7ٷMv)%Vu5F[jn՟>׽o:ݘMjD6'4J׳!y ]%&/1Y)A z!g *g *wo2n?q)RMf(;@X峪(N6=#2Y i#3epYǨ4)S8p^{)걈a>=6_I4 ʓ3 5Yn6j!$)WGM~VprZ6ib! @q:O ABy6uJYįXK2IghkMfWrk$}~:Kveأ⸤A :֢Hhj--m<~F{QRpZV4ՕVH*e]f  ѮIwhbL2eLsqXLL"yaэn-˝.] ӥAĶD2Ӕ;oW\,=zǻ5z~{WňwPQdǹn- ޽rw@  xE%`Ĩ#6X|a+G>1./wY}ް[W`*b.bϹdB FQ,5'/踄6yzhւᮣ$ɗ4ܥ#l*#O^ `vmeE{jxٶjq`jyj.y }f+CpW˅b$=G?Ǥд^BRƑ1 ))Co2Yޤ'8ڪYpi_Ífn<d0&b#P > 2q7ڿk/y{~w鏫=ttUOsۯtOtu5}utκt_lt7+/CuOm=}wV}ҿڏuۯt/=^{{O+~{~^_'纇qk~?ӀLdmo:gzm[ѿç jn~,7p$>zm푺wWpm7gnv/ʺ*Y2J%) mJ=g|o$X@|aD7}v$*ݶ(ß-A͈̓ѬՌ>Nfwiud "o1bS Xk̚r$>;-)Ǭ A0*(@͍ҨtK' lJ8'iRɮkkI+A=21`T]'C,%?Q:!%&۷7 t'r^QX-rrKc;xSXJ4˚W0~/j,o' AbFCXZ&X|F mnBor//pa] 2Xrn=QA=xcsttڗ -K'9yBBvsrѪrU뾺-7rw o%fe8z9"A9>Cːe+nNĚ Pg}Å.=!t{қ:BcG!(,_dMmt=[3h4(5\s2eXDʠ4-9fiDLxX@|M AeVYmJb̄D[iɓFfJ#7r.M4C&Emf$RS\oEbQZ?~LF:EJ7).dxvٔy{ڒDNB_0N Q05p-U"F2y@gʮ9 ۋ h=/ Ԏm-mٔ1bUpd*k)UEg][{g\5_بCRXU̯;Zlȏd^.7xBV`W:.>}|b RNzxR‡(I/ ^!7gBAt'<k; { ٣]mz6rV5ƾ%fc2ҳeNC"V=]e>Juj!H$9i)ɩǡf$et%ӿ1>R!g=Gwb I΁.!&T)'>4N$e&L%#|VX'|N&#PwG Ujߢ$L,Ͽcy䗿#tǗ׆ܝ)X[ *z/4ȭu? Tۑ7*լ%(:bV%Fh8 jӌ AE-_w}~$ 0l\9~;Z!jC |*a&{h W"%|.G鬟^5jkksh| B4g)>gJMIr>S+0dhm t)EЄOhXVmg1í˲vrcJó ZXK@ Qٳ"g66AyTrn;?\gS~D+lq6mp|KJo2aӭRhj}+?xc>)ː\ǧMx GG pMLܚB)zbP"5UHE5Z۞4@aD?VVj 4.A*gRׅ0YG'$gђq{ϕr2͂&M\)Z[c8#}R dVڢdA-!]:rMԒRԦ\bԝ;晸oвqbʷ;WktGKŞSqA/rnԮ{'\VRse,a2M_nb#?oAP8qOSl[GħdK% "YxɵʇIq OS+o.=տ84IO9}^M2@Ѐ051gOc8J n>0P"Z \K㦷t-l fzx\9se&FH"}:Kyq0ii՞a)q^j&RX,ԜH䛓=,^s7Mbɛ?qf,k( ܨ/)n莙 Vz[E`fGA[W'n%wV/{-jFǪ|R [G6;vY* $I}ڑ0 0N 3g*:&W@4N+vlwK|wj/މjFRS:ܕڸ6$KC9lH2˿'RrYSПRu5?A7Vs;r֏"׎rc"{wv?= 8z9Tf>Pe'^0^DypUGxQyɢ[B'Ӏ.vKMEc +BVE41[dF1P"UXGl 3 .ވ`_E˴xCJOz"0:w$%cT76 բj0/5(V*%`ɾd@Zt{VfJ廝aPe #4]V^g믶8_ng+A&Uq ֊ϩy$)4F8de11 6=KcG6@Tp8،%U/j7^Ouխ҆7tKe ,8kyYn\4/< $'}̺XIU]C^%e1ϫsDzd|\N.7& 1^?qx⎾(uP29noXShF)P%̢Cށ7 2_ӱeie@ܤo,gwo½ },ҕKi)}l]N ?@Ы{e {jЙWڇD)Q/<Ѽ`f޼?t{c-<~175TsuB0LiY/^5q#φx 9u#مbsgu-nJ@}F|_:' v y#pXJZd@Qh%F>n7XDEX, tAGu %G{o3 x~HYם *F82F-6 Y7X||B'yn,8F!)t7L!-H/$Q!p3o@@P盄6N8c>Z>ywc8. F1L'pp) jgw{y9RDW$]R $$(b=g,5y LH@6FgLAIp|r~*q+;v) 4?KM|,GS6W9lL>qToP6W )_fu~nH8V9 ڼ ʱ,`|+;r,u X@m䒑NV=V72C)'qfP2$#-űk_XddpKT? 3HI5`k]!@`"+%oe9O}4cZWVx9BhHrD3̼Uytʷx}"A%A-|~=L֫ #(vI@2E xCfѹu=U}Wv4ϷOHq|ec3MP>yQ*j iל'뤎KV(m@ɓoވcZ)[+q.{m`) {jG,]t:5/薯aՍ_k7kRyqeNNhjϸRV.@|P-_?@ϣ}q;7@E "zNF;IFҁv ?CEf05y ;F ,|hkSTE6w0K'9>8HsXuϼw5|rKif z|);imǹL0ߌNOkOGx#0*|5)L:1 -5*K;[7LJ?pj Frz?p7Ŧ% L=$ލ{F ."2f6&? ƒ)@_Ĝׯ8MTN1ǧ75ԓŘGA+-\|GTwKBG/Յ2^N-]Kà!Nݮd*j&rI MJՉ˲)Umw.QT?9[!7A$`eޱ5`iFz&*X) c3 ݒdѬ>;Sןz 8N[;F`߆Ussy"nfӬ$O>ֈusJ NeGP$Xsuk2Kvs"rƒm 񳞵@|55>9K?f看x!fC-KJ\G4LϢb| ?Dl/\f%;A<݂c}83It=sz&b(Kv#g3X1=!.J!6V bR]d&B6&Q2CچmMn>RVq:6EuQ,}U+M8}^0 uft |`sX%2DE L+{alKAFV%!vhB3Uw\ ZIbȘ+oFoWcF2SX{v̋k|~-y` .bJӸ _iĞkHxwnEU2^J$ExuYb}s 6hJ'%J\' 1@nLJL=)]lu`:b8賣W[X8t,p7IU"pI[A9 iCg}j*tvu̾>=)X>;:tΕ;Sζ֍Te f k?u#ʠm 2x ae ^p2 h'| Sc'ev{-SS쫳^*QMO4B3Fwxu)* ܰvt{)10RT܅*;Ź ,Eu7TyAJ?]:Ȇd{:8q'8Uԕ_Pɣ/Ͽ&4Mj^õ2I$~MD$o*cӎbx;3{,5˖Y}y2 V`W/W!j_$s-8K[Ք= R(lO8H>8e7z|~ B78סҶE%oiB;W˴0KNi;뇡DŽy}yy <}ˮ8oCƌ;~gG2zyϜ e:*H<,8܄U?f;\H;E?}ĊZ'@X[J`:p0${HP#vuJzXԉh6Ŀrܖz[KxJO:$z].^eʀ[(dGc|^^!6ʥ|!ǗWt`?yztG7@B#y=t{ЄPGѤw [Hg bǘ C6ے{ kˇS˹m+%8j\ >kp]6_=zw2F~s>;OylmG*O*e?+hHq9X *}s^s‹uWKtא.r ( I|"lCJ{ߝ ߾KZQH8c;<{:(B^/_ 0dnwĦ;%9PP0rqN#* n d&B:DEanhU#2s*d#P[ "B+k/ q^G/:R=Yo3p֞N\SX2½~ T=ZuMfh,:TPU ӦxiFk;<F c♏dfU pXt{4˓>XHL lq)ݣo}i s&e\ |HL|DЙI:`O1ao|[a4Ip\WV"h{]ZN.T˯u嬊h|-^3]{`jBsqJ-y`Ş`'TAU%.c c>ې1ҲKD F@M#Pj7?WrCM *h(tG:XG[X$ e^ xpÀbLFIbhIb bdeWttˆ.xK1AP4XaT[ 5Z$yօ܎v{)LymLX—#tWC kZ̐wKHԺPG@wG~x=)j\ql1!S(< 6V$~^ #`z<f>Vx5a>B,,5W8upA$R5t`YC׎{$}ϒt'Dlҙ?tI`@؍cƍ_dX#q#Zv*fd7^2qM%=h}</MA0 B=_e6 G q V)F?ӫ.PJ8ņЃ‡mDɐ=tj~ endstream endobj 6 0 obj <>stream h޲P0PT0U040P0W0475R0Q04210D endstream endobj 7 0 obj <>/ProcSet[/PDF/Text/ImageC]/XObject<>>>/Rotate 0/Type/Page>> endobj 8 0 obj <>stream q 595.1999969 0 0 840.9600067 0 0 cm /Im0 Do Q q 595.1999969 0 0 840.9600067 0 0 cm /Im1 Do Q BT /Suspect <>BDC 0.286 0.286 0.282 rg /T1_0 1 Tf 0.05 Tc 3 Tr 8.5158 0 0 8.2 227.94 774 Tm (ISOCYANATE )Tj EMC /Suspect <>BDC 8.3849 0 0 8.2 290.39 774 Tm (ASTHMA )Tj EMC ET BT /T1_0 1 Tf -0.0205 Tc 10 0 0 10 502.5 774 Tm (275 )Tj 0.161 0.161 0.157 rg /T1_1 1 Tf 0 Tc 9.1 0 0 9.1 39.3 750.48 Tm (T)Tj 0.286 0.286 0.282 rg -0.0068 Tc 0.63 0 Td (able )Tj 0.05 Tc 9.369 0 0 9.1 64.02 750.48 Tm (1.-)Tj ET BT /Suspect <>BDC /T1_1 1 Tf -0.0043 Tc 9.1 0 0 9.1 78.11 750.48 Tm (Clinical )Tj EMC ET BT /T1_1 1 Tf 0.003 Tc 9.1 0 0 9.1 109.4231 750.48 Tm (features )Tj 0.032 Tc 3.896 0 Td (of )Tj 0.0213 Tc 1.113 0 Td (the )Tj 0.22 0.22 0.216 rg 0.001 Tc 1.608 0 Td (162 )Tj 0.286 0.286 0.282 rg -0.0085 Tc 1.922 0 Td (subjects )Tj 0.22 0.22 0.216 rg -0.0287 Tc 3.912 0 Td (with )Tj 0.286 0.286 0.282 rg -0.0092 Tc 2.038 0 Td (history )Tj 0.161 0.161 0.157 rg 0 Tc 9.587 0 Td (1 )Tj ET BT /Suspect <>BDC /T1_1 1 Tf 9.1 0 0 9.1 334.457 750.48 Tm (0 )Tj EMC ET BT 0.286 0.286 0.282 rg /T1_1 1 Tf 0.032 Tc 9.1 0 0 9.1 39.2803 739.924 Tm (of )Tj -0.001 Tc 1.414 0 Td (isocyanate-asthma )Tj /T1_0 1 Tf 0.0155 Tc 8.8 0 0 8.8 162.68 717.85 Tm (Reactors )Tj 0.0118 Tc 6.555 -0.056 Td (Non-reactors )Tj 0 Tc -20.624 -2.4 Td (n )Tj 0.0192 Tc 1.078 0 Td (subjects )Tj 0.0067 Tc 13.639 -0.055 Td (93 )Tj 0.0064 Tc 7.417 -0.053 Td (69 )Tj 0.0159 Tc -22.081 -2.4 Td (Age )Tj 0.05 Tc 8.8544 0 0 8.1 56.55 674.17 Tm (at )Tj 0.0133 Tc 8.8 0 0 8.8 65.2 674.17 Tm (diagnosis )Tj /T1_1 1 Tf 0.05 Tc 9.321 0 0 8.2 101.72 674.17 Tm (yr )Tj /T1_0 1 Tf 0.0168 Tc 8.8 0 0 8.8 161.18 673.68 Tm (34.5\2611.2* )Tj 0.05 Tc 9.4759 0 0 8.8 224.53 673.68 Tm (34)Tj 0.161 0.161 0.157 rg 0 Tc 8.8 0 0 8.8 234.06 673.68 Tm (.)Tj 0.286 0.286 0.282 rg -0.0253 Tc 0.226 0 Td (6\2611)Tj 0.161 0.161 0.157 rg 0 Tc 1.628 0 Td (.)Tj 0.286 0.286 0.282 rg 0.173 0 Td (3 )Tj ET BT /Suspect <>BDC 0.22 0.22 0.216 rg /T1_0 1 Tf 0.0223 Tc 8.8 0 0 8.8 39.2016 652.56 Tm (Smoking )Tj EMC ET BT 0.286 0.286 0.282 rg /T1_0 1 Tf 0.0145 Tc 8.8 0 0 8.8 73.9088 652.56 Tm (habits )Tj 0.0205 Tc -2.94 -1.253 Td (Non-smoker )Tj 0.0149 Tc 13.401 0 Td (67.7% )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0064 Tc 8.8 0 0 8.8 229.3256 641.5336 Tm (67)Tj 0.161 0.161 0.157 rg 0 Tc 1.028 0 Td (.)Tj 0.286 0.286 0.282 rg 0.05 Tc 8.8145 0 0 8.8 239.91 641.53 Tm (0% )Tj EMC ET BT 0.22 0.22 0.216 rg /T1_0 1 Tf 0.0262 Tc 8.8 0 0 8.8 47.95 630.48 Tm (Ex-smoker )Tj 0.286 0.286 0.282 rg 0.0272 Tc 13.364 0 Td (24.7% )Tj -0.0006 Tc 7.281 0 Td (17.0% )Tj 0.0313 Tc -20.649 -1.255 Td (Current )Tj 0.0276 Tc 3.378 0 Td (smoker )Tj 0.023 Tc 10.531 0 Td (7.5% )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0013 Tc 8.8 0 0 8.8 229.626 618.9696 Tm (16)Tj 0.161 0.161 0.157 rg 0 Tc 0.995 0 Td (.)Tj 0.286 0.286 0.282 rg 0.05 Tc 8.8145 0 0 8.8 239.91 618.97 Tm (0% )Tj EMC /Suspect <>BDC 0.22 0.22 0.216 rg 0.0177 Tc 8.8 0 0 8.8 38.84 597.85 Tm (Positive )Tj EMC ET BT 0.286 0.286 0.282 rg /T1_0 1 Tf -0.011 Tc 8.8 0 0 8.8 70.5376 597.85 Tm (to )Tj 0.0251 Tc 1.03 0 Td (one )Tj 0.05 Tc 8.9033 0 0 8.8 94.96 597.85 Tm (or )Tj 0.0262 Tc 8.8 0 0 8.8 104.62 597.85 Tm (more )Tj 0.0144 Tc 2.392 0 Td (allergens )Tj 0.22 0.22 0.216 rg 0.0105 Tc -8.828 -1.256 Td (Allergy )Tj 0.286 0.286 0.282 rg 0.0167 Tc 3.37 0 Td (skin )Tj 0.0297 Tc 1.975 0 Td (test )Tj 0.0272 Tc 8.015 0 Td (21.5% )Tj -0.0006 Tc 7.281 0 Td (14.0% )Tj 0.017 Tc -21.68 -2.453 Td (Duration )Tj 0.05 Tc 8.9033 0 0 8.8 73.36 565.21 Tm (of )Tj 0.0166 Tc 8.8 0 0 8.8 82.92 565.21 Tm (symptoms )Tj 0.0261 Tc 4.487 0 Td (before )Tj 0.0133 Tc -8.465 -1.255 Td (diagnosis )Tj /T1_1 1 Tf 0.05 Tc 8.7727 0 0 8.2 83.96 554.17 Tm (yr )Tj /T1_0 1 Tf 0.0199 Tc 8.8 0 0 8.8 165.5 553.68 Tm (3.9\2610.4& )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0133 Tc 8.8 0 0 8.8 224.108 553.68 Tm (2.4\2610.3 )Tj EMC ET BT /T1_0 1 Tf 0.017 Tc 8.8 0 0 8.8 38.8416 532.0936 Tm (Duration )Tj 0.05 Tc 9.4598 0 0 8.8 72.87 532.09 Tm (of )Tj 0.0251 Tc 8.8 0 0 8.8 82.47 532.09 Tm (exposure )Tj /T1_1 1 Tf 0.05 Tc 9.321 0 0 8.2 117.56 532.09 Tm (yr )Tj /T1_0 1 Tf 0.0254 Tc 8.8 0 0 8.8 160.98 531.61 Tm (12.8\2611.0 )Tj 0.0001 Tc 6.709 0 Td (13.1\2613)Tj 0.161 0.161 0.157 rg 0 Tc 2.85 0 Td (.)Tj 0.286 0.286 0.282 rg 0.259 0 Td (1 )Tj 0.0196 Tc -23.752 -2.456 Td (Pulmonary )Tj 0.0202 Tc 4.793 0 Td (function )Tj 0.0464 Tc -3.811 -1.253 Td (FEY )Tj /T1_1 1 Tf 0 Tc 5.5001 0 0 5.5001 64.63 496.09 Tm (1 )Tj /T1_0 1 Tf 8.8 0 0 8.8 69.51 498.97 Tm (% )Tj 0.0275 Tc 1.102 0 Td (predicted )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0 Tc 8.8 0 0 8.8 115.9916 498.97 Tm (" )Tj EMC ET BT /T1_0 1 Tf 0.011 Tc 8.8 0 0 8.8 158.302 498.97 Tm [(95.7\2611.7 )-3014(97.1\2611.7 )]TJ 0.0302 Tc -13.687 -2.564 Td (Type )Tj 0.05 Tc 10.0163 0 0 8.8 58.46 476.41 Tm (of )Tj 0.014 Tc 8.8 0 0 8.8 69.03 476.41 Tm (asthmatic )Tj 0.0225 Tc 4.155 0 Td (response )Tj 0.0241 Tc -6.66 -1.255 Td (Inunediate )Tj 0.0211 Tc 4.687 0 Td (alone )Tj 0.0007 Tc 7.968 -0.055 Td (27 )Tj 0.0162 Tc 1.794 0 Td (\(29.0%\) )Tj 0.22 0.22 0.216 rg 0.0131 Tc -14.449 -1.2 Td (Late )Tj 0.286 0.286 0.282 rg 0.0211 Tc 2.123 0 Td (alone )Tj 0.05 Tc 9.0021 0 0 8.8 158.3 453.84 Tm (32 )Tj 0.0162 Tc 8.8 0 0 8.8 174.14 454.33 Tm (\(34.4%\) )Tj 0.22 0.22 0.216 rg 0.0127 Tc -14.448 -1.256 Td (Dual )Tj 0.286 0.286 0.282 rg 0.05 Tc 9.4759 0 0 8.8 157.81 443.28 Tm (34 )Tj 0.0162 Tc 8.8 0 0 8.8 174.14 443.28 Tm (\(36.6%\) )Tj 0.021 Tc -14.506 -2.508 Td (Treatment )Tj 0.0143 Tc 4.526 0 Td (during )Tj 0.0184 Tc 2.952 0 Td (the )Tj 0.0187 Tc 5.173 0 Td (33 )Tj 0.0071 Tc 1.855 0 Td (\(35.5%\) )Tj 0.022 Tc -14.508 -1.256 Td (challenge )Tj 0.22 0.22 0.216 rg 0.0223 Tc -1.085 -2.455 Td (Methacholine )Tj 0.286 0.286 0.282 rg 0.0186 Tc 5.997 0 Td (inhalation )Tj 0.0115 Tc 4.369 0 Td (test )Tj ET BT /Suspect <>BDC 0.22 0.22 0.216 rg /T1_0 1 Tf 0.0464 Tc 8.8 0 0 8.8 44.12 377.0424 Tm (PD)Tj 0.0094 Tc 6.3001 0 0 6.3001 55.64 373.69 Tm (20)Tj 0.0464 Tc 8.8 0 0 8.8 61.88 377.05 Tm (FEV)Tj 0 Tc 6.3001 0 0 6.3001 78.98 374.16 Tm (1 )Tj EMC ET BT 0.286 0.286 0.282 rg /T1_0 1 Tf 0.05 Tc 9.0734 0 0 8.8 84.46 377.05 Tm (mg )Tj 0.0261 Tc 8.8 0 0 8.8 99.85 377.05 Tm (before )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0 Tc 8.8 0 0 8.8 149.6668 377.05 Tm (0)Tj 0.161 0.161 0.157 rg 0.535 0 Td (.)Tj 0.286 0.286 0.282 rg 0.0486 Tc 0.18 0 Td (407 )Tj EMC ET BT /T1_0 1 Tf 0.0056 Tc 8.8 0 0 8.8 175.5828 377.05 Tm (\(1.14\)** )Tj 0.0156 Tc 4.91 0 Td (0.942 )Tj 0.0081 Tc 2.508 0 Td (\(1.14\)8 )Tj 0.161 0.161 0.157 rg 0 Tc -22.414 -1.309 Td (I)Tj 0.286 0.286 0.282 rg 0.0223 Tc 0.375 0 Td (socyanate )Tj 0.0186 Tc 4.315 0 Td (inhalation )Tj 0.22 0.22 0.216 rg -0.035 Tc 8.922 0 0 9.2 36.78 343.44 Tm (*: )Tj ET BT /Suspect <>BDC 0.286 0.286 0.282 rg /T1_0 1 Tf 8.6477 0 0 8.8 47.98 343.44 Tm (mean+SEM; )Tj EMC /Suspect <>BDC 0.22 0.22 0.216 rg -0.0172 Tc 8.8 0 0 8.8 96.3 343.44 Tm (**: )Tj EMC ET BT /T1_0 1 Tf -0.0084 Tc 8.8 0 0 8.8 109.3504 343.44 Tm (Gmean )Tj 0.286 0.286 0.282 rg -0.0069 Tc 3.545 0 Td (and )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.035 Tc 7.451 0 0 8.8 157.37 343.44 Tm (GSEM; )Tj EMC ET BT /T1_1 1 Tf 0.0368 Tc 9 0 0 9 183.73 343.44 Tm (&: )Tj /T1_0 1 Tf 0.0118 Tc 8.8 0 0 8.8 195.28 343.44 Tm (difference )Tj 0.22 0.22 0.216 rg 0.0106 Tc 4.647 0 Td (between )Tj 0.286 0.286 0.282 rg 0.0279 Tc -22.693 -1.253 Td (reac)Tj 0.161 0.161 0.157 rg 0 Tc 1.744 0 Td (t)Tj 0.286 0.286 0.282 rg 0.0265 Tc 0.266 0 Td (ors )Tj 0.0204 Tc 1.799 0 Td (and )Tj 0.0174 Tc 1.973 0 Td (non-reactors )Tj 0.0142 Tc 5.715 0 Td (statistically )Tj 0.0227 Tc 5.182 0 Td (significant )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.035 Tc 8.758 0 0 8.8 226.09 332.41 Tm (p>BDC /T1_0 1 Tf 0.0265 Tc 8.8 0 0 8.8 249.1216 321.84 Tm (non\255)Tj EMC ET BT /T1_0 1 Tf 0.016 Tc 8.8 0 0 8.8 36.4784 310.8136 Tm (reactors )Tj 0.0251 Tc 4.187 0 Td (statist)Tj 0.161 0.161 0.157 rg 0 Tc 2.46 0 Td (i)Tj 0.286 0.286 0.282 rg 0.0109 Tc 0.27 0 Td (cally )Tj 0.0173 Tc 2.888 0 Td (significant )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0268 Tc 8.8 0 0 8.8 168.9712 310.8136 Tm (p>BDC 0.22 0.22 0.216 rg /T1_0 1 Tf 0.008 Tc 8.8 0 0 8.8 171.3116 299.76 Tm (ECCS )Tj EMC ET BT 0.286 0.286 0.282 rg /T1_0 1 Tf 0.0273 Tc 8.8 0 0 8.8 198.1692 299.76 Tm (Tables )Tj 0.0071 Tc 3.311 0 Td ([41]. )Tj 0.365 0.369 0.361 rg 0.02 Tc 10 0 0 10 35.86 270 Tm (symptoms )Tj 0.286 0.286 0.282 rg -0.0091 Tc 4.719 0 Td (between )Tj -0.0043 Tc 3.789 0 Td (two )Tj 0.028 Tc 1.96 0 Td (and )Tj -0.035 Tc 9.8147 0 0 10 160.21 270 Tm (five )Tj -0.0005 Tc 10 0 0 10 179.03 270 Tm (years, )Tj 0.0075 Tc 2.867 0 Td (showing )Tj 0.05 Tc 10.215 0 0 10 246.7 270 Tm (that )Tj 0.0152 Tc 10 0 0 10 35.98 258.97 Tm (the )Tj 0.0092 Tc 1.817 0 Td (diagnosis )Tj 0.05 Tc 11.1292 0 0 10 98.29 258.97 Tm (of )Tj 0.0179 Tc 10 0 0 10 112.22 258.97 Tm (occupational )Tj 0.0316 Tc 5.952 0 Td (asthma )Tj -0.0068 Tc 3.561 0 Td (was )Tj 0.0087 Tc 2.104 0 Td (delayed. )Tj 0.0226 Tc -19.283 -1.104 Td (Ninety )Tj 0.0056 Tc 3.21 0 Td (three )Tj 0.0033 Tc 2.34 0 Td (subjects )Tj 0.0099 Tc 3.605 0 Td (developed )Tj 0.0281 Tc 4.511 0 Td (an )Tj 0.0271 Tc 1.344 0 Td (asthmatic )Tj 0.0138 Tc 4.377 0 Td (reaction )Tj 0.0375 Tc -19.401 -1.104 Td (after )Tj 0.0223 Tc 2.447 0 Td (exposure )Tj 0.0413 Tc 4.281 0 Td (to )Tj 0.0116 Tc 1.386 0 Td (isocyanates )Tj -0.035 Tc 9.9195 0 0 10 169.36 236.89 Tm (in )Tj 0.0152 Tc 10 0 0 10 182.86 236.89 Tm (the )Tj 0.024 Tc 1.818 0 Td (laboratory: )Tj -0.035 Tc 9.6396 0 0 10 253.38 236.89 Tm (27 )Tj 0.22 0.22 0.216 rg 0.0039 Tc 10 0 0 10 35.43 225.85 Tm (developed )Tj 0.286 0.286 0.282 rg 0.0281 Tc 4.559 0 Td (an )Tj 0.0153 Tc 1.394 0 Td (immediate )Tj 0.0168 Tc 4.711 0 Td (reaction, )Tj -0.0031 Tc 4.021 0 Td (34 )Tj 0 Tc 1.346 0 Td (a )Tj 0.05 Tc 10.0131 0 0 10 203.91 225.85 Tm (dua)Tj 0.161 0.161 0.157 rg 0 Tc 10 0 0 10 220.24 225.85 Tm (l )Tj 0.286 0.286 0.282 rg 0.0168 Tc 0.631 0 Td (reaction, )Tj -0.0031 Tc -19.115 -1.056 Td (32 )Tj 0 Tc 1.202 0 Td (a )Tj 0.22 0.22 0.216 rg 0.0211 Tc 0.818 0 Td (late )Tj 0.286 0.286 0.282 rg 0.0069 Tc 1.735 0 Td (reaction )Tj 0.05 Tc 10.0265 0 0 10 108.86 215.29 Tm (and )Tj -0.035 Tc 9.8266 0 0 10 127.09 215.29 Tm (33 )Tj 0.0481 Tc 10 0 0 10 139.19 215.29 Tm (requ)Tj 0.161 0.161 0.157 rg 0 Tc 1.913 0 Td (i)Tj 0.286 0.286 0.282 rg 0.0102 Tc 0.247 0 Td (red )Tj 0.22 0.22 0.216 rg 0.033 Tc 1.631 0 Td (treatment )Tj 0.027 Tc 4.265 0 Td (during )Tj 0.286 0.286 0.282 rg 0.0152 Tc 3.031 0 Td (the )Tj -0.0027 Tc -21.512 -1.104 Td (challenge. )Tj ET BT /Suspect <>BDC 0.22 0.22 0.216 rg /T1_0 1 Tf 0.05 Tc 10.6396 0 0 10 79.09 204.25 Tm (Of )Tj EMC ET BT 0.286 0.286 0.282 rg /T1_0 1 Tf 0.0152 Tc 10 0 0 10 92.62 204.25 Tm (the )Tj 0.05 Tc 8.8968 0 0 8.8 107.9 204.25 Tm (93 )Tj 0.0033 Tc 10 0 0 10 120.34 204.25 Tm (subjects )Tj -0.0145 Tc 3.565 0 Td (with )Tj 0 Tc 2.055 0 Td (a )Tj 0.002 Tc 0.78 0 Td (positive )Tj 0.0135 Tc 3.494 0 Td (isocyanate )Tj 0.022 Tc -18.384 -1.104 Td (inhalation )Tj 0.008 Tc 4.414 0 Td (challenge, )Tj ET BT /Suspect <>BDC 0.161 0.161 0.157 rg /T1_0 1 Tf 0 Tc 10 0 0 10 124.93 193.21 Tm (1)Tj 0.286 0.286 0.282 rg 0.405 0 Td (5 )Tj EMC ET BT /T1_0 1 Tf -0.035 Tc 9.7293 0 0 10 136.21 193.21 Tm (\(16.1 )Tj /T1_1 1 Tf 0.05 Tc 9.7092 0 0 9.5 157.28 193.21 Tm (%\) )Tj /T1_0 1 Tf 0.0245 Tc 10 0 0 10 172.79 193.21 Tm (had )Tj ET BT /Suspect <>BDC 0.22 0.22 0.216 rg /T1_1 1 Tf 0.0224 Tc 10.1 0 0 10.1 190.8 193.21 Tm (FEV )Tj EMC ET BT 0.286 0.286 0.282 rg /T1_0 1 Tf 0 Tc 6.2 0 0 6.2 211.95 190.8 Tm (1 )Tj 0.034 Tc 10 0 0 10 217.11 193.21 Tm (!ower )Tj 0.0194 Tc 2.719 0 Td (than )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0131 Tc 10 0 0 10 35.34 182.16 Tm (80% )Tj EMC ET BT /T1_0 1 Tf 0.0137 Tc 10 0 0 10 57.62 182.16 Tm (predicted. )Tj -0.0111 Tc 4.508 0 Td (All )Tj 0.0033 Tc 1.62 0 Td (subjects )Tj 0.0485 Tc 3.613 0 Td (had )Tj 0.0175 Tc 1.919 0 Td (methacholine )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0205 Tc 10 0 0 10 233.68 182.16 Tm (inhala\255)Tj EMC ET BT /T1_0 1 Tf 0.0108 Tc 10 0 0 10 35.5 171.13 Tm (tion )Tj 0.0028 Tc 2.208 0 Td (test )Tj 0.0099 Tc 2.019 0 Td (before )Tj 0.0103 Tc 3.109 0 Td (challenge )Tj 0.0015 Tc 4.473 0 Td (with )Tj 0.05 Tc 10.8968 0 0 10 177.03 171.13 Tm (TD)Tj 0.161 0.161 0.157 rg 0 Tc 10 0 0 10 192.42 171.13 Tm (J )Tj 0.286 0.286 0.282 rg 0.05 Tc 10.5727 0 0 10 201.5 171.13 Tm (or )Tj 10.0796 0 0 10 216.43 171.13 Tm (MDI. )Tj 0.161 0.161 0.157 rg 0 Tc 10 0 0 10 246.15 171.13 Tm (T)Tj 0.286 0.286 0.282 rg -0.0271 Tc 0.728 0 Td (he )Tj 0.0067 Tc -21.847 -1.056 Td (geometric )Tj 0.0485 Tc 4.566 0 Td (mean )Tj -0.0127 Tc 2.822 0 Td (\(Gmean\) )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.05 Tc 10.2388 0 0 10 149.23 160.57 Tm (PD)Tj 7.4484 0 0 6.6 163.16 158.16 Tm (20)Tj /T1_1 1 Tf 0.0224 Tc 10.1 0 0 10.1 171.6 160.57 Tm (FEV)Tj /T1_0 1 Tf 0 Tc 6.6 0 0 6.6 192.25 157.69 Tm (1 )Tj EMC ET BT /T1_0 1 Tf -0.0068 Tc 10 0 0 10 201.11 160.57 Tm (was )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.05 Tc 9.0925 0 0 8.8 221.67 160.57 Tm (0.407 )Tj EMC ET BT /T1_0 1 Tf 0.0234 Tc 10 0 0 10 249.58 160.57 Tm (mg )Tj 0.0017 Tc -21.466 -1.105 Td (\(geomet)Tj 0.161 0.161 0.157 rg -0.0337 Tc 3.323 0 Td (ri)Tj 0.286 0.286 0.282 rg 0 Tc 0.615 0 Td (c )Tj 0.0412 Tc 0.908 0 Td (standard )Tj 0.0474 Tc 4.131 0 Td (error )Tj 0.05 Tc 10.5727 0 0 10 151.1 149.52 Tm (of )Tj 0.0165 Tc 10 0 0 10 164.62 149.52 Tm (mean )Tj 0 Tc 2.774 0 Td (\( )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.035 Tc 7.9596 0 0 10 195.28 149.52 Tm (GSEM\) )Tj EMC ET BT 0.365 0.369 0.361 rg /T1_0 1 Tf 0 Tc 12.7 0 0 12.7 220.74 149.52 Tm (= )Tj ET BT /Suspect <>BDC 0.161 0.161 0.157 rg /T1_0 1 Tf -0.035 Tc 8.6596 0 0 8.8 230.1 149.52 Tm (1.1)Tj 0.286 0.286 0.282 rg 0.05 Tc 8.851 0 0 8.8 241.4 149.52 Tm (4\) )Tj EMC ET BT /T1_0 1 Tf -0.035 Tc 9.9195 0 0 10 254.8 149.52 Tm (in )Tj 0.0152 Tc 10 0 0 10 35.02 138.49 Tm (the )Tj 0.0324 Tc 1.914 0 Td (group )Tj 0.0015 Tc 3.127 0 Td (with )Tj 0 Tc 2.439 0 Td (a )Tj 0.002 Tc 1.164 0 Td (positive )Tj 0.22 0.22 0.216 rg 0.0273 Tc 3.83 0 Td (inhalation )Tj 0.286 0.286 0.282 rg 0.0103 Tc 4.846 0 Td (challenge )Tj -0.0067 Tc 4.616 0 Td (to )Tj 0.0116 Tc -21.99 -1.105 Td (isocyanates )Tj 0.028 Tc 5.038 0 Td (and )Tj 0.05 Tc 9.0925 0 0 8.8 103.59 127.44 Tm (0.942 )Tj 0.0234 Tc 10 0 0 10 129.1 127.44 Tm (mg )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.035 Tc 7.8073 0 0 10 145.35 127.44 Tm (\(GSEM )Tj EMC ET BT /T1_0 1 Tf 0 Tc 12.7 0 0 12.7 170.34 127.44 Tm (= )Tj ET BT /Suspect <>BDC 0.22 0.22 0.216 rg /T1_0 1 Tf -0.0349 Tc 10 0 0 10 179.65 127.44 Tm (1.14\) )Tj EMC ET BT 0.161 0.161 0.157 rg /T1_0 1 Tf 0 Tc 10 0 0 10 202.48 127.44 Tm (i)Tj 0.286 0.286 0.282 rg 0.295 0 Td (n )Tj 0.0392 Tc 0.815 0 Td (the )Tj 0.0102 Tc 1.572 0 Td (subjects )Tj 0 Tc -19.475 -1.055 Td (w)Tj 0.161 0.161 0.157 rg 0.713 0 Td (i)Tj 0.286 0.286 0.282 rg -0.0067 Tc 0.294 0 Td (th )Tj 0 Tc 1.336 0 Td (a )Tj 0.004 Tc 1.017 0 Td (negative )Tj 0.022 Tc 3.929 0 Td (inhalation )Tj 0.0103 Tc 4.702 0 Td (challenge )Tj 0.0413 Tc 4.424 0 Td (to )Tj 0.0096 Tc 1.338 0 Td (isocyanates. )Tj 0.0477 Tc -17.761 -1.105 Td (The )Tj -0.0008 Tc 2.064 0 Td (difference )Tj 0.22 0.22 0.216 rg -0.0068 Tc 4.568 0 Td (was )Tj 0.286 0.286 0.282 rg 0.0021 Tc 2.003 0 Td (significant, )Tj 0.0255 Tc 4.996 0 Td (after )Tj 0.0213 Tc 2.448 0 Td (adjustme)Tj 0.161 0.161 0.157 rg 0 Tc 3.801 0 Td (n)Tj 0.286 0.286 0.282 rg 0.527 0 Td (t )Tj 0.161 0.161 0.157 rg 0.817 0 Td (h)Tj 0.286 0.286 0.282 rg 0.0281 Tc 0.519 0 Td (ad )Tj -0.0175 Tc -21.685 -1.104 Td (been )Tj 0.0325 Tc 2.205 0 Td (made )Tj 0.0314 Tc 2.583 0 Td (for )Tj 0 Tc 1.593 0 Td (t)Tj 0.161 0.161 0.157 rg 0.337 0 Td (h)Tj 0.286 0.286 0.282 rg 0.47 0 Td (e )Tj 0.22 0.22 0.216 rg -0.035 Tc 9.951 0 0 10 115.12 94.8 Tm (level )Tj 0.286 0.286 0.282 rg 0.05 Tc 11.1292 0 0 10 136.69 94.8 Tm (of )Tj ET BT /Suspect <>BDC /T1_1 1 Tf 0.0224 Tc 10.1 0 0 10.1 149.04 94.8 Tm (FEV )Tj EMC ET BT /T1_1 1 Tf 0 Tc 5.5001 0 0 5.5001 170.23 92.4 Tm (1 )Tj /T1_0 1 Tf 0.0499 Tc 10 0 0 10 176.52 94.8 Tm (\(p )Tj /T1_1 1 Tf 0 Tc 10.1 0 0 10.1 187.04 94.8 Tm (< )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0142 Tc 10 0 0 10 195.26 94.8 Tm (0.0 )Tj EMC ET BT 0.22 0.22 0.216 rg /T1_0 1 Tf -0.0273 Tc 10 0 0 10 209.21 94.8 Tm (I\))Tj 0.365 0.369 0.361 rg 0 Tc 0.663 0 Td (, )Tj 0.286 0.286 0.282 rg -0.0345 Tc 0.58 0 Td (\(fig. )Tj ET BT /Suspect <>BDC 0.22 0.22 0.216 rg /T1_2 1 Tf 0 Tc 9.4 0 0 9.4 241.51 94.8 Tm (1 )Tj EMC ET BT 0.286 0.286 0.282 rg /T1_1 1 Tf 0.0319 Tc 9.4 0 0 9.4 245.5896 94.8 Tm (\). )Tj ET BT /Suspect <>BDC 0.22 0.22 0.216 rg /T1_1 1 Tf 0 Tc 8.9 0 0 8.9 319.57 680.89 Tm (0 )Tj EMC /Suspect <>BDC /T1_0 1 Tf -0.035 Tc 9.1955 0 0 9.9 319.49 672.73 Tm (.\247. )Tj EMC ET BT 0.286 0.286 0.282 rg /T1_1 1 Tf 0 Tc 8.1 0 0 8.1 319.68 660.24 Tm (w )Tj 0.22 0.22 0.216 rg /T1_0 1 Tf 10.4 0 0 10.4 319.62 654.48 Tm (z )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.035 Tc 7.0044 0 0 8.6 319.5 647.29 Tm (::J )Tj EMC /Suspect <>BDC 0 Tc 7.8001 0 0 7.8001 319.12 641.05 Tm (0 )Tj EMC /Suspect <>BDC 0.161 0.161 0.157 rg -0.035 Tc 6.5523 0 0 8 319.04 635.29 Tm (::t: )Tj EMC /Suspect <>BDC 0.22 0.22 0.216 rg 0 Tc 7.1 0 0 7.1 319.13 629.53 Tm (0 )Tj EMC /Suspect <>BDC /T1_1 1 Tf 0.05 Tc 7.1865 0 0 5.5001 319.12 624.73 Tm (c\( )Tj EMC /Suspect <>BDC 0.161 0.161 0.157 rg /T1_0 1 Tf -0.035 Tc 5.3091 0 0 6.8001 319.07 618.48 Tm (::1: )Tj EMC ET BT /T1_1 1 Tf 0 Tc 9.4 0 0 9.4 332.82 612.24 Tm (1 )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.035 Tc 9.7899 0 0 18.5 318.52 613.68 Tm (... )Tj EMC ET BT /T1_1 1 Tf 0 Tc 8.1 0 0 8.1 318.72 608.41 Tm (w )Tj ET BT /Suspect <>BDC /C0_0 1 Tf 6.24 0 0 6.24 318.73 601.21 Tm <007E0020>Tj EMC /Suspect <>BDC 0.22 0.22 0.216 rg 4.32 0 0 5.28 318.73 590.65 Tm <003E007E0020>Tj EMC ET BT 0.161 0.161 0.157 rg /T1_1 1 Tf 8.1 0 0 8.1 318.72 583.44 Tm (w )Tj ET BT /Suspect <>BDC /T1_1 1 Tf 0.0015 Tc 5.9001 0 0 5.9001 318.56 578.65 Tm (II.. )Tj EMC /Suspect <>BDC 0 Tc 34.6 0 0 34.6 464.09 577.21 Tm (\225 )Tj EMC /Suspect <>BDC 0.286 0.286 0.282 rg 6.9001 0 0 6.9001 323.44 569.05 Tm (& )Tj EMC /Suspect <>BDC 0.22 0.22 0.216 rg /T1_0 1 Tf 7.1 0 0 7.1 318.17 563.76 Tm (0 )Tj EMC /Suspect <>BDC 0.161 0.161 0.157 rg /T1_1 1 Tf 0.05 Tc 7.9924 0 0 6.5001 318.09 558 Tm (ll. )Tj EMC /Suspect <>BDC -0.035 Tc 10.0314 0 0 10.6 326.76 473.53 Tm (0.1 )Tj EMC ET BT /T1_0 1 Tf 0.05 Tc 12.3501 0 0 12.1 407.09 460.56 Tm (NR )Tj 0 Tc 12.1 0 0 12.1 467.94 460.56 Tm (R )Tj 0.286 0.286 0.282 rg -0.0146 Tc 8.2 0 0 8.2 288.45 447.12 Tm (Fig. )Tj ET BT /Suspect <>BDC /T1_1 1 Tf 0.05 Tc 8.7408 0 0 8.1 304.56 447.12 Tm (I. )Tj EMC ET BT /T1_0 1 Tf 0.0126 Tc 8.2 0 0 8.2 318.68 447.12 Tm (Methacholine )Tj 0.0152 Tc 5.977 0 Td (provocative )Tj 0.0177 Tc 5.14 0 Td (doses )Tj 0.365 0.369 0.361 rg 0.0259 Tc 2.574 0 Td (fo)Tj 0.22 0.22 0.216 rg 0 Tc 0.888 0 Td (r )Tj 0.365 0.369 0.361 rg 0.0122 Tc 0.689 0 Td (subjects )Tj 0.286 0.286 0.282 rg -0.01 Tc 3.643 0 Td (who )Tj 0.0099 Tc 2.04 0 Td (did )Tj 0.0071 Tc 1.706 0 Td (not )Tj -0.0017 Tc -26.341 -1.112 Td (react )Tj 0.0449 Tc 2.399 0 Td (to )Tj 0.365 0.369 0.361 rg 0.0142 Tc 1.221 0 Td (exposure )Tj 0.286 0.286 0.282 rg 0.0449 Tc 4.106 0 Td (to )Tj 0.05 Tc 8.2355 0 0 8.2 361.85 438 Tm (TDI )Tj 0.365 0.369 0.361 rg 0.0392 Tc 8.2 0 0 8.2 380.06 438 Tm (\(non-reactors= )Tj 0.286 0.286 0.282 rg 0 Tc 6.632 0 Td (N )Tj -0.035 Tc 7.9497 0 0 8.2 441.08 438 Tm (R: )Tj 0.365 0.369 0.361 rg 0.0225 Tc 8.2 0 0 8.2 452.08 438 Tm (open )Tj 0.286 0.286 0.282 rg 0.0327 Tc 2.47 0 Td (bar\) )Tj 0.0157 Tc 2.096 0 Td (and )Tj 0.365 0.369 0.361 rg 0.05 Tc 8.2167 0 0 8.2 505.35 438 Tm (for )Tj 0.286 0.286 0.282 rg 0.0038 Tc 8.2 0 0 8.2 287.88 428.89 Tm (subjects )Tj 0.0193 Tc 3.584 0 Td (who )Tj 0.0075 Tc 2.107 0 Td (reacted )Tj 0.0449 Tc 3.277 0 Td (to )Tj 0.05 Tc 8.5079 0 0 8.2 370.49 428.89 Tm (TDl )Tj 0.365 0.369 0.361 rg 0.0391 Tc 8.2 0 0 8.2 388.22 428.89 Tm (\(reactors= )Tj 0.286 0.286 0.282 rg -0.0041 Tc 4.632 0 Td (R: )Tj 0.0117 Tc 1.278 0 Td (stippled )Tj 0.0206 Tc 3.587 0 Td (bar\). )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0136 Tc 8.2 0 0 8.2 485.2424 428.89 Tm (Provoca\255)Tj EMC ET BT 0.365 0.369 0.361 rg /T1_0 1 Tf -0.0104 Tc 8.2 0 0 8.2 287.9832 420.2472 Tm (tive )Tj 0.286 0.286 0.282 rg 0.0177 Tc 2.1 0 Td (doses )Tj -0.0016 Tc 2.935 0 Td (were )Tj 0.0156 Tc 2.567 0 Td (determined )Tj -0.0102 Tc 5.326 0 Td (from )Tj 0.0058 Tc 2.701 0 Td (the )Tj 0.0118 Tc 1.866 0 Td (dose-response )Tj 0.021 Tc 6.439 0 Td (curve )Tj 0.0449 Tc 2.993 0 Td (to )Tj 0.0169 Tc -26.927 -1.113 Td (methacholine )Tj 0.0137 Tc 5.846 0 Td (aerosol, )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0 Tc 8.2 0 0 8.2 366.1128 411.1206 Tm (\225 )Tj EMC ET BT /T1_0 1 Tf 8.2 0 0 8.2 372.4924 411.1206 Tm (p )Tj 0.365 0.369 0.361 rg /T1_1 1 Tf 9.1 0 0 9.1 378.1 411.12 Tm (< )Tj ET BT /Suspect <>BDC 0.286 0.286 0.282 rg /T1_0 1 Tf 0.0004 Tc 8.2 0 0 8.2 384.4 411.12 Tm (0.0 )Tj EMC /Suspect <>BDC /T1_1 1 Tf 0.05 Tc 7.8667 0 0 7.5001 395.78 411.12 Tm (I. )Tj EMC ET BT /T1_0 1 Tf 0.0477 Tc 10 0 0 10 297.51 378.97 Tm (The )Tj 0.365 0.369 0.361 rg 0.017 Tc 2.347 0 Td (subjects )Tj 0.286 0.286 0.282 rg 0.0052 Tc 4.045 0 Td (who )Tj 0.0182 Tc 2.496 0 Td (required )Tj 0.0291 Tc 4.223 0 Td (therapy )Tj 0.0366 Tc 3.881 0 Td (during )Tj 0.0152 Tc 3.511 0 Td (the )Tj 0.0163 Tc -21.512 -1.104 Td (challenge )Tj 0.0175 Tc 4.281 0 Td (with )Tj 0.0164 Tc 2.201 0 Td (isocyanates )Tj -0.0055 Tc 5.095 0 Td (were )Tj 0.0318 Tc 2.247 0 Td (older )Tj 0.0156 Tc 2.494 0 Td (\(mean: )Tj 0.005 Tc 3.216 0 Td (36.4 )Tj 0.0187 Tc 2.027 0 Td (yr\) )Tj 0.0015 Tc -21.504 -1.056 Td (with )Tj 0 Tc 2.247 0 Td (a )Tj 0.03 Tc 0.962 0 Td (longer )Tj 0.05 Tc 10.0681 0 0 10 350.78 357.37 Tm (duration )Tj 11.1292 0 0 10 392.53 357.37 Tm (of )Tj 0.365 0.369 0.361 rg 0.0328 Tc 10 0 0 10 405.01 357.37 Tm (exposu)Tj 0.22 0.22 0.216 rg 0.0403 Tc 3.034 0 Td (re )Tj 0.286 0.286 0.282 rg 0.0156 Tc 1.237 0 Td (\(mean: )Tj 0.0223 Tc 8.8 0 0 8.8 482.1 357.37 Tm (14.1 )Tj -0.0053 Tc 10 0 0 10 503.51 357.37 Tm (yr\) )Tj 0.05 Tc 10.3398 0 0 10 287.41 346.33 Tm (and )Tj 11.1292 0 0 10 306.61 346.33 Tm (of )Tj 0.0338 Tc 10 0 0 10 318.1 346.33 Tm (symptoms )Tj 0.0156 Tc 4.706 0 Td (\(mean: )Tj 0.0466 Tc 8.8 0 0 8.8 397.32 346.33 Tm (5.3 )Tj -0.0069 Tc 10 0 0 10 412.79 346.33 Tm (yr\). )Tj 0.22 0.22 0.216 rg 0.0234 Tc 1.82 0 Td (However)Tj 0.365 0.369 0.361 rg 0 Tc (, )Tj 0.286 0.286 0.282 rg 0.0176 Tc 4.419 0 Td (there )Tj -0.0068 Tc 2.449 0 Td (was )Tj 0.0113 Tc -21.168 -1.105 Td (no )Tj 0.0129 Tc 1.427 0 Td (significant )Tj 0.0046 Tc 4.805 0 Td (difference )Tj 0.0431 Tc 4.511 0 Td (as )Tj 0.22 0.22 0.216 rg 0.0219 Tc 1.353 0 Td (regards )Tj 0.286 0.286 0.282 rg 0.0184 Tc 3.495 0 Td (age, )Tj 0.05 Tc 10.2674 0 0 10 465.02 335.28 Tm (durat)Tj 0.161 0.161 0.157 rg 0 Tc 10 0 0 10 488.56 335.28 Tm (i)Tj 0.286 0.286 0.282 rg 0.0284 Tc 0.286 0 Td (on )Tj 0.05 Tc 11.1292 0 0 10 506.29 335.28 Tm (of )Tj 0.0182 Tc 10 0 0 10 287.41 324.25 Tm (exposure, )Tj 0.0399 Tc 4.562 0 Td (duration )Tj 0.05 Tc 11.1292 0 0 10 374.77 324.25 Tm (of )Tj 0.365 0.369 0.361 rg 0.0269 Tc 10 0 0 10 388.66 324.25 Tm (symptoms )Tj 0.286 0.286 0.282 rg 0.05 Tc 10.0265 0 0 10 436.7 324.25 Tm (and )Tj 0.0139 Tc 10 0 0 10 457.93 324.25 Tm (baseline )Tj 0.0207 Tc 3.879 0 Td (lung )Tj 0.0153 Tc -20.883 -1.104 Td (function )Tj 0.0069 Tc 3.804 0 Td (between )Tj 0.0392 Tc 3.741 0 Td (the )Tj 0.017 Tc 1.524 0 Td (subjects )Tj 0.0292 Tc 3.613 0 Td (who )Tj 0.0319 Tc 2.064 0 Td (required )Tj 0.033 Tc 3.887 0 Td (treatment )Tj 0.05 Tc 10.6052 0 0 10 286.94 302.65 Tm (du)Tj 0.161 0.161 0.157 rg -0.0337 Tc 10 0 0 10 298.55 302.65 Tm (ri)Tj 0.286 0.286 0.282 rg 0.05 Tc 10.0889 0 0 10 304.79 302.65 Tm (ng )Tj 0.0327 Tc 10 0 0 10 322 302.65 Tm (inhalation )Tj 0.0103 Tc 5.038 0 Td (challenge )Tj 0.0175 Tc 4.617 0 Td (with )Tj 0.0212 Tc 2.537 0 Td (isocyanates )Tj 0.05 Tc 10.0265 0 0 10 499.1 302.65 Tm (and )Tj 0.0253 Tc 10 0 0 10 287.5 291.61 Tm (those )Tj 0.0292 Tc 2.593 0 Td (who )Tj 0.038 Tc 2.104 0 Td (did )Tj 0.0201 Tc 1.784 0 Td (not. )Tj 0.22 0.22 0.216 rg 0.0417 Tc 2.06 0 Td (During )Tj 0.286 0.286 0.282 rg 0.0273 Tc 3.405 0 Td (inhalation )Tj 0.0163 Tc 4.606 0 Td (challenge )Tj 0.0175 Tc 4.329 0 Td (with )Tj 0.22 0.22 0.216 rg 0.0184 Tc -20.887 -1.105 Td (isocyanates, )Tj 0.286 0.286 0.282 rg 0.0201 Tc 5.325 0 Td (eighteen )Tj 0.017 Tc 3.789 0 Td (subjects )Tj 0.0312 Tc 3.606 0 Td (improved )Tj 0.22 0.22 0.216 rg 0.0207 Tc 4.368 0 Td (lung )Tj 0.286 0.286 0.282 rg 0.0221 Tc 2.109 0 Td (function )Tj 0.0375 Tc -19.247 -1.103 Td (after )Tj 0.22 0.22 0.216 rg 0.0272 Tc 2.354 0 Td (inhalati)Tj 0.365 0.369 0.361 rg 0 Tc 3.214 0 Td (o)Tj 0.22 0.22 0.216 rg 0.585 0 Td (n )Tj 0.286 0.286 0.282 rg 0.05 Tc 11.1292 0 0 10 357.01 269.53 Tm (of )Tj 0.0385 Tc 10 0 0 10 368.98 269.53 Tm (salbutamol)Tj 0.502 0.506 0.498 rg 0 Tc 4.75 0 Td (, )Tj 0.286 0.286 0.282 rg 0.0197 Tc 0.638 0 Td (two )Tj 0.0182 Tc 1.921 0 Td (required )Tj ET BT /Suspect <>BDC 0.365 0.369 0.361 rg /T1_0 1 Tf 0.0319 Tc 10 0 0 10 480.82 269.53 Tm (salbuta\255)Tj EMC ET BT 0.286 0.286 0.282 rg /T1_0 1 Tf -0.0108 Tc 10 0 0 10 287.02 258.49 Tm (mo! )Tj 0.05 Tc 10.0265 0 0 10 305.66 258.49 Tm (and )Tj 0.0276 Tc 10 0 0 10 323.98 258.49 Tm (methylprednisolone )Tj -0.0085 Tc 8.6 0 0 8.6 410.81 258.49 Tm (i. )Tj 0.365 0.369 0.361 rg /T1_3 1 Tf -0.0227 Tc 9.7 0 0 9.7 416.58 258.49 Tm (v., )Tj 0.286 0.286 0.282 rg /T1_0 1 Tf 0.028 Tc 10 0 0 10 428.06 258.49 Tm (and )Tj 0.024 Tc 1.832 0 Td (thirteen )Tj 0.017 Tc 3.492 0 Td (subjects )Tj 0.0319 Tc -19.475 -1.056 Td (required )Tj 0.0384 Tc 3.875 0 Td (salbutamol, )Tj 0.0276 Tc 5.34 0 Td (methylprednisolone )Tj 0.05 Tc 10.0265 0 0 10 465.5 247.93 Tm (and )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.041 Tc 10 0 0 10 484.22 247.93 Tm (amino\255)Tj EMC ET BT /T1_0 1 Tf 0.0067 Tc 10 0 0 10 287.54 236.89 Tm (phylline )Tj -0.035 Tc 8.0698 0 0 9.4 323.93 236.89 Tm (i. )Tj /T1_3 1 Tf 8.846 0 0 9.6 329.23 236.89 Tm (v. )Tj /T1_0 1 Tf 0.05 Tc 10.0921 0 0 10 338.44 236.89 Tm (Nobody )Tj 0.0182 Tc 10 0 0 10 376.79 236.89 Tm (required )Tj 0.22 0.22 0.216 rg 0.0234 Tc 3.792 0 Td (resuscitation )Tj 0.286 0.286 0.282 rg 0.0283 Tc 5.663 0 Td (treatment. )Tj 0.22 0.22 0.216 rg 0.0237 Tc -18.439 -1.104 Td (The )Tj 0.286 0.286 0.282 rg 0.029 Tc 1.919 0 Td (characteristics )Tj 0.05 Tc 11.1292 0 0 10 370.93 225.85 Tm (of )Tj 0.0152 Tc 10 0 0 10 383.5 225.85 Tm (the )Tj 0.365 0.369 0.361 rg 0.017 Tc 1.572 0 Td (subjects )Tj 0.286 0.286 0.282 rg 0.0292 Tc 3.709 0 Td (who )Tj 0.0159 Tc 2.152 0 Td (developed )Tj 0.0281 Tc 4.655 0 Td (an )Tj 0.0331 Tc -21.744 -1.105 Td (asthmatic )Tj 0.0216 Tc 4.473 0 Td (response )Tj 0.0375 Tc 3.975 0 Td (after )Tj 0.0291 Tc 2.255 0 Td (exposure )Tj 0.05 Tc 10.4772 0 0 10 435.33 214.8 Tm (to )Tj 0.0212 Tc 10 0 0 10 447.28 214.8 Tm (isocyanates )Tj 0.05 Tc 10.0265 0 0 10 498.62 214.8 Tm (and )Tj 0.0052 Tc 10 0 0 10 287.03 203.76 Tm (who )Tj 0.014 Tc 2.104 0 Td (did )Tj 0.05 Tc 10.1333 0 0 10 324.95 203.76 Tm (not )Tj 0.0246 Tc 10 0 0 10 342.71 203.76 Tm (require )Tj 0.0291 Tc 3.359 0 Td (therapy )Tj 0.0366 Tc 3.497 0 Td (during )Tj 0.0152 Tc 3.175 0 Td (the )Tj 0.0163 Tc 1.576 0 Td (challenge )Tj 0.044 Tc 4.272 0 Td (are )Tj 0.22 0.22 0.216 rg 0.025 Tc -21.447 -1.055 Td (reported )Tj 0.286 0.286 0.282 rg -0.035 Tc 9.9195 0 0 10 326.8 193.21 Tm (in )Tj 0.0316 Tc 10 0 0 10 338.38 193.21 Tm (table )Tj 0.0369 Tc 2.348 0 Td (2. )Tj 0.0385 Tc 1.25 0 Td (Most )Tj 0.05 Tc 11.1292 0 0 10 399.73 193.21 Tm (of )Tj 0.365 0.369 0.361 rg 0.0102 Tc 10 0 0 10 411.83 193.21 Tm (rhe )Tj 0.286 0.286 0.282 rg 0.0239 Tc 1.619 0 Td (subjects )Tj 0.0285 Tc 3.7 0 Td (complained )Tj 0.05 Tc 11.1292 0 0 10 286.45 182.16 Tm (of )Tj 0.0302 Tc 10 0 0 10 300.82 182.16 Tm (shortness )Tj 0.05 Tc 11.1292 0 0 10 346.45 182.16 Tm (of )Tj 0.0403 Tc 10 0 0 10 360.97 182.16 Tm (breath )Tj 0.05 Tc 10.0265 0 0 10 393.98 182.16 Tm (and )Tj 0.0303 Tc 10 0 0 10 415.1 182.16 Tm (cough )Tj 0.05 Tc 10.0265 0 0 10 446.78 182.16 Tm (and )Tj 0.0295 Tc 10 0 0 10 468.46 182.16 Tm (many )Tj 0.0274 Tc 2.872 0 Td (also )Tj 0.0285 Tc -21.072 -1.103 Td (complained )Tj 0.05 Tc 11.1292 0 0 10 341.17 171.13 Tm (of )Tj 0.0008 Tc 10 0 0 10 354.71 171.13 Tm (wheezing. )Tj 0.0459 Tc 4.6 0 Td (There )Tj -0.0055 Tc 3.032 0 Td (were )Tj 0.05 Tc 10.0889 0 0 10 455.51 171.13 Tm (no )Tj 0.0129 Tc 10 0 0 10 471.22 171.13 Tm (significant )Tj 0.0036 Tc -18.475 -1.104 Td (differences )Tj 0.0149 Tc 4.906 0 Td (between )Tj 0.0152 Tc 3.885 0 Td (the )Tj 0.0176 Tc 1.728 0 Td (three )Tj 0.0345 Tc 2.49 0 Td (groups )Tj -0.0049 Tc 3.31 0 Td (as )Tj 0.22 0.22 0.216 rg 0.0139 Tc 1.305 0 Td (regards )Tj 0.286 0.286 0.282 rg 0.0325 Tc 3.447 0 Td (age)Tj 0.502 0.506 0.498 rg 0 Tc 1.434 0 Td (, )Tj 0.286 0.286 0.282 rg 0.0467 Tc -22.505 -1.057 Td (duration )Tj 0.05 Tc 11.1292 0 0 10 325.81 149.52 Tm (of )Tj 0.0242 Tc 10 0 0 10 337.33 149.52 Tm (exposure, )Tj 0.0362 Tc 4.369 0 Td (atopy, )Tj 0.0384 Tc 2.924 0 Td (smoking )Tj 0.0253 Tc 3.949 0 Td (habits, )Tj 0.0071 Tc 3.122 0 Td (baseline )Tj 0.0367 Tc -19.449 -1.103 Td (lung )Tj 0.0221 Tc 2.253 0 Td (function )Tj 0.05 Tc 10.0265 0 0 10 348.86 138.49 Tm (and )Tj 0.0139 Tc 10 0 0 10 369.13 138.49 Tm (baseline )Tj 0.025 Tc 3.781 0 Td (airway )Tj 0.0078 Tc 3.321 0 Td (responsiveness )Tj 0.0413 Tc 6.575 0 Td (to )Tj 0.0272 Tc -21.936 -1.105 Td (methacholine, )Tj 0.0375 Tc 6.424 0 Td (after )Tj 0.0369 Tc 2.448 0 Td (adjustment )Tj 0.0314 Tc 5.231 0 Td (for )Tj ET BT /Suspect <>BDC /T1_1 1 Tf -0.0013 Tc 10.1 0 0 10.1 445.2 127.44 Tm (FEV )Tj EMC ET BT /T1_0 1 Tf 0 Tc 6.2 0 0 6.2 465.87 125.04 Tm (1 )Tj 0.0485 Tc 10 0 0 10 474.23 127.44 Tm (had )Tj 0.0145 Tc 2.066 0 Td (been )Tj 0.0219 Tc -20.835 -1.104 Td (made. )Tj 0.22 0.22 0.216 rg 0.0477 Tc 3.113 0 Td (The )Tj 0.286 0.286 0.282 rg 0.0272 Tc 2.256 0 Td (diagnosis )Tj 0.05 Tc 11.1292 0 0 10 386.29 116.4 Tm (of )Tj 0.031 Tc 10 0 0 10 400.7 116.4 Tm (occupational )Tj 0.05 Tc 10.0133 0 0 10 461.66 116.4 Tm (asthma )Tj -0.0068 Tc 10 0 0 10 498.71 116.4 Tm (was )Tj 0.0275 Tc -21.213 -1.056 Td (particularly )Tj 0.0198 Tc 5.317 0 Td (delayed )Tj -0.035 Tc 9.9195 0 0 10 377.2 105.84 Tm (in )Tj 0.0392 Tc 10 0 0 10 389.26 105.84 Tm (the )Tj 0.0444 Tc 1.722 0 Td (group )Tj 0.05 Tc 11.1292 0 0 10 435.73 105.84 Tm (of )Tj 0.017 Tc 10 0 0 10 448.66 105.84 Tm (subjects )Tj 0.0175 Tc 3.757 0 Td (with )Tj 0 Tc 2.295 0 Td (a )Tj 0.0211 Tc -22.27 -1.104 Td (late )Tj 0.0391 Tc 2.206 0 Td (asthmatic )Tj 0.0203 Tc 4.905 0 Td (response; )Tj 0.0152 Tc 4.703 0 Td (the )Tj 0.0031 Tc 2.009 0 Td (difference, )Tj 0.22 0.22 0.216 rg 0.0112 Tc 5.144 0 Td (however)Tj 0.365 0.369 0.361 rg 0 Tc 3.537 0 Td (, )Tj ET endstream endobj 9 0 obj <>stream Hd͊zy8 >sRhF^#y QG#Oç==o/ϧ;c_mӷKv|~_oo~y>}~W=|z>{O݇q~?>Ï?o+~ߒ~;%zΏx߽w;>lp?(O?{wٸ^ PZUuTGu^5P5FjFDMԤU PjVjUmFmک]uPuNNE]E5|| _#_k55|| _#_k55|| _#_k55|| _#_k5Z||-_+_kZ||-_+_kZ||-_+_kZ||-_+_ku:||_'_uu:||_'_uu:||_'_uu:||_'_uz||=_/_z||=_/_z||=_/_z||=_/_ || ߀o77 || ߀o77 || ߀o77 || ߀o77 KG#(~? ?G#(~? ?G#(~? ?G#(~? ?z $߄o77MM&|| $߄o77MM&|| $߄o77MM&|| $߄o77MM&||3,ߌo77f||3,ߌo77f||3,ߌo77f||3,ߌo77f|| "߂oȷ[--|| "߂oȷ[--|| "߂oȷ[--|| "߂oȷ[--||+*ߊoŷʷ[V||+*ߊoŷʷ[V||+*ߊoŷʷ[V||+*ߊoŷʷ[V|| &߆o÷ɷmm6|| &߆o÷ɷmm6|| &߆o÷ɷmm6|| &߆o÷ɷmm6|ۯ\t;]~~߅ww;]~~߅ww;]~~߅ww;]~~߅w߁w;;|C߁w;;|C߁w;;|C߁w;;|C߉w;;NN|'S߉w;;NN|'S߉w;;NN|'S߉w;;NN|'S ߅w]..|K ߅w]..|K ߅w]..|K ߅w]..|?|x>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrcolrjp2cOQ/R \#B@HHPHHPHHPHHP((( ߇Izq` Up."qΙݡ馑BLF c"8@Ǜ"DA% 0mb_=M2JƗ9t4+<#VMmG#ÿ{eraM7{["V` ÉZlj1ݩRl4:=ݠ:Y00|b:} ]$B@HHPHHPHHPHHP(((]$B@HHPHHPHHPHHP(((]$B@HHPHHPHHPHHPHHP߆nVXڶ/%{[lP $%b oĞ k/bXz@zA1-zV5{`뇟9 3FMSC-3=xYȍx)#2P@e Oe.5 sݘVW C4 S>2n  D:p<:x7fsIbU+;5:xHdFW;zMNp0Q|G_6>Z ˌ" Y(nxCKn0>z(O*64b^J=#ڈAF3Sd2w?81!!9_EXJj+S:vR1ZUte";mbW; KFu>5oWCf|}YCp mbDKOduNͤ(hBu;x?^x.+{ULAS\08R $!ڍPeKF\YR0ģtؐ< ϵD\jH)v#Uދ4ͥH{ QZ<$@RρW:ߑUe^>P;h@*[iN?C]Rti  ߰Eɯ@ N|+dPD]s]~ICPޏ ]\$!TjN'tIF2z'`sDym+0P_йFCБikM+:n?oo;Ƨ4y&qx*Ħm '@~mH+w"%lLi)(ݒa28}s^[54 & I_t` @;f'm5*Z@ b̌\[^_`%FMamJVCFX=i! ye N6%GApw=KNG)r ]ZxQIIT|ĿI&)j\G䮺dǣHQRq)Fƹbq  yzR߱#ȸcE02;. f\&͹鿴55j߫C@0̝ھe gֽ!^8e䩃m{ԫ:EP#|SMac]L7U;_Q=65d鈻@J $ء>ݿ?Q+n4 6T] E9өD@طpǛr^C<ãF{I'A iV1 ,aX5~v*-2ʕ| Q:?Cݩ{_s2{ L>|&-͉PߔJz{eٙ_6"wԵ8` h Հ oH>= ++h.hL5Mx R>ٓD.),]v f/4 $ l9JԘL. 波oFF9%+NԀE ,D5XM F( \)o5qa>1ᑚJ7Q;e*u\O3-ԟAjrlii[Aa3Ynw{2vu;.6m|= iQDL's|";(øӎs?X_ . DuHM(03Ws= J놧:IW52OLټ AZfćw&kYfQU#*3M8gօ[El{h44kEA @n*_UԢW+|+E$$>5g>>_/dr(2$vcBQo[Ue# J1w{UI d5@\nw2`VEF;jEODjsviv[C#K'*\t <-ss_͵q|z7ɶe໫ݥ~Ű"k*p^q;_d3*/(ع,~N&?;̱qC/mByb*-!:+⇿fvI*^߆ӦG^6 d|RؼGq~!Wʵ\4/.C EI0ސ2:i @x-XgWOHĬ"bK`Eh#*@"󍩡Dm"} ely^ĎAZøQoxJlS5zp!?814{F9ԕ\/S_2On^:>#H[I3Y&9|X(Sg`,:Nm{ L_b}8Q%3üS-pԏׁ?Ą!N=!_&Xq_;5_$kf ˆ [VYLBgp:y"Pc4l//u5G'~Xsό91xD*;ja H %=уEo=uy5l_ݘ8.FTir[gg]f*+ȈG›b6#H 8H_ 1|m0yz.s}xocR!ٮ>R'Tպt31cj]Q#oAC.C@urso%JJ3_t0nWTϹ<Ƿ8zϟFN'(ix7v?( TƗ4N+ ܂6=dٜ^0dqDlE[i 7qײI)Kh$и!c]2N܊TۖK}q]6TT߃! >,1Iet(vWS[[OHAC^Tue"1&+޶QUct&.M:%6o.7_ $ʹ az&ę·_/fT{ \~0#4PvkJ_*efN^Ѷݎכ~i,F9^byٙ <\P"'CW,)Y ,Q>o97M| `={@'cVxF!ѺkT Ĥ %F oah/%9Ajާ5c=U죌|7Lx(?g^n>{Yi+H6^CO`kG?r85Viα1ChHøNBRqlK8z[S?(UǠ^)3 R]\ L+nttɶ%dk*jҙz)HF?r &3W9TZK+B?ms:+1,9卪i_nf?:n1Fȟ-he맊NK ;9 :)υL:/Q O=9t {֜5齲gF[qk)K =1 [kD1tUI1\hRlM|b"пo7'NtWBkZƝP#ghڌG;ZQ0I7[+ MB{y-i9? @*G'{BFFOjj\R6L=.dg %;%~,Rk#RJ!m:(t[bW)HbO>/-* >+b>`zD=Pu88@D,m6ꉜ5{gX3Y =+b"ND#z?4Knf]2sE!'J?n;uE(菳z=+Z}?-W] @ku>Xɀ*#"S2F>YdwQ9 7q]ϣ 'DqHwpG@Cw2Jᓾ_OnXTE[j5H2P̍KlAH1ZƈPeĖwm3`2ky_9_1  d5|M5(F.͓>UPbTEs 6Ϊ&Dk4@Y/N̹si1͟yT~ҿAd?$3?-8?4, SADJي^zOƼdsNFY)#J|<7<Ҹ!J,ոedKQ!3H] UCGaFLjkY7D%٧:~]5zp>v4n5Ŭ"kAp'N.ig`S'bÜIKg(7ٌt#!'q%.=,sꒉ@ׯkxΰ8rK]f<[WYG][X`QDɉ*Pnlʒ!|5uqY}.5+|%v Mr!(?)\ﯳeo"rv"n:x k[rw\2p_@_mo-6z-s!Σ=wY `iY{Z[w-e(^es!ҿ|%_`9;4V뙑9?XT-H/>pxn ֧K>__ܩ)lLf0<|;oVUxXQso,!E,UPVIT3 DRA 3X1wАф!@,hͭRiәɘwwm*?H4GJrG/J:y%lCn<$LA%utވځnU7&'XAD`` u׭V|e¬71["+t-.adE/n$(^tpi@T>W׬̣nv.9!ĦVJC bv)OFgk#Yy bTN!Go,]Pٌ@q計g 6FQ.o=^d`rڠ;`~!£= _\W0ij~ƹ^dnKeN/׋MrS3gۉԱٲu%f:ba.S8p^dkz%>|vU҆ s=SEFfP#Uph_ ]5[?wAvâKv|;?7w꿆]^~w^;ns{}oè 5S"ʽd{DAгG[U(?& -oĴH(1iۇ uζ%B]Isw`L%\p١+Ϋ~™͒1TNln-03P^bs(ynMc[ Hu˴g܆qi-[]{Y4\^hS$-;eN/BCf9e>uxJnBNJT$dm0N֣9*MQ0tHr¬SRTuZ%e>G ԒHiGSuI8GY7#K,w\3IW҅{9넪p^;M1l?Znn  XJxAt&Kz=Q_*D48ɔͭʵK19rA,D _η=ߞAQ2I xrOiQV-'39eXټ;b23F6:X=W Nl0sO·0)GN׋Ȓ]w-w \̓#HqJV(jYl·a}yU%#ӣu\6ټXŇQ+^({1Zp!dqB@0m#aڋ1Gͣ5 k7j'&)AR< :`p+ͅ?Mg](OFebɜ7eЋP2!GorH\ bKC}~UbC\@wOݒ2s9v p\'NHi8)LRCY8 ܪh46qC+Cr2ޱ>Z/l?e!bٕ{pPj=F7i1o5NY?[qE;Ox:A 3Hֈԕce[k{'c7\\KO ]Fnlߑ޾gr˔K۾?-9R TCȒua&5wPb,v\ 9ySo`Mڞ8*_5@s$ lilzǸUfl R^S9OT}bLxB/O,"JfaE.J%8v; M-]gb} F%O9v4\ܘ7{tϡi+6.4{!5hWYf JᆾϓgJ$EYwժ l$_Cjnu=Ҫ^hgGVo=:smLc 0|*g^݅f)E-2] (Wh  NgUe ! w '܅q4lN/~dF͒itc wclʆ >5% yM7[c.N` \73>] z:wEIJ`ܛ*g~Jn@d]xB% KSHwWvsINu5WԱ73h)5އ #~7;-ZU؂}@"IA/F`ss#7粬2gKP9K=6oLDaG_XۺoN ~\>k|RFEX>~= zG{w+{+A{; S7C)zE~Y[~^70&5 JAo2x}ՊH4v!oǯ0T)hngqp6v,L(x0YRMNXGf R9ǩ).GuF6<66'J8K[{gfx͢ Ⴢ=]t!mVӠǪ:JFdjۣmܗ4Ruq~;VtP {7?lzLͺ\U .FY~5Ϥy* 8ѡT0dS;æ u cFiJ P޲,ޓ+sb8㫪BF4|mj>?;)Fܛǿo?騉GN=@@tߦB-1 kN"e9:V\>"-W঵ gYP4Q1˂͌mLub+Q+@eo$Ud{Cli;/ZpBC3 (NJ%_>!ī%m$Z wӵMл;,,L&{ў֧6ŀ͆u4ƩTqʊ.p;t(*ңmړJD[RxX8zV`Rz;)/Y[*CJ ^q{f#4<ɃkDՈ@SHyh_IdMu[DL}?=9D5 m]V c,m*>΍Yim͢kBI'EV;Bӑ#ME~;(j[_ cP?qm3ɍݫټv'ӂتhTW+`?d$LU JQk35Q a(Ek> xм?9R/hBx.+!J5V"NhOu0&d 9jOEo_B7ooҙP'E"JW!(z;\k 8$+?Zq¥a+θ, YP=B h9s$\Dv/O )}NeJLi(r'Aֆ.>xeH}N(/p:P5кVA"f}/d00VDeےTvx.pWi ( N6]v -Y+) <=fDiCK>Rؒ!jD0<%r ֺ肖`x Nx޸W"+KnB)K Y?#4LQ(LSLHݪ%d%nh > cҼc"hiӧ(r>V5C}8v?7z#SpHC0qf*&`tZ 1OF7C/d%!{,u(8F(hn4w~([M= c^1rRa>$ o7!ԻL*?.Wi0+w] `r;/S4N#bt&fZG9R+*Zg̜v2Yc0w>SI#76#&|u]:L?N-.bXe*:#UuКf r(BYЄ0eTqh0ku&x;in #TYӮNjNv#xDи)-3Nj2.Z\֌8+M `:ey& 1d[r^ m.75b\+ . ƘZeb|^Iap 02S?9t(ciM#oxrM7#E& UrܖVO!qߛ[~97+>ةADuR(_|>fF-. ->x{hS*cL,#3~㆔C =g(V*>z] Pr6mNy}=6p<'gli MjH|ɩ0jL@n::9=\k؃R7D)ͪv+j\`/eȆ_ 5=o$h X]+(xSiqf_ uc"S?t"R>e@[uqiv)Un$m^.j 1lX1bS#P'"OB`1~yui:} | tjڪER-i: =ϜWHzY$nJJNi 4ʶ4NU0Y0[E%pQu,&^!(Xq@KDXD.ȓCO  ~@@fF-I:c.6=ˇ Uי=ĤϿ}\X*HPpk,hYmk0mhbЎB*FPЀ+/pj/w:LqE[).h.,kz`V+A, nCcv)Gh,t12-Eu$p"&).gvh^I?dZ]ͥ$W Fvq.SC۬do9!b Q=/ͅ9՛]|OpO4EMt9Uɘ=:b:bPu\ĶHJݖV/>\F9 5T+C$1lHm?hĘ!c ^aaIIO5([&J|a]] N}G%otNig@i`Ϩ_,Hhv/*?§<8$4b '8nǡuHb[[`km+`gi?zKj_{ ~ r%v1-XxMHYrdl؈ba#ɻ>#Rv/@4Z5xq3kC,_FhMOa]S¹`r;,.NQenEƽ[uO菳F`~2b8oMr^' L7S)8oo8J[cxC,x{K`|"JHMefsoK\)OQ %FN#}h6z )jbqV~׍X_ťӽP U(exq^פc !XNf7 !!OQpO=`o H4lrjpgnlqsN; Yj +hlRXJ@O7Sh|ms{r4<ʧ؋ckhz;tBg˰Hh`b@/5amgE)_Z4Q0qCXfCXt]ODdI Lcl:6Gi1f{:nb6գJag}4kj"#8O:ЄGӨc'$ɌZ9 Pd1Bt}W̃ o1)& & ., ?>Rqb bp nmNImY![В%/y\L#K*Jj'T[Oq7!&4G3YOFDiJGS )pĽ_GE A[&]鉚 D!NE,V~6Q8uѓO?J:iCHT_'ڊ-7 ^w'I3?ceݍEmH֙Q\\I<wLi|;{ߖ~[ ׭7W$ͤv:Km%(u3$&\n]ř`S@i"/5!Awɦ_a 9 heϪMAsϫA1n qƢO3r!SG}yλ'ɱku?2 ^d{4\_l ]?"oӫ*3}V .=u*'.l</K?5Fz.N2`4Kr~6N4kkr)/ @9pz3ٳ| D 8@'mu=kĈ8[e!GV 8%jQtS/|gGdR8|OZz %CvPnďhIHN僟&ŗkNv?*lƗzEdtKu=܆AIРS\U$h@Kُ Q;ۯ[ [y)S,u_O{7:gƵ0ђNAHHĸw{HrV0HgbkI^;C>:I/{eoq4)OV::l̬=t 8E;咭-嬭*璟.E5UPU@|ylt@>\9)Pť)~slq?Uק6y#c%$|bm!^e0T蓳)cqD #ʲ_yX϶{q\/ͫl +\!u~Q<xvygArI’׌f¾B&-tWGd Vm*͒fmo>En&{ k.^]ﮣ>=7c˿-x׏QtfiDQ}ll¦}[Ȱ#ʡ~ MɜR@ [fG@M:ը%D]Z<^'gیK]޴'4jDI|C=ΘOjJԙ}KwKJ[ F;ЍFrb8$Y"u] ):l#ʕrr{qwh Dį@(2`ëtrK#ATi"wdDQ4YY/sr݂Y 10[I0#H2C%8NXabtq vl.@" Z?ODaG^5pFT[(hJx0؇g˥GJ'rᤶˇrm3Q3J6\?Eڠ(O@H5XQ Xj]RFHp %?O._F2A ѰQgdi3T2ݣw RFS!ۀ#p69]Ev 6`($ &Y}ȅԌV׾\@,J, U;gWBR4)]#}{a@$Aq **19,tO&\=Dhʷשjw &ߦuTYఇm`Y:L{AhdOcԸf@4_[Xғ1 zBw )C%Ћ X6ꡋT4ӗN$ڒ`W:MM  .#1 ATu2#{y!I̺ι?.sz4Ǿһ:j܌rv(a)d*ae|5[;oU f2B9<&MwFqծPYoW2}Im@iA$GpxׇLIt#oq(ߐ%o$? rÈ7vQdtJ9#]qZB y*'O,tÙ_ w I;3g]aqʊ6sY|) 4rңezk/si} yH{ep WXXu'rB|3dٷn )g \ }4bD.Yt!n VdBbCy]UrjL)oL!04X. ]dym;]JqN~@?*e @ze!v=wRPwTH,ϚIجGL@0{!ɤ0kUp*LPyfN)QC̿Q^#\wy= woh_v_ut~wYZpĵ怇b{캦Yn @J#gJXƃVngio]kʅB8"bglơ8v\P9^@`22v .@9‡g~H{*#,#W+dsˏ4f)v'ʼnN<&(C2KzAځ;wx(NzX -MMe)t y[=!1g{Zqz !Su&Mȸ/;gKA# `12(VQUsU|N<ܙi#Ϋق>+MZV16p=ja`<5U.L>X/t"v.aLOʃ++ZDa67O: 斉¦ Λ}9[ >W.!Kȓ̼9Bb*ЊUYT(ˊ 3DWFkͥ<.Zm/;_K!ݴN7=oWKa)PoM.3 3yFc-LG((+`rgd.;# rRqr6Qe6lxCpU'4qV؇cɀv8o-&q[Gժ窻jj:Ni:2rݲG"Jϻe0>{L)Lr[PJbPqS!Hϭ?a!pwmҔHd^6&## "x) P|}V )Df[hF\]]􁬮RNQU"R>G(`|a ?s!?u4NOhҼzl(О<+{䞲4CX:1;zӠڂӞyNjJT@V#Oupp`:m#DeDdJ6Q-t [X$GU_Fs"kn0tޚ1p&x駙ݥIv^L}RfVAg֝ 3αqPR} -˸B,^U bvaK{e ~Okƛc@ƉE#zVPꙒ LwH@KZ=U4k\~U$2F=MeǕ4t/?GdlӶ_c+3]*)&0ԕ P_<^Tx]i9H>Y_bTujg x^m`9OХ@ ,c-c(NX+]rOj;Le_cĝ0`ǃ_ʦDZOoQ5;daUXP0Mf[@}oХ![˓2$Yafy FŸ Å)a`a@7Sh~C愸6@6^~bJͼ#|,'QGU<ϯw+m-M#|DDNWW?أcgWB & ݒWn'}dm:E;n`;A%֗9i,!ASE_7L`Q˻Qm-;왘Z؎ƎT>5"A ԰=oB5lpReqmekR+?J4<=g}YXM=HK֦a[ B:J hiKK/Dn CH\I>Kбr/h`^03ї1}uKQME1’iqsK"qi[f!]a3\)dR`?%E/'D`dL DI!9}F@(0fw>$Հu l4GOlIסM.bNUaZB2lu^znmV.o%[c.=)6E) q-6#>f%Dub ڵ "Ci*|$%jmN%ck.4,<NmGp93a]$~Ȥ5+?w[-/IH(rNNE69g˷J.IXbI _ v}] ehk!lQ,1āc&:{1j X5| )7[bND.ҪteBQw +msfܖM~%[u9@k Pj*2ƞAxH.+kP D$4|v܉eC6e%@rŖ;~5B7T6p:c;0o6r5vڢAAמ|W11z˙ I1cɘV7: >+yջ5II]=Y'毐/de|'}RgvtqUd`t9^dyǵ]Byj?]g `)QTCZ {:!x:O=ئp48pĹs$[D=LC-ȉV"L{nfя~{}|~XY[XXF#KT?HZ`ѣ /Rk!O@clnnu*kϭ txc#hmOjѷ>CèxDo۰ʇ$JXU{IZ |;e۩6E)I 6 _ pvw 4OWMz0`-/.oZ/OGN`1j$CrD#@.:jٷȽpd69a1s;1`s#fsr++Q)gNwA H"r Lx ~l8wC#(sMo<휤Z7/ ;X%>œY?69wLݥ쪘J]1Kx1:?ST68E5,AvpoLfc]/4]T5UvP6΀% fe jYq#U"'QMd:á\@u'at-H+ce 2U,>Я!$i`P,]W̓2 7u%NCyBz={B:;{?̹vYBTh۴K n8*/Gʿc/ }(eKS8錵WZ1TiJJq7x>wKl[>-w\^ žkU*"=AzL Hr C#4ΪUp>z]u_N {sU!Ju@G|q}34r+$}^ }LSDmp$x[(֏ghk:"/EG# }|J<'hktS$#D왗, ׻ݯlB̓H\Jr%'6#V$ҤuӘd3|X{G kdz @`M1NAA9*\S;-ը* oP䋿HԳbw2s8+G4G7Fp'2VfSJi8FH+ 헆-؞IvAFE{Fϲ/} WS>bha&RF ! P̨Zc\[om%~+80y\DV[IIom5a ۃ\gUaPMx"ԓmo]W8@{L$2RlֹmsoFx1#?9õ # ^[AC`>rV%$130瞸wioq2+;Yq{K+eg$(w|L vЭ[۲RB;m5ְ 'W%5=h+ҮBغOk cV+SRS샚 -ƨeUU/Ᵽ>&Xyx@ҏ 2:>!BRWQɓJM#[foDA]1(rY~}jl d!L`qB'w\xi@"3CDE$QEb ~@waHk#"cنkb5n +;v8mїdqQMc߲T6<ӁFN+x(9Z ;}i}{ ٘ЩGAE~!YTl0!vQ9  3vďaWmB\s61e" &JEwgb\P[eG!PuBuBra8$($8gמDص0͚. 9*K@dL R\$pSs/M'rX!3(~}Q|FR`yS%1,2ƭl(\zxU]0medS!êC7 pb68LBqU溊I Cg1ŀG3E0Rb e)= o3oȗ`}-Ѝ\~,dǟ7lsa -XQ{z {~z >:bC4,> & 8Rۯ~,A #(kQuМa~u9N(/)8c , ymeMl],BG!d>u2{Dhl+ٹaAyx[U wna e@s"M=u:I\竣UM]27sipUljH-i-ŗdΔBf@ څlZz(oڮӈ&2wbIe;kV>KNӏQY r8+4a-Nm$\'f)4^z5?Ұgf8pǘ jvl~>n s\{? ]Ϳ p z,|qaYɠ+Pd$l=p*~Cy|tQ甖(+GQ}Rm縏k_]6R!/.*t@n:7q8#M.AqiQk)׋ +dTU_'8ZfԂ#g T|(ͣ AW~y{yXifH J^F_"+FҶx4Y.N.bǛLh=!3M5l8˂,(P A]f7~jYI/?љ阭X^M +CRv<(d­ 3h/m7'Hu&|f!I7 „ t8 ϗ3!w"tm^^gz S [9ѣG}a8J(oĕ,;Ý|tq>wtd'-=xL\5 YVlte_}Wu1<fbq[#8s5⇺db70jYlˍR{t#2E\/'~ΐbm+KMlq3cZ([F(-+pt{Z[E13gOR+WF dHg ` e2 H`l?mfdbӀzB?Rgz~D[6ܹL* E5N VALZp-9PU[u*UhH4糯www^ z/~ ,tcKg*$ZS*a:9Tljm Y "/"@A"a:I&ENF?T"e_):J-]3z_$9L2G-XJ=k߀^yv~c@/+q'U:~AJDژ0_ѷoCt1b6V7O#`؂H_rPbAulAUhux!IXָո)ݤXL&?[S[?ZJMW_h!R}HڃB6+RjH+ Ţ~1'<7@@Vͯxg$,:aJ= j)p|7?70_TXG¤]M9@D8 oAca6+ 2J(.,ZLeto&O UHSG<҃CR9̭\[0r^%i0΄@W.N`tdy5}9nw>1G޷vTZS6l u4"PB9l( Ԑa{i D^dq|L9CyR^t+]ae ޙrA~sn!o 3j2x'&鏍dȁp8z_rj}!$$+9Å|8J"̖\U^x6\Wj7JL8SmL<tV!3ǜkE=~Gi4GQٝTHp_w Xo>k`urj4fD B&Y]n4J3S2=0#y+@C$6fK':߿P@xՆKق3S4=Zctg&땡D<]eDôޓUϸ\ `P7lkiX׭+UVYX#t'%O6;qypWڿ{)~c0È+x|߹Ovsصo=¬GֶPoTF+ْGFI[Ys .5H'`5 Ӎ~X#8b LL0"Ļ B8j(_5ʊH\IMsGTU-0CL.t,91R⥮Smˈk|>SpStcbYz 7hB`I{u:A#(z\]Reԗ9_ cz:d7pS/T(E 8D/ dGhqn13w|awiv.4]2AβY6gqb0) mn D@ԟ]3_=t}5-Æ߆f)n^66#_m⨍y..0=fHp3ch`: SgΩm^\r~e 'O0=: Wb?ɡ{;tN@>̮j,ͮnQy„7RfNxDRu&:B͉/Wnf+uGUz)*PXwp]rٹ@0ڤu'fcqއi?5dHe?Yx]e$zU~I{eI:bM=yC1ģ cáà;GT?äQ~WyT1wK9h?OmL}YZ|kJHֻ/ڡfxw(RJmiKB$Hi~EyY_>b.+]INƤ[1C[h& to36_H^J{I\^Ζ̿*Wt_[dq3q~/ Q^jmR_'u߁]_,}tREŵ[|Yl?A+}GzW?g7k{k=awyۮ{Yկk?xm?m76>tvLLfzo)hz׮yG]=7i<^}O?|tBˮD9sY'f_l| Xuv̺~/2Lxsw,nK,OVon jD߽&~y*v4IT{^/Oo.ynڝ_ }WPv*oS|d~8\*]V>#h{Z9[N[QW^u~7Vp߻'t_Y^PCjknB֒HѮ|oWԽcjǹCҰ\~PC%  Z׉hsU_Xpi Wd"d 7%\R`b6ǮP8qFEь6`n~Ġ|1}]&0v@ RAUvP'cy;gaBazqW,̿_0}p֌=b?;?èz`RJ^b*o yrT6Ѐix<~XnYCy{.̦W *^aQQT OKspNnp+D>rel.hi yb#C ,Jm&Q?I~b6@8X Wx+jzCNbЯ/M&9J|[DoV)9rABZ*Q`9Lĥר G0iKorf JLBIaoc)_yBYA8#bh!/b:IQ(; CiỿP^ezr<p4M- $H9?ߔ7FM =NVF4:s;aJ薃O}.6%MF@ Œ ろi cAI1v jQӊ8|>fI|zw/ 4oN9,Z*ы6t/gjGJG3gqǧ$vI!q{>u͐ݨ#~E{ 28 gMT.1~,Hw&S5@:tW?=sK95." Œ6O9fa{:x5 }gwHȆ$4>Ɖ?vGl^jufq(avml2+,xQ/UT#!, K Z~Jx9w5=3o7xVTIJ]%}OccHLb漓U94i|@J`Y `5T5Ճ}=A]C1/8˳"A&MQ{f+Fg q²On+`as%3 OG~>A纈Iߋ\s1֔]tރher۰ 5xyC+Uon|1HQ7Lf]Z4 ;NE|:Orٳ;j!Xt G^.E[ bF(=᎘8C;YEPT!4&gE?T^È+-Xat&J@V+#􂯙f~4`e0$:IQUP 8>2/c_ 11bZ)K5s|(X%_o8 (MdPM#ui߇h;fդ #' <\Ӭ?yoǁy ~j\ `( I;Q{WvqSq\-5͟X%Kg*7iE5k9V|ڻsV>$2o{_#/ܔ\nZM7 R؅+6y0Y/6\h ^)8tEasK)U0!6lOwY:jM\%*\&MT]he.K ={M_,<J~s~7ܦsjQ>R׀FZoʒ B? ?I&= o"m}jB!n%!!քȏGi/Y(ۻ^d|;b\1'ҕ5} }}RSWH/|Sl j!]I9~޺{>Pm@I6,mgFQ´#8X{oem"7EM*BO -V7x6Ox6%>٣dO*4q4}.X`k_CI@<>%PN4 | J˱>h>+W۳OS$v[v[2hԻ~@GL2KN#_D-biͪ yWl܅֯ V>}ib ASfpkp/>9/Ýk]03;Y0C]7\E"Ddh&?]A3T$CKlhu@%'EL, B1I"zFTKa_$|*-Fl0ۛzaCz"cZѭlR7$qVz>3)EXb,䊖8,bY)8kN\5P~ kX8_:ԒT5I9>4{_fσai0Fjp!nϘݖWĺw2wfȐC"_4u;uix R*nR S *6Ҥhl$?u>L3g<7WK U⟄hs،/@٭9iPl׶Xn8#'|P aG|s!8PvY7ZsV~3(͔5ػkM(RrAKqPSM}ѓ#Djjg/C,״1k.g4%fSiI˸xP;hSQޤГ~ޓU>'@M'VBUR-$P>k86W*履2 ZW/=ZN*>JN4%}\y2Iȋ&A_ /A;yG֪+3@t;Ob؆. hٲMy% è\ckDJpv_j~|~Ÿjm0!kV:8"q H s tjDDJ0o4T69mZQC zN:s?m+B1?4ؖ*}4  ~ᴕI%ҍNtVԑ`+1Xc~svϧ7/.c/zyV}i+c7pi\0J/`v->$'bp1lR. 'gs|FAHEuފmԂ@HwHwLW7EoΤ#k&7PGӬkƅ@8wL챀5 w֪m^aY/\(:f{0e܀nzss?!(GTOZy Nz@&epr8^TO-E3 0U=c"Eعo{^CRӛq9I<wjqhqE}"[ˌ1q0ېY/!(*$Sk8oBν]pʭ}(WJ*ݏj_&WͲ֗Oi8)[pYb#1j Eϡ[te!NҷOn쨯4bD z@w% tܔevC4ԋ":3PJG YbDh-}X2ҫxF#FcvIeIm=o)d02a9r`a&G|LK |g9$H#6ŕSlZif֔! vzFq줍^fZN$IS1Jl?l?{!yߌ^b ~`H |!Sq˿Pv냲>p2G+-Ѹ,ʆMTne׶/\=D`%ZhK!s,x.Tf^ kɟ,$SSE })a80(o?ٖ#xȏ ` Q6T_X+* @n:b~x6,0=јE<`dQߏ.tq<:H$%URɢr'2S35_=gN2C8!Vr>ҹɍxY}/J_Vr#e\, Y.$zGώ+fzÑߖIѶ߃\`=~䣟zIz_aT;ւ5uwSKx@\csi]Ly/^'fhfA D"mr fh*79Cbھ39YZ[myq.&;MȢbsp;{ Z)|WiP+p̐Q P;lOpOꓠ-Any3~-,W@.aѭx msܘ IM'8|.fvWP9(!#ނfp`uZw4kt <ŭ7憳bLώDRa5r23qw;V3\6I8=P)[}KP{2+>7!^-8vDa=!G/&-ę|G(D)2gD%r @ ȪRO 0lBCboMw1ں܅n"`Ғa6RS'Ga4.&*ႳМFL;x,' Bd3Q[Ei]J}~/8ƚA/^l .FwB[X2!EcI-mf V;Z5ґWT1'Y^Q1Wu&Ρ`BKw= U3WEӮRӔ]Z7@SNg1^F{3AL9_R\8,gH"_HՄY !c8E)$g_#6ˤxy2.Y(@Š3tہ—< ;Eu^bdJnJaJm!mjPt;?yPV͊Ub.TGFDu7"ʣ?&>E@\wtrӅ kQ!/CݏIwduSR[] ʅy0gêު FU@&}eӿo-Bt n72a0(8v< ^dCBqsTXU yTKfwq,j^o*{O@&0#0)tVz_K!7lyU2ŐǀnC)h7Uf!Pil 7_EWn!bn*V%w$4p9\ ޑ]&A6} SU=Bl$`Drz7Α\koOۂgv7֒zaצh[Whμpu%{^aL%*_lBOC@\(mВ\d߶qдsAe\i 5fV J`T,܎~լv~3 F -ӺuG:_\Ժ Ch̉|@ D$.1qRf\S{]hQ))B Ia4 ,8DxP̹pĭs[pe]μ x '\)if Jʌdl˩=%#F_5soXەU?2 Yhop*OeA &<'R =!7V ?4[ p"O`(O;qamƮ4)&ڍɄm~+w ܲן]$%anڕ1>pMMt ! FvZ>i9ꪖl1+(Sg$b]WŽ"5{-z{x;8zЊ*~S}w-$*V3eU$gTkms ([NѤ&L8.טG{Ijd_҃3xf^e90ztFR9p6, @خX4Vfљ <`^pBfkG[Vx $.)QQ&|X2>h3iTB~٘PFtu[7aAu݈ l`ݏxB-blA_w߽E&ט, 9zb0З[]ګL=;li8Uqy! U00滎{bY>ΦdsG[A*G !wQ;jhuᆚR5@+/}\p'xu聿|Ꜯ@uH GcI-uKxyXiX ]s؉_D, y巌 <V7pXY?4݁l:aszc+8X-[GTwe|0xnmиp**\y5 S#bؒRܧCzĭޢG^~.!VbʶѤ ~^n+b[ª~?.F!:WGXsn%W0]+h2>pdWbgR6Tޢ+6aؠ!foО8ғ plKf(ВzzLZGtDQ8-QX$@h pqpt8N q%CMj%b"d&CZnnnKm [XE0#޼@ %.ȶQiinpgE$ wsSAk6MKv+!:?LxC,)'3q(lͦk+i4x1`!A>USZA$Q;РG^|r 6>ĒNԸ9Bhi6w%Q-ȥ9O횽TEBo{4) n,I?9-LY|!e-aXvE#dͅˆU"rȜ~L>At!RQp-Uk*MY 9Mibo y!j*H1ށL/ ҪЙfgL5+*fk `*k6JӔ {]eZ@Zĥ˚| !6fv=zR,'ךA sK h9V#WZ=">_!{vꠂ`5[1$Ch.4R(z,N|s4qxLb>Gxw ¯HDa>+Յ@z`_ۨuib2&$P Q:/\u}{G?{Sg@=;ݏ{/mw:'un}tj^_]j~m+u۟4ཻsC>tMZn{EzuwtK;}Xi{vݭom'EiyϽͯh6j]v^oqsww_:GںxAwX n+Kjyw}f^پ6NJPhY{{g^뚾|eӴs{~~mkZ|㼧U=ZD':b|ZD6cWX^zZ r$5LH 7Xhty|1bCZsg ybU/7-3 wBe^[z;w`(Rd7F0mpvY͜miV0[jn:47ݕS ΞȷقG>"dh4g .uA34#Iqi,K{zJ9ʠU~QiVįO)i&U"^.վ9R9\oZCjаfԐخ7LjrKlf>G<ea~M N+"i'},x-z_E6?c+Lՙ+~U.U_>` 7mju$b$!u3 B!}SO^؝8acXG)[GSaj?6X" Ǹ)uvnbx,fUH]og\sAꊕ-dz'oP' ifTpݵqS!tܢΩQM3684cN>^BlO$!_p ^+vY$h탭~Q=u}4/HRy({N.Y@4ý'M4>gu!jRbFa2 *6s/݂[2}[F _]/?k"%s`St*EݛrKi`±~ߛ erAd4"֩jjѐBb nm4JZ,307 mqt<_W2u(PQtsOwfY*d9G4f96tbK>yRiFDuDd=u"02p9ʛ㥡\nYOC^emb F%IF,Y_00 15xAy- ҆Z0ND*HBDM"m)?I1Y8zqDʑji'b<.9z@A+)Uo!;hM\fG;dAt}3 (]+'^iTmI{:W `,*w}KVŽ΅_I":3'Ll3n1evN:5 D'uoY, +m1 Kt<he8Mspz~FoiTyJpS!/ޯ/z]UG5lwȯ74Yl?DkگB:I^*BۨU|&$dA׆kVɖ#{z:>i׌ga " X#=|aVFʜ#|)݈L$w|Q(R9'gOjJ3C2,ƿI9cB$ FMEYѶm8HbyzE~YᕃBLBn*ཚ"cmWy w ,M=୍"Yq n(5F6`9"C|>VO D ?LB0]۱l;MRYfɚkD&ďsBXf$`}Ћe&^{ J׏S? >mvHD 9LC`A>`}[TX9?1tw1$iv*e߮>v"V!h*$/k/OV;* a cN.O*j+%--LH$7+u6(",%zxcObOɾsvoPAAU[;JǸÔ\},֣G@ ܨ9k~Ճg.5lmu: ڪ6(W/Pvr:n>3eGUЈu9X t$JQTP_i|m~g*@q]Q-_r3HrO (syv,wstfܛRn?>){pj7@X=EBZct ZՋ}ڧ?--] gSq ΢Q T+=TyE4jsLSMhü-C"c i3)}hj6v7@/eE!jxg(0º_ݬf+. 5VY{gc4ØtF4yn3ُCL%U3ep7摳q@ZJ`y٤ ݸv/G{q$iި;ڽ~l#U9obq+t#'\G+$Uɣ*n `-~}+xo[Z6iWͶ:(2obPʹ5GŅD/q[;893Dre(C91B[C%<?m@gj};]^t^E{%{Ir:%$ti~}óM[%W 27+( %},(d!sua4+8co_oChr A KpΒ6m߸-eHq_8wOS0M|;=A ?Ar҄#,Ur{X^K͔Ezjf@,Sj0[^冏ٔ|0=[7_ZVf$7 @y1-S[s!3(~o4gBFN+W̙Kd/3Z?fB`AMSGx~l)?*5TmxwZo&ܣȲ+˴2:2/=&Vc$F"4?1窚dc%. 7n6 q-uɅgɉ8ػ@9>}ERyDɛч*͊ `'&*X5zEd&s`Yjzl&Ǯ dۻ̃p:܃k]VZLH*034n%J>,&(TZ,0 f-՚ƑD{ҋ^H()vxW}p%$͸ij |c)Ey?7Wҟ}l '"}BQyץjQEpr7ٻkLma7 7߯f;쨢Y2W]b+M# =yI_ ғSUB)ND2EU {ԍb<7(n+0IGuMREmٗ;Ph !{n'"O˓Gџd-ڙܒ9J3?ܹw6>AkRע<2 mUfj(g  _L=[Kqc )Ż{vi2,+9p.1HK EvD{YfWR_(x=/ 邳具9q1ݶ4ف%k - <MȃmYuNb>o5|/)g[krčen cW(eEɜF>aGƵpΔM47>Y/?qHʁGVͻhk )S^â۪ScJZr@b]t݆fB IxߊQG"כ5ciԫc}a\ Zov~ebo#7gCd\*mA+䛠ם D<y ╨`[!A"ƫO1<80+٣A1EQ/T2"B=sx'vM)dX6 {[.:p;Ul]b~~z[~DVěgރ][{PG\YfщImw. )tjH^ەH%5a/X#PƣMҍ ^iz3L ;SoHuUD͕񌞦FKLs./]dzL,foX?bu}2#j, h=Qmp&dG|ɋ61ekTҫ@(;dO]e4,$5 qR?L~)JrbcE@OPrwb47X(<(`$]aӴ^vz^|œ?Hc#D|Jsꆙ@w@죤隹?:*'ȀF4@Gj\ [p*,l*+W% S[z6[JNN1x${1] Xu5EMb FbEb^\Љy -HdMz$HIu=VLh}-I{)BS,G xh)raY͵|tۂ/v۷?5 ޻JQ80 h{{НÔK\)6)|a.ˏX Ae{ݐj/Йؠ͏4q˪Ӹ@&\H3ca iZMg3n]!aq Ev\*Ix@ITp{k{)m= I\iɉIҹtmk=տ-Q0`yRPǺm(W'{˝N2[ȫ ř%if+cC :"O5-&l0_N}(x9pk4o/3:8]ؚMtn>)"NLxG0YigW„d#RrQK Anԑz|14 _2u<{߽0ٔ: j `4,y1v=1g3E d U)Q"^;8BUfo4Rz!2y,=`s2)Umg~Pl*܈E.-xS9uq'!d>W-felzWܷ4䕬β"ÃÁ^ ˆ^=)s/a;8xmIR)QNx2?NO6 =쇼@Z%P~wW3rj^w횲Zz4,HUP1 \mtFj% nŠDkZκJk3E(PzܵA0A +э_8*K I.Žn1[?U=븿>c[-Ԣ-KC39L/bѤ8bw!0CiOQ /J"d:c,,f$;^iCFFk@@IE9F'gJ6]@0Di44.rֳO!^$;2?%ي,3=ݒP~ܞ@ P ,l tK.E/_p+et~ۅxj˩(CTӧULSRB9y-R>kiL*|@i0}I!Zk`&S>Ԉhr^OftSc_̙]bQ^̸$z$]WK ]4U.ACf|7X@YX&Vg7bdBjl[/+Fj.&#eP#<-d?&#nywmܝWxiPf U?2F4d$&BSœ݌j3 -fZOdv?ϓqTJlg2Lυ׸y9*uN˩''Bp&z o5834tCE p&o]\( #eKNP&[I"[8T ,}Z+d>+(Ƃ`J[Dm5-k=ͧdt3MZ>`[ k-^N˸:^- 0\6颉G/ٮRzVW܄qƵN  s\_(zlfɳ-]\Sƈ/s9e[,Bg}IV C \Sep)\Se"U_zWٙ3@/ʯ|p04ȕkm\Q>'gӲrvG *CL(/Kyv8ncrV44gҎ6$ݰYJC]t}dtgI]1BTC񛀐7ϡLNBb"љ$}:w>yHuɦ^e5#)lS#h f:XH Ibt~d}*[7E$H6$9ro9֬WĈ(ť5"6ArC|5WH'Q];aYGLЋ6): F8u'X)qizC0[V*fRɒAUewz e[JU'YF[9odBHiT5kk9uDGmygqm4|("zYj1OEVDKza3r)V}sq4O qB*32+/Ma] fufHATz˒L46`SBVurO+_DƮ4G"1S&}j ]( -AEcvT); ^ A&pB Y^Z ;7i;S^kPNm}@#tS ?х#+: 8 %i:*z@Y2q![3ن908#YI2߲V:(ըdOʩ{ܓBƛc —G pU%lpcAޘmښ%"b)aڠ琵tAʻ%F$)*SFλCQ-HT{H|D`hiuMqXE9xX,@!kRɱǡ8TRWC%SXy«=jY9$U p~ӛ :&Q&ҝu{V-\@;=nsUnޙ{&OI3{[,bHĀ4]٫j?X8 ]z 7!S3fpha<]A3 A[;;YE:RWi֓+㜓\PUPSCEs(\n}}Ijod#LǮ(5舫|s>M:$V|O`E6w؃V(aD ^2N?@ixBrg2FnjA@[2f)n; ^650) {0+ߑMoxgLթ7ZK =Kêo9u~rQ9iB"V}LGd( xXVSb>w?$NdSsK})SRvdsU#oy5w\Ażj2PX%0$NȾkU_2_Ҡi̺Zc-2Zbu\aj);SNu`ݚ?8wbTa0%4k"]Qcu|]|ۂGQ3v'W%vV o@Y.q :P:4jc >U З*aДG!_'añ9^2%xUǣ;Y>gjm;}Żԍ?G5٨Z}x|lӝ~GT%[TOw}x\Z8c&==N謩80 ~}d |DIYЮ&@3R R0H"#,EK܏rQ,@dWbk)/~n.W%ᦝ08?[U0ZNl:}dHU+"׊Kvii][XF ÝIlte!0\+ u-彯). B鉴[}КRb,ERS`@El{:ǙR{mٲMKkdk ^8(Pφ?/e ?,#}HSUPvl_7pju7$d M[jCW*yŌ{sy+:F5CK.E2j iyVH>3B}`ёh1Bb] ZLPT1s1P1X[>x zƢݡ5C_IGZYes#THCG8#i(bh\* {DZ/b"|$O's*H2K|d^t+EpS߶aeiPk{'tb –(=J?9ۚzq.Kٽg%È(Ob [L.9ȪAruVM1Řڶ(<{ju3ɒ"dW5\Q;0,%[=gӱnM}?.§h h,MħE}S;\lhLw!G]IBHp{w~ Z," 5 4ubaXv'݃R 7| ֪9abD =X*Cp $ !IHZThkawGȮ[&\ 119~)hi{޿̖dࢴ#vJWvMeZDE8B_-?Ww6fV;!sX"$עmYmظ a^LEŧjww^CPy1VmJH G"RJv([1 7bc\J7{Gύy#[a%O&#]?V)umWUH$\k*^S t뜳K}l ݿ y'bx-79LOZl3(zl/Hw=)R`֥׷J5OHĄ"9ҷ&VyY3J`9 Ħqώ)Iؿ8439 ^7U9Lԣ&buv+r@TTiYgWjΆ;_v-jo`튎ֻNjZB\2lEg- )ؖ%MVq=}ldxZD Ok2#>\ij])bQ@g$u? k -qaKMGgi4 cNV ު# 0—JyY'!)~T1Nonޠ=s)!Ƕ8ts.׮x/F^&Pogv51d`oXO|~^o |dFaO &vɉZXpabkш\!,?v/QҪnZS_-6Hjy;+B Ԗ(,si7F[d1RW;:(+4RMH 6vn1b$0iO4СQ{,AI@pC?:f:Z)vvXjP `㍔͂=^p5ebtX(;-U,BM_獚ۍv#a63Vt#{4Dͩ~Űf’i\E.%!965])!l((lE_ڛ={܃ nkdB|8kP*WjaxuF7cSOMfM(ďa'f4jPTܪ/BY JeH`|ϕޫnzrn/qVum/r2 (|:FbX71֡'?{i~+[DDw+GFYR>><.-+^=p`I<4hʆh>sfx>#LK%32դ3ӗ``SZ*cV&xyAZa~vo.K8ٲme#cEr*}+ˠFb/ eTv1Rn?GC)tAh~wC>YD:0tq*=hO 0q+kN&.z'@%;qޏj?W+9Eaom,:@R?2.YCĖLW $\-B r9ltȚ^*ÎzQZ dUakg+:ìkZ 9q&e;{ Σ1ƞa-JyF~:egXƻF'p]7xf[xɛ*DWE5S݀ٓ "e ϥx{~n$*eeDMkOK95PЧG똃itw@"usR>h2bo9 ,zJb-~ 8x^?nf$LqΨ~GNBGp<ֆb.?ȹbpyw{Vj:$,BUTmguq;Ⱥə$ kzY$A?b~.~}مWMvl WE i `fkHth}&.rXdWS yz9#@$Ev1_uKpRtpඨ3qՔ$9r"w7;y ZC:f/r9o d]S(JN[\Oʈ+R<6BAJ޴IDCBXHuuĂFFWUv"[M"0];t4bXck\9o'{AQj|< v%@_fs2;ۍHQ #zoUpTWV؋9ɿv&p|V^@Qxr^ait؃P|Qdb~Xd1/ J䉥h5ZvwkJ;'p8{ V-T䚬Bǰ$Sx; u~oyImڦ0qwtc0MV#ȷ'+Mĵmnjgyr/vF:yb|P}S/F9qN7@u6ڷ~cGHǨtb=):|b(n%asDۋ&t-l"U 'L9JD&)[3u%F?{2^֧x3UYU!|g><7 "fXZwwACެrh}EvO$uWp?sFd OA~8a;x#\3Ҹo)̧?Ơަ`glH׀'ɋNJ!_6ԥ%LPb,l۱HApץ*f [2@cz?;[*/0F`|%O F0[Q2/CWl\S!^p0 Kgybc0F D$(E<&h(!yh΄X԰Vdd+hI4\cJFpr8|MȊ}0y`+1ը>;,ڷMT F`u)}'j>#-ld^G8bJnt]*^F9JSuNd;-*;O-'|yyK8cX _cMv]%9nªN$G 3nf>m;aMS/t12EW ([TQV'o)t0K([ZE6y8`CJlVӂf&B0֯=Wq7ǁſP2;F1; 2LYM.U aW5ʠse#6wE闼Zѱ07C> z wW 9Dɏ/4_snbƒ-6>+/YNlDی)Zs49aMƩMde"w&pۆUr: ^ab 틼б^~)]敬X}@nܩDc3'AFpG sfe諻XSwp0X }'F726 b qƞ\]AY)<{j*67|<ӪJD>(MTsN{͕_զuSaU ^ :vqcK pyJ{\^вh zJ%=;tE`R"EuTCvHd%t঑v r =QO}wu׬ZˆsMOU8 ]an{ i7{hNW'slj-\L뇑W.Fm}0wjΤqO:^ h=AD=B?Yƻ{$buu$in_Z]ZJ\;%#{ ,v<~t-e}\M WYǘ#R} RL%\Ja_#~t::s<[T);f-DߦL/mI`Oe|QHk3ޟX-p ʭI;O `\MYrs,܆Kpck7x8aj )S [pQUWoo2 R䂧5hR$(f8GY&S@0&nO3;C{|J@{pł D#3w=XK?Tɫ8 9VAs :q{\K.'~o{'q2|'dPh|B JI4r9rR0t-Ŭ3Gp]AcoMS;ap#T:'j@Igz濯:9 KkȘCsjm{7$#.fTcUly (Rqi-/]Ƨ\,kE !K ̜}1| *QzN;T~ikTS:(%V̓pQd<#fcF g}BZ@y\NrReE}gX:\[2c,hg' ^^ɷP x50R)oB ZVɗ YEp70\\!Ӈ>ekZ-0" EBO c<hw,)ɣCN䄷فֻ1LPכlFѫ$ht46y aθ[0ǢP#UH~LejQ֋CFpbn9L[R-)TU$9j&,<-D) ˬ 3_{?{6gE],<,Q B{`wGVS[iI~[_k}~M͖;=Lg&L [^H;=Xgxzl4lBQ_ 7  /Y4Ӱ@N.{!IjW*) ֋;iR7QuL8t}yU$24 B)M+^z.=K; 8OQ5RВw4j{b"YlL H2u@t.ѫ)&Kow8"je7)y3p1ȄƎGq!P؆T9yLM Fݔj?(9x5kTOpmGcJP-1_$eJHw$䫏vq eqy@jPTK|lXs0z}:ZP|Lā'u5q4.Pƹ/cEϲ177O0Ld.kR?3*U^q"cɹaCbF4 pq pHÖҎ౛7kW#UpJE1P11iUeDv&N-OӏIWۃԌ "=]N~uЃqŖlq#7V4 sv*>48O@E~TX f6|K#(Da+5kq3~ʐcèՖp(.BC brffݧm~Y3^w! :x/{(,Ar4ǻ\O)qI~f?WTNz0m$. s{E34z%b>< uoTɸqcx ٣YTʠj.epo_b6a&1v +s/<XܪK0 p<{ׇ_D{ЮLLhrxit2wGOZ0e!mr=#6ʡuo_E]4\1?&YΧ~ -7OT3ޚ[XQ|ROC^U e K2)HTtEV~U]3D jIsU A–$Ggj b+&0k!/ݛDZ^FZ?3 (ޮ")z4uCbH]J w uMȺZF6V\Z(uhf|_n>42=bHcnbQٹ:S*&+_4P!l K+@Re/#PĘBu˪j3-L$$:)8Fzh $F*Mĺ&ELKb28nlsEX"%me/3 N} 6ѳIlHVST1IOFԫ WC["24XAaI)>L 4qJ [0{c| ffUshND 3o_ xvsw:'nwW;{7 _9gƍw3{Vqֿ ؕ>{/9YCIeIJ +~oUlI֎*I ƊŇF vu Pnǜ5t0YBԊ1RQV|o–gWߌн(!Qs?{:_x&Qx,#!ͰV'a0do4:ܯbR3XR#}0sUZQ8MFG!%8ZL n%MQ^ӨQ̖8fǭXw!m%`7IĩdAϘ\20OA0U'‰O"mb$!O[u7NbCq`| y0kT2ݟFVM`A25Q07Ĵ?f[kFlð6LJ!NtoP.veGixP(2x9ܘ^مҫ~Kg03cM5hGØ#t{aaW+h]nQEE'6*j^# !"u&U563UAA6d)xqˍ3Bc?> >~39~Nm2%Y n[~Uo2c+8rtAp}r)#fUG،s$3pjNƠFu~(i&55k9럽zB9L%a'+FGr=YZQ?ך7wZRm/"g`dF;Qg;Ŷ v竊ȨDN诂%8e 4㕠]ҌEGO#-}'uAk"X<ayڦ{B=n7m@뮸—[Z)KJ%v+.fY 9S7L-qbŧ3G4)-?3N -8S3]ڰنd^c\iC@uA%[Sb0M-B]TĨ$Q8 Nj X9ڈnL`m8!>ad%bP/Dbf+H`|*"L%N{ Dbl@5k)VR'.W]KmXѽ:֧Ŗ`;?YK_@| =]zpÍ:]*x5  Xa#Ċv87KwnwyQ;sChGOˇiR.V>VqP#pPƑp'Hj:8 ">Y%Q([MwvND\@s*[a %VP;|y+h:vE'-v.KCDU.F"] ެemiJ ʥݎ>|&tyVҬ@ a\SB1 c&$|v@``Fд-G'* B-ZF/)+m~E8 I<\5T-M iX4!#5xt;}G]v& {N顄@z31Hz5SSbK\Ao멥ZeR~YOH("n9p }_냝Y# lf?43o(nΩ<77>s*c8T۲Y&'8dñ~ϦC6 $C4g$/{[0LuTXs9 ep { Pq M]r(mT>=T}r8V>ԶSwU}'\=tl>PP 6 E`Ê"1LPapCp>OJ9b- RDY?eFIDqz~6 MO*EM}H M^tIA.6ʏU)ظ"A,mTt' X!A@M5P/]83ka ~mBTcH=Cׯ+Gom0|mH^ 3M<e6Sn "us ny.]-}@*⛳ItfV݆i0|nf-1 L硤apJP€U^F/FeZWcLGWઅČL.LG?]^npe_zzTBRRN02xa|ip.**aHʕGT ;u*n~"K^C%ԐGqv%$ڈ׼! o[ rk|^ _Oz]CVTe-v5CElﻒCYV6pAѮ/~J&mdahQt?ǩsC_8%%8نD҆RpAV|/xE~ 4d\; s!|v,bw8`ku.@8l*KK$HV, ʎGcׄ i3]xROیo&Uןlf5W#Y=MT`jc%%Q,ԧtjO$=/=zZJ(/}/{:_3N_p좊 8ӎREt.cxMuXgsp@XB옝{_gHa5~5THpw'[+F<0HiVdn$]b5}!<~s}}b99Y'*xMGŜ?qAUuX/l9x&ֿIg^ ϝjZˣt@"u7"Җ/p1'I,VPω\@{#!M{*xM;c+[ht9G 5>X|_8Ni|-XEvqJFAԞhL !qUo/8c<8οпl(i;):C=KL$mij|ibeT:}Q1ӈQhNEQ8 q58Fk͞2x#Xq-L]vh]5j72ek܀5sAZ^hvwf5 =NdGEپ(^_:=UȨ{&ilX##g:?w6P%`굌d+"a=ҮMr) M`uM6:}<3uaz ݂{`-g`\O n .e$l`t`=+o4``DvCUjBJYgʫHSU#%da͠TL_=wÈ6&Tt &Lo5"a-_euluWz A2R9,p4ăړt)Μ(Nڏĵ3)lo9јV2;2 kϊ3w(Q}*Cz 8hymKL4&ji < Ksp -D(-`>%QbIox $gZxj$cBcu>.wpEN v;HMU*s۲lțrPƐr|jHLq2e 71EIwa̱4mleiˏ9.W 8@a1J~-zuVݍ&#YȫsJ +AHff=;.V(X6?/B}1z͒/ί{$ׂjIdꑆ4K4_֔V| >5. zct!^ uT8Wzqunx =.1J71 r?x[ŭ,*G֩t]VjHASmIz:H3kNRvG]Q VY]1z G-j/;Sۇh<8%J*cjd|ȴR;$Kv&2m^{S SfCٖ't%OҟX΁7PZ H&Xy7%P1aq~6:SM8[CHP;V;"D@ZNWAtnak68%Y1k'*jdZ~Mv`YTf%&E PE*}x5h t2wu[Z^#0Hw Xt_i5hDc̲nHp<- DǾL`D᥮$!=qm'G Pļ=}%)\kDw'۶B54Ds|_!\%7fE W7l0fȉ,&" npoU rFy(nۺ1Hu]No)|!T8wX=u"u~-}EP5Nk.NCg rk3,% &veaN:Hlkanj* BC94j௡Ҹxaf4$mgGU'ld]vb|<4r.Za'f뛨}n>e5% ^K:U6 q^TƑCnn@2۰8?cTQ##I X~}B};zԊ{!jH pps`|v sJv e^Fn# (Mj(*lꏚ뿩Wt~|T0L88-y8)03}X՚iMb;!dZ4z&mJؙyQ ~'Ov;f|vvj?P?8?4 %-EMrÊ4Y0&)d&V^[몧 d=F& oNޣQ1'ؤNTșJ),'~zF 6R@:ꛮʸ^{6evqbhU+48$O\گ'!(R&e]i2*l+t7]Z#jKzU,xh 8-ʹM9͡h pcUȖ,;6~{UȁSexSER|r+IF6aiŒM^_'@[6c=Nk0^Yg*b4Ȼ6-n sY/|3pDTȱA zYH8F(=L)&䃎6\~@#2Nh:uC #?"\oEIf/ v2S* `!aI%E "ŭB&yNL!@gVJdkw(.tXUAn FVX)\m JBrb'DQV,O†z~.TEO|,H#1 D!`*dǨ4u4#J`==IAMCb|HCފ^{0H$`ɪ;M>H@Qvӷe]7`jǢ}_Wii/ [, p]{|;v]:ژ/iEn]O{;S‘Bz  shu_c䲉v)@x9 yՙsqc^DpbUhW1 =6zۮG(YUѿu-UOMiՓP5%$n*ː 'f5iʼ V^bo{d{9jw}3wfӺCwX]hBz,A}(~77zcTm>\t/0=oAZwSϕz,.ֱǯ , bIP!y#pCID'Zk'*KxlC:P즙Ԉ-}2#0 HSsy{887U0PV]z|h$Vh]ݜz9%ssW'PpV"z!!iNķrlU~ |7QU<#Ŋ endstream endobj 11 0 obj <>/Filter/JBIG2Decode/Height 1752/ImageMask true/Length 20662/Name/X/Subtype/Image/Type/XObject/Width 1240>>stream /}}~ggr⾙Rp,$ y"?ߘMN -~xcejB}+7(65d.|ʷ1: h+UDs"Gv6ET%kB}2~f%wT;fߡ7>|eUPw'ҤfE\P\׶PpzHkȾyT9c4&2A5-I?GașԠ旄݉O_w(OLLnckfwKxunXN{8g %Ҁ@Tӧ5~ By]%JcD\M[`]Ԟ/0ʔ"Mq3ӲTa][6FY7ÉV9>+@Xk/֯ uCu1&ҳ&' %}cK0ZZ˚NGRYiTձ^aT·ih~AyߙЖ^(ayIL_?rkńKk"%=&RtC?.ƑP.V (@_nl},Y0n͐NqwM^эp?\,tfгq`V}szv 1?QF\:N+(}1E9 \񴐻LK՟^9DL,MR@n {h,ADRf$O]P?,C^I:H6'>~i2t5pBx|-pMY;C;Be-NӠY|xZg/-**jS^ SHŠ]F4gƗ4`tĘ'BQh>6kH*NG|dJ'G}!Fh.B?P \ߪILROZSvC# 5Gy?\<ګV(ZݡSC`oo~=xW_^MeFA ڋ> OBZ STWvGV"$azPW$vF5 kp*nVWcѢw0R_X^ubYsZX8LCOw;b5J"lߘ^Ԗd`~mCB&k6y'C߳f L*f4d-z?۰)Ͽ‰ۡ]i8Og$_N$|ԏ& cT쥔/NdGk2:$DyQLwtUUl~{P L=,|}UC$W8(C>~NMktzz Rm'Kú޺jHyIElV;{F"ɑ{QEt*@bjOc!i\kuf5TȈڣ'!.9DTdPr(jy*mؾp]~fzt]P"l2YSNV[9p6cucЛ\-q&l|ӕsjO_X4;qwMM p~b)dS`5<5X#]WC\xB{Vn=0җ*Yדrh»WPqp2df4{V+MO\A1MoO`*'jQm7f#x$3]mC܊ 5lA)&&v] /dEC'~x6pYlE#A~7Jxee |4Re|m{1}mY]=.iXXض<el{Ư2@ q$4b=c+:?O}nгxprޥƒ p+{/;Bw@ϕZֽW\{ãB&(IK Mo{}VKPSFHr[s$}2$c>X#P\Ʋ,_,ϟ~{Sz0)/I}Ve U2 JtaڠTEYIA-xuwY\w{! ޺!RkTv-}˙_E@dK"cf״B\Zϝ   IVL.N|7)e)zjlzqS{/*!+.)`l^Hvdm^Rr/{ SџܔM[?ývٳvwEA?E^"Jjf4 ݆2 VX+pu?L'aqDW3r%+ {94mD#${bR3񭪨W ^JR)sY 5AtwR}P_+B{ScpZtŏd c:IR&V (LC=$Bz9ZEݗ4fV%s=*DN v IaB2觨+G:VNxoi?U쯎iVh_^!xX:{).wO\ ͩ=(Tٞykw]w˂µ?CP1n9 ޸~ƝOithɲQX5rJliDq9w2@2nWz^`jdյ(96.V|s v{$o EGZ4ZzN9!G~OK!@`I`D0T'}lhF\)k.|ojRR+ٺkz@Mj5oQ2+g" o?ɥޟpe+$7}r #aEޔBgTQnto~NV=)[`؀~X6C鿚(%0b߾OR[gM$y<ig-~FNޓUxټQxM@9|fHZ5 b iHrD^t! U-:VwQf(f|,Jn0^&Za>.벰y wN1>wP<,D?Cr&swUgv` 5<**&-'4$4+[#-~[Z*nj%ꋸ\d=JY Aܸᓅbz dz7[ji + #Cfp*H[16a65  {58lU_/H߄LGZH aV쓽3ߙqko};rpX|2ACK c[5R:z; F{݋-uyĽjffj΀Nr j$2|U)/eqU$忷 8$<]#'m g%cJax t6zz}A/l{ZI f:[J"ZnN4;ra>YRZS1Ӂ]@*N65@p*o79zyD:r A{ooQI1)Ƌ|nLhG/>5%UkY \n<|}J(HY |-d07N>;B"{D4|)lMZBrt1SImc6g+ >R#j ʭd2y *wpM嵞㲂L^{4ȋd"兘E:c362:5>csoѯ|:=ږjФR/{f9Anɉ^N"PY@vb:j۳WEcy%XWQjơgR 9}n;n^ t&R_H7oڶ^#AE5 &i ~;QW!ꗥX`NWɿ/6㮀Ipm RS#1y5$'0<=d@p~\>"'GJlq 1@"귿^)Q-%jYdD`tɌ`ōFόHsY5 F}ű8J<i/&;Cy: Cu8=RUQ&0k|\5}{>؜Nvz\dIXxNPY"k 3G; D؁/XAprMRߝ 5 ?*g޿+B H`fI *񣼌8] ,_pJ+& 4G,!jS 2ٹ/X?fN1ъ%:wi&П7* AC̼-Y =z0C8 ,ZQ/9ȾDC7sR,B.K)>ZVUFC\1K9ZY0j-@Lrbi/L@:9XmpK8@4F1`5Oas;mNS#W 'XwY XRie , ݹПs*TsE qH_.+l JRsk STXx^R'wh k'YVJoE[S"cmA[ݱRr=|\H/@\EnaȗCIe@;dcRɼ|ְ]*|{&c~M] cNb }؀_W#g9K/h5Hd126|,ľLwX7̺6x|cā{3IXt|KR3RnFp!xKZ_v(ERaa=к յ'036Ö  R1]|DR>))4J^iDsR 8@%ÏXV0X}<фTnw5 `Jv` Y'3ʍDH [)>є[54dqU翑ƻbx3 Գo7$ɉGm7 q3q! 9Dg~hǠ$>(o^,GWQ}ຏ{E?EѮ? \P8?}1:ƹ)OgvP ǑF\veG%Z#(.%ϰ91WR~͠;-sxfK?Q)`@ $a /G-Ýw(X/ !+W\.B}5 c | 4z/.a.deՀ%g}0T;ˠhͅ0nzN_ *o|ד'OO.qφl]7FlOOBŦ`9gAI~/॔M=2e]aZ3|hXvr_nv'^&*w=3X6ݿ9TR%9$-eA=zfyجJ_|ei7ADcQ7'ÖkX2qk`s2Wz^%ʡ>JA;XVa\@B>^T-=w=t$->+I@ +HU⭎K*R^TW c?Ϙu4'G@?ΓuL,;W,V2;D.ɽWGQ+e Zwxy6 LeʾCR@0ER߽!H`k֛*,/L 0w[6K'yOboN_D7d~V"|[)B*ZSL>",`7J}K9Ҍ`bO2;(iBA}E MzJ``FKr^ XT\khخ,hQFxfIwBcxɸ ƝJ_uNx_j_H U 8"xS^d҉}0,[ÃV bPط鉻 VDsʥ_:IٹYZ! 1@{c+ pן1F߳t_,|-;,4;t.MR-&%KpmuC26!r茦x^Tfstxi<<@p{[p9)s3 vٻC[ Ҕg(u5q{ [1J8#,/Nݦ2r1X9g$jȀp ʣIzo ԋ~IϤ%o"Jݚ1&Ad0̵]ʢ< ]I"QO$DinX ޛnMz0j [(z%m Ynji?BVd-Tq)qG-b5(}khJ&>\z{ho.ʴRdx0w #PD`>WhuZp` Em3f]4#knB-P@4 x N_ )BW2) G_Rl֬K><-}0w9i+y}1έ^etr倝bFԺ z< Js]6d6qݷ~xz _'wޠ̝)$vޓ 𙴶s!|.e9 ?o0߶+vsŒ 1RKI#F;8J*0Ǽ|P¾b {x3D(̖G wz҅'4c.BgI8;dx^>$Ƌ#Huw\ M+6 &46KAAۚ{&['{)~GC ā ~J<n|gɷTxеn¸nN 0l(n;p:}.teV(CsDpr4wyĻyKO![fS?$䱴3-1%>v25͈XF#)zʘ0cW^-TtNKs> F$8 )%qu7GC NEڿ1+`w?}$X^<W7@CN5>:7Q1_fgvZ& =B+ V>嵝8= *}qvg/9pכ!jKa7tvGc9%Td-BG1_jBt(>b2OO+|b+/Q@cUhW qu|SZIͭC*I}zA4O,![/;we/N$w6V Fzc YB,j#xuwΡgݔ~* y&:GףࣤW_ {/XL%@%ߒ '2MZSpɒc^I3L)PqI=E~'U.?kRO &p2tJR㓚pTFy~f`vj"dcñs/ b!{^k#{= d{Nlz_~%{\g:4=^ԅiҳ\h! V[MÆٻcqG~[nY9UĶ!K tE{-H[Cej!Tt1,}ֿB !f7E3iV t0iLħZpNSt҈>Sh?ygg"uIfl?EF]TMR`dB~yvg슄]NO9-ZO@G1wiػr+K&)^Ije]! _s3U$ }pi$TfL2ua2iG 鏇q& Ԭ*Poݪ7A8*h22 juճ{{eF [;(;m7|4A2'w+%%S M/$R`Aڜm7/A4"Vl$\к ItZt0 br߃+T=R~<"p5fI2z6yt`͕Y\g38GûV~į\1̹d植 㪝>U&'(:'j]v}$DVhHTSMa0x4v?V^S[F0t+fKw]uyck3v**s'>N#yh==Ĝ8/̵E *HpZQ*bgxa/U^XZjz~:7Ҷ4#+Z`txZ`KL0)=gӛ^ѽEBC=UAH BJִ 0"$5b>` ;wÅ۔mt5s wPaSH~yV1YG.m l2մ[a _"GI x.݈6T|1 iQ*qߍQctE*|At"ͪK]*CyX<*]6Wϩϧ =76}D}tq𿊭A[?y?j̹bU*~^dįsh K~?1^GJbܫ7Tb xd=P^eɛ4c,zUٙݹIRmSϘpC]zمUUkXo(˶C`yQ43!dfT[{*t-ʥO&g>e ~mY_\x3DNSKb5Y|Zljx0G}P"W&>Ę~\ lvǣ! CEX-x>S )RFHHcyqk;ɭ8 l'*uj^jPAC `ψ%@>eJZVqIƁ" BH3U-W%]X]1V܌TN® !vnaD .ŪFMwfp 2`bjvX:޹1#54ݖ%152?ZX%{J= qF[7udeڻ@WlPE`ᳲ[4*Қ .?-]ח4t\$G }jib~AQ/Yv#M)K6Ȁi]j$/Y ۚc:8dGk(܄GsH -CUo"cЋS6|AC|kqf'ç^Ͱ͠7=WBˠU$-_=9jw_`b%J+Zz:JroQ'h.ʿTFKpB S`Gqs9AջcȭNwx \C,N8bQ;ľ^ ;v_f&&OՆk #s#6%`2x\ PHޜA:߿x7n VEi#1wCja^Rb'Ҷh՞ˆi8U)gt F:.t>(qQ6z x1|aV7"Ggc/?,MW9e$v?U(DNV o[?lwhO cNCש\x3㢦 "jg3Fz7/э#._6r:YmϽr[u9]%`MGew_AziMn`~RjKyeL2Z0Eܜn8X<`|z3uVdJY-}hEmCikc=)Hy Rᢏe/L~I9**.Wòjs: Y]dxO~Z#nQ-97f-'F$W%gUh0zE|IseRȼ؁k"Y&fz{*SZSH br-fI7{$u^TpM^˔^,`*!KM"P+Vn_jZ c?px:eB"8ЪLVNW4U>}Ä '# RzxV4zy&IK6'5D&]& ,6Qڟ'򲖛L"r^mOؐL#5vlֲx%tx [=jih#X6֞_ST_y!a! :0V»e&]" i,ĪXpiۭKj|CH*nqa,֪^ R{u}A:] |jDojTZz t_xcl/N|\B(y$={,rE=$s.N1c0`~PTgiqjKEٖړ: TqŎ86²jaGZ+/@8K~'G$O0+fp #1\bF/ar$>ۃRLUʘ@U߇:oxtGrQ76慎JtVT7bk$_S$q, O9d^: .q^ 23\,C\-nCñm e;ad{K( >ٲ<9"^#mZq ;07ݗҊ{wU!{)!%ba+6j+?r:^d10>FӁDo{WCGi# 'q$hne*4EQo]oU%y+N's PNx>f CTbf8B(O&yCo jr6='BYfQ"C4v`E^hM> O`R%aQ3f6; ajJ& g Y cWuV1%AT)*鏯SY5[WX(oY /4Oa{ X rJ7r%̾ė2%_L$v'XzxDf̎pӴ쮂K`M;X_f3Mr 0vc E6] gWkaqW(?b`C*jB5)TWK=@|v'uzQ18JD- emu[I`%X=O;5] LT;Y5;ӣP[)A%E}-HBЋ#)pL]3L@ft\i@wug=a>q`ώzώ:s=ȷ>Z2}-x?Q _z/9OҤ`i`uʜ `b#%5\!pU ٵz̆5-9b]2~xbE&CNa8]nvPRs!~,a8xr7Վ$%e#vC-__Ȫd#ɍ&m]LkQa^t/2C.muŠj$Mîӝ-ؓt%v5ƈ~Ah `7"v sa1q>3̵P2_!)PK.KlX!RZ-QJn%o[,96`n("&}v`x9P듉ժ=o g[ppV|h%3kY2KycWiozgt4pNvg /2vl ä1EQ?q6gJd58'˔¼EG$y'4]']sFo;I1W*i苌,>ƳA.}GkU!q{I{!C4x'FʹЁtN%+ "', :qn&qhIڵ>ݦ8b!xO!j꒘f*[xT t%+¨`HW\aˑ0.T (@,Ku(\rvQ n[Aԙ,*pl0t8oA^j8 cP&a"b"TB,)΀5KG(⡮F#j0^`wQd^}F] 'qDD RyWk0''/bįu$Y9T>vX0 ;ޢԡiؓIzEh$>XqN-2TؿMk߹%s"R%GXN#ԵT/FShoo@sgnBT.;k`{N lm:qee֤4ٳDh^JuKN"S(U~nJ}a:2JȃW=A&EGKBlC8//?yTK&QI;3jV44Ӡ s]J&P!r|+J!1uW79]3n 9$A?,Ȝ6제eauqcDkt)h#B\Jgŧ_%=nomծGr9m73=6CfCF* Щ 95.c 2T#1Ov}+挲_#|5BA`29ATsf͘DlUt&]a&E^຾ U"F?}:elq3 [&QT5%̙IK Z48z ބ9 SgeS܁ 9|s4vaEWފXѫ|a:_ŧ<, j6#I1X3v.䈣.S<#U=#! :9? 5Yr z:Ӓ"`ƱTw"%[5;}ǖQBKGh -,RD<럗nK+Gvm|[3saȥ>Uy<ܖ?#ÏOosnضHy?Ҕ,x:x2FJIGQ՟ bs|hF[1Vp-='Da#i1p$9߮ˆfT۶>wA6efMHNm$6#j^w0(̩-bC# 8x0JڐF]ܩɐF1| {zO6:nYdWBI$ЯxYɸ;#6%>熄ahN56[GDx8KoBEp| >stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrllcolr$jp2cOQ/llllR \#B@HHPHHPHHPHHP((( ]$B@HHPHHPHHPHHP(((]$B@HHPHHPHHPHHP(((]$B@HHPHHPHHPHHPHHPϷM[}j|G;h؀쵑ANʢ,^=/qX+IB.|' fSTIE$d;e- =Jd!L؇ܭNW;a0!ӵ(hR%;1z:D\dNMyw 0'կ?<%X+6ǻbP.;~ rKbc5Y]8~[@ۡ#(e<][&1t08BMStYKw+AͲi(\[1ҕYhX 3;CfƊR;<XK YК$򤀀 u5wӰ*q7ғ`{t-Txd2B-Z8駜rrt <ʒ[ziy `6~-kƮm4d1Ddw3߸uYY,`.?kUׂ\QkDɥJ$'h.?V{$TХњ66'-:$^SN EAe(v~q8ZÂN۬|$5?5w;5>]P"ϸfR.ortEG%3XОI0\ypsVQ./? ]6?xw/ɡ'N=G᭿u9&]E`DۗN4smx#.ÝԘ6A'iبyvA?4y#bf;j\ҴC̔0u p Q8ji 1Lś,r99ǙVn8"H^.53ـ~GJ.P'ao@# ,na* lY4)Rg8j v7 :R@K\w+eĥM4xq:=#@&(lmN V{Ziwbv/iYeiZwx_ x@.`n\aޝymt"Lx*,0uyZH'o4kzv8y.`ȡMHFj|e`?JED'=\azYo=ŎLˌΦ 9\vtc+`BO ;XP5c;N!Ҫ6nDGrV\pipV2&MB-Nc鑅g(oٻy#ڌnl78YuG\FŒh|' -4 ?yWnVL*/^:U_:\LF/ YT=&h8:L? *' av _fFr57#O'zW.i BP[vy,S$ؕDISѡf 4 1"֮~{7"Ui _8|m7 p'5ł*gI)xHHv޷³0%  ~>On/=~d]gLJ~랱֖ _ߵ" t xZs]h#*)ŝ V}UN^%4r͙0#j7/q vUgQ^}<ey WB&Ź72Sma T#JfUسHCOL0Þ<9WZ:1 n=If~{?U~܊GP_dOELCqo'Ysel]"ό:<^T_>#?e'mN[3kkb-N0GɑU&"S맽z<.p(!:@"9rLʯ5x;P~:ʄֹ{PdűbsfM"Or (\BDJ`غqIj"BOl$⌗q9WUٹ^Je7&MߊVlF0HYNILMuލx"At&#<$H9MzpݵJڬ?,3ƃ͐9'^FhNw"MXn Rwص? $ҹ/6ȔSP@|21yQB hu1N$<SDnzt[b3O*We}L5N+sy>;&T"#]^>@07Wֿ]GWHPe,dW?Fi6sx5??=蛰499,Hgф0.frKw7/DbYM&K{7N ,v!E%JoU B1G7/~-j/=zovs/O\w]BhY?:^{{{{s⟎C7~_WEIUJ@j]\E+5##YiA؎ҷs 88)=]ףeQaDDŽ lWҢ{_7Ÿ9@{d$3O ]]hq.HԯGAػq/̲FI D<)AG~CɂVqH@!"{} 94+< ؚ@ź i)YࣽU!3眡F:Tb̞RS.Neϫe1{ؠ\ ;0.N*Il,UOc[Dڋi)-ςHlLίT5:x˳VKg2P7@a 0sNd"*ژF\h]c>jd-{Pg,{oO~ j;nswڌAHQ*p If|Vq1~o, +$VWgndR-=ozMB.Ǜ5Nb1!^2Ր>[؎]MۢK63! 7l۳r\>yv%Ⱦ+5Uky^j8ʿO`C(i!_qvc9$J%+ nb .Q+r 4ͪ#i؈#Ӳ|90'&6 +$mPo8gVؿ54@6EIi9=b7%>[Gkq!m0 GHKXͻi/Kiw7`M&fH゙w@^O8 im$H:NgUɽuV^"L꼫H47y฻LK!v\QYꯨ/‡^/xhIb+>0*Gvdpv$4n(oW-~"}Ku=s| W9x@ +`b_cNy#‡|$fE~)U B>ن^\A!Af0Vc& ܚ qCU5Dxa2N^˭9)9iDZI-Ѓ%ֺTu&{/J:i|pDVӁQGBhg7mi+cu~ʥbWiKHw׮Nuf%^[ig7d]ATրQC `5/vxwEdʽA8[aY: nkgGe⋷?k%{d==kn@(3qK$9b6]׊) Tlq38if<8BV"i"v;$mJדeQ1wE20šYht"JQ<2#ˠo : >w ȷe _/ܺO &Q"̕oACqU֓#o! & O˲ Q y|AZvNtg2#EG*XuaAnj"4ʊ1HmK-MlpsSWYl)KA]61Q R&T hUܗr&ԨB˶tjHt9($3E 3R"`Yk)lRCyp42SHJn&D=[RԜ-)SS&k`*wu,=~otM@UТT%j'G9JP&&9CԈu[EɻË) meF?+)Ŵ2Ղf.ЖFҖ@T1jW~WP浍`HY,a%F`= eߌk̔;u憦}_ Z9ROɜ/o41CJ/" E{x 'N<;I&{!Y`x R?lWc3]*G̷wZF6t/EB>TR^3\,?.N7a~Vp+iၣMr%USԁN"vh4+]>#}7\Od9%oi'S7nZ*ɖ{/Yc?/+ԡ>x49ڝ,rg7f79Cs31gfc>T#|3X42p19@Kqj4j{E,ia)1vי/a(JPfM=HY !@nZY>dHu<Λe*M( ra6`ҿ`K|D.`D˞Kc|eCRx׷SߋsjqM >Ji|)ۊK:lzrOOɫdqticdR;H=5Z8BiA.AD#]BNZ)7(rK1~Q~_ѱqJqqr'4(eHgär2yBJ6K9,'>ؿy*!DuKC O-.6/ Y&vO0}=⽫쳸?4@ wQ6!׋$3e۽UMx*)Ҳ"POSAlxdE6a1 zqZ[FṮ _D&j.*(փ[w;gT>L.黅 փYq nJI\y$jՆyxv؀imH' {۵xr}u J +)-)KoEq  QR%X lWyo$!hZ:m}nG?9#WCeWb? wa&i2H|&cp#~sN endstream endobj 13 0 obj <>stream h240T0P040R0 F & F&K endstream endobj 14 0 obj <>/ProcSet[/PDF/Text/ImageB/ImageC]/XObject<>>>/Rotate 0/Type/Page>> endobj 15 0 obj <>stream q 595.1999969 0 0 840.9600067 0 0 cm /Im0 Do Q q 595.1999969 0 0 840.9600067 0 0 cm /Im1 Do Q q 51.3600006 0 0 82.5599976 0 743.5200043 cm /Im2 Do Q q 48.9600067 0 0 14.3999939 56.1600037 810.7200012 cm /Im3 Do Q q 22.0800018 0 0 14.3999939 117.6000061 810.7200012 cm /Im4 Do Q q 48.9600067 0 0 16.3200073 140.6399994 808.8000031 cm /Im5 Do Q q 18.2400055 0 0 14.3999939 202.0800018 810.7200012 cm /Im6 Do Q q 27.8399963 0 0 20.1600037 476.6399994 804.9600067 cm /Im7 Do Q q 25.9199982 0 0 18.2400055 509.2799988 804.9600067 cm /Im8 Do Q q 14.3999939 0 0 88.3200073 0.4799957 642.7200012 cm /Im9 Do Q q 16.3200073 0 0 35.5200043 0.4799957 603.3600006 cm /Im10 Do Q q 16.8000031 0 0 87.3600006 0 490.0800018 cm /Im11 Do Q q 12.9600067 0 0 14.3999939 0 444 cm /Im12 Do Q q 12.9600067 0 0 12.4799957 0 420.9600067 cm /Im13 Do Q q 12.9600067 0 0 33.6000061 0 382.5599976 cm /Im14 Do Q q 16.8000031 0 0 29.7599945 0 311.5200043 cm /Im15 Do Q q 12.4799957 0 0 14.3999939 0.4799957 244.3200073 cm /Im16 Do Q q 11.0399933 0 0 25.9199982 0 182.8800049 cm /Im17 Do Q q 12.9600067 0 0 27.8399963 0 150.2400055 cm /Im18 Do Q q 12.9600067 0 0 37.4400024 0 86.8800049 cm /Im19 Do Q q 28.3200073 0 0 57.6000061 0 28.3200073 cm /Im20 Do Q q 12.4799957 0 0 14.3999939 563.0399933 21.6000061 cm /Im21 Do Q BT 0.278 0.278 0.275 rg /T1_0 1 Tf -0.0277 Tc 3 Tr 10.1 0 0 10.1 68.1 774.48 Tm (276 )Tj 0.05 Tc 9.0738 0 0 7.7 264.87 774.97 Tm (C.E. )Tj ET BT /Suspect <>BDC 0.204 0.204 0.196 rg /T1_0 1 Tf 8.7199 0 0 7.7 287.48 774.97 Tm (MAPP )Tj EMC ET BT 0.278 0.278 0.275 rg /T1_0 1 Tf 8.0182 0 0 7.7 317.24 774.97 Tm (ET )Tj 8.591 0 0 7.7 331.66 774.97 Tm (AL. )Tj /T1_1 1 Tf -0.0151 Tc 9.1 0 0 9.1 68.1 750.97 Tm (Table )Tj 0.05 Tc 10.0534 0 0 9.1 93.04 750.97 Tm (2.-)Tj ET BT /Suspect <>BDC 0.204 0.204 0.196 rg /T1_1 1 Tf -0.0118 Tc 9.1 0 0 9.1 108.35 750.97 Tm (Clinical )Tj EMC ET BT 0.278 0.278 0.275 rg /T1_1 1 Tf -0.0121 Tc 9.1 0 0 9.1 142.0564 750.97 Tm (features )Tj 0.032 Tc 4.054 0 Td (of )Tj 0.204 0.204 0.196 rg -0.0314 Tc 1.377 0 Td (the )Tj ET BT /Suspect <>BDC 0.278 0.278 0.275 rg /T1_1 1 Tf -0.0321 Tc 9.1 0 0 9.1 208.6957 750.97 Tm (60 )Tj EMC ET BT /T1_1 1 Tf -0.0085 Tc 9.1 0 0 9.1 223.1192 750.97 Tm (subjects )Tj 0.204 0.204 0.196 rg -0.0287 Tc 4.123 0 Td (with )Tj 0.278 0.278 0.275 rg 0 Tc 2.258 0 Td (a )Tj 0.204 0.204 0.196 rg -0.0252 Tc 1.099 0 Td (pos)Tj 0.349 0.349 0.345 rg -0.0122 Tc 1.581 0 Td (itive )Tj 0.278 0.278 0.275 rg -0.0108 Tc 2.268 0 Td (isocyanate )Tj -0.008 Tc 5.222 0 Td (inhalation )Tj -0.0067 Tc 4.71 0 Td (test )Tj -0.0049 Tc 2.157 0 Td (according )Tj 0.0184 Tc 4.806 0 Td (to )Tj ET BT /Suspect <>BDC /T1_1 1 Tf -0.0051 Tc 9.1 0 0 9.1 492.4337 750.97 Tm (the )Tj EMC ET BT /T1_1 1 Tf 0.0058 Tc 9.1 0 0 9.1 509.7146 750.97 Tm (type )Tj -0.0207 Tc 2.421 0 Td (of )Tj -0.0042 Tc -50.954 -1.214 Td (asthmatic )Tj -0.0127 Tc 4.844 0 Td (response )Tj /T1_0 1 Tf 0.0179 Tc 8.7 0 0 8.7 252.8 718.33 Tm (Subjects )Tj 0.0348 Tc 3.769 0 Td (with )Tj 0.0179 Tc 8.645 0 Td (Subjects )Tj 0.0164 Tc 3.824 0 Td (with )Tj 0.0337 Tc 8.921 0 Td (Subjects )Tj 0.0348 Tc 3.879 0 Td (with )Tj 0.0296 Tc -29.026 -1.269 Td (IAR )Tj 0.0207 Tc 2.037 0 Td (\(n=14\) )Tj 0.204 0.204 0.196 rg 0.0002 Tc 10.433 0 Td (LAR )Tj 0.278 0.278 0.275 rg 0.0207 Tc 2.256 0 Td (\(n=24\) )Tj 0.05 Tc 8.8235 0 0 8.7 472.28 707.29 Tm (DAR\(n=22\) )Tj 8.7313 0 0 8.7 67.66 685.21 Tm (Age )Tj 0.0083 Tc 8.7 0 0 8.7 85.35 685.21 Tm (at )Tj 0.012 Tc 0.994 0 Td (diagnosis )Tj 0.05 Tc 9.2761 0 0 8.7 132.47 685.21 Tm (yr )Tj 0.0136 Tc 8.7 0 0 8.7 252.91 685.21 Tm (28.3\2612.1* )Tj 0.0186 Tc 12.408 0 Td (34.2\2611.8 )Tj 0.0265 Tc 12.745 0 Td (35.7\2612.6 )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0402 Tc 8.7 0 0 8.7 67.5217 663.6079 Tm (Sex )Tj EMC ET BT /T1_0 1 Tf 0.05 Tc 10.7024 0 0 8.7 252.83 663.61 Tm (6F,8M )Tj 10.0589 0 0 8.7 360.84 663.61 Tm (6F,18 )Tj 0.204 0.204 0.196 rg 0 Tc 8.7 0 0 8.7 388.28 663.61 Tm (M )Tj 0.278 0.278 0.275 rg 0.05 Tc 10.9481 0 0 8.7 469.39 664.09 Tm (4F,I8 )Tj ET BT /Suspect <>BDC 0.204 0.204 0.196 rg /T1_0 1 Tf 0 Tc 8.7 0 0 8.7 497.72 664.09 Tm (M )Tj EMC ET BT 0.278 0.278 0.275 rg /T1_0 1 Tf 0.0212 Tc 8.7 0 0 8.7 67.6355 642.0007 Tm (Height )Tj 0.05 Tc 9.2142 0 0 8.7 96.38 642 Tm (em )Tj ET BT /Suspect <>BDC 0.349 0.349 0.345 rg /T1_0 1 Tf -0.0005 Tc 8.7 0 0 8.7 251.22 642 Tm (170.1\2612.1 )Tj EMC /Suspect <>BDC 0.278 0.278 0.275 rg 0.0133 Tc 12.634 0 Td (171.0\2611.6 )Tj EMC /Suspect <>BDC 12.248 0 Td (173.0\2611.5 )Tj EMC ET BT /T1_0 1 Tf 0.0312 Tc 8.7 0 0 8.7 67.1715 620.4066 Tm (Atopic )Tj 0.0135 Tc 3.133 0 Td (status )Tj 0 Tc 18.154 0 Td (3 )Tj 0.0226 Tc 0.772 0 Td (\(21.4%\) )Tj /T1_2 1 Tf 0 Tc 9.7 0 0 9.7 362.78 620.41 Tm (5 )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0134 Tc 8.7 0 0 8.7 369.98 620.41 Tm (\(21.0%\) )Tj EMC ET BT /T1_0 1 Tf 0 Tc 8.7 0 0 8.7 469.4036 620.41 Tm (4 )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0226 Tc 8.7 0 0 8.7 480.8615 620.41 Tm (\(18.0%\) )Tj EMC /Suspect <>BDC 0.0294 Tc -47.566 -2.538 Td (Smoking )Tj EMC ET BT /T1_0 1 Tf 0.0091 Tc 8.7 0 0 8.7 102.2288 598.3294 Tm (habits )Tj 0.0283 Tc -4.037 -1.215 Td (Current )Tj 0.0346 Tc 3.417 0 Td (smoker )Tj 0.05 Tc 10.6457 0 0 8.7 253.07 587.76 Tm (1\( )Tj 0.0228 Tc 8.7 0 0 8.7 266.31 587.76 Tm (7.1%\) )Tj 0.204 0.204 0.196 rg 0 Tc 10.9 0 Td (1 )Tj 0.278 0.278 0.275 rg 1.016 0 Td (\( )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0205 Tc 8.7 0 0 8.7 377.235 587.76 Tm (4.0%\) )Tj EMC ET BT /T1_0 1 Tf 0 Tc 8.7 0 0 8.7 469.3332 587.76 Tm (3 )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0226 Tc 8.7 0 0 8.7 480.852 587.76 Tm (\(14.0%\) )Tj EMC ET BT /T1_0 1 Tf 0.0271 Tc 8.7 0 0 8.7 66.7494 576.7284 Tm (Non-smoker )Tj 0 Tc 21.336 0 Td (9 )Tj 0.0134 Tc 0.772 0 Td (\(64.3%\) )Tj -0.035 Tc 8.5945 0 0 8.7 356.82 577.21 Tm (16 )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0134 Tc 8.7 0 0 8.7 369.98 577.21 Tm (\(67.0%\) )Tj EMC ET BT /T1_0 1 Tf 0.05 Tc 8.8284 0 0 8.7 465.06 576.73 Tm (IS )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0226 Tc 8.7 0 0 8.7 480.86 577.21 Tm (\(68.0%\) )Tj EMC ET BT /T1_0 1 Tf 0.0259 Tc 8.7 0 0 8.7 67.1489 565.6825 Tm (Ex-smoker )Tj 0 Tc 21.298 0 Td (4 )Tj 0.349 0.349 0.345 rg 0.005 Tc 0.766 0 Td (\(28)Tj 0.204 0.204 0.196 rg 0.0098 Tc 1.425 0 Td (.6)Tj 0.349 0.349 0.345 rg 0.0133 Tc 0.728 0 Td (%\) )Tj 0.278 0.278 0.275 rg 0 Tc 9.545 0.056 Td (7 )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0134 Tc 8.7 0 0 8.7 369.9872 566.1697 Tm (\(29.0%\) )Tj EMC ET BT /T1_0 1 Tf 0 Tc 8.7 0 0 8.7 468.9236 566.1697 Tm (4 )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0226 Tc 8.7 0 0 8.7 480.86 566.1697 Tm (\(18.0%\) )Tj EMC /Suspect <>BDC 0.0246 Tc -47.566 -2.593 Td (Symptoms )Tj EMC /Suspect <>BDC 0.015 Tc 0 -1.214 TD (Shortness )Tj EMC ET BT /T1_0 1 Tf 0.05 Tc 10.0163 0 0 8.7 104.06 533.05 Tm (of )Tj 0.0213 Tc 8.7 0 0 8.7 114.25 533.05 Tm (breath )Tj 0.204 0.204 0.196 rg -0.035 Tc 8.5945 0 0 8.7 248.34 533.53 Tm (13 )Tj ET BT /Suspect <>BDC 0.278 0.278 0.275 rg /T1_0 1 Tf 0.0134 Tc 8.7 0 0 8.7 259.1 533.53 Tm (\(93.0%\) )Tj EMC ET BT /T1_0 1 Tf 0.012 Tc 8.7 0 0 8.7 356.1137 533.0515 Tm (23 )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0226 Tc 8.7 0 0 8.7 371.9042 533.53 Tm (\(96.0%\) )Tj EMC /Suspect <>BDC 0.05 Tc 8.803 0 0 8.7 464.59 533.53 Tm (22\(100.0%\) )Tj EMC ET BT /T1_0 1 Tf 0.0423 Tc 8.7 0 0 8.7 66.63 522 Tm (Cough )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.05 Tc 8.829 0 0 8.7 247.85 522.48 Tm (10 )Tj EMC /Suspect <>BDC 0.0134 Tc 8.7 0 0 8.7 259.1 522.48 Tm (\(71.0%\) )Tj EMC ET BT /T1_0 1 Tf 0.05 Tc 8.845 0 0 8.7 356.11 522.48 Tm (24 )Tj ET BT /Suspect <>BDC 0.349 0.349 0.345 rg /T1_0 1 Tf 0.0206 Tc 8.7 0 0 8.7 367.58 522.48 Tm (\(100)Tj 0.204 0.204 0.196 rg 0.0008 Tc 1.922 0 Td (.0%\) )Tj EMC ET BT 0.278 0.278 0.275 rg /T1_0 1 Tf 0.05 Tc 8.829 0 0 8.7 464.81 522.48 Tm (19 )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0226 Tc 8.7 0 0 8.7 480.86 522.97 Tm (\(86.0%\) )Tj EMC ET BT /T1_0 1 Tf 0.0294 Tc 8.7 0 0 8.7 66.6878 511.4425 Tm (Wheezing )Tj 0 Tc 21.295 0 Td (4 )Tj ET BT /Suspect <>BDC 0.349 0.349 0.345 rg /T1_0 1 Tf 0.0134 Tc 8.7 0 0 8.7 259.097 511.4425 Tm (\(29.0%\) )Tj EMC ET BT 0.278 0.278 0.275 rg /T1_0 1 Tf 0 Tc 8.7 0 0 8.7 360.8087 511.4425 Tm (8 )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0226 Tc 8.7 0 0 8.7 371.9012 511.921 Tm (\(33.0%\) )Tj EMC ET BT /T1_2 1 Tf 0 Tc 10.2 0 0 10.2 469.36 510.97 Tm (9 )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0226 Tc 8.7 0 0 8.7 480.86 511.92 Tm (\(41.0%\) )Tj EMC ET BT /T1_0 1 Tf 0.0435 Tc 8.7 0 0 8.7 66.6269 500.4099 Tm (Chest )Tj 0.0184 Tc 2.656 0 Td (tightness )Tj 0 Tc 18.694 0 Td (3 )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0134 Tc 8.7 0 0 8.7 259.0883 500.4099 Tm (\(21.0%\) )Tj EMC ET BT /T1_2 1 Tf 0 Tc 9.3 0 0 9.3 360.87 500.41 Tm (5 )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0226 Tc 8.7 0 0 8.7 371.9 500.89 Tm (\(21.0%\) )Tj EMC ET BT /T1_0 1 Tf 0 Tc 8.7 0 0 8.7 469.34 500.4115 Tm (3 )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0226 Tc 8.7 0 0 8.7 480.8588 500.89 Tm (\(14.0%\) )Tj EMC ET BT 0.204 0.204 0.196 rg /T1_0 1 Tf 0.023 Tc 8.7 0 0 8.7 67.1564 478.3309 Tm (Duration )Tj 0.278 0.278 0.275 rg 0.05 Tc 9.4598 0 0 8.7 101.19 478.33 Tm (of )Tj 0.0235 Tc 8.7 0 0 8.7 111.24 478.33 Tm (symptoms )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0285 Tc 8.7 0 0 8.7 258.6702 478.33 Tm (2.5\2610.4 )Tj EMC /Suspect <>BDC 0.0131 Tc 12.243 0.055 Td (3.9\2610.8 )Tj EMC /Suspect <>BDC 0.0101 Tc 12.53 0 Td (2.7\2610.5 )Tj EMC ET BT /T1_0 1 Tf 0.0322 Tc 8.7 0 0 8.7 66.7308 467.7595 Tm (before )Tj 0.0189 Tc 2.914 0 Td (diagnosis )Tj 0.05 Tc 9.2761 0 0 8.7 131.03 467.76 Tm (yr )Tj 0.023 Tc 8.7 0 0 8.7 66.68 446.16 Tm (Duration )Tj 0.05 Tc 9.4598 0 0 8.7 101.19 446.16 Tm (of )Tj 0.0234 Tc 8.7 0 0 8.7 111.27 446.16 Tm (exposure )Tj 0.05 Tc 8.7304 0 0 8.7 148.31 446.16 Tm (yr )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0111 Tc 8.7 0 0 8.7 256.7 445.69 Tm (9.0\2611.3 )Tj EMC ET BT /T1_0 1 Tf 0.0157 Tc 8.7 0 0 8.7 363.536 446.1598 Tm (13.2\2612.4 )Tj 0.0235 Tc 12.193 0 Td (12.9\2612.4 )Tj 0.0261 Tc -46.315 -2.537 Td (Pulmonary )Tj 0.0102 Tc 4.848 0 Td (function )Tj 0.05 Tc 8.7678 0 0 8.7 66.2 413.05 Tm (FEV)Tj 0 Tc 6.2 0 0 6.2 83.79 409.69 Tm (1)Tj 0.963 0.542 Td (/ )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0223 Tc 8.7 0 0 8.7 256.7 413.05 Tm (3.8\2610.2 )Tj EMC /Suspect <>BDC 0.0039 Tc 12.469 0.055 Td (3.7\2610.1 )Tj EMC /Suspect <>BDC 0.0223 Tc 12.248 -0.055 Td (3.7\2610.1 )Tj EMC ET BT 0.204 0.204 0.196 rg /T1_0 1 Tf 0.0301 Tc 8.7 0 0 8.7 66.6746 401.5312 Tm (FEY )Tj 0.349 0.349 0.345 rg 0 Tc 6.2 0 0 6.2 84.27 398.16 Tm (1 )Tj 0.278 0.278 0.275 rg 8.7 0 0 8.7 89.19 401.53 Tm (% )Tj 0.0194 Tc 1.225 0 Td (predicted )Tj 0.0248 Tc 17.477 0 Td (98.6\2615.3 )Tj 0.009 Tc 12.524 0 Td (94.2\2615.1 )Tj 12.248 0 Td (93.3\2613.1 )Tj 0.05 Tc 9.0168 0 0 8.7 67.11 378.49 Tm (%fall )Tj 0.0116 Tc 8.7 0 0 8.7 91.13 378.49 Tm (in )Tj 0.0301 Tc 1.052 0 Td (FEV)Tj 0 Tc 6.2 0 0 6.2 117.87 375.12 Tm (1 )Tj 0.0201 Tc 8.7 0 0 8.7 67.13 366.49 Tm (immediate )Tj 0.0214 Tc 4.586 0 Td (reaction )Tj 0.0186 Tc 16.707 0 Td (39.4\2614.4 )Tj 0.349 0.349 0.345 rg 0.0265 Tc 24.717 0 Td (35.1\2613.2 )Tj 0.278 0.278 0.275 rg 0.04 Tc -46.066 -1.27 Td (late )Tj 0.0214 Tc 1.717 0 Td (reaction )Tj 0.0265 Tc 32.1 0.056 Td (33.6\2612.2 )Tj ET BT /Suspect <>BDC 0.349 0.349 0.345 rg /T1_0 1 Tf 0.03 Tc 8.7 0 0 8.7 467.4083 355.9282 Tm (37)Tj 0.204 0.204 0.196 rg 0.0065 Tc 1.094 0 Td (.0\2613.3 )Tj EMC ET BT 0.278 0.278 0.275 rg /T1_0 1 Tf 0.0283 Tc 8.7 0 0 8.7 66.1817 333.3691 Tm (Methacholine )Tj 0.0178 Tc 6.066 0 Td (inhalation )Tj 0.0353 Tc 4.42 0 Td (test )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.05 Tc 8.7762 0 0 8.7 66.68 322.81 Tm (PD)Tj 6.5174 0 0 6.2 77.72 318.97 Tm (20)Tj 0.0301 Tc 8.7 0 0 8.7 84.44 322.81 Tm (FEV)Tj 0 Tc 6.2 0 0 6.2 101.55 318.97 Tm (1 )Tj EMC ET BT /T1_0 1 Tf 0.05 Tc 8.7105 0 0 8.7 109.42 322.81 Tm (mg )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.036 Tc 8.7 0 0 8.7 247.59 322.33 Tm (0.594 )Tj EMC ET BT /T1_0 1 Tf 0.0113 Tc 8.7 0 0 8.7 270.6189 322.33 Tm (\(1.33\)** )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0222 Tc 8.7 0 0 8.7 356.0703 322.8085 Tm (0.787 )Tj EMC ET BT /T1_0 1 Tf 0.0171 Tc 8.7 0 0 8.7 379.0992 322.8085 Tm (\(1.22\) )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0222 Tc 8.7 0 0 8.7 465.0291 322.8085 Tm (0.459 )Tj EMC ET BT 0.349 0.349 0.345 rg /T1_0 1 Tf 0.0171 Tc 8.7 0 0 8.7 488.058 322.8085 Tm (\(1.31\) )Tj 0.278 0.278 0.275 rg -0.035 Tc 8.922 0 0 9.2 66.54 299.76 Tm (*: )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 8.6835 0 0 8.7 75.32 299.76 Tm (Mean\261SEM; )Tj EMC ET BT /T1_0 1 Tf 0.0173 Tc 8.7 0 0 8.7 120.3 299.76 Tm (**: )Tj -0.0002 Tc 1.5 0 Td (Gmean )Tj 0.0013 Tc 3.145 0 Td (and )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.035 Tc 7.451 0 0 8.7 175.61 299.76 Tm (GSEM; )Tj EMC ET BT /T1_0 1 Tf 0.001 Tc 8.7 0 0 8.7 199.62 299.76 Tm (IAR: )Tj 0.0132 Tc 2.371 0 Td (immediate )Tj 0.0128 Tc 4.853 0 Td (asthmatic )Tj 0.0248 Tc 4.313 0 Td (response; )Tj 0.0182 Tc 4.464 0 Td (LAR: )Tj 0.204 0.204 0.196 rg 0.04 Tc 2.867 0 Td (late )Tj 0.278 0.278 0.275 rg 0.0197 Tc 2.039 0 Td (asthmatic )Tj 0.011 Tc 4.423 0 Td (response; )Tj 0.0007 Tc 4.466 0 Td (DAR: )Tj 0.0182 Tc 2.92 0 Td (dual )Tj 0.0128 Tc 2.316 0 Td (asthmatic )Tj 0.0286 Tc -50.363 -1.269 Td (response )Tj -0.0117 Tc 10.1 0 0 10.1 65.65 248.41 Tm (failed )Tj -0.0143 Tc 2.623 0 Td (to )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0299 Tc 10.1 0 0 10.1 103.6765 248.41 Tm (reacn )Tj EMC ET BT /T1_0 1 Tf 0.0153 Tc 10.1 0 0 10.1 128.9871 248.41 Tm (statistical )Tj -0.005 Tc 4.23 0 Td (significance. )Tj 0.0196 Tc 5.382 0 Td (Airway )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0152 Tc 10.1 0 0 10.1 260.6406 248.41 Tm (respon\255)Tj EMC ET BT 0.349 0.349 0.345 rg /T1_0 1 Tf -0.0036 Tc 10.1 0 0 10.1 65.1551 237.8454 Tm (siveness )Tj 0.278 0.278 0.275 rg 0.0333 Tc 3.671 0 Td (to )Tj 0.0211 Tc 1.188 0 Td (methacholine )Tj 0.0094 Tc 5.942 0 Td (was )Tj 0.0173 Tc 1.888 0 Td (similar )Tj -0.035 Tc 9.9195 0 0 10.1 226 237.85 Tm (in )Tj 0.0124 Tc 10.1 0 0 10.1 236.98 237.85 Tm (subjects )Tj 0.0204 Tc 3.672 0 Td (who )Tj 0.0047 Tc -20.682 -1.094 Td (developed )Tj 0.05 Tc 10.7542 0 0 10.1 111.25 226.8 Tm (an )Tj 0.204 0.204 0.196 rg 0.018 Tc 10.1 0 0 10.1 125.68 226.8 Tm (immediate, )Tj 0.278 0.278 0.275 rg 0 Tc 4.988 0 Td (a )Tj 0.204 0.204 0.196 rg 0.0325 Tc 0.855 0 Td (dual, )Tj 0.278 0.278 0.275 rg 0.05 Tc 10.5727 0 0 10.1 210.14 226.8 Tm (or )Tj 0 Tc 10.1 0 0 10.1 223.1 226.8 Tm (a )Tj 0.0162 Tc 0.904 0 Td (late )Tj 0.0281 Tc 1.852 0 Td (asthmatic )Tj 0.0165 Tc -18.383 -1.093 Td (response )Tj 0.0326 Tc 3.983 0 Td (after )Tj 0.349 0.349 0.345 rg 0.016 Tc 2.328 0 Td (expos)Tj 0.204 0.204 0.196 rg 0.0276 Tc 2.435 0 Td (ure )Tj 0.349 0.349 0.345 rg 0.0333 Tc 1.756 0 Td (to )Tj 0.278 0.278 0.275 rg 0.0165 Tc 1.23 0 Td (isocyanates )Tj -0.035 Tc 10.0124 0 0 10.1 236.04 215.76 Tm (\(fig. )Tj -0.033 Tc 10.1 0 0 10.1 256.26 215.76 Tm (2\). )Tj ET BT /Suspect <>BDC 0.204 0.204 0.196 rg /T1_0 1 Tf 0.0223 Tc 10.1 0 0 10.1 271.0969 215.76 Tm (Only )Tj EMC ET BT 0.278 0.278 0.275 rg /T1_0 1 Tf 0.009 Tc 10.1 0 0 10.1 65.2589 204.7308 Tm (the )Tj 0.349 0.349 0.345 rg 0.0124 Tc 1.984 0 Td (subjects )Tj 0.278 0.278 0.275 rg -0.0033 Tc 4.1 0 Td (who )Tj 0.0133 Tc 2.519 0 Td (required )Tj 0.0281 Tc 4.276 0 Td (treatment )Tj 0.204 0.204 0.196 rg 0.0311 Tc 4.745 0 Td (during )Tj 0.278 0.278 0.275 rg 0.009 Tc 3.572 0 Td (the )Tj 0.0227 Tc -21.202 -1.093 Td (inhalation )Tj 0.0114 Tc 4.465 0 Td (challenge )Tj 0.0311 Tc 4.131 0 Td (showed )Tj 0 Tc 3.378 0 Td (a )Tj 0.013 Tc 0.769 0 Td (higher )Tj 0.0017 Tc 2.843 0 Td (degree )Tj 0.05 Tc 11.1292 0 0 10.1 252.37 193.69 Tm (of )Tj 0.0099 Tc 10.1 0 0 10.1 263.42 193.69 Tm (airway )Tj 0.0031 Tc -19.619 -1.046 Td (responsiveness )Tj -0.0143 Tc 6.462 0 Td (to )Tj 0.0211 Tc 1.141 0 Td (methacnoline )Tj 0.0326 Tc 5.98 0 Td (after )Tj 0.0317 Tc 2.281 0 Td (adjustment )Tj 0.0171 Tc 5.047 0 Td (had )Tj -0.0076 Tc -20.909 -1.093 Td (been )Tj 0.025 Tc 2.183 0 Td (made )Tj 0.0252 Tc 2.557 0 Td (for )Tj 0.0328 Tc 1.53 0 Td (the )Tj 0.204 0.204 0.196 rg -0.035 Tc 9.951 0 0 10.1 144.88 172.09 Tm (level )Tj 0.278 0.278 0.275 rg 0.05 Tc 11.1292 0 0 10.1 166.45 172.09 Tm (of )Tj 10.2291 0 0 10.1 178.04 172.09 Tm (FEY )Tj 0 Tc 6.2 0 0 6.2 198.99 169.69 Tm (1 )Tj 0.0433 Tc 10.1 0 0 10.1 205.32 172.09 Tm (\(amean )Tj 0 Tc 12.7 0 0 12.7 239.46 172.09 Tm (= )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0013 Tc 10.1 0 0 10.1 250.46 172.09 Tm (0.200 )Tj EMC ET BT /T1_0 1 Tf -0.0144 Tc 10.1 0 0 10.1 275.9827 172.09 Tm (mg; )Tj ET BT /Suspect <>BDC /T1_1 1 Tf 0.0427 Tc 6.8001 0 0 6.8001 64.7 161.05 Tm (GSEM )Tj EMC ET BT 0.349 0.349 0.345 rg /T1_1 1 Tf 0 Tc 8.5 0 0 8.5 86.74 161.05 Tm (= )Tj 0.278 0.278 0.275 rg /T1_0 1 Tf -0.035 Tc 10.0463 0 0 10.1 96.61 161.05 Tm (1.25; )Tj 0.0001 Tc 10.1 0 0 10.1 118.46 161.05 Tm (difference )Tj 0.0154 Tc 4.321 0 Td (statistically )Tj 0.0086 Tc 4.99 0 Td (significant )Tj 0 Tc 4.578 0 Td (p )Tj 0.349 0.349 0.345 rg /T1_1 1 Tf 11 0 0 11 265.74 161.05 Tm (< )Tj ET BT /Suspect <>BDC 0.278 0.278 0.275 rg /T1_0 1 Tf -0.035 Tc 10.053 0 0 10.1 273.98 161.05 Tm (0.01 )Tj EMC ET BT /T1_0 1 Tf -0.0046 Tc 10.1 0 0 10.1 65.17 150.01 Tm (from )Tj 0.0328 Tc 2.433 0 Td (the )Tj 0.349 0.349 0.345 rg 0.0124 Tc 1.651 0 Td (subjects )Tj 0.278 0.278 0.275 rg -0.0044 Tc 3.767 0 Td (with )Tj 0.0185 Tc 2.225 0 Td (an )Tj 0.0218 Tc 1.428 0 Td (immediate )Tj 0.0183 Tc 4.807 0 Td (reaction, )Tj 0.0113 Tc 4.077 0 Td (from )Tj 0.009 Tc -20.379 -1.093 Td (the )Tj 0.0124 Tc 1.651 0 Td (subjects )Tj 0.0115 Tc 3.72 0 Td (with )Tj 0 Tc 2.225 0 Td (a )Tj 0.0162 Tc 0.904 0 Td (late )Tj 0.0129 Tc 1.909 0 Td (response, )Tj 0 Tc 4.328 0 Td (p )Tj 0.349 0.349 0.345 rg /T1_1 1 Tf 10.5 0 0 10.5 221.11 138.97 Tm (< )Tj ET BT /Suspect <>BDC 0.278 0.278 0.275 rg /T1_0 1 Tf 0.0274 Tc 10.1 0 0 10.1 228.86 138.97 Tm (0.0 )Tj EMC ET BT 0.204 0.204 0.196 rg /T1_1 1 Tf 0 Tc 9.6 0 0 9.6 243.1 138.97 Tm (I)Tj 0.349 0.349 0.345 rg 0.403 0 Td (; )Tj 0.278 0.278 0.275 rg /T1_0 1 Tf -0.0046 Tc 10.1 0 0 10.1 254.29 138.97 Tm (from )Tj 0.0328 Tc 2.433 0 Td (the )Tj 0.0056 Tc -21.208 -1.093 Td (subjects )Tj 0.0115 Tc 3.577 0 Td (with )Tj 0 Tc 2.13 0 Td (a )Tj 0.0316 Tc 0.76 0 Td (dual )Tj 0.0095 Tc 2.195 0 Td (response; )Tj 0 Tc 4.185 0 Td (p )Tj 0.349 0.349 0.345 rg /T1_1 1 Tf 11 0 0 11 201.42 127.93 Tm (< )Tj ET BT /Suspect <>BDC 0.278 0.278 0.275 rg /T1_0 1 Tf 10.1 0 0 10.1 209.66 127.93 Tm (0)Tj 0.431 g 0.559 0 Td (.)Tj 0.278 0.278 0.275 rg -0.0201 Tc 0.201 0 Td (05, )Tj EMC ET BT /T1_0 1 Tf -0.035 Tc 10.0482 0 0 10.1 233.29 127.93 Tm (by )Tj 0.0103 Tc 10.1 0 0 10.1 246.62 127.93 Tm (analysis )Tj 0.05 Tc 10.5727 0 0 10.1 283.1 127.93 Tm (of )Tj 0.0136 Tc 10.1 0 0 10.1 64.22 117.36 Tm (covariance\). )Tj 0.0128 Tc 5.552 0 Td (Serologic )Tj 0.008 Tc 4.436 0 Td (testing )Tj 0.0155 Tc 3.236 0 Td (performed )Tj 0.0471 Tc 4.79 0 Td (in )Tj -0.035 Tc 9.6981 0 0 10.1 259.08 117.36 Tm (61 )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0206 Tc 10.1 0 0 10.1 273.46 117.36 Tm (sub\255)Tj EMC ET BT /T1_0 1 Tf 0.0123 Tc 10.1 0 0 10.1 63.6022 106.3207 Tm (jects, )Tj 0.0133 Tc 2.871 0 Td (49 )Tj 0.204 0.204 0.196 rg 0.0237 Tc 1.761 0 Td (reactors )Tj 0.278 0.278 0.275 rg 0.0444 Tc 4.078 0 Td (and )Tj 0.204 0.204 0.196 rg -0.035 Tc 9.1317 0 0 10.1 176.32 106.32 Tm (12 )Tj 0.0206 Tc 10.1 0 0 10.1 192.95 106.32 Tm (non-re)Tj 0.349 0.349 0.345 rg 0.0196 Tc 2.748 0 Td (acto)Tj 0.204 0.204 0.196 rg -0.0106 Tc 1.815 0 Td (rs, )Tj 0.278 0.278 0.275 rg 0.0285 Tc 1.702 0 Td (detected )Tj -0.0122 Tc -19.014 -1.093 Td (specific )Tj 0.204 0.204 0.196 rg 0.0462 Tc 3.286 0 Td (IgE )Tj 0.278 0.278 0.275 rg 0.0006 Tc 1.755 0 Td (only )Tj -0.0005 Tc 2.046 0 Td (in )Tj 0.0253 Tc 1.044 0 Td (one )Tj 0.0051 Tc 1.754 0 Td (subject. )Tj 0.018 Tc 3.44 0 Td (Nine )Tj 0.0124 Tc 2.263 0 Td (subjects )Tj 0.0161 Tc 3.519 0 Td (\(18.4%\) )Tj 0.0356 Tc 5.848 15.161 Td (among )Tj 0.0328 Tc 3.192 0 Td (the )Tj 0.0237 Tc 1.569 0 Td (reactors )Tj 0.0444 Tc 3.65 0 Td (and )Tj 0.0402 Tc 1.852 0 Td (four )Tj 0.0124 Tc 2.088 0 Td (subjects )Tj 0.024 Tc 3.614 0 Td (\(33.3%\) )Tj 0.0356 Tc 3.709 0 Td (among )Tj 0.009 Tc -19.667 -1.046 Td (the )Tj 0.0259 Tc 1.664 0 Td (non-reactors )Tj 0.0121 Tc 5.643 0 Td (showed )Tj 0.0109 Tc 3.482 0 Td (high )Tj -0.016 Tc 2.178 0 Td (levels )Tj 0.05 Tc 11.1292 0 0 10.1 473.65 237.85 Tm (of )Tj 10.225 0 0 10.1 485.74 237.85 Tm (total )Tj 0.204 0.204 0.196 rg 0.0109 Tc 10.1 0 0 10.1 509.21 237.85 Tm (IgE. )Tj /T1_3 1 Tf -0.035 Tc 10.4838 0 0 10.6 407.96 210.49 Tm (Discussion )Tj /T1_0 1 Tf 0.0371 Tc 10.1 0 0 10.1 326.33 193.69 Tm (In )Tj 0.278 0.278 0.275 rg 0.0109 Tc 1.146 0 Td (this )Tj 0.0351 Tc 1.747 0 Td (study )Tj -0.02 Tc 2.532 0 Td (we )Tj 0.0098 Tc 1.369 0 Td (described )Tj 0.009 Tc 4.238 0 Td (the )Tj 0.0042 Tc 1.513 0 Td (clinical )Tj 0.0304 Tc 3.196 0 Td (picture )Tj 0.05 Tc 11.6856 0 0 10.1 517.33 193.69 Tm (of )Tj -0.035 Tc 9.8926 0 0 10.1 529.58 193.69 Tm (162 )Tj 0.026 Tc 10.1 0 0 10.1 316.34 183.13 Tm (patients )Tj -0.0044 Tc 3.656 0 Td (with )Tj 0 Tc 2.13 0 Td (a )Tj 0.0212 Tc 0.864 0 Td (history )Tj 0.05 Tc 11.1292 0 0 10.1 416.53 183.13 Tm (of )Tj 0.022 Tc 10.1 0 0 10.1 428.56 183.13 Tm (isocyanate-asthma. )Tj 0.204 0.204 0.196 rg 0.0278 Tc -10.171 -1.093 Td (There )Tj 0.278 0.278 0.275 rg 0.0376 Tc 2.85 0 Td (are )Tj 0 Tc 1.663 0 Td (a )Tj 0.204 0.204 0.196 rg 0.026 Tc 0.904 0 Td (larg)Tj 0.349 0.349 0.345 rg 0 Tc 1.566 0 Td (e )Tj 0.204 0.204 0.196 rg 0.0364 Tc 0.865 0 Td (number )Tj 0.278 0.278 0.275 rg 0.05 Tc 11.1292 0 0 10.1 441.49 172.09 Tm (of )Tj 0.022 Tc 10.1 0 0 10.1 454 172.09 Tm (interesting )Tj 0.019 Tc 4.845 0 Td (factors )Tj -0.0005 Tc 3.235 0 Td (in )Tj 0.204 0.204 0.196 rg 0.0198 Tc -21.766 -1.093 Td (isocyanate-induced )Tj 0.278 0.278 0.275 rg 0.0273 Tc 8.695 0 Td (asthma. )Tj 0.204 0.204 0.196 rg 0.05 Tc 10.2656 0 0 10.1 442.95 161.05 Tm (The )Tj 0.0349 Tc 10.1 0 0 10.1 466.47 161.05 Tm (latent )Tj 0.278 0.278 0.275 rg 0.0235 Tc 3.005 0 Td (period )Tj ET BT /Suspect <>BDC 0.204 0.204 0.196 rg /T1_0 1 Tf -0.0304 Tc 10.1 0 0 10.1 530.8878 161.05 Tm (be)Tj 0.349 0.349 0.345 rg 0 Tc 0.938 0 Td (\255)Tj EMC ET BT 0.278 0.278 0.275 rg /T1_0 1 Tf 0.0103 Tc 10.1 0 0 10.1 315.8184 150.0107 Tm (tween )Tj 0.0237 Tc 2.748 0 Td (exposure )Tj 0.0444 Tc 4.041 0 Td (and )Tj 0.0363 Tc 1.901 0 Td (onset )Tj 0.05 Tc 11.1292 0 0 10.1 429.01 150.01 Tm (of )Tj 0.204 0.204 0.196 rg 0.0235 Tc 10.1 0 0 10.1 441.11 150.01 Tm (respiratory )Tj 0.278 0.278 0.275 rg 0.0276 Tc 4.882 0 Td (symptoms )Tj -0.035 Tc 9.3682 0 0 10.1 537.52 150.01 Tm (is )Tj 0.0245 Tc 10.1 0 0 10.1 315.86 138.97 Tm (prolonged. )Tj 0.204 0.204 0.196 rg 0.0396 Tc 4.884 0 Td (The )Tj 0.278 0.278 0.275 rg 0.039 Tc 2.007 0 Td (proportion )Tj 0.05 Tc 11.1292 0 0 10.1 435.73 138.97 Tm (of )Tj 0.037 Tc 10.1 0 0 10.1 447.74 138.97 Tm (atopic )Tj 0.0124 Tc 2.943 0 Td (subjects )Tj 0.0356 Tc 3.663 0 Td (among )Tj 0.0328 Tc -19.667 -1.093 Td (the )Tj -0.035 Tc 9.7012 0 0 10.1 333.01 127.93 Tm (93 )Tj 0.0124 Tc 10.1 0 0 10.1 346.9 127.93 Tm (subjects )Tj 0.0115 Tc 3.72 0 Td (with )Tj 0.017 Tc 2.274 0 Td (isocyanate-induced )Tj 0.0447 Tc 8.41 0 Td (asthma )Tj 0.0094 Tc 3.478 0 Td (was )Tj 0.0211 Tc -20.963 -1.047 Td (21.5%; )Tj 0.349 0.349 0.345 rg -0.005 Tc 3.473 0 Td (this )Tj 0.278 0.278 0.275 rg 0.0331 Tc 1.854 0 Td (was )Tj 0.0173 Tc 2.031 0 Td (similar )Tj 0.0333 Tc 3.291 0 Td (to )Tj 0.0328 Tc 1.283 0 Td (the )Tj 0.0496 Tc 1.667 0 Td (proportion )Tj 0.05 Tc 11.6856 0 0 10.1 503.89 117.36 Tm (of )Tj 0.037 Tc 10.1 0 0 10.1 516.86 117.36 Tm (atopic )Tj 0.0124 Tc -19.917 -1.093 Td (subjects )Tj 0.0029 Tc 3.707 0 Td (seen )Tj 0.204 0.204 0.196 rg -0.035 Tc 9.9195 0 0 10.1 375.76 106.32 Tm (in )Tj 0.278 0.278 0.275 rg 0.05 Tc 10.1049 0 0 10.1 387.74 106.32 Tm (other )Tj 0.008 Tc 10.1 0 0 10.1 414.7 106.32 Tm (types )Tj 0.05 Tc 11.1292 0 0 10.1 440.53 106.32 Tm (of )Tj 0.349 0.349 0.345 rg 0.0264 Tc 10.1 0 0 10.1 453.5 106.32 Tm (occup)Tj 0.204 0.204 0.196 rg 0.0322 Tc 2.519 0 Td (ational )Tj 0.278 0.278 0.275 rg 0.0447 Tc 3.327 0 Td (asthma )Tj 0.204 0.204 0.196 rg -0.035 Tc 9.9277 0 0 10.1 315.6 95.28 Tm ([32]. )Tj 0.278 0.278 0.275 rg 0.0413 Tc 10.1 0 0 10.1 340.78 95.28 Tm (Another )Tj 0.018 Tc 4.221 0 Td (feature )Tj 0.05 Tc 10.5727 0 0 10.1 419.9 95.28 Tm (of )Tj 0.009 Tc 10.1 0 0 10.1 435.82 95.28 Tm (the )Tj 0.0119 Tc 1.893 0 Td (disease )Tj -0.032 Tc 3.614 0 Td (is )Tj 0.0328 Tc 1.337 0 Td (the )Tj 0.204 0.204 0.196 rg -0.0049 Tc 1.997 0 Td (high )Tj ET endstream endobj 16 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ .-jp2hihdrcolr%jp2cOQ)R \#B@HHPHHPHHPHHP((( iv{ZNǮAwx,Xgqаً|K=, $%|T V>OelV cV7&7MO|\hc<9S&S{8cksjZE-ߋu@'̼>@r0mRCWY9je+k:N` 5<A$BA@LdV5{͖>^1Gc. @L)A NJx$,Z@_rZeO r_}$SbTo VlnG~5}NλtY*2 ERybEՆ" 6EXpKLBu'hx. t߃jU')?`!]" H]>-aȏɄ#^R(^'ES;pQh(|ّ5b[oI*v_n ߆ĀBOr-pJD>I>Zo_8sYN`=Rݧ_)aiM}`^ޑpckߖ8_q%kʫ[PW1+B7o֤++qR^l' N,><~h߻w=u12yKV./#v8~gv˚TD_=C_I55jmy^c엫 3 N׳F50U%ᨡH,< W>uUMIF1^[ 9$1H:)D ( ZP|H5_%H' a'CG!j4  D g wW=/HjY"?#ff7: >(|rKˣ.Pv53T-:]anue 2g )#-gHnzItK9rIop~-ptŀY hHqòVS4 \:Ъ3P_r!؋HÑvRj(qRz݆MJ #- Oz(-EB{ƬzjErlGgb!*#x5Z*d\ 9#,u;?0ӈ,F/X'[$K˨ S%Q݂/W\A'<8*ʎΏI(<g067ҶloKf7i,mݗ -jL@4^3?UN%JЉ[C}qȷZhVjݟU59'J;G酆(t.n bzGw.Uǣ 3 l.}w*ݗS֦\I >37p@x/$Wo ,1FO}}$w!$ߏ2q~g]H8)GbIҬw y||. y*OpVoWo hx9GuqJ$_ɬ ė"C8Z\fB;F+}VހT/ :?w?%i_u;߇`f8PpX}a'pO^oݼSI">ɩyY/pq&>ypZ",D3*`)1Σdz!\ZRykh3V}rYq֠IviV5z>O[)#m8=$Q+\ YM emEeگZR. e[&-9M*{jFk$4͈ji/ŀUw@$m&m+]T1*sG n2hI6e~ '-NPh,2^lGX\[2(BC UG1-HB,ڰA -%j[2DR.Izyt0*WޣmH@w#K$3ɯK||IRfDfl,Z}ƎWCLÓ:fR\9? Ј/jX-~vѫf tp-ᠯ#QלoMb(74c4 ,[F%* ԃ#"}% K R&z)iċO Xupt``ִOPtn^~v2Ŵlm- =?\'1,7u'B\\B 唏i#۳Bv{2 5 ro&h6T@Sޠ̔q~`]ǐ~2+iqV_bO)6@{ar6ڿL!.j@;{tCژ8\5$n`ԫ@؃)Hp}Ė]bQyRU1H(]ώGz +FCu2IcXsnTru1 IʦL |aRA9_Hp޳T!Md{3wi-7Z$  c I0~,-"'dt}>M?͢}#/qCr 4YɇOY`C5]{&1 Q,;,ỏOP7GflӡlWdksNk\[0v-:=&yCl~/A1 9Q?!L74'@`7, 0S ͨпp =;Sh0} *p~=ape ) ՇWÀ6f~َFp䏄.1P\e?hYgJvE<5WpwW,u1/ f u`Wj@H2Z{ɥkIЉBX3'̈YAlN+ r_'&%~@Omh,IVz0NiO]-po|Z]v3 "9jv\U.tI<=2iT':Utۢw*/_l&C3\M1?U}7= YwLh V\fۑt\gRKTr9gDSJH972-@+Un)FBG'p "s@[ꢢ^b#xJA!V9E̛)C<</X^E)q;`B۔U֘<B_a.C;kp_' \+*a/vHHb!& hB1jdݴgE[kI\4@)Wt/ 0AM^R`W5^~'53vo\w[^p#.5 q9 m> ?Y؍1OnT_X0|#o p45n]罱+pd4O#5*j TMrR,` neWIdhd/pv_M qجC]5l 'gD֝imEq)} ePg@\qD@y^* $X'D4-Niv^jRŬLԪ u eC?O1g^2 HCJ-ek6Q}ElM8[52[߿ IƲ^@^e-C«;Q8M/gzwpN"͇|Z v1C`%GCKJ-Ln[wWx΍Kߥ:~t{ [2O|;2_Ԧ 3Q33K$$위ܭXLb=@; ˬ CWq:1%oreXS:j!S"mԶ0:䖜 ? pVvgfVr-y /KtUJ a;T)SG2OZ%hb|n= @˙qOP0fdmIFsfzN^OTa5 N#QO4$q+p^LG1X%6[4S{"$q^'Lry0.;B:+ cBQ|THB Œ:{_GZ 8  nZsJf6rx=lPnԈ 1^J[S!#N§e)❽ 5>.EG,4FVݗf}5َס l W ,:\o''~`7>-m\)Gh/=Ò+g9̟ҴkȞV%/I;tY7!KU}RHʡ O" Пw8S[`}lB] \Oq.Li0v) /K"Hdٖd&y\>̀gX(S}Q@CjD`TnNEJ}$m6e_EJ z.j0ۿm B PuMoGPCD"B<$ILZK`n}b ꞥ0?LR_MwUS:Baվ)R.{N7v^Z`i{&}!1^ <;[@!vZ2V .bև( =SV%S PDtQHҰLZn靓]mף 0hswGTG^ P΂JqS( "22GJ4~wؿY{Vס d([;zěys&u7ܘZ9jef2k_<K࣊" 4Jw' czs7sOĭ)ͫ%o"̣aS$"opj20б!`35* [-~`>{OEq~ڧJ~5w[/AM2+,-~c$wd78_bN5ğ'9q%5A+,Xl+ѯZ(!͏@,wD/?!M:vl:Ҿ UAjц3hI*K(P}r9^>_"vYrto -$s;.Bꒆg ϥQqVRzU*QVw&koQQ*@pC-JYaUߢ}x`/\ ⒀Q5TpgUp= ۓ+C A!lEѲScRoYIYBp'CC"ErݔC,|4p2 Ϗh330 чzaN1HyŠˆrׯ9N''=/}de"84_ -ߚ7 Iܡ]nV4ڿUx 5퀑ܞW1+ Te Wy18q7ؗ{=&oA?$W yZQk."+UoȵF)1Σ_BP FMPԣkh;nK3yEb1er~Hv-ͬ' qؒ!e k+KQqpa9MFy6u%д;i]vcEXb8$Aػ)I 13%xW(Ϭ+,75  u]uì~M |=zzoE]ứ;Eݳ/O}㽠GKzgދ7x`l|-4լxpUkwiO*ّf }>wak]EM5]:;Iߌ@<pQnO \0?XnɈ!OTC*VYI3n,䴟zߍzp<\]ɪHl%9y]T8@PiEzt"gN=k},,~B=uc>c%>})%C l$7q1?윉+M^ܣח)`J sD Svw6=\ SWJb 3{[ kr}X1ҵG$p4W(mIb8~&4ޠ{ME7WIDuӉ`ZʋGnaɄvS1=4fQqRә4˂,~`.us!|W*Q-~Fk-ݤ=&A`}A$BG(b#2[#_x"w-&\-6vI6Dʟ۝btfQy$q5FgjD᫪6'.Dg^O*_4WS9A86,'iH uLFH:-1-l_$b}}A`j|`坘\Sk b#k![@Xi>Ak@t,>;G qB8dWW#Y;aSZ'1ds7k=s<$rtl~D+AK  wLK XnPM>Y4CrE 5z6z߽OBOa~Z>jxY`A'd $%%v˓P>9؁•%kb0_YYZk~ޙfmco 襇^H.u>zP 9#W栮 cnRV'7(Vɖ#6HHUT,&\P3'Qˮʄ<l#s婣Yc,>uw69()À-t+Um&)mW(j$Ë ^\VɎ *ƞU"M[#J5Of@Ye툝?Vz"/NlK7WqpP]S>nQe"<:{͆q~|%+yJݏUO>c\dVe] /vY'epV/xl;D7ʴ'R.pD ; ʐF~.gp3?JďcK~LS3$⎤3} zr{*=WVFUY14}e Zjpbl3\Xu=_A Oc^G}"0ŖĐpɖq"ltMpt́1M1 tM`u:4)OF-z,U׭ > r$O&d&~mXfT82 aOnH1'b]h[x,XPd :yVbeL#&%zQk/5*~?yWI*x.vnm7f0apX0g(mJ p;/pyK +<%WuFXjKǠpmI&ml ymy~`RL6$N9t| ``z.62uqqsd4\}#NʒDV#ׂƝּl>T^sK=~^ &rcd{{8 dEw7~E|ݻ0S2;k ?__ࡾ蟊o*}_'O^xxm._n=_dN@oy]{xå]߉w(՞GnYGLC |i~Bo^;Zd݈zSul ]&UԤTHQ #oSR'lȍ66BP]ER:ed I6ַ} eߙ{E=f^petr@@ŕ"nJl1b |E xtֽ x;Y1uD'F8Wى;DX6$qo2Uts8(}{Py&T:U\ijcc*NNBmqo8epccƊY2f3#(o$P,!mɈG\zn[6U}YZ gtfl#(s/iW;C-x-Ynody8OD3!׷^Pp.ٌ,, \e'+lAd])/[ L샳MAfdwΧMmLe޼Pyc\2rN#DeuA KQg7Mm(WںIU B:@aiZA}c|FK $1asrVb;)>֟Ds+ ,õM6u0bn DM-㌞!8huw>GOPfAyAz \2#y Fɇh-EH_D%a Qu|M}Zһs"Xg]ץIkpփ*"cUhp+d&d(ҾwP8;dbpB1J1m !Cߺ^Č =h{~D?!M"?3"4Ebqʁ*7mO6bTE Ri@lB?`2sk4ȣ v@+/q:g`FU7EeUKMkдw afW;$>EklݰYHc\^D*-T~j?!jn(/ֿw_ OQMvٯ笯u_J2 ;p) 3&|D^\i.ZA`|BՑ N)dF,p)I泙sqwqYd~lvEص*5zWy 9/wtvWU`-w/qXɽNude}΋һfXVznhK~Enwf-6|&nF+=qv 7!*(]q6DLޛT_V$"`Je.@֪)xٰ3.SIuuˆ_$H7QYH£ibo]C ْ5p}GDm2mk2Z\NQ9eÒ[$ 4-h'0K)MmD`z9[B k0q'07OkNx`ei#[!̱sS#qMJTV_ˑ>}@c*!L A П l7Ug5AWvNl|^KpW+ZAD#C99޹? 'd(%hw 潖?{-sQû;~<Jyu>Z;ZL}_Q4?Vjԃg>ػ8.YUPsүVEGJƘwRZú&(RjuPFiOA{8a6簿0SWLmPbcXMl`Q} "-3%o-qW'ii{{SQN3+stl+l1l Z*X/:VѺ<}Egl.9(>] {Ø͊¸3Pg~jBR02`77Bs=FJ:&\ AFB~(Ju<z`ReNdk!}h$7`JFeq{Y=S Brs0X/ ̎'_bq(}Pӝ" ܂>4@P9RC(˵e\h՛˂*\qW@niv֓7H0}_ L 5/9Pԯ^l?hGP?(H (\(c_&`oy(D#l>Km\Kvi,l`#rbϑThf`Oe0V0S(t Nݡ` P &ݠ,p7/m{S ;dluԽ0O;hY=0f qr/? #aF"fgt- "I`0J{8Ki\/6_t:,'ysin:ь"N>aaefM&0 "Gɫ\g}\aࠈIjZ6#5dBQoPZTiѭ;:)k- ة]ms4b+jQB7BgB,'ؑi4ƣgE*z4'q&brgZ*!,mA'eoLj1(]KdE֕!zы%K`n$1 -|J~BN~(w@)kZC)+gs(3^1k@?Km:ϧ"pI H4 Z-榺b8Xؑv:8$CC*>3jg;J~<SDOueΈ [SF1A{Gt*iL xXjyMM!ߗ6|Mu_L T묷(Wu]'%;#:orVxJeiTC:aj& H a,(qoK-M3|x (U-jZ!:IZ4rϳyxKf^#`_E?Ɛ+X3M%A}IC+ 7h}D^ll{ɑY&qoLcl}M mo@G;缸ۤ Tl ZkĄɝbIe F:Tf.P +jؠnuG2qJͧ1X rBQ6Zv=P6\BCdXpY9\dJg]7gB=XEe]8[gwu찞ZD8:ia bK!*T8]5jXEh!w>r_,8wcMSS[4`2(KR `b>0}֍wKޚDE5p\JTf(p'CI;O~E?_']LhRѺWO$wM))+y,xê]j2*늌G82Xqv5]t,Igöū,$u/5 y8ÿn(9,IGҠq3fY% It #pt0Q?n? Ōjz!=oB k%f{yr?'4; yx Qx:y;iPξico&\+&7u0"% ڔ 3>q3Nʷ"oɟF6\{@Պ2S^$9f[7I[ 4Q':; L Ӏv1tUKV60X'6!;hmm}LT9Vطj"rD|R1tD\Ƈ̱\=, >y4rBŐX5bq-[5'0:x$O(jLISjRܽ@X)lqx>J< V]y| LG3+ Bp^UײDsrg0%/nB=˟?T) }c6,IwVA2:;UrXňZ=oŇLwYWHJCǺ5S"dqaת39eYS)jk:bael{޹H- dnLL^OқUU18+O-R؎^@=F2F5^̤btr6_ܥT'8tC0y2{gٌMݍۅ "C9_u.ѻygɜ{PԮe~7 ЯºvCK@^.lEmPh!P׷HNg8Y!OĊc!i1޽}Sb]AQzP ^A7ʡLX!V[SkSufaHPP̴ kO8>W$Sk4˚e o m,9zIIsK`>;椩~IG.F9U2x"O IzpZK/ _̶@a>mP+IFe%9g,vR/5O:bH=ܽ? zBY!>i_C-('W,ݮ7*,qR-9UPb%[׫4#׳۫r;C^A VݰAN`&8$ $fX<(;8a''Kjr,% Z嚖G96TPflvy=MtR9t_mAzԣG|j%` 3a4LQgbƔ0}(uʥX@.}k:Qm*QK= Q42ѿVsK$ #`t+ydZx6zه@^̞ճ;OQuR6|KN|Kݭv|[n_P~ P)ПLQEthCP,x9_=HF-c^:yWHKazQPכ7-)u;@{ѿ ]\h@BSk-u`錱O?F1ُZItJ6LDXIi$5} 训/ zkC-͇Mn&æ{wX;4> 4tJPHժⲚneX^reL@|ꀀ(\bn| 4Z:ލM[7nYM;?,+h'#CJKN.:I둥a^U*Sekj$ ֩G'~a߼貾;PԎj_yҎ=6Z1&՘y8pIlW|e "d8y›c#nh1,MsخF(Qƴ[ e ]*=hmmW'V>J_jy, yrBr3/l  6W"nn LC?L}6~UL"V+\j)Ys ̂BM>`әvqm MF5s,aP.:A}fY럈֟!kU@+fAX <K=.ߍ S{%sEvg%TؽTY8-^KX5MIbM-IkZ&K)Q\Bh9ZDbzw2  *23WS7jq C5/S3}=}ox2I$ M퉮7 Evdԑ- *)NC*:p}.Jm5l( 3>(7da(1b򯄋njq@wB/ɿ[ i]"gj=G%UXQC'!6lVMjMHߓ/ӣ}@䤖|ꔣg"x}{O̝÷Mm*;©6`ů+hL)CLzZ6**U0!opǭDzh~&c3o{5k3-Ai?GƷ¶ \5`~C7V鏽l,=/jy1tֿ (g ݭ] 4 K04*=u_X9D&SDwТa@8dHp<'?s t܅4QI?>hqi5uNUGA8,#{B+އvDm~`HvXxp f-Am"J,bmAh ]T7\ T5s {HkN<Y̼=az1E`0쨲ߎ=0%5۽7/-Cw\0ZƕbEm=.7^Ӈg34WvUR%n"icg;Sk;s"zd>+!lXRGN ԨӥSK1C1 *@Hr- l7udHG/~&c[ O|uOejA}[poHiBcV>:q5yP J2VYCIׂ7{[3Q (C ;Y՛J*>1%ꡡI{ & 'QH!mF2z񹈸Euc0a\o-C Ro V]Xh1l:w7bZ͋kNB$uCGuUǘ6n@gu:e~9'(ռ`!ECA8n'ARҵni"Vr~FwڏiQl!5a`a vF[(4Zc̩ 1Lnp㼖ڡ7MGG ekG.״NNcL|Zj* D`t3P }cf{܊3g.#DaDl5 FȠ͆4*~ZZ5xt&u Έǔ=JB#sns)ye玩tOːQx-yFٶ^jvdQNH])-u|p$Dbz7w=:}qA:..=-ŏy9qd`%:^揑+ 6<Я4#Wtވwׇݍ*݁7W.\+G rUVL .H.cџFO͖=f= . &evE"^hj ^(̓VcA֩IFzicu NF&D(+o od!50` Sk ROGJaxō:R\C`BMyrsG@0qQ_ͼP* e{F~#i;Wt)ؔyB^zE=HlF =Y lE?￝/SnĆN s?TiKuٗ02Mu8򲚝F>rsF! SjQpԓB>L0%$ۉa!Үqk>?^dQ읇`iJ7bTQ<ؔ !>'ы8kK2蛗?Ma4p\ם`SyCb>-M93U }x( zAMedy:]s5h }ϗ3l蹀 ;(: 4żz.UB-hK''{alMvJU遬›HkiږM utcHO+K(e,Jotup/HҖ\הeU O'_r1oShD̑ȩC5hks8r(*Ŀ &lI aqD3\H %hvaKl?jz׌ߖS7>=2՚s]Kǿ+Ӗg?w_}Q.Inq>ރݛW·MgǺ=ҸwhC);Ӵ^Pu(>Qw*~C򿍯Az75=Iu_OtΓ7n꺿lwQZgGItWWP5}vS/h}м+y{TyP>RW(~j{>W[=U:jcK?y{T{g 3W/iO=zRx]j+=V?/'kԽ1="ߨ}OQZ(yOʞz~sR擴f<XV~Q+Hs}kǿ-,.+κ5 o5DA[.n'['DCH{ZW&C_2,{)-`"?'%T| L HP PpQGM߁QWlb(,"wʼ ΝUZ7b/fF! &+^V6ON`eN 15z~ٚUٹf83?k|>WĬM3]7i{lb֕EpbȢڭ30}^;؂mm#Eqsz=0xgZ5 12K.tzjxeJ&{T~|֬ڙUui XU@oKz3I@-tVƆXĒĺή(R7LkzޢF"?O{|\N6ɢAߧ PB]M-4eӎ|*.(ʈ80WCWmT~?zɶ.I\O!1r! ‹H[p!1*{IʏQ:b}o 7nj[i&k G!3Y;8NIK)pn)A^8$?FcbK,& *v)/!zk.j6$+ϸ.'wDj4XJ 'V_-_<20fϗ(͊Dg GxހE`.8!kM?@1`? Ol4GI[fMa$jnhĪSMzT[ec7?IvX3s$zs%G7 2s ^^y"1yWD|S 62~'6}$Rz`S`:4%RT^l-e6y\t(zmA!#޺5(_NJ@n[^ 9p9;a1RDwo+ى?e<ۊv87s .b #}Co~>E1czsV1wV?xS=2{5ߦ˃ >L w!^6R[:Q%Ռ#fL 9&ǻ홯dI1cC.)[ŒHVtTyᏂgAjIޙOH(K};2S'cEug ,9֖-pЪK\,KN5u;>SͰr8I ߠ {3:FCE/b[Oot C:|)倰tOYRs x)%vLT4'>%Ve-b y+6*mgBfَk SC3nܞGmyU R[nlG?r!^AiazޮE3"Bx'|`OX!z*"@@qBJa'Q9Ig0)d:u۶fG#&UA W#_Jkhf[H4z.4ڛ,3od;:AKA1C2⁽ w&IA)tqNu!ۤV]kI[f-qjMXDo֮+`EAI爄^s G}'K45Fk?Vi *%muH>Yv6ݺ5䂪V=޴bxYEHx+ _UD*yג#. tWx`d9 /GMh7FàF)؂gǨv,I 7$ fťLrDnp'=Q-γzOB"/ HSDtVT:EADNhl'cXQKߔ>N">S8Z-i52/w?0ء/<#mK0]#tj;vCaSb@AL_,[ *z jא5OĞYʹ׈Ew ,[+L'M I*AlATǩ5 k%|S>zfn43'dMEQ=sQ5ɇ+EǎOy5^菟ݠיQ)mtė WfIH*bU;p,TYL=C6ѱm2%a8Z*ЋHcUddJ+S8-a,QWꉣd-_ǵXT u$^&7NLdg;02Ob|1BQ񈲱ŊޤlpPr{ ek"SsOGT^S:cv/NuWU><֓3y*5jݾќzCmtRpN5԰7AI+o$!c;SR ޫXtG;ٝN{.:YcfIOi ~Ն*j:vq(?Gaxm8rjЧgoEL}2Q7Sb}ߦh,%C~{&T yw%,yQx6`?)dG|<]KzfaF; ܵOpb8SI aUKt|Fa}#78I"ۃ0l{Ɔ?Qeɱ(dzeI"9ؽԭ0.xB}ܨ7P]|b}x=F/-z$-]MK&sgK^9Q"׾LkdATrJ3}ƕnJ ȯ>+̏-[4RUQҶh+̓ ],\gM;.̓sk>E/-ag9Gxv\>̝b}ky:Zh)79iS)bAmeOafƤ7G}\ $dSrd&av.'l,Z\T=^us/{ ܱ@5u,#+".\} d* &̏60Rtv `=040[fMXF3tϖy{x N=&c#0S2DG[9:̊ a ۣޢx-.3w0U Rw*]1;wkmעłʼn ]r*6MBID^)#JV!Ӻ O{įUl;$HwXGyI!\B VlЖVma$dE%#47Q }3F8L$q:p']BƳphEݺb!3XM)j9=$|֔|FDxrU};QZ|nLncu E+RړZNۅ.AR:X4!s~uTECEd(quﾄaIJc|44mHߩga#YAɓzGnpd :9w +BJ3 13XFO+/vՏs*ѐR?=fv?Dus.ZEʢ:J@\: !ȭ kf1 @gOLmzޠQ0i FI]\Q3e0.Pd(/XCsu+va +ٴzi (=0n]/*,KQ)Ü+$rY"E=XB+v3\Ё.&Ш ԬX_&/ =+#ؒ[YXعMd[;n|w`+7<ဦ8/zz@Ҫލnew#dq&0UC BYXvsUJ~Q Id樻Kڂ-|~_p^A:%m.5ָ|mQ/n`ם+ aMgr&M*Xc3MKi\$zk$NVK1RIFphǵE #%9`q|6`czд^IfX^ŵpa+!!޿Lm~pK߃!;iYODĬHk{Q|e#2\~MvcAݣP7&cj%tzhlQ +!&`+BJS[< 'LSt/Sh&5#N *79ϐپǘ+&!Dz%:y2դ \5l:KKa)gqcgIB̝YF`X4H0or8ZeFI*< =L2z6j]x`wU2hYjL$[^M`+߆I`>mv`/*EūZR-8Qڨ9"ꫂX/95f>SrM~yVž;~Ȧ /.oZq {uYÅ蘠_#D }xN`|V $6OR acav߳)zo`r%.TJR@rHhss$k*XT֔<K)Rh W5T0}k!`aG! 3,VXYWTF>sIA9"OӎWʋN bx2S`U˝0|HoH޻~0C1X3-L֧ƅORm8\Nݚ{J+ Z'Ά#"E,~BZE2GK+P773ё49H/ײ`;&i̊罊Jjڔ @-1/`m ,H߼3ӓeS鴽)O%pSBSޗ+I9A;')?Ako!mqFjfTSpGW̝Ğ,hV?$z "@ǽ[ȺwT(ĩ'H!G`!Rh =55%{[v TPi€-ieV|QI?#j) 63e&׫H)mH͞jƕ#{:hO* a,Q޳F+4+#E :rՑJ2=2ml+8Z߃&ioF!y/fFnCş OΆ{>~)]pX8xu B8;1].^l̊ n &ZpO+؈hW/5.&f9́k '0@F+ۀ} <oj|{˽B}Aͺ5ߛ_4Y귚宱$Izq[{B}[^i/wvОGwL{·As[ տw=߻vmf=4u@ۺ/om{t+tފnvwvat/w=~^۽ +[,}GU/Uj^gvoiP|o宴ʍGOQ϶zĒI=w]-]mUw=@u}sMr7^U]vUｲOk;ڷ7h|UqDnFϖTWʾ[;XO4Fui$}u{[:_~?.ChM?v׼{u_.m/v;/Ryg]^iv}s{~]wMW~RkOwoUJk[צ/=d=r7/`I5F-UMԕM[cvM?" 綴;*`ňw"jR6[_āzQe/cb/ ?< l̍Œxۡ4#tĦ+ߡG0mZIYu^b+adfۇRy>]e)k[1rܰTR+,3&lm!aXyEq%@niHPO91eOJgOm˪kW&eLT\`V8tG˘]'o%*}U 0ZE2.Ɛ?hך'&4NFsnX~o~!dȉsˡZhi|oOݐ)U) shTrQxrApjbh4O+qIQP\`,n7H#P4V 5|529T4bV}e &ʛꭁ){FԐHK|z3,a +?)X{nk!h;W*~^h8̨@nv26('5&&aN*.v"tJ_bT5öG#ct-V4M E21"$|-̏/3ouԯpSwFr:=t7DŽ,UǧnaϵJR;rX¿ԽSNq>FNR3MzN'%Y}xy*%Vtm3Aa}Fw=ߴ*Pn=pilqhE`CJkF>T1r('덟\a_@Fx$b['{Lܮ:S$~X6H1:iRcTe]9֡EMJRSf'e3fd9% 2X-əIh˶Uч%%2Ojf$bhRLq-_ Pv UsU+Z[uH( j)PԐ 䰭QwIR[̛)4fَ]9_#^p,(. |9NV[9,r]f@_mGm?e%f)~$3djUx\ d/.kxIݵ Օ7Ct8X(bV@TKkOŖ${__t0Lk{QQULCsn=kWٞwz%Z늽1Goˡ ki M<}'"Ie"B sQgܒkq Ã2pHdiu 'MV|t4vh?9ȈU|ؔ9T*`ol9poV@bD&|' d+~F:hqڧ[Y(ҍQ&u+Βbd:$}B@TqUiχW]1mT(-tb!7CΣZ擳`r1ñMCihJŞry*[岸~OZ[V/ڎO"*"_Td8(I/Px[xo5wi][n]3 3YArr# ךY`&3$UnwHO"P~A%26vOu ?sHoI[ef{m$,=z:Y{R#î(RE5P#*D"0S7):8T?'~;-~kq0[R.ŬY ps4=ntIo[',fZLóà}qq5MSVweSZA_f %D-S /%||l[. Y"N.F3p`g`8d|zDb33Gp<$]Vf%ϼ<Ӝ1 {zjh[-?Z@Ly=w"+5[5UƝɨwjǧ,2V.v /œ4;*4:X 's*@e"m+`ǁ<^S@9]S0#Il$Óa, (T!BJBMJ~^Xz`-:%M0 Kxf;:G T_vu|5̢qO'jK@|S].k7UOńygrm>iOiux1Kpv$3DVd$;] \K+?},M .$H9UA3T[)y">?vMbupBjCs.W"Pik6tW%uu;iOъ^:^df3?/]ЖCT~4~WbqwFt.\aDN&TCSZaxsRfS!Ɲ_ߪR#_k 6G& [šПkc&Å( n{eF9_`#0lwY J~#tXH 6[&l${.: 06Ⱒ @v)j_X֊.fdyZ,5# n(w#饄.A]#T 0ctpWg𽟅,RquHj+t'LKB7y7`NGT2ѴG\?IB:pkp ڥR)//ChBʑb6Hsơ1B _DY/TLm/^MD)8XT"N@=+.\>4 ِd_FrwH",r_xvn;n2I=3 -I jT1J孭=E: h"jvݢZelX.vخ)Zg% aE7rquיq+WP!Tywv-/W[ zS,HW5B&SC$E9K6x-)B9NLy<4Xc3G3@DEоGSy|eꞀ5gy׸m8v_Z$cxà ؤ|‰;42jvNMG#[\iޓ\˿U>j?S.ى*:dX&@b(bJ`EѨ\Xk&OL%Pݭf|:t^?QuuowPC)G0eN`aJCВUVťϠ~AV-`q8VERZ prtW5XBSv|RO(&i^m=ZwPg~ RC)\ ,M my2Ժ6kv` 9c= \L:g.$!+  H/xn|A?vC}ʫPPzzȆ(1J8lOA+A*7 :HgҺ)~D nEg+r1 2*[B.#Ҿd|BMXegi'g]0g7z}6f>z&L3*\,b!R76+v\t}jBa.,뮥;J]{ ֟t"Xt'ew!%LOt  Z&ro#TA?{\"r@Y\:0̴fK9F]3 @`}$bW7l3K5 pE1 m9j]A]zV7wmDWgcu8S~ن%);5U 6ÆB0'Ѣ4`ԡU-*&pI1*i(J٢-%S6+p73K›_[j]=b5VEc_REGj^V2N fڦazO38*e]BEwN D6p采F"X/2*,M $ҁ6Z3|(6== v]FP77z |-0~@2 PT^>K :ZHa(R¸~ug}""V]к;`kJ4+JJ r*mpd߻}DL/7ίaJL+21MľxayB5ݏ>iT~c <.Y1-{=42Re{H>p ZIF "U=Ț?I ߶J۠" [laMMEA7R(7.i+N.> ۘtՏU *q@zޮbuqT Ovkؔr>lG#aҪ2ZH,\ =5g #2s3<91@nFAr &QVK c-x~D5+,g^5oPPy-3.:h3ˆXK J"'GPA(ʬto/_4F6!Y (~FܻZȉ0YfJe789΅Xƻ3s\xx4R- 7/U^igbXy+dvN eYƐ]*Q+ :12M)Ru$$wE9bX5_yiOƕm[kP.Tm`GɋėeQn{tɑ M;>'.3J؛>SWcduIt oLd=NHMԍQ 8ܴMP=Uge:SžmTH 0ϧrU1RQLS2`3O)vDrl4\5 "{(®c<~+]56=PAG/O'}CY B ,(p q5Sr$vC ٷ#gy> $%;fq}}Cbxz[Z_)ͳ">ќOt|Z]3u̝[ GJ5^nIÏCε~`S&.2 `Khv ʬT h>lA.sq"|)7Se7÷ĝDҖlpQC@BkY:tIV=@q0 hHԾ5DO ?OY >!@@" O!=;y,~a "'|dvPd Ah!{ EDZJSxE}867iP2 ľF{hjYyO%q&6܏R6Z2ܺ0Pi<8{[UQ\g=UOA|6Bqzv;15>R @]=dᦸc\kQч},hͯ^PE16ǖ5%,qخgiKf̈|^#[Ue H|Al޳JVos/0Ӗny XdnH4ˡl$$g7L.!SE8g/COEP[5̎:PҲU|7!4z%UM dC=V,"]ҹ?  *RY'@2ddch ི^^6Nf3E+-:XB4cc \)tтpQu6>&pO/n2b+W%Z̟5ezT K[Be$9ZQ@2HPF ϱtt I]Ԥ NĖ #s1ֵ&xW(LcPi}Ҝ'O%vjb+p[ǨC T_{ N:>30(^*u̹ LuCS1ISKRlF2+Kn5jZD7Hfo̴iDtr)>EFt Y/&wJΖ%xKI4pϠR71Tu8*4?x 5ēP%Y,0Il1HI+S#|N@UJ[^z]}a3dNVke!+|c;dLMwy#D.#_/ja ͧiy)x9?:XxxĹzq[0_=g5ZɝyLJHovAx-5 N̢Ne,?FĀ4K?4N:FZv{)%_C/N%cn=>_DJb-pQv+fvWZC ӗoZK[WImay"NU ?DUvu&u1i]N#B'~dM$C!&[=)5bht(RLDgٛxhog/)nv4}4 H$"r~&#wCQOW&Zԙss^.Ѹӵc"wCȂt-Aî)(G}M_|}Զ]Bݞ[q&E>%PY@9KrM:p`GhSwMFBKZFF ;kבcZ0jE/. &yOv[%W vm]Bn| ?:4?ËFX7 v0Kh}k;sd17 VD=JH%l8R98"A=.i9%?! 9؛gsTN `k>rX#`{#T?MX 2~c&IB1/WC|H>~y*!S-3>݅vk;b R lυRLrz%H!{ )6u\wrHĪbAL,[:K1k"LT,rѕK|u1#`+slr5fmc&7qgPХDChy8%}6a-d IDeʂ2Bb7+W0Y,IӅb *AU!RHTU6&JC5t"4\:sm bA"Kyw؎~mV6g>]|oAC΄B20L<,CGG@v)4qNpYOMT|Yw16t KY-, B8XM!Ao,Z WRu+o4. /lb~8*g(Աq™zrb_w9_eg$lDf%S`Ea/8HÂ0>#D^J 1^L#I=$:LdFL #Jh6vDaS;McչQxR˕=xAS9)$.td$U&'y}K\@-pOK"ٽSR}A|Je*>dNvNm()pwdz~[!eulGyT*61MҎ0-yaB|Ӎ+B0TBOv/s1Q[T+fG{g^^*2 ˞6.bHsbSQ `: cx"7hQ1E  fPl 1>4WV~l kY ƒ D\eJ/*AO uE}Ñ -wTh3Z?yV( 9. :nsځԙ㨞vwvS-vzrA~i2ti$*Ҟ#m 5WN81E@[0w&WPr#$~* æ:{ l*\c˳aGjb鎛`dFJ- g4w(Z#TƏվ "c⏏|q?ȾnP& 19GjU0%dAu$K84~L;%hյUtL8,,d^Ɖ_Wr.TԂ}2+و#h;WiT(DNbW?ǽ3fW2FtMa;r"O 5Zc+yX?ݻ_AwAՏڬ8gsp|!a5P!EAe_l3Vo]뼫{,+tɶs>_Vu`ʐ)ba`yq)K;ϮI?ƅH\qSy\aF,-(st OZD5&1m)o#+$rB]hj΁MetfyHWc88]S32yO/{)֚",[ϠtStTbd^1(1Ҿ@X%qkxHm,GÙ'n Cai:TDT<|ƥg Iѣ`'3h:']$BGJ-d>` m&%P LGm Rc Is?c (r)vv#Tx |l֜\#xbHE|)֣ f4[:If11,ug4gkvt.J!u2q@v8-,5|176*S6a=c6Ju)AƷ.ҜS|d64/ yA;h?i^3S .eB]&W[Ԟ9|"JVY43;aix*Ғz5:٥`'"-EMLZSi0VF178!62B|]0m>m WS2S}CC R 0Wz>E4ޖS ~TQ0⻚̤% eȋl-|y/IE'=!,NѩIC7Me9p*U:EvX_%f]|JYy %* S-[Wb^Uwxp^k?2:eR4-G]f0Ч!OgD.kk*߸~ ċr|cJϐ+E=DV:Z!u Cy,ʓT @.u9RA.A; "*;t@P-{^??f4jۑEa+tL g3c~!}yxYxBS,krm 7R#l؛=ؕ*ВZT.rszlta6Lÿ.hMF?M7Ƨx.Jk_ b}iNJJ5BZ5 zXRE0gfq'!KNLL, YB x l);mA ~7٭@c.ΡgXҫ":eZ$r1?[ =m]z%1NR0Ұ[]5.v`"s 'g\MB/'Oj<իij0.9/@ Oa48BtQn}<z4x%qF[[I/+ē3bBfvRo$L ҵebWP H־+r.%ߏ gĽ[ óYS^AV(*/IJ@ej@4K4^w!\լDl= %ytUX>4 jm>)oO/y|Hg|vׇw|Tah^mT$&/A#6\ϏbWxqˋbI\c4o_tm!,Q۪VKU2CIAcV`|!v!IM aN]9}8_|&SgbIey`t*{j9#aJbN B7fP mdS;?1f[6\!E]5&M<`o9=H4ø87}X0@* ]50HB"Ù4ɇ.gaaH`Z9,]ϳr6[эNٚu9YCe x砜Eg1c\in~;O5ǘd49蒢T9B̅_YS(=LRR)ds4ȵ׃IhƋx82@@#Y+Quٟ'%All"*<,JΛt_hOx!L^iA'.K43D"N)6XPqH3^j\**cBMzvv. =;w Yj ˒YIq=-#5q3 YH 7-yS'h ۮNn{ /yaŴm~Tȷ=YBGb0s4:,(<]6 ̭ hsH¼z3!ŌlC JHtް/3ADf{xߩYېQ֕OY"X2!ߪtI2 g3;g [bpe̊PY9C+mrs oG$[}= tOۘGS9脽9l <`Ǽ #LtW2ai0NfY } \4Ş*bnxFf". Ƽ@q'f]9kᤋTK e'ڱW?pD{ֹ,QaV1rpnڃ~_Yzִ`,. 8}o3Llλf^_| 7}=wZ' Ie}8SnMPF.) 4#™vcyJԞބ49P>x17n~X.]U^Yj- hB.7R9xrix E/EL ƽ~`\ :SnGj/^F׏WICߣlWK9-tXNۥFz#ו<䲨L{OM w s3If32 1iK T듟s6iѮEٟZjaezH(};Tnّt2'BNkwI$tn>>6NLT&k.,'09]n9c#xeΟ g3J]4F[cF^AFepIYERʃ] }4Q)¢Z=.vCEQ9L5yGh_bvH/$0%5|893R UTˏ`{V.R3z~2Eos"mjqUMbp`myxM \$fTf|{l5.-{_~`})9>x$o@$`KdA8jc;X$ݡ9j9 dЅP}`QdGsSS; sQƟf-cuώ;w%77%Z"9(?~-C PG"CxfM MMvfAz$v2Nݜ%ן>% *FTVC*?%>Nc %}(䊤`~t~ǎ-6N#_KLZ4Ex)M}0^=jIJ9CWcs *~˪Ie 062%f %"N~~  9*rwF[E :,Y_ź # B&CE#i~u%xªٍN%&2֬cm4{/Ӹ`7kxd#ZB-d f=tO:E!2>2 9AƘQ뾰M֑jk+aP 9Z=nu`WYks.]MH4ٔ+JϤ#pj{]h]вD;m ::`'6\B60 7l`P&AWPʄ*c' 7_jS%Y&ʋoxD\0A`!ry[h(o-c +xZcɠVyٳ7tJv{ȵk'SusxX a/ٲmMYvT2rX* SEkJ {Si%I'Ů )6j%?J4JX8 )AMwЉr$vs8C'`  9Y}p) j*I|!B&\]a.+)^y[~p&"6Ӎ=%!a 5CCwzߧjvK^,I asF^g;1<g'i6__:rۗG&0?77)p{=Cff!NekS2s.xZu\? ؉xGMuܬEsѽӁu,.)0/ckFC3dMcrRjV)\Q;: Tжl%XT{euetz<WzPj6@9[tEc :2]X4- iP!YdɗH_%]s*6\X,qkդ#+l#vK qRF *AGjX~ 3z {PM.AVL* # endstream endobj 17 0 obj <>/Filter/JBIG2Decode/Height 1752/ImageMask true/Length 15260/Name/X/Subtype/Image/Type/XObject/Width 1240>>stream $~<#<(woe 1R!YnlfeNW=.?0^Ոwai1jB ON`0tsN$t=0 112t4nq#%xRy&,y_֭@iQq•)3`.;ҢCK02x1 r?"RL! ÇX]]Š *"WHlWv}+p5ksЕx:8 uP jŶeFL|/b`9r vT537$4ۮjbĞp3QKgNWtRpWb[1IJz~Ȧ;~\L7FO0vCFi&4Uʋ-Ow4Aw5XONW Mn+ =1?I>eD{1[;{P#-mh>3J>Pi+7RIqv̟]օJH$Mj`3W8Ou|Cb8e+/Z/iT+aRJ@7ˁ)$82(|]I_1.J_Jĭ!Us+f-Y^g5u;0\7~rHG?k]p`XENY"gnN,9;5@g7&4؞+&òmJ0`0giO%]]@DBބ%UM*/s:,ك/]`a$HVkyI#CpnJQȣZr+Po16H7 tqaJV\Dr5#mM>(zTDҬ.LFLa)j~r(;XbI-~_)\RIݷqRڷΎ~BXły FhKHcg:d3q}en7M߿Tɼaxh[KOK!Lv Rۢ"7%ђA=YZ;=6 ?{IhC ¶;|k{!tl\Jhs ـpd/j8| ,W/j .E*K.Tw*+n4c QGSX[..@x(4XB/d@@mQ[R#o_YGAnTw$A^&s +";@`m]'('Qq"R8xD{hiI,Z/P; kنa.?-4Se5zeQ^i&qݚ6R`,؝0IK#K-ݸ0@B(Dg$l],HϷUyW} h[}?dVlR?pf CE;᪹OknpgUםJɍ&m0:j,gnK_~U˥糚!xJceGg%ooPwhntf5kHPurf ~ݕH2-bd 8- i`ʁݛʒ61nqmC1;5=xtRkYW@.$ϑ1k HY Yd+uХZ~nǛ@6ܦ${w֗WY z<>;Jzc 5WG>0!_ȃIJBAuCU:tJmşy]~ =#LDDCiF~RђL i^5S WZ<j˗BIĘ ｛V. а9ѯi0oJZYثll, <: Y :pǪ KK$>!%ج:f1RLE"H4|Hx)ebRf &f/KCh> ?n7MYMnb1&ä7O@a Y,5S0n蹡0k;[Ӛܓ('U]L?6q] G/N[`W5"]l&r)Fj{dp>9aeO:H3K$cuw3j%ic3iSȟujVFI%2?flH 4,ڞ  9R '9™ [Mzn Kj_8XAsHAʾt] uYՌV,r4efɘeuρEs, eu*WM-Gs' F?`} sw*Q3a3 .PagvB_YbC >kR f4[4A¦o27x50݅%Bo/dl+Yat*AȪ\SH%hC%?Һ~xOYKō @^] tPS+r=|KQ`ktd"ЦSu/{;{"WԸ=EQ?Wsn21a09Y Gw6ǻbvxH,(N1ӛGo+⎒zZ: `_Zlx!m;0ƴN T32܀xwa, p4Ĵk+n'Ͼ[hL\ɻi,Yh.5tQȟympꋧX [O%`2UhmjcJO]qMo-f}q/ !ZGSR`:NZr]] D͍ͱDJZ:/,N%ɺ5^Q}"/\2jy4isҢ) u z@E 4^)(6jU NEL CСo='Mg%lD=gIqv-tYޫ.VOL|?hЖ uc ?CiޥѩpRޭdΝpP␟[sHm9rWN,ד)QQbD]-&$ i84*=_%^-)k@b@gg2.$A}n#xw;u o0lb/4=Oy't[1gp%(jz2`o5 Bo_CG#(a@dSG⏤'gBE 1S3t ^D`e%Ug/FE}X*N x:ˢfzQ$s\EWd#i-mJm i^/ճ R&6\}퍷Z#ojVCDTHt|IU|Q$mJF冪ч9XZeY"9)stQ¯0"ԇ|O؍| v.cqvyvEZ___7V qX鳄J{2qp{GMzW>b"5Dyjz|`7?VkQtO Bm]ǹ9i*Zɠkk16Xv9d_|r׮r82o>ψ% /F{Bb0hl1ѐhõZn+9)ihԤʱ.`& Q/CJ9,f SI7g~ k4@%LO4K<:RtWx&&*Z?![4=OviL1I#dC+w/M8~#l€ag.TFæW /O\+1g(DK`TMre|# xI#IP~ќyN|/jykZSX-h Z m;yU ne)KFXOXoC`T:}Z<~tHJPvjz{ÕszuB{zb AԟemX=doz-4q'mo\?G⹋w%]t7&$+fغNq$dGʊo8txFP!i%k8xk ^?ubZ7"BCK.Q fZަEygSysfk0dC3C:pO U7EHm\A,Á2ȼ ӲLi=gtmɸj g)i.k P/1Z/ʓ1H瞒~ًO g>g=8o.]^."q̧QD̵:P`!KN̔f~c+KVU^akЇg &_Ps{!//֟NCBCed {^b9pyۙɅ߸d^ϊ,4p"@3|;RP`[~5;*ny fΔEjf2[X/ ,VB)w'^T1%5.̞jB頟RKx܋=h **mU4q8G-6jƾfi ezR$P.J۵u=I_=5UK9ٸw>L6iLrpZj2S ɃҺq4AzD >f~&hCgP:L~ TZ;9;Y#0dBD#5FƾUfT_fDd;wP?OK!)De&y4KJfz(Z׼ΡQ^ EfR/'ޚ7z*mcZu1ḧ 2{,i!-I=l5DlQB>볥ճe ?qS̆h!cCMIu}ާjMoZgzbS}gʿo\hZܗrқY`L8=ɁTĖG^]~W1)O(n 7O)>"6KI m:ti[n1 d{NN͈Z ֬QDq%;K\.|HAM}h 8 2:Mw!o>ٹMU4!{E]u%< ;xg=Hܳ].M@+_٧*6 vZ/0S!!py:IL[xOxn%f`t 3Ӎʉ({/.0 ze}#NPm{/9Q FG9J C;#<{dMrlYsUǸ1 EA4y70鷇eڌӺBxj7Ȼ̸re&O&ha6q[aOnTa%?㰺EnGo]DIF%yT$Îk^PLMѝoB9}.ļø7& [5|{p89D$T)@j f eЇ$ Ȋuidq9=E9aMiR( A!:۵,O `T-Cf›1Wb5*;f-gVv}ɔuū0ѕoAqdK@ F`XYc_1vu{bA~WSk:G14{o^`JLYAo֭ {" n7ztEH}]LǡcM 2* ",4/~!b^_1ݓԺח-Юx&3?e6FPٌU['oNB za*rLJ:Ӻ ›Ko > *ogۀaZxߤ9>6勺, Bgm7B8b9׋ a(gydnvy)8""5dy#^&UyTnF`?[4ק[ЏmZzCxcz-,jqMB;v+0@  Ш65Nj6Ȃ Gr[6hp"::+ Zd܎TS ~e .)= ,30<4WL>Jbz*n͜Jiu 6{YSgOCl4uBCɖ'P>2ws"\5 .bedq' Ljy_@RK&Ƶ }(S[eC0(xcI}x\0ͿH>ӂ:Y Ieopw@xd@[ DA‘3/m~tFϒYijG.%5c/XFU\GuQMo' z٘˓E]3lb;,ih:*xʛ38{.&6D΄X(BkuW ="8R!h$DJb0*PtidZȷ~}puB^9Rĩ\:qbmgR't#Ll?=>S,βMx S_~f5~1j춨N{GT;oIؕ8MWڡ/H}l6g*^" ,#Ht1H?ϰIV,n‹ex*ηJ9O1H`Iţh:GeiεړTkpsVM6AO/M7<HimlWXG>Gy%jp/Q 7 &Y+CZk!|)TgtF4axWqBTuIg;*ču` E3^efkC Ln[PPh{.UsIO?Dl9~l3NSj>4eVI= PzaTHf.'L*%UOnRGXX!wXx|=DX2> Mɨ!07qΚc6''҃D<'4ĠѿJȲ3"ޤʁ@YFTCT<<(jM" dI\ uG "UOi.;o-64FKiUHk@!ЎCՍ6vIsc.L_< 1B hO Zy#G}=U40~Àa7&\P_߹U@^&jj$Ca1nE$dhr^.[,JԟZed[ G ┕ZDgha"+)k{spZ%dբl~2,N\clci9W/*zjػlڅUOo uöq3c4KC_vGI4@66y < ^60u;'lk"ݿyeu| e(ȋx<=Z&Gy1{vASXǹO] u' b4i.LMOApvuaaE'5WF^3J``2Ǚ-=sxB1\ S3tY.&~ ۋQaH2)Io۽Fi7t0&HnŁ=/Uhq?`P|bZܖܯ7on9f.$ۺn̮&+"\ݚP]?1vF%Z׀=}6~- Gg< %% whcEŎKʂovdeȫmE,rl҂@k$3:F.pxOdqןMZӠNf=o?5)< }vr''LZ:yj \05減Wx3\ 7q4Jq:i?l8" gM*WxЏN,Hrkfk|ExtiKavI™8t,Aց 7 WO=zXkUokaJ6qqA:gpThC'T2@P]˲_+0c,HP?O&K\ V" (TH#ْq[10GLaߌ^A+$@ZcV۬ߤ xQEМyƯ([.Zj:e3d2:U,,c#SC(.*hί ȹ`k6QS^+k}f-v3_:g읣(.Йe"hDU*LScIjJ+SP dע~6dQcdփVߓS?LCMU$iڃž9:k\8& N!=,iQL'U"l?HS@AxMX@(K %ZujE*9/-LV:*>A5 V CGkf]{?'UkDsk9a'g @KGɖLAL=a2D0s)r,|pѓ-c!Uu|cA KP'ى{ť7Hy\B.X@pNx^?i=o~%K%;O-/ _dεY'a`!d`R]2G / 3bc5yӕ d +9exl*}ZD՜y7Ac<ތD)VU<ſ{uZ}[Gi\'BiV .Ktrv(S~Zcd%nנv*ch7UB;-o0!QFZRj3#O .ۑ'lj,&13\F SCnsV-Τ gTVbM#؈_ɽl$ݎJv&XE}KDj]ٺg)?r>hUPt\sٸI9y|_)^pú)A").B!F9CR;#^$RQ,"<6R&lqj|[xP̏J}߄as&<6t :8k9vNޭIhwg;Wo>'%ϭ?m)ŅWYY*!~-ջ.].=iעt3Y^fA\%b VFab/j8L_T-68m#ã WKuIp ?Of%wɱYkxɔqBGgO=f*_FK ֝M"QQ[|h${gPfֳxzd"t;)H[p((jYU3z{>J?\lf"PAR6Jf22)VP Oά.VDO᷾k`-a0L.oʘ}/5x*,F֒)@d9:?G+TǝmZT3=IiKohO|,AY綛GWKwI 5!@{jwkrT.yU"8drܣȻ Wi=ONvCOH2wRyBaJt AHޒ5vtQ4|C[c;&pG7lBzyZeDR5GQ)X%IVϐ:GW'^s8(j6;^44FjXRǬwwojG螘jWMDFDxX+~LCdeo4scؾ#m&Cr:MF}S?ɝΤYv1>秂։i FU6 p'/d"б@[yK˧@/A,(z{3`]K>stream jP ftypjp2 jp2 jpxbjpx rreq@ .-jp2hihdrllcolr +jp2cOQ)llllR \#B@HHPHHPHHPHHP((( bϷTtD=at*bqĆ^׬$3qwƺŰȜͮi?$9P8]bRX0 T7y~FQ5#`@(G]U @EQo}//*NSV>t*΅I;E-&z5{:cn‰RҌHuàKL"\&żâ"jmm*0g^N8{F5DǤ6sw= joS%~ew3C(>$8`[c:\hGc!|k:!=mMVG+a}6Dy >y'Z|Bh cY#++0lؔ]I^v%ӓA:;kmeP7D\ &1Rgs<+Z8׉坞y )T  sQqa ̢EYª@ֻ̿oFsɚ (ɼ>P7 y Zs_[>귯{SUC~v?aWh>c'QҽO zY+֩+x=B=b]帩,PXrP' z';o/z>i{:`KVAvr׆k95?&ľOZK8;C\v7nW0x)e4^&i!YQwOQ<̅K˒d[v~51Fs:L7-z?:t~`8o~lMtȾs {"t/n"Qp7i5K|UbJ"EUu]?=Bwh O;qϭ2k4xZ66#|y+g)xj,K2(r8]9 w22JglUt 1}W?h=oZ]Ohag?[W\Wop Ӳvq*{A"x-:*_Iע>6ϷE1}Kz]$+'۷3q,ٱ0cŭH8DfܖufS9kJ&5x@_|4ba(OxDSkh 67ޔga@P:.Yh@u3Ht}3c)҆R֚yɇN,䕫F&ӅR~(F=Lfp2=Lķ9g QrkRt{_/.v~.֑b6K~L=|=AWOaR>fL&`L(e%@z!^~->sF]N+B |X&x KWmSGWV7gU=H+bg0Y`' {m-t[_u*"_0xU 0i1۳j5P0חĵ c=q-n=q-nΆ? endstream endobj 19 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrJ"colrfjp2cOQ/"J"JR \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ1Gt0v |!: i. >'p    endstream endobj 20 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr#colrjp2cOQ/##R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ \+`njF㞍)!* '|"@:$ ! ::4yiI:<@( ZI?'uԒ,X\VX 3:ZoěR6 }/Jb   endstream endobj 21 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrcolrqjp2cOQ/R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴt :  !|!: S[CҀ :   endstream endobj 22 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrcolrpjp2cOQ/R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴt  ) :> 5     endstream endobj 23 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrFcolrjjp2cOQ/FFR \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ"Rt "X :  |#_EGD    endstream endobj 24 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr>#colrjp2cOQ/#>#>R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴAC Y" - B:D  #)|"r    endstream endobj 25 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrcolrqjp2cOQ/R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴt @ !|!: QB< :   endstream endobj 26 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr6colrjjp2cOQ/66R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ t ! :1: m |! s    endstream endobj 27 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr:colrojp2cOQ/::R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ 0t ! : m #|": um    endstream endobj 28 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrNcolrjp2cOQ/NNR \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ"C i" " @ 2|":q6M#.#.]:$#" :8nqS   endstream endobj 29 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrkcolr6jp2cOQ/kkR \#B@HHPHHPHHPHHP880 4ϴ8XDIe?JꫛtPyi Q:, R.wt|$@|#@ @ sm[kI{@:/h dG}T4u8F:tt~XsbNg)>]_oY$17ƒ y P /ʠl@FpF}CW;A]MJ/[u<[X#wtdz| ;?!*Ⱥ9_apfB[F_|:G}K4 S Ie#Վz:K!$ uG1&]i]3€  endstream endobj 30 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrx;colrjp2cOQ/;x;xR \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ_c=E Uo#" 8@@):$@ 2G.6 I:4ueL |%:<р8Bf[k$,,B'[t镾Q5Ul 8-Q]   endstream endobj 31 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrcolrzjp2cOQ/R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴt @ )@ |!: r D:~   endstream endobj 32 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrfcolrjp2cOQ/ffR \#B@HHPHHPHHPHHP880 ϴ[ t T" 'P@|!zz - >6€ (¶,   endstream endobj 33 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr.colrjjp2cOQ/..R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ [t  : : 'ˈ    endstream endobj 34 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr"fcolrjp2cOQ/f"f"R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴڞ$,EN_," < 0@ :Ѐ 5@ 5: ,-t  1O   endstream endobj 35 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr&colrujp2cOQ/&&R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ t  "@: @@ $ @|"2<    endstream endobj 36 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr*:colrjp2cOQ/:*:*R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ;>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr&6colrkjp2cOQ/6&6&R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ;>C $" &@:Ѐ 4 @     endstream endobj 38 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrcolrjp2cOQ/R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ&t0qe %|! }} )G|%@ɈDj? -|)@8P+?"`QnPt߇}   endstream endobj 39 0 obj <>stream h240Q0P040U0f F & F&L) endstream endobj 40 0 obj <>/ProcSet[/PDF/Text/ImageC]/XObject<>>>/Rotate 0/Type/Page>> endobj 41 0 obj <>stream q 595.1999969 0 0 840.9600067 0 0 cm /Im0 Do Q q 595.1999969 0 0 840.9600067 0 0 cm /Im1 Do Q BT /Suspect <>BDC 0.286 0.286 0.278 rg /T1_0 1 Tf 0.05 Tc 3 Tr 8.5862 0 0 7.7 228.9 778.8 Tm (ISOCYANATE )Tj EMC /Suspect <>BDC 8.3849 0 0 7.7 291.83 778.8 Tm (ASTHMA )Tj EMC ET BT /T1_0 1 Tf 0.0095 Tc 9.6 0 0 9.6 503.46 778.33 Tm (277 )Tj 0.153 0.153 0.145 rg /T1_1 1 Tf 0.05 Tc 11.0158 0 0 9.2 49.66 755.76 Tm (10 )Tj /T1_2 1 Tf 0.0011 Tc 9.5 0 0 9.5 46.45 498.97 Tm (0.1 )Tj ET BT /Suspect <>BDC 0.286 0.286 0.278 rg /T1_2 1 Tf -0.035 Tc 14.7228 0 0 28.2001 237.39 496.56 Tm (OOJ )Tj EMC /Suspect <>BDC 0.153 0.153 0.145 rg /T1_3 1 Tf -0.0291 Tc 10.9 0 0 10.9 94.98 486.49 Tm (IAR )Tj EMC /Suspect <>BDC 0.0321 Tc 4.051 -0.088 Td (LAR )Tj EMC /Suspect <>BDC -0.0178 Tc 4.802 0 Td (DAR )Tj EMC ET BT /T1_3 1 Tf 0 Tc 10.5 0 0 10.5 249.01 485.53 Tm (T )Tj 0.286 0.286 0.278 rg /T1_0 1 Tf -0.0267 Tc 8.4 0 0 8.4 39.32 471.12 Tm (Fig. )Tj -0.035 Tc 8.2747 0 0 8.4 54.67 471.12 Tm (2. )Tj 0.0056 Tc 8.4 0 0 8.4 69.08 471.12 Tm (Methacholine )Tj 0.0036 Tc 5.949 0 Td (provocative )Tj -0.0101 Tc 5.132 0 Td (doses )Tj 0.0074 Tc 2.627 0 Td (for )Tj -0.0071 Tc 1.596 0 Td (subjects )Tj -0.0016 Tc 3.556 0 Td (who )Tj -0.0174 Tc 2.163 0 Td (devel\255)Tj -0.0123 Tc -24.629 -1.086 Td (oped )Tj 0.0312 Tc 2.514 0 Td (after )Tj 0.0017 Tc 2.456 0 Td (exposure )Tj -0.0318 Tc 4.237 0 Td (to )Tj 0.05 Tc 8.51 0 0 8.4 127.13 462 Tm (TDI )Tj 8.7989 0 0 8.4 146.79 462 Tm (an )Tj 0.0038 Tc 8.4 0 0 8.4 160.25 462 Tm (immediate )Tj 0.016 Tc 4.799 0 Td (asthmatic )Tj -0.0022 Tc 4.523 0 Td (reaction )Tj 0.0135 Tc -23.839 -1.027 Td (\(IAR\), )Tj 0 Tc 3.031 0 Td (a )Tj 0.227 0.227 0.22 rg 0.0203 Tc 0.801 0 Td (late )Tj 0.286 0.286 0.278 rg 0.016 Tc 1.77 0 Td (asthmatic )Tj -0.0022 Tc 4.237 0 Td (reaction )Tj 0.0038 Tc 3.589 0 Td (\(LAR\), )Tj 0 Tc 3.26 0 Td (a )Tj 0.0201 Tc 0.743 0 Td (dual )Tj 0.016 Tc 2.114 0 Td (asthmatic )Tj 0.0059 Tc 4.237 0 Td (reaction )Tj 0.412 0.412 0.404 rg 0 Tc -23.782 -1.086 Td (\()Tj 0.286 0.286 0.278 rg 0.0102 Tc 0.407 0 Td (DAR\) )Tj 0.05 Tc 8.9033 0 0 8.4 65.2 444.25 Tm (or )Tj -0.0021 Tc 8.4 0 0 8.4 76.31 444.25 Tm (required )Tj 0.0058 Tc 3.713 0 Td (therapy )Tj 0.0169 Tc 3.364 0 Td (during )Tj 0.0088 Tc 3.03 0 Td (inhalation )Tj 0.0028 Tc 4.399 0 Td (challenge )Tj -0.0191 Tc 4.18 0 Td (with )Tj 0.227 0.227 0.22 rg 0.05 Tc 8.51 0 0 8.4 250.49 444.25 Tm (TDI )Tj ET BT /Suspect <>BDC 0.286 0.286 0.278 rg /T1_0 1 Tf 9.0429 0 0 7.9001 38.29 435.61 Tm (\(f\). )Tj EMC ET BT /T1_0 1 Tf 0.0341 Tc 10.2 0 0 10.2 38.42 405.37 Tm (proportion )Tj 0.05 Tc 11.1292 0 0 10.2 88.21 405.37 Tm (of )Tj 0.0157 Tc 10.2 0 0 10.2 100.79 405.37 Tm (non-smokers )Tj 0.0386 Tc 9.6 0 0 9.6 158.29 405.37 Tm (\(67.7%\). )Tj 0.0177 Tc 10.2 0 0 10.2 198.05 405.37 Tm (Similar )Tj 0.227 0.227 0.22 rg -0.0069 Tc 3.349 0 Td (findings )Tj 0.0001 Tc -19.002 -1.082 Td (have )Tj 0.286 0.286 0.278 rg -0.0137 Tc 2.449 0 Td (been )Tj 0.227 0.227 0.22 rg 0.022 Tc 2.351 0 Td (reported )Tj 0.286 0.286 0.278 rg 0.0286 Tc 4.038 0 Td (among )Tj 0.0078 Tc 3.29 0 Td (subjects )Tj 0.0056 Tc 3.777 0 Td (with )Tj 0.227 0.227 0.22 rg -0.0026 Tc 2.306 0 Td (red )Tj 0.0292 Tc 1.779 0 Td (cedar )Tj 0.286 0.286 0.278 rg 0.0294 Tc -20 -1.083 Td (asthma )Tj -0.035 Tc 9.6519 0 0 10.2 76.57 383.28 Tm ([32]. )Tj 0.227 0.227 0.22 rg /T1_2 1 Tf 0.05 Tc 10.4329 0 0 10.1 101.95 383.28 Tm (In )Tj /T1_0 1 Tf 0.0071 Tc 10.2 0 0 10.2 119.06 383.28 Tm (previous )Tj 0.286 0.286 0.278 rg 0.0084 Tc 4.22 0 Td (studies, )Tj 0.05 Tc 10.2654 0 0 10.2 201.5 383.28 Tm (an )Tj 0.017 Tc 10.2 0 0 10.2 219.76 383.28 Tm (interaction )Tj 0.227 0.227 0.22 rg 0.0038 Tc -17.779 -1.081 Td (between )Tj 0.286 0.286 0.278 rg 0.0186 Tc 3.797 0 Td (smoking )Tj 0.037 Tc 4.004 0 Td (and )Tj 0.036 Tc 1.976 0 Td (atopy )Tj 0.227 0.227 0.22 rg -0.0079 Tc 2.825 0 Td (in )Tj 0.286 0.286 0.278 rg 0.0209 Tc 1.23 0 Td (workers )Tj 0.0065 Tc 3.755 0 Td (exposed )Tj -0.0217 Tc 3.868 0 Td (to )Tj 0.0232 Tc -21.459 -1.035 Td (tetrachlorophtalic )Tj 0.227 0.227 0.22 rg 0.0254 Tc 7.992 0 Td (anhydride )Tj 0.0186 Tc 4.798 0 Td (\(TCPA\) )Tj 0.286 0.286 0.278 rg 0.0183 Tc 3.917 0 Td (has )Tj -0.0137 Tc 1.978 0 Td (been )Tj 0.227 0.227 0.22 rg -0.035 Tc 10.1666 0 0 10.2 254.39 361.69 Tm (re\255)Tj 0.286 0.286 0.278 rg 0.0183 Tc 10.2 0 0 10.2 38.42 350.65 Tm (ported )Tj -0.0202 Tc 9.6 0 0 9.6 69.85 350.65 Tm ([33]. )Tj 0.227 0.227 0.22 rg 0.05 Tc 10.2656 0 0 10.2 91.59 350.65 Tm (The )Tj -0.0106 Tc 10.2 0 0 10.2 112.79 350.65 Tm (high )Tj 0.286 0.286 0.278 rg 0.0393 Tc 2.168 0 Td (proportion )Tj 0.05 Tc 10.5727 0 0 10.2 185.66 350.65 Tm (of )Tj 10.2211 0 0 10.2 198.23 350.65 Tm (non)Tj 0.412 0.412 0.404 rg 0 Tc 10.2 0 0 10.2 214.44 350.65 Tm (-)Tj 0.286 0.286 0.278 rg 0.0137 Tc 0.375 0 Td (smokers )Tj 0.227 0.227 0.22 rg -0.0079 Tc 3.818 0 Td (in )Tj 0.286 0.286 0.278 rg 0.0078 Tc -21.512 -1.082 Td (subjects )Tj -0.0101 Tc 3.589 0 Td (with )Tj 0.0164 Tc 2.111 0 Td (isocyanate-asthma )Tj 0.0015 Tc 7.947 0 Td (suggests, )Tj 0.0261 Tc 3.957 0 Td (as )Tj 0.022 Tc 1.185 0 Td (reported )Tj 0.008 Tc -18.774 -1.083 Td (previously )Tj -0.0349 Tc 5.056 0 Td ([32\), )Tj 0.0351 Tc 2.611 0 Td (that )Tj 0.227 0.227 0.22 rg 0.0129 Tc 2.448 0 Td (non-smokers, )Tj 0.286 0.286 0.278 rg 0.0317 Tc 6.344 0 Td (compared )Tj 0.0253 Tc 4.996 0 Td (to )Tj 0.0097 Tc -21.471 -1.081 Td (smokers, )Tj 0.0313 Tc 3.91 0 Td (are )Tj 0.023 Tc 1.561 0 Td (more )Tj 0.0058 Tc 2.341 0 Td (susceptible )Tj 0.0253 Tc 4.765 0 Td (to )Tj 0.0214 Tc 1.075 0 Td (occupational )Tj 0.0294 Tc 5.647 0 Td (asthma )Tj 0.0359 Tc -19.341 -1.035 Td (due )Tj 0.0253 Tc 1.89 0 Td (to )Tj 0.227 0.227 0.22 rg 0.0094 Tc 1.171 0 Td (isocyanates. )Tj 0.0317 Tc -2.072 -1.082 Td (The )Tj 0.286 0.286 0.278 rg 0.0268 Tc 2.117 0 Td (commonest )Tj 0.0216 Tc 5.314 0 Td (symptoms )Tj 0.0336 Tc 4.757 0 Td (amongst )Tj 0.0265 Tc 4.102 0 Td (the )Tj 0.0078 Tc 1.776 0 Td (subjects )Tj 0.0128 Tc -19.056 -1.082 Td (examined )Tj 0.227 0.227 0.22 rg -0.0181 Tc 4.433 0 Td (were )Tj 0.286 0.286 0.278 rg 0.0205 Tc 2.246 0 Td (shortness )Tj 0.05 Tc 11.1292 0 0 10.2 149.17 284.89 Tm (of )Tj 0.0298 Tc 10.2 0 0 10.2 162.25 284.89 Tm (breath )Tj 0.037 Tc 3.048 0 Td (and )Tj 0.0113 Tc 1.929 0 Td (cough. )Tj 0.0248 Tc 3.251 0 Td (Late )Tj 0.029 Tc -20.475 -1.083 Td (asthmatic )Tj 0.0094 Tc 4.432 0 Td (react)Tj 0.153 0.153 0.145 rg 0 Tc 2.017 0 Td (i)Tj 0.286 0.286 0.278 rg 0.0216 Tc 0.28 0 Td (ons )Tj 0.0146 Tc 1.788 0 Td (occurred )Tj 0.227 0.227 0.22 rg -0.0079 Tc 4.002 0 Td (in )Tj 0.286 0.286 0.278 rg 0.05 Tc 9.8093 0 0 9.6 176.54 273.84 Tm (71% )Tj 10.5727 0 0 10.2 200.06 273.84 Tm (of )Tj 0.0029 Tc 10.2 0 0 10.2 212.62 273.84 Tm (the )Tj 0.005 Tc 1.588 0 Td (subjects, )Tj 0.227 0.227 0.22 rg 0.0019 Tc -18.764 -1.081 Td (whilst )Tj 0.0223 Tc 2.817 0 Td (immediate )Tj 0.286 0.286 0.278 rg 0.0231 Tc 4.704 0 Td (asthmatic )Tj 0.0141 Tc 4.432 0 Td (reactions )Tj 0.015 Tc 4.085 0 Td (alone )Tj 0.0151 Tc 2.635 0 Td (occur)Tj 0.153 0.153 0.145 rg 0 Tc 2.315 0 Td (r)Tj 0.286 0.286 0.278 rg -0.0291 Tc 0.32 0 Td (ed )Tj -0.0079 Tc -21.315 -1.083 Td (in )Tj 0.0106 Tc 1.367 0 Td (29% )Tj 0.05 Tc 11.1292 0 0 10.2 76.69 251.76 Tm (of )Tj 0.0265 Tc 10.2 0 0 10.2 91.18 251.76 Tm (the )Tj -0.0009 Tc 1.824 0 Td (subjects. )Tj 0.227 0.227 0.22 rg 0.0041 Tc 4.106 0 Td (Airway )Tj 0.286 0.286 0.278 rg 0.0058 Tc 3.577 0 Td (responsiveness )Tj 0.0253 Tc 6.681 0 Td (to )Tj 0.227 0.227 0.22 rg 0.0161 Tc -21.459 -1.034 Td (methacholine )Tj 0.286 0.286 0.278 rg -0.0218 Tc 5.977 0 Td (was )Tj 0.0126 Tc 1.917 0 Td (similar )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0391 Tc 10.2 0 0 10.2 150.1564 241.2132 Tm (in )Tj EMC ET BT /T1_0 1 Tf 0.0078 Tc 10.2 0 0 10.2 162.58 241.2132 Tm (subjects )Tj 0.0118 Tc 3.683 0 Td (who )Tj 0.227 0.227 0.22 rg 0.0055 Tc 2.109 0 Td (developed )Tj 0.286 0.286 0.278 rg 0.0265 Tc -18.063 -1.083 Td (the )Tj 0.227 0.227 0.22 rg 0.0192 Tc 1.506 0 Td (three )Tj 0.286 0.286 0.278 rg 0.0065 Tc 2.298 0 Td (different )Tj 0.227 0.227 0.22 rg 0.0269 Tc 3.729 0 Td (patterns )Tj 0.286 0.286 0.278 rg 0.05 Tc 11.1292 0 0 10.2 151.09 230.16 Tm (of )Tj 0.029 Tc 10.2 0 0 10.2 162.14 230.16 Tm (asthmatic )Tj 0.227 0.227 0.22 rg 0.0114 Tc 4.291 0 Td (response )Tj 0.286 0.286 0.278 rg 0.0396 Tc 3.803 0 Td (after )Tj 0.0185 Tc -20.377 -1.081 Td (exposure )Tj 0.0253 Tc 4.291 0 Td (to )Tj -0.0083 Tc 1.406 0 Td (isocya)Tj 0.153 0.153 0.145 rg 0 Tc 2.595 0 Td (n)Tj 0.286 0.286 0.278 rg -0.0007 Tc 0.509 0 Td (ates, )Tj 0.0487 Tc 2.411 0 Td (but )Tj 0.0029 Tc 1.926 0 Td (the )Tj 0.0059 Tc 1.78 0 Td (degree )Tj 0.05 Tc 11.6856 0 0 10.2 221.65 219.13 Tm (of )Tj 0.0139 Tc 10.2 0 0 10.2 236.06 219.13 Tm (airway )Tj ET BT /Suspect <>BDC /C0_0 1 Tf 0 Tc 4.4229 0 0 7.68 36.97 208.09 Tm <00720065007E0070006F006E0073006900760065006E0065007300730020>Tj EMC ET BT /T1_0 1 Tf -0.0217 Tc 10.2 0 0 10.2 107.98 208.09 Tm (to )Tj 0.0161 Tc 1.6 0 Td (methacholine )Tj 0.227 0.227 0.22 rg -0.0218 Tc 6.401 0 Td (was )Tj 0.286 0.286 0.278 rg 0.0017 Tc 2.34 0 Td (significantly )Tj 0.227 0.227 0.22 rg 0.0172 Tc -17.305 -1.082 Td (higher )Tj ET BT /Suspect <>BDC 0.153 0.153 0.145 rg /T1_0 1 Tf 0 Tc 10.2 0 0 10.2 69.5158 197.0536 Tm (i)Tj 0.286 0.286 0.278 rg 0.289 0 Td (n )Tj EMC ET BT /T1_0 1 Tf 0.0265 Tc 10.2 0 0 10.2 83.4898 197.0536 Tm (the )Tj 0.0078 Tc 1.824 0 Td (subjects )Tj 0.0353 Tc 3.825 0 Td (who )Tj 0.0138 Tc 2.4 0 Td (reacted )Tj 0.0253 Tc 3.575 0 Td (to )Tj 0.227 0.227 0.22 rg 0.0118 Tc 1.406 0 Td (isocyanates )Tj 0.286 0.286 0.278 rg 0.025 Tc -17.649 -1.082 Td (compared )Tj 0.0253 Tc 4.525 0 Td (to )Tj 0.227 0.227 0.22 rg 0.0145 Tc 1.129 0 Td (those )Tj 0.286 0.286 0.278 rg 0.0056 Tc 2.495 0 Td (with )Tj 0 Tc 2.109 0 Td (a )Tj 0.0012 Tc 0.809 0 Td (negative )Tj 0.0197 Tc 3.711 0 Td (isocyanate )Tj 0.0268 Tc 4.659 0 Td (inhala\255)Tj 0.0161 Tc -19.382 -1.082 Td (tion )Tj 0.0095 Tc 2.251 0 Td (challenge. )Tj 0.227 0.227 0.22 rg 0.0219 Tc 4.848 0 Td (There )Tj 0.286 0.286 0.278 rg 0.05 Tc 10.2757 0 0 10.2 140.54 174.97 Tm (are )Tj 0.0123 Tc 10.2 0 0 10.2 160.66 174.97 Tm (studies )Tj 0.0089 Tc 3.482 0 Td (suggesting )Tj 0.227 0.227 0.22 rg 0.0351 Tc 5.047 0 Td (that )Tj -0.0022 Tc -20.609 -1.035 Td (baseline )Tj 0.286 0.286 0.278 rg 0 Tc 3.566 0 Td (a)Tj 0.153 0.153 0.145 rg 0.0179 Tc 0.52 0 Td (ir)Tj 0.286 0.286 0.278 rg -0.0067 Tc 0.619 0 Td (way )Tj 0.227 0.227 0.22 rg 0.0022 Tc 2.071 0 Td (responsiveness )Tj 0.286 0.286 0.278 rg 0.0253 Tc 6.399 0 Td (to )Tj 0.0161 Tc 1.176 0 Td (methacholine )Tj 0.227 0.227 0.22 rg -0.035 Tc 9.3682 0 0 10.2 244.24 164.41 Tm (is )Tj 0.286 0.286 0.278 rg 0.05 Tc 10.2654 0 0 10.2 253.82 164.41 Tm (an )Tj 0.227 0.227 0.22 rg 0.04 Tc 10.2 0 0 10.2 36.4 153.37 Tm (important )Tj 0.286 0.286 0.278 rg 0.0198 Tc 4.891 0 Td (factor )Tj -0.035 Tc 9.9195 0 0 10.2 117.52 153.37 Tm (in )Tj 0.0029 Tc 10.2 0 0 10.2 131.98 153.37 Tm (the )Tj 0.0261 Tc 1.875 0 Td (outcome )Tj 0.05 Tc 11.1292 0 0 10.2 194.29 153.37 Tm (of )Tj 0.0256 Tc 10.2 0 0 10.2 209.18 153.37 Tm (occupational )Tj 0.0388 Tc -16.941 -1.082 Td (asthma )Tj -0.035 Tc 9.776 0 0 10.2 70.8 142.33 Tm ([34]; )Tj 0.037 Tc 10.2 0 0 10.2 92.06 142.33 Tm (and )Tj 0.0239 Tc 1.882 0 Td (others )Tj 0.0141 Tc 2.867 0 Td (suggesting )Tj 0.05 Tc 10.215 0 0 10.2 188.62 142.33 Tm (that )Tj 0.0078 Tc 10.2 0 0 10.2 208.66 142.33 Tm (subjects )Tj 0.227 0.227 0.22 rg 0.0056 Tc 3.636 0 Td (with )Tj 0.286 0.286 0.278 rg 0.0092 Tc -20.526 -1.082 Td (an )Tj 0.009 Tc 1.555 0 Td (isolated )Tj 0.227 0.227 0.22 rg 0.027 Tc 3.764 0 Td (late )Tj 0.286 0.286 0.278 rg 0.0112 Tc 2.078 0 Td (reaction )Tj 0.0158 Tc 3.906 0 Td (have )Tj 0 Tc 2.438 0 Td (a )Tj 0.0267 Tc 1.036 0 Td (greater )Tj -0.0035 Tc 3.481 0 Td (degree )Tj 0.05 Tc 11.1292 0 0 10.2 255.25 131.29 Tm (of )Tj 0.0045 Tc 10.2 0 0 10.2 36.38 120.25 Tm (airway )Tj 0.0058 Tc 3.256 0 Td (responsiveness )Tj 0.0253 Tc 6.54 0 Td (to )Tj 0.0161 Tc 1.271 0 Td (methacholine )Tj -0.035 Tc 9.6519 0 0 10.2 210.97 120.25 Tm ([35]. )Tj ET BT /Suspect <>BDC 0.227 0.227 0.22 rg /T1_0 1 Tf 0.0238 Tc 10.2 0 0 10.2 233.18 120.25 Tm (On )Tj EMC ET BT 0.286 0.286 0.278 rg /T1_0 1 Tf 0.0265 Tc 10.2 0 0 10.2 251.0198 120.25 Tm (the )Tj 0.033 Tc -21.043 -1.036 Td (other )Tj 0.227 0.227 0.22 rg 0.0292 Tc (hand, )Tj 0.286 0.286 0.278 rg 0.027 Tc 5.125 0 Td (some )Tj 0.0123 Tc 2.447 0 Td (studies )Tj 0.0065 Tc 3.153 0 Td (suggest )Tj 0.05 Tc 10.215 0 0 10.2 179.98 109.68 Tm (that )Tj 0 Tc 10.2 0 0 10.2 199.58 109.68 Tm (a )Tj 0.0257 Tc 0.8 0 Td (dual )Tj 0.227 0.227 0.22 rg 0.0112 Tc 2.174 0 Td (reaction )Tj 0.153 0.153 0.145 rg 0 Tc -18.965 -1.082 Td (r)Tj 0.286 0.286 0.278 rg 0.0143 Tc 0.32 0 Td (epresents )Tj 0 Tc 4.472 0 Td (a )Tj 0.0387 Tc 1.09 0 Td (more )Tj 0.0207 Tc 2.769 0 Td (advanced )Tj 0.011 Tc 4.561 0 Td (stage )Tj -0.0079 Tc 2.735 0 Td (in )Tj 0.0029 Tc 1.465 0 Td (the )Tj 0.227 0.227 0.22 rg 0.0325 Tc 1.883 0 Td (natural )Tj 0.286 0.286 0.278 rg 0.0086 Tc 5.694 64.329 Td (history )Tj 0.05 Tc 11.1292 0 0 10.2 322.93 754.8 Tm (of )Tj 0.0178 Tc 10.2 0 0 10.2 334.09 754.8 Tm (bronchial )Tj 0.0294 Tc 4.177 0 Td (asthma )Tj 0.0008 Tc 9.6 0 0 9.6 409.69 754.8 Tm ([36, )Tj -0.0154 Tc 1.862 0 Td (37]. )Tj 0.05 Tc 10.2355 0 0 10.2 445.42 754.8 Tm (An )Tj 0.227 0.227 0.22 rg 0.0388 Tc 10.2 0 0 10.2 461.21 754.8 Tm (IgE )Tj 0.029 Tc 1.699 0 Td (mediated )Tj 0.286 0.286 0.278 rg 0.0078 Tc -18.353 -1.082 Td (type )Tj 0 Tc 2.16 0 Td (I )Tj 0.0143 Tc 0.899 0 Td (mechanism )Tj 0.0183 Tc 5.13 0 Td (has )Tj -0.0137 Tc 1.884 0 Td (been )Tj 0.0155 Tc 2.401 0 Td (proposed )Tj 0.0383 Tc 4.328 0 Td (both )Tj 0.227 0.227 0.22 rg 0.0192 Tc 2.435 0 Td (for )Tj 0.286 0.286 0.278 rg 0.0029 Tc 1.75 0 Td (the )Tj 0.0164 Tc -21.041 -1.034 Td (immediate )Tj 0.037 Tc 4.563 0 Td (and )Tj 0.0192 Tc 1.787 0 Td (for )Tj 0.0029 Tc 1.515 0 Td (the )Tj -0.0043 Tc 1.546 0 Td (late )Tj 0.05 Tc 10.5727 0 0 10.2 404.06 733.21 Tm (or )Tj 0.0257 Tc 10.2 0 0 10.2 415.58 733.21 Tm (dual )Tj 0.029 Tc 2.071 0 Td (asthmatic )Tj 0.227 0.227 0.22 rg 0.0138 Tc 4.338 0 Td (reaction. )Tj 0.0288 Tc -18.641 -1.082 Td (In )Tj 0.286 0.286 0.278 rg 0.021 Tc 1.371 0 Td (red )Tj 0.0175 Tc 1.779 0 Td (cedar )Tj 0.0299 Tc 2.682 0 Td (asthma, )Tj 0.153 0.153 0.145 rg 0 Tc 3.721 0 Td (I)Tj 0.286 0.286 0.278 rg 0.0341 Tc 0.375 0 Td (gE )Tj 0.0208 Tc 1.599 0 Td (antibodies )Tj 0.0146 Tc 4.8 0 Td (occurred )Tj 0.227 0.227 0.22 rg 0.0056 Tc 4.103 0 Td (with )Tj 0.0078 Tc -20.424 -1.083 Td (higher )Tj 0.286 0.286 0.278 rg 0.0041 Tc 3.284 0 Td (frequency )Tj 0.227 0.227 0.22 rg -0.0079 Tc 4.756 0 Td (in )Tj 0.286 0.286 0.278 rg 0.001 Tc 1.5 0 Td (subjects )Tj 0.227 0.227 0.22 rg 0.0056 Tc 3.966 0 Td (with )Tj 0.0114 Tc 2.533 0 Td (late )Tj 0.286 0.286 0.278 rg 0.0349 Tc 2.164 0 Td (asthmatic )Tj 0.02 Tc -18.25 -1.035 Td (reactions )Tj 0.0392 Tc 4.47 0 Td (than )Tj 0.227 0.227 0.22 rg -0.0079 Tc 2.535 0 Td (in )Tj 0.286 0.286 0.278 rg 0.0263 Tc 1.465 0 Td (those )Tj 0 Tc 2.872 0 Td (w)Tj 0.153 0.153 0.145 rg 0.699 0 Td (i)Tj 0.286 0.286 0.278 rg 0.0253 Tc 0.288 0 Td (th )Tj 0.0164 Tc 1.5 0 Td (immediate )Tj 0.05 Tc 10.5727 0 0 10.2 483.26 700.56 Tm (or )Tj 0.0257 Tc 10.2 0 0 10.2 499.1 700.56 Tm (dual )Tj 0.0141 Tc -20.415 -1.081 Td (reactions )Tj -0.035 Tc 9.9277 0 0 10.2 331.92 689.53 Tm ([14]. )Tj 0.227 0.227 0.22 rg 0.0288 Tc 10.2 0 0 10.2 353.21 689.53 Tm (In )Tj 0.286 0.286 0.278 rg 0.0061 Tc 1.228 0 Td (this )Tj 0.0078 Tc 1.788 0 Td (type )Tj 0.05 Tc 11.1292 0 0 10.2 405.01 689.53 Tm (of )Tj 0.0214 Tc 10.2 0 0 10.2 417.02 689.53 Tm (occupational )Tj 0.0299 Tc 5.694 0 Td (asthma, )Tj 0.227 0.227 0.22 rg -0.0202 Tc 3.625 0 Td (it )Tj 0.0183 Tc -21.687 -1.083 Td (has )Tj -0.0137 Tc 1.743 0 Td (been )Tj 0.286 0.286 0.278 rg 0.0223 Tc 2.213 0 Td (proposed )Tj 0.0351 Tc 4.184 0 Td (that )Tj 0.0265 Tc 1.976 0 Td (the )Tj 0.0164 Tc 1.594 0 Td (immediate )Tj 0.0299 Tc 4.657 0 Td (component )Tj 0.05 Tc 11.1292 0 0 10.2 509.17 678.48 Tm (of )Tj 0 Tc 10.2 0 0 10.2 290.78 667.44 Tm (a )Tj 0.0101 Tc 0.847 0 Td (dual )Tj 0.0112 Tc 2.221 0 Td (reaction )Tj 0.0128 Tc 3.764 0 Td (may )Tj 0.0268 Tc 2.11 0 Td (occur )Tj -0.0209 Tc 2.729 0 Td (as )Tj 0 Tc 1.224 0 Td (a )Tj 0.227 0.227 0.22 rg 0.008 Tc 0.903 0 Td (result )Tj 0.286 0.286 0.278 rg 0.05 Tc 11.1292 0 0 10.2 458.77 667.44 Tm (of )Tj 0.227 0.227 0.22 rg 0.0102 Tc 10.2 0 0 10.2 471.83 667.44 Tm (heightened )Tj -0.0037 Tc -17.741 -1.034 Td (non-specific )Tj 0.286 0.286 0.278 rg 0.0178 Tc 5.32 0 Td (bronchial )Tj 0.0074 Tc 4.327 0 Td (reactivity, )Tj 0.0089 Tc 4.505 0 Td (suggesting )Tj 0.05 Tc 10.215 0 0 10.2 483.82 656.89 Tm (that )Tj 0.0265 Tc 10.2 0 0 10.2 504.94 656.89 Tm (the )Tj 0.227 0.227 0.22 rg 0.0059 Tc -21.043 -1.082 Td (degree )Tj 0.286 0.286 0.278 rg 0.05 Tc 11.1292 0 0 10.2 321.49 645.85 Tm (of )Tj 0.0178 Tc 10.2 0 0 10.2 334.09 645.85 Tm (bronchial )Tj 0.227 0.227 0.22 rg 0.0047 Tc 4.327 0 Td (reactivity )Tj 0.009 Tc 4.181 0 Td (is )Tj 0.286 0.286 0.278 rg 0.05 Tc 10.2654 0 0 10.2 431.42 645.85 Tm (an )Tj 0.0459 Tc 10.2 0 0 10.2 445.36 645.85 Tm (important )Tj 0.0292 Tc 4.609 0 Td (factor )Tj 0.227 0.227 0.22 rg -0.035 Tc 9.9195 0 0 10.2 290.8 634.8 Tm (in )Tj 0.286 0.286 0.278 rg 0.017 Tc 10.2 0 0 10.2 301.82 634.8 Tm (determining )Tj 0.0029 Tc 5.325 0 Td (the )Tj -0.0078 Tc 1.6 0 Td (type )Tj 0.037 Tc 2.063 0 Td (and )Tj -0.003 Tc 1.831 0 Td (sever)Tj 0.153 0.153 0.145 rg 0 Tc 2.124 0 Td (i)Tj 0.286 0.286 0.278 rg -0.0217 Tc 0.288 0 Td (ty )Tj 0.05 Tc 10.5727 0 0 10.2 448.22 634.8 Tm (of )Tj 0.0029 Tc 10.2 0 0 10.2 460.3 634.8 Tm (the )Tj 0.029 Tc 1.592 0 Td (asthmatic )Tj 0.008 Tc -18.203 -1.082 Td (reaction. )Tj /T1_2 1 Tf 0.05 Tc 11.0125 0 0 9.8 334.26 623.76 Tm (In )Tj /T1_0 1 Tf 0.0029 Tc 10.2 0 0 10.2 351.82 623.76 Tm (the )Tj 0.227 0.227 0.22 rg 0.0148 Tc 1.98 0 Td (present )Tj 0.286 0.286 0.278 rg 0.0295 Tc 3.655 0 Td (study )Tj 0.227 0.227 0.22 rg -0.035 Tc 9.8086 0 0 10.2 440.15 623.76 Tm (we )Tj 0.286 0.286 0.278 rg 0.0248 Tc 10.2 0 0 10.2 458.78 623.76 Tm (did )Tj 0.227 0.227 0.22 rg 0.0455 Tc 2.079 0 Td (not )Tj 0.286 0.286 0.278 rg -0.0254 Tc 2.061 0 Td (find )Tj 0.0045 Tc -20.662 -1.034 Td (significant )Tj 0.153 0.153 0.145 rg 0 Tc 4.71 0 Td (d)Tj 0.286 0.286 0.278 rg -0.0173 Tc 0.567 0 Td (ifferences )Tj -0.0209 Tc 4.28 0 Td (as )Tj 0.0118 Tc 1.326 0 Td (regards )Tj 0.0365 Tc 3.474 0 Td (duration )Tj 0.227 0.227 0.22 rg 0.05 Tc 11.1292 0 0 10.2 478.45 613.21 Tm (of )Tj 0.286 0.286 0.278 rg 0.0051 Tc 10.2 0 0 10.2 491.86 613.21 Tm (symp\255)Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0276 Tc 10.2 0 0 10.2 290.3794 602.1736 Tm (toms )Tj EMC ET BT 0.227 0.227 0.22 rg /T1_0 1 Tf 0.0092 Tc 10.2 0 0 10.2 315.8488 602.1736 Tm (before )Tj 0.286 0.286 0.278 rg 0.0257 Tc 3.048 0 Td (diag)Tj 0.153 0.153 0.145 rg 0 Tc 1.797 0 Td (n)Tj 0.286 0.286 0.278 rg 0.0009 Tc 0.509 0 Td (osis, )Tj 0.037 Tc 2.259 0 Td (and )Tj 0.227 0.227 0.22 rg 0.0045 Tc 2.034 0 Td (baseline )Tj 0.286 0.286 0.278 rg 0.0139 Tc 3.754 0 Td (airway )Tj 0.0102 Tc 3.303 0 Td (respon\255)Tj -0.0082 Tc -19.213 -1.083 Td (siveness )Tj 0.0253 Tc 4.106 0 Td (to )Tj 0.0161 Tc 1.647 0 Td (methacholine )Tj 0.227 0.227 0.22 rg 0.0038 Tc 6.403 0 Td (between )Tj 0.286 0.286 0.278 rg 0.0145 Tc 4.174 0 Td (subjects )Tj 0.227 0.227 0.22 rg -0.0101 Tc 4.154 0 Td (with )Tj 0.0007 Tc -20.479 -1.081 Td (different )Tj 0.286 0.286 0.278 rg 0.0269 Tc 4.106 0 Td (patterns )Tj 0.05 Tc 10.5727 0 0 10.2 372.86 580.09 Tm (of )Tj 0.0231 Tc 10.2 0 0 10.2 387.74 580.09 Tm (asthmatic )Tj 0.0109 Tc 4.668 0 Td (reactions. )Tj 0.227 0.227 0.22 rg 0.0027 Tc 4.655 0 Td (Baseline )Tj 0.286 0.286 0.278 rg 0.0139 Tc -18.875 -1.082 Td (airway )Tj 0.227 0.227 0.22 rg 0.0022 Tc 3.162 0 Td (responsiveness )Tj 0.286 0.286 0.278 rg 0.0253 Tc 6.399 0 Td (to )Tj 0.0266 Tc 1.129 0 Td (methac)Tj 0.153 0.153 0.145 rg 0 Tc 3.06 0 Td (h)Tj 0.286 0.286 0.278 rg 0.509 0 Td (o)Tj 0.153 0.153 0.145 rg -0.035 Tc 9.5286 0 0 10.2 441.52 569.05 Tm (li)Tj 0.286 0.286 0.278 rg 0.0015 Tc 10.2 0 0 10.2 446.87 569.05 Tm (ne )Tj 0.0248 Tc 1.262 0 Td (did )Tj 0.153 0.153 0.145 rg 0 Tc 1.75 0 Td (n)Tj 0.286 0.286 0.278 rg 0.0434 Tc 0.556 0 Td (ot )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0078 Tc 10.2 0 0 10.2 495.2792 569.05 Tm (influ\255)Tj EMC ET BT /T1_0 1 Tf -0.007 Tc 10.2 0 0 10.2 290.2898 558.4828 Tm (ence )Tj 0.0265 Tc 2.409 0 Td (the )Tj -0.0078 Tc 1.882 0 Td (type )Tj 0.05 Tc 11.1292 0 0 10.2 357.49 558.48 Tm (of )Tj 0.227 0.227 0.22 rg 0.0231 Tc 10.2 0 0 10.2 372.38 558.48 Tm (asthmatic )Tj 0.286 0.286 0.278 rg 0.0246 Tc 4.574 0 Td (reaction )Tj 0.0487 Tc 4.002 0 Td (but )Tj 0.0262 Tc 1.966 0 Td (only )Tj 0.0265 Tc 2.408 0 Td (the )Tj 0.0023 Tc -21 -1.035 Td (severity )Tj 0.05 Tc 11.1292 0 0 10.2 325.81 547.92 Tm (of )Tj 0.0029 Tc 10.2 0 0 10.2 338.38 547.92 Tm (the )Tj 0.0138 Tc 1.601 0 Td (reaction. )Tj ET BT /Suspect <>BDC 0.686 0.69 0.674 rg /T1_0 1 Tf 0 Tc 10.2 0 0 10.2 409.2292 547.92 Tm (\267 )Tj EMC ET BT 0.153 0.153 0.145 rg /T1_0 1 Tf 0.05 Tc 10.5034 0 0 10.2 299.93 536.41 Tm (In )Tj 0.286 0.286 0.278 rg 0 Tc 10.2 0 0 10.2 313.82 536.41 Tm (a )Tj 0.0138 Tc 0.953 0 Td (previous )Tj 0.0178 Tc 3.984 0 Td (study )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.035 Tc 9.9277 0 0 10.2 391.92 536.41 Tm ([30\), )Tj EMC ET BT /T1_0 1 Tf -0.0311 Tc 10.2 0 0 10.2 414.23 536.41 Tm (we )Tj 0.006 Tc 1.587 0 Td (showed )Tj 0.227 0.227 0.22 rg 0.0351 Tc 3.635 0 Td (that )Tj 0.286 0.286 0.278 rg 0.0045 Tc 2.11 0 Td (airway )Tj 0.227 0.227 0.22 rg 0.0022 Tc -19.474 -1.083 Td (responsiveness )Tj 0.286 0.286 0.278 rg 0.0253 Tc 7.105 0 Td (to )Tj 0.0204 Tc 1.835 0 Td (methacholine )Tj 0.227 0.227 0.22 rg 0.0033 Tc 6.629 0 Td (increases )Tj 0.286 0.286 0.278 rg 0.0279 Tc 4.751 0 Td (after )Tj 0.0185 Tc -20.377 -1.035 Td (exposure )Tj 0.0253 Tc 4.009 0 Td (to )Tj 0.0118 Tc 1.076 0 Td (isocyanates )Tj 0.0105 Tc 4.939 0 Td (only )Tj -0.0079 Tc 2.073 0 Td (in )Tj 0.001 Tc 1.029 0 Td (subjects )Tj 0.0212 Tc 3.495 0 Td (with )Tj 0 Tc 2.062 0 Td (a )Tj 0.0086 Tc 0.762 0 Td (history )Tj 0.05 Tc 10.5727 0 0 10.2 290.3 503.76 Tm (of )Tj 0.153 0.153 0.145 rg 0 Tc 10.2 0 0 10.2 304.24 503.76 Tm (i)Tj 0.286 0.286 0.278 rg 0.0216 Tc 0.229 0 Td (socyanate-asthma, )Tj -0.0117 Tc 8.295 0 Td (who )Tj 0.227 0.227 0.22 rg 0.0077 Tc 2.25 0 Td (develop )Tj 0.286 0.286 0.278 rg 0 Tc 3.812 0 Td (a )Tj 0.027 Tc 0.989 0 Td (late )Tj 0.05 Tc 10.5727 0 0 10.2 484.22 503.76 Tm (or )Tj 10.326 0 0 10.2 498.62 503.76 Tm (dua)Tj 0.153 0.153 0.145 rg 0 Tc 10.2 0 0 10.2 514.95 503.76 Tm (l )Tj 0.286 0.286 0.278 rg 0.029 Tc -22.072 -1.082 Td (asthmatic )Tj 0.227 0.227 0.22 rg 0.0138 Tc 4.385 0 Td (reaction, )Tj 0.286 0.286 0.278 rg 0.05 Tc 10.3398 0 0 10.2 373.81 492.72 Tm (and )Tj 0.0455 Tc 10.2 0 0 10.2 393.11 492.72 Tm (not )Tj -0.0079 Tc 1.687 0 Td (in )Tj 0.0145 Tc 1.076 0 Td (subjects )Tj 0.0056 Tc 3.589 0 Td (with )Tj 0 Tc 2.156 0 Td (a )Tj 0.227 0.227 0.22 rg 0.0164 Tc 0.762 0 Td (history )Tj 0.286 0.286 0.278 rg 0.05 Tc 11.1292 0 0 10.2 289.81 481.69 Tm (of )Tj 0.227 0.227 0.22 rg 0.0194 Tc 10.2 0 0 10.2 302.32 481.69 Tm (isocyanate-asthma )Tj 0.286 0.286 0.278 rg 0.0118 Tc 8.101 0 Td (who )Tj 0.0155 Tc 2.109 0 Td (develop )Tj 0.05 Tc 10.2654 0 0 10.2 443.42 481.69 Tm (an )Tj 0.0118 Tc 10.2 0 0 10.2 457.81 481.69 Tm (early )Tj 0.0179 Tc 2.457 0 Td (reaction )Tj 0.05 Tc 10.5727 0 0 10.2 289.82 471.12 Tm (or )Tj -0.0079 Tc 10.2 0 0 10.2 301.84 471.12 Tm (in )Tj 0.041 Tc 1.033 0 Td (asthmat)Tj 0.153 0.153 0.145 rg 0 Tc 3.343 0 Td (i)Tj 0.286 0.286 0.278 rg 0.233 0 Td (c )Tj 0.005 Tc 0.702 0 Td (subjects, )Tj 0.0252 Tc 3.777 0 Td (without )Tj 0.0185 Tc 3.473 0 Td (exposure )Tj 0.0253 Tc 4.009 0 Td (to )Tj 0.227 0.227 0.22 rg 0.0038 Tc 1.124 0 Td (isocyan)Tj 0.412 0.412 0.404 rg 0 Tc 3.102 0 Td (\255)Tj 0.286 0.286 0.278 rg 0.0197 Tc -21.975 -1.081 Td (ates )Tj 0.227 0.227 0.22 rg 0.037 Tc 1.929 0 Td (and )Tj 0.286 0.286 0.278 rg 0 Tc 1.891 0 Td (w)Tj 0.153 0.153 0.145 rg 0.0269 Tc 0.699 0 Td (it)Tj 0.286 0.286 0.278 rg 0.0364 Tc 0.619 0 Td (hout )Tj 0 Tc 2.25 0 Td (a )Tj 0.0243 Tc 0.715 0 Td (history )Tj 0.05 Tc 11.1292 0 0 10.2 405.97 460.09 Tm (of )Tj 0.227 0.227 0.22 rg 0.0201 Tc 10.2 0 0 10.2 418 460.09 Tm (isocyanate-asthma, )Tj 0.286 0.286 0.278 rg 0.0251 Tc 8.385 0 Td (but )Tj 0.0056 Tc -20.943 -1.082 Td (with )Tj 0.0131 Tc 2.118 0 Td (hyperreact)Tj 0.153 0.153 0.145 rg 0 Tc 4.37 0 Td (i)Tj 0.286 0.286 0.278 rg -0.035 Tc 9.5735 0 0 10.2 359.02 449.05 Tm (ve )Tj 0 Tc 10.2 0 0 10.2 370.94 449.05 Tm (a)Tj 0.153 0.153 0.145 rg 0.473 0 Td (i)Tj 0.286 0.286 0.278 rg 0.0033 Tc 0.242 0 Td (rways )Tj 0.227 0.227 0.22 rg -0.0117 Tc 2.729 0 Td (who )Tj 0.0077 Tc 2.015 0 Td (develop )Tj 0.286 0.286 0.278 rg 0.0386 Tc 3.491 0 Td (no )Tj 0.029 Tc 1.309 0 Td (asthmatic )Tj 0.0179 Tc -18.203 -1.083 Td (reaction )Tj 0.0279 Tc 3.756 0 Td (after )Tj 0.0118 Tc 2.305 0 Td (exposure )Tj 0.0253 Tc 4.103 0 Td (to )Tj 0.0094 Tc 1.218 0 Td (isocyanates. )Tj 0.227 0.227 0.22 rg 0.0196 Tc 5.364 0 Td (These )Tj 0.0046 Tc 2.878 0 Td (results )Tj 0.286 0.286 0.278 rg -0.0013 Tc -19.636 -1.081 Td (suggest )Tj 0.05 Tc 10.215 0 0 10.2 323.02 426.97 Tm (that )Tj 0.0029 Tc 10.2 0 0 10.2 342.7 426.97 Tm (the )Tj 0.0118 Tc 1.45 0 Td (early )Tj 0.029 Tc 2.26 0 Td (asthmatic )Tj 0.153 0.153 0.145 rg 0 Tc 4.291 0 Td (r)Tj 0.286 0.286 0.278 rg 0.0248 Tc 0.32 0 Td (eaction )Tj -0.035 Tc 10.1489 0 0 10.2 461.2 426.97 Tm (is )Tj 0.153 0.153 0.145 rg 0 Tc 10.2 0 0 10.2 469.34 426.97 Tm (d)Tj 0.286 0.286 0.278 rg -0.0012 Tc 0.622 0 Td (ue )Tj 0.0105 Tc 1.167 0 Td (only )Tj 0.0253 Tc 2.078 0 Td (to )Tj 0.0282 Tc -21.471 -1.082 Td (smooth )Tj -0.0096 Tc 3.447 0 Td (muscle )Tj 0.0241 Tc 3.098 0 Td (contraction, )Tj 0.05 Tc 10.215 0 0 10.2 411.34 415.93 Tm (that )Tj 0.0229 Tc 10.2 0 0 10.2 431.42 415.93 Tm (oedema )Tj 0.05 Tc 10.3398 0 0 10.2 467.41 415.93 Tm (and )Tj 0.227 0.227 0.22 rg -0.0089 Tc 10.2 0 0 10.2 487.12 415.93 Tm (inflam\255)Tj 0.286 0.286 0.278 rg 0.0202 Tc -19.335 -1.035 Td (mation )Tj 0.0078 Tc 3.192 0 Td (are )Tj 0.227 0.227 0.22 rg 0.022 Tc 1.562 0 Td (not )Tj 0.286 0.286 0.278 rg 0.0042 Tc 1.593 0 Td (involved, )Tj 0.037 Tc 4.045 0 Td (and )Tj 0.05 Tc 10.215 0 0 10.2 414.7 405.37 Tm (that )Tj ET BT /Suspect <>BDC 0.227 0.227 0.22 rg /C0_0 1 Tf 0 Tc 6.24 0 0 7.2 433.93 405.37 Tm <005400440049>Tj 0.412 0.412 0.404 rg 3.36 0 0 7.2 453.13 405.37 Tm <007E>Tj 0.286 0.286 0.278 rg 5.12 0 0 7.2 456.49 405.37 Tm <0061007300740068006D00610020>Tj EMC ET BT /T1_0 1 Tf 0.0095 Tc 10.2 0 0 10.2 489.98 405.37 Tm (occurs )Tj 0.0105 Tc -19.624 -1.082 Td (only )Tj 0.0404 Tc 2.165 0 Td (among )Tj 0.001 Tc 3.243 0 Td (subjects )Tj 0.0056 Tc 3.636 0 Td (with )Tj 0.0118 Tc 2.202 0 Td (exposure )Tj 0.037 Tc 4.095 0 Td (and )Tj 0 Tc 1.929 0 Td (a )Tj 0.0164 Tc 0.903 0 Td (history )Tj 0.05 Tc 11.1292 0 0 10.2 508.21 394.33 Tm (of )Tj 0.0146 Tc 10.2 0 0 10.2 289.84 383.28 Tm (isocyanate-asthma. )Tj 0.227 0.227 0.22 rg 0.0155 Tc 8.613 0 Td (Isocyanates )Tj 0.286 0.286 0.278 rg 0.0158 Tc 5.465 0 Td (have )Tj 0.0386 Tc 2.588 0 Td (no )Tj -0.0092 Tc 1.684 0 Td (effect, )Tj 0.05 Tc 11.3843 0 0 10.2 508.68 383.28 Tm (at )Tj 0.0172 Tc 10.2 0 0 10.2 289.35 372.25 Tm (least )Tj 0.05 Tc 10.7518 0 0 10.2 311.41 372.25 Tm (at )Tj 0.227 0.227 0.22 rg -0.0125 Tc 10.2 0 0 10.2 322.47 372.25 Tm (low )Tj 0.286 0.286 0.278 rg 0.0213 Tc 1.74 0 Td (concentrations, )Tj 0.05 Tc 10.2564 0 0 10.2 407.9 372.25 Tm (on )Tj 0.0219 Tc 10.2 0 0 10.2 421.91 372.25 Tm (hyperreactive )Tj 0.006 Tc 5.874 0 Td (airways, )Tj 0.0089 Tc -18.875 -1.082 Td (suggesting )Tj 0.05 Tc 10.215 0 0 10.2 338.86 361.21 Tm (that )Tj 0.0029 Tc 10.2 0 0 10.2 361.42 361.21 Tm (the )Tj -0.0175 Tc 1.732 0 Td (effect )Tj 0.05 Tc 11.1292 0 0 10.2 406.93 361.21 Tm (of )Tj 0.153 0.153 0.145 rg 10.3738 0 0 10.2 420.87 361.21 Tm (TDJ )Tj 0.286 0.286 0.278 rg -0.035 Tc 10.1489 0 0 10.2 445.36 361.21 Tm (is )Tj 0.227 0.227 0.22 rg 0.022 Tc 10.2 0 0 10.2 457.43 361.21 Tm (not )Tj 0.0025 Tc 1.922 0 Td (linked )Tj 0.286 0.286 0.278 rg 0.0253 Tc 3.113 0 Td (to )Tj 0.227 0.227 0.22 rg 0.0266 Tc -21.512 -1.035 Td (irritation )Tj 0.286 0.286 0.278 rg 0.05 Tc 11.1292 0 0 10.2 331.09 350.65 Tm (of )Tj 0.0265 Tc 10.2 0 0 10.2 343.66 350.65 Tm (the )Tj 0.0022 Tc 1.592 0 Td (airways; )Tj 0.05 Tc 10.3398 0 0 10.2 398.29 350.65 Tm (and )Tj 10.215 0 0 10.2 418.06 350.65 Tm (that )Tj 0.0152 Tc 10.2 0 0 10.2 438.7 350.65 Tm (therefo)Tj 0.153 0.153 0.145 rg 0 Tc 2.966 0 Td (r)Tj 0.286 0.286 0.278 rg -0.0144 Tc 0.32 0 Td (e, )Tj 0.0045 Tc 1.094 0 Td (baseline )Tj 0.0233 Tc -19.023 -1.082 Td (airway )Tj 0.0058 Tc 3.444 0 Td (responsiveness )Tj -0.0217 Tc 6.775 0 Td (to )Tj 0.0161 Tc 1.506 0 Td (methacholine )Tj -0.035 Tc 9.3682 0 0 10.2 472.72 339.61 Tm (is )Tj 0.227 0.227 0.22 rg 0.0455 Tc 10.2 0 0 10.2 485.75 339.61 Tm (not )Tj 0.286 0.286 0.278 rg 0.05 Tc 10.2654 0 0 10.2 506.3 339.61 Tm (an )Tj 0.04 Tc 10.2 0 0 10.2 289.36 328.56 Tm (important )Tj 0.0274 Tc 4.845 0 Td (determinant )Tj 0.0192 Tc 5.693 0 Td (for )Tj 0.0265 Tc 1.891 0 Td (the )Tj 0.0078 Tc 1.929 0 Td (type )Tj 0.05 Tc 11.1292 0 0 10.2 460.21 328.56 Tm (of )Tj 0.029 Tc 10.2 0 0 10.2 475.58 328.56 Tm (asthmatic )Tj 0.0138 Tc -18.25 -1.081 Td (reaction. )Tj 0.227 0.227 0.22 rg 0.0186 Tc 3.996 0 Td (Moreover, )Tj 0.286 0.286 0.278 rg -0.035 Tc 9.9195 0 0 10.2 379.12 317.53 Tm (in )Tj 0 Tc 10.2 0 0 10.2 390.62 317.53 Tm (a )Tj 0.227 0.227 0.22 rg 0.0049 Tc 0.846 0 Td (follow-up )Tj 0.286 0.286 0.278 rg 0.0295 Tc 4.374 0 Td (study )Tj 0.05 Tc 11.1292 0 0 10.2 470.77 317.53 Tm (of )Tj 0.227 0.227 0.22 rg 0.0214 Tc 10.2 0 0 10.2 483.38 317.53 Tm (patients )Tj -0.0101 Tc -19.015 -1.082 Td (with )Tj 0.286 0.286 0.278 rg 0.0164 Tc 2.628 0 Td (isocyanate-asthma)Tj 0.412 0.412 0.404 rg 0 Tc 7.71 0 Td (, )Tj 0.286 0.286 0.278 rg -0.0311 Tc 1.003 0 Td (we )Tj 0.227 0.227 0.22 rg 0.012 Tc 1.92 0 Td (found )Tj 0.286 0.286 0.278 rg 0.05 Tc 10.215 0 0 10.2 457.9 306.49 Tm (that )Tj 0.227 0.227 0.22 rg -0.0022 Tc 10.2 0 0 10.2 483.37 306.49 Tm (baseline )Tj 0.286 0.286 0.278 rg 0.0139 Tc -19.07 -1.083 Td (airway )Tj 0.227 0.227 0.22 rg 0.0058 Tc 3.209 0 Td (responsiveness )Tj 0.286 0.286 0.278 rg -0.0217 Tc 6.493 0 Td (to )Tj 0.0159 Tc 1.176 0 Td (methachol)Tj 0.153 0.153 0.145 rg 0 Tc 4.371 0 Td (i)Tj 0.286 0.286 0.278 rg 0.0015 Tc 0.242 0 Td (ne )Tj -0.035 Tc 10.1489 0 0 10.2 460.72 295.44 Tm (is )Tj 0.0164 Tc 10.2 0 0 10.2 470.78 295.44 Tm (also )Tj 0.0034 Tc 2.08 0 Td (unim\255)Tj 0.0396 Tc -19.857 -1.081 Td (portant )Tj 0.0192 Tc 3.376 0 Td (for )Tj 0.227 0.227 0.22 rg 0.0265 Tc 1.468 0 Td (the )Tj 0.286 0.286 0.278 rg 0.0151 Tc 1.557 0 Td (prognosis )Tj 0.05 Tc 11.1292 0 0 10.2 398.29 284.41 Tm (of )Tj 0.227 0.227 0.22 rg 0.0265 Tc 10.2 0 0 10.2 409.9 284.41 Tm (the )Tj -0.0027 Tc 1.498 0 Td (disease. )Tj 0.286 0.286 0.278 rg 0.0121 Tc 3.426 0 Td (Subjects )Tj 0 Tc 3.735 0 Td (w)Tj 0.153 0.153 0.145 rg 0.699 0 Td (i)Tj 0.286 0.286 0.278 rg 0.0253 Tc 0.288 0 Td (th )Tj 0.0233 Tc -21.514 -1.036 Td (airway )Tj 0.0202 Tc 3.538 0 Td (hyper)Tj 0.153 0.153 0.145 rg 0 Tc 2.4 0 Td (r)Tj 0.286 0.286 0.278 rg 0.015 Tc 0.32 0 Td (espons)Tj 0.153 0.153 0.145 rg 0 Tc 2.826 0 Td (i)Tj 0.286 0.286 0.278 rg -0.0141 Tc 0.288 0 Td (veness )Tj 0.0253 Tc 3.341 0 Td (to )Tj 0.227 0.227 0.22 rg 0.0204 Tc 1.553 0 Td (methacholine )Tj 0.286 0.286 0.278 rg 0.0128 Tc 6.306 0 Td (may )Tj 0.0028 Tc -20.517 -1.081 Td (recover)Tj 0.412 0.412 0.404 rg 0 Tc 3.044 0 Td (, )Tj 0.286 0.286 0.278 rg 0.037 Tc 0.665 0 Td (and )Tj 0.227 0.227 0.22 rg 0.0139 Tc 1.976 0 Td (airway )Tj 0.286 0.286 0.278 rg 0.0022 Tc 3.256 0 Td (responsiveness )Tj 0.0253 Tc 6.493 0 Td (to )Tj 0.0204 Tc 1.224 0 Td (methacholine )Tj 0.0128 Tc -16.706 -1.083 Td (may )Tj 0.0019 Tc 2.262 0 Td (become )Tj 0.0127 Tc 3.622 0 Td (normal. )Tj 0.227 0.227 0.22 rg 0.0073 Tc 3.714 0 Td (However, )Tj 0.286 0.286 0.278 rg -0.035 Tc 9.9195 0 0 10.2 432.4 251.76 Tm (in )Tj 0.0145 Tc 10.2 0 0 10.2 444.82 251.76 Tm (subjects )Tj 0.227 0.227 0.22 rg 0.0353 Tc 3.73 0 Td (who )Tj 0.0443 Tc 2.25 0 Td (do )Tj 0.286 0.286 0.278 rg 0.05 Tc 10.4827 0 0 10.2 288.95 240.73 Tm (not )Tj 0.0071 Tc 10.2 0 0 10.2 308.15 240.73 Tm (recover, )Tj 0.0192 Tc 3.811 0 Td (there )Tj 0 Tc 2.533 0 Td (a)Tj 0.153 0.153 0.145 rg 0.526 0 Td (r)Tj 0.286 0.286 0.278 rg 0.32 0 Td (e )Tj 0.227 0.227 0.22 rg 0.0386 Tc 0.904 0 Td (no )Tj 0.286 0.286 0.278 rg 0.0082 Tc 1.544 0 Td (changes )Tj 0.227 0.227 0.22 rg -0.0079 Tc 3.767 0 Td (in )Tj 0.286 0.286 0.278 rg 0.0265 Tc 1.276 0 Td (the )Tj 0.0059 Tc 1.733 0 Td (degree )Tj 0.05 Tc 11.1292 0 0 10.2 507.73 240.73 Tm (of )Tj 0.0139 Tc 10.2 0 0 10.2 288.86 229.69 Tm (airway )Tj 0.0058 Tc 3.585 0 Td (responsiveness )Tj 0.227 0.227 0.22 rg 0.0253 Tc 6.87 0 Td (to )Tj 0.286 0.286 0.278 rg 0.0161 Tc 1.647 0 Td (methacholine)Tj 0.412 0.412 0.404 rg 0 Tc 5.586 0 Td (, )Tj 0.286 0.286 0.278 rg 0.05 Tc 10.3398 0 0 10.2 479.41 229.69 Tm (and )Tj 0.0029 Tc 10.2 0 0 10.2 503.98 229.69 Tm (the )Tj 0.0078 Tc -21.094 -1.082 Td (subjects )Tj 0.0102 Tc 4.107 0 Td (remain )Tj 0.0131 Tc 3.671 0 Td (hyperreact)Tj 0.153 0.153 0.145 rg 0 Tc 4.37 0 Td (i)Tj 0.286 0.286 0.278 rg -0.035 Tc 9.8793 0 0 10.2 415.66 218.65 Tm (ve. )Tj 0.227 0.227 0.22 rg 0.0288 Tc 10.2 0 0 10.2 435.77 218.65 Tm (In )Tj 0.286 0.286 0.278 rg 0.05 Tc 10.5338 0 0 10.2 452.54 218.65 Tm (our )Tj -0.035 Tc 9.9854 0 0 10.2 475.57 218.65 Tm (fo)Tj 0.153 0.153 0.145 rg -0.0065 Tc 10.2 0 0 10.2 484.23 218.65 Tm (llow)Tj 0.286 0.286 0.278 rg 0.0279 Tc 1.785 0 Td (-up )Tj 0.0295 Tc -20.99 -1.035 Td (study)Tj 0.412 0.412 0.404 rg 0 Tc 2.304 0 Td (, )Tj 0.286 0.286 0.278 rg -0.0311 Tc 0.768 0 Td (we )Tj 0.0007 Tc 1.638 0 Td (also )Tj 0.0031 Tc 2.161 0 Td (showe)Tj 0.153 0.153 0.145 rg 0 Tc 2.592 0 Td (d )Tj 0.286 0.286 0.278 rg 0.05 Tc 10.5068 0 0 10.2 395.49 208.09 Tm (that )Tj 0.0078 Tc 10.2 0 0 10.2 417.46 208.09 Tm (subjects )Tj -0.0101 Tc 3.825 0 Td (with )Tj 0.0092 Tc 2.344 0 Td (an )Tj 0.0118 Tc 1.505 0 Td (early )Tj 0.0179 Tc -20.273 -1.082 Td (reaction )Tj 0.227 0.227 0.22 rg 0.0001 Tc 3.953 0 Td (recovered, )Tj 0.286 0.286 0.278 rg 0.05 Tc 10.215 0 0 10.2 378.22 197.05 Tm (that )Tj 0.0404 Tc 10.2 0 0 10.2 400.22 197.05 Tm (among )Tj 0.0145 Tc 3.384 0 Td (subjects )Tj 0.0212 Tc 3.872 0 Td (with )Tj 0.0257 Tc 2.297 0 Td (dual )Tj 0.227 0.227 0.22 rg 0.0109 Tc -20.462 -1.082 Td (reactions, )Tj 0.286 0.286 0.278 rg 0.027 Tc 4.317 0 Td (some )Tj 0.0078 Tc 2.494 0 Td [(subjects )-141(recovered )]TJ 0.05 Tc 10.6532 0 0 10.2 439.57 186.01 Tm (and )Tj 0.0113 Tc 10.2 0 0 10.2 459.22 186.01 Tm (some )Tj 0.227 0.227 0.22 rg 0.0104 Tc 2.499 0 Td (lost )Tj 0.286 0.286 0.278 rg 0.0265 Tc 1.842 0 Td (the )Tj 0.227 0.227 0.22 rg 0.0164 Tc -21.041 -1.082 Td (immediate )Tj 0.286 0.286 0.278 rg 0.0301 Tc 4.61 0 Td (component, )Tj 0.0269 Tc 5.278 0 Td (maintaining )Tj 0.0265 Tc 5.365 0 Td (the )Tj -0.0043 Tc 1.64 0 Td (late )Tj 0.153 0.153 0.145 rg 0 Tc 1.796 0 Td (r)Tj 0.286 0.286 0.278 rg 0.0153 Tc 0.32 0 Td (eaction; )Tj 0.037 Tc -19.058 -1.082 Td (and )Tj 0.05 Tc 10.215 0 0 10.2 309.1 163.93 Tm (that )Tj 0.227 0.227 0.22 rg 0.0386 Tc 10.2 0 0 10.2 330.71 163.93 Tm (no )Tj 0.286 0.286 0.278 rg 0.0078 Tc 1.493 0 Td (subjects )Tj -0.0101 Tc 3.73 0 Td (with )Tj 0 Tc 2.25 0 Td (a )Tj 0.227 0.227 0.22 rg 0.0114 Tc 0.942 0 Td (late )Tj 0.286 0.286 0.278 rg 0.029 Tc 1.928 0 Td (asthmatic )Tj 0.0246 Tc 4.479 0 Td (reaction )Tj 0.227 0.227 0.22 rg 0.0019 Tc -18.918 -1.082 Td (recovered )Tj 0.286 0.286 0.278 rg -0.035 Tc 9.6519 0 0 10.2 334.81 152.89 Tm ([38]. )Tj 0.227 0.227 0.22 rg 0.0288 Tc 10.2 0 0 10.2 358.01 152.89 Tm (In )Tj 0.286 0.286 0.278 rg 0.05 Tc 10.2564 0 0 10.2 371.9 152.89 Tm (ou)Tj 0.153 0.153 0.145 rg 0 Tc 10.2 0 0 10.2 383.03 152.89 Tm (r )Tj 0.286 0.286 0.278 rg 0.0057 Tc 0.79 0 Td (experience, )Tj 0.0265 Tc 5.138 0 Td (the )Tj 0.0114 Tc 1.781 0 Td (late )Tj 0.227 0.227 0.22 rg 0.0112 Tc 2.031 0 Td (reaction )Tj 0.286 0.286 0.278 rg -0.0039 Tc -19.025 -1.035 Td (seems )Tj -0.0217 Tc 3.259 0 Td (to )Tj 0.0078 Tc 1.603 0 Td (be )Tj 0.023 Tc 1.738 0 Td (more )Tj 0.04 Tc 2.912 0 Td (important )Tj 0.025 Tc 4.986 0 Td (compared )Tj 0.0253 Tc 4.949 0 Td (to )Tj 0.0029 Tc 1.647 0 Td (the )Tj 0.0223 Tc -21.135 -1.082 Td (immediate )Tj 0.015 Tc 4.845 0 Td (alone )Tj 0.05 Tc 10.5727 0 0 10.2 364.7 131.29 Tm (or )Tj 0.0029 Tc 10.2 0 0 10.2 378.7 131.29 Tm (the )Tj 0.0257 Tc 1.686 0 Td (dual )Tj 0.029 Tc 2.259 0 Td (asthmatic )Tj 0.0179 Tc 4.526 0 Td (reaction )Tj -0.0044 Tc 3.802 0 Td (for )Tj 0.0265 Tc -21.121 -1.082 Td (the )Tj 0.227 0.227 0.22 rg 0.009 Tc 1.698 0 Td (persistence )Tj 0.286 0.286 0.278 rg 0.05 Tc 11.1292 0 0 10.2 356.05 120.25 Tm (of )Tj 0.0237 Tc 10.2 0 0 10.2 369.11 120.25 Tm (respiratory )Tj 0.0171 Tc 4.975 0 Td (symptoms. )Tj 0.0203 Tc 4.996 0 Td (Long-term )Tj 0.0049 Tc -17.84 -1.083 Td (follow-up )Tj 0.0123 Tc 4.468 0 Td (studies )Tj 0.0313 Tc 3.298 0 Td (are )Tj -0.0026 Tc 1.75 0 Td (necessary )Tj 0.0253 Tc 4.375 0 Td (to )Tj 0.0179 Tc 1.368 0 Td (better )Tj -0.008 Tc 2.813 0 Td (define )Tj 0.0029 Tc 2.973 0 Td (the )Tj 0.227 0.227 0.22 rg 0.0325 Tc -21.081 -1.082 Td (natural )Tj 0.0164 Tc 3.435 0 Td (history )Tj 0.286 0.286 0.278 rg 0.05 Tc 11.1292 0 0 10.2 357.49 98.16 Tm (of )Tj 0.0029 Tc 10.2 0 0 10.2 371.02 98.16 Tm (the )Tj 0.227 0.227 0.22 rg -0.0027 Tc 1.639 0 Td (disease, )Tj 0.286 0.286 0.278 rg 0.037 Tc 3.576 0 Td (and )Tj 0.0253 Tc 2.031 0 Td (to )Tj 0.0095 Tc 1.216 0 Td (confirm )Tj -0.0065 Tc 3.725 0 Td (these )Tj ET endstream endobj 42 0 obj <>stream Hd͊zy8 >sRhF^#y QG#Oç==o/ϧ;c_mӷKv|~_oo~y>}~W=|z>{O݇q~?>Ï?o+~ߒ~;%zΏx߽w;>lp?(O?{wٸ^ PZUuTGu^5P5FjFDMԤU PjVjUmFmک]uPuNNE]E5|| _#_k55|| _#_k55|| _#_k55|| _#_k5Z||-_+_kZ||-_+_kZ||-_+_kZ||-_+_ku:||_'_uu:||_'_uu:||_'_uu:||_'_uz||=_/_z||=_/_z||=_/_z||=_/_ || ߀o77 || ߀o77 || ߀o77 || ߀o77 KG#(~? ?G#(~? ?G#(~? ?G#(~? ?z $߄o77MM&|| $߄o77MM&|| $߄o77MM&|| $߄o77MM&||3,ߌo77f||3,ߌo77f||3,ߌo77f||3,ߌo77f|| "߂oȷ[--|| "߂oȷ[--|| "߂oȷ[--|| "߂oȷ[--||+*ߊoŷʷ[V||+*ߊoŷʷ[V||+*ߊoŷʷ[V||+*ߊoŷʷ[V|| &߆o÷ɷmm6|| &߆o÷ɷmm6|| &߆o÷ɷmm6|| &߆o÷ɷmm6|ۯ\t;]~~߅ww;]~~߅ww;]~~߅ww;]~~߅w߁w;;|C߁w;;|C߁w;;|C߁w;;|C߉w;;NN|'S߉w;;NN|'S߉w;;NN|'S߉w;;NN|'S ߅w]..|K ߅w]..|K ߅w]..|K ߅w]..|?|x>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrcolrKjp2cOQ/R \#B@HHPHHPHHPHHP(((  ߇N Ѓz3 e%4{u*F}EDz_=a B_JU~찏Kl?06{ʣG#%5* \1 2F+5$)@ͱ"[{ODXvz Vu^&~by!/Y~)aU917{چ3lQe!_kTMIq8j~ze9ۤɞ$T &HK9 ]IR4U1УYt\욎ř[(*6^n qݏ6K'M&7' Եxj\Q("\q 8/-=[:=8P$FB ϵ\TR%Oj > F@:|v d[v6[QyWKq9(!&j J$I,ÅcSc?O"mL|6pRs󾋅JmaQ `<!X Gw㟞ۥhvO( Vں}I$=u/) 7GH'$ՋW߈q.C`s;;HJ{e)l_7YFnAt$;^"cudd:S0ɏ[![ Mhz:x1s|BD ,F}T3)!@LzXQ꿵ҀXjD$ X&ZN.c gM~rR&5ŧhe;N \+9g\C*6XsYNA e+oh#yeV,ao@Cn7eUqɾG~_(y~54-)r;hawL/t ORB)G A>7sؾ؟al@?Cא`$W|r1!RrB&S-0jt0BiQh(WP,uk~6TyY E\i$m ͗APL"1$PLV@^UUS~'PI&+I@6|q|'+ƎImGANhplp~&5ʎhs"`]\wtgYa#AGc1=+kŽ5UNuB_O)'Y+;=MYoZ?d=n v/f2 `'х 8~ {Z>‘.3^ .'+AFlP? PUjs٧HJz,0Ǿ.*ޘi`*PMif D eӹm—+p0<z;ʈWLE'1ܱuņ&9Ea,?2g}Fd=` 8AsmLί.ϳ_<ݖθ3ȗ{&١T4s#MlEVM#Y܎#̜;8;'pǙ`;9&\Xy[O FCe+#)&uC 2a.lBkGP(p!seC=țCJQKizN d[ɀ0csw'xɆѻU^QWZlu\G358k q'n}`r R>?3[tU?c~tOCzd@C#$@maNYȽ{Yhؗq^p%Gg12tiU9h9ع}V`(ːZU(Xa puԁ@:8ަ!/ޜ)2:uEM NN^+Vy/#*г)K1CRd/QzYvj0FPP5@=XTa+ܢԷޜ~n"d'N$7*25'xѵ~ȺX2pY-G*|Dz2n g\\5JDoc1i\W9eT>.dG;Pzx|}Ќ /֌ idotRJQfK~h>C#pWü,q× ɗ6 ~\FF/:g g˽/nk}w\THtz&|N:fA#cf"q-[> dܿNQb D`Kxv%fWo 0)d^j'r7Q\ 501;{ 5v<+yoXiiMG(EeLpv?ϕbm̌%iWg' .$ƧU)J?Ȼ+Uk~7hl;qe-̵l@hVF4$]KrANy3$HCO +v,΁9R_U~|o2EljgA c]ȇV]  1R*;P5@F)00~g!e"Fv'0)r7̨X{ˑdVZ^VVb.nhP5M,?vf蟹eZBpz۲xWɹ qu(=qIEIztn0 UAG&e\"CO4ɬpӚN,0vꃼaH'Gt'%Wd ] bB7Syy"[p bY['ImCVyPYtg(c6k 3[`;޲RvVx-dbO ;WBa4<ԩI3t`Y[ ]??Ҍm+w:X >Iy-J*萬[1hkFꄌƮR/hQS9kg&СXU"#oީ0~I\:6F? _ ˷Mu#j ՞CSL ۪}j|9fQն1F/B67d0ҥuq |D#>1_YHH؟Y׏ػt {J" c(KvNAPtͥKژʝ%fGnUVxT0PX.>_A@]ݲC@'q9%>H(K2&>)3iũ7lwETagϻR me7~Q/N~hkѧXBqiRíA#K jܼFdeuy^YBllC)SꤎBd 7]Bv+xC܍"H}Sc x3t.2??L֜lWݶ2W{w׎ilB7#!)@ų۵Mihmb ɑ54EQ8MN8/| ll)+4X'=e^*?]-nW[L„W?Ml't2v%䮩l3BMDGnEyhOW9Z#C!\)zoZ .X~Z!#[ضޔs5_9,YP( a=bX뱡AZQYvc'Gn˵:»W,_VgPt8 &\J(.f{,$M5Ԥu/mydfɦ2_@W99|Y2[6׶"HiiBJx8-b[xT-j@)0{bURR9PUI 2`~Kh^!z(s2,9< J6%Ni]>;GVj:W0e*LޥS0wNdѩ⏖SXx6BЁ<@' pi@vs_ 8.>!־+S ۮД0 obװ %2Fv  gYqZ5q/Wzi';El F?S~ X>[$EJ^U>tQQLQJp# t`G?2lĆQ#LOcV| 4.6JlkyJ!6dM~ܛع6! ;4Q؜ה E6HFSH= Q S~̡ 9w tZԙ7x[MQQt * S@c>Aɮ}c Mr}`Jt O=T(l;&-.Kw{//pab[&f9Qme{ Mߐ7/6?%[("gdU7?>zw5k)e"ԝ4NiM?n>Dj)OBݝ93L8:!VTft@sEhpek;Y{ej`zZZ˃=fiAbxqƞi|wND 3nQ&@XXlMn=dUźT]5܏ Vh  ? Cg Z6J(?1k==R9;8 Um2=^fFi\VûH { #^T?kOV*'kuʚxK9TY&= 72ړrIgtXPfa\ ye鍬cA:/"#P4Ύ B*} C"oƎaaF"%ҽُ301Lb6ʅ]9~+/?a y ^nхfr(c>r,DQ̗}/ ީP_>~rGq7_ycl*L O4MQ/AKuAoTr"F-Aqs>y0]g_"g)/Zft鴗e<h$maBx`HW&tHݕ-HS8"ʐA˛ co'@͵%-B(=e ~2JAY=uA/(*aæ1M<$1+<*EI?rn^'o42\6Qa+#_Tl,^>+Rt#Ww!B <(NBT$y:'쥜;>q",-(I'#7ȥlGi5">"G)iܬG N8_ hpX6P$ֵ/Zm!{v]aMۍ͞B@$T_6.m2+ޥp[IC'+}W 3s vHõKx 5@;HD&3``!ڡ[zhg:Ce2:R#-kߎh6 ;WxXc%0,Q'þ-A 6p-bĆh m/n;d?'; -$quY7`99?\5 Mddeq⏾ Uo>ǐpO8@᱾S<$<Qmn鵦RmU`X{r4@U? jwXZsgCMV0V t8 } H*G#iZ!HUU0'1Op Eǖ! edjDŽƷn l{_Z6b;<&^my;>=dh;zxڥ_ ߄9Vh yG! xpe٬M[ }|gE:ZX6YK1D7XM_7aBvn wqlP;Iw3z%Nujq xX/TM3O' p֌P2ݓ`xT28DyT1&ϋ(A 6\1Rusizi||=<(O|je*dcXbgFu4#Z'Zp6tn]>n u`E`ܠs,Utڰ!c27?*.2JPԯ0""e4ITE7?E[K,6+tJ;~׈U`8'kN(nM"|&F^coAM𔣀e!݉kekoFz]*@ʥ_E~gs4x oFD?qwb_o47:cIǰ HÍV y(XCy2SNiς^ȲCRY>#QZ3ܯ[p~k(pqy \?AUDizF%B4)լo Vg v /߇{~=|=?|={G qMuö_ 5:~:_n н U򧍻WzKyw݇߇}O߇؎ǾIL[vbFԵ}|Ty@*`yNY84%T4MBWiދ(r?.p 9z6GУn$bF'4訍RK3[p5fVY3M':=5 PчfeHMYCs RFW݃.M;b1m IJEyK3쁑9Pb nҴP/5iU5dRKPyZ!`Y8:E|֎+Pp1y? (H yT0Zyc-Հz|O=E\p;2]1X\RvG%H).^򾪤I8:7EWPK3&jv9_D$HT&>v/nvx#nV}Ӎ2tIӫCu#c? ͒,?PS4u HJHH݉bNF&4bL%nEX<υޓi u5Hz5fςk |A!Adm7DWNdF']Dz:~F>řfyQUʙ',5l{Buڕʍ?u9$P묲H%tS*>mZα%4{l h_5F]6<Ѿc{X'֭F% 7IJt-(ɫhW8#e;TB=TY2qpN][h$nmE]sw  ~--|P*s8,uAr~)x;>CNbUp$$ڀp`%,9vκa)楜 &Ab]_so\Yt+Pvҙ.W5;h"{?8rF}~z$T!ZgOmSa4XlDޚ~ J{`gE!KS_qiw|9$+jt86 0/FGd\Jlnk{xr+k/' l܃(M4g }' [jZߧf+1Ո#|c׫W T<Ǜ Pz1ݷul6vʽ 05V lnS a_wa1*&DЋͦ(1Bќ`p886&e+~0Ȗ./#zJL/~-Ԍt2 <e|U\Es(`s=(sZFh+$I DVZ]L%Q@P}O{$&@3be!r 3Beg.잳Ud~u*H\I i¹>~~|҆\EȞKiӓz1,'x)b_yRN{Ep*$IkuDI߻Pse~A,$')/CPC;]3{8ՠPTxp'٭n:>1^~rU2\ rb1=RLAl3 ʼnж`ч?BA/?vY4č-|~-{+iFiIkPf-#0FՏEZ{G3ˋDr,6%67&p=6F^tfWV#͓R=ِ0M\֨:=FxEDHָU9V S3$^`~ SLNe; Oi[gҨ5 PI9܆ ?1tz0{m$KWa*փ!{\#kGᷟͷoeG}H1)  )tͽu?ƿnVɂ{Oi;n|!ȡek'gVrz4gY 4DKͲ(An]Z4^i#<_?|q>K++:S}7cU5z5; E7_E,)bh~vLnx˺.19kN5X}+j`Vqs>v!Q'?󨓱5Q'˨r%АYvmՈZҪGp%4j0mО_Y&CͽeU\OM.7QVS4HMgmBn`x -Cn4ɇ aRmJAzHcÌb=p* "\><xn*m4kMZ|đɋѕLo'sBOkf?Rr'<٭X,_`X%= >-?~..elFnJj^-]D&z{f04ߊIEA򋕕;Ⱥ+DWyݲyo xnJ[9bE:R#t=giOM>z\^b,2y"'(d|G],UҢ PWxTj7jichK#҄tT ḪjЭ yx] ;߯e7!\[WtOWfvK.wj2$F N+b! ~a"d m3m x?GO@QKs*䡵CRb|J5aod!HBQq>.WրVNKD얖֒ 1#N,%악T vu*TW%$Q4+vĐBsT䋝hAϹx5m)3b,+ zƗ2|f'v{h4"O"в04Q?mi:b݅dx[.ϵݫ;4F9!PfAz " !-gv'liބfW z&AdF6凵럟" peQm#©64w𿣘1V[vYy(~Yq!/rY8n0zmuOu}mtjYjEuLh0\wOX[,ݩx҉@vYݥo:Q9`p4i@ǎxoBJvgiwJoA8gRVE:W,:UQc_LQ.\9F~miу i/E‰7Z4 $yJݕ ږ%c#]/}dNɓv?:VGcne}}Iwי‡'$908I)N+oLm%];R9JnR(+]lޥq/1gu9;N"-uubk&d˲"rGt~tNU)b7cW!7)̀V V曲kʔ3مҞO5t\/V:gTa's:g"H{qUF ^@M b"R2k74'&ۊj*G|=H@fcKX|G. asȾUyQW7'R5__ j+:ѓ!A:oIԴ2"k(g{xw:֘LWA,#ee_5*b  xSYڇmL|/TLNcz۝f o3^$Czy8ÈXJ{s~oIB/>p&L-꘽H':bȚ\n@,+e IJg)6&7 w7H6jRgO0 =Kk57*e4d7Od%k7I h3hd-[/29d@wu[(.h 624,#hGZږZAR9ڱ(2O^%N"{[;`y/go+w1kFO i\` BHR H~lԢ@ѵFh e/B>dЅC/5.~J ͺO'sl ;< !|#-6M.eNw"Il+(UfV|2MDqڊpp%?3i8[!Y!=1-f;󳂈eTb07~A H'Rvnv c؈qa!=$;Vhbr EQ,NkX/)'ׄ>v 93]=W^ʙpJVv3 )"6?8R#(9GP5n`ME*E]8F>N{Cf?#vR04[|<U]+?b2F\+u)/ Ƌ 8\*Qj$@k R=myU &э<ʧ%aFpYJxf:'/"K$DϗY ՙ ]m .Օ *{ބh+q&tp%:) `9_L>N)׌/eΟZQacJ5x71 O*:j8V#& n){m6%R?͇MhT신ȭGRf$5ݽ lMC2@N-ϦΉ|ZA9 c >y(q~4"(W1VMYWaqQ>2v k .w$XDYː0'g9~l_0P u-7֜(KSQE!%6}xdB/ 'Tb OQ#GOY eI z9SRO|Z+|kI@a{y1tjQyI[6r Q3¿pd"I^\]CS:k2TH1*pUQ"yqQZR{ of:@شG5Xy`[\Zt֗pf?GJX2Wota ..IeHX7kΤfohMBfӠXGVie"F]M7km(G1ھb*|̓7CLu U?7u=)D, 96[LWM^du*U̔|"]DIOw.W91L5'nUGcF7PtosWs$^5Z=9QK[qhxihbusn~H]p,0#b5%VtDU:XeV7vKxfę4|aL{6ˈNӰK[>^o<<ќBG{GJE3~LR%cTfC\'\$pzn> F}8mHMVDm}v4qyÁ6 x7d @4#0o1Ҳ)v!jؽG;S4(ŦN_,9OfI*%6>$RT40]4}<Yݬv  k`x{(dq%%Qdf mtaB<4>S;Nj_Z!%>>)l[8]ǂ>%O25j#t9 $tOv7Mjgh>;,L-1:9ڑ.)v ~ Nֳ0RPSC;˓RkH"@yVO}92FR^: fqX'lCŏ4_mO!os}m04Ʉ-A9K]X؟ZLiM*L T'V-%D2>y{E~N92kB\)hgli@3HM*Ymۃn8-bt|r՗ /u d `ŅL?@\yfN Vrh=5KQ&  HD*oB0$.WaMO)źW6pm !6Ww\0XH5E& nM#41C}c2_;qG[Jbe=n(gRt K"kߏ7_eknQںARgEpժuܰm׺l *WmeʧT*\a^.|WF@2ީNJY? ۮF1vOh:7f538ХRKŞtrGGG fѥY:22DG t Z$cNп*1U/qiYxĶnvQԍV`4)̕6CxyTmftSc&FddXm"Ż,[g+Ly~pF<, @;0( h?fỠ~zW ڏN(:ulXき (չՀ}J|)}I|6hHejȘE-gH `R[ϝm%x.Yܑo &9F 5^ܳnUkwMt3&]xV^}0 hÖ~Џ2Gdd!L%X(}d'nx]VNNj^Y}iTbğ59-R> yv a߾5C?:}͐q6ɹm*@ 3_bs_᩼W==%v7/qzwwϙ[Exzwz~;Y?zhk?ҿuͿvwe=#M~߇߇L~̑lwj5ނ~ʻ_zO=Jݷ=)tt{/~;?aԿACCҗo.쿇N$^aӷu/ó~%7}>9vxvé |oá?wf]ҿâ]lzouۻ_=۽ï#Hů ;i-Ҿ=3&Adű@s:5Rԧқ.9,F{/[D~y9ZjҜ'6K5,eBuĔIpFxXbr;X8TD%|UT)7tNGQc+EB[9ׂ>X&P覿REn7777)cV*j uѰch.~ X! hi 0Ga_g0q^%SX_ijgkfY"kNܘe."x]e ppCtDRmV r*8_=Hb`f~g4Λ- $\.,z O['HXwܾɇ5jĩ0;uk%\}K5*d\~)qEŀSTC{dDkEa!D _9.c/ʍu ""_>߇6uQ )Uib;D 'AhK[+uz8\XfZ+w!판9HӉFt#&] &ʵ.oKTdz*SOq[ ν.Jk$eBV, 74BtʯCZjl+/_}^ 56; o؁u5];Vhgd]Z} ͐WrBvsӭ}UpK#X-|Anǿii~yEsR"JE)O AtntF=5nƷyT^#>&"Y=l)&e65]i0W6"#h¤.O$7u?>Ljrp[|x/v\ŝzlGS/f{ْXςZ,D?TP/U ڧ3ʹi{'N"<?$B! /9dVx`X`5>݁2Vt $L,K{Ro'YiCUU)wB!NLG.yr ?G\miRSk[amtc=gzr u 5=$ 3:SL(TPzOe f0{o*^Eb+VTҏ؏b:@[*90V_LW6:ƻf.A2 țzdr;ߋ=<( J46x? RF XX,wk BMp`ANn@ӜyT3Uݷ QN} ң_^u^L@{I9p#sY'},Q(+¥TQWC]zl*|Kmϲ \pMgx0z YDZ=#=#[b}h(6.L*H\`W QFjabJe#- 5/!4nedAڀLϬW[>C֏k=ZQ'OJh929P{] ipUvT ̶,B ԉNa@LA U2l޷b+{tm~bӔ2U-҇-4Ui$ e}6זs1qeZax݆"c8%vHAo1SI2#Ykif%5֞ (L*DJ-Y̒2]nS1N j0_d !z΍\ NZ(j1&w[z?_d*MldU_׸yB kZ/m'^ĩ40#42 dE1od_X&ofUeNݷ `&T(@Ѕ `U?$df4ۻG2z jWc/Q$)|f 6sf3iE.x2K;V^jjc1Ud;9bKRCT n.F: 2¥`+OA8Ӛٟ{>bQ!˖ } jg4JИD bi#Kʞ ;\[L}΀ % 5  ź]F$|PԴ594!*{OEVݿ[qҚ(i 2}Pڰ쎇&%E݁-";DS?F%XGԁoy)ol̟:g><6͖x7EsnaіrFF7(_ cl#!֡نŀp*OYM;ް`xaHÝߊ/Nܻ[W>OcY%R/pAfP!{3qdNdal$7WQ-6FmĦ60ѓUn ƀr6H(17DCkvkفC; jyѪ@vk+kg?*$l*׮mwݪin֊hغfA?32)~I~oJ[!PPXV==ߙ9tA-KҝY7`s p.ȚX ;} ]r1b7<( Cp>͵?<,MPt]^P~ven&T|5!7J3{@f͟HETmc̎&pP>{etH$jdV_bC  k^ oi@"~f:x x[PY!'Er&1EK/FE:TrUFc\_c3AccG C&˺m8Q,/]@,>g7FE)>^xmFD&b ۂ,$T)PFz 6]0?ⲯASot׿O.)d fnNQFŃ*+ZoAcvPKK_jr񋳎J0(N bkk[P2nNeӯ4-$X(n _K| j遛Z!z$SۮG&r$]': paOƵ*ɇ`4?ot4Ў7rSGվT'gN P/CuH<}i(jP]$ͻ&tMjx @d1`YˌB|PL'Q,?wx2 kޣs9(Ԛ:Es$zlF#۸1˭2>-_Ut?( Z qT;2Gh&Yz{HEcAaٱ:Y\-^aK{uxk*G/ F14$8qԒצks= TF؍N I)#-qہlBBuUt'_L&g%wz(jN"ֳj:NWvZgX ?;>9>MU,#/xO} L?/uy|~WP?o.mA]\ VAu$ 0< cR? f#Z^$n%Fk1tJ<3a<} oыО 2B<27N{IXRc$8:MOw!trkiԧ!W퓪%an5´$Oiy~2LɖTzPǂYzHXB,֋Y? 1 n`TH-z֜(4eceD\U*AI#_a࣏: T*D5U*?b9 . T@gn/*t%^yVl^p->(- .'4n 0aCKQ6LvT(A8B63_|N9B)Ey1N }ՊzfLI2A#I.6VݥDy|bMzh6y5p:.)Z,whT&nHzרJIg 85l ,$wD]9{1w"^Ո2wi@kEײ>4'{X A{kdjɭQ~-'&ai57(ZMc=8u?@V&v)w@9*1:@yRe}ᏛvdJ|^ H*Z~((bӪӭᬨ"^)`F-,5=`}mqEX2ZE*lryDֱ8!X HNfdŃ|amQ.1՟n drI nU-DMȿ8e .|A |30wwbMHL,$m~fs=9CniTP"۵fPG`ۂï+b栊c<ҠSĒ 9TD!ijwoOLI?$hwOm7Ȩ C@;z a&XC+nLSWQi@8{'/9d9[wqaC-wªSȋ46cwUDne"BܐP[WNsSz87DWl,Y;*Jd:M(w썃N?HO 6R$)1N3)F08ۗS9h/!ic"amӴiaq~N^ta%O" ;Jl^HEA:ԝsplj(ث{1qדG?]qecgoԛmd3hK_uF#$|4%*>4B!H1>!h_}j4>|,/a"MÁ,n9NIn_+NZ4!{QkOR\nvo<5 rd&i7LJbI5dI9[nr{zg2p҃Lb1b?lyžWb .*` c"jF$,,ٷ?!dj۴!^جh3mgIw[ܙToNL` @h疀aOR}Y*o_l7x K%mqݭbcG#a[HV]xX,T-qvKP뇹Z.!|S3zvl:ޕBx'[I^snc avʉʇӕlT[[c Ukʹ5AnŒP|͍2h_s(ucTA/qiD.<cIϯ#E%+W%|l _ Uc%E*;;Տ)$K%Zf #$$~>.dj?`'HTr2ZGK3y?nEy|W%04*G@z&Ѫ|1@&\KZڣR3uGA0*m ܿ;}d]'ՌT_+ѥ6R5T+;b%ui mvr+d**@\E];t@F4`>s5$V;g ~WWE[&RTzoZew0he@ꐷ:M±SV2֊g71gJBM R4gN(:A[B|$bN4^{%x0#iVч{4ø=(vSzN9aHFƑ[c.ҥBi]mh x:_gL:J\?uf?65Ck֪UV:zf%Gp 'Ͽvn#z[sؚ k#lߧEm`Ty2j*l0C/~9h_GEomyY $xΩ{>a}ԟ_vYAPOvo"'ǔ)BSwGR[ZAGkѝ+~ւ<\E1~YiKȚuŹ0R,}q <봈UpO Jap.M} U(7G|Pj~xQ\6ssln#= jݔ}3¼}kgCyp]Ƞ0wlikΰPZ@`6ģ.߈,NUd]:& E&G֣yIIVUɇ# E[=053ƛW؄EK5tjQv@g;]7XxP? hlcWyDVVAheQNPfcOm˧~߳JO ׮ hIZOrޤyigI4v^Td@`|V\a$ r&3 _-F,-8q~؇#!SPwwB="ot,dn8$qU>|& ,VsIj^bJ|&j%#xʶN`'Pi@K%\VsKM^l9`e"C@;T[|l}ȩcԟ*[9}e\7#+0 ͏Kfb"64rcV]_HovMIA|ȂU2Th&b:;nx=UjS 5k:`2UzYSl_4uw_쀯V1Uŕ!~;{2Bą\+/\FO,ḊjЁĮqG#s֎۟.5).0o>+8 QGfC=/R-ѷVMm@gx:,mYܛ{X%uy8QA?#M?YukӔe7a1h|obSLE0auo6zV,L\tIM4TE_|,j&R^!."~Qnl?,+mrqibVF ~j a0f /6 &Fh25j)րeH9f &r{ήQ:z8NG8ʓ shSq.srBm|Y};E֧tŰ,]m WzS3_.Zqks|Ӑe̱.Wk.YS Hqf믉tP X' \}Tc]h0q'T01ޫG^?b$OU-[A/yTXnu֡`UH ԭt={I=Z|ʶj?"YY-0 {0M}3ex 4X.YBd#-I=ԑxm=.WH=!7k]rc;`mc;DVFر`vs~ЕԄ`?;,UPeroI?gh|t# WݻT)jU8cWNm(.>eMP֊: @ff/?&OiB: mMU4elV#j 6etjqoZ]-obޗmY!mn<mcnƃso5=1~xt]j{,mZϷWynZQ=Nz!xBjG Hʯ|p[e{tfCgٓO0&>1k5]mJ^0Dظ^~fsSZX3%BLL 8Ȧ),#H *VWgRCZ|g-V;t\}\ ߘee|hAצѠ 5zf/l뚮OS&L# ak+ @RѲ؆[g?bKO:Ϥ^;zUwG*+ t3kBjBNQp$4JC64L)Vp "m(Z*$q9^#bJ$E<a+*{q(E3f >t[~E` P=)6mBSGX H~Ӹ~7lyeq4(#e}bbwx)d_n|bKt:zH[ Ё`M6֑W[ydCv; M֗uӸ@K3;Jq0aZYQs%fdVC$:+l4qxD P=$4$k=y©.FZ!z4JjuVM,%[jת 6pKD:{L#W-C~6rAz'yBK!gYVipߏRQdZ[) ʾۧH/^̣dE(2w%Rf.T#wٖ,P7ÑesVA`!hutP! ;7âoëuAm^+[4/+?t߀W5J .4cMTWٲnwr41ili} h6 Y{_Pg^ĄN?y%zqαCfX}-Z!<A鍎]狞Ʊˌ{k|yϨObdJQâ2VS6=̔)wE%n[#3(]#LLQY((,%FnXYi1*9<<Oh{5US܍Qg0뉗cfTzp& Z?Ӥ{˧[p\ut4M#) =Mj.Jl6& |++y+|i-cxq;/x۷9HrPbD!5u@gG Z~z؆W_BQF#Ɠ}"rn΃MY'Dp㠍]Eq[ e7\E+)ȯS4w<8Ox}G]7eC˻&$hblmSqi?[+K?:~f "7H/v. ,3wQ2+~Ku T `. 02'{{zGރ过q~z~z;??o]ۿuͽwGi:7~WǷ>~ZiKݺ{{{^ǻ'᷻{{^}A[bdBZeBl&3G;yx:3v =7 yMѸG"|+ă[йbU3mn_dWBckl#`FNP:k9y|E K9 :;y=u,Ve!6Igc7wۇyNpBZ]1+E]t?Ǚ=\aP߭>f%HHDq{+AOcYǝBҙ.q9\8 f07alZ\MG+\j?C;d~+҇ t\8 X-H7 ItwT\g(4YsTQqJv]f3VRdBPXr ,@ˉ<$ J.9`Rt `(GFvcۙȖϫl :t8]أXLzp#><-r\Gm~&7 ]u_H!0XM05Fh,I;#wbzxĊ<^T%QϢZ< xm[ٱr̬[.ex}$6 m/J0(x%еNe .Ή| [#I^;6‹-2a,QDzY#Ly5}0+M #c`f=o,JbOH`II#IGs> ЕRmW3kR+WҬ}yX5 _Jc#KgXY59|>B.m$IyX<,^O@IFeMK9y'<\ ?G Ztdg@x126.Dr|a9Põ <%fg+>n/*Ein(*no\8XxZ^wVa6LwSnr*ż5o&0Ov9)dT-s[zA{ɭj-r2r󑈲+rWƧIhoH跠F4,Hkpu7?,){ &z WAH]61|@rdWeYًhsP8eBC#ϧ 3 ;-%Yk?nnb?>Glr>66E y%RwIqljsxBZⳅ \$l(ѷىjyE_-π2oߙ&l7(N!k:o6MܨzVo jø2˧d5Vۅ[tDS0diYSnrE ]V02#Ec)b#}S p"0c b L$ZNE)gJ۴kC{1;B/<6tc;8MMi@l>hKO`&4{ctBI.Ib1A&-%cنUP QzQwM%?|_2u<v 4c Bo7_oˬCj yIȕ"h| ׂ≁2 ('6!h Aop$s bP˪kfZ e 9yaާ#s3AerLM.zœQ½`zxj!6(˯UiqˀiES[[|61 h+ٿ2b/) eCb/91Ǻ_0{-|+ Lt(I|Y]<m('5!'VM u\\H}L೑b.>,FTGdjߺ0bMWHŨ~W q˻˿ڡ 6ִ؇/-!b~s{l9O%g>͐38cF' U#j{an2Pe.Ħ?Ñ}Z;$7&&}`ٮNکk$lo%< a) yG-Ny1ֹ1ơ]yzfEy ע9v* mIx]wԐCW- --7-R=o8h5v0¿t y"C& h '5y~<3 GeLT:y^ 3@h9W@'"~<#S,%5ZS.#+ Lđ瘓ˋZrnG/<Q3MF+e2t=4% !{tQYG 1a:M}Up>p4ZQr@0ZvLEWW]-4L{p4ֈ O2L(j(Un,t$?mCk'^/O$bl; ϪH}\=)F m&y̳<.B5֫@N:j|( }WtYi䎄KyLzor۾|$ 8EoXlH}P<(dR? W3s}4u(,T Hh r2w6 iWZt6u€O8 Ӹin)P@+ichT|'A|42"r r|NGavu?9,yWVx툑L"sE8c',[Ψ5ظltmJޒ]\<YZZ L3'/vvCI_%֮q j% JTeP-@.Qа,AkI4F^B\n [@b@*ɛ5SYnA[#"SZ.q@P]30[.OUX 0r0ς:0`f1S)u3Ib[,Y?^ONJ'Yk{)'!KG )ʃBHbK D~"D-qAS+_cm/yL[R@J#γi"ѣI%굕_EO:wu8æ޲d.wz9_wt :̆J&hJ[rz,~ ba=vӗqwk~=8UCwt5<zO|8 $oT9> \3tYFmC$6T8*yU%f>MCKP=?S0KNUV3!&r7K=•'˝m*iNg<-g~ ۅ3ʥ=&=?LٯpMɷk2O@b:#%ǺԨho3}."/T({BȻ[AC%pIW#ZL+zDž3q__BaFzbU\lLxiHg!_V"ܴN=d*r>AB6)LO eIYlR%obZߘ'JU3Њ*Wo⍸ЬFF}Qau_LM,޼j)RSZ .Uܾ"b@`KgμA?48DRҗ~'Ei6[p;Sam|;YА*hNyS{Z? r&QtA0c[^z! F=[{c0[r]зM>!3Y!'M98Npz,&K{- ^g-}gPQ3 Nv" MZdHҵ t 1Gh0~D:^fȡ_z;zW%d>RQp|SZw1߆E NL;t;!~*D "y,Nc^U8gPH)gϭ$ +lu7ɻ(D4@kOǾ "u- pHF>Г9;"7Fű@/e}ˇZ_*E9Q>WXX&EX[ tݨe3r/h%bN1~j_Jv(63K?JFjyrGLkf!jgiZm'fI6(h` 4pQ}5(a+f͙hJXfs|Bś2']@{@z`D?S/xU@:zucL}TI(X&yF_! l/4|S>0"} y*@&PmBOxk Š=M_dϊn0A q7^'D}K7Fg X`BQ^osv$rp-,C\u '}Zy`K,ma _p5_ 3lV -pT1P}_ 5?TS24@d9C?$6n#k)$6V;hs1Ckg])j)>}:HB"h0¡Y'ORkqv`}wM}Ydk 5 ոx=龐ag'xkx1ʪ*Vxw'*yG/@p'bu3+#C ֖@zr~ӗQPu( `@ǃ_ON1Ԣ+[NRXbN0Ao 1_1+ԝ2P%tWIY"5zH.e,k;M~ayu#q|Y: ƶ1iwBBj2UblޕJP$_Ef@SZ PeX7w&A!=Q%dξ=yu)#ځz%pKqNbt&xƤavl{> 'y7_ X~3 f[۴;f'!V>vQ20f~W '8h(0΅PkXEO'ݠ{k,Rŕ͗wcG *b*^*(c oa !oHYBH^ޘ';-8b Ak ƨL,BUB_8 ~)sP0 p>Z\ɨEnGMfdKtB7N36sĔ7%N }|0:Tz?OEКi\};҆ZS\y$@Jǂj:I/=ڮO}%k@&"Ѵ75㮫s^&!ː\)xyd{MZutMϿx&y9YDV#y'bST9|<ńwa}!Ui(9.g"C^rWEId-~}~"D?A=Z9jO!6JA:;R%ex5.:a hۖ^*bI3&&,K":wֈ?+.x輬.|ӤH #3ٹk\^薭}(JƂQf3YiWg5xXD^z@"\skݯ}w:5T$`ԜƟI#72įn=@S\o~y&$>6\RҏcH''jPA>+Q}syN@$1D>3yS3Kn%\dF@+4JAfo=`8d3dCZl_}-=/!%&( )Qc^OLs.ua]It{1h`!,?~ WUaEK4n օ/HJٛEQȌKҀ E@~ _X߇Bomߞxߧzy2-w7̘~x֙K}vv8{Xb1S+j΢Ã{;[ߝCv{|_=?'B|ԅweҘhvjH]PtjKHL„"``zcJ]>n%dxbUWo;Ct##O$˛q; 'Ӯkt+;zah4D|!CǗ!<htUS>}16%`9BM--!E<B[~v^E2yo7r&Pf ̣tq{mCFU*O xS/{PS;rfW0x*b2M$˿$VlkwU'bN][IH/QF64eŜ*9gjB1%W_CנKafÄP},CvxIx1.>c= àDY-өB݈| 9ʤ< [8IQ`!@r?Eߏq*VՀ luW_o]j{WmE{Ѿt:Mÿg۵w^[Xqw~ܔ^[]er_[cnwm;W柿;_vOë~+w{5KvYZS=YP=giҗzZ{?۶7kMn?/nmPA}~{ۻWT?nm~tވpYAyڮ}u\[z'Cvݵ]cq޹e߻?5?h>Wk;Oпgw}΃6XU !qN\[}s}mͶ5^~ =ۭGּowmҝ|]Ӿ=G}.:㈏S֝{O^noǦ拫Z_#]nb/v?v]![߻md~}\oiZI/_wվּ+yU{E~kjv?tA5>XqnGh}oh>qoWOjyh?vw?vݿZj{A_v_v]awLCaI 2*'cR1~$4@Rr @$BOOWW#si6OvnĤ%]qi]sk u5aNr7,P"LP_#|h%Ɣzvyu@eXaHg{ ?vLy%#Jˮ#6씩ʴ)jn+7RgDZq{hϧ%ɲxQwQ`lu- ? DH("}cP^s+͆ jytyV|]u[W Oќ[ ySkw 0Չ8ESUTYbSP20ߌp_[;ey<^LuMX]Yp-^H"&UMw9o,l%ì]PB8 <'CIq.Wʸ#>#T|u25Ð} bj/;-!-čgBi;N ̬oΞ =FbbۤV{N 'ZnnWVkWޣ//)r;_OxǠ#@t% |F@$Asj8&v&7h93G5;]$/C #R{jtmMH !4hr))r x\gr?tpe ,(Cg˙!;5a^+¼ .]mƝ#}uW2$T/`IXf0-ڸ\AǭpzY| R_]KևL$ʗ09*eqJ=_˜*ol6G4Ʀ$ү$ WGq˳}y!yG.}B]Xh\"R榳)s񲀥ƙp95|p<I'\Slbޗ!+py,2x\VoY>7 "y+4"u _7x;ǐ)i[_r_Vv-ƃK=m3xӸ6S~vA=g6|-Ȃ0>$* iwYiHW*ڃ1qsF(5<2m#&qWAo6cۊz`@ Zc-n;@%ԭ!b!10Cmm4:}>%/lo7N%sW(֊ld,Do-` *#yMSVROư{ 0 =*J/=(*\NSBg!숼hk~\b٘ƒId71 Ǩ(<9Zå/h,2Z@ْӃǮJz?Ov4_ikRrͳ|?f3vz N%|q3N,"E F>H՜ g# /+aT(cgOj1+#zO!AJg^wf M | 'e\ _(6m/HstM~#%Ó3ߒ,3^w'7ܰݞ WeDX ~F.@1ChNxndNW&MÏF4m/% ]Ĭ\/t6;mUn~%>XZF  '> u#S9m}8<+W@3I]'gYkyP}m#bČz@|zG6Y~d" > 1"u-^( LVVWOW6 Zץ(;1DzCWlՎm 0K ^dhyZo5fRƒZ^]B_ Htos{Dx{9T'W+6d:pu{Ry+ c7*\C#TBel+aLW5*C 7.,A]sU,㵟fһ5ENmK+1 lFk#2='ō03@ t~eP6Ia5*CT1(U?j;\Lu~0Ɓ1_OՃTf\ l(Wä%4px@stIGB.ע50<VPzb!}BX_J!ՎB^ XWF-j33MyӺ1iL[ xB7+aB 1b F܌@ `TAH@;9&0;63CΈևgu' ௿_m'Pcr㑐ke13cfdKV/SAgkZ[ETPs`>IAD+1'f4* += g yTmV hh/H!q%v/d5}VRxd"i_?Ŏ` 4&?RF}1ݽe5𸄗0eťeNb愑p")#rRoi(ȁ^C9 d^%4>Z0~hw@c7+Ҳ5VྖX߁DE'B-|TM3$aCR+]K 6}z6]tM '2-pz`fgM~ X"e"bNL-A+;TUW/ ! Jaf&wRf,,ݮJS_򸀃 hacҋ6;%S+>*p\)#iZ׋۠"5UGU؋Ռ}=rZ>[nv䁸ܲ.#(jBir CdwA8s%{泤fW/ #[Vo)8PL٨q/_hڻky!nOrt5CRt6$KKa[)7Z@olXIH;qHybd,MzǞI?==1"Ǽ-돒噇JY:T iX`N},< +VMt٬csM؋ķ6L#F{| k#8]&O#кҮ%qP+>tdQjAw!*62Uko^'p8$Sb4yfG ƨ%7בx;4i`;opqeu}߭yI'eT+/qhW , cJ?儰`#E*:Tɑk Hq O`S2{Jjk]ێL#L\껯ÙLBCD%6mi^3!sq 7 pzcgBrNÄ GT! 0?ԛ/O"i>s ] ! #p1scH@)24\/k}dמԵ Hu{AK͏UKi 2ŮeBG˂IĔ+-~@؍C8>w4"K47ס\X1v~^'(M}T\Aˁ́CZAg_~śFIsxm EIn7Ú@Vxd8 i1WkYz8eTVYH=$@ki],9dg x4@GA 4vƑ*ߝ¿qlwU񆵱Do }X'6bht=ѳџtYӛDKEڨIDgjO5`P*Kφ>I]Y˔#ףfiMǮ0R%{`Jo>h YAjta MX#Drv *F #!?Mtc{ Bysx<aÍc4SA|>W{(3)00T &0N|+%q84JIYiZAV>KwLD5YvpWbkf%I>=PqґWjsA @b> DRJ~ ?{ގ*DFKj.NlЗ:܇ܹ* fe(چEsXEq 4LLt4mto [}`:4/HP"ܬh?D1LO0ZJ[(:[aQr+> {T;x76 ?2j'1[ *yQw_l>ʊ7i-=ycdx@;FyMX˭C-go16L˷R;i)ua50!Q&$8;HS`Nb^%iUKDR~|xHbo>8!1 ĸ:~mL@ʟOTvO>#Oq:ɳ#_-D]d 1D#ʋ&ubg 1-c ;xgMM.CYbĶwwflqCU?8r&a7B.#!1'4(Bӎ|X=[}ϗ43~O  o oM^ $HNyLwϞ mG;h˷o 8OcmۚgPyh|/c*'Iۚ8Y N :NQ> ҄7X۵+ 偉vX_ouGaNWw2'kmh'|v!1U؃f/9N = 5[]4$ճjkQ6ٷF-YD.w p&m;שEzqMV:ijCk!G` cY٦ hjN}X1K* N=w#^ uˬYS QC)68b\i\XPAٵ1ᔸݶ ,ÒAEZBSAܧW69jGsgy6k]rzμ4\\Nvh zcB)Y`$ųp P]Wd6lNKwB,5/0F ^[ޫn[JHK٢ _¹jeeG>&04=aΗڸK&Ap[$MLdٿa߷s i5&wKwVD 7pm_$B> S]CQ1zU` ^%T pݳe/P{W'&Q r\7MX-h̴`4 4)ΔrʙaIE=15R_A ʱ]>OoBPtYMXL²iژfe,7 LXzsc}r9i4^V,58嫭s:$! b֌&qz.zbcyN&_!*&jEu hJoGaI`Z; q>^ܨa'9OZ2ΗhcDze dKq4ю.i-KD dD_[C]H*0PSz"?S ʸW~?#Ѝ4@.@?sAMYzZS{Ԁ ɉBYt9鈱3!үvhnī<>`7Sk Ne+PN_o6QVTVmGz'8V 2Yo(טw;F`9=sZ[YU M ;-Rs&O+^6J!v~oalɗr=2r".YXPR^E]UG;BAzNJ?;zo˩Ut:#>/'F&,F9ȩ' 59h#i٣>ؑg]ueu&%%7_CNUɊ:+Sܭ! sb6%,QjܳV-U: rurv;XpktsN,=?*N\$1'Io!P@#@QrHk]/`YT}xT^qj%߲Vu5 Dk &e&|A 0E ¹ ʶ¿jvxj 欣-)%N7GrR;fUa#m6`; #]'=RUuMXh6Č.}2SBa'psEWmZrZnmL"pRc ?Ǯ7O],uĦЪ LGˑܘr~ ~G79/fWݠaW q1`vvdu$1yE|g%r7wo2[  _E5 .$P#7gh&;6< qBo{3k:Amh*(p7a66i}7 UC{[мIgYD壄UɦC¸f~\ o]5uLQNZҾ /(oh ? ̠ߙtb-y1O|^׺_\z%-e'Rwsg-kSmngř'DF$2/L^M (_fRX9/@&  ;M97]3H.cnUT*5΅|esX!'مt^ˎ? Av#(0Yȧ")2(-!;W@Ula6]k] ^ *)F]eEXbzg`u*x_~unX\Ff8ɾrT$ɉ(8?{^%K Ttܙo0|2 Zf@Q(cp2PtmqlKc}mf6JCAvඔB X:)0:2Wr/짝d+抾0@|&VA|,BsӃ591ELg/t1''Ӷ2 VM19NY|Dʹ4O&20~mj= t@,bn.\/tqZAk% tBGJb ѧxWT({ 9Mk0`Z_߼!6([snKis)@).g(yo|AzيHr?_#x_I9ö߄i/#A`^ן&p6L' CjpqbPF:,[dG5OSp I:+ڠᬘqJM=j}R#[N ǞѧJ ^b.8 4S gUu) Bl_$Bmt3jϙ#+3(H'Đ(:iUѢK"唬9N1ZC|.峠zlBe%&YM u:.U?'in,/Wh@_n_9qh7[Tp/a[L.Ӄn6 éyzqiճ|iQ5 ?<Z!i1鑙gU ~lÝWN# ZRN5@`MbGuWP[9nv9 q۫^qVau߁R f XA/P~}AӹyIbZI}KbFq>*a}̀hsy?</fE𵡺f 5V61 s4 yœrgk C+_&C>;uU?F9Eh76 :߇+&НX:~d >ɋl}"1΅r͸GWƭ"ρ)2^Z1-Wx]Qb$6kVvDDr-eof:5TԕT%TLY퇓$(?x.GOzЇ+7T$qc` $([nZ^tM8?$i`P[>pURQ?g*#_Hb{_68>V"D%K /+8Ҟ# MS7Oۚ@ @;HUd[[EC|i=*=>]A,zdvPCEΝCb%HI9MՃ ՠ&BP^Y9T޻{3꜏FYb,>|@yu MyEEШ*^Pjߍ UأL1𺁿h&DwN?guBM;&zKD'S( M#`_cߊ9|O7K#&@N<0fNAYCf@S鷵l@I^yT]ضD^m)<֌Pނ|QR$ElW6 )z"вrC,u.Gj{~,6eTAedՔ`ywW3 R=݋ݒ^,8Ȥp @B5 }sSfyb#7R, gqmq*Jðym9eB{4OҗXE M8 j[$VJ_&7=LV:k!~CW䆯x΅J&kźB8 u=)u8ZJ],8 "k|}17xqK/VeJhհ=Yx8:m,q\WїX׺82S~gr}[6mB3]KEtG`iQ]-, Xzﮪ+Cꮯ,Q ֿtbbWi{h>jDtDq.hC

hs)qLZ{s)X0Iذ\/ȀC&Ss}\Vr|yjMKhJ 8,HVق? m8/qC|S׸DQ(QQqk ˮ5?!c?y'X0(Vw7TV B0Guߣ谰%.]n^YD[cy[5Bw9{8Y*mC0s4ܤU4Dyeth j Y:WmZrhT=aQAL8.\9͇u㋇7#sn^qp` +H,,y?B 4<4LWѨ|Vjט":sx+NPܧ B.eq49-a,-/|[>>T)U ghU[t 3t{pKBBy# #dAmwXXc%Ea,-z=Vw DyJ·mw.80&,]9[aIqNtM(!e#NZlpIg' <ۋ:(N~<`aP qV?%<tf36J*m!r1e^VB"Lfl=B&-> JFmsZosΈn%y-sBKr;Rw lۤ^\<>(6טjqIyOދBfF$G2NP3ΉU=X;}N`7K;+&KW!&,a;vd},EsJF3.~X/wIF8.8_)Zʷq#ڞ+}Bvy{^kA:V[S2UlצwIf+ )X%αu^Hqۏ%{Mݶ/%N{x}VpnK*Sg^F2N1S%r"54*`g0ƴUZw]1^m`ok-Ϭ6Er( 7P %k΄jNJHܕW6UDnfN`T֙;bHϫ .Mq-:"kM)rWPH~$XZ#Ў R$ۆrM# EtGj&5XQ,ݲ7Nq7!s6wEH]g{5Ő ˸Ӏ ӗg:(3!R.h+ Ǣ'JL`eimۆZd"HRq=}APH外)xtR6 L} ="l<{Y @ix$´.wS9"*ޚgN6\4c;Z04D(id0ɛ>7䃘Q_~`?F#(:>L ~ HM#$}:c5)B#Nʁ*?߾. S< $"Ʌ]J&sH~Ђf8c}3۱~T&+v'ϚK^Ћ͍2DQOv:T*Jt)]udtU~GB\' 5S@mXflVYkXːJ?5ŖƋ.7O4B8_mh.jIۜIiAћ_8`3}EW,+l_2yS2Һ)@՟ gJ s*1GXsQt,+e]N $ԕ*Q%`IRTxc`ZLS"phWB/VhJ`x4XV6,٣@eQ>mp,خs(7 7B[BPmؾ:Kd8J^#jƼVhRիiJIr̊Ҁ5M 󔦡4䙨o>SSt%;Hx@#l^e5Tkڀ(.]dhXɅP8aIDj|ů`).K%@nߓFtOɨ+@cai8ɐW|ӾV@$K@(D(_pj\sO(,mo&ʑǸMn*jBfD6d Ssm9Hx8GGɛ¾f~'()b@F^߮S+7;~r e}tݸU 6ωypHUtUD`fVUWÞ5qc´BUZvI=RTw=Ewl:J^ r=# e=S [辧kCZ * iہ,hԻR:48E^rɝڵ) ǫ@<˽EfK]й:mWJRRP ϸ F,+#Y"͛/+{tJ.7{%Ɏ nC4Ʀ&U싊B nIG-tͱw'ʐ`A4À͆:tᯯ!yǎsĭzn1=Y&Rd D` nSJ5U[?_e)r0)/Q3OG*b 1 ^Qݴf4, YIKk{͊Ōiw᭛[f)HH+S[8tOJHkJB0J"@n]7gO\ªOw<] ;\hSZ7ZO˻yP}*W’ɭ?P}R3ϣ( ubl( D5=/ݚd>U|2)B!߶-rDin~NSҀ2Lg휝^bUSԃfT19c@BLQuIJn ZZ7UoV7".,> R2;"M*ö>y'mzJ $@5(m :YAFTÕ# pzYA[} bd;2UpIꗢPk眉 N֘K1~Ohj6KHAE l[$e!Ri7:4t"M4~/ߚSJ(6= '0W\AH"XdUD* Q-&ݬ(FXgV8[ >F+RN Cbl_)oC[gn,$lP{Q>mw5JD#jI(SPϗIFCZ :`0*6-{`ED[-{Bs0Ri!ԮKD)$͢Ȥx Qt܀frFr0a q) o.tK̏fi؂m%਄qRe!|IVJ|m_=* >&v?ZM>Xv wtx?&te/H;2MC)q!y˔6{4UT!ltBPi,:NuTR|dKRo"aVH< >KVX)xk< y/_g F@扐/]q0^l%Z+u (Ii/3ǽR^5nJB=iez]m)(2=}!bTwo@] PՋ!| YWcq<\_\Lӣ1+.@2J5N`7!9}ؼS 'NsRoZ߶i+AJ7|Vy5C 2ޗFi)$MND:6A0/+y& +(u|8o/"ΰu|V߼+ibFWJ$uki!@ n-YOw̉w5>t8vUx:eݙ^F ]+"·pTJ i(&wvL^g: @7q"l\^U$xJ!_\1gl?IMMl\!eLydm`]_B1m k]t e9 bO`RBɟzs۟/ڈqI>"⥏|irh^Sl䞐-Bj3g8Hu/bq:`toK\`._3L3[&ȣg bʎ;yř=~~Z Gu9iy(W/,w"$]v `[$d3y0n/(lE&dgKVuZVs@yI햠B\'q4/b0Z'Xx]9{$%/;+Hb1r ގpGLn0{ZUrG_2p,o֛*e򰤘Oj};P*%%ƙ Xf}bXxsXr>?!iɌ|py=B!8W~Vvɭ.zUM; i;5kǛ baH) 'U@5N~\)$EHkPMQj6> 1}7 CE\Fz=NHUjSR-Խ"ljez uپ Τ(!hlzNZOvz.X7TJ^1<K}Meae(HnLo_Niju# ؛53%Um# c>LļM z51HŧEh5L\47!GG&L{cIXa c5&ؽd@{`tϤ9sed S@~!:j.āmPeVLAtW|\>t0k2S- B{$s)GdWc_n-ίlZm>݇ȌgUBǴ1hE?P"q;LAR?Y9Ld ~8~"E18LUPr3;Aud5-.Rr\;xl;lĚ|:&ǽ[b` nʭSbqdr.ΛD#_ m6}*  3{mY~+2f|b LRq&@fH@S]JLt&S (s;`"yE-mJH'38N<Q`'Inu:Z;3y"_չA)I<$e4zwLzr*Q([m-d2QVGռM͝Ldi|l'{G+v+}w, ))E9%#EW51JUFGF-q 0ֶX]}Ki'zvKqs48Hᄪw JdYO5%eC|a1$H/tQf5?F֚~UYmm<#;cߐ_lN`όlʞHZe.&39|Xͧ\1` YZi6S: Ncd{aZğJ$%nJT>,{b{sQ0B%F.+v6]X}#Ma_RHn䠠6 d,KKT4nrgYݳ5BW=n[s!8O`/T 67qj3w2 A5j5 l!I}goTJՈTWKTvdcoc]+,<_wLHKFޅ\+2͡~@E| o")M=gjP-pJ~j n@zZЎsTTl_OW PGaGjemGANHҎ7@ udMU(ǘBUfJ TͰ StpB(*Le衣cY5@tc.mݚ_lᥱmd`ٟo+ϗ\z-UZԂlyu4ޅ9voWx/sckYeER 'f_Lt V5ݦm&gpERtA"`s6e6/ܨ?zm(O/`:tK&2](7V1sWp7gaU[i2=tC8#|ǭ9NTAA=Ĩx2jd)S"}p(HcrR"bƯ'(kmO h%&HZz_&OLJA!dXHn }]k:.n{^4{xXS3fmbm+}F_dcUb6 %'kxFt5ܤx׆^&ix7oj7^v)Tev$rmU3ǖp#HK뵖Iɔ9/7u=˕w&=jxdgr,Iӂ̮FT(|1 JdjHvֶhp:Ez ~3nyuq"iFDڋ Fd?Ėżq􏄻0c*Bjԙ[Daegko2%.ЫeL dlHgɟ'HKW!^%xfQ([M8=sHgȍ#RbtGXwUxI#.qP- `=VC$KŨpG%qm"w/dy'e6ĚyzrkAC \d%\5?SQE&yaxR)~&Ճw2(A_u/`Q+W7^jDrpwC]- gk~Qï]>OlY*MV[R& K{7-ɘT~q4poP\' Bpj -^^>|| fS)'Wrh1E@(7qGݷkg+NpRCvoq3R Kbc!{q<}$$U[n J_Y7[ItB0AwYĸ xvlX!oBX9%<݂L5OHW|m֝l}"΍]@|GfO$RlS^K U1vXگwP$ 5o3#țw۴c`G?p?K>"0=DH@p\e9|;)G\|HޢTRy?ÜUݒZ}yne9V$ZċI9.)J_M>& B:7xL; -\m"~x?T&:zi\MF3Ku\bۘؒ7rSAyUt!A2 _4fWZ,9RW 9Ǻ@o_PT_|T4 Qt_1:Q-|0Y3#J?MyAϏՆZn0}OS1J"gp5:@8J/rxb\nxnxßh:zz*{Nڀ.Azkr#C;Q)ZQqNPo Qc0R(_ }FዱxN,+MY.'g"D4iF#KѤȁb?߶l`bVlwg ]X!d 闾~ xe D؛PT7mQ@ jgHLAN-BZlNhyUqk\jt|םmZݞ˹ 5n %/Hɤ` -ނ=@TϤfھ isXWwN %0-l.`/xc?ׅ ;,CډZ>~l喝,R Uu)'Ts;f2F`Qwj_oᶢ"x|":^wy.xc],I=5:/fڐU#T𾲑TԅNz ;F QKQ#On_ C W06g*/8m UT$*(DOU·tii$T JX)Fh?SgԜW2f.b$ LOdc(퐌EkIJ [7-I7x"`- ?|5Yݕt`wu1^uF1ӕ!@x2[?ꕭ-'@\{X ї{_Iޡ5K>ȚU{ 27e0R1cW9 ix"oL vTNHz-ySNhehLͮY҆w0lWNg˩%'q,K@Vβm(M ~x<{G}$U.@$?,X}O%MNA0a-@m.6i{z@jATL{Ř1$iWY@ @9$_ (ς#+ޒ8'dkjbra'W,\Kǔ̓ v\i#{j;diH{ɞ$$.CGLۓG<ܸ1l72X=Hյ8\W6: &u%>M.x&x6ZE8# X[n35) VAMgOcތ"7 K!l*A })|r0hvLAbڬӾ,,i<ƚ~xKN/keb yl`ʏF@QMr:5;YI!G8XL,5/hp_cE#,QRtXm:㬛}]Z$p< φ(?GB3Vpks!alZ}@6E[Ҁ2CTQ^a[|~|G9Fr3^ Bɽƚ9e(߭@ԐEͬ]5?8gI{K,گSbudE]?0+`.EczPIh@D=;^<OƐhoyox,S6 tZiXOZ7ҙٵ7QVBVCZweCAӂ2u ? F'0Z@eg0sD7^ m2Jpߝ: 7=%[Yɭkbx% L%db`Ң} >l cbv-dZJõGsT T݉@eTdM7 r-KpOQւ%.\ZxzJrހJX([liLGVsn.l_зMܺP5! sFR Z //b''8X֭¼WKSLdojJfi Drt5:tn+9NE0CK'-(MT:OioXάP~$`BQk-T'J\eM)omE\G2 /&j5Lf2$BӾe:;1Z,Z[2\ܘU wa [ DOOddt r_)7Ud Q|]{)/@cvHI)97:H1Rk9tB D:tر*|YOXإUۿ?M"$P+MY +5e QoZOF X*R8me䉍gwt^띅_[۫ΰh]rZP_EF@68[tm1;n4@]ෘ8QmahEU QE\{xPٚH bIߴVe go(!|h/ݧ%_/ϺP>>XPbqFC3N3xFƅ|C4ׇ GJǧ1 ٭)XE/5h kb&/%~I43(,jŔ=PLz3iF³/1\8GہU=d!"o&ki})V3ii+{ڞ3yIkp'8FF6kIp#l[e1&g0SP=҄҂k^SG o|y`VЂk?pq>j\X٩"&f}pwOer@|?:NGhR=66)ƥy[x\'4}:@ru_N兡jƴ&I[AWR[gc %씯+Z\̑3]/wB)DG`e#c3me{0d@AVl6d(*䚴t ^Jٙ˓dEl̙f^9EdozAm_CسԲ%46&F/Tc* !{L^ҔV*AM`cWP_&@2IѶѯoOS[vB4 MQ>)=Pyg4c>h}5G0׍v o0EH,pdZ%" 0Nu=6tb>[&H #b?U]hF`6Δ$ӯi6k"N U@0 %NGƷ'ܩIeɆ^c;ؕ,|E诎4>W CQ'V Ld-5W[x.B^Dej=x DvK&38)e>N2-GSS7}. AGi2 ۉ͸rM^TtM snS7dM4=GyƍDX>M<$G~)XE9t1[aہJx͎cE$#u#힛*{cf 6_nͼX,b\:M"mǝ;4~$d2ul{Q Gzَqfv |j,B#qą %$o*'b0:~ {ĝS!&.^=H_SF{ eeJ}kH&T~y*)N3ZKkf2Z3"f+!rR0t@v"*{Z-ƌ ^/=Q·Y` Hy~&S+Z^T7G_?;Ld'%Bkfbm4Av=lSv˷Sw::45T>3Z4hԆt;h\I?JkwJAnýSY+ ON +{wR˽*+NJqF2Uz0L^|.5GB xOg쑎ulrj2 @Yz i$}q _4+y"ķ<'CJ0BYJpN>j5@]UC2MȐ?KUGAnZۋf@%FFٍ@[ f-Xxd=Ū%z,희T|ڇĚHzZBIb@%#%]\r렙i,.Lt!:>gJɦULfkEMw-kz/vjunP4Q8X ֤a[b5}bua )Ie XD#>j}>U'2'퓊!.f\Qad`R.R%MƐplaYg6*6Im+"S"pN1e9p*$R>O^D*bw⯋SqƻT&71-S< vp~3)nA_ŮPȰlԤǻBb RrAjUs&8|`$A;ೳ4EӼ U^4Kb[J;+co@ri\D w4l )e6B֌G5HK Ǝe{DdGЙ;_6X_3KƒP9dȃaQp^}bg__}}ǎ4/2D _IL~f* \ǵ7d=UcB{`#؟6rhIF`K$HQwl Lͳx,>UJΥ*eA{,alͽY70G0LTيyLYb ߆DM*@fS'B?BY760@my/bDџ%*jf~TAg~ kjAboA7E(jJ%CdO^=x—үyM=*_$ ѽHKoHgC8Ց Ζ UVúfϬ$$&Ӫf.t',!^T5M}i0WH[-Y >ˎ|> `VV8]`C u FkB2p靗uq9 1A&gN}̫WTj} ( Su%U@6(.$bLWԜm5h*; f]27o:h~ ݉aA"C4<[E&oz!&b hAh*5fʨhflos`شZQqB7s#V:=pP%3Ǘ#$:RMov(/Ăڇ?hvHyo4C(.FuF.LNUQEo-!*R@]. W^g5MPw2bIo,+769HF simr2YM<E~[?xoxġiQlzE'16r5LOc*x&fE=! I  {ac,T#@6RUv$A""}{KǎvVZhe?KX~uF-:vMUS7&FNb0iЪ(sHEb%6F݃'EӒ ׿SwkRgT )#,:ژMQ5NPsMFK%eRyst kKG?&\tZ:w)Zӏ_e"=~0$!7t> M rCAy,n ;DG Hxs{hݥ>^(5v䮑C<B"{L$ΩL?@0NAq\@b??F3Z${=:=F9e(.IWMEGM!x%au\*KtyL#h/=_t-U Կ^ѳcd  VA2h=7=t5(munu/vΝv櫷];eھvv͗i;H?wwxݽIwWнto75οnzs^Χmtw}|u>t^nsv~=<=;kKHնh߻ln?-ݼ?ml;>l'wo.l{ۧo۾ӻuW?4׺o,[jEӶm%hݣinv_vVmýi׽v:i_{C[v]ӷV˭_Z~yY{6vhoڕVvϯEamwnݬ?YVҝm5]YumsS״;nmѼu[W~kkm;뻖;[򏺯县Smnѽ{=mM_vy^Oo?>ju_c_~ou4gAϖ{AUy{k[寭_gmگ.{yGiOWm_Mwm5Qccikռ{[WǮam-^忭u=kQϬo=>꿋]u|? ua ~Fn俋*z) ?NT:ÕhH ;\ >vNPfCb'Q{^ ې*̈ZKt`vb/QkW} *͓wN52C5[pIPΞ5Wj ߰?t%[OJgV:蘸OaC@ji4'R㽒qn-`aNz7:COJϐ} ծOf:*Qt~ *ʒ'Y6neZB @zS[Mm=*ǐwateEG$hA C{Б1ʟװ)w*G.u~xȴ@Տ+ -z0bdZPx4yi\ț4D?nXC#b@=@xM ?N9(Lci`{YKC9'Mdk_@R@DZhkto;WY~7P 3sϖՕG;eCaQ[J2Uf}sc\`a%&|_ Ri:Dњ3nzsݒ'rq(=[x"D.ȫsUҾAnP|́ry?I :DJ|6OJ.{8E#r,glvJd-TwF-%(N ~z3%ʙ" |zI@L(D+q1Xֱ i@AsH_Q[boi],m fJ7,¸Hg^g|@ dVq t=}.O9}KU20"c< `$knkb#6ҤInٌe +3G!RnrH!l#=r9G9lv`bl;-u,Kl;Z3اt6qc͊&P:kڔYoM%Y  XoK\̱ ֭ZYxi`tl8x5yS} [Bg&+ lrhh&҄fTBaou+-5異gOi9]9PZzX sPxT*Sڏl+w DVBܓPa@,+8Tg Xv,PUh_+)e;Ne#`.LCgE8+A!jXay6`SBgUz*M~B@G:>)χB3c_2͂'/ =ਢ #+aiu JsEW>TI廘0w íJ]5"s')eǿ'E?$sLE\(Ub/㷑V1& Zkh5,>eRi9ٱبF~x]bni,X,J_*,+#v7eo#]Lx5#^&=)jotȷFT4%\@9X@a `PXGMe3_܏pBg>AвTvK`.U`} I˅V'2#ۛGbk:2Ǩr"5╇槝VtFa"ZB+jJbhhU$Ӗt;=w@Q`w3cRM 񙜚pY]^d FLXh3&*eO@於(!>R?0'x.wXY}mtgn=s;*{XuԐcFBAso\o#ڛZN1:/ѮŷX]fPN5s.]@k{Nd.E$x'a~US$ $K ƈ"8fRe[.D Q&JnDkQ}@_kktئD3EIZp\(r*N'N"|z)ү6]1;b7A:+N5DJ] i)3S4~dӞdhy> ݇Q§]mҁtq_xGFz4/#<ÕGdKߵsmݥ_)K)kE0íZ56BE2f uWY5Kg_/*8x_s/(gٗIh\Rmpz/)+!թjSQP2 b~00do9IɓVhQ0E#Һkd`~7M; ղVqzGhvnRڹ`㯗V5~{W `M)h.`-okoWwŔU8Y-cBɶr.7tOƗ I܂J9+~ "JPF-PJIRŽ!s= i5/U?'#oiuYf +y :"Ќx2<2+A}+MpMZ]UaWrh̽ltɬ G}Hi9P[g$u8PI(>oL@AY *ȶ3{r ooXmV?&DϝgI8o YM AZY>E',E90YKVC|o$ws(>=;lx@yG A*os8n\hCҪ_P(V";6N S;-]&jSP ũXADdUIġS K&YP#bo%uo= _o+V (]5NۡmZ%%E*VH `gJk<PW(Ζg+˂c7o>]aT}g1Iz>%]'jPY8Aȷ_]C_Y-FK*?QC-t_ G[Qwzq~ʾhP(EM"ڑ"uPӆNn f: =Z+I =yJHfavSt~O ۝Dt&HVv/aϲ d27xsx5%.'6fXO^͌5Vg9PG;2 >VZr-p2ts{8<㗤 }g1yN$u)(cߝV>兕r68NJKeMS^;wb6  Fs N#{W.ż,9-,f!OnaBEO h-9oYm)R\֙; kgspW+)kD]\7Cc|!>Jsql98;15̚a>>Q\q ptxÀfO}@sc+RIA` Gaim472= s'!K(ե k' $>'*Y#NhaO%Bz hb%EifuͬJ;(W+h$H/Ci*>1m`FɆDYܹſQF9aטW,Ti#VhSn$ CdzoX'Ŕˇ؆f3Q}n4l ª-,{mkMX\VH׿>D~A- 4 OΠD@+ԘZ/x֏2ښZy #m:f .azԎFbDvcmD"Y:# 8-УkޘL:nԟ(@_u{ٺљJhv7k`|YyҠld=^H^Mwќkz!Op,xlzZ߫?Q'9.-kнb08e*Jl7_.W3sGICH?ڧ ҞU탔ȉ6c?Tw*7 W\Ӝæ4` H"1<Lj;jx=眙7om+C7(nذ)>4 `37 w0]@يN喩 KKeDWO]7KXyQa<&qz0)5/&r鿤~cfqޞl_ƧFgeftD(ίT/ k Uw Y3Y9Z{1>jmCe+{BйDC"7SfbEN~,`i1ee 䤲N/Qn4/``cC Ȇ%\׀-Va:n0Z5~kIʀ$X-ȍE sG`ͷ_Gx>l1oA1iCn׸^ntx$;eiR8K̈́s`)ϩKHN{3~)b{o`/bUHpW5luf< MɕjrL񪀭\  7-%P i cCxh/ KW+{IJ;̚bg<@c-9\kNrH^{Ce] vY;EmDeeeb[1=[%,+jXA ".-dvNLd'r&Ēe_]Ђ̹vϷ }SQuI~`׉Gss 6ؾ^pO[\ W:"0yTzLU#:lZ_[0oX]Ғɢ)X]mRhzm'%/:&/HTk]_gު^2DPR截.hkˊە9t{\" :HR@C6I~EF_W@J6G ?#'lc.~jɒ %m Yѳl5SIب^%~WyI[Z:U5P'gíh`:ꟷ̍30wg//5s"hY6fe:[yEo#zшu@iiRmG$p7mE,'CFXGP հVqzUڂM7\ޣ$XݦđO޺fʏ`Hhb6A`Y+Iu-(Ht:?-ŽUV/!Ն.|0zeT Ƴ5&悡--'xo]?m70wK:~VaDei@ѫcLHԁ m@,p졃YI)n]X"ZѳvDEu 8ᔩW}|rXg1 I2E9sG( Q-LyTi65x|1A e?g IaJQXq3a<*ש- F-ٜX]aaВ5G8Ychdִ#>ӌx3E9DIi,}mhȀS=Lu`< .Dm]zXh1-[{D }r<.K${Q{PM:kH@|XM5-*tI=n{x =Sa1 "4=Q)n-]v: 3U/'|՝iU+i[CH*sOͻ@ >dkz=Sbugz䲵nƵd|jQEV(;!PyӊA({OPP>/CxH'3%.O9@m3yg*{[VX`B\tVBv["Ceh a͜!\գga 4%EVjKs*IR߫vc<߭'[)U@O X`\nos.Jykkޝts* gC˞[IRKv_88Ąw-%yho.HB)8䑳ala78偪m ǘL2Vb ʙWELAΩ _c4")]J^N,T¤^P"_TK3W$6Z6l;0+i`Tˡ|8c.gҵXQ)@)H\::W$%f%|`~(}NVFP;t[W- KH_Dz2p$_Ӵ`㊤ߊE1$p &d$V*.H \ӯмn%vQqf$4xv| B+0`a}J!ƌ) O pd? 5+ystk=[5jة T)<\}JYR-nICi2v̌uE{CAj3'udDw2w2!rU001%DdP$6q#f~<%9f'пq -F+kjjҴA((y60p _9`mlGHG59tfv$.qB0. f! bEL5.|.$f0*БNDY`!f3xVܩ&,8VC._m=`ΛwSh*8P' 6sKcbmYڊ-^㽚 WG| m<~QoLz$ɺK =[<*l" VۨWzZߥʌ&xsX@.7= P\g)@JFـcEǤu{).s(Ô1d/z,J~o4Bu^%kkAR OKTE욆8nWk oi?cQ(kpBāq%ގƱ@DHie6ҿpװBo>3qR5տx}cW Ftzk6@.ɤSG} LYu#ٱnH(J8ËT{.ZNmA2SYLY Hn4LÌ* tBp~=JP0Mu-W}u-N(:K? s0Ɗ]^ Z}{rrĦ_oFAYwޥ ܧj BuNNn!\_ yvQKԠiO" VyF8%WxJ/=?"7MCk%fPF}hEuٛ|ЇTϸ7R3-29XM* r?VMR|#ΕYgb(Z#0ȱ]|@-Ĉs:1ƾZ<|^b6E;zn^F?y4p2̰ѩ3İLdPhOK=`"p,*2aդm.(pt!$%}~ah?@ji;-T6 )O̤? Ljiw)' !X&M^ǣRIeb{"X>Wh[ qX :_s.,) }U˽ťE 7>[0.^[3ZWNasr5u&#UO e: #~t4HZbXsr ߁J s1wHf?]k)3[x1i2bg,V{/r.%4@0DwU!>$?8S5-wKUT5^kk$ ^d|$>ksg~K3mߵX-e15$"]&8RhXʰ>g6Kq09N9ӢICc:'$cz몒s$< mZLOyB0i#ޮr/ ɻ\ ń`mQA"!&<1ٶR^ G%9cDk;#bk;QN->X`55~\<ө[==+}Vo,gfuU1]zݣZpWOpt0MD_?ejXZ78kN/b !H j$ABnoQtS{)*gr+?l0~;?$|{_eGFL? ,+7jӶd2. z 6)A}2xJ jtvKAf &/ƺ${.5O8ZTL vnl^{9|ǚ$c14"Oٍ )#/ ɂڽ0 gYs6J˓)1A &Op!.7TT KP?.cdn'nC z.¿Ty;\{ȗOD An#{+}˺w42 (%I8j.Ӹ1UmIQ/ KQ ݤIw{ؙ4n{Y[jI l_o3[ <4Uvir{3(;$X{OYom^Wb93sVfuJ"GL.#-;/* EEDYNc3TQ+ Sq}nMK,>Mv3jq AߺNT'wi%VV,46K_c~LkjΨ;^ESPI)4!?]fT3e)Kgӯ :h~qED]1A\/D+&d2t>kOHA=NKK+N-pcDbWwbUp t{W1`GiՓK/xFE6`OOȘdLdcw'ܪ=aڧHHՕ]F%4E[ͯ,5!Uj9E tÛeFEΨ#cKQ52%EhO]sC_ q(΢ћ5ji-2BhTU4&vFބ[l| ى"0Fkh@R8/$h]P&bx"ɎפcI*#qIoG:²4!-JX=4{OP0J$X"1U\6߽E^,d'Lya\›${rNQB9(tX? -۴E:2NÙ4Qkeet%SvkWV@T1<^ZuU)ɚ)aQ=+lpjR}El=/f!{䯚I]6 3]3|faý2"Z+"u|w= qj枵u8'µM:/{Kew-PؓN6! BwfOeBC1]M i p:? iV Kgh,/6g,+p9jz}PYO\t9Gf<>/uYk: ջ 7 Md WdSX:W/b/=vVN,# J 6g1S-rѭ>A^v~)D,m0vg(j"{\/s)Rm dXIXQd/fL+auu %erz!1ؤ* 6 ݻ6'4_^a;*4DbnRj/RW&<|+ r!U5d?%AnjnzRP&=վ!CɇN߶k6M3;< r|*:~ϑ8&X=bX,l]٧8"Heļ߼/(nEf(M4yDVTtmM" M:2ȝqr;:V1"N\w-$4<z9ne_HmuLj- `faA;672q F䜐{m0 O0l4_Q cL_gM~Q_rؠ~L\"T៞K1 2_6j8FNfh#Cf#ڌ8Lb[ }=+)T>XM?pmSϼ$W<ȴ @p3%sj'U%WQRzӡ!ȂN;s x.mȇ' .lcwSY@A): o@hϩmÚ;z2jvlnS2[n+*0tU-8/\s9&JyuY'~WU$v:KߪOreNNMjQbP߄ˣ4^ GwI_o)ǻMk؈<#Ja3m 38SX]V-XIn8@ R<+aB6{@O>dhS̏c񡄪Rl~7d0Yv\=jv55~'%6(YaǷɈ Ko X2vE n;eV@yN{ vsMC}i`[:7`W9.-8܃3n&*'=L vx $ O]\ā_ S c]KB#vLTP@X1ht[߀pq1 %| zO'=ˏƖu~rfjXn(3 X6&AWȥ`t]pGz˻tt_Q`o np~\Ot!7 /E$EsyZrdK?ݧRD _s=/UOz̈́Ic5g,a'P{= ASG%fO##6( >.&ĉ0$mHfwWk07$Ɇ=X.jTk|fnV^xjRh=}̓u,Cixp9;kJc{RxrJ9E_H9S44}ʩ4 U9i|'7~Mw^ٝHZ@8CQu}Oz[@Y92u1T~_FM<ko`J.^w*qs7:oE+׷XPƹtrJ G5 #uC:DU\UF[ǟ$TQBp<"nbš֬=(QӅV Z{ VVhhihv L]gn:^.Spk3|"P\RO^7'o_pLԬ{eœ:hn~<kpe8GjLI/*4d1c!:m5!/)݂Ԃ@A}"V1r|C™?X2?ҏQ քd)n luƙ/ۡވ/:%TDܲfj)X-ݜަ%-ͨa5֒"zR|d>uĤG6 Yçnxoų|9ɇvvڞj4FaXҋNv~`_ NVx&Ǡ;Tr*USZÎ>3}yTs5'0|P* 9䊭h pƩm6O*L5~j>{g(/cs*/Hj=̤DބEbÀU' voj ;C,. <~fkKɎ+wwƂ dDwX>fLȟ S&8uexd"zMq]5ˆUn^pvJ~h #Vn* h7:=s+X!yLTq&Hmk k3I֯,w!3!4LkOBo#֍grl]3rL&AnvbnU/BT"% &O+z= 1$nL6<#⥰P"WB,OMB6 zXo0L/+7i!E Gbu06Ì9`ac 2_-|]c &y} Q䊅[1)~0ܝ h.y^kF07MS%  h?Vߺw} S0DYFpdYD2jyU!K䂞Sg)nU7 Hon9T4f"[gr\W,,H%TA^RiXYRkۈ/IONWāgkU)wfJ5U,zCBRU!GF0Nr'}7ò- F/ hc*آ%53Eʊ:%c֏.pEנ|W (1+E+U0<:O&茓 XgBzM-4ri[]|*ȇ_FAtDR{ʊ) *x\kah?G,2u,F,X4Ŗcf#'7:<*NwinW ̮Z(†Iő 4y!$]ŽiMt/Y%4"&݋H廾ԏJIh}sryd?b2x+09hB:766aC'Pg%}y F v: > ~iz.3NnyV@]Z̲|Hͯ:|4cȅ$Rp>6S`!1{{Ӽn%x L/6gI26봅tE-nxI]: lLY4+>/>tJ)Jsʝ)f\rKMfCʞ[ ^mpT[adχ<.OvX F+>&NaZ61Qڍ>*F|7l;upǂf[WH14^y @Z(UV7drEAsz SY UV\.@tuQEe; jݍv~!fNDb_ ^zz|癒ȱ9๟* R8.>TtfӍz`(}Ґc'o@^zadO%A j*zI i-Aɢet d: 5* N!8=tu[>ϳf0Y jTX^jy-Z6ٌ~Bs/=3 1쵋p&RZh֣DxV#)`<\-uoqn7U{2jj:.38=uūzc4^=R7&u*]gE qU_=+ ڔ6Y@U2Hb[quS0R}O* +4/ЌLW㜖փșm'g{`cB[Q<#r>}kg~ 8X~x_v S{lg:3B:Z;)o q)dLUD4ljQR'C??]a$3o!0@BT9z1XcP7,D[y8Ӣs>:RA}9 [7\ALq3pOi<;+7`7%!=_ *-lmcNxKg@j/1q,c"OK%LHL3DޥS478 #SDIRcT/N6P+( *g}1#Od7zʬɳF sȪ_,&cC/* 83D.:㈬"_ҭ\9J:s_`t>6>=],=BzLzDoTKltc5Krǀ_ɲZ`|L ϓX65MbDx7ϣ&"fB7?!#`U-[K5$8-˓klh$!M-UNMQm\">M6m 1ghF.e?aNQVKt,ͦte7>ԉC4k'Xٽ&cލH ?ǒ"}*z=߅Cږ+K݊.pyEX;`=?wdrp'a` [7CUBөP8pDc&pVOXH&`SC'cPQ{0M‹#Zd0]K+ ȌBآ$nE!D L t7"^D XG̿wE"pJ+>Z$Ua 3,l==Hhԥ>!(;禺cbBE N6a w Iǭ 8`g&oM}zk{ȵLP,2} CmJZ14"¾vJt8MuDH{ $xNZ~s_<BUT1q@ `9%MlK^WX3Z1M_L@)? a_mx4,Jco [Y,"jrTS*,pO 4csg*zmip݀seEؖ\+6B(epY\q_ q&004.m@g[-@ES$qu"!7&TÈS FJ"gDžA)ub3߁qAq~yE!xZBq3=WMO ׯ'9 )ۭwT"}=rتᣮInNDq"hWe$QQu w< L2hZA39U[^Qt]y21Qojj&51twv~8j[:d\ojXإܵAWvG(C~gۦw,k'~@q EcL#yطÆ]Un8>Too-RdJIh P5{@]R# m>Lmc [69W!]tXXj#kA!,0{t,e3j W,K-`ǟx-d?fZa Ұ 6.eG+6-"JFz8 VW4i#c/J`ZN#TmzY΋xĉ]G@.WŞ{\Zbr(;yd-y+!URKڠT .ۺǽ|a;T:=@^uf>P$Y㧎az~"NF5Գ;v;^BFz0'5\Y"c؁RXa an»{^ת&O6J TӤmVA4ޯiԜcZ񇋺, oᰪ wxF/6U;sȝ"t}$ʐj̩/yؤfRw2H3iJ@b8/?I(6E fu9hNo RLBZ!xz2c. m?a>8[ThOٌ xz1N H_.떊HHe%M-cEzIR5fTv[S|6&?`fϦ8Z㤊ي퉯*+c#Og+,c|ĉ5TE׃)qH'uAA$4"ݻ?\[$N5*Gũ([HZg "LOܵ{q_6+= tS|ƒ>oB$I.hk&9$erU(4dp᧢q|+ A=imc|<نN˶kb~̟$~zg)RK6׷>/Filter/JBIG2Decode/Height 1752/ImageMask true/Length 23636/Name/X/Subtype/Image/Type/XObject/Width 1240>>stream /a w wkwo܉@j,hK`uAJ2#JE%ONELv4=CUzV_r!4~{t-f[@`ժzqM_hbhsבR'_]};>]_>fboD/&Y^AhQ1?-b-ט"2O:r"4 yW6ʓ})/.2.2[l2Nf]*HPz$a]fJ=km> r cڰl㍱{VJR{vq ̀z9 XQcax59 BC񚫀מ_d+>(ðp"=1V7B|9ls_QtL`#PT2+Js GiZgpw.\K6&nPwRZ@T+ 3߰Kb`Y4r=&ԥ$:.'yq+?F>_Ŭ2tE %1'ӞֵLv2im/JV=7H循eιDɡwf T?N GDH$cۜ&ivf/}UI8TFdRsǣXj[(qiRuEuQ:cuQ;j 5 hNo˳$iBtO;JxN\C{I%@.;U)_M y_2p&k:@W$UPubwyTѦOban ?RAJ5S.d,ET短LOjcgawDsNIB dOWq8 RK:{?HXt<9xg#4GD17+ #ACʊ j8qWzǍ"y"Z`q6=o]jb?ƿEMOm3ʹpGz=J4w13eZFܵA~*!^C7&OM>a#3=ǃH^ETc%h|́A Zv2LdcIC71$ XĻQߩT|$`E E [Uu˟y>~K]V8C O=eV|(x? !d/=R YglZȩsV-3"܄c(͌`\=p78YSlunɀ!OZr?ˍٸnNdkv<;e)ʫ:Q&8ur/@Xy=/'3r3|e05etQKG^h,2q;J@ow$yxp+gidKP ͦNikWnw#6X" rNׇEԹa?~Uvߜ@ ʎƾU-6[yU>f^qshkbm~H4HcL.hߕ{ZfnvEҫWw4A]vTtq񗋎)K=+$*qzEHv-穵y-41Ʊ(3BسKh]bq(/uN!뭳0RB c!QSNgpT9I}?GJP/òSKTȓ:o)b1L[[' զfY/&d[Q"!MׇtnZ\ s3 a.VC_R~~xī>vTk)HjxzHK߳|M}<ɾE?5COX;l[ʊal@!K)آc=H~ejĬA;ym-=ʶ9q|Jrx9f S.<o$'e[cL?)5`rwr08/dLiUnPomY,lЮV()7|whԅv}X?aLO,z*ͻ3u<@w3uO" [{r/-& FD候"x(s w {i#w$$ƀaT">fH(49H؆^z,>嬞b2A7$I[z'υ/ p%+Džg>_0#iBsᕭ€Ĭaf7o^jC~ܦ*ɠ0D0U}K^P;t )A)J& L^B {ӤT MdXgK47fj$M ,O^8X'V`2ZNs6)s}>iDik[j"`) YWer l &U3΄to{-Z1"%_iMmwp^1Ƚ;ԯ:n>u倂 #(z<&>CQ>ҕ2 Ko Cڷ }93GFh:qI GJ'cjxsq4w*#VKqaYoiX\=0NX 2Z+*oBbAԨK-dyF%vkQ S z)cc+u/ *Ù;,DH誋顉&1-T|ܞp|pj3i `QusNU\sDW,P6{&Ts > Nv7?SFC\e.Z^٧ E\jCM0'lJGm`VmIGRclc \i[ N9@'XJEx::Jj< ,İY(Vy?gVܲ[k/*.(ޱȂ'm'9*LeVP&AE=1|PFٜsvM#95%t"|;V4޸sV^ 3W+jMr?͟ wAXᴀ_ ĉE/G5;e hJQؾcQb%K o#L\3jb6e:SE@d˫sUaQråW n& B^,il,YGG-aֲAmohɆa፥-?@S|&9”pʾT>3̿X4Ӓ%>n 㙕sryiP+d̳ <ګH>gMk @3j$0+4^)Sd;a%^1:omOFq{C,U9kuCExF\z|ZE2$rUͫrsE:ͫFUaX5<7AFמ9{"wQ:;3P *6.JecjuR x2K& (;EX̓BiӶr2L4~73:# FRml5eK:Z>f@YcP1Iu`:짟#-zn~b}`0M8syz`yȘGq<vpm"PJ 9:me2F'#XKO :fR~bC6ڴTw"uEOvU5H]H/gNQr8)y<4Wd|(ZCbMt -"kBݛgGP7f]P|T Q20H\GvF@j_?TA*zB1*ٸƉ)$Վ. AD*^IsF" h^U-&> `jbuhȾYDGȳ1N鎂7Rlw Gj FQ"jd2:C`$tu'eFOq. +\=W#%$yu(9[GUAQ=;6NDJ1%SPN`uk;X(o?은u׋Ւῗr#~:~ /q_EnJi5e\]qAe(\PH!.o@c0j3mvI ٙp#Kk6|$^&P.Q=' cX)}Z(Q5# e'-+PېBIRƪhABӠKA+ZPӥSFQV7O XzP Zh%rSalַ:)&`Jo2:xVOs g` -tRS/cX .2YbF9lX'f˛bp]}0Cx wSOS>gWt$DMิYP9|D١ <G=5-3QT9Ji(n A0iǕj.S(MI7 "ʴ '#f?|m1oAx$4M廧!g#[d`|^c Du! WJ^d On[ϡd*g  !;#v:A?m":EWH?}vo_3=y%ɺVŚe5gMu^'_e},5]w&!$wP`^ SF'Pj<2ou 'vve0]'v.6L^I0pCBǩQo7(@fw"&S3%MFZyej}),&=C(VYR.Rt@dt%?Mt+4O[ʦXbI 1X79+](l考w>8#Y#\M(6jXh:왹(@0*_>&P7ėQr xva^~H|:QȧdnA s_HOf.1ʎU[I7NVdvu WwwGs&&jbXӊ8x9#Mye-j񬸛w<[􉲣cQ_fwվc̀7tR& 4r 0/X 3p=SI4->CNwaK::UUTNar*NҸ3jQ̭6_T:\8}"zfz> ԰9j*=s)`4O6ohe}PGGgCvhiSn pz/%I.:f#,\pBK0{e H"jМ4| 5E6g_hB/kˆ^ΔtD3o;V3G{j+AvB1;3[A|Gn uta`Oa~  'Y13h.sc(N?7t$xܐRU ZO4ѺLM=[NŦa+(A'=j:\;N,.OHAa4c60 hjZʧgۿ%CPbazS7؞D/][ NZ(sozJdB=QYwo8Hu=Ej=, ~Pv9XWWkH=ОZVBk!zWYjY77yd[J`!Nz L>ޘfeg}a *&7G \4JQ(F dT[jk,^ hͶpS ĒA_Jv0fv@0v\Voբ2u݊?w;ߥ@Ğހu6/~1CN$^ u|QD"Y.E FwImNӢ-,\~_v 庬"!K$*;'Qb\خ9Fs]^% nC :B.%iWZפ^ohgUTenq%f@82IfmQk:GQ3UR᜝w˟{wÅ^{5ؖf}}a*=Pw!C[H6.&i4^_٧ң jR6Xr nTgj;jȻ԰2Ѕژ&J8rMIdq?$ I%1(ŖP ,dR0)Z7e &D)ݩ+CݳQ1;Wx*QD]53֍%rOe1wh!>8jӑ;𨤖.;h2d09RKjhF ҞsTGk\ Y "Ū ۪ꡱHC !_M`ڟs)gwI=[ ̞Fz页5<(Ӱ3偏@THɺ{Oy)k%Ƕ4=]Ɠ eW{e MSY r|~x8PHiTYH7tG$r3X:`gr/h% 7-tq QT PN]1@13oy2ղ;71?E~W^+Jk*iC0*o#׏opcUSki?̮=LyI4@0`z{NÇfaқq.SEi g"?܋֓1uJ:9ozWĹ?雐TN/{xG!o/(1 לYsthw-\1pAvW '?>~yɷS9~yýJ{*a)oDFgӡJv=mT\o>U(r|YBx aUD5EqIࢅ2IS68Bo5qJѓ/Fuߢ.q=9$TT*7z_#AfD>[tM뷛-eb@=oL&c`ڋS|6u4%vcvDYH[PbN&Zbl/˺> xMkinCzm:οVP;8Z{1Du jhw{xɷRzL~Ps?fRZQ. ",>L_;-F`pd.wDr3t?:FbA *L;^h88[b+A7Yay;M_TȖG@O(0ݕ`Eyȷ~Pm'4 rb )%8d#.ܣ@wN$wpH&Y^7-krM@1U+ۨB)rfM+L2p:>^hO]uKC=oC}qجizF#i!3ЕlV*fI#"WF\* Nv[S>4WB3|q~*IB]i#*?/bem?e3I[5oW5֎ \/Jyo2vM%Um II:Wr̋pv нw&q^TAzFFsZ!GCJ_/oG(icv %R@|F}~mcXtiyhʲu~exnc`N>Aѡ ?M3|.We]wh d'x L;W9smyvgHHzʶZ8OPFYL(LDF{S-25W*K=ud3!.7HPm-@a+hyl,q8ic t& \RgH,o jlk]0|ͅ OJI8- x VqS<ZbN[Ӷ6`r(᫝AC~ГEDxd \'ySËOrĒQbR'Y nVzDء d95j:V2#-\݂W Ò:/!B[CwǬ Vu*@vMɲ\f{ψhc0وZH8!-Hˊi*?ɵfiE|#z#۴9Ð .aFQ6I@ 22P>΁|3C&)ڈ|v:?=}S! %'Pb6M] >O2iג8CA[YJ4΂q44`qu*qu~"~$:?$@xA+O,r1QK'tA7|t Me xL.8w**-Sqܯx80Ō?jOFf?*`;1/6\.r{#I/MAUP1Cq}r~Ŗ]E3 J`wOBU7TCڞ?5`W~*rBi;d0ku*sj{4RW=Tnd{-.NL)(ru-O-_,37TK1{Zl46\$$>Q[[+F% ]3ev 3?ǽi˞+eHgqUA!3_N(Om-H=&/l d5/EYP*B) ^gЛj#j!8RT 7YF`a"Ng#eQ<爠G Bge>62+LH}4!p3^5%'ɨqs^Wf? M^VAD=iw '3E2l|+O@8C+M$6#rIA]:V Us:S]\#>FWJEuAqҤ;06І!sIne݇(N:1 ܑͥ`tJ={FTZG}ۚd"6L7CT˞A pEUhdb;W)ʯH֧s9Elet.Z<*I»%a=ۢ͠ HXF@+1@BЍ/f:֭s)7vtf=le Yr[Q5VNHPe{Q8^ôX1"8fWQeYg F؀.BC/”.r};`(Yq?}՝͕A`l4dS[=7z ׹L9hLP%XLCn-[IY)}7PJ'$\O!>mԸcCO┚b@Y|`sNNE׈^:9(M)H )A98tͻ1 lN|ظMq7\%W!u٬o*KĹJa0ݲfL =" SM(m<9Eg7&w;82AYWv$Ii^:-k.jAQ9q=ѵLS4Isyx0iK j^)jڒ0) z\NiJXVDR~c{&֦ϵޭjSbQ2qJ[yI;"ZiG4\XD5ɪ.Iۀڂ2d{xDHA3e;P~(g r!ד?c$o,!%FeIy MóR{E.RڽBJs}NRRp}@"on2p򈩜=AWZ8#$ 1AE&$E8Y(#y41ÞR>-_᪔a^NuFҺazlm>JUyy%ݯ8`KVVf0%Mx6;01!"76)81bHI g ׃>؜C1xBADX+-r{Ѷ>lBSxߎ6( (t~?U͈T%$7ҏ:wja&rAA=9@PKgƚe&CZ\ Ƌ~Go}&J=d*Rc*AGl2O;M Ŧeq+8hŢ n) `vMbuFOws$AJ-C˶aQa$m[L LYx{<L 82JwC&)/ՁhyZ=;jD s#|~'˔iuTi ] bz-OǴԼY~a<#͂<0 X)"ȔEяDmLot ̔= ;,[չ5Ju{0I"0gay_'4a ߽uv]J @Ӿ|lfַd0}~V¶857OqbFSA{6##@Hq:sIĤ1A$*ڣ@^/`thȒvrh8zwKo Kǀܓ a̴mkCůЪ fpά$Qtj0vX4\L`6-!]/ԱES>egpW}a`';Fs $|.꿛kZS4#Ɩd̊td'Sv: =V|QOZvy6$GUEsyZ/P=mvP]G"?# Cpk )Vs6g5'sc3 )4$C Z~|x_=]="4jTӪm#jE)VADTkX!BAzImt31 g ŁP~b.:_F h끑T> qe3W.=`P( 4}c7tz{E-9GIn'u2!~T)2nwaı*ƃn!lp8z)vLt~ -6iH-E~.Uo9 V ]UG[;dL0au㰣LZkUj.UK,4`ùqE%ԨGy~ڮWBˎLvcxugZ ,U Ƃ5Ч^S)|Q)5}$й홣^$[;F> 4ߖ '@8%p[Ub)Zɘ:%A9B1 2'@,9 Na<]Ш_7柱%9!ut7s6Aiғg+ hؗcآ-=͢rSs5Rj@YtD-쀉Ӵ`Jd8zcWA-hzJ+`Ue>6;X&>> $cP! O_stp7DGS"6P,ԩ0H۠LuWN^ÙĆDELAڡp&!L#͠UIJǎ)y/ȁ{%ebd=:T+}ẍ́`CKQZq9m|cݖq=28pPÀ8*ձzXJo͸Idn * fڞ[SH4i;h 9ڪÄ8;@5eԠl4m&WIK*4ꃇkeƥ]?BJ驑5{S"jq[BڥA N-V`AOZiO9of,H>p>t?I R4VS5F=yz;՜yc$MdC\g4c,reEQ2ɑ *zE-J^Z(sTo)ԅ4bm'&,.ˍ:bk! #,>AXDl(c?ZpVcDhXZ=";--bl0vQa-si5C&.KZr;T<@]! ǡ_s"И&JwC=~ kĢ~O~V<:tvrk*v'*Kt 4mA]:e";x eJnB;to7lI'vNxԝr}7͟@] $[@'jwa8 jocW=7/)6@9TS8N|a@G a)qPLLz ^QQH\nqRGo7FcũvpF@wSS=tVNx3s2QTj`tgL1Y͡+%BnQQV4yj2p@(iѡRiO?[ /ema}}`j+:|\D+mk50W {o*r2; %W% >,xa,^؄cMX6mE?p}mtS-iXnTB]>Wzd!RˆX\3o!m=Č7Em@~€{Y˾YU?Ԟna:9RUVIߕnWDWleՈL>t_6>g-voA ) {rWg8+vؠby)$[4m⛲K t>'L3MtCkW7εGbq O2h@UT).'4<9#M.|ԚD *ON_Ecp_k4淚o-OO*vjw2K(jZͥꖞ*eH;nbiQ~FXr(8jqV~,(7MN.bI5]rDm#yibm]=?0sʫ&$VHz! O7b,,/V)^)k4zt9yx.f#E]2 ^acEhJ:,6%SV5CqK=MQj^A\p]#QzK?f9grR|38nڼKGF.(i,#rPEɥr.z@c~~ R`6.=0֬BJRw#dAB6ջC0f8ԮS"|EyJ:cQ<&'+:u^ +A\g;ޓ3g Jr6M Y:@a&q<2˼8wUxqծN;l}UUQcj#kH㶁CW^l;N+z(7o+4L.l F[Sۤ{'e2-P8 kc՘H21 &}IED ΠaX"Mox|?Opbti)P\TN W.m5Qz:/8FiXաєI|5Ć9&Xv'>hV8Hyh)ȊlSIQAg!Z k=] Ɠ;al1 k(IO@zCt*嘠մOUc!#^ +rFBmE8?b͸HQo;aHJ?1Pjf69m);EfK:988v .C=wڷ ?e G'SÀRpxQkB+A<7>:Z]:(U~֜aZ/Jkf~ 3q[R>D@xeD5QMSw E Vy~%rY m>9/Z3\ԋtI~O~@"a2mtж O\ٛ^[` p}n ApC0U>uꌜy'hr俕Y=CMQע0t.E:F 2HCq; |8T9)y5ou yj g8RE[pS) ]pOr${t 3s?rCѥ 9@/Fò·ti^D}L6q`\l7#`Ml~o&05"=^O~9u'yntNoW[[$lxzx0%\Uto&jQȍ؂Xؾ"4?S#M+X7Joe4 VIՏ &ձ\`)}֒]ࡀ 7nVS#醵y!T2 &΂B="9 ؏Obl:J#8p+ $L,Xf+``̺ΠR#ܷ?Eu&!r(` +i Jg`m:菞fy/o k5d[Mxc5}X%. O1&{Ȗ-&P;Z,tG3oэ֓[C`̭Aa}s'Lѡ̓9j3yB0eٻ,-}Rg tSH[ (]WЍ}܉rjq: ;-i-9Qa PR"Dt: Վ{> _}|k~)|:xV'qtsH7f+>ݫg^0m4'ٗe/ g8Wzb0ÌcT/WN᤽UOa= vwdž- O@7iGɟF GZg\}6FH0:/Ī,Jld>hwG()3Ok_ xC ?u ܄a!,1'٩RF;[mQ͟ǶΡ 5fpkuu+Qx9j(tug"mM| 0DwMc:9_ endstream endobj 45 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrllcolr0jp2cOQ/llllR \#B@HHPHHPHHPHHP((( q]$B@HHPHHPHHPHHP(((]$B@HHPHHPHHPHHP(((]$B@HHPHHPHHPHHPHHPϮPTE rd%Z^ nz,:Eywa$:kQDS_>FʢILt ^q"PYSTR Bhix-j;t\Qnv }GZNDK5I"Tǂ{+ %;РoC~o! e~6)AvAf&r3HA6@N.WgnZF iHRwdM`1' ce},iq#[7 >"fyAW[3^#R d"QXmkqfY'YE!{^ 莙[eKx6əzȾWz- R;ƪ2_Tl+-#,x'K\ 1G\n`fcN+ywmn|WELbeCm D$o+s!I1m pl_^5:e^6S+Xn+El؃'y4| OJ;/ R >!&UWD٣U[WcrrcM|_H wa࠲ y۽SMՠ#TJxFiFݳl`WуBL 6wS6E|=#|(;n7 黡$cv|ȐNG{H̸6N{o8(t3(L$cQ|4f?WM+î"Cyդp"`9~P)r%[ C|Zy`w A 12JWraJ >7A"Ym FߵmTpG!]=_(zCEhrjm_hM;3ב,,.g:ٽWw<1ܨ_bRG5Sֺ9;x;YRtc7IJl=SX;|"qh%YlMSC*>Ƕ =g4xa jA{uXo'h-InGbH\+3/'DQAn- 7Q(c̳GJd 0W$cd:gfH4T&DsHbvJ~C3H QZz%' -b,Mzq)m#za"+0P,j@QЋheW ޖ/ͥi# |THr'\lט@M$ s}vsk9k߀sQx*vcrʎBU~\IUA:n?Pko5 JS}Kؒ#kхHZ\U߄h Ѝb#;fGsl`crM;[,@V[ߢ)nqV>4!@hni>x(6ɨzC|ͥ7]y_QP._s_'tJ鄀lYI,>(_=Qn}[lJHhL|ͼâM.>q̜P}BuAޠOc`>SFlisjprG(\(ݡ*B$SO!gö\@T_j3C(<)5a'21Q5ώ.1|IշAj'0+j+ 8Y˼C1MS( 5AdU@)?RZAGRYTVwP\e(;vQ3$dm}̚G챿ԇp~3tn a b4.W_ILcZe&ۭy!3T"%UH֟gxbf|gqytKǣc>R[_(!LA@e)U.q0JI:hϪ@'|m&ϤBʺ3fΰ9է&gX| <Ջ"܊?cm|!uO}['1.nLk_"ZOsו<,\AL#H;>]C6G} yybl_pxC<m_S~aj=I qvS#\FBJ,saIν׭ۣQ A~hiԫSk.%b&ɓznƯ볇21zTQ60Ap ^\J޹ 4OYT)|=!.-Tf:Wy-/Rj*Mo|(1ڸNFs?EoFW,03&ˬ.{(RGD Ɂc-:|!$AA*w vqB DJ,a?W[)F׌$ qmشI;B71U$$V'O[<=!KeXU0bQTf5bݻslfCC]CvpQ+҆!ֹ|ӷvQobR1o % H κ*ijm={I퇯RE堺oiIznU룵{A&yўv7 tQFRYwJ"y"eLM=ɒb~noŸ0@qj-0u9g40Rw$iCiP%is&Ÿ?R]|z68Q\hhϛ|;j2 |Iä\&sB v$>'h*eG" jiLL BPK ^DvQb)j{8d?cN@X)Kxy-5}ݑp'FҼ^u" 0l{>/'"x5luB` 88vRK䖿qlM^j |{fÎfj :ɓ}?zwOWg-^WSߴg}]v^Qk~i=uOlƞǶ{{P+{=F[WBMaF:?uOt݃OA[/uot:/a|n:C{[>] Gڏ{q]z~>@I wϺ7Dpt55=\zM'w-ܷ]/]v]/Zo! Zéd4;!qQqȁpȩt 7%H{? 3Gî=)K7(0֕e{ 6?֞hD > 1L<Т$)깃p3xvoRv&g-^KY3.ؼr%\_{|?N+zڅaY2ϙe4.=|F~1ə21P[쑡1$xx oܒK}9ln=Dp;ySWP$e93[^9Aׄ  'Wy=:(ѱG}ԩ, [f9ޘÛ.r.tΉS h0S9e 6-5sڂnT?.DU, ~0w4X`Gfȭ/Opf´u(t}5AS]X(K$p+.&흉Gôb)K̫ ^&.{8FA2Wg3l,q&Uۓ}0 7+6nb]A m8Tۄ$%+<۹ vMQ1Q:lpvэ@5hjR#15\| 9JɜZx#T /#TY,6'@"$9fX*M"b)D*#g&S;VcZ?Z2kD=+͎riq%^A*Y|^VIoP s:<`|*"ZsjMZ$rf;(1*@mP%&)9|,m"JxAkO? ${v}0.BM3Cɇ]SJ !(M:s(ņ1tWXL<گѴ ?Ä ޠ-xxЈT'/k̽H|ݧXAόXj@\s}Ӏ!Km4͖\9}pCB2SŒ6 2>жVQ@$5 61CV?̇\9X2;m R21X`wexRIԟ1zgN381j6WjD m5ܡڧ>"bLma}-a)00zB5Lmnm(mkÌYoqXw. )4fJ$P5]íW:ZᏉ[;;Rpd'yi O\KZl̂B0׾%4$*F ~( <6l&rAgpV]픫 [)e1+GhCC?l~X%H_va8?唶,I,HrIІ^='|!ݩcH<-984Sb#LzsMA8O ZH|m;r}Q`Pgi.ŚwgyTiH½`fbԲ)7 1qZ%\`Nk"PL;jyi6Y PZH 奴+ 4<`(`Jic`蒐2106SFrZ }vאl |͜ qV7WE+rD"S+\_Of,UX'fLiLb 9d^\%by0 J-1ۺ r'_We k/>)’l<[XJrHl1%#SJ3²Fw0yamk NW!ԙ,XW ?71Qj'8יm(Q+mӽ(*(n.$Bl";/53wTdHt}uvRGKmSG{ @H'L-/HAObt N7Tt>²՞yAe j/L(6w.ʢ{h?8> ]S F6ĿIW0/_IiWQthTmh\KeY=xmdKs}&0r}L0ȯ<|#ZSm!\J6֥c~OD_-x %Xh1q~ \2UBgM.τ6H)}u~' ć$vX< 'm FUy%`V$lgT9rHG%&G=}_Ns^ ju,CCCqņ@1!DIA_FK̒Ζ*nG>V:),!*ǟW0 v /=sl2FMЫ FsVs)@J'dV# /:.瘐s]MG_,ӻQ8xQ}AE}N=88ǠAFgoDCfRd6jL=CI:<e3 5 d~mB{mQ͖w_=b{snfywو?` 6dpQMFR$/^Lu7)^)sus \>7 xBcK\M6+\`4@pn&$g$ 8N9('??OwtDG$JhAQ/ 'f-q.,jw1{ 5D_q78<2PNCl#̦4fyV Wm64sXF ffwEfB@`RvQhP޽xz^t|]h['XD߱!h"~ޏ.{ fp&Ht?5]%Jr'&'fAx葍Qa cY>TEwv:s~FɂC6 +1i T^.\"3A^w;6 EP)1VuAoi:WL2y,&Xn*hIOo<4; 5s1dg V\[`+/oHK(p&L%(X=d  ʜKJ^m9|E&ĘvgowڔsI]yz&.Y˕R9f|]z0~%kɴV-,rܦ4-;ZwMQPmTKB16*3پY艟@'͵ x,4-=Y KLe̯""yK&)L@FA>@'|>0Zz.c書r\Du!Ivܾ"Ķ B¬v,GC+r9b KŽH[iw 2ð6EBrKܾ-k㱰530x6d4iWRRʑrq|RY읷nˑ g=*aP@v. "t>RQ~ OiΔ3{kgW~UAb.I&zfrr-BЈY|Qŗ wT%^x:?#tQW/TbHy Lh$VfQ$^NQ1>8Iq'Q|4(M[Hx\I. <%u> ftgup!0,&Yw䍥ndTD0oPڕ+6s-Lao&.ߣ~<1_xWqaK, 4ٲ1xG=NlBi+U7 }6\3:Lj( s*Y-^䐶FcZ8i*NCڛ34`-RUM>>H o#!4 ]?H~VXTG˔Qa{6eIѽϭ pIG~^I(xl} Kɜo0ƛ&f+`~UHSU)+&D' p( .j0eUmuhX=p(JW@DSլɆt<q7nwyRYl!3Sp]P;ɿ?8 DȈP bůf3| Y$q>y`xT23/>\v`2 W(sثH~>qFC}0R L|GqlDfp RG/$/p/nQd']B"36sOd ޓѺMSM2v+ N$a0o98^YPhuhojr[SlB{ cB+ʣo z(ü ^.'\8!J8 K_0 s#Iϑ!6)SpkeDmMHɣI8 UgWOTo!ѮӈYt_MH+(b= 7jAdo*GA|Kixbdz7췆Shoz *߀ endstream endobj 46 0 obj <>stream h240W0P04P0 F & F&Mp2 endstream endobj 47 0 obj <>/ProcSet[/PDF/Text/ImageB/ImageC]/XObject<>>>/Rotate 0/Type/Page>> endobj 48 0 obj <>stream q 0.204 0.204 0.204 rg 595.1999969 0 0 840.9600067 0 0 cm /Im0 Do Q q 89.7599945 0 0 191.0399933 0 634.0800018 cm /Im1 Do Q q 95.0399933 0 0 22.0800018 117.6000061 803.0399933 cm /Im2 Do Q q 37.4400024 0 0 16.3200073 305.7599945 808.8000031 cm /Im3 Do Q q 41.2799988 0 0 16.3200073 509.2799988 808.8000031 cm /Im4 Do Q q 20.6399994 0 0 29.7599945 563.0399933 795.3600006 cm /Im5 Do Q q 52.8000031 0 0 21.6000061 432.4799957 803.0399933 cm /Im6 Do Q q 18.2400055 0 0 15.3600006 217.4400024 808.8000031 cm /Im7 Do Q q 29.7599945 0 0 21.1199951 263.5200043 803.0399933 cm /Im8 Do Q q 14.3999939 0 0 12 397.9199982 803.5200043 cm /Im9 Do Q q 14.8800049 0 0 23.0399933 0 592.8000031 cm /Im10 Do Q q 18.2400055 0 0 14.3999939 2.3999939 532.3200073 cm /Im11 Do Q q 12.9600067 0 0 18.2400055 0 482.3999939 cm /Im12 Do Q q 20.6399994 0 0 25.9199982 0 405.6000061 cm /Im13 Do Q q 14.8800049 0 0 48.9600067 0 344.1600037 cm /Im14 Do Q q 12.9600067 0 0 59.0399933 0 282.7200012 cm /Im15 Do Q q 20.6399994 0 0 61.4400024 0 216.4799957 cm /Im16 Do Q q 12.9600067 0 0 22.0800018 0 179.0399933 cm /Im17 Do Q q 20.6399994 0 0 153.6000061 0 24.4799957 cm /Im18 Do Q BT 0.275 0.275 0.271 rg /T1_0 1 Tf -0.035 Tc 3 Tr 9.8647 0 0 11.1 64.26 778.8 Tm (278 )Tj 0.05 Tc 9.0738 0 0 8.4 261.03 779.29 Tm (C.E. )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 8.5522 0 0 8.4 283.64 779.29 Tm (MAPP )Tj EMC ET BT /T1_0 1 Tf -0.0072 Tc 8.4 0 0 8.4 312.91 779.29 Tm (ET )Tj 0.0452 Tc 1.719 0 Td (AL)Tj 0.372 0.372 0.365 rg 0 Tc 1.524 0 Td (. )Tj 0.275 0.275 0.271 rg 0.0299 Tc 10.2 0 0 10.2 63.74 755.29 Tm (data. )Tj 0.212 0.216 0.208 rg 0.0033 Tc 2.546 0 Td (Different )Tj -0.0014 Tc 4.192 0 Td (result)Tj 0.372 0.372 0.365 rg 0 Tc 2.199 0 Td (s )Tj 0.275 0.275 0.271 rg 0.0128 Tc 0.859 0 Td (may )Tj 0.0007 Tc 2.204 0 Td (also )Tj 0.0078 Tc 2.128 0 Td (be )Tj 0.0359 Tc 1.354 0 Td (due )Tj -0.0217 Tc 1.984 0 Td (to )Tj 0.212 0.216 0.208 rg 0.0065 Tc 1.216 0 Td (different )Tj 0.275 0.275 0.271 rg 0.0095 Tc -18.682 -1.035 Td (agents )Tj 0.024 Tc 3.01 0 Td (\(TD)Tj 0.126 0.126 0.122 rg 0 Tc 1.746 0 Td (I)Tj 0.275 0.275 0.271 rg 0.368 0 Td (, )Tj -0.0073 Tc 0.626 0 Td (western )Tj -0.0261 Tc 3.529 0 Td (red )Tj 0.0132 Tc 1.638 0 Td (cedar\) )Tj 0.0345 Tc 2.965 0 Td (or )Tj 0.0007 Tc 1.224 0 Td (different )Tj 0.212 0.216 0.208 rg 0.0182 Tc 3.871 0 Td (popula\255)Tj 0.275 0.275 0.271 rg -0.0028 Tc -18.922 -1.083 Td (tions )Tj 0.0035 Tc 2.25 0 Td (examined. )Tj 0.05 Tc 10.2656 0 0 10.2 132.87 733.68 Tm (The )Tj 0.0145 Tc 10.2 0 0 10.2 152.5 733.68 Tm (subjects )Tj 0.212 0.216 0.208 rg 0.005 Tc 3.58 0 Td (described )Tj 0.0391 Tc 4.19 0 Td (in )Tj 0.0265 Tc 1.135 0 Td (the )Tj 0.0069 Tc 1.604 0 Td (present )Tj 0.275 0.275 0.271 rg 0.0178 Tc -19.216 -1.081 Td (study )Tj 0.212 0.216 0.208 rg -0.0181 Tc 2.601 0 Td (were )Tj -0.0224 Tc 2.25 0 Td (all )Tj 0.018 Tc 1.326 0 Td (working )Tj -0.035 Tc 9.9195 0 0 10.2 165.52 722.65 Tm (in )Tj 0.275 0.275 0.271 rg -0.005 Tc 10.2 0 0 10.2 176.98 722.65 Tm (small )Tj 0.0194 Tc 2.544 0 Td (furniture )Tj 0.0171 Tc 3.997 0 Td (shops, )Tj 0.0134 Tc 2.969 0 Td (and )Tj 0.0334 Tc -20.603 -1.082 Td (had )Tj 0.212 0.216 0.208 rg -0.001 Tc 1.882 0 Td (never )Tj -0.0137 Tc 2.59 0 Td (been )Tj 0.275 0.275 0.271 rg 0.0065 Tc 2.2 0 Td (exposed )Tj 0.0253 Tc 3.679 0 Td (to )Tj 0 Tc 1.169 0 Td (a )Tj -0.0119 Tc 0.796 0 Td (spill )Tj 0.05 Tc 11.1292 0 0 10.2 210.13 711.61 Tm (of )Tj 0.212 0.216 0.208 rg 0.0094 Tc 10.2 0 0 10.2 222.16 711.61 Tm (isocyanates. )Tj ET BT /Suspect <>BDC 0.275 0.275 0.271 rg /T1_0 1 Tf -0.0121 Tc 10.2 0 0 10.2 73.2502 701.053 Tm (Specific )Tj EMC ET BT 0.212 0.216 0.208 rg /T1_0 1 Tf 0.0153 Tc 10.2 0 0 10.2 110.8066 701.053 Tm (IgE )Tj 0.275 0.275 0.271 rg 0.0126 Tc 1.926 0 Td (antibodies, )Tj 0.212 0.216 0.208 rg 0.0249 Tc 4.988 0 Td (demonstrated )Tj 0.275 0.275 0.271 rg -0.035 Tc 10.0482 0 0 10.2 244.81 701.05 Tm (by )Tj ET BT /Suspect <>BDC 0.212 0.216 0.208 rg /T1_0 1 Tf 0.0055 Tc 10.2 0 0 10.2 260.11 701.05 Tm (RAST, )Tj EMC ET BT 0.275 0.275 0.271 rg /T1_0 1 Tf -0.0024 Tc 10.2 0 0 10.2 63.352 690.0034 Tm (were )Tj 0.0002 Tc 2.343 0 Td (found )Tj 0.0086 Tc 2.825 0 Td (on)Tj 0.126 0.126 0.122 rg 0 Tc 1.083 0 Td (l)Tj 0.275 0.275 0.271 rg 0.243 0 Td (y )Tj 0.0391 Tc 0.84 0 Td (in )Tj 0.0416 Tc 1.175 0 Td (one )Tj 0.0142 Tc 1.878 0 Td (subject, )Tj 0.0036 Tc 3.576 0 Td (suggesting )Tj 0.0351 Tc 4.718 0 Td (that )Tj 0.0061 Tc 2.024 0 Td (this )Tj 0.0128 Tc -20.706 -1.081 Td (may )Tj 0.212 0.216 0.208 rg 0.05 Tc 10.4827 0 0 10.2 87.35 678.97 Tm (not )Tj -0.035 Tc 10.1515 0 0 10.2 108.01 678.97 Tm (be )Tj 0.275 0.275 0.271 rg 0.0265 Tc 10.2 0 0 10.2 123.82 678.97 Tm (the )Tj 0.026 Tc 1.835 0 Td (majo)Tj 0.126 0.126 0.122 rg 0 Tc 2.119 0 Td (r )Tj 0.212 0.216 0.208 rg 0.0143 Tc 0.94 0 Td (mechanism )Tj 0.275 0.275 0.271 rg 0.05 Tc 11.6856 0 0 10.2 226.93 678.97 Tm (of )Tj 0.0127 Tc 10.2 0 0 10.2 241.84 678.97 Tm (isocyanate\255)Tj 0.022 Tc -17.508 -1.035 Td (asthma. )Tj 0.212 0.216 0.208 rg 0.0188 Tc 3.817 0 Td (However)Tj 0.372 0.372 0.365 rg 0 Tc 3.754 0 Td (, )Tj 0.275 0.275 0.271 rg -0.0097 Tc 0.802 0 Td (specific )Tj 0.0388 Tc 3.583 0 Td (IgE )Tj 0.0208 Tc 2.068 0 Td (antibodies )Tj 0.0128 Tc 4.855 0 Td (may )Tj -0.035 Tc 10.1515 0 0 10.2 280.33 668.41 Tm (be )Tj 0.0148 Tc 10.2 0 0 10.2 63.38 657.36 Tm (present )Tj 0.0391 Tc 3.237 0 Td (in )Tj 0.0265 Tc 1.088 0 Td (the )Tj 0.0029 Tc 1.546 0 Td (lung, )Tj 0.212 0.216 0.208 rg 0.0251 Tc 2.41 0 Td (but )Tj 0.275 0.275 0.271 rg -0.035 Tc 9.9195 0 0 10.2 164.56 657.36 Tm (in )Tj 0.0231 Tc 10.2 0 0 10.2 175.68 657.36 Tm (unmeasurab)Tj 0.126 0.126 0.122 rg 0 Tc 5.074 0 Td (l)Tj 0.275 0.275 0.271 rg 0.233 0 Td (e )Tj 0.212 0.216 0.208 rg 0.0233 Tc 0.707 0 Td (quantitie)Tj 0.372 0.372 0.365 rg 0 Tc 3.667 0 Td (s )Tj 0.275 0.275 0.271 rg 0.0391 Tc 0.618 0 Td (in )Tj 0.0253 Tc -21.312 -1.081 Td (th)Tj 0.372 0.372 0.365 rg 0 Tc 0.838 0 Td (e )Tj 0.275 0.275 0.271 rg 0.0112 Tc 0.954 0 Td (peripheral )Tj 0.0102 Tc 4.694 0 Td (circulation. )Tj 0.212 0.216 0.208 rg 0.0317 Tc 5.177 0 Td (The )Tj 0.275 0.275 0.271 rg 0.0063 Tc 2.128 0 Td (presence )Tj 0.05 Tc 11.1292 0 0 10.2 245.17 646.33 Tm (of )Tj -0.0097 Tc 10.2 0 0 10.2 258.58 646.33 Tm (specific )Tj 0.126 0.126 0.122 rg 0 Tc -19.193 -1.082 Td (I)Tj 0.275 0.275 0.271 rg 0.0341 Tc 0.375 0 Td (gE )Tj 0.0128 Tc 1.419 0 Td (may )Tj 0.0151 Tc 2.016 0 Td (occur )Tj 0.0391 Tc 2.543 0 Td (in )Tj 0.0065 Tc 1.032 0 Td (exposed )Tj 0.212 0.216 0.208 rg 0.0131 Tc 3.586 0 Td (workers )Tj 0.275 0.275 0.271 rg 0.0252 Tc 3.624 0 Td (without )Tj 0.0199 Tc 3.474 0 Td (asthma )Tj 0.05 Tc 10.5727 0 0 10.2 280.22 635.29 Tm (or )Tj 0.212 0.216 0.208 rg 0.0033 Tc 10.2 0 0 10.2 63.35 624.73 Tm (rhinitis, )Tj 0.275 0.275 0.271 rg 0.0181 Tc 3.381 0 Td (indicating )Tj 0.372 0.372 0.365 rg 0 Tc 4.373 0 Td (')Tj 0.275 0.275 0.271 rg 0.0096 Tc 0.233 0 Td (sensitization)Tj 0.372 0.372 0.365 rg 0 Tc 5.178 0 Td (' )Tj 0.212 0.216 0.208 rg 0.023 Tc 0.48 0 Td (more )Tj 0.275 0.275 0.271 rg 0.0392 Tc 2.353 0 Td (than )Tj 0 Tc 2.11 0 Td (d)Tj 0.126 0.126 0.122 rg 0.52 0 Td (i)Tj 0.275 0.275 0.271 rg -0.0146 Tc 0.276 0 Td (sease. )Tj 0.05 Tc 11.1577 0 0 10.2 282.16 624.73 Tm (It )Tj -0.035 Tc 9.3682 0 0 10.2 63.28 613.68 Tm (is )Tj 0.0007 Tc 10.2 0 0 10.2 74.78 613.68 Tm (also )Tj 0.0017 Tc 2.176 0 Td (possible, )Tj 0.0351 Tc 4.137 0 Td (that )Tj 0.0265 Tc 2.165 0 Td (the )Tj -0.0304 Tc 1.837 0 Td (use )Tj 0.05 Tc 11.1292 0 0 10.2 198.13 613.68 Tm (of )Tj 0.023 Tc 10.2 0 0 10.2 212.62 613.68 Tm (more )Tj 0.0356 Tc 2.627 0 Td (appropriate )Tj 0.0138 Tc -17.318 -1.081 Td (conjugates )Tj 0.212 0.216 0.208 rg -0.0107 Tc 4.761 0 Td (may )Tj 0.275 0.275 0.271 rg 0.0056 Tc 2.065 0 Td (increase )Tj 0.0029 Tc 3.676 0 Td (the )Tj 0.0013 Tc 1.588 0 Td (sensitivity )Tj 0.05 Tc 11.1292 0 0 10.2 231.25 602.65 Tm (of )Tj 0.0265 Tc 10.2 0 0 10.2 243.82 602.65 Tm (the )Tj 0.212 0.216 0.208 rg -0.0084 Tc 1.6 0 Td (test. )Tj 0.0317 Tc -18.36 -1.035 Td (The )Tj 0.275 0.275 0.271 rg -0.0059 Tc 2.022 0 Td (finding )Tj 0.05 Tc 11.1292 0 0 10.2 127.09 592.09 Tm (of )Tj 0 Tc 10.2 0 0 10.2 140.06 592.09 Tm (a )Tj 0.212 0.216 0.208 rg 0.0012 Tc 0.95 0 Td (negative )Tj 0.0197 Tc 3.805 0 Td (isocyanate )Tj 0.0007 Tc 4.798 0 Td (challenge )Tj -0.0079 Tc 4.284 0 Td (in )Tj 0.275 0.275 0.271 rg 0.0078 Tc -21.418 -1.082 Td (subjects )Tj 0.212 0.216 0.208 rg -0.0101 Tc 3.919 0 Td (with )Tj 0 Tc 2.391 0 Td (a )Tj 0.275 0.275 0.271 rg 0.0185 Tc 1.082 0 Td (consistent )Tj 0.0086 Tc 4.809 0 Td (history )Tj 0.0192 Tc 3.473 0 Td (for )Tj 0.0127 Tc 1.838 0 Td (isocyanate\255)Tj 0.0294 Tc -17.508 -1.083 Td (asthma )Tj 0.0128 Tc 3.396 0 Td (may )Tj 0.0078 Tc 2.168 0 Td (be )Tj 0.0053 Tc 1.306 0 Td (explained)Tj 0.372 0.372 0.365 rg 0 Tc 3.995 0 Td (, )Tj 0.275 0.275 0.271 rg 0.05 Tc 10.7518 0 0 10.2 179.89 570 Tm (at )Tj 0.0054 Tc 10.2 0 0 10.2 192.39 570 Tm (least )Tj 0.212 0.216 0.208 rg -0.035 Tc 9.9195 0 0 10.2 215.44 570 Tm (in )Tj 0.275 0.275 0.271 rg 0.0113 Tc 10.2 0 0 10.2 227.38 570 Tm (some )Tj 0.0078 Tc 2.541 0 Td (subjects)Tj 0.372 0.372 0.365 rg 0 Tc 3.287 0 Td (. )Tj 0.275 0.275 0.271 rg 0.05 Tc 10.762 0 0 10.2 62.83 558.97 Tm (For )Tj 0.0015 Tc 10.2 0 0 10.2 82.45 558.97 Tm (example, )Tj 0.212 0.216 0.208 rg -0.0079 Tc 4.05 0 Td (in )Tj 0.275 0.275 0.271 rg 0.0113 Tc 1.171 0 Td (some )Tj 0.0078 Tc 2.541 0 Td (subjects)Tj 0.372 0.372 0.365 rg 0 Tc 3.292 0 Td (, )Tj 0.275 0.275 0.271 rg 0.0029 Tc 0.673 0 Td (the )Tj 0.0198 Tc 1.592 0 Td (dose )Tj 0.05 Tc 11.1292 0 0 10.2 241.33 558.97 Tm (of )Tj 0.212 0.216 0.208 rg 0.0028 Tc 10.2 0 0 10.2 254.32 558.97 Tm (isocyan\255)Tj 0.275 0.275 0.271 rg 0.004 Tc -18.778 -1.083 Td (ates )Tj 0 Tc 1.929 0 Td (o)Tj 0.126 0.126 0.122 rg 0.574 0 Td (r )Tj 0.275 0.275 0.271 rg 0.0265 Tc 0.658 0 Td (the )Tj 0.212 0.216 0.208 rg 0.0119 Tc 1.64 0 Td (length )Tj 0.275 0.275 0.271 rg 0.05 Tc 11.1292 0 0 10.2 141.01 547.92 Tm (of )Tj 0.0185 Tc 10.2 0 0 10.2 153.01 547.92 Tm (exposure )Tj 0.0253 Tc 4.103 0 Td (to )Tj 0.0118 Tc 1.171 0 Td (isocyanates )Tj 0.212 0.216 0.208 rg -0.0144 Tc 5.09 0 Td (used )Tj 0.275 0.275 0.271 rg -0.035 Tc 9.9195 0 0 10.2 281.2 547.92 Tm (in )Tj 0.0061 Tc 10.2 0 0 10.2 62.86 537.36 Tm (this )Tj 0.0295 Tc 1.871 0 Td (study )Tj 0.0128 Tc 2.694 0 Td (may )Tj -0.035 Tc 10.1515 0 0 10.2 132.01 537.36 Tm (be )Tj -0.0057 Tc 10.2 0 0 10.2 145.84 537.36 Tm (insufficient )Tj 0.05 Tc 10.4772 0 0 10.2 195.81 537.36 Tm (to )Tj 0.212 0.216 0.208 rg -0.009 Tc 10.2 0 0 10.2 208.69 537.36 Tm (elicit )Tj 0.275 0.275 0.271 rg 0.05 Tc 10.2654 0 0 10.2 233.18 537.36 Tm (an )Tj 0.0231 Tc 10.2 0 0 10.2 248.06 537.36 Tm (asthmatic )Tj 0.0023 Tc -18.156 -1.081 Td (response. )Tj 0.212 0.216 0.208 rg 0.0288 Tc 4.229 0 Td (In )Tj 0.275 0.275 0.271 rg 0.05 Tc 10.5338 0 0 10.2 119.42 526.33 Tm (our )Tj 0.0265 Tc 10.2 0 0 10.2 139.11 526.33 Tm (laboratory)Tj 0.372 0.372 0.365 rg 0 Tc 4.37 0 Td (, )Tj 0.275 0.275 0.271 rg -0.0079 Tc 0.714 0 Td (in )Tj 0.027 Tc 1.171 0 Td (some )Tj 0.005 Tc 2.588 0 Td (subjects, )Tj 0 Tc 3.957 0 Td (a )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0219 Tc 10.2 0 0 10.2 279.2478 526.33 Tm (30 )Tj EMC ET BT /T1_0 1 Tf 0.0017 Tc 10.2 0 0 10.2 62.3856 515.2936 Tm (min )Tj 0.212 0.216 0.208 rg 0.05 Tc 10.4316 0 0 10.2 81.51 515.29 Tm (TDI )Tj 0.275 0.275 0.271 rg 0.0066 Tc 10.2 0 0 10.2 102.14 515.29 Tm (challenge )Tj 0.0248 Tc 4.094 0 Td (did )Tj 0.212 0.216 0.208 rg 0.022 Tc 1.656 0 Td (not )Tj 0.275 0.275 0.271 rg 0.0004 Tc 1.59 0 Td (elicit )Tj 0.0236 Tc 2.271 0 Td (bronchospasm)Tj 0.372 0.372 0.365 rg 0 Tc 6.054 0 Td (, )Tj 0.275 0.275 0.271 rg 0.0487 Tc 0.534 0 Td (but )Tj 0 Tc 1.64 0 Td (2 )Tj -21.689 -1.082 Td (h )Tj 0.05 Tc 10.5727 0 0 10.2 70.46 504.25 Tm (of )Tj 0.0118 Tc 10.2 0 0 10.2 81.01 504.25 Tm (exposure )Tj 0.0253 Tc 3.962 0 Td (to )Tj 0.212 0.216 0.208 rg 0.05 Tc 10.3738 0 0 10.2 131.91 504.25 Tm (TDJ )Tj 0.275 0.275 0.271 rg 0.0198 Tc 10.2 0 0 10.2 153.14 504.25 Tm (provoked )Tj 0.05 Tc 10.7542 0 0 10.2 195.73 504.25 Tm (an )Tj 0.029 Tc 10.2 0 0 10.2 208.7 504.25 Tm (asthmatic )Tj 0.126 0.126 0.122 rg 0 Tc 4.291 0 Td (r)Tj 0.275 0.275 0.271 rg 0.0171 Tc 0.32 0 Td (esponse )Tj 0.0325 Tc -18.966 -1.035 Td (\(Mapp, )Tj 0.0152 Tc 3.826 0 Td (personal )Tj 0.0134 Tc 4.176 0 Td (observations\). )Tj 0.212 0.216 0.208 rg 0.0085 Tc 6.596 0 Td (Alternatively)Tj 0.372 0.372 0.365 rg 0 Tc 5.398 0 Td (, )Tj 0.275 0.275 0.271 rg 0.0265 Tc 0.908 0 Td (the )Tj 0.0145 Tc -20.9 -1.082 Td (isocyanate )Tj 0.212 0.216 0.208 rg 0.0212 Tc 4.572 0 Td (non-reactors )Tj 0.275 0.275 0.271 rg 0.0128 Tc 5.458 0 Td (may )Tj 0.0158 Tc 2.025 0 Td (have )Tj 0.026 Tc 2.157 0 Td (lost )Tj 0.0137 Tc 1.748 0 Td (their )Tj 0.0013 Tc 2.106 0 Td (sensitivity )Tj 0.0253 Tc -18.059 -1.082 Td (to )Tj 0.212 0.216 0.208 rg 0.0118 Tc 1.312 0 Td (isocyanates )Tj 0.275 0.275 0.271 rg 0.0161 Tc 5.222 0 Td (after )Tj 0.0114 Tc 2.409 0 Td (removal )Tj 0.0048 Tc 3.896 0 Td (from )Tj 0.0085 Tc 2.447 0 Td (exposure. )Tj 0.212 0.216 0.208 rg 0.0196 Tc 4.473 0 Td (These )Tj 0.275 0.275 0.271 rg 0.0078 Tc -19.77 -1.083 Td (subjects )Tj 0.212 0.216 0.208 rg 0.0128 Tc 3.588 0 Td (may )Tj 0.0315 Tc 2.119 0 Td (have )Tj 0.0055 Tc 2.297 0 Td (developed )Tj 0.275 0.275 0.271 rg 0.0216 Tc 4.561 0 Td (symptoms )Tj 0.212 0.216 0.208 rg 0.0124 Tc 4.616 0 Td (due )Tj 0.0253 Tc 1.89 0 Td (to )Tj 0.0332 Tc 1.177 0 Td (non\255)Tj 0.275 0.275 0.271 rg -0.0097 Tc -20.295 -1.035 Td (specific )Tj 0.0045 Tc 3.251 0 Td (airway )Tj 0.212 0.216 0.208 rg 0.0061 Tc 3.068 0 Td (hyperresponsiveness )Tj 0.275 0.275 0.271 rg 0.0252 Tc 8.659 0 Td (without )Tj 0.0021 Tc 3.47 0 Td (sensitiza\255)Tj 0.0004 Tc -18.388 -1.081 Td (tion )Tj 0.0253 Tc 1.976 0 Td (to )Tj 0.372 0.372 0.365 rg 0 Tc 1.118 0 Td (s)Tj 0.212 0.216 0.208 rg -0.012 Tc 0.392 0 Td (pecific )Tj 0.275 0.275 0.271 rg 0.0054 Tc 2.906 0 Td (agents. )Tj 0.212 0.216 0.208 rg 0.0129 Tc 3.253 0 Td (Finally, )Tj 0.275 0.275 0.271 rg -0.0065 Tc 3.531 0 Td (these )Tj 0.0078 Tc 2.341 0 Td (subjects )Tj 0.212 0.216 0.208 rg 0.0128 Tc 3.635 0 Td (may )Tj 0.0078 Tc 2.074 0 Td (be )Tj 0.275 0.275 0.271 rg -0.0008 Tc -21.285 -1.082 Td (sensitized )Tj 0.0253 Tc 4.247 0 Td (to )Tj 0.033 Tc 1.122 0 Td (other )Tj 0.0189 Tc 2.447 0 Td (agents )Tj 0 Tc 2.929 0 Td (p)Tj 0.126 0.126 0.122 rg 0.562 0 Td (r)Tj 0.275 0.275 0.271 rg 0.0213 Tc 0.32 0 Td (esent )Tj -0.0079 Tc 2.403 0 Td (in )Tj 0.0029 Tc 1.088 0 Td (the )Tj 0.0251 Tc 1.5 0 Td (industry )Tj 0.0095 Tc 3.712 0 Td (such )Tj 0 Tc -20.325 -1.082 Td (a)Tj 0.372 0.372 0.365 rg 0.467 0 Td (s )Tj 0.275 0.275 0.271 rg 0.0011 Tc 0.898 0 Td (amines )Tj 0.05 Tc 10.5727 0 0 10.2 109.82 416.89 Tm (or )Tj 0.0139 Tc 10.2 0 0 10.2 124.22 416.89 Tm (catalysts )Tj -0.0144 Tc 4.104 0 Td (used )Tj 0.0391 Tc 2.298 0 Td (in )Tj 0.212 0.216 0.208 rg 0.0029 Tc 1.324 0 Td (the )Tj 0.033 Tc 1.694 0 Td (manufacture )Tj 0.275 0.275 0.271 rg 0.05 Tc 11.1292 0 0 10.2 279.73 416.89 Tm (of )Tj 0.212 0.216 0.208 rg 0 Tc 10.2 0 0 10.2 61.84 405.84 Tm (i)Tj 0.372 0.372 0.365 rg 0.229 0 Td (s)Tj 0.275 0.275 0.271 rg 0.0162 Tc 0.427 0 Td (ocyanates )Tj -0.035 Tc 9.8344 0 0 10.2 113.16 405.84 Tm (\(39]. )Tj 0.212 0.216 0.208 rg 0.0288 Tc 10.2 0 0 10.2 71.93 395.28 Tm (In )Tj 0.275 0.275 0.271 rg 0.0061 Tc 1.417 0 Td (this )Tj 0.0311 Tc 1.977 0 Td (report)Tj 0.372 0.372 0.365 rg 0 Tc 2.574 0 Td (, )Tj 0.275 0.275 0.271 rg -0.035 Tc 9.3821 0 0 10.2 141.11 395.28 Tm (we )Tj 0.006 Tc 10.2 0 0 10.2 157.3 395.28 Tm (showed )Tj 0.0351 Tc 3.682 0 Td (that )Tj 0.0265 Tc 2.118 0 Td (the )Tj 0.0116 Tc 1.827 0 Td (diagnosis )Tj 0.05 Tc 11.1292 0 0 10.2 279.73 395.28 Tm (of )Tj 0.0145 Tc 10.2 0 0 10.2 61.84 384.25 Tm (isocyanate)Tj 0.126 0.126 0.122 rg 0 Tc 4.325 0 Td (-)Tj 0.275 0.275 0.271 rg 0.0294 Tc 0.331 0 Td (asthma )Tj 0.212 0.216 0.208 rg 0.0017 Tc 3.256 0 Td (was )Tj 0.275 0.275 0.271 rg 0.0213 Tc 1.826 0 Td (often )Tj -0.0008 Tc 2.4 0 Td (delayed. )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0007 Tc 10.2 0 0 10.2 223 384.25 Tm (Several )Tj EMC ET BT 0.212 0.216 0.208 rg /T1_0 1 Tf 0.0104 Tc 10.2 0 0 10.2 256.7824 384.25 Tm (reasons )Tj 0.275 0.275 0.271 rg 0.0229 Tc -19.162 -1.082 Td (can )Tj 0.0153 Tc 1.928 0 Td (explain )Tj 0.0265 Tc 3.538 0 Td (the )Tj 0.212 0.216 0.208 rg 0.0093 Tc 1.733 0 Td (delayed )Tj 0.275 0.275 0.271 rg 0.0057 Tc 3.671 0 Td (diagnosis)Tj 0.372 0.372 0.365 rg 0 Tc 3.895 0 Td (. )Tj 0.212 0.216 0.208 rg 0.0108 Tc 0.77 0 Td (Firstly, )Tj 0.275 0.275 0.271 rg 0.001 Tc 3.473 0 Td (subjects )Tj 0.0178 Tc -19.008 -1.083 Td (complained )Tj 0.05 Tc 11.1292 0 0 10.2 115.09 362.16 Tm (of )Tj 0.0178 Tc 10.2 0 0 10.2 128.54 362.16 Tm (cough )Tj 0.0134 Tc 3.012 0 Td (and )Tj 0.0146 Tc 2.02 0 Td (shortness )Tj 0.05 Tc 11.1292 0 0 10.2 224.05 362.16 Tm (of )Tj 0.0224 Tc 10.2 0 0 10.2 237.61 362.16 Tm (breath, )Tj 0.037 Tc 3.425 0 Td (and )Tj -0.0065 Tc -20.651 -1.082 Td (these )Tj 0.212 0.216 0.208 rg 0.019 Tc 2.495 0 Td (respiratory )Tj 0.275 0.275 0.271 rg 0.0216 Tc 4.975 0 Td (symptoms )Tj 0.0128 Tc 4.718 0 Td (may )Tj 0.0386 Tc 2.204 0 Td (occur )Tj 0.0105 Tc 2.776 0 Td (only )Tj 0.212 0.216 0.208 rg 0.0257 Tc 2.259 0 Td (during )Tj 0.0029 Tc -19.427 -1.035 Td (the )Tj 0.001 Tc 1.507 0 Td (night. )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0082 Tc 10.2 0 0 10.2 103.9798 340.5666 Tm (Secondly, )Tj EMC ET BT /T1_0 1 Tf 0.0265 Tc 10.2 0 0 10.2 147.8296 340.5666 Tm (the )Tj -0.0051 Tc 1.545 0 Td (only )Tj 0.275 0.275 0.271 rg 0.0273 Tc 2.02 0 Td (symptom )Tj 0.212 0.216 0.208 rg 0.0128 Tc 4.153 0 Td (may )Tj -0.035 Tc 10.1515 0 0 10.2 247.69 340.56 Tm (be )Tj 0.275 0.275 0.271 rg 0.0207 Tc 10.2 0 0 10.2 259.58 340.56 Tm (cough, )Tj 0.037 Tc -19.435 -1.081 Td (and )Tj 0.0061 Tc 2.078 0 Td (this )Tj 0.0168 Tc 2.024 0 Td (together )Tj 0.212 0.216 0.208 rg 0.0056 Tc 3.907 0 Td (with )Tj 0.275 0.275 0.271 rg 0.0029 Tc 2.352 0 Td (the )Tj 0.0019 Tc 1.732 0 Td (finding )Tj 0.05 Tc 11.1292 0 0 10.2 219.73 329.53 Tm (of )Tj 0.212 0.216 0.208 rg 0.0182 Tc 10.2 0 0 10.2 234.23 329.53 Tm (normal )Tj 0.0088 Tc 3.475 0 Td (lung )Tj 0.275 0.275 0.271 rg 0.0013 Tc -20.417 -1.082 Td (volumes )Tj 0.0128 Tc 4.188 0 Td (may )Tj 0.212 0.216 0.208 rg -0.0159 Tc 2.534 0 Td (lead )Tj 0.275 0.275 0.271 rg 0.0029 Tc 2.454 0 Td (the )Tj 0.0107 Tc 2.027 0 Td (physician )Tj 0.0253 Tc 4.702 0 Td (to )Tj 0 Tc 1.592 0 Td (a )Tj 0.212 0.216 0.208 rg 0.0065 Tc 1.224 0 Td (different )Tj 0.275 0.275 0.271 rg 0.0035 Tc -18.729 -1.083 Td (diagnosis. )Tj 0.212 0.216 0.208 rg 0.05 Tc 10.2656 0 0 10.2 108.87 307.44 Tm (The )Tj -0.0031 Tc 10.2 0 0 10.2 131.89 307.44 Tm (fact )Tj 0.275 0.275 0.271 rg 0.0351 Tc 2.174 0 Td (that )Tj 0.0139 Tc 2.204 0 Td (airway )Tj 0.126 0.126 0.122 rg 0 Tc 3.444 0 Td (r)Tj 0.275 0.275 0.271 rg 0.0043 Tc 0.32 0 Td (esponsiveness )Tj 0.212 0.216 0.208 rg 0.05 Tc 10.4772 0 0 10.2 279.33 307.44 Tm (to )Tj 0.275 0.275 0.271 rg 0.0118 Tc 10.2 0 0 10.2 61.42 296.89 Tm (methacholine )Tj -0.035 Tc 10.1489 0 0 10.2 122.8 296.89 Tm (is )Tj 0.0276 Tc 10.2 0 0 10.2 134.39 296.89 Tm (normal )Tj 0.0455 Tc 3.426 0 Td (cannot )Tj 0.0033 Tc 3.34 0 Td (exclude )Tj 0.008 Tc 3.626 0 Td (isocyanate\255)Tj 0.0142 Tc -17.555 -1.083 Td (asthma. )Tj 0.212 0.216 0.208 rg 0.0288 Tc 3.768 0 Td (In )Tj 0.275 0.275 0.271 rg 0 Tc 1.409 0 Td (a )Tj 0.0138 Tc 1 0 Td (previous )Tj 0.0178 Tc 4.031 0 Td (study)Tj 0.372 0.372 0.365 rg 0 Tc 2.304 0 Td (, )Tj 0.275 0.275 0.271 rg -0.035 Tc 9.8086 0 0 10.2 196.79 285.84 Tm (we )Tj 0.0315 Tc 10.2 0 0 10.2 213.11 285.84 Tm (have )Tj 0.0124 Tc 2.481 0 Td (shown )Tj 0.05 Tc 10.215 0 0 10.2 271.18 285.84 Tm (that )Tj 0.0164 Tc 10.2 0 0 10.2 61.36 274.81 Tm (isocyanate-asthma )Tj 0.0229 Tc 8.045 0 Td (can )Tj 0.0151 Tc 1.882 0 Td (occur )Tj -0.0103 Tc 2.634 0 Td (even )Tj 0.212 0.216 0.208 rg 0.05 Tc 10.4373 0 0 10.2 213.51 274.81 Tm (if )Tj 0.275 0.275 0.271 rg -0.035 Tc 9.9712 0 0 10.2 223.58 274.81 Tm (ai)Tj 0.126 0.126 0.122 rg 0 Tc 10.2 0 0 10.2 231.35 274.81 Tm (r)Tj 0.275 0.275 0.271 rg 0.0168 Tc 0.329 0 Td (way )Tj 0.0102 Tc 2.118 0 Td (respon\255)Tj -0.0082 Tc -19.166 -1.083 Td (siveness )Tj 0.0253 Tc 3.635 0 Td (to )Tj 0.212 0.216 0.208 rg 0.0247 Tc 1.082 0 Td (methacholine )Tj 0.275 0.275 0.271 rg 0 Tc 5.971 0 Td (i)Tj 0.372 0.372 0.365 rg 0.276 0 Td (s )Tj 0.275 0.275 0.271 rg 0.0276 Tc 0.719 0 Td (normal )Tj -0.035 Tc 9.9277 0 0 10.2 213.84 263.76 Tm ([19]. )Tj 0.0154 Tc 10.2 0 0 10.2 70.98 252.73 Tm (Early )Tj 0.0116 Tc 2.443 0 Td (diagnosis )Tj 0.037 Tc 4.094 0 Td (and )Tj 0.0118 Tc 1.787 0 Td (early )Tj 0.0036 Tc 2.316 0 Td (removal )Tj 0.0204 Tc 3.567 0 Td (from )Tj 0.0118 Tc 2.259 0 Td (exposure )Tj 0.0253 Tc 3.962 0 Td (to )Tj 0.0118 Tc -21.418 -1.082 Td (isocyanates )Tj 0.0313 Tc 4.939 0 Td (are )Tj 0.04 Tc 1.555 0 Td (important )Tj 0.05 Tc 10.3398 0 0 10.2 172.21 241.69 Tm (and )Tj 0.0391 Tc 10.2 0 0 10.2 190.48 241.69 Tm (in )Tj 0.0113 Tc 1.076 0 Td (some )Tj 0.212 0.216 0.208 rg 0.0077 Tc 2.357 0 Td (cases )Tj 0.275 0.275 0.271 rg 0.0128 Tc 2.361 0 Td (may )Tj -0.0002 Tc 2.017 0 Td (lead )Tj 0.0253 Tc -20.511 -1.035 Td (to )Tj 0.0178 Tc 1.122 0 Td (complete )Tj 0.212 0.216 0.208 rg -0.0018 Tc 4.103 0 Td (recovery )Tj -0.035 Tc 9.9277 0 0 10.2 152.88 231.13 Tm ([25]. )Tj 0.275 0.275 0.271 rg 0.05 Tc 10.4358 0 0 10.2 174.67 231.13 Tm (For )Tj 0.0078 Tc 10.2 0 0 10.2 193.3 231.13 Tm (subjects )Tj 0.212 0.216 0.208 rg 0.0118 Tc 3.589 0 Td (who )Tj 0.275 0.275 0.271 rg 0.0224 Tc 2.062 0 Td (continue )Tj 0.0253 Tc -18.627 -1.082 Td (to )Tj 0.0067 Tc 1.272 0 Td (work )Tj 0.212 0.216 0.208 rg 0.0056 Tc 2.541 0 Td (with )Tj 0.275 0.275 0.271 rg 0.0094 Tc 2.252 0 Td (isocyanates, )Tj 0.0269 Tc 5.412 0 Td (it )Tj 0.212 0.216 0.208 rg -0.035 Tc 10.1489 0 0 10.2 188.08 220.09 Tm (is )Tj 0.0136 Tc 10.2 0 0 10.2 199.12 220.09 Tm (imperative )Tj 0.275 0.275 0.271 rg 0.0351 Tc 4.853 0 Td (that )Tj 0.212 0.216 0.208 rg 0.0078 Tc 2.071 0 Td (they )Tj 0.275 0.275 0.271 rg 0.0268 Tc -20.471 -1.082 Td (take )Tj 0.212 0.216 0.208 rg 0.0148 Tc 2.072 0 Td (regular )Tj 0.0147 Tc 3.246 0 Td (medication )Tj 0.275 0.275 0.271 rg 0.0192 Tc 4.932 0 Td (for )Tj 0.0265 Tc 1.562 0 Td (the )Tj 0.212 0.216 0.208 rg 0.029 Tc 1.6 0 Td (treatment )Tj 0.05 Tc 11.1292 0 0 10.2 242.29 209.05 Tm (of )Tj 0.275 0.275 0.271 rg 0.0299 Tc 10.2 0 0 10.2 253.82 209.05 Tm (asthma. )Tj 0.212 0.216 0.208 rg 0.0087 Tc -18.913 -1.082 Td (Keeping )Tj 0.275 0.275 0.271 rg 0.0391 Tc 3.715 0 Td (in )Tj 0.212 0.216 0.208 rg 0.007 Tc 1.135 0 Td (mind )Tj 0.275 0.275 0.271 rg 0.0351 Tc 2.447 0 Td (that )Tj 0.212 0.216 0.208 rg 0.0029 Tc 1.976 0 Td (the )Tj -0.0043 Tc 1.593 0 Td (late )Tj 0.275 0.275 0.271 rg 0.0299 Tc 1.74 0 Td (component )Tj -0.035 Tc 10.1489 0 0 10.2 240.4 198.01 Tm (is )Tj 0 Tc 10.2 0 0 10.2 249.98 198.01 Tm (a )Tj 0.0132 Tc 0.799 0 Td (feature )Tj 0.05 Tc 11.1292 0 0 10.2 60.37 187.44 Tm (of )Tj 0.0265 Tc 10.2 0 0 10.2 72.46 187.44 Tm (the )Tj 0.029 Tc 1.545 0 Td (asthmatic )Tj 0.212 0.216 0.208 rg 0.0179 Tc 4.338 0 Td (reaction )Tj 0.275 0.275 0.271 rg 0.0253 Tc 3.67 0 Td (to )Tj 0.0094 Tc 1.124 0 Td (isocyanates, )Tj 0.037 Tc 5.316 0 Td (and )Tj 0.0351 Tc 1.89 0 Td (that )Tj 0.0265 Tc 1.929 0 Td (the )Tj 0.027 Tc -20.995 -1.081 Td (late )Tj 0.0112 Tc 1.89 0 Td (reaction )Tj 0.009 Tc 3.617 0 Td (is )Tj 0.0106 Tc 1.033 0 Td (associated )Tj 0.0056 Tc 4.574 0 Td (with )Tj 0.212 0.216 0.208 rg 0.05 Tc 10.2654 0 0 10.2 195.74 176.41 Tm (an )Tj 0.0123 Tc 10.2 0 0 10.2 209.68 176.41 Tm (increase )Tj -0.0079 Tc 3.718 0 Td (in )Tj 0.275 0.275 0.271 rg 0.0045 Tc 1.127 0 Td (airway )Tj 0.212 0.216 0.208 rg 0.0022 Tc -19.474 -1.082 Td (responsiveness )Tj 0.275 0.275 0.271 rg 0.037 Tc 6.391 0 Td (and )Tj 0.212 0.216 0.208 rg 0.0128 Tc 1.937 0 Td (may )Tj 0.275 0.275 0.271 rg 0.0074 Tc 2.062 0 Td (explain )Tj 0.0209 Tc 3.401 0 Td (perennia)Tj 0.126 0.126 0.122 rg 0 Tc 3.613 0 Td (l )Tj 0.275 0.275 0.271 rg 0.0388 Tc 0.611 0 Td (asthma)Tj 0.372 0.372 0.365 rg 0 Tc 3.053 0 Td (, )Tj 0.275 0.275 0.271 rg -0.0202 Tc 0.62 0 Td (it )Tj 0.126 0.126 0.122 rg 0 Tc -21.694 -1.082 Td (i)Tj 0.275 0.275 0.271 rg 0.229 0 Td (s )Tj 0.04 Tc 0.759 0 Td (important )Tj 0.0253 Tc 4.618 0 Td (to )Tj -0.0304 Tc 1.273 0 Td (use )Tj 0.212 0.216 0.208 rg 0.0232 Tc 1.637 0 Td (drugs )Tj 0.275 0.275 0.271 rg 0.006 Tc 2.691 0 Td (wh)Tj 0.126 0.126 0.122 rg 0 Tc 1.264 0 Td (i)Tj 0.275 0.275 0.271 rg 0.0182 Tc 0.233 0 Td (ch )Tj 0.0313 Tc 1.365 0 Td (are )Tj -0.0105 Tc 1.646 0 Td (effective )Tj 0.212 0.216 0.208 rg 0.0086 Tc 3.813 0 Td (on )Tj 0.275 0.275 0.271 rg 0.0265 Tc 1.467 0 Td (the )Tj 0.126 0.126 0.122 rg 0 Tc -20.995 -1.082 Td (l)Tj 0.275 0.275 0.271 rg 0.0358 Tc 0.234 0 Td (ate )Tj 0.008 Tc 1.609 0 Td (reaction. )Tj 0.212 0.216 0.208 rg 0.0317 Tc 3.898 0 Td (The )Tj 0.275 0.275 0.271 rg -0.0069 Tc 1.938 0 Td (use )Tj 0.05 Tc 11.1292 0 0 10.2 155.41 143.29 Tm (of )Tj 0.212 0.216 0.208 rg 0.0147 Tc 10.2 0 0 10.2 167.44 143.29 Tm (inhaled )Tj 0.275 0.275 0.271 rg 0.0168 Tc 3.335 0 Td (steroids )Tj 0.009 Tc 3.535 0 Td (is )Tj 0.0033 Tc 0.948 0 Td (necessary )Tj 0.0192 Tc -18.316 -1.082 Td (for )Tj 0.0053 Tc 1.516 0 Td (workers )Tj 0.212 0.216 0.208 rg 0.0118 Tc 3.576 0 Td (who )Tj 0.275 0.275 0.271 rg 0.0455 Tc 2.015 0 Td (cannot )Tj -0.005 Tc 3.154 0 Td (leave )Tj 0.0265 Tc 2.36 0 Td (the )Tj 0.0157 Tc 1.554 0 Td (workplace )Tj 0.0166 Tc 4.555 0 Td (environ\255)Tj 0.212 0.216 0.208 rg 0.0103 Tc -18.721 -1.036 Td (ment )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.035 Tc 9.9277 0 0 10.2 83.76 121.68 Tm ([40]. )Tj EMC ET BT /T1_0 1 Tf 0.0186 Tc 10.2 0 0 10.2 104.59 121.68 Tm (Moreover, )Tj 0.275 0.275 0.271 rg 0.0265 Tc 4.615 0 Td (the )Tj 0.212 0.216 0.208 rg -0.0069 Tc 1.555 0 Td (use )Tj 0.275 0.275 0.271 rg 0.05 Tc 11.1292 0 0 10.2 183.25 121.68 Tm (of )Tj 0.0142 Tc 10.2 0 0 10.2 194.87 121.68 Tm (home )Tj 0.037 Tc 2.532 0 Td (and )Tj 0.212 0.216 0.208 rg 0.0224 Tc 1.797 0 Td (work )Tj 0.024 Tc 2.403 0 Td (peak\255)Tj -0.035 Tc 10.1707 0 0 10.2 59.89 110.64 Tm (flow )Tj 0.275 0.275 0.271 rg 0.005 Tc 10.2 0 0 10.2 84.46 110.64 Tm (meters )Tj 0.212 0.216 0.208 rg 0.0138 Tc 3.298 0 Td (provides )Tj 0.275 0.275 0.271 rg 0.0029 Tc 4.184 0 Td (the )Tj 0.0298 Tc 1.875 0 Td (opportunity )Tj -0.0217 Tc 5.655 0 Td (to )Tj 0.012 Tc 1.403 0 Td (examine )Tj -0.004 Tc -18.823 -1.082 Td (objectively )Tj 0.212 0.216 0.208 rg 0.0265 Tc 5.09 0 Td (the )Tj 0.275 0.275 0.271 rg 0.0001 Tc 1.827 0 Td (clinical )Tj 0.0189 Tc 3.576 0 Td (course )Tj 0.05 Tc 11.1292 0 0 10.2 200.53 99.6 Tm (of )Tj 0.0265 Tc 10.2 0 0 10.2 215.98 99.6 Tm (the )Tj 0.212 0.216 0.208 rg 0.0071 Tc 1.875 0 Td (disease )Tj ET BT /Suspect <>BDC 0.275 0.275 0.271 rg /T1_0 1 Tf 0.037 Tc 10.2 0 0 10.2 271.1008 99.6 Tm (and )Tj EMC ET BT /T1_0 1 Tf 0.0071 Tc 10.2 0 0 10.2 313.9408 755.2866 Tm (provides )Tj 0.0265 Tc 3.902 0 Td (the )Tj 0.0111 Tc 1.682 0 Td (subject )Tj -0.0101 Tc 3.307 0 Td (with )Tj 0.0016 Tc 2.203 0 Td (confidence )Tj 0.05 Tc 10.215 0 0 10.2 476.62 755.29 Tm (that )Tj 0.0344 Tc 10.2 0 0 10.2 497.74 755.29 Tm (therapy )Tj -0.035 Tc 10.1489 0 0 10.2 534.64 755.29 Tm (is )Tj -0.0164 Tc 10.2 0 0 10.2 313.33 744.73 Tm (effective )Tj 0.05 Tc 10.5727 0 0 10.2 352.7 744.73 Tm (or )Tj 0.212 0.216 0.208 rg 0.0113 Tc 10.2 0 0 10.2 366.64 744.73 Tm (indicates )Tj 0.275 0.275 0.271 rg 0.0029 Tc 4.194 0 Td (the )Tj 0.0392 Tc 1.686 0 Td (opportunity )Tj 0.0253 Tc 5.561 0 Td (to )Tj 0.212 0.216 0.208 rg -0.0097 Tc 1.309 0 Td (find )Tj 0.275 0.275 0.271 rg 0.0448 Tc 2.119 0 Td (other )Tj 0.372 0.372 0.365 rg 0 Tc -20.098 -1.083 Td (s)Tj 0.275 0.275 0.271 rg 0.0078 Tc 0.38 0 Td (afe )Tj 0.0147 Tc 1.553 0 Td (alternatives )Tj 0.05 Tc 10.4772 0 0 10.2 384.93 733.68 Tm (to )Tj 0.0169 Tc 10.2 0 0 10.2 396.98 733.68 Tm (permit )Tj -0.0032 Tc 2.996 0 Td (sufficient )Tj 0.0336 Tc 4.004 0 Td (control )Tj 0.0253 Tc 3.349 0 Td (to )Tj 0.0205 Tc 1.169 0 Td (assure )Tj 0 Tc -19.718 -1.081 Td (a )Tj 0.212 0.216 0.208 rg 0.0182 Tc 0.856 0 Td (normal )Tj -0.006 Tc 3.286 0 Td (lifestyle )Tj 0.275 0.275 0.271 rg 0.05 Tc 10.7518 0 0 10.2 391.09 722.65 Tm (at )Tj 0.212 0.216 0.208 rg 0.0142 Tc 10.2 0 0 10.2 402.71 722.65 Tm (home )Tj 0.275 0.275 0.271 rg 0.037 Tc 2.626 0 Td (and )Tj 0.05 Tc 10.7518 0 0 10.2 448.69 722.65 Tm (at )Tj 0.212 0.216 0.208 rg 0.0131 Tc 10.2 0 0 10.2 460.79 722.65 Tm (work. )Tj 0.275 0.275 0.271 rg 0.0288 Tc -13.465 -1.082 Td (In )Tj 0.01 Tc 1.315 0 Td (conclusion, )Tj 0.212 0.216 0.208 rg 0.0194 Tc 5.131 0 Td (isocyanate-asthma )Tj 0.275 0.275 0.271 rg -0.035 Tc 9.3682 0 0 10.2 472.24 711.61 Tm (is )Tj 0.05 Tc 10.2654 0 0 10.2 482.78 711.61 Tm (an )Tj 0.04 Tc 10.2 0 0 10.2 497.68 711.61 Tm (important )Tj 0.0035 Tc -18.073 -1.035 Td (cause )Tj 0.05 Tc 11.1292 0 0 10.2 339.73 701.05 Tm (of )Tj 0.0277 Tc 10.2 0 0 10.2 352.22 701.05 Tm (occupationa)Tj 0.126 0.126 0.122 rg 0 Tc 5.13 0 Td (l )Tj 0.275 0.275 0.271 rg 0.019 Tc 0.62 0 Td (respiratory )Tj -0.0027 Tc 4.932 0 Td (disease. )Tj 0.0317 Tc 3.53 0 Td (The )Tj 0.126 0.126 0.122 rg 0.05 Tc 10.5463 0 0 10.2 517.35 701.05 Tm (int)Tj 0.275 0.275 0.271 rg -0.0034 Tc 10.2 0 0 10.2 529.33 701.05 Tm (er\255)Tj 0.0068 Tc -21.176 -1.083 Td (esting )Tj 0.0001 Tc 2.777 0 Td (clinical )Tj 0.0096 Tc 3.387 0 Td (features )Tj 0.05 Tc 11.6856 0 0 10.2 413.65 690 Tm (of )Tj 0.0194 Tc 10.2 0 0 10.2 427.12 690 Tm (isocyanate-asthma )Tj 0.05 Tc 10.2757 0 0 10.2 509.66 690 Tm (are )Tj 0.0029 Tc 10.2 0 0 10.2 527.98 690 Tm (the )Tj 0.018 Tc -21.031 -1.035 Td (prolonged )Tj 0.0183 Tc 4.847 0 Td (period )Tj 0.212 0.216 0.208 rg -0.004 Tc 3.293 0 Td (between )Tj 0.275 0.275 0.271 rg 0.0185 Tc 3.941 0 Td (exposure )Tj 0.037 Tc 4.33 0 Td (and )Tj 0.0308 Tc 2.165 0 Td (onset )Tj 0.05 Tc 11.6856 0 0 10.2 531.73 679.44 Tm (of )Tj 0.019 Tc 10.2 0 0 10.2 313.43 668.41 Tm (respiratory )Tj 0.0149 Tc 4.881 0 Td (symptoms)Tj 0.372 0.372 0.365 rg 0 Tc 4.28 0 Td (, )Tj 0.275 0.275 0.271 rg 0.0029 Tc 0.578 0 Td (the )Tj -0.0125 Tc 1.593 0 Td (low )Tj 0.0393 Tc 1.846 0 Td (proportion )Tj 0.212 0.216 0.208 rg 0.05 Tc 11.1292 0 0 10.2 498.13 668.41 Tm (of )Tj 0.0245 Tc 10.2 0 0 10.2 510.14 668.41 Tm (atopies )Tj 0.275 0.275 0.271 rg 0.037 Tc -19.294 -1.083 Td (and )Tj 0.05 Tc 11.1292 0 0 10.2 333.01 657.36 Tm (of )Tj 0.0338 Tc 10.2 0 0 10.2 345.5 657.36 Tm (current )Tj 0.0137 Tc 3.384 0 Td (smokers)Tj 0.372 0.372 0.365 rg 0 Tc 3.433 0 Td (, )Tj 0.212 0.216 0.208 rg 0.037 Tc 0.618 0 Td (and )Tj 0.275 0.275 0.271 rg 0.0265 Tc 1.984 0 Td (the )Tj 0.005 Tc 1.648 0 Td (high )Tj 0.0393 Tc 2.215 0 Td (proportion )Tj 0.212 0.216 0.208 rg 0.05 Tc 11.1292 0 0 10.2 531.73 657.36 Tm (of )Tj 0.126 0.126 0.122 rg 0 Tc 10.2 0 0 10.2 313.35 646.8 Tm (l)Tj 0.275 0.275 0.271 rg 0.0358 Tc 0.234 0 Td (ate )Tj 0.0231 Tc 1.694 0 Td (asthmatic )Tj 0.212 0.216 0.208 rg 0.0112 Tc 4.479 0 Td (reaction)Tj 0.372 0.372 0.365 rg 0 Tc 3.328 0 Td (s)Tj 0.275 0.275 0.271 rg 0.464 0 Td (. )Tj 0.212 0.216 0.208 rg 0.0301 Tc 0.627 0 Td (Moreover)Tj 0.372 0.372 0.365 rg 0 Tc 4.177 0 Td (, )Tj 0.212 0.216 0.208 rg 0.0045 Tc 0.723 0 Td (baseline )Tj 0.275 0.275 0.271 rg 0.0139 Tc 3.754 0 Td (airway )Tj 0.212 0.216 0.208 rg 0.0022 Tc -19.474 -1.082 Td (responsiveness )Tj 0.275 0.275 0.271 rg -0.0217 Tc 6.446 0 Td (to )Tj 0.0161 Tc 1.176 0 Td (methacholine )Tj 0.009 Tc 5.924 0 Td (is )Tj -0.003 Tc 1.029 0 Td (sim)Tj 0.126 0.126 0.122 rg 0 Tc 1.465 0 Td (i)Tj 0.275 0.275 0.271 rg 0.0223 Tc 0.281 0 Td (lar )Tj 0.212 0.216 0.208 rg -0.0079 Tc 1.507 0 Td (in )Tj 0.275 0.275 0.271 rg 0.0145 Tc 1.124 0 Td (subjects )Tj 0.0118 Tc -18.999 -1.081 Td (who )Tj -0.0004 Tc 2.438 0 Td (developed )Tj 0.0092 Tc 4.847 0 Td (an )Tj 0.013 Tc 1.649 0 Td (immediate, )Tj 0 Tc 5.269 0 Td (a )Tj 0.212 0.216 0.208 rg 0.0274 Tc 1.129 0 Td (dual, )Tj 0.275 0.275 0.271 rg 0.05 Tc 10.5727 0 0 10.2 497.66 624.73 Tm (or )Tj 0 Tc 10.2 0 0 10.2 513.5 624.73 Tm (a )Tj 0.212 0.216 0.208 rg 0.027 Tc 1.13 0 Td (late )Tj 0.275 0.275 0.271 rg 0 Tc -20.801 -1.083 Td (a)Tj 0.372 0.372 0.365 rg 0.467 0 Td (s)Tj 0.275 0.275 0.271 rg 0.0269 Tc 0.435 0 Td (thmatic )Tj 0.212 0.216 0.208 rg 0.0179 Tc 3.577 0 Td (reaction )Tj 0.275 0.275 0.271 rg 0.0279 Tc 3.803 0 Td (after )Tj 0.0118 Tc 2.352 0 Td (exposure )Tj 0.05 Tc 10.4772 0 0 10.2 463.65 613.68 Tm (to )Tj 0.0417 Tc 10.2 0 0 10.2 476.55 613.68 Tm (TDI. )Tj ET BT /Suspect <>BDC 0.212 0.216 0.208 rg /T1_0 1 Tf 0.0156 Tc 10.2 0 0 10.2 502.458 613.68 Tm (Only )Tj EMC ET BT 0.275 0.275 0.271 rg /T1_0 1 Tf 0.0192 Tc 10.2 0 0 10.2 527.8866 613.68 Tm (for )Tj 0.0078 Tc -21.085 -1.081 Td (subjects )Tj -0.0117 Tc 4.107 0 Td (who )Tj 0.212 0.216 0.208 rg 0.0227 Tc 2.541 0 Td (require )Tj 0.275 0.275 0.271 rg 0.0265 Tc 3.764 0 Td (therapy )Tj 0.212 0.216 0.208 rg 0.0351 Tc 3.945 0 Td (during )Tj 0.0197 Tc 3.578 0 Td (isocyanate )Tj 0.0181 Tc -17.882 -1.035 Td (inhalation )Tj 0.275 0.275 0.271 rg 0.0066 Tc 4.751 0 Td (challenge)Tj 0.372 0.372 0.365 rg 0 Tc 3.947 0 Td (, )Tj 0.275 0.275 0.271 rg -0.035 Tc 10.1489 0 0 10.2 409.84 592.09 Tm (is )Tj 0.0029 Tc 10.2 0 0 10.2 422.86 592.09 Tm (the )Tj 0.212 0.216 0.208 rg 0.0059 Tc 1.827 0 Td (degree )Tj 0.275 0.275 0.271 rg 0.05 Tc 11.1292 0 0 10.2 475.09 592.09 Tm (of )Tj 0.0006 Tc 10.2 0 0 10.2 490.07 592.09 Tm (non-specific )Tj 0.0139 Tc -17.374 -1.082 Td (airway )Tj 0.0022 Tc 3.162 0 Td (responsiveness )Tj -0.0038 Tc 6.4 0 Td (higher. )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0049 Tc 10.2 0 0 10.2 322.8512 570.007 Tm (Since )Tj EMC ET BT /T1_0 1 Tf 0.0192 Tc 10.2 0 0 10.2 349.4222 570.007 Tm (there )Tj 0.212 0.216 0.208 rg -0.035 Tc 10.1489 0 0 10.2 374.32 570 Tm (is )Tj 0.0386 Tc 10.2 0 0 10.2 384.95 570 Tm (no )Tj 0.275 0.275 0.271 rg 0.0201 Tc 1.446 0 Td (satisfactory )Tj 0.212 0.216 0.208 rg 0.0071 Tc 5.238 0 Td (biochemical )Tj 0.275 0.275 0.271 rg 0.0302 Tc 5.362 0 Td (met)Tj 0.126 0.126 0.122 rg 0 Tc 1.601 0 Td (h)Tj 0.275 0.275 0.271 rg 0.05 Tc 10.2564 0 0 10.2 529.34 570 Tm (od )Tj 0.0192 Tc 10.2 0 0 10.2 312.85 559.44 Tm (for )Tj 0.212 0.216 0.208 rg 0.0175 Tc 1.883 0 Td (diagnosis )Tj 0.275 0.275 0.271 rg 0.05 Tc 11.1292 0 0 10.2 379.09 559.44 Tm (of )Tj 0.126 0.126 0.122 rg 0 Tc 10.2 0 0 10.2 394.96 559.44 Tm (i)Tj 0.275 0.275 0.271 rg 0.0216 Tc 0.229 0 Td (socyanate-asthma, )Tj 0.212 0.216 0.208 rg 0.0192 Tc 8.435 0 Td (there )Tj 0.275 0.275 0.271 rg 0.05 Tc 10.2757 0 0 10.2 511.58 559.44 Tm (are )Tj 10.7518 0 0 10.2 532.21 559.44 Tm (at )Tj 0.0148 Tc 10.2 0 0 10.2 312.98 548.41 Tm (present )Tj 0.0046 Tc 3.478 0 Td (two )Tj 0.0448 Tc 1.969 0 Td (other )Tj 0.0017 Tc 2.647 0 Td (possibilities. )Tj 0.212 0.216 0.208 rg 0.0175 Tc 5.547 0 Td (Firstly, )Tj 0.126 0.126 0.122 rg 0.0253 Tc 3.484 0 Td (to )Tj 0.275 0.275 0.271 rg 0.0066 Tc 1.263 0 Td (challenge )Tj 0.0029 Tc -18.345 -1.083 Td (the )Tj 0.0033 Tc 1.541 0 Td (subject )Tj 0.05 Tc 10.7518 0 0 10.2 361.81 537.36 Tm (at )Tj 0.212 0.216 0.208 rg -0.0163 Tc 10.2 0 0 10.2 373.43 537.36 Tm (his )Tj 0.275 0.275 0.271 rg 0.0157 Tc 1.459 0 Td (workplace )Tj -0.0022 Tc 4.661 0 Td (by )Tj 0.0159 Tc 1.319 0 Td (provi)Tj 0.126 0.126 0.122 rg 0 Tc 2.2 0 Td (d)Tj 0.275 0.275 0.271 rg 0.0284 Tc 0.52 0 Td (ing )Tj 0.212 0.216 0.208 rg 0.0014 Tc 1.654 0 Td (him )Tj 0.275 0.275 0.271 rg 0.0056 Tc 1.929 0 Td (with )Tj 0 Tc 2.109 0 Td (a )Tj 0.0175 Tc -21.776 -1.081 Td (peak )Tj -0.035 Tc 10.1707 0 0 10.2 335.41 526.33 Tm (flow )Tj 0.0211 Tc 10.2 0 0 10.2 356.14 526.33 Tm (meter )Tj 0.05 Tc 10.6532 0 0 10.2 381.97 526.33 Tm (and )Tj 0.0215 Tc 10.2 0 0 10.2 400.78 526.33 Tm (measuring )Tj 0.212 0.216 0.208 rg 0.0175 Tc 4.569 0 Td (peak )Tj 0.275 0.275 0.271 rg -0.035 Tc 10.1707 0 0 10.2 469.81 526.33 Tm (flow )Tj 0.212 0.216 0.208 rg 0.0229 Tc 10.2 0 0 10.2 490.55 526.33 Tm (rates )Tj 0.275 0.275 0.271 rg 0.0186 Tc 2.214 0 Td (before )Tj 0.0029 Tc -19.626 -1.036 Td (the )Tj 0.212 0.216 0.208 rg 0.019 Tc 1.592 0 Td (onset )Tj 0.275 0.275 0.271 rg 0.05 Tc 11.1292 0 0 10.2 354.61 515.76 Tm (of )Tj 0.212 0.216 0.208 rg 0.0118 Tc 10.2 0 0 10.2 366.61 515.76 Tm (exposure )Tj 0.275 0.275 0.271 rg 0.0253 Tc 4.056 0 Td (to )Tj 0.0118 Tc 1.124 0 Td (isocyanates )Tj 0.037 Tc 5.08 0 Td (and )Tj 0.0235 Tc 1.89 0 Td (then )Tj 0.212 0.216 0.208 rg 0.0247 Tc 2.119 0 Td (hourly )Tj 0.275 0.275 0.271 rg 0.0351 Tc -19.585 -1.082 Td (during )Tj 0.0029 Tc 3.349 0 Td (the )Tj 0.212 0.216 0.208 rg 0.0359 Tc 1.827 0 Td (day )Tj 0.275 0.275 0.271 rg 0.037 Tc 2.071 0 Td (and )Tj 0.0167 Tc 2.174 0 Td (night )Tj -0.0068 Tc 2.72 0 Td (following. )Tj 0.212 0.216 0.208 rg 0.0082 Tc 4.698 0 Td (Secondly, )Tj 0.275 0.275 0.271 rg 0.0253 Tc 4.675 0 Td (to )Tj 0.0066 Tc -21.514 -1.081 Td (challenge )Tj 0.0029 Tc 4.337 0 Td (the )Tj 0.0111 Tc 1.682 0 Td (subject )Tj 0.212 0.216 0.208 rg -0.0079 Tc 3.347 0 Td (in )Tj 0.275 0.275 0.271 rg 0.0029 Tc 1.276 0 Td (the )Tj 0.126 0.126 0.122 rg 0 Tc 1.64 0 Td (l)Tj 0.275 0.275 0.271 rg 0.05 Tc 10.3398 0 0 10.2 440.53 493.69 Tm (abo)Tj 0.126 0.126 0.122 rg 0 Tc 10.2 0 0 10.2 456.47 493.69 Tm (r)Tj 0.275 0.275 0.271 rg 0.05 Tc 10.2768 0 0 10.2 460.22 493.69 Tm (atory )Tj 0.212 0.216 0.208 rg -0.035 Tc 10.0482 0 0 10.2 488.17 493.69 Tm (by )Tj 0.0116 Tc 10.2 0 0 10.2 502.45 493.69 Tm (exposing )Tj 0.275 0.275 0.271 rg -0.0221 Tc -18.578 -1.082 Td (him )Tj 0.0253 Tc 1.834 0 Td (to )Tj 0.212 0.216 0.208 rg -0.0125 Tc 1.075 0 Td (low )Tj -0.0204 Tc 1.741 0 Td (levels )Tj 0.05 Tc 10.5727 0 0 10.2 385.82 482.65 Tm (of )Tj 0.275 0.275 0.271 rg 0.0094 Tc 10.2 0 0 10.2 396.88 482.65 Tm (isocyanates, )Tj 0.05 Tc 10.3398 0 0 10.2 450.13 482.65 Tm (and )Tj 0.0215 Tc 10.2 0 0 10.2 468.46 482.65 Tm (measuring )Tj 0.212 0.216 0.208 rg 0.05 Tc 10.2291 0 0 10.2 515.48 482.65 Tm (FEY )Tj 0 Tc 6.2 0 0 6.2 536.43 480.25 Tm (1 )Tj 0.275 0.275 0.271 rg 0.0092 Tc 10.2 0 0 10.2 312.97 472.09 Tm (before )Tj 0.0265 Tc (the )Tj 0.212 0.216 0.208 rg 0.0252 Tc 4.365 0 Td (exposure )Tj 0.275 0.275 0.271 rg 0.05 Tc 10.3398 0 0 10.2 398.29 472.09 Tm (and )Tj 0.0235 Tc 10.2 0 0 10.2 417.58 472.09 Tm (then )Tj 0.212 0.216 0.208 rg 0.0461 Tc 2.071 0 Td (throughout )Tj 0.0265 Tc 5.035 0 Td (the )Tj 0.0359 Tc 1.545 0 Td (day )Tj 0.275 0.275 0.271 rg 0.037 Tc 1.788 0 Td (and )Tj 0.212 0.216 0.208 rg 0.0104 Tc -20.744 -1.082 Td (night. )Tj 0.0196 Tc 2.627 0 Td (These )Tj 0.0281 Tc 2.689 0 Td (two )Tj 0.275 0.275 0.271 rg 0.0246 Tc 1.788 0 Td (methods )Tj 0.0464 Tc 3.757 0 Td (can )Tj 0.212 0.216 0.208 rg 0.0182 Tc 1.753 0 Td (provide)Tj 0.372 0.372 0.365 rg 0 Tc (, )Tj 0.212 0.216 0.208 rg -0.0079 Tc 3.661 0 Td (in )Tj 0.275 0.275 0.271 rg 0 Tc 1.033 0 Td (a )Tj 0.0092 Tc 0.702 0 Td (significant )Tj 0.212 0.216 0.208 rg 0.0341 Tc -18.008 -1.083 Td (proportion )Tj 0.275 0.275 0.271 rg 0.05 Tc 11.1292 0 0 10.2 362.29 450 Tm (of )Tj 0.0078 Tc 10.2 0 0 10.2 374.26 450 Tm (subjects)Tj 0.372 0.372 0.365 rg 0 Tc 3.292 0 Td (, )Tj 0.275 0.275 0.271 rg 0.0265 Tc 0.578 0 Td (the )Tj 0.212 0.216 0.208 rg 0.0116 Tc 1.592 0 Td (diagnosis )Tj 0.275 0.275 0.271 rg 0.05 Tc 10.5727 0 0 10.2 473.18 450 Tm (of )Tj 0.212 0.216 0.208 rg 0.0256 Tc 10.2 0 0 10.2 484.7 450 Tm (occupational )Tj 0.275 0.275 0.271 rg 0.022 Tc -16.894 -1.081 Td (asthma. )Tj ET BT /Suspect <>BDC 0.212 0.216 0.208 rg /T1_0 1 Tf -0.0049 Tc 10.2 0 0 10.2 348.7748 438.9738 Tm (Since )Tj EMC ET BT 0.275 0.275 0.271 rg /T1_0 1 Tf 0.0052 Tc 10.2 0 0 10.2 373.9076 438.9738 Tm (these )Tj 0.0046 Tc 2.4 0 Td (two )Tj 0.0246 Tc 1.835 0 Td (methods )Tj 0.0313 Tc 3.804 0 Td (are )Tj 0.212 0.216 0.208 rg 0.0147 Tc 1.561 0 Td (time-consuming )Tj 0.275 0.275 0.271 rg 0.037 Tc -15.631 -1.082 Td (and )Tj 0.0128 Tc 1.796 0 Td (may )Tj 0.027 Tc 1.969 0 Td (cause )Tj 0.212 0.216 0.208 rg 0.022 Tc 2.541 0 Td (discomfort )Tj 0.275 0.275 0.271 rg 0.0192 Tc 4.752 0 Td (for )Tj 0.212 0.216 0.208 rg 0.0265 Tc 1.515 0 Td (the )Tj 0.275 0.275 0.271 rg 0.019 Tc 1.494 0 Td (subject )Tj 0.212 0.216 0.208 rg 0.0153 Tc 3.156 0 Td (examined, )Tj 0.275 0.275 0.271 rg -0.0202 Tc 4.521 0 Td (it )Tj -0.035 Tc 10.1489 0 0 10.2 312.4 417.37 Tm (is )Tj 0.05 Tc 11.1292 0 0 10.2 323.41 417.37 Tm (of )Tj 0.0341 Tc 10.2 0 0 10.2 336.87 417.37 Tm (great )Tj 0.0254 Tc 2.589 0 Td (importance )Tj 0.0253 Tc 5.229 0 Td (to )Tj -0.035 Tc 9.9699 0 0 10.2 429.97 417.37 Tm (fin)Tj 0.126 0.126 0.122 rg 0 Tc 10.2 0 0 10.2 441.02 417.37 Tm (d )Tj 0.275 0.275 0.271 rg 0.0192 Tc 0.988 0 Td (accurate, )Tj 0.212 0.216 0.208 rg 0.05 Tc 10.531 0 0 10.2 494.41 417.37 Tm (but )Tj 10.7518 0 0 10.2 513.49 417.37 Tm (at )Tj 0.275 0.275 0.271 rg 0.0265 Tc 10.2 0 0 10.2 527.02 417.37 Tm (the )Tj 0.0146 Tc -21.047 -1.082 Td (same )Tj 0.0005 Tc 2.6 0 Td (time, )Tj 0.0184 Tc 2.532 0 Td (easier )Tj 0.0168 Tc 2.926 0 Td (methods )Tj 0.0253 Tc 4.047 0 Td (to )Tj 0.212 0.216 0.208 rg 0.0182 Tc 1.31 0 Td (diagnose )Tj 0.0127 Tc 4.19 0 Td (isocyanate\255)Tj 0.275 0.275 0.271 rg 0.022 Tc -17.602 -1.083 Td (asthma. )Tj 0.212 0.216 0.208 rg /T1_1 1 Tf 0.0059 Tc 8.2 0 0 8.2 367.81 377.05 Tm (Acknowledgements: )Tj ET BT /Suspect <>BDC 0.275 0.275 0.271 rg /T1_0 1 Tf 0.0193 Tc 8.4 0 0 8.4 439.05 377.05 Tm (Supported )Tj EMC ET BT /T1_0 1 Tf -0.019 Tc 8.4 0 0 8.4 480.4872 377.05 Tm (by )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0088 Tc 8.4 0 0 8.4 493.8936 377.05 Tm (the )Tj EMC ET BT /T1_0 1 Tf 0.023 Tc 8.4 0 0 8.4 509.316 377.05 Tm (National )Tj 0.212 0.216 0.208 rg -0.0001 Tc -17.724 -1.086 Td (Research )Tj 0.275 0.275 0.271 rg 0.0002 Tc 4.737 0 Td (Council )Tj 0.0275 Tc 4.285 0 Td (\(Grants )Tj 0.0082 Tc 4.245 0 Td (Nos. )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0169 Tc 8.4 0 0 8.4 497.1276 367.9276 Tm (86.00443.04, )Tj EMC /Suspect <>BDC -0.0193 Tc -16.343 -1.03 Td (86.01762.56\))Tj 0.372 0.372 0.365 rg 0 Tc 5.145 0 Td (, )Tj EMC ET BT 0.212 0.216 0.208 rg /T1_0 1 Tf -0.019 Tc 8.4 0 0 8.4 408.4824 359.2756 Tm (by )Tj 0.275 0.275 0.271 rg -0.0088 Tc 1.425 0 Td (the )Tj 0.0155 Tc 1.595 0 Td (Italian )Tj 0.212 0.216 0.208 rg 0.0077 Tc 3.088 0 Td (Minister )Tj 0.275 0.275 0.271 rg 0.05 Tc 8.9033 0 0 8.4 491.92 359.28 Tm (of )Tj 0.0096 Tc 8.4 0 0 8.4 502.51 359.28 Tm (Education)Tj 0.372 0.372 0.365 rg 0 Tc 4.162 0 Td (, )Tj 0.275 0.275 0.271 rg -0.019 Tc -21.126 -1.086 Td (by )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0097 Tc 8.4 0 0 8.4 370.5124 350.1576 Tm (ECCS )Tj EMC ET BT /T1_0 1 Tf 0.0178 Tc 8.4 0 0 8.4 393.5032 350.1576 Tm (\(European )Tj 0.0117 Tc 4.573 0 Td (Comunity )Tj 0.05 Tc 9.4598 0 0 8.4 468.39 350.16 Tm (of )Tj 0.0331 Tc 8.4 0 0 8.4 477.51 350.16 Tm (Carbon )Tj 0.0269 Tc 3.373 0 Td (and )Tj ET BT /Suspect <>BDC 0.212 0.216 0.208 rg /T1_0 1 Tf -0.0132 Tc 8.4 0 0 8.4 520.6524 350.16 Tm (Steel\) )Tj EMC ET BT 0.275 0.275 0.271 rg /T1_0 1 Tf 0.0269 Tc 8.4 0 0 8.4 359.9184 341.046 Tm (and )Tj -0.019 Tc 2.125 0 Td (by )Tj 0.212 0.216 0.208 rg -0.0021 Tc 1.594 0 Td (Regione )Tj -0.0071 Tc 3.888 0 Td (Veneto. )Tj 0.126 0.126 0.122 rg 0 Tc 3.708 0 Td (T)Tj 0.275 0.275 0.271 rg 0.0323 Tc 0.636 0 Td (he )Tj 0.0258 Tc 1.535 0 Td (authors )Tj 0.212 0.216 0.208 rg 0.0313 Tc 3.721 0 Td (thank )Tj 0.275 0.275 0.271 rg 0.0197 Tc 2.914 0 Td (the )Tj -0.0071 Tc -20.126 -1.029 Td (subjects )Tj -0.0016 Tc 3.442 0 Td (who )Tj 0.0158 Tc 2.002 0 Td (partic)Tj 0.372 0.372 0.365 rg 0 Tc 2.39 0 Td (i)Tj 0.275 0.275 0.271 rg 0.0186 Tc 0.238 0 Td (pated )Tj -0.018 Tc 2.505 0 Td (in )Tj -0.0318 Tc 1.092 0 Td (th)Tj 0 g 0 Tc 0.725 0 Td (.)Tj 0.275 0.275 0.271 rg 0.067 0 Td (e )Tj 0.0133 Tc 0.682 0 Td (study, )Tj -0.035 Tc 8.2683 0 0 8.4 493.4 332.41 Tm (L. )Tj 0.0076 Tc 8.4 0 0 8.4 503.01 332.41 Tm (Zedda )Tj 0.0269 Tc 2.851 0 Td (and )Tj ET BT /Suspect <>BDC 0.212 0.216 0.208 rg /T1_0 1 Tf -0.035 Tc 7.8213 0 0 8.4 359.86 323.28 Tm (S. )Tj EMC ET BT 0.275 0.275 0.271 rg /T1_0 1 Tf 0.0077 Tc 8.4 0 0 8.4 371.96 323.28 Tm (Miante )Tj 0.0074 Tc 3.537 0 Td (for )Tj -0.0072 Tc 1.837 0 Td (technical )Tj 0.002 Tc 4.164 0 Td (assistance)Tj 0.459 0.459 0.451 rg 0 Tc 3.994 0 Td (, )Tj 0.275 0.275 0.271 rg 0.867 0 Td (L)Tj 0.372 0.372 0.365 rg 0.671 0 Td (. )Tj 0.212 0.216 0.208 rg 0.0203 Tc 0.812 0 Td (Tolin )Tj 0.275 0.275 0.271 rg -0.0212 Tc 2.912 0 Td (for )Tj -0.0019 Tc -20.232 -1.086 Td (secretarial )Tj 0.002 Tc 4.519 0 Td (assistance )Tj 0.0269 Tc 4.4 0 Td (and )Tj 0 Tc 1.951 0 Td (A)Tj 0.372 0.372 0.365 rg 0.781 0 Td (.)Tj 0.275 0.275 0.271 rg 0.238 0 Td (C)Tj 0.372 0.372 0.365 rg 0.733 0 Td (. )Tj 0.212 0.216 0.208 rg 0.0199 Tc 0.644 0 Td (Frigo )Tj 0.275 0.275 0.271 rg 0.0074 Tc 2.68 0 Td (for )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0085 Tc 8.4 0 0 8.4 507.2336 314.1576 Tm (statistical )Tj EMC ET BT /T1_0 1 Tf -0.0035 Tc 8.4 0 0 8.4 359.4356 305.5308 Tm (analysis. )Tj 0.212 0.216 0.208 rg -0.026 Tc 9.6 0 0 9.6 405.56 277.69 Tm (References )Tj ET BT /Suspect <>BDC 0.275 0.275 0.271 rg /T1_2 1 Tf 0 Tc 8.1 0 0 8.1 312.74 261.37 Tm (I)Tj 0.372 0.372 0.365 rg 0.415 0 Td (. )Tj EMC ET BT 0.212 0.216 0.208 rg /T1_0 1 Tf -0.008 Tc 8.4 0 0 8.4 325.88 261.37 Tm (Boushey )Tj 0.0443 Tc 3.657 0 Td (HA, )Tj 0.275 0.275 0.271 rg 0.0185 Tc 2 0 Td (Holtzman )Tj 0.212 0.216 0.208 rg 0.0127 Tc 4.343 0 Td (MJ, )Tj ET BT /Suspect <>BDC 0.275 0.275 0.271 rg /T1_0 1 Tf -0.0086 Tc 8.4 0 0 8.4 425.126 261.37 Tm (Sheller )Tj EMC ET BT /T1_0 1 Tf 0.0373 Tc 8.4 0 0 8.4 449.7044 261.37 Tm (JR, )Tj 0.0037 Tc 1.668 0 Td (Nadel )Tj 0.212 0.216 0.208 rg 0.05 Tc 10.197 0 0 8.4 485.7 261.37 Tm (JA.-)Tj -0.004 Tc 8.4 0 0 8.4 506.36 261.37 Tm (Bronchial )Tj 0.275 0.275 0.271 rg -0.0042 Tc -23.139 -1.086 Td (hyperreactivity. )Tj /T1_1 1 Tf 0.05 Tc 8.3646 0 0 8.2 367.81 252.25 Tm (Am )Tj 0.0437 Tc 8.2 0 0 8.2 382.14 252.25 Tm (Rev )Tj -0.0059 Tc 1.932 0 Td (Respir )Tj -0.0009 Tc 2.929 0 Td (Dis, )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.035 Tc 8.1597 0 0 8.4 438.92 252.25 Tm (1980)Tj 0.372 0.372 0.365 rg 0 Tc 8.4 0 0 8.4 453.95 252.25 Tm (, )Tj EMC ET BT 0.275 0.275 0.271 rg /T1_0 1 Tf -0.035 Tc 7.4195 0 0 8.4 459.58 252.25 Tm (121)Tj 0.372 0.372 0.365 rg 0 Tc 8.4 0 0 8.4 470.75 252.25 Tm (, )Tj 0.275 0.275 0.271 rg 0.0077 Tc 0.575 0 Td (389-413. )Tj 0 Tc -19.48 -1.086 Td (2)Tj 0.126 0.126 0.122 rg (. )Tj 0.275 0.275 0.271 rg 0.0216 Tc 1.658 0 Td (Fuchs )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0286 Tc 8.4 0 0 8.4 350.7224 243.1276 Tm (S, )Tj EMC ET BT /T1_0 1 Tf -0.0043 Tc 8.4 0 0 8.4 361.8944 243.1276 Tm (Valade )Tj 0.212 0.216 0.208 rg -0.035 Tc 8.2578 0 0 8.4 390.2 243.13 Tm (P. )Tj 0.372 0.372 0.365 rg 0 Tc 8.4 0 0 8.4 401.66 243.13 Tm (-)Tj 0.275 0.275 0.271 rg 0.0207 Tc 1.092 0 Td (Etude )Tj -0.0077 Tc 2.911 0 Td (clinique )Tj -0.0145 Tc 3.713 0 Td (et )Tj 0.0017 Tc 1.2 0 Td (experimentale )Tj 0.05 Tc 8.5136 0 0 8.4 528.36 243.13 Tm (sur )Tj 0.0002 Tc 8.4 0 0 8.4 311.44 234.49 Tm (quelques )Tj 0.0011 Tc 3.886 0 Td (cas )Tj 0.212 0.216 0.208 rg 0.0165 Tc 1.6 0 Td (d'intoxication )Tj 0.05 Tc 8.4273 0 0 8.4 408.49 234.49 Tm (par )Tj 0.275 0.275 0.271 rg -0.035 Tc 7.8836 0 0 8.4 422.81 234.49 Tm (le)Tj 0.372 0.372 0.365 rg 0 Tc 8.4 0 0 8.4 428.52 234.49 Tm (s )Tj 0.275 0.275 0.271 rg 0.0198 Tc 0.695 0 Td (Desmodur )Tj 0.212 0.216 0.208 rg 0 Tc 4.568 0 Td (T )Tj 0.275 0.275 0.271 rg 0.006 Tc 1.025 0 Td (\(Diisocyanate )Tj 0.0374 Tc 5.945 0 Td (de )Tj 0.212 0.216 0.208 rg 0.0013 Tc -26.17 -1.086 Td (Tolylene )Tj 0.126 0.126 0.122 rg 0 Tc 3.829 0 Td (l)Tj 0.275 0.275 0.271 rg -0.035 Tc 8.0621 0 0 8.4 346.95 225.37 Tm (-2)Tj 0.126 0.126 0.122 rg 0 Tc 8.4 0 0 8.4 353.18 225.37 Tm (-)Tj 0.275 0.275 0.271 rg 0.05 Tc 9.1976 0 0 8.4 355.64 225.37 Tm (4et )Tj -0.035 Tc 8.1699 0 0 8.4 370.76 225.37 Tm (1-2-6\). )Tj /T1_1 1 Tf -0.0018 Tc 8.2 0 0 8.2 394.21 225.37 Tm (Arch )Tj 0.0243 Tc 2.22 0 Td (Mal )Tj ET BT /Suspect <>BDC 0.212 0.216 0.208 rg /T1_1 1 Tf 0.05 Tc 8.4286 0 0 8.2 428.23 225.37 Tm (Prof )Tj EMC ET BT 0.275 0.275 0.271 rg /T1_1 1 Tf 0.0462 Tc 8.2 0 0 8.2 445.05 225.37 Tm (MedTrav )Tj ET BT /Suspect <>BDC /T1_1 1 Tf 0.0335 Tc 8.2 0 0 8.2 479.5064 225.37 Tm (Sec )Tj EMC /Suspect <>BDC 0.0175 Tc 1.639 0 Td (Soc, )Tj EMC ET BT /T1_0 1 Tf -0.0304 Tc 8.4 0 0 8.4 509.47 225.37 Tm (1951, )Tj -0.035 Tc 8.2267 0 0 8.4 529.64 225.37 Tm (12, )Tj 6.7129 0 0 8.4 312.73 216.25 Tm (191)Tj 0.549 0.549 0.537 rg 0 Tc 8.4 0 0 8.4 323.42 216.25 Tm (-)Tj 0.212 0.216 0.208 rg -0.035 Tc 8.1261 0 0 8.4 329 216.25 Tm (196)Tj 0.372 0.372 0.365 rg 0 Tc 8.4 0 0 8.4 340.15 216.25 Tm (. )Tj -3.42 -1.029 Td (3)Tj 0.275 0.275 0.271 rg 0.506 0 Td (. )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0226 Tc 8.4 0 0 8.4 325.7692 207.6064 Tm (Scheel )Tj EMC ET BT 0.212 0.216 0.208 rg /T1_0 1 Tf 0.05 Tc 8.4103 0 0 8.4 352.75 207.61 Tm (LD)Tj 0.459 0.459 0.451 rg 0 Tc 8.4 0 0 8.4 364.67 207.61 Tm (, )Tj 0.275 0.275 0.271 rg -0.0138 Tc 0.925 0 Td (Killens )Tj 0.05 Tc 8.4674 0 0 8.4 401.72 207.61 Tm (R, )Tj -0.0027 Tc 8.4 0 0 8.4 415.63 207.61 Tm (Josephs)Tj 0.372 0.372 0.365 rg 0 Tc 3.139 0 Td (o)Tj 0.275 0.275 0.271 rg 0.523 0 Td [(n )-393(A)]TJ 0.372 0.372 0.365 rg 1.924 0 Td [(. )-365(-)]TJ 0.275 0.275 0.271 rg 0.0041 Tc 2.07 0 Td (Immunochemical )Tj -0.0026 Tc -20.06 -1.086 Td (aspects )Tj 0.05 Tc 9.4598 0 0 8.4 337.35 198.49 Tm (of )Tj 0.0056 Tc 8.4 0 0 8.4 346.54 198.49 Tm (toluene )Tj 0.0093 Tc 3.136 0 Td (diisocyanate )Tj 0.05 Tc 8.5219 0 0 8.4 417.02 198.49 Tm (\(TD)Tj 0.126 0.126 0.122 rg 0 Tc 8.4 0 0 8.4 431.46 198.49 Tm (I)Tj 0.275 0.275 0.271 rg 0.401 0 Td (\) )Tj -0.0029 Tc 0.575 0 Td (toxicity)Tj 0.372 0.372 0.365 rg 0 Tc 3.011 0 Td (. )Tj 0.275 0.275 0.271 rg /T1_1 1 Tf 0.05 Tc 8.3646 0 0 8.2 469.57 198.49 Tm (Am )Tj 0.212 0.216 0.208 rg 8.3907 0 0 8.2 482.79 198.49 Tm (lnd )Tj 0.0285 Tc 8.2 0 0 8.2 495.91 198.49 Tm (Hyg )Tj 0.275 0.275 0.271 rg 0.0184 Tc 1.939 0 Td (Assoc )Tj /T1_3 1 Tf 0.0021 Tc 8 0 0 8 532.73 198.49 Tm (J, )Tj /T1_0 1 Tf -0.0173 Tc 8.4 0 0 8.4 312.68 189.37 Tm (!964)Tj 0.372 0.372 0.365 rg 0 Tc 1.732 0 Td (, )Tj 0.275 0.275 0.271 rg -0.035 Tc 8.1176 0 0 8.4 332.11 189.37 Tm (25)Tj 0.372 0.372 0.365 rg 0 Tc 8.4 0 0 8.4 340.19 189.37 Tm (, )Tj 0.212 0.216 0.208 rg 0.0241 Tc 0.668 0 Td (!79)Tj 0.372 0.372 0.365 rg 0 Tc 1.336 0 Td (-)Tj 0.275 0.275 0.271 rg -0.035 Tc 7.9309 0 0 8.4 362.61 189.37 Tm (184. )Tj 0 Tc 8.4 0 0 8.4 311.49 180.73 Tm (4)Tj 0.372 0.372 0.365 rg 0.498 0 Td (. )Tj 0.275 0.275 0.271 rg 0.0175 Tc 1.215 0 Td (Karol )Tj ET BT /Suspect <>BDC 0.212 0.216 0.208 rg /T1_0 1 Tf 0.0176 Tc 8.4 0 0 8.4 352.2804 180.73 Tm (MH, )Tj EMC ET BT 0.275 0.275 0.271 rg /T1_0 1 Tf 0.0323 Tc 8.4 0 0 8.4 373.8516 180.73 Tm (loset )Tj 0.212 0.216 0.208 rg 0.0157 Tc 2.804 0 Td (HH, )Tj 0.275 0.275 0.271 rg 0.0027 Tc 2.518 0 Td (Alari)Tj 0.372 0.372 0.365 rg 0 Tc 2.048 0 Td (e )Tj 0.275 0.275 0.271 rg -0.0153 Tc 1.151 0 Td (YC. )Tj ET BT /Suspect <>BDC 0.372 0.372 0.365 rg /T1_0 1 Tf 0 Tc 8.4 0 0 8.4 465.0252 180.73 Tm (-)Tj EMC ET BT 0.212 0.216 0.208 rg /T1_0 1 Tf -0.0165 Tc 8.4 0 0 8.4 475.6176 180.73 Tm (Tolyl-specific )Tj 0.0284 Tc 6.114 0 Td (lgE )Tj 0.275 0.275 0.271 rg 0.0085 Tc -25.658 -1.086 Td (antibodies )Tj -0.018 Tc 4.401 0 Td (in )Tj 0.0069 Tc 1.036 0 Td (workers )Tj 0 Tc 3.486 0 Td (with )Tj -0.0023 Tc 2.057 0 Td (hypersensitivity )Tj 0.0253 Tc 6.57 0 Td (to )Tj 0.212 0.216 0.208 rg 0.0056 Tc 1.086 0 Td (toluene )Tj 0.275 0.275 0.271 rg 0.0041 Tc 3.136 0 Td (diisocyanate)Tj 0.459 0.459 0.451 rg 0 Tc 5.132 0 Td (. )Tj ET BT /Suspect <>BDC 0.275 0.275 0.271 rg /T1_1 1 Tf 0.05 Tc 8.3646 0 0 8.2 311.65 162.49 Tm (Am )Tj EMC ET BT /T1_1 1 Tf 8.3907 0 0 8.2 325.83 162.49 Tm (lnd )Tj 0 Tc 8.2 0 0 8.2 339.91 162.49 Tm (H)Tj 0.372 0.372 0.365 rg 0.05 Tc 8.5078 0 0 8.2 345.81 162.49 Tm (yg )Tj 0.275 0.275 0.271 rg 0.0184 Tc 8.2 0 0 8.2 356.77 162.49 Tm (Assoc )Tj /T1_3 1 Tf 0 Tc 7.7 0 0 7.7 378.65 162.49 Tm (J)Tj 0.372 0.372 0.365 rg 0.564 0 Td (, )Tj 0.275 0.275 0.271 rg /T1_0 1 Tf -0.035 Tc 8.241 0 0 8.4 388.52 162.49 Tm (1978, )Tj 8.275 0 0 8.4 408.86 162.49 Tm (39)Tj 0.372 0.372 0.365 rg 0 Tc 8.4 0 0 8.4 416.99 162.49 Tm (, )Tj 0.275 0.275 0.271 rg 0.0046 Tc 0.526 0 Td (454-458. )Tj 0 Tc -13.096 -1.029 Td (5)Tj 0.459 0.459 0.451 rg 0.451 0 Td (. )Tj 0.212 0.216 0.208 rg 0.0318 Tc 1.215 0 Td (Karol )Tj 0.275 0.275 0.271 rg 0.05 Tc 8.4341 0 0 8.4 348.44 153.85 Tm (MH)Tj 0.372 0.372 0.365 rg 0 Tc 8.4 0 0 8.4 362.75 153.85 Tm (, )Tj ET BT /Suspect <>BDC 0.275 0.275 0.271 rg /T1_0 1 Tf 0.0126 Tc 8.4 0 0 8.4 367.5296 153.85 Tm (Sandberg )Tj EMC ET BT 0.212 0.216 0.208 rg /T1_0 1 Tf 0.05 Tc 8.595 0 0 8.4 402.17 153.85 Tm (T, )Tj 0.275 0.275 0.271 rg -0.0259 Tc 8.4 0 0 8.4 413.24 153.85 Tm (Riley )Tj -0.0147 Tc 2.399 0 Td (EJ)Tj 0.372 0.372 0.365 rg 0 Tc 1.076 0 Td (, )Tj 0.212 0.216 0.208 rg 0.005 Tc 0.529 0 Td (Alarie )Tj 0.275 0.275 0.271 rg -0.0153 Tc 2.856 0 Td (YC.)Tj 0.372 0.372 0.365 rg 0 Tc 1.933 0 Td (-)Tj 0.275 0.275 0.271 rg 0.0099 Tc 0.92 0 Td (Longitudinal )Tj 0.372 0.372 0.365 rg 0 Tc -21.894 -1.086 Td (s)Tj 0.275 0.275 0.271 rg -0.0011 Tc 0.469 0 Td (tudy )Tj 0.05 Tc 8.9033 0 0 8.4 332.56 144.73 Tm (of )Tj -0.0286 Tc 8.4 0 0 8.4 342.7 144.73 Tm (tolyl )Tj -0.0023 Tc 2.115 0 Td (reactive )Tj 0.126 0.126 0.122 rg 0 Tc 3.479 0 Td (l)Tj 0.275 0.275 0.271 rg 0.0476 Tc 0.286 0 Td (gE )Tj 0.0148 Tc 1.427 0 Td (antibodies )Tj -0.035 Tc 7.9356 0 0 8.4 442.5 144.73 Tm (in )Tj -0.0026 Tc 8.4 0 0 8.4 451.67 144.73 Tm (workers )Tj 0.212 0.216 0.208 rg -0.0041 Tc 3.543 0 Td (hypersensitive )Tj 0.275 0.275 0.271 rg -0.0318 Tc 6.056 0 Td (to )Tj 0.05 Tc 8.7877 0 0 8.4 310.97 135.61 Tm (TD)Tj 0.126 0.126 0.122 rg 0.0031 Tc 8.4 0 0 8.4 322.98 135.61 Tm (I. )Tj 0.275 0.275 0.271 rg /T1_1 1 Tf 0 Tc 8.2 0 0 8.2 331.29 135.61 Tm (J )Tj ET BT /Suspect <>BDC /T1_1 1 Tf 8.2 0 0 8.2 337.7762 135.61 Tm (O)Tj 0.372 0.372 0.365 rg 0.0055 Tc 0.712 0 Td (cc)Tj 0.275 0.275 0.271 rg 0.0093 Tc 0.877 0 Td (up )Tj EMC ET BT /T1_1 1 Tf 0.0291 Tc 8.2 0 0 8.2 362.0072 135.61 Tm (Med)Tj 0.372 0.372 0.365 rg 0 Tc 1.866 0 Td (, )Tj 0.275 0.275 0.271 rg /T1_0 1 Tf -0.035 Tc 8.241 0 0 8.4 382.76 135.61 Tm (1979, )Tj 7.6102 0 0 8.4 402.68 135.61 Tm (21)Tj 0.372 0.372 0.365 rg 0 Tc 8.4 0 0 8.4 410.75 135.61 Tm (, )Tj 0.275 0.275 0.271 rg 0.0126 Tc 0.575 0 Td (354-358)Tj 0.372 0.372 0.365 rg 0 Tc 3.42 0 Td (. )Tj 0.275 0.275 0.271 rg -15.877 -1.03 Td (6)Tj 0.459 0.459 0.451 rg 0.506 0 Td (. )Tj 0.212 0.216 0.208 rg 0.0099 Tc 1.215 0 Td (Butcher )Tj -0.0093 Tc 3.429 0 Td (BT, )Tj 0.275 0.275 0.271 rg 0.0174 Tc 1.767 0 Td (O'Neil )Tj 0.05 Tc 8.4637 0 0 8.4 393.99 126.96 Tm (CE)Tj 0.372 0.372 0.365 rg 0 Tc 8.4 0 0 8.4 404.99 126.96 Tm (, )Tj 0.275 0.275 0.271 rg -0.0166 Tc 0.582 0 Td (Reed )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0059 Tc 8.4 0 0 8.4 429.0812 126.96 Tm (MS)Tj 0.372 0.372 0.365 rg 0 Tc 1.475 0 Td (, )Tj EMC /Suspect <>BDC 0.275 0.275 0.271 rg -0.0095 Tc 0.455 0 Td (Salvaggio )Tj EMC ET BT /T1_0 1 Tf 0.0081 Tc 8.4 0 0 8.4 480.4304 126.96 Tm (JE.)Tj 0.459 0.459 0.451 rg 0 Tc 1.537 0 Td (-)Tj 0.212 0.216 0.208 rg 0.008 Tc 0.864 0 Td (Radioaller)Tj 0.372 0.372 0.365 rg 0 Tc 4.221 0 Td (\255)Tj 0.275 0.275 0.271 rg 0.0162 Tc -26.796 -1.086 Td (gosorbent )Tj 0.0042 Tc 4.292 0 Td (testing )Tj 0.05 Tc 8.9033 0 0 8.4 371.43 117.84 Tm (of )Tj 0.0056 Tc 8.4 0 0 8.4 381.1 117.84 Tm (toluene )Tj 0.002 Tc 3.193 0 Td (diisocyanate-reactive )Tj 0.0033 Tc 8.744 0 Td (individuals )Tj 0.0015 Tc 4.694 0 Td (using )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0044 Tc 8.4 0 0 8.4 311.0524 109.1964 Tm (p-tolyl )Tj EMC ET BT /T1_0 1 Tf 0.0033 Tc 8.4 0 0 8.4 338.8144 109.1964 Tm (isocyanate )Tj 0.003 Tc 4.799 0 Td (antigen. )Tj 0.212 0.216 0.208 rg /T1_3 1 Tf 0 Tc 7.8001 0 0 7.8001 411.29 109.2 Tm (J )Tj 0.275 0.275 0.271 rg /T1_1 1 Tf 0.0183 Tc 8.2 0 0 8.2 420.61 109.2 Tm (Allergy )Tj -0.0044 Tc 3.594 0 Td (Clin )Tj 0.212 0.216 0.208 rg 0.0087 Tc 2.35 0 Td (lmmunol, )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.035 Tc 8.241 0 0 8.4 506.6 109.2 Tm (1980, )Tj EMC ET BT /T1_0 1 Tf 8.3089 0 0 8.4 528.86 109.2 Tm (66, )Tj 0.275 0.275 0.271 rg 0.0191 Tc 8.4 0 0 8.4 310.99 100.08 Tm (213-216)Tj 0.372 0.372 0.365 rg 0 Tc 3.414 0 Td (. )Tj ET endstream endobj 49 0 obj <>/Filter/JBIG2Decode/Height 1752/ImageMask true/Length 25888/Name/X/Subtype/Image/Type/XObject/Width 1240>>stream 3 ÔeZ,Feu:nAyvBeZ#2x#mΜ3$gZA݉&eLdWtp4"|# V!E1KaO25I]Pp%U.hqv >yvX&b#b#{ɧ<^:g55a5h+hmO-EAKLD[_.r;9P8SLT@eo/K*Hi?nͪ7CǞ-\ ޜƐS"hE:th^01_`yٺcFSn:Ƭf`%::.rW(sfFѯQ1S^Sg'1oV_Asszn'¾94٣Qt 20V.MI͛=lsJ-J֠?l Xk̋bvf_0Ag,6gSPa|ԲػܚfyF+IkЧ9<]r(#e7!sEke #u(%=W.?Ve>Ѹ818a>ܞA0ct*кb٤easҔDfw&c'kDRV%EZV"v47{kPIDJUbnoSP>"9:*tQ m n& o|4:⣞-;AuqlNSK-n ?!d;~8щE~-̭ݷM JmLakϏ?x=d59ºxCIuL MjzD-׏>2hƬom%bU ~Q D^dCKAUȝ1eQꆼ_F`H*-KQվBh8H/ *{T:ljr Am!>9DapՑvɝ~e^ݵQw'TxL q2v ²i\f5^>Ehx څ%ƒ"z k\<"߅q >7?E.ۣF-&*\wzCiڄ-X+>CMԲՅZVJ5 œfs%kD^>xq좈Ɗ4X };= 4WN$h,sѰ1+4nO zJBT>5j]Gx-ӷE͘'0 .4#0{\q=G։.d[!D})!=Yd)Cdƶt:bSefa'i/ %88es(T~txdu\ )xҬ3 e@>I=)N9o+QcuB넠owag>^E|%e'%+,XPc]$g[凗 a:rJx\>x93Hx>EܽYO$X ny/*Eg̣\g=D82Kod_*{7\]NOP@0GˁLZבƊt zOu\t$ ]𱦹2 :R/2dpkrW8|a?v|=x?y,Gxd|'tHJFE0n;" '6LGeBXrϧ7Qs󾸂m z+PFF˹ u;عUlZH,H̀zlt|k"wR\g6:[SxP /%ܻ((xE]TRe^(Qr9Oך.2UDJb2Z )E,V G磧Bv?;@dO3A~AӼ"eIpWRᏕ8@Ak!}Z>2RvGusqQ9 VQ-aH7ji@FmjY6Fzr@:D}+vA#jDRR.]6:9?3Ԏ F P=?}2!nH?݆Z#I^as9~g> ;a 2BXRhPø:{ zި"ʊ_&a#i"i}SzAzS}u9C)@$U)о 5 zcD4g^l̆1b-I MN w5\ꕯXSi VmY肅*9u6S.@׸^~[Wߘs«J䂢:k}^Fe!pxy+(Cdrg=-ѐ݌h_#SnT%mRRyrzӛz~G<" DDƸ0aU <e'7$Ͱ+쪙# ìmգT^Dw;g|3ŚGʨuѭ4/*Q5j@~ω%O ,1ϳc۫)u𨬣'Ȝ /i?ꪞk+2%y;?Lf.}1>Ťq-FEE@G'0"Z'21mp뻮A@Ƨ쀐sף9%lj 2/ icsJxlC.P/^7)22ޘX~T1j9tQKsrCw :=Mht5H}f2;m8$Mq@NRQ5j CJ?d>CRxe]^YXL NRGdi!b^֪j-՘Y߷(/.9WzJ.'7#;2r 6*Pt˰ ~{Qd]XIj0pł򠥓{h_1r;{(lKUmUq%2^ %~KXF, '"D,n3Ca \U_4Vaf# ^hx@}D*mHy=l]cvMiz(3vuftgRAq`TlK)C<Άg_71C.j%뿳8Gb~>k$ #Zrkn\('"rHLTzNK }"f7C.x]xϠ(tU<,whHUHKF,EjSgll05PλBYS>Ǫfy5h۹*=ьb"Hq2i}S";aT.,뉲bRDZ~5y3O${S@JIg^SXg7[` s1,n?6AŦ3a(n±-x= Q:V5*'Ttz<|0X7~d]Z)EذLb_i" ?9u7/z _ʓ&A&t8_F3D[Gh>g(;͖vh(&~"3 J*Iom GrPBҢѵ5 ^{ioӘчh]:/NiLh[??5{j {dO߼nG/u'>5+RZKGJ[e׃+0BO &%Diι Z'K*Mgt"2L:xy\4dFxeqX| t|ܗJ?Z.D6M'4݁ `+ܑLg?xuf"ag{1kuv0'k 3M.lb7y ǚ[UFg '[*:yUADܽf11zW%LJRcTJәǸ5HBJM{/.\?"@@au!o쭴qIܬKΕ #hEVRwSXUr29\~|[C-FFؤ9)&[4HmDܲ =x#/l0$zi ? MaLez'ۊA5w@:O SRɶC~~Tv"Ϩ̶b)4A'pzwfDCe|sL`L;Kг=b)m ƄJ6>X.i*eD֘T|%3}7^$QE #V.̾l]t8}YIٰlag. ̟E2ruXBzdxqENf }Dd"MtXX˖x+[+ŝUs;T| !߷Ib L˛&ͪRv>N=~%Lm `Dz5zH=p7;Y. PXfJqܜmP$v$9zo[vggh4C6O8.m"RSEïw q:7>sފ|JUbO-' UTng貗jvs= pRaTrK:59ro9X[ c+-s]B_(M1[_g M~C{UCGL1[ 1?s~{F؂8: 73Iʅ +qܟ ,nyQ0b1#ΝOpMjPB{(G tMd6䉀)BTV!R~ד^q󸱕#Az1<&&CucMQ(ЕFRj?SH$_LjbрuA\Wy~oc)Rgx&$;Uogy޻#}+(3I'T}>ShGQ@ +2AhkAkVn3`*QͲ̯OOQkZ/|1$Ui@h~nԢ5q~(SJ DMr֧22])[Ӝ4S!cIUp)%MY::C3PS&uSw*fX8lC6ЂB[3<:3JZhĘ0@EQР$:EZ+DveF*`X">mG{ qG*N?J",kz 1 b&눷r˱@md6J>T 1O2|B8>{bAvFEXI[2g!|qW\ NDonm7B^4a9T|w:uǙ:Ӂhd4IN7?bD^: ?蜳rn$8TqG`>5RE`3ˤiҏ; yYs ʑ4R<0 lOB5+SY8s1%xVWK#t*@!K\ϔ˿|Zb¥g,^JWfI $ >^AåBr`1m ]aD$ڤ}ݰC]@8B䞄SSɏw-VvK/r,Q^"cŸbKm5&1+3[?z˴[H&z&ܯ{.VTeA{TsIpy`ga nu$MalKhh,zL46$j zyǞr_ l;lT+:@,Q0rSڳ$0z %4iE?\oRs\&I LzW7Bz4!"r޳@=nhջ Ts@t$O,3}d9R$:U] VQ̺+!=E^Rvo%y1Nt!.+)04FUɀ~uDox#~ 'kP[`ղzr80lLV;߰+ߘ! %zq\zF8v2!<^o`̇~B(뫇 =Caz0oEzOc'II`Fe1 fBjVr ;]r/{u>n0;\q-7b0dֲaR$d1b | xZGkg4\bAr>a@V6EuQmgե8Fl3'G ڗen[ZLtᔊ<1L~zQY)ěU:7'o*b9ړpY%#pPkVn6ljÙ(TKk:!K7>69Û??ipajfb_a]zOeOYnF hMP؏k-:X|#І= _ :^47bU2lYn#ͿN ֓ 6ioȥ7Pk&/~^J9~]6۽jmδ2E5&~hI+iYGDLZUe A!z0k=J|x͂׈%_M"-uFTPLB+ XUyHՏ=&y9?㎐6s$2AK|iڂQE2\egW!q5msoHb]1Ъǧ8!vJJ+)p˱yeI73mN""Mr<ݍf OR 9gmB T aC6ZcjΑ|~ {'i0[NUŁ{%ڶM2'NS\-g" 'ڋU XG=iy{'K0^s23b'uL12+8Ρ }3|sh .Oⅳ##haċtژn*0f]^9\F9lW*#pDY9qeݺ!dfm}?s30T,TH.lF2z@ӉłLG(-SM+9^Tpt[3ӸN=,P) q`>̢[ &BXHq#0ARغ |9V'4Ֆ>&QN6>37~nr~Y۪# gɿW*kKtuCEfK~u\n?&҇ kt[h m }B%2h>̜2U44"a-*S q5vqe zq'Kzh}a$= 0/8xC1;P:x"YE]5 j=АMګZjeb¡a? ֈXVHA!k?nVÍmeBSH:)d,!jih%l~_կ(:A+3=f&T^8MEoslWx?%&冀>+Va}qؚJ}A?9ԡ3ѮTׂPWf/CܸD9RkJ_e4Q"׳:;Vyih<%;cP?X,r_ p+95WO@V6A$ڥ0` :1\lX[sbl\eZЊq5Lx&İ@.X Qj*I0 dĉ}h7R1Ng[CRvt-/䟐Ĭ\˛PZ:c<=.9>;_YY]9FPcAl '|pF8nK_ꌐwy06#*n 3s}ogA0S%YR. ̍MrKFfc5>IkR':,D .ԑ۝^A_ΉU2Ɪ9^9}'HӜ1d&XnK';(]scs-nGyP(z pǵZ`|n- Y/GuLSJoHqSBrV|?nͬ !쇄 8gh׽$NO|ʤoDj V(M-5Z.5S "RYKCo^|/'/m}J\dByF>Ux<Y2sK0.7-< %SQRE]%X.E?ibMVa 8Zi7&ndrN$,(hZ7lsw ׶0A)Ί8N-1+SwsyDvH0M@et n[2\W74אSý!5#$A3w^LM'eŲH2{Be!w|6?+gUhI}(P[s?kQ|DcF~;.-?(uVB]IoKwQe?._(DMt*t*':FeK'4RH86L7Amݝn-0$d8*6CPh6[͟D8Lov[D=p5 jt]P,>#eVTt}(%gv+%z_ܣ M }Vrq[gtAQf ;RL /Pw W,ro6g)9);Z#WȸrKC 20,kv݄:CF[#sKdpE\Ak#9b%e 񠣻I!6!'j5F@yvu4g#O[ Y]FCe* b'Y9ň^vClWm˸{BxЏ34Q dH/{<7]%zO}j3UF0dzt`C6!O9,D'h^r8aڿN?}6W- 3c4kwst45N=b0۴ejp[qn.MK! Ij̧$j,!q+N>e:b@r4Մ]HD~)rcR*R̈́jۙlOU_'?fnw kpQ"6Q`T6*Q DqW4DD[b)D `>YcכtBI:ҶAv?qhW(>'p=+9- |V]|,w`KG/vZmO #Ft˴"8pũpF$jcԲ=~r#xg4Cۥ8wYYF,^:~P5݋V_1ݲ59/D%s>O@7q>Wq;ѓAI]Qg=ksW,zxӆ9#6B` c˛vuUT#!R!֗ɍlJRļ?)ތf슁0@ 1wOߨlJM-P| ~` (&V".`/2Ξw0>|Bů i/_RAfjIyHX|p)&:QD t7bVLzY"nT3N6q̽sl$jɂdG[Gܭ{!>d3=6|z4?'-'c$3[tCXd6Ʒ 3tǖIp O=[n)ƓEa~݆#!k|.VSg5e#h ^~XBx+ZI?g' P8@#Sl8ͧo-z[iTX$=9=mh?g[6 fy$GMK .+'4$xJEtol!]s(\Jǽ P umPS5BUkt#(OPV$d!pl YA@ /OCZ]kES+`Ae 󸨕ol,aKXv[[=Vnp78*t 5;N"l䂻iFrA1; o\Êy̅J=4!@^ & lvI?oF9SV_~Qja[isAAy ng(@&a=t"&'d3G k,&4ʎ[<^mriKIilG ʖee H$A0qWTw8,T0: Sx`I{tk!/bę Xeqd%B$7kRcWss[^$eIՅ'/sܰ"g n5t<1"st 10T`(;7({vZ%S$[]Tc:<;]كH@ }N:c{ ͑̀^#) ZE-St_ojQ`iS@gװ~U?,__j^+?c@,4Go)ϭ< pI=TߞkF]yh3y8 =|!x!w ܡy\XRqӐi.;(qi'3MKR|vzN2Up$%]1=p^_d&uMtM 9!YS I4Wkta dt/c.w yܖ2aˆ>>Z\,YJ!dD H*ʎ/u[@YX3%s rE97L 6ZI9]٤/0RQX >*i 2:|m$DR?t%Q0%`q*"˶I=X4l cTPAZ9I{|b-Np .2T"lL}Ř%SWLI%lѪlP)J]՛bbr4\ 7/MGrER<7;=iyi/gn6pRT]JtSyIi%+^%Wg9bO66\:Rc9Еȣ.+ ͯT;p0ӞXݼzœ@K=l9 gBs(%xyȦiϊ&m֕//솦ac (5 Si;pZzۆe#]Uʙ2pTB`UA JBI㻻1Æ=ICP|zّ/Ґۣ;޳l nl3jb]M°~ 58FX~D{j#DkHA*ee?ҝ0ϏJC/,̩),(`O>^5|&uPG'!hȚW"2ˈ+'z_wvJ{Z&wAL[7bowEjX׼$svɗI([^Ssړ{՗9)VDh0$9e <*9m:'>tؽPvj?A1Ω#PT8r84 NbEJ/@mcK=d OS}6U6d[t_GƠv8Өs)}d5N% X99 *xěQ3>c >/{2 p~IHfkbZ}LF'86t*c TZ֖on_h\fB̒[4~RH?f=u,va@b_RH*7Xe$0 J=+?> 템݄*s+1Mf+G(:_ |(T!*ʅ~O{ǖD>Jˮf6ɧe7@]׌&BH4C~m{1RfY+` )3ܥ\&BANh u8u&@} A@bwpyj̐5HzB.{&aVz2E@Wʤ\]:c%y($)/eImb׈ymľKϊ)y }DGU`̍PPZbdLj9Y kp/:\ƑUMrIMOXE@{6cG9b#Q"(F G ɛ$L(z͆DEit 9X !]7QG#*1 s9RGla],E4Qmy3`qx`qiEƉ3B|Y*պӰ tt(`WwO*9MOeϮ~/P3+>=_Yf=-boeJ&6@X_cPgj{fʈHO?qIt%V]< YFSV syUml%갇r0mZ("Jx%/6.WO Vxӗ3~ ^",9)1۩h $az.U5|9bڧNW>EsFEK:̧2|2rů6T,LVodXe٩^1L@ߦUOngGч:jNVi]c3CԪN^-\բd:MxҁJ{Bm^jccı`!*6(-;G uGcs4县A6/nH{eB00]OO +%+ ⥓V5X0=W2V_A| ^ ڝ5"sV1T2m6 #P9]sךBFi!U\>/O Pd77xFE$08@U2~f3:&ʚb+P rE:tt Q-^I1U8(H6 g%n Tq^ C 7S{E4y+6 )JC5o"'DL },u;>Pb''M3׃mjQ:B-~?!Md]uO(<QF.x+!(_Xg 9KgjW/y}<ѻAI-zp݁4~/Jk,8(fCi9/>P mj.~2i:xi@V~r#\mrQ#>KZZ,촡 lè$nߋaMJC7? l뤘=#? ߎRo: r,)|UI" Z9w9Vå/MT3Z^,scSjH.@41Fܰv)XH:3B7u . gO,O› 1BL`=~\ PA=bt O 3Fם`5*,.xv2תWܜrp&ۨ( aǨ~_bD U* $擴yY~ E?qT_n9uwϭKZKV=˘ )^.K 4oj׭kX/aoO- :<y]xqޥA(=#e*=-/!33ُ9ɳL, \/ 'Y@XI &$QB!c=NI[.tX?KoT$H^I,dE tW" K:@IO=e98m*c1oh&`wz.Pꦅ-^ pbzqLdž+ãz2]ƨ}j>+Zȟ hx-MM:|$0(6|Y;_6"1(P!Pr<~3GݪiKs-۫8ٟ佁Y뜔¯"'8{"JqgePeL;YuE-RvtvQF;atf]>dK Ѕ==" SK>Mo& LT\G& qm28PSuAG7&@\`uy[V~$܇cV=Y >OlE\_20M]gP= fIRPyxJ}.I1x|^*Z/W} 8Ac{e^cVP4}6 a:#QwO*I\0ʗ!Lƫ-E8ҮA+[g jB-uA} $D4]H~bpH{!^~P:s'KC}mF{Z-q ǁǹ\hl|@־nJ+wNw}+s# hОo7vG{:\MWf\BW{I3*Ŵ;^ U u3͢2qާ:C̨`%3I~j^m9VЍ;RupǛ1(8K*J.GnҪVN]N鋭y]z0; HAM QHGu:ns!hw<UV7;='R $TMWM}0ӍB$٫=R]Ӳbp7E,x]Yv]zL֘ ~dc0]gKLIxU*(-TfCNa:C_v-|'`v;+FAɇz\1P$ *8p|\x$DA5$\X2NyYlӎs]֘6'atSkO4u̘E+Zq:wցbHhFc1TíBlbwTPxkP&2g2N]@׋xZ_̤Dtô&Jxl0=ZݛT[hU$3H)#=e17Of1SJsu}ȃ +,*g|^[<2ߩwʞA_CH( anfܫ %,4` W>&tctS>7z?^물CTiRi Cvr V9YuCb|z+z 3(V$'^=.OU'M#^AAoqlZ 2~Cȏ0 X̪/:'[ficfђbl$~I+&1[7;H+I[GE*Z:K ;FźT1QԞ&;+1'hqx?| g:VG0>'옛V8{ШgrL-tS F8+I 3 ,7ykhcNb8yeLV1c?d|{aj+}]g hHMTy3'%\w~ǿ\"vC>#4 >ar>BYө~].iou{{vE^MVSzwH۹3Yۥ]#*_bͶbk59ڗ89l\oY9sR>L4Tp'` #o1=AAbW*mB}trAy\Jy_2[#!i=IyI Eḅ:CK6A1ԅ]I'MIc]pzPW9u* È{RIt5攜3RձwB 'QD|%{v+~_%fp%lrln~q LR_Y-`]G1Ey}ɳSsJH1\ 'BGpH@P CJwxy/R䅤8raj."X4{ҠY;J!oԃ-4UN״bKQ_2ieybq 2Ӯ; :F~K^ )>\uio Ab1dA{{co&XLG<ApbvA-3LŪ ѴW 咒>]S{G5+kЬ "$*vEz/e{t/ld! b;X!4'G즰zN{I.h\ѳaϽ?bϛ/ ݴ!nws\]Ohf\jjԾ0vCF"x DzBն FXh2/ew>7$MUI,!Hpu1l5'(O\b@k:`DbF,Z{ a{,'}|B%:e#>GuBBNSWۡcu?JVsZ'?tC0sf5əQQNhn6}xꍳ~!fYR$QN˥G$XlIpx *yi^9W xôBD2c,Ƚr*-^O<.>; $qu}>UN Or FBeuF ?B]#uo,*6`\' SO䭾U`QM`RSIٹ:wz?T clYhs_e`) [˅yjqărPjUXat_H"tEo݊5Ym|xDr|xS>WYH:]ѵts*~L0.R8<yI[ 횑P"ULQ(|'׺wڐzm7ME>A)wNRYw׃T5LdԼY{ˎe#uzy8waiLGq53L2ZS\w{W^C!A&<#7tf6u/Ö9f>eW[ 0nD] œ@8S/I;dV{ĥ CrN^ID'lx2l7UMˀ%f+aE<|342d2;alsMF9ncK_gh3|s#U;a=Cae֠4㞅Ȑ FyU~/ds6iTA_8n QP*jz``9,hx2U^LQ% aJHɢx&/BSYmVp$[6D y&֦3J/ڱׁ1'HuaIs#?Qo(tNV @lq*kdgz["@pU^/ yGb0ړ YTL 2ua.otXg"]3x>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrcolrjp2cOQ/R \#B@HHPHHPHHPHHP880 n߁a@ c'f QyH4Fipz {Y Tp1't=g&{ODtѴض j1R.pZgrʘUDDv`Ҵ+E.{Ã\عoz.kjEJ2lKXeRj p (utq7 >j>WxfmuIcֲ-XrrBغO.n_8D A6we[vhw6 G;L]Z'$LWp´ecB)Q қm쾯:mH7ipirK , "$ћc6m.+ ӿ5jo 7;y~־&e*Mhq> |71~ڱ?u-s%c+18ѵ#<xd^s!z0Y6ckہh6l_唫(?cDVh Ƃ(&%uXh t]S½.V#!#$@sbq:ȇڧS}]wXoKGo6 gW_ɫ&mv--|EɢL1BszRe)qjjno{]F9K{,CF.u8 Q>y[P'&`2|:5]aLI:h骷;זD 0<,5gGHGFy^B+w2dSS$J L*FznĢ߿8jjxC9w0,F*0Q)Ţnی׮le/H((23/.pA.{\43tmƕM[ =Oٸ\`$*ي$:4w rb5PFI߷gFtt 9|?–o2_[?Snzr EXCֵl?V}dCe]%"jz\]!\;Vȼn<ݩ(zo 0!y;&p|R=̧c$D$NZAuMy<KEu(5ƂG+g<' mQ-qv2k!o17)wehp=VW0ȿՃ'm">XpݧhM[%?xXT6@8k_Fiv EUtU,Dݰ[^Fק'p+˩,/C!4w7_j-#zC/H#񾷮B'Nȯ޴fI]_RIH!/h)] NQTRZjǵ z:aϞw˨u6X3H9 " y#$yvjtr*1/2rUStc.VʧaJlgVDdWBf5Ad< +bH2'miT5"a@֘܏2?2ͻ;۫oe:.hԢΡzg8HrM\^O,(ҴQ1L/`,phoJizou~L֕|Z||uy>.TaBM(3oER;Qh3!^s {2Cjoh_û__V~{ukvh#JSyKݒ"5yM^*4E4 %ac#ɍ;$76 (*Q o$p ic h5 ϙ&ζ鷘p2jp!'U㳔%,4ǥc+b2FanDZkκ.|؊.^))&i0B.?)nnXҝt"^Tu)O_[;tgq*ѩSP kIuݼG2E?3Hs])s81|ˈ PES]lZZY~Q%!g482ոK06Ŵ)}B(zɺO#Nje+L$Љ&&F&UZZufN& j>]skBn<@,rlԦ,p#$PFf=8³WĢ ҨҜ].hۮ#3(h32+ۙ}z3>Ԧoֆ K0J679y-+k c@1 ;͸ݳ^'+E@]z<MV*|bŤ oBd)ɓ8|U9B=K"zuaLljXFSnQ]"yhd6`NP՜sόCYS";?aqXBV@'6GWxLq^iM ĸykN2*Zl(s_nīWrHhſ)e :9X&.W`u\=Pz ƗO5hK@GP3՞LN=pM0&lP` c؊ Y {<w}r rd?F۟p2nn쒮<gs lUL{ep [ղI殰$'Xwa-*CyL"V&~^RA˯4ֵS & gWbkur-H$Ԉ;'vQ~sHe86$vxQJ.LBX! n}8O#ө@q\ؼDHM`O3^S'[lPHTgsxVTD@,ӦT,-ņ697]?JWM0ˈEV%I[ܘ]lW$"l]EműxB1kN5ߒiQwXrC; sE\kh}[?!qVqY*M 녈lt(dS}ȯDGTVA LN;C?) 8cK٘4">stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr0colrnjp2cOQ/00R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ B ! |!@  $|"@|!>(Zl    endstream endobj 52 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr&colrhjp2cOQ/&&R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ t ! @: @ >:c    endstream endobj 53 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr&colrsjp2cOQ/&&R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ t ! @:  %:d|"@,     endstream endobj 54 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr6+colrjp2cOQ/+6+6R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴGC $" 4: p h: U m 5:75|":$@ԨEY@b 4*P.G Hb/   endstream endobj 55 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrfcolrjp2cOQ/ffR \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴC "j ! :q z ':  7|#~{1 'l]eX   endstream endobj 56 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr{colrjp2cOQ/{{R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴt q" )@ :  0 ;:4 84 [-|#:L$B$B :Ho-W*XT   endstream endobj 57 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr+colrjp2cOQ/++R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ_ E !# 1@@U|!:Ѐ&cO@ ,|%@:0qy?  ]m   endstream endobj 58 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr.colrxjp2cOQ/..R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ t ! :  .@ |"@: (J ,Q I    endstream endobj 59 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr@+colr5jp2cOQ/+@+@R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ0RZS1*BH Sј0%"7 C@ c|"@:4р U]36"c%ȴ@LWuB ' o TcZCW]0|+@|%>@,hHb^$T ;W>="Kp]BL.5c#p`}' 3t D86wB[PIosai,A6|\UlrM,ϑu47x{xԵ R\dkO2  endstream endobj 60 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr.colr;jp2cOQ/..R \#B@HHPHHPHHPHHP880 'ϴ$CE\h#  4@:  ؍:,$ & ; خ 0 >hi:4Rx$2>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr"Ncolrjp2cOQ/N"N"R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴM`DLU" & @|!@ d tHD%\  1y   endstream endobj 62 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr"Vcolrjp2cOQ/V"V"R \#B@HHPHHPHHPHHP880 "ϴMDL" ) :v s     endstream endobj 63 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr>+colrjp2cOQ/+>+>R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴPC O"q 5:' h: @@\ *|":,ȳ}門    endstream endobj 64 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr-ncolr'jp2cOQ/n-n-R \#B@HHPHHPHHPHHP880 #ϴ8$DUh# 8@: z:Ѐ Y J@:$ * ) @ 01 >13(HIŀ    endstream endobj 65 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr &colrkjp2cOQ/& & R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ  t ! #@:  @ >s    endstream endobj 66 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr,>colrxjp2cOQ/>,>,R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ[}C z"8 &@:@>D@ :$j<h    endstream endobj 67 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrcolr}jp2cOQ/R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴt @ 1@ : bC@  z   endstream endobj 68 0 obj <>stream h244P0P044T0F F & F&K endstream endobj 69 0 obj <>/ProcSet[/PDF/Text/ImageB/ImageC]/XObject<>>>/Rotate 0/Type/Page>> endobj 70 0 obj <>stream q 0.231 0.231 0.231 rg 595.1999969 0 0 840.9600067 0 0 cm /Im0 Do Q q 28.3200073 0 0 14.3999939 0 810.7200012 cm /Im1 Do Q q 33.6000061 0 0 12.4799957 40.8000031 812.6399994 cm /Im2 Do Q q 13.4400024 0 0 12.4799957 417.1199951 810.7200012 cm /Im3 Do Q q 22.0800018 0 0 20.1600037 463.1999969 803.0399933 cm /Im4 Do Q q 14.3999939 0 0 18.2400055 534.2400055 804.9600067 cm /Im5 Do Q q 15.8399963 0 0 12.4799957 179.0399933 803.0399933 cm /Im6 Do Q q 12.4799957 0 0 14.3999939 568.8000031 682.0800018 cm /Im7 Do Q q 11.5200043 0 0 18.2400055 570.7200012 605.2799988 cm /Im8 Do Q q 12.4799957 0 0 18.2400055 565.9199982 474.7200012 cm /Im9 Do Q q 19.1999969 0 0 45.1199951 563.0399933 386.3999939 cm /Im10 Do Q q 12.4799957 0 0 18.2400055 568.8000031 344.1600037 cm /Im11 Do Q q 12.4799957 0 0 14.3999939 568.8000031 317.2799988 cm /Im12 Do Q q 12.4799957 0 0 18.2400055 563.0399933 90.7200012 cm /Im13 Do Q q 18.2400055 0 0 43.1999969 563.0399933 27.3600006 cm /Im14 Do Q q 18.2400055 0 0 20.1600037 17.7599945 21.6000061 cm /Im15 Do Q q 12.9600067 0 0 18.2400055 0 21.6000061 cm /Im16 Do Q BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf 0.05 Tc 3 Tr 8.7455 0 0 7.7 234.91 776.89 Tm (!SOC )Tj EMC /Suspect <>BDC 0 Tc 7.7 0 0 7.7 257.26 776.89 Tm (Y )Tj EMC ET BT /T1_0 1 Tf 0.05 Tc 8.0635 0 0 7.7 263.51 776.89 Tm (AN )Tj 8.2507 0 0 7.7 276.95 776.89 Tm (ATE )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 8.2774 0 0 7.7 298.07 776.89 Tm (ASTHMA )Tj EMC ET BT /T1_0 1 Tf -0.035 Tc 10.545 0 0 11.1 509.7 776.41 Tm (279 )Tj 7.6478 0 0 8.3 46.96 753.36 Tm (7. )Tj -0.0079 Tc 8.3 0 0 8.3 61.4 753.36 Tm (Davies )Tj -0.0117 Tc 3.239 0 Td (RJ)Tj 0.467 0.467 0.459 rg 0 Tc 1.088 0 Td (, )Tj 0.239 0.239 0.235 rg -0.0167 Tc 0.705 0 Td (But)Tj 0.376 0.376 0.372 rg 0.0313 Tc 1.383 0 Td (cher )Tj 0.314 0.318 0.31 rg -0.035 Tc 8.2664 0 0 8.3 133.4 753.36 Tm (BT)Tj 0.467 0.467 0.459 rg 0 Tc 8.3 0 0 8.3 143.39 753.36 Tm (, )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0123 Tc 8.3 0 0 8.3 149.2 753.36 Tm (O'Neil )Tj EMC /Suspect <>BDC 0.0285 Tc 3.123 0 Td (CE, )Tj EMC /Suspect <>BDC -0.0036 Tc 2.016 0 Td (Salvaggio )Tj EMC ET BT /T1_0 1 Tf 0.0157 Tc 8.3 0 0 8.3 227.9504 753.36 Tm (JE. )Tj ET BT /Suspect <>BDC 0.467 0.467 0.459 rg /T1_0 1 Tf 0 Tc 8.3 0 0 8.3 242.3011 753.36 Tm (-)Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0414 Tc 8.3 0 0 8.3 250.4932 753.36 Tm (The )Tj ET BT /Suspect <>BDC /T1_1 1 Tf -0.035 Tc 7.9445 0 0 8.1 267.26 753.36 Tm (in )Tj EMC ET BT 0.376 0.376 0.372 rg /T1_1 1 Tf -0.0253 Tc 8.1 0 0 8.1 47.47 744.24 Tm (vitro )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf -0.0225 Tc 8.3 0 0 8.3 64.23 744.24 Tm (effect )Tj EMC ET BT 0.376 0.376 0.372 rg /T1_0 1 Tf 0.05 Tc 8.9033 0 0 8.3 84.4 744.24 Tm (of )Tj 0.314 0.318 0.31 rg 0.0116 Tc 8.3 0 0 8.3 94.06 744.24 Tm (toluene )Tj 0.0097 Tc 3.231 0 Td (diisocyanate )Tj 0.0035 Tc 5.436 0 Td (on )Tj 0.376 0.376 0.372 rg 0.0045 Tc 1.331 0 Td (lymphocyte )Tj 0.314 0.318 0.31 rg -0.0099 Tc 4.972 0 Td (cyclic )Tj 0.008 Tc 2.545 0 Td (adenosine )Tj 0.0175 Tc -23.183 -1.04 Td (monophosphate )Tj 0.376 0.376 0.372 rg 0.0211 Tc 7.001 0 Td (production )Tj 0.314 0.318 0.31 rg -0.0073 Tc 5.031 0 Td (by )Tj 0.0102 Tc 1.436 0 Td (isoproterenol)Tj 0.467 0.467 0.459 rg 0 Tc 5.487 0 Td (, )Tj 0.314 0.318 0.31 rg 0.015 Tc 0.653 0 Td (prostaglandin )Tj 0.0358 Tc 6.061 0 Td (and )Tj -0.0056 Tc -25.669 -1.1 Td (histamine: )Tj 0.376 0.376 0.372 rg 0 Tc 4.387 0 Td (a )Tj 0.314 0.318 0.31 rg -0.0039 Tc 0.763 0 Td (possible )Tj 0.0133 Tc 3.466 0 Td (mode )Tj 0.376 0.376 0.372 rg 0.05 Tc 8.9033 0 0 8.3 139.12 726.48 Tm (of )Tj 0.314 0.318 0.31 rg 0.0065 Tc 8.3 0 0 8.3 148.24 726.48 Tm (action. )Tj /T1_1 1 Tf 0 Tc 8.2 0 0 8.2 173.37 726.48 Tm (J )Tj 0.0147 Tc 8.1 0 0 8.1 179.64 726.48 Tm (Allergy )Tj 0.0026 Tc 3.225 0 Td (Clin )Tj 0.03 Tc 1.964 0 Td (lmmunol)Tj 0.467 0.467 0.459 rg 0 Tc 3.63 0 Td (, )Tj 0.376 0.376 0.372 rg /T1_0 1 Tf -0.035 Tc 8.241 0 0 8.3 256.04 726.48 Tm (1917, )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0253 Tc 7.9001 0 0 7.9001 46.46 717.85 Tm (60, )Tj EMC ET BT /T1_0 1 Tf -0.035 Tc 8.1639 0 0 8.3 59.47 717.85 Tm (223)Tj 0.565 0.569 0.557 rg 0 Tc 8.3 0 0 8.3 71.42 717.85 Tm (-)Tj 0.314 0.318 0.31 rg -0.035 Tc 8.1639 0 0 8.3 75.79 717.85 Tm (229)Tj 0.467 0.467 0.459 rg 0 Tc 8.3 0 0 8.3 88.15 717.85 Tm (. )Tj 0.314 0.318 0.31 rg -0.035 Tc 7.7659 0 0 8.3 46.9 708.73 Tm (8. )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0233 Tc 8.3 0 0 8.3 60.4 708.73 Tm (O'Brien )Tj EMC ET BT /T1_0 1 Tf 0.0282 Tc 8.3 0 0 8.3 92.604 708.73 Tm (M, )Tj 0.0131 Tc 1.793 0 Td (Harries )Tj 0.029 Tc 3.643 0 Td (MG, )Tj -0.0123 Tc 2.602 0 Td (Burge )Tj ET BT /Suspect <>BDC 0.239 0.239 0.235 rg /T1_0 1 Tf -0.035 Tc 8.1383 0 0 8.3 184.76 708.73 Tm (PS)Tj 0.376 0.376 0.372 rg 0 Tc 8.3 0 0 8.3 193.79 708.73 Tm (, )Tj EMC /Suspect <>BDC 0.314 0.318 0.31 rg -0.0149 Tc 0.878 0 Td (Pepys )Tj EMC ET BT /T1_0 1 Tf -0.0169 Tc 8.6 0 0 8.6 225.07 708.73 Tm (J. )Tj ET BT /Suspect <>BDC 0.565 0.569 0.557 rg /T1_0 1 Tf 0 Tc 8.6 0 0 8.6 235.5792 708.73 Tm (-)Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0163 Tc 8.3 0 0 8.3 245.21 708.73 Tm (Toluene )Tj 0.0042 Tc -23.943 -1.041 Td (diisocyanatc-induced )Tj 0.0092 Tc 8.848 0 Td (asthma. )Tj /T1_2 1 Tf 0.05 Tc 8.7408 0 0 8.1 148.56 700.09 Tm (I. )Tj /T1_0 1 Tf 0.0068 Tc 8.3 0 0 8.3 156.44 700.09 Tm (Reactions )Tj -0.0228 Tc 4.34 0 Td (to )Tj 0.0418 Tc 1.035 0 Td (TDI, )Tj 0.0453 Tc (MDI)Tj 0.467 0.467 0.459 rg 0 Tc 4.446 0 Td (, )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0424 Tc 8.3 0 0 8.3 242.3616 700.09 Tm (HOI )Tj EMC ET BT /T1_0 1 Tf 0.0358 Tc 8.3 0 0 8.3 260.0821 700.09 Tm (and )Tj -0.0026 Tc -25.726 -1.099 Td (histamine. )Tj ET BT /Suspect <>BDC 0.376 0.376 0.372 rg /T1_1 1 Tf -0.035 Tc 7.2739 0 0 8.1 84.34 690.97 Tm (Clii1 )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_1 1 Tf 0.0023 Tc 8.1 0 0 8.1 101.4 690.97 Tm (Allergy, )Tj /T1_0 1 Tf -0.035 Tc 8.241 0 0 8.3 130.76 690.97 Tm (1979, )Tj -0.0311 Tc 8.3 0 0 8.3 150.63 690.97 Tm (9, )Tj 0 Tc 1.133 0 Td (1)Tj 0.565 0.569 0.557 rg 0.428 0 Td (-)Tj 0.314 0.318 0.31 rg -0.0314 Tc 0.52 0 Td (6. )Tj 0.376 0.376 0.372 rg -0.035 Tc 7.6511 0 0 8.3 46.47 681.85 Tm (9. )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0137 Tc 8.3 0 0 8.3 60.4 681.85 Tm (O'Brien )Tj EMC ET BT /T1_0 1 Tf 0.0282 Tc 8.3 0 0 8.3 90.6784 681.85 Tm (M, )Tj 0.0136 Tc 1.571 0 Td (Newman-Taylor )Tj -0.0064 Tc 7.165 0 Td (AJ)Tj 0.467 0.467 0.459 rg 0 Tc 1.142 0 Td (, )Tj 0.314 0.318 0.31 rg -0.0136 Tc 0.705 0 Td (Burge, )Tj ET BT /Suspect <>BDC 0.376 0.376 0.372 rg /T1_1 1 Tf -0.0294 Tc 8.8 0 0 8.8 203.59 681.85 Tm (PS )Tj EMC ET BT /T1_1 1 Tf 0.05 Tc 10.9819 0 0 8.1 216.38 681.85 Tm (eta/.-)Tj 0.239 0.239 0.235 rg /T1_0 1 Tf 0 Tc 8.3 0 0 8.3 245.21 681.85 Tm (T)Tj 0.376 0.376 0.372 rg 0.0151 Tc 0.635 0 Td (oluene )Tj 0.314 0.318 0.31 rg 0.0042 Tc -24.636 -1.041 Td (diisocyanate-induced )Tj 0.0263 Tc 9.137 0 Td (asthma)Tj 0.467 0.467 0.459 rg 0 Tc 2.996 0 Td (. )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_2 1 Tf -0.035 Tc 7.2258 0 0 8.1 153.4 673.21 Tm (IT)Tj 0.467 0.467 0.459 rg 0 Tc 8.1 0 0 8.1 159.14 673.21 Tm (. )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0336 Tc 8.3 0 0 8.3 165.06 673.21 Tm (Inhalation )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0224 Tc 8.3 0 0 8.3 204.8834 673.21 Tm (chaUcnge )Tj EMC ET BT /T1_0 1 Tf -0.0094 Tc 8.3 0 0 8.3 241.42 673.21 Tm (tests )Tj 0.0358 Tc 2.248 0 Td (and )Tj 0.0139 Tc -25.724 -1.099 Td (bronchial )Tj -0.0012 Tc 4.219 0 Td (reactivity )Tj 0.0011 Tc 4.035 0 Td (studies. )Tj ET BT /Suspect <>BDC 0.376 0.376 0.372 rg /T1_1 1 Tf 0.0026 Tc 8.1 0 0 8.1 143.36 664.09 Tm (Clin )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_1 1 Tf 0.0107 Tc 8.1 0 0 8.1 160.4429 664.09 Tm (Allergy, )Tj 0.239 0.239 0.235 rg -0.0338 Tc 7.6 0 0 7.6 190.43 664.09 Tm (191)Tj 0.376 0.376 0.372 rg 0.0193 Tc 1.462 0 Td (9, )Tj 0.314 0.318 0.31 rg /T1_0 1 Tf -0.0311 Tc 8.3 0 0 8.3 210.15 664.09 Tm (9, )Tj 0.376 0.376 0.372 rg 0 Tc 1.099 0 Td (7)Tj 0.565 0.569 0.557 rg 0.461 0 Td (-)Tj 0.314 0.318 0.31 rg -0.035 Tc 7.7937 0 0 8.3 228.21 664.09 Tm (15. )Tj 0.376 0.376 0.372 rg -23.28 -1.042 Td (10. )Tj ET BT /Suspect <>BDC 0.239 0.239 0.235 rg /T1_0 1 Tf -0.0058 Tc 8.3 0 0 8.3 64.28 655.44 Tm (Pepy)Tj 0.376 0.376 0.372 rg 0 Tc 1.957 0 Td (s )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf -0.035 Tc 8.8613 0 0 8.9 86.35 655.44 Tm (J, )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0004 Tc 8.3 0 0 8.3 95 655.44 Tm (Pickering )Tj EMC /Suspect <>BDC 0.0296 Tc 4.043 0 Td (CAC, )Tj EMC ET BT /T1_0 1 Tf 0.0132 Tc 8.3 0 0 8.3 151.1246 655.44 Tm (Terry )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0246 Tc 8.3 0 0 8.3 172.7129 655.44 Tm (OJ. )Tj EMC ET BT 0.467 0.467 0.459 rg /T1_0 1 Tf 0 Tc 8.3 0 0 8.3 187.0968 655.44 Tm (-)Tj 0.314 0.318 0.31 rg 0.0157 Tc 0.878 0 Td (Asthma )Tj 0.0059 Tc 3.519 0 Td (due )Tj 0.035 Tc 1.8 0 Td (to )Tj 0.0139 Tc 1.093 0 Td (inhaled )Tj 0.376 0.376 0.372 rg -0.0079 Tc -24.29 -1.098 Td (chemical )Tj 0.0123 Tc 4.106 0 Td (agents )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0 Tc 8.3 0 0 8.3 105.9726 646.3266 Tm (-)Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf -0.0048 Tc 8.3 0 0 8.3 115.169 646.3266 Tm (tolylene )Tj 0.0073 Tc 3.694 0 Td (diisocyanate. )Tj ET BT /Suspect <>BDC 0.376 0.376 0.372 rg /T1_1 1 Tf -0.0171 Tc 8.1 0 0 8.1 195.2 646.33 Tm (Clin )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_1 1 Tf 0.0107 Tc 8.1 0 0 8.1 213.2387 646.33 Tm (Allergy, )Tj /T1_0 1 Tf -0.035 Tc 7.8965 0 0 8.3 245.01 646.33 Tm (1972)Tj 0.467 0.467 0.459 rg 0 Tc 8.3 0 0 8.3 260.03 646.33 Tm (, )Tj 0.314 0.318 0.31 rg -0.035 Tc 7.5852 0 0 8.3 266.84 646.33 Tm (2, )Tj 0.376 0.376 0.372 rg 0.0031 Tc 8.3 0 0 8.3 46.03 637.68 Tm (225-236. )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0427 Tc 8.3 0 0 8.3 46.9762 628.5583 Tm (II)Tj 0.467 0.467 0.459 rg 0 Tc 0.854 0 Td (. )Tj EMC /Suspect <>BDC 0.376 0.376 0.372 rg 0.0124 Tc 1.167 0 Td (Cirla )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.05 Tc 8.3471 0 0 8.3 84.47 628.56 Tm (AM, )Tj -0.0073 Tc 8.3 0 0 8.3 104.63 628.56 Tm (Aresini )Tj 0.239 0.239 0.235 rg 0 Tc 3.404 0 Td (G)Tj 0.376 0.376 0.372 rg 0.804 0 Td (, )Tj 0.314 0.318 0.31 rg -0.002 Tc 0.705 0 Td (Briatico )Tj 0.0262 Tc 3.696 0 Td (G, )Tj 0.376 0.376 0.372 rg /T1_1 1 Tf 0.05 Tc 8.2481 0 0 8.1 188.09 628.56 Tm (et )Tj 0.314 0.318 0.31 rg 0.014 Tc 7.8001 0 0 7.8001 197.71 628.56 Tm (a/. )Tj 0.376 0.376 0.372 rg /T1_0 1 Tf 0 Tc 1.533 0 Td (-)Tj 0.314 0.318 0.31 rg 0.0097 Tc 8.3 0 0 8.3 218.38 628.56 Tm (Valutazione )Tj 0.0017 Tc 5.313 0 Td (dei )Tj 0.376 0.376 0.372 rg -0.0083 Tc -26.082 -1.099 Td (criteri )Tj 0.314 0.318 0.31 rg -0.0162 Tc 3.007 0 Td (di )Tj 0.005 Tc 1.388 0 Td (diagnosi )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0121 Tc 8.3 0 0 8.3 116.5556 619.4383 Tm (dell'asma )Tj EMC ET BT /T1_0 1 Tf 0.005 Tc 8.3 0 0 8.3 154.0882 619.4383 Tm (professionale )Tj 0.0491 Tc 6.004 0 Td (da )Tj -0.0012 Tc 1.678 0 Td (isocianati. )Tj /T1_1 1 Tf 0.0406 Tc 8.1 0 0 8.1 257.84 619.44 Tm (Med )Tj ET BT /Suspect <>BDC /T1_1 1 Tf 0.0005 Tc 8.1 0 0 8.1 46.1627 610.7973 Tm (Lavoro, )Tj EMC ET BT /T1_0 1 Tf -0.035 Tc 8.241 0 0 8.3 75.08 610.8 Tm (1975, )Tj -0.0055 Tc 8.3 0 0 8.3 94.94 610.8 Tm (66, )Tj 0.376 0.376 0.372 rg 0.0365 Tc 1.56 0 Td (5-23)Tj 0.239 0.239 0.235 rg 0 Tc 2.017 0 Td (. )Tj ET BT /Suspect <>BDC 0.376 0.376 0.372 rg /T1_0 1 Tf -0.035 Tc 8.2267 0 0 8.3 45.8 601.68 Tm (12. )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.026 Tc 8.3 0 0 8.3 63.32 601.68 Tm (Butcher )Tj -0.0293 Tc 3.933 0 Td (BT, )Tj 0.0458 Tc 2.14 0 Td (Karr )Tj 0.05 Tc 8.3251 0 0 8.3 135.32 601.68 Tm (RM, )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0239 Tc 8.3 0 0 8.3 156.4 601.68 Tm (O'Neil )Tj EMC /Suspect <>BDC 0.0285 Tc 3.354 0 Td (CE, )Tj EMC ET BT /T1_1 1 Tf 0.05 Tc 8.2481 0 0 8.1 202.49 601.68 Tm (et )Tj -0.0054 Tc 8.1 0 0 8.1 213.55 601.68 Tm (a/. )Tj ET BT /Suspect <>BDC 0.565 0.569 0.557 rg /T1_0 1 Tf 0 Tc 8.1 0 0 8.1 226.9474 601.68 Tm (-)Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0207 Tc 8.3 0 0 8.3 237.06 601.68 Tm (Inhalation )Tj -0.0059 Tc -23.077 -1.099 Td (challenge )Tj 0.0358 Tc 4.395 0 Td (and )Tj 0.0128 Tc 2.208 0 Td (pharmachologic )Tj 0.0044 Tc 7.155 0 Td (studies )Tj 0.05 Tc 8.9033 0 0 8.3 188.08 592.56 Tm (of )Tj 0.002 Tc 8.3 0 0 8.3 200.62 592.56 Tm (toluene )Tj 0.0097 Tc 3.578 0 Td (diisocyanate )Tj 0.0034 Tc -22.267 -1.041 Td (\(TDI\)-sensitive )Tj 0.0006 Tc 6.951 0 Td (workers. )Tj /T1_3 1 Tf 0 Tc 8 0 0 8 138.65 583.92 Tm (J )Tj /T1_1 1 Tf 0.0147 Tc 8.1 0 0 8.1 149.4 583.92 Tm (Allergy )Tj ET BT /Suspect <>BDC /T1_1 1 Tf -0.0171 Tc 8.1 0 0 8.1 180.3177 583.92 Tm (Clin )Tj EMC ET BT /T1_1 1 Tf 0.0154 Tc 8.1 0 0 8.1 200.0655 583.92 Tm (lmmunol, )Tj /T1_0 1 Tf -0.0242 Tc 8.3 0 0 8.3 238.27 583.92 Tm (1979, )Tj -0.0344 Tc 2.914 0 Td (64, )Tj 0.0023 Tc -26.047 -1.04 Td (146-152. )Tj -0.035 Tc 7.7937 0 0 8.3 46.29 566.17 Tm (13. )Tj 0.0162 Tc 8.3 0 0 8.3 63.8 566.17 Tm (Moscato )Tj 0.0262 Tc 3.87 0 Td (G, )Tj -0.0052 Tc 1.335 0 Td (Pozzoli )Tj 0.05 Tc 11.9845 0 0 8.3 134.32 566.17 Tm (I.-)Tj 0.0113 Tc 8.3 0 0 8.3 148.76 566.17 Tm (Presentazione )Tj -0.0162 Tc 5.952 0 Td (di )Tj 0.0306 Tc 1.108 0 Td (una )Tj 0.0264 Tc 1.783 0 Td (cabina )Tj 0.05 Tc 8.4273 0 0 8.3 246.73 566.17 Tm (per )Tj 0.0014 Tc 8.3 0 0 8.3 260.62 566.17 Tm (test )Tj 0.0416 Tc -25.973 -1.099 Td (di )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0053 Tc 8.3 0 0 8.3 55.2116 557.0483 Tm (broncostimol!lzione: )Tj EMC ET BT 0.376 0.376 0.372 rg /T1_0 1 Tf 0.0087 Tc 8.3 0 0 8.3 126.16 557.0483 Tm (comunicazione )Tj 0.314 0.318 0.31 rg 0.009 Tc 6.488 0 Td (preliminare )Tj 0.0193 Tc 5.029 0 Td (riguardantc )Tj -0.0281 Tc 5.082 0 Td (gli )Tj 0.376 0.376 0.372 rg 0.0012 Tc -26.314 -1.041 Td (aspetti )Tj 0.314 0.318 0.31 rg -0.0106 Tc 3.014 0 Td (tecnici. )Tj /T1_1 1 Tf 0 Tc 8.4 0 0 8.4 97.27 548.41 Tm (G )Tj 0.0103 Tc 8.1 0 0 8.1 105.68 548.41 Tm (It )Tj 0.05 Tc 8.5221 0 0 8.1 113.37 548.41 Tm (Med )Tj ET BT /Suspect <>BDC /T1_1 1 Tf 0.0097 Tc 8.1 0 0 8.1 132.08 548.41 Tm (Lav, )Tj EMC /Suspect <>BDC /T1_0 1 Tf -0.035 Tc 8.0056 0 0 8.3 150.44 548.41 Tm (1980, )Tj EMC ET BT /T1_0 1 Tf 0.0207 Tc 8.3 0 0 8.3 169.87 548.41 Tm (2, )Tj -0.035 Tc 7.7728 0 0 8.3 179.73 548.41 Tm (167)Tj 0.565 0.569 0.557 rg 0 Tc 8.3 0 0 8.3 190.94 548.41 Tm (-)Tj 0.314 0.318 0.31 rg -0.035 Tc 7.7728 0 0 8.3 196.53 548.41 Tm (169)Tj 0.467 0.467 0.459 rg 0 Tc 8.3 0 0 8.3 207.67 548.41 Tm (. )Tj 0.314 0.318 0.31 rg -0.035 Tc 7.7937 0 0 8.3 45.81 538.8 Tm (14. )Tj -0.0125 Tc 8.3 0 0 8.3 63.8 538.8 Tm (Lam )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0196 Tc 8.3 0 0 8.3 83.3714 538.8 Tm (S, )Tj EMC ET BT /T1_0 1 Tf 0.0414 Tc 8.3 0 0 8.3 93.5306 538.8 Tm (Tan )Tj 0.05 Tc 8.5832 0 0 8.3 111.8 538.8 Tm (F, )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0367 Tc 8.3 0 0 8.3 122.8 538.8 Tm (Chan )Tj EMC ET BT /T1_0 1 Tf 0.0223 Tc 8.3 0 0 8.3 145.8823 538.8 Tm (H, )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0197 Tc 8.3 0 0 8.3 158.324 538.8 Tm (Chan-Yeung )Tj EMC ET BT /T1_0 1 Tf -0.0297 Tc 8.3 0 0 8.3 206.3644 538.8 Tm (M. )Tj 0.647 0.647 0.639 rg 0 Tc 1.67 0 Td (-)Tj 0.314 0.318 0.31 rg 0.0091 Tc 1.106 0 Td (Relationship )Tj -0.0133 Tc -22.143 -1.04 Td (between )Tj 0.0083 Tc 4.045 0 Td (types )Tj 0.05 Tc 8.9033 0 0 8.3 103.6 530.17 Tm (of )Tj 0.0219 Tc 8.3 0 0 8.3 117.04 530.17 Tm (asthmatic )Tj 0.0078 Tc 4.808 0 Td (reaction, )Tj -0.007 Tc 4.337 0 Td (non-specific )Tj 0.0067 Tc 5.67 0 Td (bronchial )Tj 0.239 0.239 0.235 rg -0.0039 Tc -23.424 -1.041 Td (reactivit)Tj 0.376 0.376 0.372 rg -0.035 Tc 8.0935 0 0 8.3 72.95 521.53 Tm (y, )Tj 0.314 0.318 0.31 rg 0.0069 Tc 8.3 0 0 8.3 82.48 521.53 Tm (and )Tj 0.376 0.376 0.372 rg -0.0242 Tc 1.961 0 Td (spec)Tj 0.239 0.239 0.235 rg -0.035 Tc 7.9415 0 0 8.3 113.22 521.53 Tm (ific )Tj 0.0087 Tc 8.3 0 0 8.3 126.66 521.53 Tm (IgE )Tj 0.314 0.318 0.31 rg 0.0141 Tc 1.848 0 Td (antibodies )Tj -0.009 Tc 4.686 0 Td (in )Tj 0.012 Tc 1.224 0 Td (patients )Tj -0.0122 Tc 3.641 0 Td (with )Tj -0.0017 Tc 2.198 0 Td (red )Tj 0.0284 Tc 1.669 0 Td (cedar )Tj 0.0188 Tc -25.099 -1.099 Td (asthma. )Tj /T1_1 1 Tf 0 Tc 8.2 0 0 8.2 74.49 512.41 Tm (J )Tj 0.0147 Tc 8.1 0 0 8.1 81.24 512.41 Tm (Allergy )Tj ET BT /Suspect <>BDC /T1_1 1 Tf -0.0171 Tc 8.1 0 0 8.1 108.7962 512.41 Tm (Clin )Tj EMC /Suspect <>BDC 0.0239 Tc 1.964 0 Td (lnmumol, )Tj EMC ET BT /T1_0 1 Tf -0.035 Tc 8.241 0 0 8.3 160.04 512.41 Tm (1983, )Tj 0.376 0.376 0.372 rg -0.0344 Tc 8.3 0 0 8.3 180.39 512.41 Tm (72, )Tj 0.314 0.318 0.31 rg 0.0023 Tc 1.595 0 Td (134-139. )Tj -0.035 Tc 7.7937 0 0 8.3 45.81 503.28 Tm (15. )Tj 0.0307 Tc 8.3 0 0 8.3 63.32 503.28 Tm (Durham )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.027 Tc 8.3 0 0 8.3 93.9304 503.28 Tm (SR)Tj 0.467 0.467 0.459 rg 0 Tc 1.275 0 Td (, )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0265 Tc 8.3 0 0 8.3 108.4056 503.28 Tm (Graneek )Tj -0.0345 Tc 3.88 0 Td (BJ, )Tj 0.0169 Tc 1.504 0 Td (Hawkins )Tj ET BT /Suspect <>BDC 0.239 0.239 0.235 rg /T1_0 1 Tf -0.035 Tc 8.194 0 0 8.3 185.72 503.28 Tm (R, )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0088 Tc 8.3 0 0 8.3 195.88 503.28 Tm (Newman-Taylor )Tj -0.0125 Tc 6.992 0 Td (AJ.)Tj 0.565 0.569 0.557 rg 0 Tc 1.608 0 Td (\255)Tj 0.314 0.318 0.31 rg 0.0414 Tc -26.83 -1.04 Td (The )Tj 0.0054 Tc 1.972 0 Td (temporal )Tj 0.0077 Tc 3.992 0 Td (relationship )Tj -0.0037 Tc 5.149 0 Td (between )Tj -0.0073 Tc 3.634 0 Td (increases )Tj -0.035 Tc 7.9356 0 0 8.3 199.62 494.65 Tm (in )Tj 0.0138 Tc 8.3 0 0 8.3 208.24 494.65 Tm (airway )Tj -0.0096 Tc 3.131 0 Td (responsive\255)Tj -0.0135 Tc -22.786 -1.099 Td (ness )Tj -0.0228 Tc 2.428 0 Td (to )Tj 0.0139 Tc 1.505 0 Td (histamine )Tj 0.0358 Tc 4.676 0 Td (and )Tj 0.0263 Tc 2.257 0 Td (late )Tj 0.0219 Tc 2.196 0 Td (asthmatic )Tj 0.376 0.376 0.372 rg -0.0014 Tc 4.693 0 Td (responses )Tj 0.314 0.318 0.31 rg -0.004 Tc 4.677 0 Td (induced )Tj -0.035 Tc 8.0386 0 0 8.3 264.01 485.53 Tm (by )Tj 0.0111 Tc 8.3 0 0 8.3 45.04 476.41 Tm (occupational )Tj 0.0071 Tc 5.552 0 Td (agents. )Tj /T1_1 1 Tf 0 Tc 7.8001 0 0 7.8001 117.68 476.41 Tm (J )Tj 0.0048 Tc 8.1 0 0 8.1 124.92 476.41 Tm (Allergy )Tj ET BT /Suspect <>BDC 0.376 0.376 0.372 rg /T1_1 1 Tf 0.0465 Tc 8.1 0 0 8.1 151.5204 476.41 Tm (Cli)Tj 0.239 0.239 0.235 rg 0 Tc 1.259 0 Td (n )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_1 1 Tf 0.0154 Tc 8.1 0 0 8.1 168.3846 476.41 Tm (lmmunol, )Tj /T1_0 1 Tf -0.035 Tc 8.0056 0 0 8.3 203.72 476.41 Tm (1987, )Tj -0.0344 Tc 8.3 0 0 8.3 223.59 476.41 Tm (79, )Tj 0.0193 Tc 1.502 0 Td (398-406)Tj 0.467 0.467 0.459 rg 0 Tc 3.461 0 Td (. )Tj 0.314 0.318 0.31 rg -0.035 Tc 7.3607 0 0 8.3 45.83 467.76 Tm (16. )Tj -0.0125 Tc 8.3 0 0 8.3 63.32 467.76 Tm (Lam )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0 Tc 8.3 0 0 8.3 81.9286 467.76 Tm (S)Tj 0.467 0.467 0.459 rg 0.523 0 Td (, )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf -0.0025 Tc 8.3 0 0 8.3 91.6479 467.76 Tm (Wong )Tj 0.0116 Tc 2.833 0 Td (R, )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0197 Tc 8.3 0 0 8.3 126.1593 467.76 Tm (Chan-Yeung )Tj EMC ET BT /T1_0 1 Tf -0.0297 Tc 8.3 0 0 8.3 173.2369 467.76 Tm (M. )Tj 0.467 0.467 0.459 rg 0 Tc 1.554 0 Td (-)Tj 0.314 0.318 0.31 rg -0.0064 Tc 0.942 0 Td (Non-specific )Tj 0.0139 Tc 5.49 0 Td (bronchial )Tj -0.0076 Tc -23.424 -1.098 Td (reactivity )Tj 0.376 0.376 0.372 rg -0.009 Tc 4.157 0 Td (in )Tj 0.314 0.318 0.31 rg 0.0164 Tc 1.155 0 Td (occupational )Tj 0.0188 Tc 5.667 0 Td (asthma. )Tj /T1_1 1 Tf 0 Tc 8.2 0 0 8.2 166.65 458.65 Tm (J )Tj 0.0147 Tc 8.1 0 0 8.1 173.88 458.65 Tm (Allergy )Tj ET BT /Suspect <>BDC 0.376 0.376 0.372 rg /T1_1 1 Tf -0.0171 Tc 8.1 0 0 8.1 201.9222 458.65 Tm (C/in )Tj EMC ET BT 0.239 0.239 0.235 rg /T1_1 1 Tf 0.0069 Tc 8.1 0 0 8.1 219.2724 458.65 Tm (lmmuno/, )Tj 0.314 0.318 0.31 rg /T1_0 1 Tf -0.035 Tc 7.8965 0 0 8.3 254.61 458.65 Tm (1979)Tj 0.467 0.467 0.459 rg 0 Tc 8.3 0 0 8.3 269.63 458.65 Tm (, )Tj 0.314 0.318 0.31 rg -0.0344 Tc -27.119 -1.042 Td (63, )Tj 0.0192 Tc 1.567 0 Td (28-34. )Tj -0.035 Tc 7.7937 0 0 8.3 45.33 440.41 Tm (17. )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0047 Tc 8.3 0 0 8.3 62.73 440.41 Tm (Smith )Tj EMC ET BT 0.239 0.239 0.235 rg /T1_0 1 Tf 0.0058 Tc 8.3 0 0 8.3 86.8664 440.41 Tm (AB)Tj 0.376 0.376 0.372 rg 0 Tc 1.431 0 Td (, )Tj 0.314 0.318 0.31 rg 0.0282 Tc 0.647 0 Td (Brooks )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0225 Tc 8.3 0 0 8.3 133.28 440.41 Tm (SM)Tj 0.467 0.467 0.459 rg 0 Tc 1.506 0 Td (, )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0173 Tc 8.3 0 0 8.3 151.6313 440.41 Tm (Blanchard )Tj 0.0053 Tc 4.741 0 Td (J, )Tj 0.376 0.376 0.372 rg /T1_1 1 Tf 0.05 Tc 8.2481 0 0 8.1 200.57 440.41 Tm (et )Tj 0.314 0.318 0.31 rg 0.0022 Tc 8.1 0 0 8.1 211.15 440.41 Tm (a/)Tj 0.467 0.467 0.459 rg 0 Tc 0.826 0 Td (. )Tj ET BT /Suspect <>BDC 0.565 0.569 0.557 rg /T1_0 1 Tf 8.1 0 0 8.1 223.5916 440.41 Tm (-)Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf -0.0037 Tc 8.3 0 0 8.3 232.31 440.41 Tm (Absence )Tj 0.376 0.376 0.372 rg 0.05 Tc 8.9033 0 0 8.3 264.88 440.41 Tm (of )Tj 0.314 0.318 0.31 rg 0.0022 Tc 8.3 0 0 8.3 44.56 431.76 Tm [(airway )-203(hyperreactivity )]TJ 0.035 Tc 9.723 0 Td (to )Tj 0.0108 Tc 1.214 0 Td (methacholine )Tj -0.009 Tc 5.893 0 Td (in )Tj 0.376 0.376 0.372 rg 0 Tc 1.155 0 Td (a )Tj 0.314 0.318 0.31 rg 0.013 Tc 0.934 0 Td (worker )Tj -0.0107 Tc 3.283 0 Td (sensitized )Tj ET BT /Suspect <>BDC 0.376 0.376 0.372 rg /T1_0 1 Tf -0.0228 Tc 8.3 0 0 8.3 264.9333 431.76 Tm (to )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.002 Tc 8.3 0 0 8.3 44.6098 422.6466 Tm (toluene )Tj 0.0097 Tc 3.289 0 Td (diisocyanate )Tj 0.0081 Tc 5.434 0 Td (\(TDI\). )Tj /T1_3 1 Tf 0 Tc 7.7 0 0 7.7 141.53 422.65 Tm (J )Tj ET BT /Suspect <>BDC /T1_1 1 Tf 0.0046 Tc 8.1 0 0 8.1 148.66 422.65 Tm (Occup )Tj EMC ET BT 0.239 0.239 0.235 rg /T1_1 1 Tf 0.05 Tc 8.2715 0 0 8.1 172.89 422.65 Tm (Med)Tj 0.376 0.376 0.372 rg 0 Tc 8.1 0 0 8.1 188.19 422.65 Tm (, )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf -0.035 Tc 8.0056 0 0 8.3 193.64 422.65 Tm (1980, )Tj EMC ET BT /T1_0 1 Tf 8.2681 0 0 8.3 213.55 422.65 Tm (22, )Tj -0.0087 Tc 8.3 0 0 8.3 225.98 422.65 Tm (327)Tj 0.467 0.467 0.459 rg 0 Tc 1.446 0 Td (-)Tj 0.314 0.318 0.31 rg -0.0313 Tc 0.578 0 Td (331. )Tj -0.035 Tc 7.7937 0 0 8.3 44.85 414 Tm (18. )Tj 0.239 0.239 0.235 rg 0.0091 Tc 8.3 0 0 8.3 62.84 414 Tm (Hargreave )Tj 0.314 0.318 0.31 rg 0.0235 Tc 4.684 0 Td (FE, )Tj 0.239 0.239 0.235 rg 0.0161 Tc 1.966 0 Td (Ramsdale )Tj 0.314 0.318 0.31 rg 0.0251 Tc 4.452 0 Td (EH, )Tj ET BT /Suspect <>BDC 0.239 0.239 0.235 rg /T1_0 1 Tf -0.0045 Tc 8.3 0 0 8.3 172.2755 414 Tm (Pugsley )Tj EMC /Suspect <>BDC 0.314 0.318 0.31 rg 0.05 Tc 10.443 0 0 8.3 201.89 414 Tm (SO.-)Tj EMC /Suspect <>BDC 0.0226 Tc 8.3 0 0 8.3 226 414 Tm (Occupational )Tj EMC ET BT /T1_0 1 Tf 0.0263 Tc 8.3 0 0 8.3 44.0806 404.8866 Tm (asthma )Tj 0.0124 Tc 3.247 0 Td (without )Tj 0.0067 Tc 3.414 0 Td (bronchial )Tj -0.0008 Tc 4.104 0 Td (hypcrresponsiveness. )Tj /T1_1 1 Tf 0.0357 Tc 8.1 0 0 8.1 207 404.89 Tm (Am )Tj -0.0058 Tc 1.711 0 Td (Rev )Tj 0.0123 Tc 1.719 0 Td (Respir )Tj -0.0139 Tc 2.906 0 Td (Dis, )Tj /T1_0 1 Tf -0.035 Tc 8.0056 0 0 8.3 45.32 396.25 Tm (1984, )Tj 8.1261 0 0 8.3 65.48 396.25 Tm (130)Tj 0.467 0.467 0.459 rg 0 Tc 8.3 0 0 8.3 77.15 396.25 Tm (, )Tj 0.314 0.318 0.31 rg 0.0052 Tc 0.581 0 Td (513-515. )Tj -0.035 Tc 7.5202 0 0 8.3 44.86 387.12 Tm (19)Tj 0.467 0.467 0.459 rg 0 Tc 8.3 0 0 8.3 52.63 387.12 Tm (. )Tj 0.239 0.239 0.235 rg 0.0358 Tc 1.23 0 Td (Mapp )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0377 Tc 8.3 0 0 8.3 86.8011 387.12 Tm (Cl;, )Tj EMC ET BT 0.239 0.239 0.235 rg /T1_0 1 Tf 0 Tc 8.3 0 0 8.3 104.6046 387.12 Tm (D)Tj 0.376 0.376 0.372 rg -0.015 Tc 0.747 0 Td (al )Tj 0.314 0.318 0.31 rg -0.0138 Tc 1.222 0 Td (Vecchio )Tj -0.035 Tc 8.2683 0 0 8.3 152.6 387.12 Tm (L, )Tj 0.0093 Tc 8.3 0 0 8.3 164.12 387.12 Tm (Boschetto )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.019 Tc 8.3 0 0 8.3 201.5613 387.12 Tm (P, )Tj EMC ET BT 0.376 0.376 0.372 rg /T1_1 1 Tf 0.05 Tc 8.2481 0 0 8.1 212.57 387.12 Tm (et )Tj 0.314 0.318 0.31 rg -0.035 Tc 8.0998 0 0 8.1 222.67 387.12 Tm (a/. )Tj ET BT /Suspect <>BDC 0.467 0.467 0.459 rg /T1_0 1 Tf 0 Tc 8.1 0 0 8.1 235.11 387.12 Tm (-)Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0163 Tc 8.3 0 0 8.3 243.77 387.12 Tm (Toluene )Tj 0.0097 Tc -24.059 -1.099 Td (diisocyanate)Tj 0.467 0.467 0.459 rg 0 Tc 5.087 0 Td (-)Tj 0.314 0.318 0.31 rg -0.004 Tc 0.351 0 Td (induced )Tj 0.0147 Tc 3.527 0 Td (asthma )Tj 0.022 Tc 3.247 0 Td (without )Tj 0.0138 Tc 3.519 0 Td (airway )Tj -0.0039 Tc 3.131 0 Td (hyperresponsiveness. )Tj /T1_1 1 Tf -0.0152 Tc 8.1 0 0 8.1 44.7 369.37 Tm (Eur )Tj /T1_3 1 Tf 0 Tc 7.8001 0 0 7.8001 58.97 369.37 Tm (J )Tj /T1_1 1 Tf 0.0123 Tc 8.1 0 0 8.1 65.82 369.37 Tm (Respir )Tj -0.0143 Tc 3.025 0 Td (Dis)Tj 0.467 0.467 0.459 rg 0 Tc 1.416 0 Td (, )Tj 0.314 0.318 0.31 rg /T1_0 1 Tf -0.035 Tc 8.0056 0 0 8.3 107.24 369.37 Tm (1986, )Tj -0.0055 Tc 8.3 0 0 8.3 126.62 369.37 Tm (68, )Tj 0.376 0.376 0.372 rg 0.0225 Tc 1.555 0 Td (89-95. )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf -0.035 Tc 8.1176 0 0 8.3 44.11 360.25 Tm (20)Tj 0.467 0.467 0.459 rg 0 Tc 8.3 0 0 8.3 52.15 360.25 Tm (. )Tj EMC ET BT 0.239 0.239 0.235 rg /T1_0 1 Tf -0.0014 Tc 8.3 0 0 8.3 62.359 360.25 Tm (Bernstei)Tj 0.376 0.376 0.372 rg 0 Tc 3.358 0 Td (n )Tj 0.314 0.318 0.31 rg 0.05 Tc 8.3411 0 0 8.3 99.3 360.25 Tm (IL)Tj 0.467 0.467 0.459 rg 0 Tc 8.3 0 0 8.3 107.83 360.25 Tm (. )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 8.3 0 0 8.3 113.6566 360.25 Tm (-)Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0066 Tc 8.3 0 0 8.3 123.7743 360.25 Tm (Isocyanate-induced )Tj 0.0165 Tc 8.567 0 Td (pulmonary )Tj -0.0124 Tc 5.02 0 Td (disease: )Tj 0 Tc 3.701 0 Td (a )Tj 0.0234 Tc -26.949 -1.1 Td (current )Tj -0.0043 Tc 3.596 0 Td (perspective. )Tj 0.239 0.239 0.235 rg /T1_3 1 Tf 0 Tc 7.4001 0 0 7.4001 118.01 351.12 Tm (J )Tj 0.314 0.318 0.31 rg /T1_1 1 Tf 0.0147 Tc 8.1 0 0 8.1 127.32 351.12 Tm (Allergy )Tj ET BT /Suspect <>BDC 0.376 0.376 0.372 rg /T1_1 1 Tf 0.0169 Tc 8.1 0 0 8.1 156.804 351.12 Tm (Cli)Tj 0.239 0.239 0.235 rg 0 Tc 1.2 0 Td (n )Tj EMC ET BT /T1_1 1 Tf 0.0205 Tc 8.1 0 0 8.1 175.7742 351.12 Tm (/mmun)Tj 0.376 0.376 0.372 rg 0.0003 Tc 2.884 0 Td (ol, )Tj /T1_0 1 Tf -0.035 Tc 8.241 0 0 8.3 212.84 351.12 Tm (1982, )Tj 0.314 0.318 0.31 rg -0.0028 Tc 8.3 0 0 8.3 235.11 351.12 Tm (70\(suppl.\), )Tj -0.035 Tc 8.1176 0 0 8.3 44.11 342.49 Tm (24)Tj 0.467 0.467 0.459 rg 0 Tc 8.3 0 0 8.3 51.74 342.49 Tm (-)Tj 0.314 0.318 0.31 rg -0.0282 Tc 0.578 0 Td (31. )Tj -0.035 Tc 7.1029 0 0 8.3 43.64 333.37 Tm (21)Tj 0.467 0.467 0.459 rg 0 Tc 8.3 0 0 8.3 52.15 333.37 Tm (. )Tj 0.314 0.318 0.31 rg 0.0358 Tc 1.23 0 Td (Mapp )Tj ET BT /Suspect <>BDC 0.376 0.376 0.372 rg /T1_0 1 Tf 0.0285 Tc 8.3 0 0 8.3 84.8769 333.37 Tm (CE, )Tj EMC /Suspect <>BDC 0.314 0.318 0.31 rg 0.0245 Tc 1.855 0 Td (Polato )Tj EMC ET BT /T1_0 1 Tf 0.0116 Tc 8.3 0 0 8.3 125.2315 333.37 Tm (R, )Tj 0.0076 Tc 1.214 0 Td (Maestrelli )Tj ET BT /Suspect <>BDC 0.239 0.239 0.235 rg /T1_0 1 Tf 0 Tc 8.3 0 0 8.3 172.2676 333.37 Tm (P)Tj 0.376 0.376 0.372 rg 0.567 0 Td (, )Tj EMC ET BT 0.239 0.239 0.235 rg /T1_0 1 Tf 8.3 0 0 8.3 181.381 333.37 Tm (H)Tj 0.376 0.376 0.372 rg 0.0148 Tc 0.746 0 Td (endrick )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf 0.05 Tc 8.3406 0 0 8.3 215.44 333.37 Tm (OJ, )Tj EMC ET BT /T1_0 1 Tf 0.0368 Tc 8.3 0 0 8.3 230.36 333.37 Tm (Fabbri )Tj -0.0009 Tc 3.123 0 Td (LM. )Tj ET BT /Suspect <>BDC 0.376 0.376 0.372 rg /T1_0 1 Tf 0 Tc 8.3 0 0 8.3 43.5851 324.2483 Tm (-)Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0164 Tc 8.3 0 0 8.3 50.8144 324.2483 Tm (Time )Tj 0.0145 Tc 2.428 0 Td (course )Tj 0.05 Tc 9.4598 0 0 8.3 95.91 324.25 Tm (of )Tj 0.0273 Tc 8.3 0 0 8.3 106.06 324.25 Tm (the )Tj -0.0023 Tc 1.613 0 Td (increase )Tj -0.009 Tc 3.528 0 Td (in )Tj 0.376 0.376 0.372 rg 0.0022 Tc 1.155 0 Td (airway )Tj 0.314 0.318 0.31 rg -0.0029 Tc 3.131 0 Td (responsiveness )Tj 0.0015 Tc 6.295 0 Td (associated )Tj -0.0315 Tc -23.182 -1.1 Td (with )Tj 0.007 Tc 2.075 0 Td (late )Tj 0.0219 Tc 1.849 0 Td (asthmatic )Tj 0.0048 Tc 4.346 0 Td (reactions )Tj 0.035 Tc 4.047 0 Td (to )Tj 0.002 Tc 1.214 0 Td (toluene )Tj 0.0097 Tc 3.289 0 Td (diisocyanate )Tj -0.009 Tc 5.495 0 Td (in )Tj 0.376 0.376 0.372 rg -0.0073 Tc 1.093 0 Td (sensitize)Tj 0.239 0.239 0.235 rg 0 Tc 3.359 0 Td (d )Tj 0.314 0.318 0.31 rg -0.0038 Tc -26.839 -1.04 Td (subjects. )Tj /T1_3 1 Tf 0 Tc 8 0 0 8 74.81 306.49 Tm (J )Tj /T1_1 1 Tf 0.0147 Tc 8.1 0 0 8.1 82.2 306.49 Tm (Allergy )Tj ET BT /Suspect <>BDC 0.376 0.376 0.372 rg /T1_1 1 Tf -0.0171 Tc 8.1 0 0 8.1 109.2783 306.49 Tm (C/in )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_1 1 Tf 0.03 Tc 8.1 0 0 8.1 125.6646 306.49 Tm (lmmunol)Tj 0.467 0.467 0.459 rg 0 Tc 3.689 0 Td (, )Tj 0.314 0.318 0.31 rg /T1_0 1 Tf -0.035 Tc 8.241 0 0 8.3 161 306.49 Tm (1985, )Tj -0.0344 Tc 8.3 0 0 8.3 181.35 306.49 Tm (75, )Tj 0.0189 Tc 1.501 0 Td (568-575)Tj 0.467 0.467 0.459 rg 0 Tc 3.463 0 Td (. )Tj 0.314 0.318 0.31 rg -0.035 Tc 8.2681 0 0 8.3 43.63 297.37 Tm (22. )Tj 0.0368 Tc 8.3 0 0 8.3 61.88 297.37 Tm (Fabbri )Tj 0.239 0.239 0.235 rg -0.0009 Tc 3.354 0 Td (LM, )Tj ET BT /Suspect <>BDC 0.376 0.376 0.372 rg /T1_0 1 Tf 0.0061 Tc 8.3 0 0 8.3 108.8746 297.37 Tm (Chicsur)Tj 0.239 0.239 0.235 rg 0 Tc 3.181 0 Td (a )Tj EMC /Suspect <>BDC 0.376 0.376 0.372 rg 0.0405 Tc 0.983 0 Td (Corona )Tj EMC /Suspect <>BDC 0.239 0.239 0.235 rg -0.035 Tc 8.2578 0 0 8.3 174.2 297.37 Tm (P, )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0102 Tc 8.3 0 0 8.3 185.24 297.37 Tm (Dal )Tj -0.0138 Tc 2.084 0 Td (Vecchio )Tj 0 Tc 3.814 0 Td (L )Tj /T1_1 1 Tf 0.05 Tc 8.2481 0 0 8.1 243.29 297.37 Tm (et )Tj 0.0022 Tc 8.1 0 0 8.1 253.87 297.37 Tm (a/)Tj 0.467 0.467 0.459 rg 0 Tc 0.767 0 Td (. )Tj ET BT /Suspect <>BDC 0.647 0.647 0.639 rg /T1_0 1 Tf 8.1 0 0 8.1 266.3116 297.37 Tm (-)Tj EMC /Suspect <>BDC 0.314 0.318 0.31 rg 0.0095 Tc 8.3 0 0 8.3 43.64 288.25 Tm (Prednisone )Tj EMC ET BT /T1_0 1 Tf 0.012 Tc 8.3 0 0 8.3 85.3724 288.25 Tm (inhibits )Tj 0.007 Tc 3.586 0 Td (late )Tj 0.0292 Tc 1.965 0 Td (asthmatic )Tj 0.0048 Tc 4.577 0 Td (reactions )Tj 0.0358 Tc 4.213 0 Td (and )Tj -0.0016 Tc 2.089 0 Td (the )Tj 0.0079 Tc 1.728 0 Td (associated )Tj -0.0023 Tc -23.189 -1.041 Td (increase )Tj 0.239 0.239 0.235 rg -0.035 Tc 7.9356 0 0 8.3 73.38 279.61 Tm (in )Tj 0.314 0.318 0.31 rg 0.0022 Tc 8.3 0 0 8.3 82.48 279.61 Tm (airway )Tj 0.239 0.239 0.235 rg -0.0009 Tc 3.131 0 Td (respon)Tj 0.376 0.376 0.372 rg -0.0177 Tc 2.705 0 Td (siveness )Tj 0.314 0.318 0.31 rg -0.004 Tc 3.592 0 Td (induced )Tj -0.0073 Tc 3.537 0 Td (by )Tj 0.239 0.239 0.235 rg 0.0116 Tc 1.326 0 Td (toluene )Tj 0.314 0.318 0.31 rg 0.0097 Tc 3.289 0 Td (diisocyanate )Tj -0.009 Tc -22.322 -1.099 Td (in )Tj -0.0042 Tc 1.093 0 Td (sensitized )Tj -0.0038 Tc 4.28 0 Td (subjects. )Tj /T1_1 1 Tf 0.05 Tc 8.3646 0 0 8.1 119.65 270.49 Tm (Am )Tj -0.0058 Tc 8.1 0 0 8.1 134.46 270.49 Tm (Rev )Tj -0.0152 Tc 1.841 0 Td (Jtespir )Tj 0.0059 Tc 2.962 0 Td (Dis, )Tj 0.239 0.239 0.235 rg /T1_0 1 Tf -0.035 Tc 8.1597 0 0 8.3 190.28 270.49 Tm (1985)Tj 0.376 0.376 0.372 rg 0 Tc 8.3 0 0 8.3 205.79 270.49 Tm (, )Tj 0.314 0.318 0.31 rg -0.035 Tc 7.9309 0 0 8.3 211.41 270.49 Tm (132, )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0065 Tc 8.3 0 0 8.3 228.19 270.49 Tm (1010-1014. )Tj EMC ET BT 0.376 0.376 0.372 rg /T1_0 1 Tf -0.035 Tc 8.2681 0 0 8.3 43.15 261.37 Tm (23. )Tj 0.314 0.318 0.31 rg 0.0021 Tc 8.3 0 0 8.3 61.88 261.37 Tm (Boschetto )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.019 Tc 8.3 0 0 8.3 97.404 261.37 Tm (P, )Tj EMC ET BT 0.239 0.239 0.235 rg /T1_0 1 Tf 0.0252 Tc 8.3 0 0 8.3 106.5257 261.37 Tm (Fabbri )Tj 0.314 0.318 0.31 rg 0.028 Tc 3.007 0 Td (LM, )Tj 0.015 Tc 2.083 0 Td (Zocca )Tj 0.0203 Tc 2.716 0 Td (E, )Tj 0.376 0.376 0.372 rg /T1_1 1 Tf 0.0423 Tc 8.1 0 0 8.1 180.41 261.37 Tm (era/. )Tj ET BT /Suspect <>BDC 0.565 0.569 0.557 rg /T1_0 1 Tf 0 Tc 8.1 0 0 8.1 199.1129 261.37 Tm (-)Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.003 Tc 8.3 0 0 8.3 206.36 261.37 Tm (Prednisone )Tj 0.0038 Tc 4.739 0 Td (inhibits )Tj -0.0123 Tc -24.347 -1.041 Td (late )Tj 0.0219 Tc 2.023 0 Td (asthmatic )Tj 0.0048 Tc 4.635 0 Td (reactions )Tj 0.0358 Tc 4.213 0 Td (and )Tj 0.0022 Tc 2.198 0 Td (airway )Tj 0.0065 Tc 3.355 0 Td (inflammation )Tj 0.0056 Tc 6.13 0 Td (induced )Tj -0.0073 Tc 3.827 0 Td (by )Tj 0.239 0.239 0.235 rg 0.0116 Tc -26.433 -1.099 Td (toluene )Tj 0.314 0.318 0.31 rg 0.0149 Tc 3.231 0 Td (diisocyanate )Tj -0.009 Tc 5.38 0 Td (in )Tj -0.0042 Tc 1.093 0 Td (sensitized )Tj 0.376 0.376 0.372 rg -0.0038 Tc 4.164 0 Td (subjects. )Tj 0.314 0.318 0.31 rg /T1_3 1 Tf 0 Tc 7.8001 0 0 7.8001 189.53 243.61 Tm (J )Tj /T1_1 1 Tf 0.0147 Tc 8.1 0 0 8.1 196.44 243.61 Tm (Allergy )Tj ET BT /Suspect <>BDC /T1_1 1 Tf -0.0171 Tc 8.1 0 0 8.1 223.0404 243.61 Tm (Clin )Tj EMC ET BT /T1_1 1 Tf 0.0154 Tc 8.1 0 0 8.1 238.9488 243.61 Tm (lmmunol, )Tj /T1_0 1 Tf -0.035 Tc 8.1597 0 0 8.3 43.88 234.97 Tm (1987)Tj 0.467 0.467 0.459 rg 0 Tc 8.3 0 0 8.3 58.91 234.97 Tm (, )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf -0.0002 Tc 8.3 0 0 8.3 63.6908 234.97 Tm (80, )Tj EMC ET BT 0.376 0.376 0.372 rg /T1_0 1 Tf 0.0113 Tc 8.3 0 0 8.3 76.7467 234.97 Tm (261-267. )Tj 0.314 0.318 0.31 rg -0.035 Tc 8.2681 0 0 8.3 43.15 225.85 Tm (24. )Tj 0.0166 Tc 8.3 0 0 8.3 60.95 225.85 Tm (Adams )Tj 0.029 Tc 3.525 0 Td (WG. )Tj ET BT /Suspect <>BDC 0.467 0.467 0.459 rg /T1_0 1 Tf 0 Tc 8.3 0 0 8.3 111.7377 225.85 Tm (-)Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0096 Tc 8.3 0 0 8.3 121.3989 225.85 Tm (Long-term )Tj -0.0161 Tc 4.967 0 Td (effects )Tj 0.0035 Tc 3.182 0 Td (on )Tj 0.239 0.239 0.235 rg -0.0016 Tc 1.684 0 Td (the )Tj 0.314 0.318 0.31 rg 0.0101 Tc 1.852 0 Td (health )Tj 0.05 Tc 8.9033 0 0 8.3 244.24 225.85 Tm (of )Tj -0.0192 Tc 8.3 0 0 8.3 256.3 225.85 Tm (men )Tj -0.0021 Tc -25.743 -1.099 Td (engaged )Tj -0.009 Tc 3.646 0 Td (in )Tj 0.0273 Tc 1.047 0 Td (the )Tj 0.0159 Tc 1.561 0 Td (manufacture )Tj 0.05 Tc 8.9033 0 0 8.3 139.6 216.73 Tm (of )Tj 0.0116 Tc 8.3 0 0 8.3 149.26 216.73 Tm (toluene )Tj 0.0073 Tc 3.231 0 Td (diisocyanate. )Tj /T1_1 1 Tf 0.05 Tc 8.2317 0 0 8.1 223.26 216.73 Tm (Br )Tj /T1_3 1 Tf 0 Tc 8 0 0 8 233.69 216.73 Tm (J )Tj /T1_1 1 Tf -0.0302 Tc 8.1 0 0 8.1 240.09 216.73 Tm (Jnd )Tj 0.003 Tc 1.658 0 Td (Med, )Tj /T1_0 1 Tf -0.035 Tc 8.241 0 0 8.3 43.88 208.09 Tm (1975, )Tj -0.0282 Tc 8.3 0 0 8.3 63.74 208.09 Tm (32, )Tj 0.0204 Tc 1.563 0 Td (72-78. )Tj -0.035 Tc 7.8547 0 0 8.3 43.15 198.97 Tm (25. )Tj ET BT /Suspect <>BDC 0.239 0.239 0.235 rg /T1_0 1 Tf 0.0029 Tc 8.3 0 0 8.3 60.92 198.97 Tm (Paggia)Tj 0.376 0.376 0.372 rg 0.0348 Tc 2.78 0 Td (ro )Tj EMC /Suspect <>BDC 0.314 0.318 0.31 rg 0.05 Tc 8.3955 0 0 8.3 94.04 198.97 Tm (PL)Tj 0.467 0.467 0.459 rg 0 Tc 8.3 0 0 8.3 104.51 198.97 Tm (, )Tj EMC ET BT 0.239 0.239 0.235 rg /T1_0 1 Tf -0.0223 Tc 8.3 0 0 8.3 109.3987 198.97 Tm (Loi )Tj 0.314 0.318 0.31 rg 0.0266 Tc 1.681 0 Td (AM, )Tj 0.0113 Tc 2.31 0 Td (Rosso )Tj ET BT /Suspect <>BDC /T1_2 1 Tf 0.05 Tc 8.9725 0 0 8 165.97 198.97 Tm (0, )Tj EMC ET BT 0.376 0.376 0.372 rg /T1_1 1 Tf 8.6887 0 0 8.1 176.56 198.97 Tm (eta/. )Tj 0.467 0.467 0.459 rg /T1_0 1 Tf 0 Tc 8.3 0 0 8.3 196.7 198.97 Tm (-)Tj 0.239 0.239 0.235 rg 0.0281 Tc 0.875 0 Td (Foll)Tj 0.376 0.376 0.372 rg 0.0025 Tc 1.73 0 Td (ow-up )Tj 0.314 0.318 0.31 rg 0.0142 Tc 2.887 0 Td (study )Tj 0.05 Tc 8.9033 0 0 8.3 263.43 198.97 Tm (of )Tj 0.0202 Tc 8.3 0 0 8.3 42.73 189.85 Tm (patients )Tj 0.0071 Tc 3.467 0 Td (with )Tj 0.0125 Tc 2.082 0 Td (respiratory )Tj 0.0028 Tc 4.676 0 Td (disease )Tj 0.0348 Tc 3.065 0 Td (due )Tj 0.376 0.376 0.372 rg 0.035 Tc 1.8 0 Td (to )Tj 0.314 0.318 0.31 rg 0.0116 Tc 1.099 0 Td (toluene )Tj 0.0149 Tc 3.173 0 Td (diisocyanate )Tj 0.376 0.376 0.372 rg 0.0081 Tc 5.376 0 Td (\(TDI\). )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_1 1 Tf -0.0171 Tc 8.1 0 0 8.1 43.04 181.21 Tm (Clin )Tj EMC ET BT /T1_1 1 Tf 0.0147 Tc 8.1 0 0 8.1 59.6369 181.21 Tm (Allergy)Tj 0.467 0.467 0.459 rg 0 Tc 3.011 0 Td (, )Tj 0.314 0.318 0.31 rg /T1_0 1 Tf -0.035 Tc 8.0056 0 0 8.3 89.96 181.21 Tm (1984, )Tj 0.376 0.376 0.372 rg 8.2267 0 0 8.3 110.12 181.21 Tm (14, )Tj 0.314 0.318 0.31 rg 0.0108 Tc 8.3 0 0 8.3 122.37 181.21 Tm (463-469. )Tj -0.035 Tc 8.2681 0 0 8.3 42.67 172.09 Tm (26. )Tj 0.0135 Tc 8.3 0 0 8.3 60.92 172.09 Tm (Moller )Tj 0.0278 Tc 3.123 0 Td (DR, )Tj 0.0166 Tc 2.024 0 Td (Brooks )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0083 Tc 8.3 0 0 8.3 130.4076 172.09 Tm (SM, )Tj EMC ET BT /T1_0 1 Tf 0.0173 Tc 8.3 0 0 8.3 147.3147 172.09 Tm (Mckay )Tj 0.0189 Tc 3.181 0 Td (RT, )Tj /T1_1 1 Tf 0.05 Tc 9.4029 0 0 8.1 189.04 172.09 Tm (eta/)Tj 0.467 0.467 0.459 rg 0 Tc 8.1 0 0 8.1 204.4 172.09 Tm (. )Tj ET BT /Suspect <>BDC 0.376 0.376 0.372 rg /T1_0 1 Tf 0.05 Tc 8.9119 0 0 8.3 208.7 172.09 Tm (-Chronic )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0263 Tc 8.3 0 0 8.3 245.68 172.09 Tm (asthma )Tj 0.0059 Tc -24.463 -1.099 Td (due )Tj 0.035 Tc 1.8 0 Td (to )Tj 0.002 Tc 1.214 0 Td (toluene )Tj 0.0025 Tc 3.289 0 Td (diisocyanate. )Tj ET BT /Suspect <>BDC 0.376 0.376 0.372 rg /T1_1 1 Tf 0.0065 Tc 8.1 0 0 8.1 141.92 162.97 Tm (Chest, )Tj EMC ET BT 0.239 0.239 0.235 rg /T1_0 1 Tf -0.035 Tc 8.1597 0 0 8.3 166.76 162.97 Tm (1986)Tj 0.376 0.376 0.372 rg 0 Tc 8.3 0 0 8.3 181.79 162.97 Tm (, )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf -0.0342 Tc 8.3 0 0 8.3 186.6289 162.97 Tm (90, )Tj EMC ET BT /T1_0 1 Tf -0.0195 Tc 8.3 0 0 8.3 199.6516 162.97 Tm (494)Tj 0.565 0.569 0.557 rg 0 Tc 1.437 0 Td (-)Tj 0.314 0.318 0.31 rg -0.0192 Tc 0.529 0 Td (499. )Tj -0.035 Tc 8.2681 0 0 8.3 42.67 154.33 Tm (27. )Tj 0.239 0.239 0.235 rg 0 Tc 8.3 0 0 8.3 60.92 154.33 Tm (L)Tj 0.376 0.376 0.372 rg -0.0026 Tc 0.573 0 Td (osewicz )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf -0.0196 Tc 8.3 0 0 8.3 94.4022 154.33 Tm (S, )Tj EMC ET BT /T1_0 1 Tf -0.0162 Tc 8.3 0 0 8.3 103.665 154.33 Tm (Assoufi )Tj 0.239 0.239 0.235 rg 0.0215 Tc 3.408 0 Td (BK)Tj 0.376 0.376 0.372 rg 0 Tc 1.377 0 Td (, )Tj 0.314 0.318 0.31 rg 0.0169 Tc 0.589 0 Td (Hawkins )Tj 0.239 0.239 0.235 rg 0.0116 Tc 4.048 0 Td (R, )Tj 0.314 0.318 0.31 rg 0.0184 Tc 1.224 0 Td (Newman-Taylor )Tj -0.0125 Tc 7.165 0 Td (AJ.)Tj 0.647 0.647 0.639 rg 0 Tc 1.666 0 Td (\255)Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0102 Tc 8.3 0 0 8.3 42.6268 145.2083 Tm (Outcome )Tj EMC ET BT /T1_0 1 Tf 0.05 Tc 9.4598 0 0 8.3 75.75 145.21 Tm (of )Tj 0.0263 Tc 8.3 0 0 8.3 85.84 145.21 Tm (asthma )Tj -0.004 Tc 3.298 0 Td (induced )Tj -0.0073 Tc 3.537 0 Td (by )Tj 0.0018 Tc 1.32 0 Td (isocyanates. )Tj /T1_1 1 Tf 0.0078 Tc 8.1 0 0 8.1 197.34 145.21 Tm (Br )Tj /T1_3 1 Tf 0 Tc 7.7 0 0 7.7 207.77 145.21 Tm (J )Tj /T1_1 1 Tf 0.0153 Tc 8.1 0 0 8.1 214.64 145.21 Tm (Dis )Tj ET BT /Suspect <>BDC 0.376 0.376 0.372 rg /T1_1 1 Tf 0.0065 Tc 8.1 0 0 8.1 228.7988 145.21 Tm (Chest, )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf -0.035 Tc 8.241 0 0 8.3 252.68 145.21 Tm (1987, )Tj -0.0291 Tc 8.3 0 0 8.3 42.57 136.57 Tm (81, )Tj -0.035 Tc 7.5202 0 0 8.3 55.9 136.57 Tm (14)Tj 0.467 0.467 0.459 rg 0 Tc 8.3 0 0 8.3 63.26 136.57 Tm (-)Tj 0.314 0.318 0.31 rg -0.035 Tc 8.2681 0 0 8.3 67.63 136.57 Tm (22. )Tj 0.376 0.376 0.372 rg -3.077 -1.158 Td (28. )Tj 0.239 0.239 0.235 rg 0.05 Tc 8.4609 0 0 8.3 59.94 126.96 Tm (Inn)Tj 0.376 0.376 0.372 rg 0.0019 Tc 8.3 0 0 8.3 72.4 126.96 Tm (ocenti )Tj 0.314 0.318 0.31 rg 0.0169 Tc 2.842 0 Td (A, )Tj 0.0028 Tc 1.384 0 Td (Franzinelli )Tj 0 Tc 4.746 0 Td (A)Tj 0.467 0.467 0.459 rg 0.795 0 Td (, )Tj 0.314 0.318 0.31 rg 0.0086 Tc 0.576 0 Td (Sartorelli )Tj 0.376 0.376 0.372 rg -0.035 Tc 8.2744 0 0 8.3 193.39 126.96 Tm (E. )Tj ET BT /Suspect <>BDC 0.565 0.569 0.557 rg /T1_0 1 Tf 0 Tc 8.3 0 0 8.3 203.42 126.96 Tm (-)Tj EMC /Suspect <>BDC 0.314 0.318 0.31 rg 0.0285 Tc 0.919 0 Td (Studio )Tj EMC ET BT /T1_0 1 Tf 0.0008 Tc 8.3 0 0 8.3 237.0516 126.96 Tm (longitudi-)Tj -0.0135 Tc 7.294 75.47 Td (nale )Tj -0.009 Tc 2.075 0 Td (in )Tj 0.0072 Tc 1.272 0 Td (lavoratori )Tj -0.0001 Tc 4.452 0 Td (affetti )Tj 0.0491 Tc 2.776 0 Td (da )Tj 0.376 0.376 0.372 rg 0.0137 Tc 1.446 0 Td (asma )Tj 0.314 0.318 0.31 rg 0.0491 Tc 2.545 0 Td (da )Tj -0.0143 Tc 1.512 0 Td (resine )Tj 0.0084 Tc 2.836 0 Td (poliuretaniche. )Tj /T1_1 1 Tf 0.0406 Tc 8.1 0 0 8.1 509.84 753.36 Tm (Med )Tj -0.0094 Tc -26.193 -1.126 Td (Lavoro, )Tj /T1_0 1 Tf 0.0276 Tc 8.3 0 0 8.3 326.59 744.24 Tm (1981,72,231)Tj 0.467 0.467 0.459 rg 0 Tc 5.343 0 Td (-)Tj 0.314 0.318 0.31 rg -0.035 Tc 8.2652 0 0 8.3 375.79 744.24 Tm (236. )Tj 8.2681 0 0 8.3 297.07 735.12 Tm (29. )Tj 0.239 0.239 0.235 rg 0.05 Tc 8.3514 0 0 8.3 315.32 735.12 Tm (Mapp )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf -0.0004 Tc 8.3 0 0 8.3 341.2 735.12 Tm (CE, )Tj EMC ET BT /T1_0 1 Tf 0.0102 Tc 8.3 0 0 8.3 359.4766 735.12 Tm (Dal )Tj -0.0138 Tc 2.142 0 Td (Vecchio )Tj -0.035 Tc 8.2683 0 0 8.3 409.88 735.12 Tm (L, )Tj 0.0084 Tc 8.3 0 0 8.3 422.36 735.12 Tm (Bochetto )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.035 Tc 8.2578 0 0 8.3 458.36 735.12 Tm (P, )Tj EMC ET BT /T1_0 1 Tf 0.0252 Tc 8.3 0 0 8.3 470.84 735.12 Tm (Fabbri )Tj -0.035 Tc 8.2659 0 0 8.3 499.64 735.12 Tm (LM)Tj 0.467 0.467 0.459 rg 0 Tc 8.3 0 0 8.3 512.47 735.12 Tm (. )Tj 0.376 0.376 0.372 rg 0.876 0 Td (-)Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0115 Tc 8.3 0 0 8.3 297.0435 726.4797 Tm (Combined )Tj EMC ET BT /T1_0 1 Tf 0.0147 Tc 8.3 0 0 8.3 335.4393 726.4797 Tm (asthma )Tj 0.0069 Tc 3.296 0 Td (and )Tj -0.0006 Tc 1.851 0 Td (alveolitis )Tj 0.0059 Tc 3.99 0 Td (due )Tj 0.035 Tc 1.858 0 Td (to )Tj 0.0132 Tc 1.149 0 Td (diphenylmethane )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0042 Tc 8.3 0 0 8.3 497.6711 726.4797 Tm (diisocy\255)Tj EMC ET BT /T1_0 1 Tf 0.0257 Tc 8.3 0 0 8.3 297.0352 717.358 Tm (anate )Tj 0.0317 Tc 2.947 0 Td (\(MDI\) )Tj 0.0071 Tc 3.481 0 Td (with )Tj 0.016 Tc 2.536 0 Td (demonstration )Tj 0.05 Tc 8.9033 0 0 8.3 427.12 717.36 Tm (of )Tj 0.0443 Tc 8.3 0 0 8.3 440.63 717.36 Tm (no )Tj 0.005 Tc 1.727 0 Td (crossed )Tj 0.239 0.239 0.235 rg 0.0125 Tc 3.883 0 Td (respiratory )Tj 0.314 0.318 0.31 rg -0.0012 Tc -22.901 -1.04 Td (reactivity )Tj -0.0228 Tc 4.163 0 Td (to )Tj 0.002 Tc 1.157 0 Td (toluene )Tj 0.0097 Tc 3.231 0 Td (diisocyanate )Tj 0.0196 Tc 5.376 0 Td (\(TDI\). )Tj /T1_1 1 Tf 0.0146 Tc 8.1 0 0 8.1 438.36 708.73 Tm (Annals )Tj 0.0192 Tc 3.141 0 Td (Allergy, )Tj /T1_0 1 Tf -0.035 Tc 8.1597 0 0 8.3 494.12 708.73 Tm (1985)Tj 0.467 0.467 0.459 rg 0 Tc 8.3 0 0 8.3 509.63 708.73 Tm (, )Tj 0.314 0.318 0.31 rg -0.0296 Tc 0.581 0 Td (54, )Tj -0.0195 Tc -26.246 -1.099 Td (424)Tj 0.467 0.467 0.459 rg 0 Tc 1.495 0 Td (-)Tj 0.314 0.318 0.31 rg -0.0195 Tc 0.529 0 Td (429)Tj 0.467 0.467 0.459 rg 0 Tc 1.487 0 Td (. )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf -0.035 Tc 7.9784 0 0 8.3 297.03 690.48 Tm (30. )Tj EMC ET BT /T1_0 1 Tf 0.0358 Tc 8.3 0 0 8.3 315.32 690.48 Tm (Mapp )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0285 Tc 8.3 0 0 8.3 338.3193 690.48 Tm (CE, )Tj EMC ET BT /T1_0 1 Tf 0.0007 Tc 8.3 0 0 8.3 354.1972 690.48 Tm (Di )Tj 0.0187 Tc 1.325 0 Td (Giacomo )Tj 0.05 Tc 8.7706 0 0 8.3 399.27 690.48 Tm (GR)Tj 0.467 0.467 0.459 rg 0 Tc 8.3 0 0 8.3 411.71 690.48 Tm (, )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0035 Tc 8.3 0 0 8.3 416.5572 690.48 Tm (Omini )Tj EMC /Suspect <>BDC 0 Tc 2.892 0 Td (C)Tj 0.467 0.467 0.459 rg 0.746 0 Td (, )Tj EMC ET BT 0.376 0.376 0.372 rg /T1_1 1 Tf 8.1 0 0 8.1 451.13 690.48 Tm (e)Tj 0.239 0.239 0.235 rg 0.472 0 Td (t )Tj 0.314 0.318 0.31 rg -0.0054 Tc 0.598 0 Td (a/. )Tj ET BT /Suspect <>BDC 0.467 0.467 0.459 rg /T1_0 1 Tf 0 Tc 8.1 0 0 8.1 470.7968 690.48 Tm (-)Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0033 Tc 8.3 0 0 8.3 479 690.48 Tm (Late, )Tj 0.0314 Tc 2.377 0 Td (but )Tj 0.0282 Tc 1.733 0 Td (not )Tj 0.0058 Tc -26.092 -1.04 Td (early, )Tj 0.376 0.376 0.372 rg 0.0465 Tc 2.835 0 Td (as)Tj 0.239 0.239 0.235 rg 0.0338 Tc 0.875 0 Td (thm)Tj 0.376 0.376 0.372 rg 0.0249 Tc 1.612 0 Td (atic )Tj 0.314 0.318 0.31 rg 0.0121 Tc 2.033 0 Td (reactions )Tj -0.004 Tc 4.272 0 Td (induced )Tj -0.035 Tc 8.0386 0 0 8.3 424.33 681.85 Tm (by )Tj 0.0116 Tc 8.3 0 0 8.3 437.26 681.85 Tm (toluene )Tj 0.0097 Tc 3.52 0 Td (diisocyanate )Tj 0.0322 Tc 5.667 0 Td (are )Tj 0.0015 Tc -26.14 -1.099 Td (associated )Tj -0.0122 Tc 4.577 0 Td (with )Tj 0.0005 Tc 2.19 0 Td (increased )Tj 0.0138 Tc 4.105 0 Td (airway )Tj -0.0029 Tc 3.189 0 Td (responsiveness )Tj 0.035 Tc 6.36 0 Td (to )Tj 0.0083 Tc 1.214 0 Td (methacholine. )Tj /T1_1 1 Tf -0.0152 Tc 8.1 0 0 8.1 297.18 664.09 Tm (Eur )Tj /T1_3 1 Tf 0 Tc 8 0 0 8 311.45 664.09 Tm (J )Tj /T1_1 1 Tf 0.0005 Tc 8.1 0 0 8.1 318.78 664.09 Tm (Respir )Tj -0.0336 Tc 3.025 0 Td (Dis, )Tj 0.376 0.376 0.372 rg /T1_0 1 Tf -0.035 Tc 8.0056 0 0 8.3 359.72 664.09 Tm (1986, )Tj 0.314 0.318 0.31 rg -0.0344 Tc 8.3 0 0 8.3 379.58 664.09 Tm (69, )Tj 0.376 0.376 0.372 rg 0.0113 Tc 1.51 0 Td (276-284. )Tj 0.314 0.318 0.31 rg -0.0282 Tc -11.514 -1.099 Td (31. )Tj 0.376 0.376 0.372 rg 0.05 Tc 8.4394 0 0 8.3 314.79 654.97 Tm (Co)Tj 0.239 0.239 0.235 rg 0.0076 Tc 8.3 0 0 8.3 324.89 654.97 Tm (lton )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf -0.0269 Tc 8.3 0 0 8.3 344.561 654.97 Tm (C. )Tj EMC /Suspect <>BDC 0.376 0.376 0.372 rg 0 Tc 1.675 0 Td (-)Tj EMC /Suspect <>BDC 0.314 0.318 0.31 rg 0.0017 Tc 1.324 0 Td (Statistics )Tj EMC ET BT /T1_0 1 Tf -0.009 Tc 8.3 0 0 8.3 406.0107 654.97 Tm (in )Tj -0.0017 Tc 1.51 0 Td (medicine)Tj 0.467 0.467 0.459 rg 0 Tc 3.683 0 Td (. )Tj 0.314 0.318 0.31 rg 0.0098 Tc 0.999 0 Td (Little )Tj 0.239 0.239 0.235 rg -0.0098 Tc 3.007 0 Td (Brown )Tj 0.314 0.318 0.31 rg 0.0358 Tc 3.465 0 Td (and )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0306 Tc 8.3 0 0 8.3 296.5586 646.3297 Tm (Company)Tj 0.467 0.467 0.459 rg 0 Tc 4.042 0 Td (, )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0008 Tc 8.3 0 0 8.3 335.4773 646.3297 Tm (Boston, )Tj -0.035 Tc 8.241 0 0 8.3 364.52 646.33 Tm (1974, )Tj 8.1639 0 0 8.3 384.91 646.33 Tm (274)Tj 0.467 0.467 0.459 rg 0 Tc 8.3 0 0 8.3 396.38 646.33 Tm (-)Tj 0.314 0.318 0.31 rg -0.035 Tc 8.2652 0 0 8.3 401.23 646.33 Tm (276. )Tj -0.0282 Tc 8.3 0 0 8.3 296.54 637.21 Tm (32. )Tj ET BT /Suspect <>BDC 0.376 0.376 0.372 rg /T1_0 1 Tf 0.0373 Tc 8.3 0 0 8.3 314.8 637.21 Tm (Chan\267 )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0151 Tc 8.3 0 0 8.3 335.9816 637.21 Tm (Yeung )Tj 0 Tc 3.005 0 Td (M)Tj 0.467 0.467 0.459 rg 0.91 0 Td (.)Tj 0.647 0.647 0.639 rg 0.529 0 Td (-)Tj 0.314 0.318 0.31 rg 0.0052 Tc 0.936 0 Td (rmmunologic )Tj 0.0358 Tc 5.659 0 Td (and )Tj 0.0133 Tc 1.859 0 Td (nonimmunologic )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0157 Tc 8.3 0 0 8.3 503.5088 637.21 Tm (mech\255)Tj EMC ET BT /T1_0 1 Tf 0.0024 Tc 8.3 0 0 8.3 296.5649 628.0883 Tm (anisms )Tj -0.035 Tc 7.9356 0 0 8.3 324.42 628.09 Tm (in )Tj 0.0263 Tc 8.3 0 0 8.3 334.96 628.09 Tm (asthma )Tj 0.0059 Tc 3.47 0 Td (due )Tj -0.0228 Tc 2.031 0 Td (to )Tj -0.0062 Tc 1.331 0 Td (western )Tj -0.0017 Tc 3.643 0 Td (red )Tj 0.0284 Tc 1.784 0 Td (cedar )Tj /T1_1 1 Tf 0.0013 Tc 8.1 0 0 8.1 459.68 628.09 Tm (\(Thujia )Tj 0.0012 Tc 3.49 0 Td (plicata\))Tj 0.467 0.467 0.459 rg 0 Tc 3.216 0 Td (. )Tj 0.239 0.239 0.235 rg /T1_3 1 Tf 8 0 0 8 519.77 628.09 Tm (J )Tj 0.314 0.318 0.31 rg /T1_1 1 Tf 0.0245 Tc 8.1 0 0 8.1 296.28 619.44 Tm (Allergy )Tj ET BT /Suspect <>BDC 0.376 0.376 0.372 rg /T1_1 1 Tf 0.0026 Tc 8.1 0 0 8.1 323.8362 619.44 Tm (Clin )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_1 1 Tf 0.0069 Tc 8.1 0 0 8.1 340.7085 619.44 Tm (lmmunol, )Tj 0.376 0.376 0.372 rg /T1_0 1 Tf -0.035 Tc 8.241 0 0 8.3 375.08 619.44 Tm (1982, )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0344 Tc 8.3 0 0 8.3 395.43 619.44 Tm (70, )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf -0.035 Tc 8.275 0 0 8.3 407.9 619.44 Tm (32)Tj 0.467 0.467 0.459 rg 0 Tc 8.3 0 0 8.3 416.06 619.44 Tm (-)Tj 0.314 0.318 0.31 rg -0.035 Tc 8.275 0 0 8.3 420.86 619.44 Tm (37)Tj 0.467 0.467 0.459 rg 0 Tc 8.3 0 0 8.3 428.95 619.44 Tm (. )Tj 0.314 0.318 0.31 rg -0.035 Tc 7.9784 0 0 8.3 296.55 610.33 Tm (33. )Tj -0.0096 Tc 8.3 0 0 8.3 314.38 610.33 Tm (Venables )Tj 0.239 0.239 0.235 rg 0.0104 Tc 3.988 0 Td (KM)Tj 0.376 0.376 0.372 rg 0 Tc 1.666 0 Td (, )Tj 0.314 0.318 0.31 rg 0.0166 Tc 0.528 0 Td (Topping )Tj 0.0001 Tc 3.82 0 Td (MD, )Tj 0.0177 Tc 2.198 0 Td (Howe )Tj -0.0297 Tc 2.719 0 Td (W, )Tj 0.376 0.376 0.372 rg /T1_1 1 Tf 0.05 Tc 8.4405 0 0 8.1 450.65 610.33 Tm (eta/.)Tj 0.565 0.569 0.557 rg 0 Tc 8.1 0 0 8.1 469.86 610.33 Tm (-)Tj 0.239 0.239 0.235 rg /T1_0 1 Tf 0.0084 Tc 8.3 0 0 8.3 477.54 610.33 Tm (Interaction )Tj 0.376 0.376 0.372 rg 0.05 Tc 8.9033 0 0 8.3 516.88 610.33 Tm (of )Tj 0.314 0.318 0.31 rg -0.001 Tc 8.3 0 0 8.3 296.52 601.68 Tm (smoking )Tj 0.0358 Tc 3.88 0 Td (and )Tj 0.376 0.376 0.372 rg 0.0116 Tc 2.024 0 Td (atopy )Tj 0.314 0.318 0.31 rg /T1_2 1 Tf -0.0266 Tc 8.1 0 0 8.1 368.48 601.68 Tm (in )Tj /T1_0 1 Tf -0.0016 Tc 8.3 0 0 8.3 379.18 601.68 Tm (the )Tj 0.0082 Tc 1.681 0 Td (production )Tj 0.05 Tc 8.9033 0 0 8.3 433.84 601.68 Tm (of )Tj -0.0269 Tc 8.3 0 0 8.3 444.84 601.68 Tm (specific )Tj 0.0377 Tc 3.419 0 Td (IgE )Tj 0.0012 Tc 1.964 0 Td (antibodies )Tj 0.0026 Tc -23.248 -1.099 Td (against )Tj 0 Tc 3.181 0 Td (a )Tj 0.0118 Tc 0.818 0 Td (hapten )Tj 0.0021 Tc 3.067 0 Td (protein )Tj -0.0008 Tc 3.17 0 Td (conjugate. )Tj /T1_1 1 Tf 0.05 Tc 8.2317 0 0 8.1 418.62 592.56 Tm (Br )Tj 0.0406 Tc 8.1 0 0 8.1 430.16 592.56 Tm (Med )Tj /T1_3 1 Tf -0.035 Tc 7.7536 0 0 8 447.29 592.56 Tm (J. )Tj /T1_0 1 Tf 8.241 0 0 8.3 457.16 592.56 Tm (1985, )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.018 Tc 8.3 0 0 8.3 476.59 592.56 Tm (290, )Tj EMC /Suspect <>BDC 0.0113 Tc 2.024 0 Td (201-204. )Tj EMC ET BT /T1_0 1 Tf -0.0282 Tc 8.3 0 0 8.3 296.5381 583.4383 Tm (34. )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.031 Tc 8.3 0 0 8.3 314.3167 583.4383 Tm (Chan-)Tj EMC ET BT /T1_0 1 Tf 0.0006 Tc 8.3 0 0 8.3 335.9797 583.4383 Tm (Yeung )Tj 0.239 0.239 0.235 rg 0 Tc 8.4 0 0 8.4 360.44 583.44 Tm (M)Tj 0.376 0.376 0.372 rg 0.961 0 Td (, )Tj 0.239 0.239 0.235 rg 0.0087 Tc 8.3 0 0 8.3 372.92 583.44 Tm (Ma)Tj 0.376 0.376 0.372 rg -0.001 Tc 1.325 0 Td (clean )Tj 0.239 0.239 0.235 rg 0 Tc 2.434 0 Td (L)Tj 0.467 0.467 0.459 rg 0.625 0 Td (, )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf 0.007 Tc 8.3 0 0 8.3 413.7145 583.44 Tm (Paggiaro )Tj EMC /Suspect <>BDC 0.239 0.239 0.235 rg 0.05 Tc 8.7952 0 0 8.3 445.88 583.44 Tm (PL)Tj 0.467 0.467 0.459 rg 13.8213 0 0 8.3 456.19 583.44 Tm (.-)Tj EMC ET BT 0.376 0.376 0.372 rg /T1_0 1 Tf 0.0038 Tc 8.3 0 0 8.3 467.96 583.44 Tm (Follow)Tj 0.239 0.239 0.235 rg 0.0106 Tc 2.884 0 Td (-up )Tj 0.376 0.376 0.372 rg 0.0287 Tc 1.559 0 Td (study )Tj 0.314 0.318 0.31 rg 0.05 Tc 8.9033 0 0 8.3 296.56 574.8 Tm (of )Tj -0.0177 Tc 8.3 0 0 8.3 306.67 574.8 Tm (232 )Tj 0.012 Tc 1.858 0 Td (patients )Tj 0.0071 Tc 3.583 0 Td (with )Tj 0.376 0.376 0.372 rg 0.0164 Tc 2.189 0 Td (occupational )Tj 0.314 0.318 0.31 rg 0.0147 Tc 5.725 0 Td (asthma )Tj 0.004 Tc 3.354 0 Td (caused )Tj -0.0073 Tc 3.192 0 Td (by )Tj -0.0159 Tc 1.443 0 Td (western )Tj -0.0017 Tc 3.47 0 Td (red )Tj 0.0284 Tc -26.09 -1.099 Td (cedar )Tj 0.376 0.376 0.372 rg /T1_1 1 Tf 0.0112 Tc 8.1 0 0 8.1 317.12 565.68 Tm (\(Thujia )Tj 0.314 0.318 0.31 rg -0.0005 Tc 3.312 0 Td (plicata\). )Tj /T1_3 1 Tf 0 Tc 7.4001 0 0 7.4001 373.85 565.68 Tm (J )Tj /T1_1 1 Tf 0.0245 Tc 8.1 0 0 8.1 380.76 565.68 Tm (Allergy )Tj ET BT /Suspect <>BDC /T1_1 1 Tf -0.0171 Tc 8.1 0 0 8.1 408.3162 565.68 Tm (Clin )Tj EMC ET BT /T1_1 1 Tf 0.0023 Tc 8.1 0 0 8.1 424.8726 565.68 Tm (Immunol, )Tj /T1_0 1 Tf -0.035 Tc 8.0056 0 0 8.3 460.04 565.68 Tm (1987, )Tj 0.376 0.376 0.372 rg -0.0344 Tc 8.3 0 0 8.3 479.91 565.68 Tm (79, )Tj 0.0121 Tc 1.561 0 Td (792-796. )Tj 0.314 0.318 0.31 rg -0.035 Tc 7.9784 0 0 8.3 296.55 557.05 Tm (35. )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0152 Tc 8.3 0 0 8.3 314.36 557.05 Tm (Paggiaro )Tj EMC /Suspect <>BDC 0.239 0.239 0.235 rg 0.05 Tc 8.3955 0 0 8.3 348.44 557.05 Tm (PL)Tj 0.376 0.376 0.372 rg 0 Tc 8.3 0 0 8.3 358.91 557.05 Tm (, )Tj EMC /Suspect <>BDC 0.314 0.318 0.31 rg 0.0166 Tc 0.642 0 Td (Chan-)Tj EMC ET BT /T1_0 1 Tf 0.0006 Tc 8.3 0 0 8.3 385.4202 557.05 Tm (Yeung )Tj -0.0297 Tc 3.178 0 Td (M. )Tj ET BT /Suspect <>BDC 0.467 0.467 0.459 rg /T1_0 1 Tf 0 Tc 8.3 0 0 8.3 424.6958 557.05 Tm (-)Tj 0.314 0.318 0.31 rg 0.0323 Tc 0.99 0 Td (Pattern )Tj EMC ET BT /T1_0 1 Tf 0.05 Tc 9.4598 0 0 8.3 461.67 557.05 Tm (of )Tj -0.0186 Tc 8.3 0 0 8.3 472.68 557.05 Tm (specific )Tj 0.0138 Tc 3.359 0 Td (airway )Tj -0.0038 Tc -24.57 -1.1 Td (response )Tj -0.009 Tc 4.041 0 Td (in )Tj 0.0147 Tc 1.329 0 Td (asthma )Tj 0.0348 Tc 3.47 0 Td (due )Tj 0.035 Tc 2.089 0 Td (to )Tj -0.0062 Tc 1.389 0 Td (western )Tj -0.0017 Tc 3.643 0 Td (red )Tj 0.376 0.376 0.372 rg 0.0428 Tc 1.784 0 Td (cedar )Tj /T1_1 1 Tf 0.0112 Tc 8.1 0 0 8.1 467.36 547.92 Tm (\(Thujia )Tj 0.314 0.318 0.31 rg -0.0109 Tc 3.549 0 Td (p/icata\): )Tj /T1_0 1 Tf 0.0077 Tc 8.3 0 0 8.3 296.63 538.8 Tm (relationship )Tj 0.0071 Tc 5.205 0 Td (with )Tj 0.376 0.376 0.372 rg 0.001 Tc 2.19 0 Td (length )Tj 0.314 0.318 0.31 rg 0.05 Tc 8.9033 0 0 8.3 382.48 538.8 Tm (of )Tj 0.376 0.376 0.372 rg 0.0079 Tc 8.3 0 0 8.3 392.55 538.8 Tm (exposure )Tj 0.314 0.318 0.31 rg 0.0358 Tc 4.049 0 Td (and )Tj 0.239 0.239 0.235 rg 0.0103 Tc 1.967 0 Td (lung )Tj 0.314 0.318 0.31 rg 0.0007 Tc 2.253 0 Td (function )Tj 0.239 0.239 0.235 rg 0.0051 Tc 3.825 0 Td (measure)Tj 0.376 0.376 0.372 rg 0 Tc 3.345 0 Td (\255)Tj 0.314 0.318 0.31 rg -0.0058 Tc -26.998 -1.04 Td (ments. )Tj ET BT /Suspect <>BDC /T1_1 1 Tf -0.0171 Tc 8.1 0 0 8.1 321.44 530.17 Tm (Clin )Tj EMC ET BT /T1_1 1 Tf 0.0107 Tc 8.1 0 0 8.1 338.0369 530.17 Tm (Allergy, )Tj 0.239 0.239 0.235 rg /T1_0 1 Tf -0.035 Tc 8.1261 0 0 8.3 367.88 530.17 Tm (198)Tj 0.376 0.376 0.372 rg 7.6478 0 0 8.3 379.6 530.17 Tm (7, )Tj 0.239 0.239 0.235 rg 8.2267 0 0 8.3 388.52 530.17 Tm (17, )Tj 0.314 0.318 0.31 rg 8.2694 0 0 8.3 400.7 530.17 Tm (333)Tj 0.565 0.569 0.557 rg 0 Tc 8.3 0 0 8.3 412.7 530.17 Tm (-)Tj 0.314 0.318 0.31 rg -0.0313 Tc 0.578 0 Td (339. )Tj -0.0282 Tc -14.631 -1.099 Td (36. )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0197 Tc 8.3 0 0 8.3 314.3201 521.0483 Tm (Chan-Yeung )Tj EMC /Suspect <>BDC 0.239 0.239 0.235 rg 0.0282 Tc 5.672 0 Td (M, )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0164 Tc 8.3 0 0 8.3 374.8354 521.0483 Tm (Lam )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.035 Tc 7.8213 0 0 8.3 393.94 521.05 Tm (S, )Tj EMC ET BT 0.239 0.239 0.235 rg /T1_0 1 Tf 0 Tc 8.3 0 0 8.3 404.12 521.05 Tm (K)Tj 0.376 0.376 0.372 rg 0.0142 Tc 0.747 0 Td (oener )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf -0.0196 Tc 8.3 0 0 8.3 432.3317 521.05 Tm (S. )Tj EMC /Suspect <>BDC 0.565 0.569 0.557 rg 0 Tc 1.22 0 Td (-)Tj 0.376 0.376 0.372 rg -0.0022 Tc 0.986 0 Td (Clinical )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0001 Tc 8.3 0 0 8.3 480.3887 521.05 Tm (features )Tj 0.0358 Tc 3.645 0 Td (and )Tj 0.0299 Tc -25.842 -1.1 Td (natural )Tj 0.0103 Tc 3.354 0 Td (history )Tj 0.05 Tc 8.9033 0 0 8.3 350.8 511.92 Tm (of )Tj 0.0164 Tc 8.3 0 0 8.3 360.88 511.92 Tm (occupational )Tj 0.0263 Tc 5.667 0 Td (asthma )Tj 0.0348 Tc 3.354 0 Td (due )Tj 0.376 0.376 0.372 rg 0.035 Tc 1.916 0 Td (to )Tj 0.314 0.318 0.31 rg -0.0062 Tc 1.216 0 Td (western )Tj -0.0017 Tc 3.528 0 Td (red )Tj 0.0284 Tc 1.669 0 Td (cedar )Tj 0.376 0.376 0.372 rg /T1_1 1 Tf 0.0013 Tc 8.1 0 0 8.1 296 503.28 Tm (\(Thujia )Tj 0.314 0.318 0.31 rg 0.0069 Tc 3.253 0 Td (plicata\). )Tj 0.05 Tc 8.7132 0 0 8.1 352.93 503.28 Tm (Am )Tj /T1_3 1 Tf 0 Tc 8 0 0 8 367.13 503.28 Tm (J )Tj /T1_1 1 Tf 0.003 Tc 8.1 0 0 8.1 374.48 503.28 Tm (Med, )Tj /T1_0 1 Tf -0.035 Tc 7.8965 0 0 8.3 395.25 503.28 Tm (1982)Tj 0.467 0.467 0.459 rg 0 Tc 8.3 0 0 8.3 410.27 503.28 Tm (, )Tj 0.314 0.318 0.31 rg -0.0055 Tc 0.525 0 Td (72, )Tj 0.239 0.239 0.235 rg -0.035 Tc 7.4645 0 0 8.3 427.65 503.28 Tm (411)Tj 0.647 0.647 0.639 rg 0 Tc 8.3 0 0 8.3 439.58 503.28 Tm (-)Tj 0.239 0.239 0.235 rg 0.587 0 Td (4)Tj 0.376 0.376 0.372 rg -0.035 Tc 7.3607 0 0 8.3 449.51 503.28 Tm (15. )Tj 0.314 0.318 0.31 rg 7.9784 0 0 8.3 296.07 494.16 Tm (37. )Tj 0.007 Tc 8.3 0 0 8.3 314.36 494.16 Tm (Paggiaro )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0064 Tc 8.3 0 0 8.3 347.0039 494.16 Tm (PL, )Tj EMC ET BT /T1_0 1 Tf 0.0073 Tc 8.3 0 0 8.3 361.3878 494.16 Tm (Innocenti )Tj -0.035 Tc 8.2476 0 0 8.3 395.99 494.16 Tm (A, )Tj -0.0132 Tc 8.3 0 0 8.3 406.52 494.16 Tm (Bacci )Tj 0.0203 Tc 2.486 0 Td (E, )Tj 0.376 0.376 0.372 rg /T1_1 1 Tf 0 Tc 8.1 0 0 8.1 436.73 494.16 Tm (e)Tj 0.239 0.239 0.235 rg 0.05 Tc 9.6178 0 0 8.1 440.53 494.16 Tm (ta/)Tj 0.376 0.376 0.372 rg 0 Tc 8.1 0 0 8.1 451.6 494.16 Tm (. )Tj ET BT /Suspect <>BDC 0.565 0.569 0.557 rg /T1_0 1 Tf 8.3 0 0 8.3 455.42 494.16 Tm (-)Tj 0.314 0.318 0.31 rg -0.0164 Tc 0.861 0 Td (Specific )Tj EMC ET BT /T1_0 1 Tf 0.0139 Tc 8.3 0 0 8.3 491.0436 494.16 Tm (bronchial )Tj -0.0012 Tc -23.482 -1.098 Td (reactivity )Tj 0.035 Tc 4.047 0 Td (to )Tj 0.0116 Tc 1.041 0 Td (toluene )Tj 0.239 0.239 0.235 rg 0.0081 Tc 3.173 0 Td (diiso)Tj 0.376 0.376 0.372 rg 0.0069 Tc 1.966 0 Td (cyanate: )Tj 0.239 0.239 0.235 rg -0.0239 Tc 3.652 0 Td (re)Tj 0.376 0.376 0.372 rg 0.0137 Tc 0.802 0 Td (lationship )Tj 0.314 0.318 0.31 rg -0.0122 Tc 4.287 0 Td (with )Tj 0.0049 Tc 2.027 0 Td (baseline )Tj -0.0036 Tc 3.459 0 Td (clinical )Tj -0.0166 Tc -24.464 -1.041 Td (findings. )Tj /T1_1 1 Tf 0.0092 Tc 8.1 0 0 8.1 328.16 476.41 Tm (Thorax, )Tj /T1_0 1 Tf -0.035 Tc 8.241 0 0 8.3 357.8 476.41 Tm (1986, )Tj -0.0101 Tc 8.3 0 0 8.3 377.73 476.41 Tm (41, )Tj 0.376 0.376 0.372 rg -0.0177 Tc 1.559 0 Td (279)Tj 0.565 0.569 0.557 rg 0 Tc 1.44 0 Td (-)Tj 0.314 0.318 0.31 rg -0.0177 Tc 0.527 0 Td (282)Tj 0.467 0.467 0.459 rg 0 Tc 1.489 0 Td (. )Tj 0.314 0.318 0.31 rg -0.035 Tc 7.9784 0 0 8.3 296.07 467.28 Tm (38. )Tj 0.0358 Tc 8.3 0 0 8.3 314.36 467.28 Tm (Mapp )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0179 Tc 8.3 0 0 8.3 339.2766 467.28 Tm (CE)Tj 0.467 0.467 0.459 rg 0 Tc 1.324 0 Td (, )Tj EMC /Suspect <>BDC 0.314 0.318 0.31 rg 0.008 Tc 0.758 0 Td (Chiesura )Tj EMC /Suspect <>BDC 0.0405 Tc 4.222 0 Td (Corona )Tj EMC /Suspect <>BDC 0.239 0.239 0.235 rg 0 Tc 8.4 0 0 8.4 421.88 467.28 Tm (P)Tj 0.376 0.376 0.372 rg 0.618 0 Td (, )Tj EMC ET BT 0.239 0.239 0.235 rg /T1_0 1 Tf 0.0252 Tc 8.3 0 0 8.3 433.88 467.28 Tm (Fabbri )Tj 0.314 0.318 0.31 rg 0.028 Tc 3.296 0 Td (LM. )Tj ET BT /Suspect <>BDC 0.467 0.467 0.459 rg /T1_0 1 Tf 0 Tc 8.3 0 0 8.3 481.3394 467.28 Tm (-)Tj EMC /Suspect <>BDC 0.239 0.239 0.235 rg -0.0186 Tc 1.106 0 Td (Persi)Tj 0.376 0.376 0.372 rg 0.0408 Tc 1.957 0 Td (stent )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0263 Tc 8.3 0 0 8.3 295.602 458.1583 Tm (asthma )Tj 0.0348 Tc 3.47 0 Td (due )Tj -0.0228 Tc 2.031 0 Td (to )Tj 0.0018 Tc 1.266 0 Td (isocyanatcs. )Tj 0 Tc 5.386 0 Td (A )Tj -0.0036 Tc 1.263 0 Td (follow-up )Tj 0.376 0.376 0.372 rg 0.0287 Tc 4.392 0 Td (study )Tj 0.314 0.318 0.31 rg 0.05 Tc 8.9033 0 0 8.3 466.48 458.16 Tm (of )Tj 0.0065 Tc 8.3 0 0 8.3 477 458.16 Tm (subjects )Tj -0.0315 Tc 3.83 0 Td (with )Tj 0.376 0.376 0.372 rg 0.0166 Tc -25.686 -1.04 Td (occupa)Tj 0.239 0.239 0.235 rg 0.0199 Tc 2.957 0 Td (tional )Tj 0.314 0.318 0.31 rg 0.0263 Tc 2.711 0 Td (asthma )Tj 0.0348 Tc 3.296 0 Td (due )Tj -0.0228 Tc 1.916 0 Td (to )Tj 0.002 Tc 1.214 0 Td (toluene )Tj 0.0073 Tc 3.289 0 Td (diisocyanatc. )Tj /T1_1 1 Tf 0.05 Tc 8.3646 0 0 8.1 471.49 449.53 Tm (Am )Tj 8.1354 0 0 8.1 485.82 449.53 Tm (Rev )Tj 0.0123 Tc 8.1 0 0 8.1 501.66 449.53 Tm (Respir )Tj -0.0139 Tc -25.36 -1.126 Td (Dis, )Tj /T1_0 1 Tf -0.035 Tc 8.1597 0 0 8.3 312.68 440.41 Tm (1988)Tj 0.467 0.467 0.459 rg 0 Tc 8.3 0 0 8.3 327.71 440.41 Tm (, )Tj 0.314 0.318 0.31 rg 0.0067 Tc 0.584 0 Td (accepted )Tj 0.0146 Tc 3.873 0 Td (for )Tj 0.0059 Tc 1.573 0 Td (publication. )Tj -0.035 Tc 7.7578 0 0 8.3 296.07 431.76 Tm (39)Tj 0.467 0.467 0.459 rg 0 Tc 8.3 0 0 8.3 303.67 431.76 Tm (. )Tj 0.314 0.318 0.31 rg -0.0149 Tc 1.23 0 Td (Belin )Tj -0.035 Tc 8.2683 0 0 8.3 335 431.76 Tm (L, )Tj -0.0059 Tc 8.3 0 0 8.3 345.57 431.76 Tm (Wass )Tj ET BT /Suspect <>BDC 0.376 0.376 0.372 rg /T1_0 1 Tf -0.035 Tc 8.2417 0 0 8.3 367.19 431.76 Tm (U, )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0165 Tc 8.3 0 0 8.3 378.71 431.76 Tm (Audunsson )Tj 0.0262 Tc 5.081 0 Td (G, )Tj 0.0226 Tc 1.451 0 Td (Mathiasson )Tj -0.035 Tc 7.6777 0 0 8.3 477.08 431.76 Tm (L. )Tj 0.376 0.376 0.372 rg 0 Tc 8.3 0 0 8.3 487.58 431.76 Tm (-)Tj 0.239 0.239 0.235 rg -0.0049 Tc 0.936 0 Td (Amin)Tj 0.376 0.376 0.372 rg -0.035 Tc 8.006 0 0 8.3 514.48 431.76 Tm (es: )Tj 0.314 0.318 0.31 rg -0.0039 Tc 8.3 0 0 8.3 295.69 422.65 Tm (possible )Tj 0.008 Tc 3.633 0 Td (causative )Tj 0.0007 Tc 4.164 0 Td (agents )Tj 0.376 0.376 0.372 rg -0.035 Tc 7.9356 0 0 8.3 385.38 422.65 Tm (in )Tj 0.314 0.318 0.31 rg -0.0016 Tc 8.3 0 0 8.3 395.02 422.65 Tm (the )Tj 0.0054 Tc 1.612 0 Td (development )Tj 0.376 0.376 0.372 rg 0.05 Tc 9.4598 0 0 8.3 454.95 422.65 Tm (of )Tj 0.314 0.318 0.31 rg 0.0139 Tc 8.3 0 0 8.3 465.61 422.65 Tm (bronchial )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0005 Tc 8.3 0 0 8.3 501.1091 422.65 Tm (hyper\255)Tj EMC ET BT /T1_0 1 Tf -0.0012 Tc 8.3 0 0 8.3 295.6675 413.5283 Tm (reactivity )Tj -0.035 Tc 7.9356 0 0 8.3 330.66 413.53 Tm (in )Tj 0.0038 Tc 8.3 0 0 8.3 340.31 413.53 Tm (workers )Tj 0.239 0.239 0.235 rg 0.0161 Tc 3.642 0 Td (manufacturing )Tj 0.05 Tc 6.423 0 Td (po)Tj 0.376 0.376 0.372 rg 0.0113 Tc 1.089 0 Td (lyuret)Tj 0.239 0.239 0.235 rg 0.0033 Tc 2.378 0 Td (han)Tj 0.376 0.376 0.372 rg -0.0026 Tc 1.494 0 Td (es )Tj 0.314 0.318 0.31 rg 0.0014 Tc 1.214 0 Td (from )Tj -0.0104 Tc 2.431 0 Td (isocyan\255)Tj 0.0005 Tc -24.059 -1.041 Td (ates. )Tj /T1_1 1 Tf 0.0078 Tc 8.1 0 0 8.1 313.98 404.89 Tm (Br )Tj /T1_3 1 Tf 0 Tc 8 0 0 8 324.41 404.89 Tm (J )Tj ET BT /Suspect <>BDC 0.239 0.239 0.235 rg /T1_1 1 Tf 0.05 Tc 8.3968 0 0 8.1 331.11 404.89 Tm (lml )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_1 1 Tf 0.0228 Tc 8.1 0 0 8.1 345.2 404.89 Tm (Med, )Tj /T1_0 1 Tf -0.035 Tc 8.241 0 0 8.3 365.96 404.89 Tm (1983, )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0101 Tc 8.3 0 0 8.3 385.89 404.89 Tm (40, )Tj EMC ET BT /T1_0 1 Tf -0.035 Tc 7.8237 0 0 8.3 398.83 404.89 Tm (251)Tj 0.565 0.569 0.557 rg 0 Tc 8.3 0 0 8.3 410.78 404.89 Tm (-)Tj 0.314 0.318 0.31 rg -0.035 Tc 8.2652 0 0 8.3 415.63 404.89 Tm (257. )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0016 Tc 8.3 0 0 8.3 295.17 395.76 Tm (40)Tj 0.082 g 0 Tc 1.024 0 Td (. )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0358 Tc 8.3 0 0 8.3 313.8782 395.76 Tm (Mapp )Tj ET BT /Suspect <>BDC 0.376 0.376 0.372 rg /T1_0 1 Tf 0.0285 Tc 8.3 0 0 8.3 337.8403 395.76 Tm (CE, )Tj EMC ET BT 0.239 0.239 0.235 rg /T1_0 1 Tf -0.0005 Tc 8.3 0 0 8.3 354.681 395.76 Tm (Boschett)Tj 0.376 0.376 0.372 rg 0 Tc 3.523 0 Td (o )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf 0.019 Tc 8.3 0 0 8.3 391.6409 395.76 Tm (P, )Tj EMC ET BT 0.239 0.239 0.235 rg /T1_0 1 Tf 0.0102 Tc 8.3 0 0 8.3 402.1985 395.76 Tm (Dal )Tj 0.314 0.318 0.31 rg -0.0138 Tc 1.911 0 Td (Vecchio )Tj 0 Tc 3.757 0 Td (L)Tj 0.467 0.467 0.459 rg 0.567 0 Td (, )Tj 0.376 0.376 0.372 rg /T1_1 1 Tf 8.1 0 0 8.1 459.29 395.76 Tm (e)Tj 0.239 0.239 0.235 rg 0.472 0 Td (t )Tj 0.314 0.318 0.31 rg -0.035 Tc 8.0998 0 0 8.1 468.91 395.76 Tm (a/. )Tj ET BT /Suspect <>BDC 0.467 0.467 0.459 rg /T1_0 1 Tf 0 Tc 8.1 0 0 8.1 480.87 395.76 Tm (-)Tj EMC /Suspect <>BDC 0.239 0.239 0.235 rg 0.008 Tc 8.3 0 0 8.3 488.6 395.76 Tm (Protective )Tj EMC ET BT 0.376 0.376 0.372 rg /T1_0 1 Tf -0.0109 Tc 8.3 0 0 8.3 295.1104 386.6466 Tm (effect )Tj 0.314 0.318 0.31 rg 0.05 Tc 8.9033 0 0 8.3 318.64 386.65 Tm (of )Tj 0.02 Tc 8.3 0 0 8.3 330.16 386.65 Tm (antiasthmatic )Tj 0.0251 Tc 6.13 0 Td (drugs )Tj 0.376 0.376 0.372 rg 0.0035 Tc 2.949 0 Td (on )Tj 0.314 0.318 0.31 rg 0.0263 Tc 1.62 0 Td (late )Tj 0.0292 Tc 2.081 0 Td (asthmatic )Tj 0.0048 Tc 4.635 0 Td (reactions )Tj 0.0358 Tc 4.271 0 Td (and )Tj -0.0067 Tc -25.849 -1.042 Td (increased )Tj 0.376 0.376 0.372 rg 0.0138 Tc 4.047 0 Td (airway )Tj 0.314 0.318 0.31 rg -0.0029 Tc 3.016 0 Td (responsiveness )Tj -0.004 Tc 6.239 0 Td (induced )Tj -0.035 Tc 8.0386 0 0 8.3 434.89 378 Tm (by )Tj 0.0116 Tc 8.3 0 0 8.3 444.94 378 Tm (toluene )Tj 0.0097 Tc 3.231 0 Td (diisocyanate )Tj 0.0488 Tc 5.38 0 Td (in )Tj -0.0042 Tc -26.666 -1.098 Td (sensitized )Tj 0.0034 Tc 4.222 0 Td (subjects. )Tj /T1_1 1 Tf 0.05 Tc 8.3646 0 0 8.1 362.53 368.89 Tm (Am )Tj -0.0058 Tc 8.1 0 0 8.1 377.34 368.89 Tm (Rev )Tj 0.0005 Tc 1.896 0 Td (Respir )Tj -0.0139 Tc 2.906 0 Td (Dis, )Tj /T1_0 1 Tf -0.035 Tc 8.241 0 0 8.3 433.16 368.89 Tm (1987, )Tj 8.1261 0 0 8.3 453.8 368.89 Tm (136)Tj 0.467 0.467 0.459 rg 0 Tc 8.3 0 0 8.3 465.47 368.89 Tm (, )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf -0.035 Tc 8.1597 0 0 8.3 470.6 368.89 Tm (1403)Tj 0.467 0.467 0.459 rg 0 Tc 8.3 0 0 8.3 486.14 368.89 Tm (-)Tj 0.314 0.318 0.31 rg -0.035 Tc 8.241 0 0 8.3 491.24 368.89 Tm (1407. )Tj EMC ET BT /T1_0 1 Tf 8.2425 0 0 8.3 295.17 359.76 Tm (41. )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0075 Tc 8.3 0 0 8.3 313.36 359.76 Tm (Commissions )Tj EMC ET BT /T1_0 1 Tf -0.0254 Tc 8.3 0 0 8.3 364.239 359.76 Tm (des )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0264 Tc 8.3 0 0 8.3 380.0754 359.76 Tm (Communautes )Tj EMC ET BT /T1_0 1 Tf 0.0115 Tc 8.3 0 0 8.3 435.3036 359.76 Tm (Europccnncs )Tj ET BT /Suspect <>BDC 0.376 0.376 0.372 rg /T1_0 1 Tf 0.0028 Tc 8.3 0 0 8.3 484.2155 359.76 Tm (\(ECCS\). )Tj EMC /Suspect <>BDC 0.565 0.569 0.557 rg 0 Tc 4.106 0 Td (-)Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0145 Tc 8.3 0 0 8.3 295.1249 351.1197 Tm (Tables )Tj 0.0491 Tc 3.064 0 Td (de )Tj -0.0088 Tc 1.396 0 Td (reference )Tj 0.0474 Tc 3.993 0 Td (pour )Tj -0.035 Tc 7.9707 0 0 8.3 384.89 351.12 Tm (les )Tj 0.376 0.376 0.372 rg 0.0087 Tc 8.3 0 0 8.3 395.91 351.12 Tm (examens )Tj 0.314 0.318 0.31 rg 0.0101 Tc 3.871 0 Td (spirometriques. )Tj 0.376 0.376 0.372 rg 0 Tc 6.755 0 Td (: )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf -0.0315 Tc 8.3 0 0 8.3 489.036 351.12 Tm (Office )Tj EMC ET BT /T1_0 1 Tf 0.0036 Tc 8.3 0 0 8.3 511.5954 351.12 Tm (des )Tj 0.0143 Tc -26.071 -1.099 Td (publications )Tj 0.376 0.376 0.372 rg -0.035 Tc 8.0146 0 0 8.3 341.2 342 Tm (offi)Tj 0.239 0.239 0.235 rg 7.9406 0 0 8.3 352.24 342 Tm (ci)Tj 0.376 0.376 0.372 rg -0.0186 Tc 8.3 0 0 8.3 357.99 342 Tm (elles )Tj 0.314 0.318 0.31 rg 0.0325 Tc 2.199 0 Td (des )Tj ET BT /Suspect <>BDC 0.376 0.376 0.372 rg /T1_0 1 Tf 0.0206 Tc 8.3 0 0 8.3 392.0781 342 Tm (Communautes )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0172 Tc 8.3 0 0 8.3 445.8704 342 Tm (Europeennes)Tj 0.467 0.467 0.459 rg 0 Tc 5.311 0 Td (, )Tj ET BT /Suspect <>BDC 0.239 0.239 0.235 rg /T1_0 1 Tf 0.0185 Tc 8.3 0 0 8.3 496.2846 342 Tm (Luxem)Tj 0.376 0.376 0.372 rg 0 Tc 2.884 0 Td (\255)Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0174 Tc 8.3 0 0 8.3 295.2088 332.8866 Tm (bourg, )Tj 0.239 0.239 0.235 rg -0.035 Tc 8.0056 0 0 8.3 321.32 332.89 Tm (1971. )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0209 Tc 8.3 0 0 8.3 295.64 315.12 Tm (RESUME: )Tj EMC /Suspect <>BDC 0.376 0.376 0.372 rg 0.0138 Tc 4.737 0 Td (Cette )Tj EMC /Suspect <>BDC 0.314 0.318 0.31 rg 0.028 Tc 2.37 0 Td (etude )Tj EMC ET BT /T1_0 1 Tf -0.0017 Tc 8.3 0 0 8.3 374.7971 315.12 Tm (decrit )Tj -0.0163 Tc 2.612 0 Td (un )Tj 0.0146 Tc 1.271 0 Td (nombre )Tj 0.0197 Tc 3.353 0 Td (total )Tj -0.0087 Tc 2.133 0 Td (de )Tj 0.239 0.239 0.235 rg -0.035 Tc 8.1261 0 0 8.3 462.92 315.12 Tm (162 )Tj 0.314 0.318 0.31 rg 0.0011 Tc 8.3 0 0 8.3 476.04 315.12 Tm (sujets )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0036 Tc 8.3 0 0 8.3 496.707 315.12 Tm (exposes )Tj EMC ET BT 0.376 0.376 0.372 rg /T1_0 1 Tf 0.05 Tc 8.3101 0 0 8.3 294.64 306 Tm (au)Tj 0.239 0.239 0.235 rg 0 Tc 8.3 0 0 8.3 303.33 306 Tm (x )Tj 0.314 0.318 0.31 rg 0.0096 Tc 1.152 0 Td (isocyanatcs)Tj 0.467 0.467 0.459 rg 0 Tc 4.677 0 Td (, )Tj 0.314 0.318 0.31 rg 0.0403 Tc 0.874 0 Td (ayant )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0011 Tc 8.3 0 0 8.3 383.4416 306 Tm (dcveloppe )Tj EMC ET BT /T1_0 1 Tf 0.0036 Tc 8.3 0 0 8.3 422.8002 306 Tm (des )Tj 0.0125 Tc 2.019 0 Td (symptomes )Tj 0.0141 Tc 5.336 0 Td (pendant )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.035 Tc 7.2698 0 0 8.3 516.91 306 Tm (Ia )Tj EMC ET BT /T1_0 1 Tf 0.013 Tc 8.3 0 0 8.3 295.21 297.37 Tm (periode )Tj -0.0087 Tc 3.343 0 Td (de )Tj 0.0337 Tc 1.157 0 Td (contact )Tj 0.05 Tc 8.3916 0 0 8.3 360.4 297.37 Tm (ou )Tj -0.0108 Tc 8.3 0 0 8.3 371.45 297.37 Tm (le )Tj 0.0292 Tc 0.919 0 Td (soir )Tj 0.05 Tc 8.3916 0 0 8.3 394.48 297.37 Tm (ou )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.035 Tc 7.9307 0 0 8.3 405.55 297.37 Tm (Ia )Tj EMC ET BT /T1_0 1 Tf 0.0057 Tc 8.3 0 0 8.3 414.23 297.37 Tm (nuit; )Tj -0.0202 Tc 2.131 0 Td (ccs )Tj 0.0011 Tc 1.499 0 Td (sujets )Tj 0.0129 Tc 2.549 0 Td (avaient )Tj 0.03 Tc 3.239 0 Td (done )Tj 0.0325 Tc 2.255 0 Td (des )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0153 Tc 8.3 0 0 8.3 294.6353 288.2483 Tm (antecedents )Tj EMC ET BT /T1_0 1 Tf 0.0168 Tc 8.3 0 0 8.3 337.3554 288.2483 Tm (compatibles )Tj -0.0084 Tc 5.378 0 Td (avec )Tj 0.376 0.376 0.372 rg 0.0114 Tc 2.143 0 Td (J'asthme )Tj 0.314 0.318 0.31 rg 0.0112 Tc 3.872 0 Td (induit )Tj 0.05 Tc 8.4273 0 0 8.3 455.05 288.25 Tm (par )Tj -0.0264 Tc 8.3 0 0 8.3 469.85 288.25 Tm (les )Tj 0.0018 Tc 1.388 0 Td (isocyanates. )Tj ET BT /Suspect <>BDC /C0_0 1 Tf 0 Tc 4.5334 0 0 6.24 295.21 279.12 Tm <0053006F0075007E006F006E006E006500730020>Tj EMC ET BT /T1_0 1 Tf 0.0293 Tc 8.3 0 0 8.3 341.2 279.12 Tm (d'etre )Tj 0.0193 Tc 2.892 0 Td (atteints )Tj 0.0287 Tc 3.643 0 Td (d'asthme )Tj 0.0099 Tc 4.29 0 Td (profcssionncl)Tj 0.467 0.467 0.459 rg 0 Tc 5.535 0 Td (, )Tj 0.314 0.318 0.31 rg -0.035 Tc 7.8427 0 0 8.3 484.26 279.12 Tm (ils )Tj 0.05 Tc 8.4919 0 0 8.3 496.24 279.12 Tm (ont )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0356 Tc 8.3 0 0 8.3 512.55 279.12 Tm (etc )Tj EMC /Suspect <>BDC -0.035 Tc 7.9696 0 0 8.3 294.58 270.49 Tm (SOumis )Tj EMC /Suspect <>BDC /T1_2 1 Tf 0 Tc 11.1 0 0 11.1 321 270.49 Tm (a )Tj EMC ET BT /T1_0 1 Tf -0.0254 Tc 8.3 0 0 8.3 327.28 270.49 Tm (des )Tj -0.0094 Tc 1.627 0 Td (tests )Tj 0.0491 Tc 2.017 0 Td (de )Tj 0.0152 Tc 1.283 0 Td (provocation )Tj 0.0358 Tc 5.194 0 Td (aux )Tj 0.0096 Tc 1.794 0 Td (isocyanates )Tj 0.006 Tc 4.97 0 Td (\(diisocyanale )Tj -0.0087 Tc 5.67 0 Td (de )Tj 0.002 Tc -26.422 -1.099 Td (toluene )Tj 0.05 Tc 8.3173 0 0 8.3 325.83 261.37 Tm (et )Tj 0.0097 Tc 8.3 0 0 8.3 338.32 261.37 Tm (diisocyanate )Tj 0.0491 Tc 5.841 0 Td (de )Tj -0.0026 Tc 1.677 0 Td (diphcnyl )Tj -0.0087 Tc 4.28 0 Td (de )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0039 Tc 8.3 0 0 8.3 450.702 261.37 Tm (methylene\) )Tj EMC ET BT /T1_0 1 Tf 0.05 Tc 8.3173 0 0 8.3 493.83 261.37 Tm (et )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0 Tc 13.4 0 0 13.4 505.78 261.37 Tm (a )Tj EMC /Suspect <>BDC -0.035 Tc 7.9307 0 0 8.3 516.43 261.37 Tm (Ia )Tj EMC ET BT /T1_0 1 Tf 0.016 Tc 8.3 0 0 8.3 294.7 252.25 Tm (methacholine )Tj 0.05 Tc 8.4273 0 0 8.3 345.13 252.25 Tm (par )Tj 0.0225 Tc 8.3 0 0 8.3 360.89 252.25 Tm (inhalation. )Tj 0.0003 Tc 5.096 0 Td (Aucun )Tj -0.0087 Tc 3.288 0 Td (de )Tj -0.0202 Tc 1.504 0 Td (ces )Tj 0.0127 Tc 1.73 0 Td (sujets )Tj -0.0144 Tc 2.905 0 Td (ne )Tj 0.0065 Tc 1.49 0 Td (souffrait )Tj 0.0287 Tc -23.995 -1.041 Td (d'asthme )Tj 0.376 0.376 0.372 rg 0.0189 Tc 4.101 0 Td (symptomatique )Tj 0.314 0.318 0.31 rg 0.0403 Tc 6.713 0 Td (avant )Tj 0.0491 Tc 2.66 0 Td (de )Tj 0.0129 Tc 1.33 0 Td (commencer )Tj 0.0121 Tc 5.084 0 Td (son )Tj 0.0091 Tc 1.863 0 Td (travail )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0033 Tc 8.3 0 0 8.3 500.0727 243.6097 Tm (actuel. )Tj EMC ET BT /T1_2 1 Tf -0.0195 Tc 7.7 0 0 7.7 295.04 234.49 Tm (Le )Tj /T1_0 1 Tf 0.0139 Tc 8.3 0 0 8.3 307.6 234.49 Tm (diagnostic )Tj 0.0491 Tc 4.684 0 Td (de )Tj 0.0202 Tc 1.505 0 Td (l'asthme )Tj 0.0051 Tc 3.942 0 Td (professionnel )Tj 0 Tc 5.888 0 Td (a )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0067 Tc 8.3 0 0 8.3 448.7083 234.49 Tm (ete )Tj EMC ET BT /T1_0 1 Tf 0.0421 Tc 8.3 0 0 8.3 462.7021 234.49 Tm (tardif )Tj 0.0139 Tc 2.766 0 Td (\(duree )Tj 0.0036 Tc 3.067 0 Td (des )Tj 0.0052 Tc -26.087 -1.041 Td (symptomes )Tj 0.0259 Tc 5.267 0 Td (avant )Tj 0.0021 Tc 2.892 0 Td (diagnostic: )Tj ET BT /Suspect <>BDC 0.376 0.376 0.372 rg /T1_0 1 Tf 0.05 Tc 8.4081 0 0 8.3 404.54 225.85 Tm (3,9\2610,4 )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0011 Tc 8.3 0 0 8.3 437.68 225.85 Tm (ans\). )Tj 0.03 Tc 2.607 0 Td (L'asthme )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.002 Tc 8.3 0 0 8.3 495.7551 225.85 Tm (dii )Tj EMC ET BT 0.239 0.239 0.235 rg /T1_0 1 Tf 0.0358 Tc 8.3 0 0 8.3 509.6742 225.85 Tm (aux )Tj 0.376 0.376 0.372 rg 0.0096 Tc -25.907 -1.099 Td (isocyanates )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0241 Tc 8.3 0 0 8.3 338.3124 216.7283 Tm (demontre )Tj EMC ET BT /T1_0 1 Tf 0.0316 Tc 8.3 0 0 8.3 376.7995 216.7283 Tm (par )Tj -0.0163 Tc 1.965 0 Td (un )Tj -0.0178 Tc 1.675 0 Td (test )Tj -0.0087 Tc 2.017 0 Td (de )Tj 0.0209 Tc 1.572 0 Td (provocation )Tj 0.0194 Tc 5.61 0 Td (positif )Tj 0.0069 Tc 3.17 0 Td (aux )Tj 0.376 0.376 0.372 rg -0.0013 Tc -25.907 -1.099 Td (isocyana)Tj 0.239 0.239 0.235 rg -0.0039 Tc 3.592 0 Td (tes )Tj 0.314 0.318 0.31 rg 0.0316 Tc 1.392 0 Td (par )Tj 0.0142 Tc 1.61 0 Td (inhalation )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0239 Tc 8.3 0 0 8.3 386.3196 207.6066 Tm (etait )Tj EMC ET BT /T1_0 1 Tf 0.0122 Tc 8.3 0 0 8.3 403.2184 207.6066 Tm (present )Tj -0.0054 Tc 3.228 0 Td (chez )Tj -0.0011 Tc 2.078 0 Td (57,4% )Tj 0.0036 Tc 2.895 0 Td (des )Tj -0.0022 Tc 1.557 0 Td (sujets. )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0086 Tc 8.3 0 0 8.3 508.3213 207.6066 Tm (Une )Tj EMC /Suspect <>BDC -0.0029 Tc -25.745 -1.041 Td (faculte )Tj EMC ET BT /T1_0 1 Tf 0.0491 Tc 8.3 0 0 8.3 319.1311 198.9663 Tm (de )Tj 0.0044 Tc 1.223 0 Td (response )Tj 0.0133 Tc 3.751 0 Td (accrue )Tj 0.0036 Tc 2.892 0 Td (des )Tj -0.0199 Tc 1.569 0 Td (voies )Tj 0.0071 Tc 2.248 0 Td (acriennes )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0356 Tc 8.3 0 0 8.3 449.6901 198.9663 Tm (eta )Tj EMC ET BT /T1_0 1 Tf -0.0174 Tc 8.3 0 0 8.3 460.2726 198.9663 Tm (it )Tj 0.0133 Tc 0.761 0 Td (presente )Tj -0.0054 Tc 3.633 0 Td (chez )Tj -0.0264 Tc 2.025 0 Td (les )Tj 0.376 0.376 0.372 rg 0.0127 Tc -26.435 -1.099 Td (sujets )Tj 0.314 0.318 0.31 rg 0.0468 Tc 2.665 0 Td (dont )Tj -0.035 Tc 7.8836 0 0 8.3 335.93 189.85 Tm (le )Tj 0.0014 Tc 8.3 0 0 8.3 345.1 189.85 Tm (test )Tj 0.0491 Tc 1.728 0 Td (de )Tj 0.0209 Tc (provocation )Tj 0.0358 Tc 6.708 0 Td (aux )Tj 0.0039 Tc 1.91 0 Td (isocyanates )Tj 0.0316 Tc 5.099 0 Td (par )Tj 0.0142 Tc 1.725 0 Td (inhalation )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0239 Tc 8.3 0 0 8.3 294.1546 180.7283 Tm (etait )Tj EMC ET BT /T1_0 1 Tf 0.029 Tc 8.3 0 0 8.3 313.4521 180.7283 Tm (positif )Tj 0.05 Tc 8.3173 0 0 8.3 338.79 180.73 Tm (et )Tj 0.0035 Tc 8.3 0 0 8.3 349.43 180.73 Tm (non )Tj 0.376 0.376 0.372 rg 0.0139 Tc 2.016 0 Td (chez )Tj 0.314 0.318 0.31 rg -0.0051 Tc 2.255 0 Td (ceux )Tj 0.0468 Tc 2.371 0 Td (dont )Tj -0.035 Tc 6.6933 0 0 8.3 424.76 180.73 Tm (Je )Tj 0.0014 Tc 8.3 0 0 8.3 434.38 180.73 Tm (test )Tj 0.0491 Tc 1.843 0 Td (de )Tj 0.0209 Tc 1.457 0 Td (provocation )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0239 Tc 8.3 0 0 8.3 506.7892 180.73 Tm (etait )Tj EMC ET BT /T1_0 1 Tf 0.0203 Tc 8.3 0 0 8.3 294.7076 172.0897 Tm (negatif )Tj 0.0102 Tc 3.17 0 Td (\(moyenne )Tj 0.05 Tc 10.3737 0 0 8.3 357.5 172.09 Tm (Get )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0203 Tc 6 0 0 6 376.74 172.09 Tm (GESM: )Tj EMC /Suspect <>BDC -0.0222 Tc 8.3 0 0 8.3 398.8 172.09 Tm (0,407 )Tj EMC ET BT /T1_0 1 Tf -0.0168 Tc 8.3 0 0 8.3 420.38 172.09 Tm (\(1,14\) )Tj -0.0003 Tc 2.728 0 Td (mg )Tj 0.376 0.376 0.372 rg 0.0253 Tc 1.612 0 Td (contre )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf 0 Tc 8.3 0 0 8.3 481.3601 172.09 Tm (0)Tj 0.467 0.467 0.459 rg 0.457 0 Td (,)Tj 0.314 0.318 0.31 rg -0.035 Tc 8.1988 0 0 8.3 487.59 172.09 Tm (942 )Tj EMC ET BT 0.376 0.376 0.372 rg /T1_0 1 Tf 0 Tc 8.3 0 0 8.3 502.46 172.09 Tm (\()Tj 0.239 0.239 0.235 rg 0.44 0 Td (1)Tj 0.376 0.376 0.372 rg -0.035 Tc 8.2942 0 0 8.3 509.63 172.09 Tm (,14\) )Tj 0.314 0.318 0.31 rg -0.0221 Tc 8.3 0 0 8.3 294.22 162.97 Tm (mg\))Tj 0.467 0.467 0.459 rg 0 Tc 1.601 0 Td (. )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf -0.035 Tc 8.5907 0 0 8.6 312.91 162.97 Tm (La )Tj EMC ET BT /T1_0 1 Tf 0.0128 Tc 8.3 0 0 8.3 324.46 162.97 Tm (majorite )Tj 0.0036 Tc 3.752 0 Td (des )Tj 0.0011 Tc 1.614 0 Td (sujets )Tj -0.035 Tc 8.0856 0 0 8.3 390.61 162.97 Tm (se )Tj 0.0141 Tc 8.3 0 0 8.3 399.85 162.97 Tm (plaignaient )Tj -0.0087 Tc 4.847 0 Td (de )Tj 0.0276 Tc 1.28 0 Td (manque )Tj -0.0087 Tc 3.578 0 Td (de )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0149 Tc 8.3 0 0 8.3 490.9176 162.97 Tm (souffle )Tj EMC ET BT /T1_0 1 Tf 0.05 Tc 8.3173 0 0 8.3 515.43 162.97 Tm (et )Tj 0.0279 Tc 8.3 0 0 8.3 294.16 153.85 Tm (d'avoir )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.035 Tc 7.9307 0 0 8.3 321.07 153.85 Tm (Ia )Tj EMC ET BT /T1_0 1 Tf 0.006 Tc 8.3 0 0 8.3 329.74 153.85 Tm (toux)Tj 0.467 0.467 0.459 rg 0 Tc 1.89 0 Td (. )Tj ET BT /Suspect <>BDC 0.314 0.318 0.31 rg /T1_0 1 Tf 0.0086 Tc 8.3 0 0 8.3 350.3904 153.85 Tm (Une )Tj EMC ET BT 0.239 0.239 0.235 rg /T1_0 1 Tf -0.0074 Tc 8.3 0 0 8.3 366.6335 153.85 Tm (faible )Tj 0.314 0.318 0.31 rg 0.0205 Tc 2.614 0 Td (proportion )Tj 0.0491 Tc 4.731 0 Td (de )Tj 0.0011 Tc 1.21 0 Td (sujets )Tj 0.0143 Tc 2.607 0 Td (atopiques )Tj 0.376 0.376 0.372 rg 0.011 Tc 4.219 0 Td (\(21,5%\) )Tj 0.314 0.318 0.31 rg 0.05 Tc 8.9571 0 0 8.3 293.67 145.21 Tm (et )Tj 0.0491 Tc 8.3 0 0 8.3 302.32 145.21 Tm (de )Tj 0.0004 Tc 1.271 0 Td (fumeurs )Tj -0.035 Tc 8.0093 0 0 8.3 342.63 145.21 Tm (\(7 )Tj 0.376 0.376 0.372 rg 0.0048 Tc 8.3 0 0 8.3 349.79 145.21 Tm (,5% )Tj 0.314 0.318 0.31 rg 0.0142 Tc 1.629 0 Td (\), )Tj 0.05 Tc 8.3173 0 0 8.3 370.47 145.21 Tm (et )Tj 0.0017 Tc 8.3 0 0 8.3 379.2 145.21 Tm (une )Tj 0.0269 Tc 1.736 0 Td (proportion )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.02 Tc 8.3 0 0 8.3 432.8761 145.21 Tm (clevee )Tj EMC ET BT /T1_0 1 Tf 0.0491 Tc 8.3 0 0 8.3 454.9541 145.21 Tm (de )Tj 0.376 0.376 0.372 rg 0.0011 Tc 1.21 0 Td (sujets )Tj 0.314 0.318 0.31 rg 0.0268 Tc 2.502 0 Td (presentant )Tj 0.239 0.239 0.235 rg -0.035 Tc 7.8836 0 0 8.3 294.17 136.09 Tm (le )Tj 0.314 0.318 0.31 rg 0.0325 Tc 8.3 0 0 8.3 301.36 136.09 Tm (composant )Tj 0.376 0.376 0.372 rg 0.0441 Tc 4.865 0 Td (tardifde )Tj 0.314 0.318 0.31 rg -0.035 Tc 7.9307 0 0 8.3 372.43 136.09 Tm (Ia )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0115 Tc 8.3 0 0 8.3 380.63 136.09 Tm (reaction )Tj EMC ET BT /T1_0 1 Tf 0.0274 Tc 8.3 0 0 8.3 409.8377 136.09 Tm (asthmatique )Tj 0.376 0.376 0.372 rg -0.035 Tc 7.7165 0 0 8.3 453.99 136.09 Tm (\(71 )Tj 0.05 Tc 8.4331 0 0 8.3 464.56 136.09 Tm (%\) )Tj 0.314 0.318 0.31 rg 0.0007 Tc 8.3 0 0 8.3 477 136.09 Tm (semblent )Tj ET BT /Suspect <>BDC 0.376 0.376 0.372 rg /T1_0 1 Tf 0.0477 Tc 8.3 0 0 8.3 508.706 136.09 Tm (etre )Tj EMC ET BT 0.314 0.318 0.31 rg /T1_0 1 Tf -0.0264 Tc 8.3 0 0 8.3 294.1676 126.96 Tm (les )Tj 0.0177 Tc 1.394 0 Td (traits )Tj 0.0207 Tc 2.422 0 Td (communs )Tj -0.0087 Tc 4.337 0 Td (de )Tj 0.0114 Tc 1.214 0 Td (cette )Tj 0.0053 Tc 2.324 0 Td (pathologic. )Tj ET endstream endobj 71 0 obj <>stream Hd͊zy8 >sRhF^#y QG#Oç==o/ϧ;c_mӷKv|~_oo~y>}~W=|z>{O݇q~?>Ï?o+~ߒ~;%zΏx߽w;>lp?(O?{wٸ^ PZUuTGu^5P5FjFDMԤU PjVjUmFmک]uPuNNE]E5|| _#_k55|| _#_k55|| _#_k55|| _#_k5Z||-_+_kZ||-_+_kZ||-_+_kZ||-_+_ku:||_'_uu:||_'_uu:||_'_uu:||_'_uz||=_/_z||=_/_z||=_/_z||=_/_ || ߀o77 || ߀o77 || ߀o77 || ߀o77 KG#(~? ?G#(~? ?G#(~? ?G#(~? ?z $߄o77MM&|| $߄o77MM&|| $߄o77MM&|| $߄o77MM&||3,ߌo77f||3,ߌo77f||3,ߌo77f||3,ߌo77f|| "߂oȷ[--|| "߂oȷ[--|| "߂oȷ[--|| "߂oȷ[--||+*ߊoŷʷ[V||+*ߊoŷʷ[V||+*ߊoŷʷ[V||+*ߊoŷʷ[V|| &߆o÷ɷmm6|| &߆o÷ɷmm6|| &߆o÷ɷmm6|| &߆o÷ɷmm6|ۯ\t;]~~߅ww;]~~߅ww;]~~߅ww;]~~߅w߁w;;|C߁w;;|C߁w;;|C߁w;;|C߉w;;NN|'S߉w;;NN|'S߉w;;NN|'S߉w;;NN|'S ߅w]..|K ߅w]..|K ߅w]..|K ߅w]..|?|x>/Filter/JBIG2Decode/Height 1752/ImageMask true/Length 36050/Name/X/Subtype/Image/Type/XObject/Width 1240>>stream J1prU̾j|4Meê˱=ɫ҅듰`^F!qyY'.HajWJNI V}).(r&=+C!X gڦI7_ \vp)C|'@uTG$geU͍$^.j`#dF`Ĉ_"O˺ReD0[LAp,4ꭳ \VP =k $HҿPQfhŔq>.^H ''>PN.[4b<;pqb01vT.ƣޠDI4&IS4Pf0Zi-베04mo)qycӴw*~Z2ۡƒ'PlG)-A;c/C!g xAZ^ "+ *K뻠+~b=;sԝܑ"mP"DQ- ,Kl5Z^ZS!%ߜbz%D']N+a)M̢?d}nlo bN1nSq!L,G,yKNط]g#P'JsIkڄQ]r.Fx=xOF[[r_a7ɤ摽jL7HX(Qv]YY>.F]U H(_fz@C addUlh;+sS÷n*=&E[@fz ׻x~"A`{zK S +'q /ߦP)KmJ/qhK_hט[<:rbQ~pB2*;iKtQn'ܫ5 D>1MR%L[F*V4bݶvEƟWXwi~$Hc =BB.KX=o$y6࿭iyo&I,]`({G^=+{n#UP ѩ̗ujk!|0@ PԱGôfw]˽k+P2Nt4on}4C}` .4뼰 M ܙt^} ^JU*8B4ķ9VEmǩNuYvsU.VYߨX}vb(d'0Wd&=(L͑@oxYpb njNrbֹ[xK&d^1HʗTi\{Fnb;h_+կ+kNjQ׏/rOg\ed^/@\4uaԘ5dkU!kqJ{L *fvZǗB-J0}?^il[6 3hXe >Y3\-䣒"8>OHֳWGQ?IbKd!c罗 h!b iږyЖ-)2kwR pEP%*l_xGrPWgqڜE%cRUI@-b~nE:;?ڽs|H$-%$y, CnHpKAvRs;a+Kc(3x( 2mEAqIB +A,:!@y3+Hn*`Zx8^ g¬P K1<*0} `@]z b '&QC!HCM')ebxd)I.ǥ ๩@mDYеMf?=邫 6YއA嶫My{qB!n<ɔb$U4 L%IH.s΃$;@0 uR3M  H.KU°Eyʆ>]Ќ\J'%<2FTnX rm ]3.X}%XDkw0nɞEx[χFoj]<ї!`s7m=&>CK! BŜ|K~טP6`OrtQ9)fm+eksXCr+ǹ0 ʄ|Ւ߱.[扂V8a5뀕xRL3{c+1Rϴp. 8y7鎰dr-GEӊyL,0;x.AF! ׈M,AM Cmi% $ؐ!Zc(½- &R_j*C 0| ʂUVs>Bdo/N=r7H4jC8HK!$J|7v nYa]IT߷BYXXB[e1Gr_,6y5" bvUgMّqn R䁭t v _Y&Êًq&(\z8אM6#pt%"naOjlHc`Uej;7\IH I],øj0eH^T뢣;Р|v<.HeA!zŪ-P 7sIIw!=3yψG%v¥fPOX{-Vo/^B܉",)0Ive-Y_52J4M!Rӄdܦa}^>-e[D8m"E i.s:Y"ޘuxNT y89fD7X\b{ּ[xHAglPH8T*d559ynyp:1J_!kC&ro:Hᑹk3L4APMmߡ%~+J0ӥ|#4Pئ3y*x(bfՅg')(mL.YՀI~@Fgن5=sOvX/EOiX-zygtD)yiHRihݠG}ED΢òΈ,̐5ah/1IvCƯ%%i(u;d"H,:$HNo3~:%g2,tUUY>B9I :V +"e{M6a,a%i<}K]Z.ݻo9{$fsjz!= iQgPVw?%pȠ u#w K2'˾w|M1y)Yϯ8rlrH/ 'dlcȾ77T:4vinF6J:qX:(y,_~̲q@ҹǎlnvƒh7[}HFs [E(E11V+ny)"coPz|![ġ=lM1a){vtsf ?Fb1HוEJU%UJ3NJػn]v,7y^=5BAS-*NܔJ& aۚtai+aMVĻ.JBK[=Jְ)KA 1emliP0';\R3Rq8FBHMYP>>\Sq7'JfCMQ3 YXPE{^IJ\ҵgnM+*r73m|d'7_4Q)-`ӝd?[e=ƙ's]'O‘a2{HFA} lZBov"e}^"J_}U2H',ڑ,Ƈ+?x{敮l8GsnY2 ]*G0JbeɵL b9kg/w>ׯ Z|Ǵ_ "u1w<;;2=SgL;l=&:dd1s@W!ߵL}LӋ0g'",N iȯY Q@9=DFe^w9YtX jhYgVOҒója ＿tݲ0"jƹP{DzW-y|#yRQLJ$E7Ȧ U-g|>u+BReIR|E:`)OVV<]XSBZgWPJGȮɂCLmCi>JcFu^NoE|xDL~C"Mwe^\Pjs3TdSVg<5Kx3% p&,{(K/*ښ>HF|X>NA:^ O{^>NB]ymlz^G/u]St׸ hX((U 4|wZU8 s!hP@tTU\/4)m),<[/\.lfg-'8)S=gN;R&r`rl} cceSY| +Hqf¨)>4XN DNf?[&Zߖ]]{Ԭ90 v oV?K![T4ٖ),S.Ƈ=sR ةg+0U0Fʬ PIǩM[wl Nf>Aճ.yĊY`)]ur^duec?/piկao&@{mg #v`NstߞOlH9Ѻ=c>U/lՇ۽}3y T~:f!.c>7- }e!#ʷZv\{9 vjo5v}[${=Fܕ xpGw62jZ/bE{CrAãmhvLfIY2{|Ug2;1HJ`7WU[&rd4~_]}┣e:=AH6 2lty==-υT<-2zv)}_ _5h %Ck-JWbZ'ΪnCꍕ&r8nG|W&6)&㟕h=dkG#’0oMYbOՊhY^~L솮vun ='FxGI\/e۸c{֨Z]>r=,IQN6-텏^7Tt # 1${Z [M@hBGk]^PK(`qj_f߱1S_wzE;4ܵ aրl/r5+ɼxCC;JS vh:h"ѮSk0AoG官y>2WP}*E2x`bBۑ$ZGUt/Es[[Eͨ;(X:iK6%3(Lut]֮ƄtaT"⭥΋;2:m4uț[=YxZ䤩=DAz+2Gnm_m-3WKqnTps p̃xD+A<SQY锽mx ۪5}_5}`*sUcXss.h5bSAtƳ#{oz?GK*XoJ_¾xB.0!#5JyDS ۲]P,6eu.1Α N\PH{O`XOR! VdXjf\RaO ;:a[ch1]vw}jw B7RÛ(ou!>$Q,AkB0YQ{T,]5xt2i+hv4͙+ NȬ6B9 ٗ!Pwd췵l,Q\EO(0P|Jï2,Qͦ@)˥9J-h.8F 0ٗrXoQ`2oHqΥxI2a!?wqN "ZjD"[1SfOS4"܅.2mk w"`Ħzb| @" Ȃ,nSHnA`hOm[ Ie>*1M]B\NCC>b#Oi>6W#E;U0X+,+s!cD3GVua)" ɩq 9NMIDs복H_ ?YHje{Q/8hѥh'.ƜӸZ-)\ 7"uqBo~֕S0wi^0 @8ec qԨ;ox@+b c/> 038-NF{Tր&VFϺЍM~ÿͿKc5%)*qdApT윫,>UO&b/t=c-\l2]g;rˊ +(n~Of1R<Ρk Oiɥn SGe6 }iWxՕcs&$h[0g۶y84hhC(ˉWZϢ8Vߒk${? pAK>gID8Fp$d9/+Q!DubpbmǔyiDErD_]?U\ѽ~vŴ"PH ^~AYlseϟ6' pVLNy 9l0R's`dQx>BY mE:RY:WU;٣Le=od=0 ddc[ \wjl K0`S1c|EjI mj[Tnڴ;E-uKGeJ 8ޚ zb,Ka' V 9?Y%9 X_Kfm'1Dudc1>7ЀJȿ}9ƱX 1N I2@kub٥2*^qժD-X,CTKOĸbȀa0Zufwz` &@dԩq95Hc,i{ƺqǬv 0!8!PjZkj#@GM1,uTp_@:"SֿGS>ZswKjhmIF|kh'C#Ylƞę/Z0bkB|OhDry mDZ\mHܲNu>6GڲW7 K%'rxHCd*:a5ΕnEA+ň~DU9]xF@t.l^UK @.Y,x)TՀ?E_.O峻{v}vw:kUިQʢڥ7h|??v[!1,kz}gro0sXhW'Yiaޏ׎. āF7p+[Cjn lU5;a{]މ0s*s,s'ldDNa cn Ohody0M H%R:QߦԆPfMQ8u}{;*Pܰz .yJU1*'+d+Sr_Y Ot'_;p;#a=:OZ@DC8H1ߡ|ۃCo>uCX0pBvi IQefuVn=׶!% .v`! wwG_=_@j3׸ƻ-0=qSVe?qfbb,{g<ʷgt\0sFڵ։XȓnaS~ | #?lB %Dy);®2S)FCC OFqxeH-RjHYZOX uR"Pi/ҷl{䣒¹E]'9Y[β+f,40d1vMǾpk(fzn݄*3sgCOf_cBv. H륛bgD-k:243'/0[t(\%[c(9uoWPG`2eM|_T p4|Rnj}U՛j-cf(%lBPQE ШBg(F4KcrD6.cT׾dO}u6ec5 ۔.,U>*uJV9JriT '\Өpi& q)JV0&); l}I_kku(-#͟$2!mUl/5PTE~#x3WF|tс y?B}^D3Tu B(̴5P=Ğ6 1ݼaJ + \c\n +rk<¬ʀfAZJ #G4Gǹk e9FTv4N M0VW"{ HP<Q4 LG8-ZKJc+90Ifyf3!w&sksT/v.n6Xґݚ`k~z9jvu<']39sw&c>ɫZZ[wbnI@n $eBHui1>U۠;/?In1Eٗr(K0BJr*,p m<\>A}IvS߹ОnZH>^1qPGjG}, T ~4ڵVN2=.Ƌ;WC(X|usd8KEo)*?U&LJHhi'HFKU(Ye(9*붞 B|Sx0!4xtig$UfQgInaO/]/p j.uj;O~ގɹr,:<~ W׭,'皬z;ѹnfI[nϊpj}{" UQ"GsNKWKOڃSV)yNJMjߛ;(گ3 . )2ܣbv8)0+m9Ud"IgJE|zʉ(5|ĊuCWe*Vƨ)ak&_\i[,4m}е/$H2GBBGt!Y$K T0ٮF#Qgc UIg|D[!ϾW]N@AXl_0)7җԖuhd\*gs5<5O h,1ܚQ욼+cRjhY ؂d4wouH,Mj8˖eLM*WܬCt!5`\N ޓBɄi%N~*d=;EU,DHjeH8NE0A_4pApʨhyl0+%jTDPjfZs ]G PH k_0DƭO*G5fQel~^C@ uU>#:L[%CN BW*6"rPBvmQvesP'żrޔ߈bjJkY #[7>''5)ȼ~NFj\E4BBor)Z7nĝ1<ѕ[5Xe NCtU`bu Uk,|k^R/FV]] xʯ58Dsq,ֿ -Kqߡ8#⥥O$h?3ΝY;ێ(4vWnZ JIҵXT#>2[iMvU@d}gJ",M BCCK\ x9{h#x"p7|^ĩU]4'ЊP*ʗP.;U`$!3Y,'P)|+ 3 F&K"AQ.7}^#nǴ_'`3:1p/˚̾atb2[:H~2R=})~F0#>UJ{Bխt1{ut܈ `Dc)f'N}&;I&^A;eg4ۢV_94«"6W]GGd֘8V\)=yfݺOlT@LRW+dm=5EM6XsKeONeX=JժQE'o0.vRnhxgfE<"`3 WZ_vIF5,tDdݑh.,LGp K-'&CUSX3Ѓρwҭcl].~/'1j ǣN JةPC|=OVK)Dl!|rh l:qyF#0uX *?3ɜYW: ]XXڵS qir< !*U. '#!aVOY)^UjYV@d/7vJs+uNcZWgQ gF˼ä{AY{G_s*ej&jakJfc,m$w#윓@(G @g,k=`W<ҿy-I6,NBu"!D^ B3L$3VŚ >ߨͼ%U OH<sºN;2s>X &*lKɌ:> 6[b]yU)br>8# x%"=|SУ,2hF?Dq"3ʊ%> gKPȇm2,c.#xE> !I2/ nRL4Wblc'0<[o7W9cpƟas #('r3h g QR$0yE9ں+5&sv0/$eBj~EEYu ˤo䉾 m=8H[>g DT1,ccwhdl ȟ0TW0LxWסѓǯ UX1>KnLLن8w]ejy/~?-:\e=* mYgi[3((N`TJPl%,(gijǪ] CQ5"#kZϋCf.cc t*jxB2wr֧kvCPE8I"Yh/^Qy!6A 0GqS#ȺTC<%]ccg,b( z&,7cVDOvkj؊\=" ~{de7lX|mfh؊8Dz%Wt7GYq,ӍDDY:6'.8\A*K~h2/Lw 6K@ޱ!"_#+wq]Ɂ Hϩ;vpJR&9sSVY[n1/#zhSX bŗI32Uk,ISvjMEDڒ}Q`Ns$ȭ8Z&dp;yf2uhoƑԬ.R.V끞vWF47ƕDȔ _CϖX܎\+5%ޠwuP3i{9a*NޫJ4}A8Ȣt=AMp LBگ- ;-KhpJ; _pL)E RֵQ4r!E3b%D^ocNZP0]R։ڥ_J%99-gt0og3[z~80WQKI#f NVbng@#oں'F)hj0k!h84}'iպ/V&Hl_j;iw+ Rwؼ /PAÒ.'h)L$4';m2ls\x؈7MPab '8%V70KSuNG "-ps"Y$ S@8AXGû 5\ &l5Þ$^/#I8x`iYEHҪ*9L1;qm*f "9 {nط$iC p;ehr% 2xr aWո4ۊK!AoQ =:ZKВ%ƌG'&w.:`ˆ?B^]yN7A~=݌qq[kx΁5 pI^F"('Ka\hLc-_̓ȡY!J?j[5mQʝJ!k@Jk:>*2*S9OHhum\3wW!]QA3ӂbW3FD^B=] +&%י0@ Bά rzeFw߷8 *bۊ9|pZ/hHf(fD{n*<(ⵐ1fEbYw}u]iA(ݱ;HT1Ӂ!M߯[T0O`b2/ c@P^2? SO.Z[4pSP@1\Vʬ%(-Ge֙Rx'_G*qDRj%0Tl mhIx ٚh #u v3wKbPWM^[=R~VRZoFYއ6X-XiC hRM\*m}%(mTq0KRtx"8sl7`:J:48\oTh5_0XJe+WOQ8s X?R 2ayi WplȩZ"BcwTlx0ҧvف6*?>wٕ ˆo.,LQyOs)%t5{½ǫUm#jRur9[%0<'">,e| aD)wh4}ҖN|ųgLi:][9QwO_Lf/d;pk쫏N/q9I`a?>s~c>)S_ο|;eebq֐TMs6y*VW1J>KxnD?hWz\'~z _ s$PߎL]H"2ֹh5feU;,x1va"`/7xNtsujmg|N*'PGYpLZ[Ɨ,~E/#J8V8-kBeKnJ>V*Q=ARe,7|i 5QB^7\T/"2zqH_kkI1uX}!Dt~1{t]05KzL>d9%m(ivGËj̝Z5԰ޓhN0C2Kkӷa,zŁ{mR?l{w˱n]MUvwB dh4XC!ZSj=($}pBrd{Ef@4e 佋y嶪0P5#@DĢ.jv4QKx!\0V ,\[z̻{?3"HW1\1ѧoU A0%ƀ 3RPTڅy/%8xX/R)E9>0ΐmKV 71O8E֫q"noҧV0E I}/,fT6㰺|m%cÓ!It7֛ءѯ>V[Gy2=vxg!ڲW^?] &S c>tٝqKtCp+hCt>i|Qcv_F{!G,l M d {޺bN^zqVlEXs㙼5>7ϻfm$IIR's-B[ ]ol>Z-+AD6{nù2z 茓xqר s^RRM4eS>%҆@L#PȧcF_8 NCk&T3Q^ FrBX"bU]]{=D^:.>F/sqVw]܌w|ae켼9 #(;[m3"콝}閵^YT68i ɿ5I@_GE1Wf& JJco@%Hŗ*Z*9Vzۛ+f._,+C[Vq"l x( [) -}h*ɺd Nۍ%w6֑~8 ϛDBf#oҧ ]-o5{d@O`t#[B?㫄Q:$;xP`v5BN#pu$1Ƙd/V)XWz~i$:?v̽U@C8vfsum"] {%pEsBWL~vtd)RQ2i<֠`QDñoPI-mjk3o3*P#?V_6K-457w$_`z(%2CN 1XIВ/V Qx-jU[;mڊScI"Z,\Ya*!z͋>=ɚ[ȓq NPcT~3'N&^qtlKEHƐ1@ۺ|8 7>D9-oT5K>AM}K3vVּTSR=15xAa(O|g8B/b=^ZK..ŐaM䬮4(x]Cj@.w$?f\XoQtOLe/lsL z);6y+NP#H_洜?"vH(N,5GcOL$zт.=ׅ;g`?ê l<hU,&wM iK|WZ[nNB$m<,LD_(w5P*E Y64:/JdSܽך@EAɳQE*fYPH6JmO|>]T-]NާFl:hpFmǕk]{SDƹvb}(e%9I; ]_g)Z۩4#O]CjMQ*+ ̅AGOe-Nl6='07DvYyvdd;Ӱح 08 4VϠ5_PV\̇)$|&ʤJ&.,?y:Cdعހ>{Gnެ}fPLMI̊6ue?/ȇ&Q1a KZ OCnl-FKϝt,h)]y 1 ,neKw WcBQ i7_P"[u1m5ȃ,i(hI#]'Vz:xA` kiu)ďԑ(@\N/e-4uC`Ǹ;/{&?O9ϗ|KdN8ݕo3vmUogKA]M" d%&{]QY<nk5.bN {K؍v{Bځׅh]+G՞0޺[PȰGxRi~^z4!SVam6`9INIZ }"߁{_BkM.` f]A\b#+ -xM$X Bh}a5@7q/H/jM2ԁdH0F||Bۼ;\H23yF^8+=b D~=*1B6C/^E[K6,gR2ߝOh4hD_2pԇr~@[t(Qv_8fJE EE#VgC%ȈK ynS#X-1$?/t, @:>z[\V$@XqT3fR#)IȕZ!ў\Cwy%3ڙigR EdAcD*$$td#I!/9ʘ F}!y[߳xJta֤dzĽ#َ̾GX{_t.bh)ށdjMkaƣ4]>aϿH{3>ԇ0tOl4׹ IR%]7& mD5ry'lKN߄5˯C6?CQ9Q1f4!q}$k-?p_X&iՃίZ4̼!,Ǜ 9yϢCTp{F 498(REV5-U;|8np<`( '[,\"XyӀray1TumPrdUbY>dWdJ pܛ([rGKH`AC{Eve[ղmz%EL G"M'E1oyB:MEBv?FD]jcpߪ{ XLR) D{? VuV<[pT@Q츬v#:AMh"#VuZx.u(%e>9JSܥtdfc ҂r2\8y&Ѳw ?YoCv2RJlg*tA@`D!U, h0'iLbj=YFUdLsg>CCyD9Y wH~C($.%Zzd0I˘)D/B69F> #`)>71_' Ljrvks 72р;!ˆ=8cQ UM?* ,s遥zqj2)ೆa2G|L,vTKGܳeox EÃd#H/7BA<0Zat4t 3RPD򯏳ȭ|Rj:]2Nܷ%4h(-D n8-hEK_ f mIC|G%jrrI`RDW8}`F);H [Z]i(EhQrQ\eGϽDzpDϟcmtMzX>anv̷yЕ59L)+֥M)=-Vw4- q(q||&q&O2vs{2SYRt ,:Tb$by|ٽW4fg%D. j7q #n8[9Y!liK'7ܜ̖? nRNrF!WE0WKD#[`60ptT29l~VW\f U&ѳj1nUQLp֩))TRnmdK"2J=$C7a﹎yN:X>|JJX+\v:>gvN/s-=ҲO@bpe%$WwD`"a<ųǣ^Ro~zn)Ět.ÿIp)9t '}Gܖ)㧐}7F=R^(9k x0Ӌw||Eڧc -?v 8K5Iжz!WA(e0zp@a/EI5FD%4M%~Y,Zddx] "vZ yd1?m6nX/3w!D,J3LsIJu xkHF6ÛX]lp6QH)Y}>$Dn3bZ@(@~yShvo_mv\^j<ZKd3\I!/X1j{%/_ko#\SuuītBLvFi} #9ucGGlJCW*hèwhHC Տf&YBM] X0v6?>G w8Wqh#"!sPM`QarNO)>2B J:V&KE^[ k@5[p^#y8UW#ٴgy/ZFp31 $* kƑ\Gt8:Hit/O߃bOAq~wC[n~uZ|QJ۴2v^OV {)jpǹ0󶛪J7>3Au3 `Bx;S)ذaz][-FJ>s:JAu75vpS]>^sA>5SY?!ۄ2c3xQ۔Ȥk"]|C'A#fOh^"}H٭6ކ/N3wdN~XQeFj!N?1e4|x`q%d8韏#|h:z] CSwP`ѭt߃ YwtCc08jl^X~(uzEA PJ*G%plVZ£rKV[jeJMNp8vŴlW\!iȪRj 'Fڗãe{ƹO~F#|aBZ렰0uկkIB.eܑ)-9pMƵ^>k)d3i 10mz*Ý( It G#7ul&\S,O(Whq  1yE,Y*.$I˘^YQ`%o2̀V ?OXZzow~&6H&Vr/7H}\EM魍Ll ˁǯ|OX\M؁WمO3jIYDǎ3-hꮆ`R΀{~\rd>'e2?׃f+}e D!ؗ2 kQ GIM $i w8"'r/JEb }U87/W)8 eV~hI2LP=}etSi}*e!oG G~ _@UpV֙C˽3=۷ds]5unj=q_.(nWG~݂9UˢIv  OJm9e yU(g9t"9Hk7r%` *J.¸Mc؊a_CS4J]Q$Jxp\Up㠂Y[!Y(B,D|6F }-i㥓QOUDCTCT3%e <;RnɯK3d;]ZBϚ^_EV80kdsTv-Xwzt^8qL#h =?o G+8 PHkoQ4hl(D\2xfŅJYxK)}#wQ %ㅳr+^/F0aĸ 6n'TUeZKwݼmzO?woKJ42J<6Q(סmQﮠu2!3>UyqYDd5;䋛{:&-~:^N;E*WGe¾R48O_e-)o__r 60[Sz#0zhޟK| \F^_hkĉL7D/ ٫W2ihxZ*`=8lF}e.ǞCI䋶u ]xt 2^k *Q{n ܕ뭤4Gxx}`@}nbe-~xi/M9, "@SH]"t-@%D9?7ɂ :LHbI˅c>o]l"ap Z2ց#a{QXS0sVou…v1 E*|-'N$ɕ~(6+ [5iHP,9MS$.G >wS{7VCI=|o9la=C]xijcmUfrβ9$9P;1Ku*Ibc( WfvkIqyek+Lwт\Իmg=UӜ@n"T8'$)ǕWffxEuAy]͟tݢ9)V=hf63Q~>olXJ޽VapQ}ga{$gư1[M7 ygJ"# %vxpa6ʎߘ^HD+? $&ohk+Ҫuv$_!.fѥ- x g3guYC)Xj/uK4d2 qϡ@ZJ O(X,Kϥs!SU񐚿HUlTV &<}p[aC$8昤bP7J+(÷(,"6Fܱr $`*߇UNnVF_]&ɏdW E)\Β+&se~/$l/.FkseAS5:^W&$VH/МV. 삍LR=pòEÆ؅ë2p`풟<XXFh4YL&FY[9ɛɘ FPͻ2k^ke{`LYL/%c+"E),Yxvѡݣ"2#b_T E:KZ[e^(8ӎ$)P $/"a:zq&N}x5U'YimGv C}d7FN? 7ool k,a[<Lݡj~X3xKz_IOu6!g}vo:vxiҐ?X^. yo7ن%#ةjsCyFu QX ηF @#m"mދ}ڤZ^iHeS! \ml-Q(>GIc]m ]}%f*R 8@ڄǦY `8-u%eXQz!㡸&KskfDZ7%[w4qWO^ux# So(VŢ&JZ6s·.,% B I&6oBf 2rphg3TQ@@-M:f&u4 L>e0MOb=]l GEJ=+D)y*(FIq1CoZ=#F&5%d}/O%#~b;7Oן$aaG ?`#;fdK޼M0I#yzPktFVkb`fGo&LxyЏ/0G^Zz7d)Z$CR}Hxu9n.^_p4eUN|,Ip +ժQfty6K2k0|`LitR<#HܪtX_$(w[<m\+pZ-anX{G~0qtu-˒1ԛQa||354P+Rs+ eMSNG]{V6[AKX=6da}XV<>jmxZ7.8El#7L4_P& Z&N\7u?$R@ =_8Tdd1E[u):2-KsFCUsvJpFql=R$S_qZt(}q"~g#D,|Pq>ŖpdTYt=+O5N`_pL[g \mav;P' }+ }SHS>TH0}v=!(:YG$ȹJĜO;s:Z6Z꼺IȻF0 3ԃWaӦO!͒B66,(T @dR3;0I7*{co2S!9D:ܼǞ)=}\ʑ Yqf@r1de?GH>&XQ[Eڹ4[KM\U^>[17!|T<x G\S5`9{;=Q:ahQiuVIU(4:4抇*suq]qH6\l6#{G2xבjz`NBHg e\yf4zFj6=BIx4Ux_ %&\VkϭH6E+9{!ToE؝;,ʺZs|ț6]?$CF3,KD1Vٳ41yϚV/h2fsc^UV(usޝ\ĞOw\Bc=\+Ak;֖1Kk[!@ IW.;և~TC7⹘, 3(ƬGw@vFEGT-*8a&X>C\fmB,e-.ȑ9LT៰NlCƘ]uI<1w1SbQVRg&#VnOe;ZHA?kK ?Wn| hY w G Te-\$\NOxH1i&SZϬ즗$n4ziX*I,twI)!1tW'fYA[]/wuEB'W16FW"8^JQo v:Խyy| \)SEcQUoxl.Nc%#}rL9{D#w=kECVYdAqYia"IcSӁ'EaEű@K˟jKR1f=V<ђ wScй0A.irl~)Q{u\l]+p}J ci:0/6'P e ;6]}ځ[~,hN< -rj%4 Ա2!e\#uO >Ob5g&Nr1G~6@3\7* v~(" wg+OA\q 0N!n2.Xw6EmI¥IP7xbhI1Ǫ򱟼 23l˓U"@$t)@q,kSeKhUb"nTV\>XӗLk6FTSOs7"n \nJS[tҕoP(fKFOKNk 汄HJzq,2q[P5zh!pz}1M O"gI:>QCԁw_DZr.pdqU#Б˃13`.Ʃ?`yèRkjÇ$BiDȑ0vڋnBv>RyC,'n'߱oo " q57=G0Aَl4l ]'Hu63*]8#QbYf~ ,~T^+;HoGC^t/mNǣT#/_:f׻!CL]ߞ_zr%3CV0HJ؄A ܀Lao兊Z䥈X(#wP~aМQ:FKV l*{I=¤}"88lΙdהvga+zo(72hY6@yaz!Mo^S,ݍWNp3-bzxV{CB륵^NvQߪN!]a|h6ҷc8cOeA,g鄹x=*G1IpAZ3|-3wOlA#o t3B3;A"/U26nדa>GQCiEv+nA* LƟ"N"qgb+T;o`ZXlu-RoͽJ=)g\jN1ͣI*%\Y.ٶ5%ְ\, qR^V;"˚>Xm s!Q`'LolV RAd/␌HF(d*CR/L/FjJ"gRT#32nZBE2|=k?%d(NsAϤY}KĆKpj=&i*ZSdHCˁ;.Oz&wX |$c50 |,@5``US Ӽ@:j u?["&"dU+ަo endstream endobj 73 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr;colrwjp2cOQ/;;R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ t  $@@:Ѐ hD@ $ y:$( #4c 7    endstream endobj 74 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr^(colrjp2cOQ/(^(^R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ1HѐD3"  )|!:Ѐ #)R  :$Ӊ$0  *%S׸   endstream endobj 75 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr&colrujp2cOQ/&&R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ t  $@@@  :ү|" :o2   endstream endobj 76 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrcolr}jp2cOQ/R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴt  -@ |!:Q`  :$   endstream endobj 77 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr&colryjp2cOQ/&&R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ t  %@ :  %:|"@ (    endstream endobj 78 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrZ&colrjp2cOQ/&Z&ZR \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ1HFUDf݁" +@|!@ h 2:$"1ov|# }p1ɼԠO &gH   endstream endobj 79 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr*&colrpjp2cOQ/&*&*R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴf7C O ):@   "p    endstream endobj 80 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr&colrujp2cOQ/&&R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ t ! @: @ $|"@ Z    endstream endobj 81 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrFcolrajp2cOQ/FFR \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ #t ؀   >@xS    endstream endobj 82 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrcolr~jp2cOQ/R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴt @@ /@: ` B: @qy0  !   endstream endobj 83 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr*.colrijp2cOQ/.*.*R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴPC " @ @  %    endstream endobj 84 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr&colrsjp2cOQ/&&R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ t  (: :|!Ҁ    endstream endobj 85 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr!colrzjp2cOQ/!!R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ t  # :   # @|!A]  9   endstream endobj 86 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrcolrljp2cOQ/R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴt @ % |!: @    endstream endobj 87 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr&colrzjp2cOQ/&&R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ t  :  : ܀ #n|#@aM r  endstream endobj 88 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr&colrvjp2cOQ/&&R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ t  !:  |"@]! : bр   endstream endobj 89 0 obj <>stream h244V0P044Q0 F & F&L) endstream endobj 90 0 obj <>stream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endstr endstream endobj 91 0 obj <>stream hTKo0 +<@O1Pcs$25W-{:,-mt:(>>RH3H$nS`2=A0NA$x dnCsAcy i`4(ԣ`0S< k>HzBǘI8 ܇ǑgGr뽹!ܪ8rke'ۦ `MMI̍N"w+b\sː/}POjX4U1gYx].3v Kf+a V2`H endstream endobj 92 0 obj <>stream h|n0 _O0i֦@ [=,kshhVlӏϧ],H].\.%/zY' =R4 fhSS@̏2?ayW<4P}0MCEb #BPƫ7~v".ѥEz)k@o$Dc5w\.K TZmɟ][ k!k А:N G &csZKMgyvz3s)ࠥ N_p&#ClϜ9}ƣGM=7h ߂;U$zц8U<0K!"uA"R7WP%e *Nl7jl`J$9 zZCSZx3G \H<0<Ďc*E>OG)Z>ITj 'LF*(6Rm3l|`3m}/ئϗ &j+h3vTG)N仙|wLTl4{^н >wU&m%3,N)0󼌁&iDјL1 RΉ܉,(mftI4D$NO%]~~_ endstream endobj 93 0 obj <>stream h241S0P041W07R  66`! ĢԼT4_jEwj~HeA~pIQi2X"(?hPPXWK~ri.P'H # endstream endobj 94 0 obj <>stream 2012-10-24T10:08:27+01:00 2012-09-17T11:29:27+01:00 2012-10-24T10:08:27+01:00 Canon iR-ADV C2020L PDF application/pdf uuid:e69a0e30-b882-491d-a679-2c094957461c uuid:887ded00-8ff1-484c-97ec-bd2aa1f16c3d Adobe Acrobat 10.14 Paper Capture Plug-in endstream endobj 95 0 obj <>stream h24T0Pw/+Q0L)645)IsL@(HwP~HeA~@bzj@"l endstream endobj 96 0 obj <>stream hḺ 0_MX ZGPrr肀0 *K{c$ƞ:";!EWIzo0gUp(%p*a_S9´>Zp~ oy5U`.L endstream endobj 97 0 obj <>/Filter/FlateDecode/ID[<9D214E4BFEECAE46902997841A5DDEB1>]/Info 150 0 R/Length 341/Root 152 0 R/Size 151/Type/XRef/W[1 3 1]>>stream h̒?(aǟyYNWrVe2Y, -AY".W.)dP-N" A  .sMV7|yYs^4|%#% L'"G~:D3'/U;m yyNyf('f}$BgwE.wb!.Vwhܐ|Gl2Ńx|8%O6xAS WKrl-}=ͮbҳLu;q[V+ gWvB|['ǟ̕Xöɛ/SXg*ݓ$uEFI~šo/dJ endstream endobj startxref 116 %%EOF